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Longmire, called it a “hostile” organ because it welcomes malignant cells and sepsis 
so warmly, bleeds so copiously, and is often the ?rst organ to be injured in blunt 
abdominal trauma. To balance these negative factors, the liver has two great attributes: 
its ability to regenerate after massive loss of substance, and its ability, in many cases, 
to forgive insult. This book covers a wide spectrum of topics including, history of 
liver surgery, surgical anatomy of the liver, techniques of liver resection, benign and 
malignant liver tumors, portal hypertension, and liver trauma. Some important topics 
were covered in more than one chapter like liver trauma, portal hypertension and 
pediatric liver tumors.
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Preface
Longmire, called it a ‘‘hostile’’ organ because it welcomes malignant cells and sepsis so
warmly, bleeds so copiously, and is often the first organ to be injured in blunt abdominal
trauma. To balance these negative factors, the liver has two great attributes: its ability to re‐
generate after massive loss of substance, and its ability, in many cases, to forgive insult.
This book covers a wide spectrum of topics including, history of liver surgery, surgical anat‐
omy of the liver, techniques of liver resection, benign and malignant liver tumors, portal
hypertension, and liver trauma. Some important topics were covered in more than one
chapter like liver trauma, portal hypertension and pediatric liver tumors.
As the editor, I wish to thank my colleagues, the authors, for their co-operation and desire to
share their precious experience with the medical community. They are well-known experts
from many centers across the world. On their behalf, I wish to express the hope that our
publication will facilitate access to the latest scientific achievements in the field of liver sur‐
gery all across the world.
This book is dedicated to our Patients without whose goodwill and trust, no progress in
medicine would be possible. To all my colleagues at the National Liver Institute in Egypt
who supported me, and embraced me with their warm feelings: I love you all. To professor,
Amr Helmy, and all my professors who so generously guided me by their example, wisdom
and insights: thank you. Finally, to Ms. Romana Vukelic, who shared me the birth of this
book, and to Ms. Danijela Duric who completed the job as the publishing manager: thank







Longmire, called it a ‘‘hostile’’ organ because it welcomes malignant cells and sepsis so
warmly, bleeds so copiously, and is often the first organ to be injured in blunt abdominal
trauma. To balance these negative factors, the liver has two great attributes: its ability to re‐
generate after massive loss of substance, and its ability, in many cases, to forgive insult.
This book covers a wide spectrum of topics including, history of liver surgery, surgical anat‐
omy of the liver, techniques of liver resection, benign and malignant liver tumors, portal
hypertension, and liver trauma. Some important topics were covered in more than one
chapter like liver trauma, portal hypertension and pediatric liver tumors.
As the editor, I wish to thank my colleagues, the authors, for their co-operation and desire to
share their precious experience with the medical community. They are well-known experts
from many centers across the world. On their behalf, I wish to express the hope that our
publication will facilitate access to the latest scientific achievements in the field of liver sur‐
gery all across the world.
This book is dedicated to our Patients without whose goodwill and trust, no progress in
medicine would be possible. To all my colleagues at the National Liver Institute in Egypt
who supported me, and embraced me with their warm feelings: I love you all. To professor,
Amr Helmy, and all my professors who so generously guided me by their example, wisdom
and insights: thank you. Finally, to Ms. Romana Vukelic, who shared me the birth of this
book, and to Ms. Danijela Duric who completed the job as the publishing manager: thank







General Introduction: Advances in Hepatic Surgery
J.H.M.B. Stoot, R.J.S. Coelen, J.L.A. van Vugt and
C.H.C. Dejong
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/54710
1. Introduction
Hepatic resection is a commonly performed procedure for a variety of malignant and benign
hepatic tumours [1, 2]. Historically, liver resection, irrespective of the indication, was associ‐
ated with a high morbidity and mortality [2-4]. During the last decades however, perioperative
outcome after hepatic resection has improved, due to increased knowledge of liver anatomy
and function, improvement of operating techniques and advances in anaesthesia and postop‐
erative care [1, 3, 4].
Hepatic resectional surgery is possible since the liver has the ability to regenerate. Although
it is doubtful whether the ancient Greeks already appreciated this unique quality of the liver,
it was first described in the myth of Prometheus (Προμηθεύς): he enraged the Gods for his
disrespect (ὕβρις) after climbing the Mount Olympus and stealing the torch in order to give
fire to the humans. He was punished by Zeus and chained to a rock in the Kaukasus Mountains.
Every couple of days, an eagle came and ate part of his liver. As the liver regenerated every
time, the eagle returned again and again to eat the liver and thereby torture poor Prometheus
(figure 1). With this ancient knowledge it was considered possible to take parts of the liver, as
this organ has enough capacity to work with a smaller part and is able to regenerate.
Apart from the eagle, no human dared to remove a part of the liver. In the ancient period of
the Assyrian and Babylonian cultures of 2000 - 3000 BC the liver played an important role to
predict the future by reading the surface of sacrificed animals [5]. This was also common in
the Etruscan society, where the haruspices predicted the future from sheep livers. Hippocrates
(460-377 BD), one of the founding fathers of ancient medicine, produced not only an oath with
ethical rules, which is still used in modern times for all doctors. His careful observations also
led to the recommendation to incise and drain abscesses of the liver with a knife [5]. Celsus
documented the treatment of exposed liver in war wounds. Although he was not a physician,
© 2013 Stoot et al.; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
© 2013 Stoot et al., licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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he described his observations in the first century AD from the Alexandrian school led by
Herophilus of Chalcedon and Erisastratus of Chios [5]. In the same era, the Greek Galen became
one of the emperor’s physicians in Rome and wrote reports about the dissection of many
species of animals, including primates. He described the central role of the liver in absorption
and digestion and his work remained of great importance for the coming centuries [5]. In the
centuries thereafter many reports were produced describing the treatment of war or trauma
wounds.
Figure 1. Prometheus chained (243 x 210 cm), Peter Paul Rubens, ca. 1611-1618, Philadelphia, Philadelphia Museum
of Art.
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Glisson performed extensive investigations of the vascular anatomy in 1654 (figure 2) [6]. It
took more than two centuries before his work was rediscovered and further clarified by Rex
(1888) in Germany and Cantlie (1897) in England [5, 7]. These contributions led to the division
of the liver in a left and right lobe [5].
Figure 2. Francis Glisson (1599-1677).
2. History of hepatic surgery
It still took 17 centuries before Hildanus successfully performed the first partial liver resec‐
tion for trauma [8]. The introduction of ether anaesthesia (1846) and the growing knowledge
of antisepsis (1867) made successful elective abdominal operations possible (table 1) [5].
Langenbuch was the first to perform a successful elective liver resection in 1887 (figure 3)
and Wendel did the first hemihepatectomy in 1911 [8]. The principles of liver haemostasis
and regeneration were determined in the period 1880-1900 [8]. The knowledge of the princi‐
ple of inflow and outflow of the liver and vascular control was one of the major advance‐
ments. Before that, wedge resections and mattress sutures were mostly used. This insight of
inflow and outflow reduction was marked by the publication of James Hogart Pringle of
Glasgow, Scotland (figure 4) [9]. He described the idea of digital control of the hilar liga‐
ment to reduce liver haemorrhage. In his famous report (1908) on liver haemorrhage after
trauma, eight patients were included. Three died before the operation, one refused the oper‐
ation and all four operated patients died; two died during the operation and two shortly
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thereafter [5, 9]. However, his idea of digital vascular control of the hilum was more success‐
ful in the laboratory setting, where he operated three rabbits with better results, which led to
his publication. Nowadays, more than a century later, the ‘Pringle manoeuvre’ or ‘Pringle’s
pinch’ is still used worldwide in hepatic resectional surgery and taught to all young sur‐
geons to control haemorrhage of the liver.
1846 Introduction of Ether anaesthesia Morton
1863 Bacterial fermentation of wine Pasteur
1867 Antisepsis Lister
1870 First successful excision of section of the liver Bruns
1880 Discovery of Streptococci, staphylococci and pneumococci Pasteur
1881 First successful gastrectomy Billroth
1882 First successful cholecystectomy Langenbuch
1883 First human colon anastomosis Billroth and Senn
1884 Pancreas excised for cancer Billroth
1886 Report on appendicitis Fitz
Introduction of sterilisation by steam Von Bergmann
First elective liver resection for adenoma Lius
1887 First successful elective liver resection Langenbuch
1887 Successful packing of stabwound of liver Burckhardt
1888 First successful laparotomy for traumatic liver injury Willet
Table 1. Advances in the beginning of surgery [5].
Figure 3. James Hogarth Pringle (1863-1941).
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Figure 4. Carl Langenbuch (1846-1901).
Liver surgery became gradually more popular as a better understanding of anatomic segments
was established after the work of Couinaud [10]. The classic morphological (outside) anatomy
with two main lobes (left and right) was extended by the internal hepatic anatomy with several
independent functional segments (figure 5). Each hepatic segment consists of liver parenchy‐
ma with an efferent hepatic vein branch and a portal triad; a hepatic artery branch, an afferent
portal vein, and an efferent bile duct. The classic right lobe consists of four segments, the left
lobe consists of three segments and the caudate lobe is segment 1.
With knowledge of the segmental anatomy of the liver, a safe transection plane could be chosen
for resection without excessive blood loss and without necrosis of remnant liver. This specific
anatomy of independent functional segments made it possible to resect parts of the liver
without compromising the hepatic function of remnant segments. Moreover, as already
described by the myth of Prometheus, the liver has regeneration capacity in contrast to other
human organs. In other words after partial resections, the liver can recover its mass and
function. The term ‘function of the liver’ is actually a collective term for a range of functions
including amongst others ammonia detoxification, urea synthesis, bile synthesis and secretion,
protein synthesis, gluconeogenesis and clearance or detoxification of drugs, bacterial toxins
and bacteria [11]. As the liver is the main detoxifying organ in humans, adaptation of its
function is crucial to survive. Regeneration however, takes time. After liver surgery with a
reduction of the hepatic cell mass, a ‘survival programme’ may start for vital liver functions
[12]. Some of these functions are increased rapidly in the remnant liver after resection [13]. In
the light of major hepatic resections, it is conceivable that too little functional liver remnant
may lead to liver failure, a lethal complication of liver surgery.
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Figure 5. The anatomy of the liver with separate segments following Couinaud’s classification. In this drawing only
major venous vessels are displayed (portal vein, caval vein and hepatic veins).
3. Resectional hepatic surgery
Hepatobiliary surgery incorporates a wide range of indications for surgical treatment of the
liver, varying from biopsy and resection to liver transplantation. The most important indica‐
tions for surgical treatment are liver lesions: these comprise a wide range of both benign and
malignant lesions, which can be either primary tumours (hepatocellular carcinoma) or
secondary tumours (i.e. metastases). Also, some infectious diseases of the liver (such as
echinococcosis) may be an indication for surgery. Irreversible liver dysfunction caused by
acute or chronic liver diseases, may be an indication for transplantation of the liver. Other
benign diseases of the liver such as symptomatic simple cysts and Polycystic Liver Disease
(PCLD) may also warrant surgical treatment. Other reasons for surgery of the liver may be
after severe injury or trauma of the liver. The latter indications are beyond the scope of this
chapter. Since hepatic lesions form the main surgical indication for hepatic diseases, the focus
will be on resectional liver surgery.
3.1. History of hepatic surgery for malignant lesions
The report of the first anatomical right hepatectomy for cancer by Lortat-Jacob in 1952 marked
a new era in liver surgery [14]. In the beginning, however, blood loss and mortality were
considerable. A multicentre analysis in 1977 of more than 600 hepatic resections for various
indications showed an operative mortality of 13%, which rose to 20% for major resections [15].
Despite this, pioneers in liver surgery continued the quest for improving this challenging field
of expertise and gradually mortality decreased to 5.6% [16]. The 5 year survival rates have
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increased from 20% in the beginning [16, 17] to as high as 67% in selected patients [18]. Earlier
developments in liver surgery have been marked by major contributions of Starzl (USA),
Bismuth (France) and Ton That Tung (Vietnam) [19-22]. With better knowledge of the
segmental anatomy, it was shown that parenchyma-sparing segmental resections were equally
effective as classic lobar resections, and in this way more functional remnant liver was
preserved [3, 23, 24]. Also, anaesthetic care and liver transection techniques were modernized
and improved over time [1, 3, 4, 25, 26].
Over the last decades, it was shown in several large series that perioperative results became
more encouraging, with operative mortality rates less than 5% in high volume centres [3, 24,
25]. Due to these improvements in liver surgery which not only proved to prolong life but also
to be a potentially curative treatment option for primary and metastatic cancers [27, 28], liver
surgery became standard of care for selected patients with primary and secondary hepato‐
biliary malignancies. Moreover, with the increasing improvements in the safety of hepatic
resections, this evolved to the most effective treatment for some benign diseases [29].
It is hard to pinpoint one discriminating factor that made the improvements in outcome
possible [3]. Many factors contribute to the gradually improved outcome. Most important
factors in this regard are probably the better knowledge of hepatic anatomy and thus ana‐
tomically  based  resections,  better  patient  selection,  general  improvements  in  operative
and anaesthetic  care and the development of  hepatobiliary surgery as a  distinct  area of
specialisation [3].
3.2. Transection techniques in hepatic resection
Parenchymal transection is the most challenging part of liver resection. Due to the complicated
vascular and biliary anatomy of the liver, haemorrhage is a great risk [30-35]. The firstly
performed liver resections failed as a consequence of haemorrhage or patients died shortly
after because of bleeding [31]. Before the 1980s, mortality after hepatic resection was 10 to 20%
and haemorrhage was a common cause [30]. Moreover, blood transfusion in the perioperative
period is associated with poorer outcome in the long term [33]. In contrast to patient- or
tumour-related factors, surgical techniques can be changed in order to prevent blood loss and
transfusion.
Parenchymal division was first described in 1958 when Lin and colleagues introduced the
finger fracture technique (digitoclasy) in which liver tissue is crushed between the surgeon’s
fingers [30]. Vessels and bile ducts are exposed, identified and then divided. Soon this
technique was improved by using surgical clamps (i.e. Kelly clamp) and called the crush-clamp
technique [30, 31]. Division of the vessels and bile ducts can be achieved by suture ligation,
bipolar electrocautery, vessel sealing devices or vascular clips. It is frequently combined with
intermittent inflow occlusion by portal triad clamping (Pringle maneuver) [31].
Subsequently, many transection techniques have been developed in order to improve results.
The Cavitron Ultrasonic Surgical Aspirator (CUSA, Tyco Healthcare, Mansfield, MA, USA)
combines ultrasonic energy with aspiration and results in a more precise transection plane.
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Vessels and bile ducts are exposed and can then be divided with a method according to the
surgeon’s preference [30, 31]. In a recent study, liver parenchyma transection using CUSA was
associated with higher numbers of potentially dangerous air embolism although patients did
not show clinical symptoms [36]. The Harmonic Scalpel (Ethicon Endo-Surgery, Cincinnati,
OH, USA) is comparable to the CUSA, but it uses ultrasonic shears and vibration to cut through
the parenchyma. It instantly coagulates blood vessels by protein denaturation and is mainly
used in laparoscopic procedures, because of the difficulties using the other transection
instruments in this setting. The hydro or water jet uses a high-pressure water jet to dissect liver
parenchyma and expose vessels and bile ducts after which they can be divided. Like with the
Harmonic Scalpel, less thermal damage is caused. In radiofrequency-assisted liver resection
radiofrequent electrodes are inserted in the transection plane and radio frequent energy is
applied for one to two minutes, followed by transection of the coagulated liver using a
conventional scalpel. [30, 31].
In a review including seven randomized controlled trials with a total of 556 patients, the clamp-
crush technique was quicker and associated with lower rates of blood loss and transfusion
compared with CUSA, hydrojet and radiofrequency dissecting sealer. No significant differ‐
ences in mortality, morbidity, liver dysfunction, ICU stay and length of hospital stay were
found. The crush-clamp technique comes with low costs and does not need any extra advanced
tools. However, not all techniques in the trials were combined with vascular occlusion. This
may have led to a bias in favour of the clamp-crush technique [32, 34]. The CRUNSH trial will
demonstrate whether vascular stapling is superior to the crush-clamp method in elective
hepatic resection [37]. Palavecino and colleagues developed the so-called ‘two-surgeon
method’, combining a saline-linked cautery and an ultrasonic dissector. Exposure of vessels
and biliary ducts and haemostasis are performed simultaneously. Retrospectively, signifi‐
cantly lower transfusion rates were seen [33].
In conclusion, the clamp-crush technique seems to be superior especially as it is an easy method
and comes with low costs. It might be regarded as the golden standard with which new devices
or methods should be compared. However, high-quality randomized controlled trials are
missing. Besides, the surgeon’s experience plays an important role. Because of this, one could
say that the method of choice is the clamp-crush technique and other techniques can be applied,
or combined, dependent on the surgeon’s experience and preference.
3.3. Malignant lesions
The liver has an important function as a detoxifying organ and due to the anatomical position
in the abdomen; most gastro-intestinal organs drain their venous blood to the liver. This makes
the liver a frequent location of metastases from a variety of intra-abdominal and sometimes
even extra-peritoneal primary cancers. Also, primary cancers can arise in the liver. Of these
the hepatocellular carcinoma is the most common malignancy. With a normal functioning
liver, resection is the treatment of choice for most of these malignant lesions.
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Metastases of colorectal origin are the most frequent malignant lesions in the liver. With near‐
ly one million new cases diagnosed each year and around half a million deaths annually, color‐
ectal cancer is one of the most common causes of cancer related death worldwide [38]. Over
half of the patients with colorectal cancer will develop liver metastases [39]. Moreover, up to
25% of these patients present with liver metastases at the same time of the primary diagnosis
[40]. Colorectal liver metastases may therefore be regarded as a major health problem [39].
The only chance of long-term survival in patients with liver metastases is provided by re‐
section of these liver metastases, with 5-year survival rates around 30-40% [41]. Until re‐
cently,  however,  few  patients  with  malignant  liver  lesions  were  considered  for  partial
hepatic resection. Due to the restricted resection criteria, only 10-20% of the patients with
malignant  lesions  were  selected.  Palliative  chemotherapy was  offered for  the  remaining
proportion of  the patients,  resulting in a median survival  of  6-12months [8,  42].  Due to
the increased safety of liver surgery, liver resection is currently also used for other meta‐
stases such as neuroendocrine tumours [43], sarcoma’s [44], melanoma [45-47], gastric can‐
cer [48-50] and breast cancer [48, 51, 52].
The selection criteria for liver resections were initially fairly strict:  unilobar distribution,
less  than four metastases,  maximum tumour size of  5  cm and tumour free margin of  1
cm. These resection criteria have been evaluated over time and have gradually been aban‐
doned, as these appeared to be not as important as previously assumed [53-55]. Even in
elderly patients and poor prognostic groups, complete tumour resection results in a good
long-term survival [56-58].
In the treatment of malignant liver disease, many improvements have been developed in recent
years: new surgical strategies for safer resection (including two stage hepatectomy and portal
vein embolisation), more effective chemotherapy, and additional techniques such as local
ablation therapies to increase possible curative treatment [59-64]. The combination of these
developments has led to an important progress and has resulted in more patients being
considered suitable for liver resection to almost 30% [62]. Better survival of patients with
primary or metastatic liver cancer has been reported in recent years and liver resection is
currently the only potentially curative treatment option.
3.4. Benign hepatic lesions
In case of malignant hepatic disease, surgical resection is currently felt justified despite a
morbidity and mortality, which may be as high as 42% and 6.5% respectively [1, 3, 65-67]. In
case of benign hepatic disease, however, this decision remains more difficult. Due to the
widespread use of imaging modalities such as ultrasonography, computed tomography (CT),
and magnetic resonance imaging (MRI), benign hepatic masses are increasingly being
identified. However, not all benign hepatic tumours require resection. Careful diagnosis with
contrast enhanced CT or MRI needs to be performed first. Benign lesions can grossly be divided
in solid and non-solid lesions (table 2).
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Solid lesions Symptoms Treatment
Hepatocellular adenoma
Variable: from incidental finding to severe
abdominal pain and shock in case of rupture
<5cm watchful waiting, stop
oral contraceptives
≥5cm resection to prevent
rupture and malignant
degeneration
Focal Nodular Hyperplasia Mostly incidental finding Surgery rarely indicated
Angiomyolipoma Mostly incidental finding Surgery rarely indicated
Nodular regenerative
hyperplasia
Mostly asymptomatic, should be considered in
patients with clinical signs of portal hypertension




Variable: from incidental finding to abdominal
pain
Surgery indicated only in case
of symptoms
Biliary cystadenoma
Variable: from incidental finding to abdominal
pain
Surgery may be indicated
(malignant degeneration)
Biliary hamartoma None Surgery not indicated
Cavernous haemangioma Variable, depending on size Surgery rarely indicated
Hydatid disease
Variable: from incidental finding to severe
abdominal pain and shock
Surgery indicated to relieve
symptoms and to prevent
rupture
Table 2. Most important benign liver lesions, divided in solid and non-solid lesions.
3.5. History of hepatic surgery for benign lesions
The first case of surgical resection for a presumably benign liver tumour was described in 1886
by Antonio Lius in Italy [68]. Lius was the assistant of Theodore Escher who excised a
pedunculated adenoma with the size of a child’s head (15.5 cm in greatest diameter) from the
left liver lobe of 67-year-old women. An uncontrollable bleeding was encountered during the
operation and the patient died several hours following surgery. The German surgeon Von
Langenbuch was the first to perform a successful resection of a benign solid pedicled liver
mass weighing 370 gram of the left liver in a 30-year-old woman who complained of abdominal
discomfort in the years following her first child’s birth in 1887 [69]. Postoperatively, secondary
haemorrhage occurred due to a bleeding hilar vessel. This was managed at re-exploration and
the patient survived. The course of symptoms and events in the latter case suggests the tumour
was most likely a hepatocellular adenoma.
It is nowadays well established that small benign lesions compatible with a diagnosis of
haemangioma, focal nodular hyperplasia (FNH) or hepatocelular adenomas (HCAs) are no
indication for liver resection [53]. Hepatocellular adenomas are considered the most important,
albeit uncommon, benign tumours of the liver that mostly occur in women. They are known
for their increased risk of haemorrhage and malignant transformation into hepatocellular
carcinoma (HCC) if size exceeds 5 cm. Therefore, surgical resection of HCAs is recommended
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for larger lesions [53, 54]. Focal nodular hyperplasia and haemangiomas have not been
regarded as potentially premalignant lesions.
The first case report of malignant transformation of a HCA was published in 1981 by Tesluk
and Lawrie [70]. The patient was a 34–year-old female with a large HCA measuring 16 cm in
diameter. She first presented with tumour haemorrhage after which her oral contraceptive use
was discontinued and the tumour subsequently shrank to a stable 5 cm. Three years later a
partial hepatectomy was performed when the tumour had reverted to its size at first presen‐
tation. Histological analysis revealed a well-differentiated HCC. The patient died of sepsis five
weeks postoperatively.
Foster and Berman were the first to report an estimated risk of malignant transformation in
1994, as they found a frequency of 13% in their series of 13 patients [71]. More recently, a
systematic review of the literature of the past 40 years containing more than 1600 HCAs
worldwide identified 68 reports of malignant transformation resulting in an overall frequency
of 4.2% among all adenoma cases [72]. Nowadays several other risk factors for malignant
potential of HCAs apart from size have been identified [73-84]. These are listed in table 3.
Risk factors
Tumour size ≥5 cm
Presence of β-catenin activating mutation
Presence of liver cell dysplasia within HCA
Patients with glycogen storage disease
History of androgen or anabolic steroid intake
Male sex
Obesity/overweight
Table 3. Risk factors for malignant transformation of hepatocellular adenomas.
3.6. Surgical treatment of hepatocellular adenomas
The identification of several risk factors for malignant potential of HCAs in recent years,
provides better indications for surgical treatment of these presumably benign tumours. Also,
the Bordeaux adenoma tumour markers (table 4) have greatly contributed to the subtype
classification of HCAs and have given clearer insights into the pathological mechanism of
malignant evolvement [79]. More recently, MR imaging techniques have been shown to be of
value in identifying premalignant HCAs [85, 86]. These advances in risk factor stratification,
together with tumour subtyping prior to hepatic surgery, might aid in selecting HCAs at high
risk of malignant evolvement for surgical resection. Unfortunately, routine performance of
biopsy of an HCA has not been implemented yet owing to the risk of sampling error, bleeding,
needle-track tumour seeding and the difficult interpretation of β-catenin staining. However,
a change towards a more stringent selection process in the near future is inevitable and may
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imply a major reduction of the number of liver resections, and thus morbidity and even
mortality, in a selected group of predominantly young patients.
HCA type Frequency (%) Malignant transformation Markers
β-catenin activated 10-15 Yes β-catenin+/GS+
HNF1α inactivated 30-50 Rarely LFABP-
Inflammatory 35 No SAA+/CRP+
Unclassified 5-10 No None
CRP, C-reactive protein; GS, glutamine synthetase; HCA, hepatocellular adenoma; HNF1a, hepatocyte nuclear factor 1a;
LFABP, liver-fatty acid binding protein; SAA, serum amyloid A; +, positive; -, negative. Table adapted with permission
from Stoot et al. 2010 [72].
Table 4. Types of HCAs and their immunohistochemical markers.
Concerning the management of ruptured HCAs, emergency surgery is associated with high
morbidity and mortality rates [73, 85]. Although this treatment is still suggested by some
authors [86], the maximally invasive therapy of immediate liver resection has gradually been
abandoned. Many liver surgeons prefer conservative management of ruptured HCAs con‐
sisting of immediate resuscitation with laparotomy and gauze packing [74]. Selective arterial
embolisation for ruptured HCAs may be a valuable alternative although it has rarely been
reported [55, 63, 70, 72, 87].
In conclusion, hepatic resection for benign tumours is mainly reserved for HCAs at risk for
malignant evolvement or haemorrhage. Advances in pathological subtyping, radiological
imaging and risk stratification have led to new insights and aid in justifying hepatic resection
in a more selected population.
4. Advances in the surgical treatment of benign cystic lesions: hydatid
disease
Surgical treatment may also be indicated for infectious diseases of the liver such as benign
lesions caused by the parasitic infection called Echinococcosis. Human echinococcosis is a
zoonosis caused by larval forms (metacestodes) of Echinococcus (E.) tapeworms found in the
small intestine of carnivores. Two species are of clinical importance – E. granulosus and E.
multilocularis – causing cystic echinococcosis (CE) and alveolar echinococcosis (AE) in humans,
respectively [87]. Besides, in the beginning of the 20th century the so-called neotropical
echinococcosis species E. oligarthrus and E. vogeli were discovered to cause polycystic echino‐
coccosis (PE). E. vogeli causes disease similar to AE and E. oligharthrus has a more benign
character [88]. Echinococcosis is endemic worldwide in large sheep-raising areas including
Africa, the Mediterranean region of Europe, the Middle East, Asia, South America, Australia
and New Zealand [89-96]. Human cystic echinococcosis is one of the most neglected parasitic
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diseases in the world. In many endemic regions most infected patients suffer considerably
from this disease, usually because of the lack of treatment possibilities due to poor infrastruc‐
ture and shortage of equipment and drugs [97, 98]. The incidence of hydatid disease in Western
industrial nations is relatively low [93, 94, 99]. Migration and travelling has led to an increase
of the prevalence of this disease in Northern parts of Europe and North America [96, 100]. The
diagnosis of hepatic echinococcosis can be made with a combination of patients’ symptoms,
liver imaging findings, detection of Echinococcis-specific antibodies and microscopic or
molecular examination of cyst fluid. The most frequent site for cystic lesions is the liver (60%
of patients), followed by the lungs in about 20% of patients. The remaining lesions are found
throughout the body [92, 95, 99, 101, 102].
The natural course of this infection can be extremely variable [101]. The hepatic cysts can
spontaneously collapse, calcify or even disappear. These patients can remain symptom-free
for years. It is not uncommon that the cysts are detected when abdominal imaging is performed
for a different reason. On the other hand, the cysts can also steadily grow about 1-3 cm in
diameter per year [96, 99]. They do not tend to grow infiltratively or destructively, but pressure
or mass effects of the cysts can displace healthy tissue and organs. Thus, most patients present
with symptoms from mechanical effects on other organs or structures, which can lead to pain
in the upper right quadrant, hepatomegaly and jaundice, depending on the location and nature
of the cysts [91, 96, 99, 101]. Infection of the cysts can result in sepsis and/or the formation of
liver abscesses. A feared complication is rupture of hepatic hydatid cysts into the peritoneal
cavity. This can result in serious anaphylaxis, sepsis and/or peritoneal dissemination. The
content of the ruptured cyst can disseminate into the biliary tract leading to cholangitis or
cholestasis, but also to the pleurae or lungs leading to pleural hydatidosis or bronchial fistula,
respectively [91, 92, 102].
4.1. History of hepatic surgery for hydatid disease
Hydatid disease was already recognized by Hippocrates more than two millennia ago. This
benign disease has been shown to act as a malignant disease as it has the tendency to dissem‐
inate to other organs and to cause a devastating disease sometimes even leading to death. The
serious effects of this disease were known in the late 1880s, when Loretta performed the first
left lateral liver resection for echinococosis in Bologna [8]. Last years many developments have
improved the course of hydatid disease: better medical therapy, improved surgical procedures
and the development of minimally invasive techniques.
From a historical perspective, the main treatment option of hepatic hydatid disease was the
open surgical approach with side packing and several radical or more conservative surgical
techniques [96, 99]. This terminology in literature might be confusing. Conservative surgery
means that tissue-sparing techniques are used; the hydatid cyst is evacuated and the pericyst
is left in situ, while in radical procedures both the cyst and the pericyst are removed. The most
common conservative techniques include simple tube drainage, marsupialization, capiton‐
nage, deroofing, partial cystectomy or open or closed total cystectomy with or without
omentoplasty. Conservative operations have good results regarding blood loss and length of
hospital stay [103, 104]. In contrast, the cyst content and the entire pericystic membrane are
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imply a major reduction of the number of liver resections, and thus morbidity and even
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authors [86], the maximally invasive therapy of immediate liver resection has gradually been
abandoned. Many liver surgeons prefer conservative management of ruptured HCAs con‐
sisting of immediate resuscitation with laparotomy and gauze packing [74]. Selective arterial
embolisation for ruptured HCAs may be a valuable alternative although it has rarely been
reported [55, 63, 70, 72, 87].
In conclusion, hepatic resection for benign tumours is mainly reserved for HCAs at risk for
malignant evolvement or haemorrhage. Advances in pathological subtyping, radiological
imaging and risk stratification have led to new insights and aid in justifying hepatic resection
in a more selected population.
4. Advances in the surgical treatment of benign cystic lesions: hydatid
disease
Surgical treatment may also be indicated for infectious diseases of the liver such as benign
lesions caused by the parasitic infection called Echinococcosis. Human echinococcosis is a
zoonosis caused by larval forms (metacestodes) of Echinococcus (E.) tapeworms found in the
small intestine of carnivores. Two species are of clinical importance – E. granulosus and E.
multilocularis – causing cystic echinococcosis (CE) and alveolar echinococcosis (AE) in humans,
respectively [87]. Besides, in the beginning of the 20th century the so-called neotropical
echinococcosis species E. oligarthrus and E. vogeli were discovered to cause polycystic echino‐
coccosis (PE). E. vogeli causes disease similar to AE and E. oligharthrus has a more benign
character [88]. Echinococcosis is endemic worldwide in large sheep-raising areas including
Africa, the Mediterranean region of Europe, the Middle East, Asia, South America, Australia
and New Zealand [89-96]. Human cystic echinococcosis is one of the most neglected parasitic
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from this disease, usually because of the lack of treatment possibilities due to poor infrastruc‐
ture and shortage of equipment and drugs [97, 98]. The incidence of hydatid disease in Western
industrial nations is relatively low [93, 94, 99]. Migration and travelling has led to an increase
of the prevalence of this disease in Northern parts of Europe and North America [96, 100]. The
diagnosis of hepatic echinococcosis can be made with a combination of patients’ symptoms,
liver imaging findings, detection of Echinococcis-specific antibodies and microscopic or
molecular examination of cyst fluid. The most frequent site for cystic lesions is the liver (60%
of patients), followed by the lungs in about 20% of patients. The remaining lesions are found
throughout the body [92, 95, 99, 101, 102].
The natural course of this infection can be extremely variable [101]. The hepatic cysts can
spontaneously collapse, calcify or even disappear. These patients can remain symptom-free
for years. It is not uncommon that the cysts are detected when abdominal imaging is performed
for a different reason. On the other hand, the cysts can also steadily grow about 1-3 cm in
diameter per year [96, 99]. They do not tend to grow infiltratively or destructively, but pressure
or mass effects of the cysts can displace healthy tissue and organs. Thus, most patients present
with symptoms from mechanical effects on other organs or structures, which can lead to pain
in the upper right quadrant, hepatomegaly and jaundice, depending on the location and nature
of the cysts [91, 96, 99, 101]. Infection of the cysts can result in sepsis and/or the formation of
liver abscesses. A feared complication is rupture of hepatic hydatid cysts into the peritoneal
cavity. This can result in serious anaphylaxis, sepsis and/or peritoneal dissemination. The
content of the ruptured cyst can disseminate into the biliary tract leading to cholangitis or
cholestasis, but also to the pleurae or lungs leading to pleural hydatidosis or bronchial fistula,
respectively [91, 92, 102].
4.1. History of hepatic surgery for hydatid disease
Hydatid disease was already recognized by Hippocrates more than two millennia ago. This
benign disease has been shown to act as a malignant disease as it has the tendency to dissem‐
inate to other organs and to cause a devastating disease sometimes even leading to death. The
serious effects of this disease were known in the late 1880s, when Loretta performed the first
left lateral liver resection for echinococosis in Bologna [8]. Last years many developments have
improved the course of hydatid disease: better medical therapy, improved surgical procedures
and the development of minimally invasive techniques.
From a historical perspective, the main treatment option of hepatic hydatid disease was the
open surgical approach with side packing and several radical or more conservative surgical
techniques [96, 99]. This terminology in literature might be confusing. Conservative surgery
means that tissue-sparing techniques are used; the hydatid cyst is evacuated and the pericyst
is left in situ, while in radical procedures both the cyst and the pericyst are removed. The most
common conservative techniques include simple tube drainage, marsupialization, capiton‐
nage, deroofing, partial cystectomy or open or closed total cystectomy with or without
omentoplasty. Conservative operations have good results regarding blood loss and length of
hospital stay [103, 104]. In contrast, the cyst content and the entire pericystic membrane are
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removed in radical procedures; a total pericystectomy or liver resection (hemihepatectomy or
lobectomy) is performed [90, 94, 101, 104].
In surgical interventions of hepatic hydatid cysts, complete removal of the parasite should be
performed. Also, prevention of intraoperative spilling of cyst content and saving healthy
hepatic issue is of utmost importance [91, 93, 96]. Spilling could not only lead to recurrence of
hydatid disease, it could also lead to anaphylactic shock before the introduction of the
antihelmintic drugs. Therefore, surgeons need to perform procedures with a focus on safe and
complete exposure of the cyst, safe decompression of the cyst, safe evacuation of the cyst
contents, sterilization of the cyst, treatment of biliary complications and management of the
remaining cyst cavity. Especially in non-endemic areas where the number of operations is low,
the technique needs to be safe and easily reproducible, with a low complication rate. In the
former century, hydatid disease was operated with a high risk of morbidity and recurrence,
possibly due to the spilling of cyst content during the operation. In the 1970s, Saidi developed
a special cone, which was frozen to the cyst in order to reduce the risk of spilling cyst contents.
This cone also simplified the disinfection of the cyst cavity [105]. Recently, this old treatment,
also known as the ‘frozen seal method’, was evaluated in a non-endemic area and it was
concluded to be an effective surgical treatment for hepatic hydatid disease [104]. In this
retrospective study, 112 consecutive patients were treated surgically with the ‘frozen seal’
method for hydatid disease between 1981 and 2007. Recurrence rate was observed in 9 (8%)
patients and morbidity occurred in twenty patients (17.9%). More importantly, no mortality
was observed in this study of more than 25 years of surgically treated ‘echinococcosis'. It was
concluded that this surgical method used in the past century was still safe and effective in the
new millennium. This technique is especially useful in non-endemic areas as it provides high
efficacy and low morbidity rates.
Apart from the ‘frozen-seal method’, surgical treatment options may vary from conservative
treatment (cystectomy) to radical treatment (complete open resection) to laparoscopic techni‐
ques. The debate on best surgical treatment is still ongoing: should this be conservative surgery
or radical surgery in which the cyst is totally removed including the pericyst by total pericys‐
tectomy or partial hepatectomy or should it be the open or laparoscopic approach [101, 102].
4.2. Percutaneous treatments
With the introduction of antihelmintic drugs, new possibilities for treatment arose. By using
this medication, the risk of anaphylaxis became smaller and percutaneous treatments were
developed. One of these treatments for hydatid disease is PAIR: Percutaneous Aspiration,
Injection and Re-aspiration. In a recent meta-analysis of operative versus non-operative
treatment (PAIR) of hepatic echinococcosis [92], PAIR plus chemotherapy proved to be
superior compared to surgery. The meta-analysis showed that PAIR was associated with
improved efficacy, lower rates of morbidity, mortality, disease recurrence and shorter hospital
stay [92].
In conclusion, the main treatment options for hepatic cystic echinococcosis are threefold:
medical therapy, surgery and percutaneous drainage (Puncture Aspiration Injection and
Reaspiration, also known as PAIR) or a combination of these therapies [91, 92, 100]. In the last
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revision of the WHO IWGE it was stated that surgery remains the cornerstone of treatment of
hydatid disease, since it has the potential to remove the hydatid cyst and lead to complete cure.
However, it is advised to evaluate surgical treatment carefully against other less invasive
options such as percutaneous interventions. [88]
5. Improvements in pre-operative planning
An important way to improve the outcome in liver surgery is to prevent liver resection related
complications. One of the main feared complications in liver surgery remains postresectional
liver failure. This major complication may occur if the extent of tumour involvement requires
major liver resection (3 or more segments), leaving a small postoperative remnant liver [3, 106,
107]. Due to impaired liver function this may even result in mortality. Obviously, limiting the
liver resection, in order to leave enough liver remnant volume for proper function of the liver,
can prevent this. However, major hepatectomies are performed increasingly often, mainly
because indications for liver resection are continuously being extended. Former contraindica‐
tions such as bilobar disease, number of metastases and even extrahepatic disease have been
abandoned gradually and compromised liver function may be expected after aggressive
induction chemotherapy. Consequently, postoperative remnant liver volume and function
have become the main determinants of respectability [108-110]. In order to improve outcome
in extended resections and thus to prevent postoperative liver failure after liver resection, a
reliable volumetric assessment of the part of the liver to be resected as well as future residual
liver volume should be a critical part of preoperative evaluation particularly. The safety of
liver resection may increase if an estimate of minimal remnant liver volume is obtained via
CT-volumetry [106, 111].
The utility of existing professional image-processing software is often limited by costs, lack of
flexibility and specific hardware requirements such as coupling to a CT-scanner. In addition,
the intended operation should be known to the investigator to predict the remnant liver
volume accurately and requires the expertise of a liver surgeon. Therefore, CT-volumetry has
hitherto been a multidisciplinary modality requiring the efforts of dedicated surgeons and
radiologists and expensive software. Prospective CT-volumetric analysis of the liver on a
Personal Computer performed by the operating surgeon in patients undergoing major liver
would greatly enhance this preoperative assessment. ImageJ is a free, open-source Java-based
image processing software programme developed by the National Institute of Health (NIH)
and may be used for this purpose [112]. OsiriX® is Apple’s version for image analysis and has
been tested for CT volumetry of the liver [113]. It is also a freely available, user-friendly
software system, which can be used for virtual liver resections and volumetric analysis [113].
As more major liver resections are performed, it is becoming more important to perform liver
volumetry. Recently, these two open source image processing software packages were
investigated to measure prospectively the remnant liver volume in order to reduce the risk of
post-resectional liver failure. Volumes of total liver, tumour and future resection specimen of
the included patients were measured preoperatively with ImageJ and OsiriX by two surgeons
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tectomy or partial hepatectomy or should it be the open or laparoscopic approach [101, 102].
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With the introduction of antihelmintic drugs, new possibilities for treatment arose. By using
this medication, the risk of anaphylaxis became smaller and percutaneous treatments were
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Injection and Re-aspiration. In a recent meta-analysis of operative versus non-operative
treatment (PAIR) of hepatic echinococcosis [92], PAIR plus chemotherapy proved to be
superior compared to surgery. The meta-analysis showed that PAIR was associated with
improved efficacy, lower rates of morbidity, mortality, disease recurrence and shorter hospital
stay [92].
In conclusion, the main treatment options for hepatic cystic echinococcosis are threefold:
medical therapy, surgery and percutaneous drainage (Puncture Aspiration Injection and
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107]. Due to impaired liver function this may even result in mortality. Obviously, limiting the
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can prevent this. However, major hepatectomies are performed increasingly often, mainly
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tions such as bilobar disease, number of metastases and even extrahepatic disease have been
abandoned gradually and compromised liver function may be expected after aggressive
induction chemotherapy. Consequently, postoperative remnant liver volume and function
have become the main determinants of respectability [108-110]. In order to improve outcome
in extended resections and thus to prevent postoperative liver failure after liver resection, a
reliable volumetric assessment of the part of the liver to be resected as well as future residual
liver volume should be a critical part of preoperative evaluation particularly. The safety of
liver resection may increase if an estimate of minimal remnant liver volume is obtained via
CT-volumetry [106, 111].
The utility of existing professional image-processing software is often limited by costs, lack of
flexibility and specific hardware requirements such as coupling to a CT-scanner. In addition,
the intended operation should be known to the investigator to predict the remnant liver
volume accurately and requires the expertise of a liver surgeon. Therefore, CT-volumetry has
hitherto been a multidisciplinary modality requiring the efforts of dedicated surgeons and
radiologists and expensive software. Prospective CT-volumetric analysis of the liver on a
Personal Computer performed by the operating surgeon in patients undergoing major liver
would greatly enhance this preoperative assessment. ImageJ is a free, open-source Java-based
image processing software programme developed by the National Institute of Health (NIH)
and may be used for this purpose [112]. OsiriX® is Apple’s version for image analysis and has
been tested for CT volumetry of the liver [113]. It is also a freely available, user-friendly
software system, which can be used for virtual liver resections and volumetric analysis [113].
As more major liver resections are performed, it is becoming more important to perform liver
volumetry. Recently, these two open source image processing software packages were
investigated to measure prospectively the remnant liver volume in order to reduce the risk of
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the included patients were measured preoperatively with ImageJ and OsiriX by two surgeons
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and a surgical trainee [114]. Results were compared with the actual weights of resected
specimens and the measurements of the radiologist using professional CT scanner-linked
Aquarius iNtuition® software. It was concluded that the prospective hepatic CT-volumetry
with ImageJ or OsiriX® was reliable and can be accurately used on a Personal Computer by
non-radiologists. ImageJ and OsiriX® yield results comparable to professional radiological
software iNtuition®.
6. Minimally invasive surgery
To minimize the damage of treatment, laparoscopic surgery was introduced to avoid large in‐
cisions for many gastrointestinal operations in the previous century. After the first laparoscop‐
ic  cholecystectomy in  1987  [115],  the  number  of  indications  for  this  minimally  invasive
approach increased. The outcome has encouraged surgeons to develop a laparoscopic techni‐
que for many procedures including liver resections [116]. Although this type of surgery is tech‐
nically more demanding and thereby time-consuming [117, 118], it proved to be beneficial for
patients with less pain and better recovery compared to open liver surgery [119-121].
6.1. The history of laparoscopic surgery
The fundamentals of laparoscopic surgery were laid down in the early twentieth century when
the German surgeon Kelling reported on the endoscopic visualization of the peritoneal cavity
in an anesthetized dog using a Nitze cystoscope (1887) in 1902 [122]. Following the introduction
of endoscopic inspection of the abdominal contents in an animal model, fellow countryman
Jacobeus started experimenting with laparoscopy in human cadavers as well asliving humans.
In 1911 he reported on 80 laparoscopic examinations of the abdominal cavity [123, 124]. In the
years thereafter the laparoscopic approach was enhanced with the introduction of illumination
techniques, advancement in lens systems, the use of more than one single trocar and induction
of pneumoperitoneum (Goetze and Veress). The era of therapeutic laparoscopy was then born,
making it possible to minimize damage of treatment and avoid large incisions for many
gastrointestinal operations. However, it was not until 1987 that the first laparoscopic chole‐
cystectomy was performed [115].
At first, liver surgery was thought to be unsuitable for laparoscopic techniques since it might
impose the risk of gas embolisms and major blood loss during transection of the liver. Also,
sceptics pointed out the suspected risk of trocar site metastases in skin incisions. Gradually,
as some expert centres progressively reported feasibility and safety, it became more popular.
This novel approach for liver resections was introduced during the 1990s. At first the procedure
was only used for diagnostic laparoscopies and liver biopsies, later indications were extended
to fenestration of liver cysts and anatomic liver resections. In 1992, Gagner et al. reported the
first laparoscopic wedge resection of the liver. Only three years later, Cuesta et al. were the
first to perform two cases of limited laparoscopic liver surgery of segment II and IV in the
Netherlands [125]. The first laparoscopic left lateral bisegmentectomy of the liver was per‐
formed by the group of Azagra [126]. Since then, several studies have reported the feasibility
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and safety of laparoscopic resections for liver tumours in centres with extensive experience in
both hepatobiliary surgery and laparoscopic surgery [116, 117, 127-130].
However, after its introduction, laparoscopic liver resection remained challenging because of
the difficulties concerning safe mobilization and exposure of this fragile and heavy organ.
Therefore, in the beginning only superficial and peripheral lesions in anterolateral segments
were selected for the laparosopic approach. In recent times, centres with extensive experience
in laparoscopy and hepatic surgery have also performed major hepatic resections laparoscop‐
ically with satisfactory outcomes. Importantly, no evidence of a compromised oncological
clearance in laparoscopic liver resection has hitherto been found [120]
6.2. Advantages of the laparoscopic technique
The laparoscopic approach is said to have shifted the pain of the patient to the surgeon, as the
latter had to obtain new operative skills and more demanding techniques. In fact laparoscopic
surgery is a totally different concept of surgery. The conventional three-dimensional field is
inherently two-dimensional, and the tactile feedback is impaired as compared to open surgery.
Moreover, a full ambidexterity is required, as well as the skills to manipulate fragile structures
with long instruments under minimal tactile feedback. Also, the surgeon becomes even more
dependent on his team and instruments, as he will need experienced assistance for traction
and camerawork and needs to trust the material even more compared to open surgery. For
patients the most important presumed advantages of the laparoscopic procedure are reduced
blood loss [119, 120], less postoperative pain [118, 127, 131], earlier functional recovery [127,
130], shorter postoperative hospital stay [118, 120, 121, 127, 130-132] and improved cosmetic
aspects [127, 130]. Reoperations are reported to be easier due to reduced adhesions [127,
130-132]. Also, open-close procedures with large incisions can be avoided if peritoneal
metastases are detected at laparoscopy.
However, up till now no randomised controlled trials comparing the open and laparoscopic
liver resection technique have been reported. This may well be one of the reasons why many
surgeons remained reluctant to incorporate this new laparoscopic approach. The currently
available evidence is primarily based on case-series and identifies a technique that is repro‐
ducible with limited morbidity and mortality. In a consensus statement on laparoscopic liver
resections, Buell J et al [133] concluded that resection of segments 2 and 3 by the laparoscopic
approach should be the standard of care. In that same year a large international study reported
comparable encouraging results concerning the superiority of laparoscopic liver resections in
terms of complications from 109 patients: the complication rate was only 12% and there were
no perioperative deaths [134]. Median hospital length of stay was 4 days. Negative margins
were achieved in 94.4% of patients.
Overall survival rates and disease-free survival rates for the entire series were 50% and 43%
at 5-year respectively. It was concluded that laparoscopic liver resection for colorectal meta‐
stases was safe, feasible and comparable to open liver resection for both minor and major liver
resections in oncologic surgery. This is confirmed in a recent meta-analysis on short and long-
term outcomes after laparoscopic and open resection. This study included a total of 26 studies,
incorporating a population of 1678 patients [135]. Although laparoscopic liver resections
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and a surgical trainee [114]. Results were compared with the actual weights of resected
specimens and the measurements of the radiologist using professional CT scanner-linked
Aquarius iNtuition® software. It was concluded that the prospective hepatic CT-volumetry
with ImageJ or OsiriX® was reliable and can be accurately used on a Personal Computer by
non-radiologists. ImageJ and OsiriX® yield results comparable to professional radiological
software iNtuition®.
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que for many procedures including liver resections [116]. Although this type of surgery is tech‐
nically more demanding and thereby time-consuming [117, 118], it proved to be beneficial for
patients with less pain and better recovery compared to open liver surgery [119-121].
6.1. The history of laparoscopic surgery
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the German surgeon Kelling reported on the endoscopic visualization of the peritoneal cavity
in an anesthetized dog using a Nitze cystoscope (1887) in 1902 [122]. Following the introduction
of endoscopic inspection of the abdominal contents in an animal model, fellow countryman
Jacobeus started experimenting with laparoscopy in human cadavers as well asliving humans.
In 1911 he reported on 80 laparoscopic examinations of the abdominal cavity [123, 124]. In the
years thereafter the laparoscopic approach was enhanced with the introduction of illumination
techniques, advancement in lens systems, the use of more than one single trocar and induction
of pneumoperitoneum (Goetze and Veress). The era of therapeutic laparoscopy was then born,
making it possible to minimize damage of treatment and avoid large incisions for many
gastrointestinal operations. However, it was not until 1987 that the first laparoscopic chole‐
cystectomy was performed [115].
At first, liver surgery was thought to be unsuitable for laparoscopic techniques since it might
impose the risk of gas embolisms and major blood loss during transection of the liver. Also,
sceptics pointed out the suspected risk of trocar site metastases in skin incisions. Gradually,
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and safety of laparoscopic resections for liver tumours in centres with extensive experience in
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and camerawork and needs to trust the material even more compared to open surgery. For
patients the most important presumed advantages of the laparoscopic procedure are reduced
blood loss [119, 120], less postoperative pain [118, 127, 131], earlier functional recovery [127,
130], shorter postoperative hospital stay [118, 120, 121, 127, 130-132] and improved cosmetic
aspects [127, 130]. Reoperations are reported to be easier due to reduced adhesions [127,
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available evidence is primarily based on case-series and identifies a technique that is repro‐
ducible with limited morbidity and mortality. In a consensus statement on laparoscopic liver
resections, Buell J et al [133] concluded that resection of segments 2 and 3 by the laparoscopic
approach should be the standard of care. In that same year a large international study reported
comparable encouraging results concerning the superiority of laparoscopic liver resections in
terms of complications from 109 patients: the complication rate was only 12% and there were
no perioperative deaths [134]. Median hospital length of stay was 4 days. Negative margins
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resections in oncologic surgery. This is confirmed in a recent meta-analysis on short and long-
term outcomes after laparoscopic and open resection. This study included a total of 26 studies,
incorporating a population of 1678 patients [135]. Although laparoscopic liver resections
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resulted in longer operation time, most endpoints were superior for the laparoscopic approach
compared with open resection, including reduced blood loss, portal clamp time, overall and
liver specific complications, ileus and length of hospital stay. As for the long-term outcomes,
no difference was found for oncologic outcomes between the laparoscopic and open surgical
techniques. Therefore, it was concluded that the laparoscopic liver resection was a feasible
alternative to open surgery in experienced hands [135].
7. Enhanced Recovery After Surgery (ERAS) or fast-track liver surgery
Another recent development in elective liver surgery is the introduction of Enhanced Recovery
After Surgery (ERAS) programmes, also referred to as fast track perioperative care. These
multimodal enhanced recovery programmes proved to be beneficial in open colonic and liver
surgery [136, 137]. The multimodal recovery programme is evidence based and combines
several interventions in perioperative care to reduce the stress response and organ dysfunction
with a focus on enhancing recovery [137, 138]. In patients undergoing colorectal surgery, the
ERAS® programme enabled earlier recovery and consequently shorter length of hospital stay
[137-140]. Also, reduction of postoperative morbidity in patients undergoing intestinal
resection was reported [141-144]. In other fields of elective surgery similar programmes have
also shown a reduction in hospital stay of several days [145, 146].
One of the pioneers of the fast track colonic surgery is the Danish surgeon Henrik Kehlet. He
treated 60 consecutive patients with colonic resection in a fast track surgery programme and
reported a median postoperative hospital stay of 2 days. At that time, patients undergoing a
colonic resection usually required 5 to 10 days postoperative hospital stay [147, 148]. Previ‐
ously, he stressed the importance of a multimodal approach in order to improve rehabilitation
after surgery (figure 6) [149]. This rehabilitation programme after surgery combined a number
of interventions to reduce stress of the surgical intervention, risk of organ dysfunction and loss
of functional capacity. Stress induced organ dysfunction, pain, nausea and vomiting, ileus,
hypoxemia and sleep disturbances, immobilisation and semi-starvation had to be reduced.
Factors were identified that contribute to postoperative functional deterioration. These were
actually traditional postoperative care principles such as use of drains, nasogastric tubes,
fasting regimes and bed rest. Kehlet initiated a multimodal programme that abandoned the
traditional care principles and introduced innovations such as: carbohydrate loading before
surgery, regional anaesthetic techniques, maintenance of normal temperature during surgery,
minimally invasive or laparoscopic surgical techniques, optimal treatment of postoperative
pain and prophylaxis of nausea and vomiting [139, 150]. This programme improved postop‐
erative recovery, physical performance and pulmonary function and reduced hospital length
of stay [142].
In collaboration with Kehlet, the Enhanced Recovery After Surgery (ERAS) group was initiated
to investigate the perioperative care in four other hospitals (Royal Infirmary, Edinburgh, UK,
The Karolinska Institutet at Ersta Hospital, Stockholm, Sweden, the University Hospital of
Nothern Norway, Tromso, Noway and Maastricht University Medical Centre) [151]. Thus,
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with Kehlet’s programme as a starting point, a new evidence based programme was developed
incorporating different aspects leading to faster recovery. Preoperative counselling, perioper‐
ative intravenous fluid restriction, optimal pain relief preferably without the use of opioid
analgesia, early oral nutrition, enforced mobilisation, no nasogastric tubes and no drains are
the key elements of this protocol (figure 7). Since the colonic programme showed improve‐
ments in recovery, the liver surgeons of the ERAS® group (Maastricht, Edinburgh and Tromso)
set up an ERAS-programme for every patient undergoing open liver resection [136]
(www.erassociety.org).
So far, the ERAS programmes have shown promising results with respect to improved
recovery and outcome in open elective colorectal and liver surgery [136, 137]. One of the first
studies on ERAS for liver surgery showed that the majority of patients treated within this
multimodal enhanced recovery programme tolerated fluid within four hours of surgery and
a normal diet one day after surgery. As an effect of the accelerated functional recovery, these
patients were discharged two days earlier than the patients treated with traditional care,
without significant differences in readmission, morbidity and mortality rates [136].
These results were confirmed in a recent systematic review including seven studies on fast-
track programmes for hepatopancreatic resections, incorporating more than 550 patients
treated in fast track setting [152]. This study showed that the primary hospital stay was reduced
significantly after the introduction of a multimodal perioperative care programme for open
liver surgery [152]. Moreover, there were no significant differences in rates of readmission,
morbidity and mortality.
7.1. Synergy of ERAS and laparoscopic liver surgery
For solid tumours in the liver, the open approach for resection is gradually replaced by the
laparoscopic technique in many expert centres worldwide. The results, mostly from cohort
studies, suggest benefits with notably shorter postoperative stay [120]. Recently, the added
value of a fast-track ERAS-programme in laparoscopic liver surgery specifically has been
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Figure 6. Multimodal interventions may lead to a reduction in postoperative morbidity and improved recovery. [149]
Figure adapted with kind permission from Kehlet et al. 1997.
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elucidated [153]. A group consisting of patients undergoing laparoscopic liver resections in an
ERAS-setting was compared with historical data from consecutive laparoscopic liver resec‐
tions performed either in that same centre before the introduction of the ERAS-programme or
in other major liver centres in the Netherlands performing laparoscopic liver surgery in a
traditional perioperative care programme.
• A significant difference with a median of two days in time to full functional recovery was
observed between the ERAS-treated group and the traditional care group. The difference in
median hospital length of stay (LOS) of two days between these two groups did not attain
significance. The authors suggested that it was probably due to the small number of patients
in this multicentre pilot-study. Apart from faster functional recovery in patients in the
enhanced recovery group, this study also showed reduced blood loss in this group.
• As from a historical perspective, this multicentre fast-track laparoscopic liver resection
study was the first study to explore the effect of ERAS and laparoscopic surgery. This small
study suggests that a multimodal enhanced recovery programme for laparoscopic liver
surgery is feasible, safe and may lead to accelerated functional recovery and reduction in
length of hospital stay. With these findings it may be concluded that the additional effect of
ERAS leads to an improvement of liver surgery and outcome.
Early mobilisation
Warm air body































Figure 7. Important elements of the Enhanced Recovery After Surgery programme. [138] Figure adapted with kind
permission from Fearon et al. 2005.
8. Recent developments in hepatic malignancies
As for the recent developments in the treatment of liver diseases, these can be mainly divided
into surgical and non-surgical treatment modalities. Developments in surgical treatment can
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be divided in true surgical and perioperative care improvements. The focus is on the surgical
treatments in this chapter, but some thoughts will also be spent on the non-surgical treatment
modalities, an interesting and expanding field of expertise.
For malignant liver tumours, the majority of which are colorectal liver metastases, the main
concern is the resectability if colorectal cancer is diagnosed. Colorectal cancer is one of the most
common causes of cancer related death worldwide [38] and more than half of patients with
colorectal cancer will develop liver metastases [39]. Unfortunately, only 20% of the patients
can be treated with surgical resection of these liver metastases [154]. The remaining 80% of the
patients present with lesions, which are not suitable for a safe resection. This can be caused by
large diameters of the lesions, location of the lesion near vascular and biliary structures and
extrahepatic disease. Also, the number of lesions can be the cause of non-resectability: resection
can only be carried out safely if 25-30% of functioning liver remains after resection [155]. The
non-surgical treatment by means of chemotherapy for the patients with unresected liver
metastases has proven very successful in decreasing the size and number of liver lesions. It
was shown that new chemotherapy regimens could change the previously unresectable liver
metastases into resectable liver disease [156]. With neoadjuvant chemotherapy more patients
with colorectal liver metastases can be offered a treatment with curative intent [156]. It was
concluded that neoadjuvant chemotherapy enables liver resection in some patients with
initially unresectable colorectal metastases. Long-term survival proved to be similar to that
reported for a priori surgical candidates [56]. As for the future perspective of chemotherapy,
neoadjuvant treatment will improve curability and long-term survival for selected patients.
Other non-surgical therapies for malignant liver disease are external irradiation (whole liver
irradiation) [157, 158], stereotactic liver irradiation [159-162] and injectable small radioactive
particles that irradiate the tumours within the liver (e.g. Yttrium-90(90Y) radio-embolisation
[163, 164], radioactive holmium microspheres [165, 166]). These modalities may have curative
potential but future studies have to be awaited. Another attractive field of development are
the thermal ablative therapies for unresectable liver metastases. These ablative thermal
therapies can be used either percutaneously or in adjunct with surgery and have shown to
decrease focal liver lesions [167-170]. Microwave ablation is a tumour destruction method to
treat patients with unresectable liver lesions [169]. It can be used with a single insertion of the
probe and it was shown to be a safe and effective method for treating unresectable hepatic
tumours, with a low rate of local recurrence [170]. Overall survival is comparable to alternative
ablation modalities [169].
8.1. Future perspectives
As for surgical treatments, different treatment strategies have been developed to increase the
number of patients suitable for surgery as described earlier. Current research has focussed on
improving resectability in terms of the quantity of resected liver tissue, but at the same time
studies focussed on reducing perioperative distress in patients undergoing liver resections by
multimodal perioperative treatment protocols and minimally invasive surgery. Since the
introduction of laparoscopic liver surgery in 1992, more liver resections have been performed
with this minimally invasive approach for primary and secondary malignant liver lesions [129,
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elucidated [153]. A group consisting of patients undergoing laparoscopic liver resections in an
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tions performed either in that same centre before the introduction of the ERAS-programme or
in other major liver centres in the Netherlands performing laparoscopic liver surgery in a
traditional perioperative care programme.
• A significant difference with a median of two days in time to full functional recovery was
observed between the ERAS-treated group and the traditional care group. The difference in
median hospital length of stay (LOS) of two days between these two groups did not attain
significance. The authors suggested that it was probably due to the small number of patients
in this multicentre pilot-study. Apart from faster functional recovery in patients in the
enhanced recovery group, this study also showed reduced blood loss in this group.
• As from a historical perspective, this multicentre fast-track laparoscopic liver resection
study was the first study to explore the effect of ERAS and laparoscopic surgery. This small
study suggests that a multimodal enhanced recovery programme for laparoscopic liver
surgery is feasible, safe and may lead to accelerated functional recovery and reduction in
length of hospital stay. With these findings it may be concluded that the additional effect of
ERAS leads to an improvement of liver surgery and outcome.
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134, 153]. For future perspectives, some gain might be expected from even less invasive
modalities as the first reports on single incision laparoscopic resections have been presented
[171-173]. Also, a two-stage laparoscopic approach for malignant liver disease and the robotic
approach for liver resections have been published [174-176].
As discussed previously in this chapter, the recent developments in liver surgery include the
introduction of laparoscopic surgery and enhanced recovery programmes, which focus on
improvement of postoperative recovery and/or shorter hospital length of stay. A significantly
accelerated recovery after open liver resection was previously reported if patients were
managed within a multimodal ERAS protocol. Median hospital length of stay was reduced
from 8 to 6 days (25%) [136]. Moreover, since there was a delay between recovery and discharge
of the patients a further reduction of stay should be possible. Regarding the results of previous,
non-randomised randomized studies and case series, it seems that laparoscopic left lateral liver
sectionectomy is associated with shorter hospital length of stay, less postoperative pain, better
quality of life and a faster recovery [177]. In most trials aiming at a reduction of hospital length
of stay, surgery and/or perioperative management are not standardised. No randomised trials
have hitherto been reported to study the added value of ERAS and/or laparoscopy for liver
surgery. There is a need for a randomised controlled trial covering these aspects of improving
the recovery and outcome of liver surgery.
9. Liver transplantation
Liver transplantation surgery is one of the main advances in hepatic surgery. Until recently,
it was considered to be too complex, since artificial organ support, like haemodialysis in renal
failure, was considered impossible. The term liver transplantation was first used in an article
of Welch (NY, USA) in 1955 [178]. The first experimental liver transplantation surgery was
performed on animals (dogs) in the 1950s and 1960s by Starzl (Denver, USA, figure 8) and
Moore (Boston, USA). These transplantations failed as a result of the stagnation of blood in the
mesenterial vessels and a lack of blood flow to the heart after clamping the inferior vena cava.
Methods for a venovenous bypass to the superior vena cava were developed, whereupon
transplantation seemed to be realizable. Despite the fact that immunosuppressive drugs
became available at that time, most grafts were rejected though. As a result, only a few dogs
survived [178-181].
9.1. The history of liver transplantation in humans
In 1963 the first three orthotropic liver transplantations in humans were performed by Starzl
and colleagues. All livers came from non-heart beating donors (NHBDs). Although the first
transplantation was performed in one session, the second and third took two sessions; the first
session was designated for the preparation of the removal of the liver from the donor and in
the second session the liver was removed and transplanted in the recipient after the donor
died. In the donor patient extracorporeal perfusion was performed via the femoral vein and
artery. The structures in the hepatoduodenal ligament were cut through and the liver was
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taken out with the vena cava. In the recipient the liver was taken out likewise and a venovenous
bypass was made to circumvent the hemodynamic effects of clamping the vena cava [182].
Immunosuppressive therapy, by ways of azathioprine and prednisone, was applied since these
drugs were proven to be effective in renal transplantation [183]. The first patient was a three-
year-old boy with biliary atresia who died during the operation due to haemorrhage, the
second and third patient were adult males suffering from liver cancer who died 7 and 22 days
postoperative, as a result of lung embolism [182]. Starzl then decided to take a break to have
a period of reflection. Four years later, in 1967, he decided to try again and he then performed
the first successful liver transplantation with a one-year-survival [184].
Infections were frequently occurring complications [185]. The most important complication of
these early transplantations however, was severe blood loss. This was caused by manipulation
of abdominal veins which had been under great pressures due to chronic liver diseases [179].
The first orthotropic liver transplantation in Europe was performed in Cambridge in 1968 by
Calne [186]. In the same year consensus was achieved concerning the concept of cerebral death.
From that moment on, heart-beating donation with donor organs originating from heart
beating, brain dead donors was possible [184]. Nowadays the above described venovenous
bypass has been abandoned in many centres in Europe. Since the beginning of the 1990’s most
centres use the so called ‘piggyback’ technique. The liver is exposed from the vena cava after
which the vena cava is partially clamped longitudinally. After the liver has been flushed with
albumin to remove ischemic waste products, a side-to-side cavocaval anastomosis is made. In
doing so, the hemodynamic stability of the patient is guaranteed. Then, the portal liaison is
Figure 8. Thomas E. Starzl (1926).
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doing so, the hemodynamic stability of the patient is guaranteed. Then, the portal liaison is
Figure 8. Thomas E. Starzl (1926).
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made by an end-to-end anastomosis, the liver is perfused and the arterial anastomosis is made.
Finally the biliary ducts are connected by way of end-to-end anastomosis and in case of
sclerosis a Roux-en-Y-reconstruction [187, 188].
9.2. Immunsuppressive drugs
The discovery and appliance of immunosuppressive medication to prevent graft rejection has
been an important development in transplantation surgery. Despite the fact that graft rejection
has been a serious problem during the early years of liver transplantation, many transplanted
patients survived more than 20 years as a result of this immunosuppressive therapy with an
azathioprine-prednisone cocktail. Some time later, a third immunosuppressive drug, antilym‐
phocyte-globulin (ALG), was added to the therapy [178, 189, 190]. Then Calne discovered the
possibility to use cyclosporin A, a calcineurin inhibitor, as an immunosuppressive drug [191].
After cyclosporine A was first used in renal transplantations in 1980 [192], it was then applied
in liver transplantation and the one-year-survival rate in liver transplantation turned out to
have increased to 80% [193]. Currently Tacrolimus (FK 506), also a calcineurin inhibitor, is
recommended [194-197]. A detailed overview of the development and the working mecha‐
nisms of immunosuppressive drugs is beyond the scope of this chapter.
9.3. Split liver transplantation
The concept of liver transplantation has been developed gradually, which made it a widely
accepted treatment with an increasing number of indications and good survival rates. This
caused a shortage of donor organs, especially among children, and long waiting lists. New
techniques had to be developed to answer to this growing demand. In 1984 Bismuth developed
the reduced-size adult liver transplantation; an adult left lobe was transplanted into a child.
This is a unique method, only applicable in liver transplantation surgery because of its
segmental anatomy with independently functioning parts [198]. Further development of
segmental liver surgery resulted in the split liver transplantation (SLT); the donor liver is
splitted, the left part (segment 2 and 3 with the common hepatic duct and common hepatic
artery) is transplanted into a child and the right part (segment 1, 4-7 with the vena cava) into
an adult. In the recipient of the left liver part, the vena cava is preserved and an anastomosis
is made with the left hepatic vein. The other anastomoses are made in the usual way. In the
recipient of the right liver part, an anastomosis is made between the right hepatic artery of the
donor liver and the common hepatic artery of the recipient by means of a saphenous vein
interposition graft. Two intrahepatic biliary ducts are connected with the jejunum through a
Roux-en-Y loop, the other anastomosis are executed in the usual way [199]. There are two ways
of splitting the liver, in situ and ex situ, both with its (dis)advantages. The main disadvantage
of in situ splitting is a longer operation time and therefore the need for a haemodynamically
stable patient. Splitting ex situ on the other hand, is done in blood vacuum. The time of cold
ischemia is longer and it is harder to distinguish structures from each other. Hence, strict donor
selection is essential and there is a trend to only select donors <50 years or who are heamody‐
namically stable. Bile spill is reported as the most common complication. Other complications
are an insufficient hepatic artery, portal vein thrombosis, intra-abdominal haemorrhage and
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gastro-intestinal bleeding. Mortality rates of 11% have been reported [200, 201]. In Europe, in
2003, 89% of all liver transplantations consisted of full-size transplantations, 4% of SLT’s and
5% of reduced-liver transplantations. In specialized centres, the survival rates of these
techniques are comparable to the survival rates of regular transplantation [202].
9.4. Living-donor liver transplantation (LDLT)
In 1987 Raia (Brazil) developed the living-donor liver transplantation (LDLT) from an adult
into a child. The operation itself was successful, but the recipient child died due to a transfusion
reaction [203]. The first successful LDLT from mother to son with a left liver lobe was per‐
formed in Australia by Strong [204] after which this method was refined by many other
pioneers. It is a very difficult operation technique in which precise knowledge of the anatomy
is a prerequisite. Because of a great shortage of donor organs in Asia, most experience with
the LDLT was gained there. Innovative surgery was the only possibility to tide over this
shortage. These techniques seemed to be effective; waiting-list-related mortality among
children was reduced to almost 0% [205, 206]. Since Fan (Honk Kong) introduced the adult-
to-adult living liver transplantation with a hemi-liver (dependent on the size of donor and
recipient either the right or left lobe is transplanted) in 1997, the availability of donor livers for
adults increased [207].
The main advantage of LDLT is limitation of warm ischemia because operations can be planned
simultaneously [208]. The results of LDLT are comparable to those of regular (orthotopic) liver
transplantation. According to the Japanese Liver Transplantation Society the 5-year-survival
rate in adults is 69%. In children this rate is significantly higher with 83% [205]. In the USA the
reported survival rate in adults is 80% [209]. In Europe, a 5-year-survival of 75% (80% in
children, 66% in adults) between 1991 and 2001 was reported [202, 205]. In Europe, in 2003,
only 1.6% of all liver transplantations consisted of LDLT [202].
The main disadvantages of  this  technique are the potential  complications in the healthy
donor  and  the  psychological  impact  [189,  210].  The  number  of  postoperative  complica‐
tions in donors is reported to be 20%. Worldwide 10 (0.15%) donor deaths have been re‐
ported. The mortality rate in Europe, in 2010, was 0.2% (6/2906) [211]. The critical period
for death and primary dysfunction is within 6 months from the operation. In a graft too
small for the recipient, dysfunction will develop with hyperbilirubinemia, ascites and liv‐
er function failure resulting in coagulation disorders and renal  failure.  A graft  which is
too big for the recipient will  result  in necrosis because of shortage in blood supply.  Be‐
sides good patient selection, proper calculation to determine the correct graft size has to
be done to prevent these complications [189, 205].
9.5. Improving survival
In 1997 the Institute of Medicine (USA) declared NHBD-organs to be medically effective and
ethically acceptable [178]. From that time on, the trend exists to use NHBD- and marginal
organs (livers with steatosis) again to tide over the shortage of donor organs and shorten the
waiting lists. Marginal livers are associated with primary non-function [212]. The main
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possibility to use cyclosporin A, a calcineurin inhibitor, as an immunosuppressive drug [191].
After cyclosporine A was first used in renal transplantations in 1980 [192], it was then applied
in liver transplantation and the one-year-survival rate in liver transplantation turned out to
have increased to 80% [193]. Currently Tacrolimus (FK 506), also a calcineurin inhibitor, is
recommended [194-197]. A detailed overview of the development and the working mecha‐
nisms of immunosuppressive drugs is beyond the scope of this chapter.
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caused a shortage of donor organs, especially among children, and long waiting lists. New
techniques had to be developed to answer to this growing demand. In 1984 Bismuth developed
the reduced-size adult liver transplantation; an adult left lobe was transplanted into a child.
This is a unique method, only applicable in liver transplantation surgery because of its
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segmental liver surgery resulted in the split liver transplantation (SLT); the donor liver is
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is made with the left hepatic vein. The other anastomoses are made in the usual way. In the
recipient of the right liver part, an anastomosis is made between the right hepatic artery of the
donor liver and the common hepatic artery of the recipient by means of a saphenous vein
interposition graft. Two intrahepatic biliary ducts are connected with the jejunum through a
Roux-en-Y loop, the other anastomosis are executed in the usual way [199]. There are two ways
of splitting the liver, in situ and ex situ, both with its (dis)advantages. The main disadvantage
of in situ splitting is a longer operation time and therefore the need for a haemodynamically
stable patient. Splitting ex situ on the other hand, is done in blood vacuum. The time of cold
ischemia is longer and it is harder to distinguish structures from each other. Hence, strict donor
selection is essential and there is a trend to only select donors <50 years or who are heamody‐
namically stable. Bile spill is reported as the most common complication. Other complications
are an insufficient hepatic artery, portal vein thrombosis, intra-abdominal haemorrhage and
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gastro-intestinal bleeding. Mortality rates of 11% have been reported [200, 201]. In Europe, in
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5% of reduced-liver transplantations. In specialized centres, the survival rates of these
techniques are comparable to the survival rates of regular transplantation [202].
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reaction [203]. The first successful LDLT from mother to son with a left liver lobe was per‐
formed in Australia by Strong [204] after which this method was refined by many other
pioneers. It is a very difficult operation technique in which precise knowledge of the anatomy
is a prerequisite. Because of a great shortage of donor organs in Asia, most experience with
the LDLT was gained there. Innovative surgery was the only possibility to tide over this
shortage. These techniques seemed to be effective; waiting-list-related mortality among
children was reduced to almost 0% [205, 206]. Since Fan (Honk Kong) introduced the adult-
to-adult living liver transplantation with a hemi-liver (dependent on the size of donor and
recipient either the right or left lobe is transplanted) in 1997, the availability of donor livers for
adults increased [207].
The main advantage of LDLT is limitation of warm ischemia because operations can be planned
simultaneously [208]. The results of LDLT are comparable to those of regular (orthotopic) liver
transplantation. According to the Japanese Liver Transplantation Society the 5-year-survival
rate in adults is 69%. In children this rate is significantly higher with 83% [205]. In the USA the
reported survival rate in adults is 80% [209]. In Europe, a 5-year-survival of 75% (80% in
children, 66% in adults) between 1991 and 2001 was reported [202, 205]. In Europe, in 2003,
only 1.6% of all liver transplantations consisted of LDLT [202].
The main disadvantages of  this  technique are the potential  complications in the healthy
donor  and  the  psychological  impact  [189,  210].  The  number  of  postoperative  complica‐
tions in donors is reported to be 20%. Worldwide 10 (0.15%) donor deaths have been re‐
ported. The mortality rate in Europe, in 2010, was 0.2% (6/2906) [211]. The critical period
for death and primary dysfunction is within 6 months from the operation. In a graft too
small for the recipient, dysfunction will develop with hyperbilirubinemia, ascites and liv‐
er function failure resulting in coagulation disorders and renal  failure.  A graft  which is
too big for the recipient will  result  in necrosis because of shortage in blood supply.  Be‐
sides good patient selection, proper calculation to determine the correct graft size has to
be done to prevent these complications [189, 205].
9.5. Improving survival
In 1997 the Institute of Medicine (USA) declared NHBD-organs to be medically effective and
ethically acceptable [178]. From that time on, the trend exists to use NHBD- and marginal
organs (livers with steatosis) again to tide over the shortage of donor organs and shorten the
waiting lists. Marginal livers are associated with primary non-function [212]. The main
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problem of NHBD’s is the prolonged period of warm ischemia. A distinction between
controlled NHBD’s (Maastricht type I and II) and uncontrolled NHBD’s (Maastricht type III
and IV) is made. Controlled NHBD’s provide organs with less chance on ischemic damage and
a greater chance on good post-transplantation function. In this group of patients a controlled
end of vital support takes place after which a circulation stop occurs. In most cases the patient
is already in the operation theatre with a transplantation team on site. This way, the time of
warm ischemia is minimalised. In uncontrolled NHBD’s a non-foreseen circulation stop
occurs, usually before arrival in the hospital, possibly followed by resuscitation. A variable
period of warm ischemia occurs with a higher chance on complications [212, 213]. Cold
ischemia causes damage of sinusoidal endothelial cells and warm ischemia of hepatocytes
[214]. Besides, warm ischemia intensifies the effects of cold ischemia and predisposes for a
higher incidence of ischemic biliary structures both on the short and the long term. In such
cases, re-transplantation might be needed [215]. Since the University of Wisconsin Solution,
introduced in 1988, has become the golden standard for cooling donor organs and the
maximum period of cold ischemia has been limited to 12 hours, ischemic damage due to cold
ischemia has been reduced drastically with increased graft survival [202]. However, as a
consequence of warm ischemia graft survival is lower in NHBD’s compared to heart-beating
donors with a 3-year-survival of 63.3% versus 72.1%. The risk of primary non-function is also
significantly higher among NHBD’s: 11.8% versus 6.4% [189, 216]. For this reason NHBD’s can
be used to overcome organ shortage, on condition that strict criteria are maintained: strict
donor (<60 years) and recipient (haemodynamically stable and not intubated) selection, minor
warm (<30 minutes) and cold (<8 hours) ischemia, no extensive steatosis of the donor liver and
the use of at most one inotropic drug (to prevent hypotension and thus hypoperfusion) [212].
With the gradual progression in surgical competences, management of postoperative com‐
plications  and the  development  of  immunosuppressive  drugs  to  prevent  graft  rejection,
liver transplantation has nowadays become a widely accepted treatment for an increasing
number of indications and it has become the golden standard for patients with irreversi‐
ble decompensated chronic liver failure (e.g. as a result of cirrhosis or hepatocellular can‐
cer)  and  acute  liver  failure  (e.g.  as  a  result  of  hepatic  viruses  or  intoxication  with
medication). In the early days cancer was the most common indication for liver transplan‐
tation. In Europe, however, with 50% the most important indication for liver transplanta‐
tion was cirrhosis (of which 24% was caused by a virus (especially Hepatitis C) and 18%
by  alcohol  abuse),  followed  by  pathology  of  the  biliary  tract  (13%),  primary  liver  tu‐
mours (10%), of which hepatocellular cancer is the most common, and acute liver failure
(9%), with fulminant viral hepatitis as the most important cause. The most important indi‐
cations in children are biliary atresia (56%) and metabolic diseases (21%) [202]. Due to the
development of different methods and techniques, organ shortage has been reduced and
waiting lists have been shortened. Hence, one can conclude that liver transplantation is a
recent and very important advancement, which has expanded in a short time. It is a per‐
fect example of modern and innovative medical practice, in which the challenge remains
to find solutions to new problems time after time.
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1. Introduction
That every surgeon will experience complications is a certainty. Indeed, it has been said that
if one has no complications, one does not do enough surgery. Yet, major surgical complications
are often avoidable and frequently the result of three tragic surgical errors. These errors are:
1) a failure to possess sufficient knowledge of normal anatomy and function, 2) a failure to
recognize anatomic variants when they present, and 3) a failure to ask for help when uncertain
or unsure. All but the last of these errors are remediable with study and effort. In regard to the
last error, most surgeons learn humility through their failures and at the expense of their
patients, while some never learn.
The importance of a precise knowledge of parenchymal structure, blood supply, lymphatic
drainage, and variant anatomy on outcome is perhaps nowhere more apparent than in
hepatobiliary surgery. Though the liver was historically an area where few brave men dared
to tread, and even less returned a second time, recent advances in anesthetic technique and
perioperative care now permit hepatic surgery to be performed with low morbidity and
mortality in both academic and community hospitals. That said, surgeons are duly cautioned
to inventory their own skills and knowledge before venturing forward into the right upper
quadrant. This chapter will review functional biliary and hepatic anatomy necessary for the
conduct of safe and successful hepatic operations.
2. The liver
2.1. Surface anatomy
The liver is situated primarily in the right upper quadrant, and usually benefits from complete
protection by the lower ribs. Most of the liver substance resides on the right side, although it
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is not uncommon for the left lateral segment to arch over the spleen. The superior surface of
the liver is molded to, and abuts the undersurface of the diaphragm on both the right and left
side. During normal inspiration, the liver may rise as high as the 4th or 5th intercostal space on
the right.
The liver itself is completely invested with a peritoneal layer except on the posterior surface
where it reflects onto the undersurface of the diaphragm to form the right and left triangular
ligaments. The liver is attached to the diaphragm and anterior abdominal wall by three
separate ligamentous attachments, namely the falciform, round, and right and left triangular
ligaments. (Figure 1) The falciform ligament, which is situated on the anterior surface of the
liver, arises from the anterior leaflets of the right and left triangular ligaments and terminates
inferiorly where the ligamentum teres enters the umbilical fissure. The gallbladder is normally
attached to the undersurface of the right lobe and directed towards the umbilical fissure. At
the base of the gallbladder fossa, is the hilar transverse fissure through which the main portal
structures to the right lobe course. Additional important landmarks on the posterior liver
surface include a deep vertical groove in which the inferior vena cava is situated, and a large
bare area (i.e. no peritoneal coating) that is normally in contact with the right hemidiaphragm
and right adrenal gland. The left lateral segment of the liver arches over the caudate lobe that
is situated to the left of the vena cava. The caudate lobe is demarcated on the left by a fissure
containing the ligamentum venosum (a remnant of the umbilical vein). Additional left-sided
important surface features include the gastrohepatic omentum that is located between the left
lateral segment and the stomach. The gastrohepatic omentum may contain replaced or
accessory hepatic arteries. Finally, there is usually a thick fibrous band that envelops the vena
cava high on the right side and runs posteriorly towards the lumbar vertebrae. This band,
which is sometimes referred to as the vena caval ligament, must be divided to allow proper
visualization of the suprahepatic cava and right hepatic veins.
2.2. Parenchyma (the liver substance)
The liver is comprised of two main lobes, a large right lobe, and a smaller left lobe. Although
the falciform ligament is often thought to divide the liver into a right and left lobe, the true
“anatomic” or “surgical” right and left lobes of the liver are defined by the course of the middle
hepatic vein that runs through the main scissura of the liver. Although various descriptions
of the internal anatomy of the liver have been proffered over the last century, Couinaud’s (1957)
segmental anatomy of the liver is the most useful for the surgeon.
Couinaud’s classification system divides the liver into four unique sectors based upon the
course of the three major hepatic veins. Each sector receives its blood supply from a separate
portal pedicle. Within the main scissura lies the middle hepatic vein that courses from the left
side of the suprahepatic vena cava to the middle of the gallbladder fossa. Functionally, the
main scissura divides the liver into separate right and left lobes which have independent portal
inflow, and biliary architecture. (Figures 2 and 3) An artificial line that divides the liver into
right and left hemilivers is known as Cantlie’s line. The right hepatic veins runs within the
right segmental scissura and divides the right lobe into a right posterior and anterior sector,
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while the left hepatic veins follows the path of the falciform ligament and divides the left lobe
into a medial and lateral segment.
The right and left lobes of the liver are further divided into 8 segments based upon the
distribution of the portal scissurae. At the hilus, the right portal vein pursues a very short course
(1 – 1.5 cm) before entering the liver. Once entering the hepatic parenchyma, the portal vein
divides into a right anterior sectoral branch that arches vertical in the frontal plane of the liver,
and a posterior sectoral branch that follows a more posterolateral course. The right portal vein
supplies the anterior (or anteriomedial) and posterior (or posterolateral) sectors of the right
lobe. The branching pattern of these sectoral portal veins subdivides the right liver into 4
segments -- segments V (anterior and inferior) and VIII (anterior and superior) form the
anterior sector, and segments VI (posterior and inferior) and VII (posterior and superior) form
the posterior sector.
Figure 1. Surface anatomy of the liver. (A) Anterior surface, (B) Inferior surface of the liver. Reprinted with permission
from Hahn and Blumgary, Functional Hepatic and Radiologic Anatomy in Surgery of the Liver and Biliary Tract (3rd
Edition), Blumgart LH, Fong Y and WH Jarnigan (Eds.) Lippincott Williams, London, UK (2000).
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In contrast to the right portal vein, the left portal vein has a long extrahepatic length (3 – 4 cm)
coursing beneath the inferior portion of the quadrate lobe (segment 4B) enveloped in a
peritoneal sheath (the hilar plate.) Upon reaching the umbilical fissure, the left portal vein runs
anteriorly and superiorly within the liver substances, and gives off horizontal branches to the
quadrate lobe medially (segments IV A (superior) and B (inferior)) and to the left lateral
segment (segments III (inferior) and II (superior)) (Figure 3).
The caudate lobe (segment I) is neither part of the left nor right lobes, though it lies mostly on
the left side (Figure 4). More precisely, it is the most dorsal portion of the liver situated behind
the left lobe and embracing the retrohepatic vena cava from the hilum to the diaphragm. The
portion of the caudate lobe that is within the right liver is usually quite small, and lies posterior
to segment 4B. Figure 3 illustrates the location of the caudate lobe which lies between the left
portal vein and vena cava on the far left, and the middle hepatic vein and vena cava within
the right liver. The caudate lobe receives blood vessels and biliary tributaries from both the
right and left hemilivers. The right side of the caudate lobe, and the caudate process, receives
its blood supply from branches of the right or main portal vein, while the left side of the caudate
receives a separate vessel from the left portal vein.
Figure 2. Segmental and sectoral anatomy of the liver. The liver is divided into three main scissura by the right, middle,
and left hepatic vein branches. The middle hepatic courses through the main scissura (or Cantlie’s line) and divides the
liver into right and left lobes. The right hepatic vein divides the right liver into anterior (segments V and VIII) and pos‐
terior (segment VI and VII) sectors, while the left hepatic vein divides the left lobe into medial (segments IV A and B)
and lateral segments (segments II and III). The intrahepatic branching of the right and left hepatic ducts, arteries and
portal veins (shown) in the horizontal plane of the liver divides the liver into eight separate segments. The caudate
lobe (segment I) is neither part or left lobe. Rather the caudate lobe receives venous and arterial branches from both
the right and left side of the liver, and drains directly into the inferior vena cava.
Hepatic Surgery44
Aberrant segmental anatomy of the liver is uncommon. The presence of a diminutive left lobe
is the most common anomaly reported, and is important only because it may serve as a
limitation to the performance of extended right hepatectomies. Although reports of “accesso‐
ry” hepatic lobes are not uncommon, these do not represent separate segments with inde‐
pendent intrahepatic vascular supply, but rather elongated tongues of normal liver tissue.
Riedel’s lobe is the most common of these “accessory” lobes, and is reality, an extended piece
of liver tissue hanging inferiorly off segments 5 and 6.
Figure 3. Couninaud’s segmental anatomy of the liver. (a) in vivo appearance; (b) ex vivo appearance.
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3. Hepatic veins (Outflow)
The three major hepatic veins (the right, middle and left) comprise the main outflow tract for
the liver, although additional veins (5 – 20) of varying size are always present as direct
communications between the vena cava and the posterior surface of the right lobe. Uniquely,
the caudate lobe (segment I) drains principally through direct communications with the
retrohepatic cava.
The hepatic veins lie within the three major scissura of the liver dividing the parenchyma into
the right anterior and posterior sectors, and the right and left lobes. (Fig 2 and 3) The right
hepatic vein lies within the right scissura (or segmental fissure) and divides the right lobe into
a posterior (segments VI and VII) and anterior (segments V and VIII) sector. The middle hepatic
veins lies within the main hepatic scissura (or main lobar fissure) separating the right anterior
sector (segments V and VIII) from the quadrate lobe (segment IV). Anatomically, the main
scissura separates the liver into right and left lobes. The left hepatic vein lies within the left
scissura (or the left segmental fissure) in line with or just to the right of the falciform ligament.
The right hepatic vein drains directly into the suprahepatic cava, while the middle and left
hepatic vein coalesce to form a short common trunk prior to entry. The umbilical vein
represents an additional alternative site of venous efflux. It is located beneath the falciform
ligament and eventually terminates in the left hepatic vein, or less commonly in the confluence
of the middle and left hepatic veins.
4. Hepatic venous anomalies
Although the outline above should suffice as cursory knowledge of hepatic venous anatomy,
it is far from exhaustive. For example, large accessory right hepatic veins are commonly found,
and an appreciation of these structures on axial imaging can be important to operative
planning. If a large accessory right hepatic vein is present, it may be possible to divide all three
major hepatic veins in the performance of an extended left hepatectomy. Most importantly,
the surgeon embarking on hepatic resection should have a thorough knowledge of the internal
course of the hepatic veins, as the danger posed by hepatic venous bleeding cannot be
overestimated.
5. Hepatic arteries (Inflow)
5.1. Extrahepatic arterial anatomy
“Normal” hepatic arterial anatomy is anything but normal. Indeed standard celiac arterial
anatomy as described in most major anatomic treatise is found in only 60% of cases. An
accessory hepatic artery refers to a vessel that supplies a segment of liver that also receives
blood supply from a normal hepatic artery. An aberrant hepatic artery is called a replaced
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 hepatic artery as it represents the only blood supply to a specific hepatic segment. Precise
knowledge of normal hepatic arterial anatomy is necessary to appreciate abnormal anatomy
and will be the focus of this section.
The celiac artery arises from the aorta shortly after it emerges through the diaphragmatic
hiatus. The celiac trunk itself is typically very short and divides into the left gastric, splenic,
and common hepatic artery shortly after its origin. (Figure 5). The common hepatic artery
typically passes forward for a short distance in the retroperitoneum where it them emerges at
the superior border of the pancreas and left side of the common hepatic duct. The common
hepatic artery supplies 25% of the liver’s blood supply, with the portal vein supplying the
remaining 75%.
Figure 4. Caudate lobe anatomy. The caudate lobe is situated to the left of the inferior vena cava (I.V.C). Superiorly
the caudate lobe is covered by segments II and III which are reflected laterally in this diagram. The ligamentum ve‐
nousm, a remnant of the fetal umbilical vein, courses across the anterior surface of the caudate lobe to enter the left
hepatic vein. The caudate lobe runs along the retrohepatic vena cava from the common trunk of the middle and left
hepatic veins (M.H.V., L.H.V.) to the portal vein (P.V.) inferiorly. (Left (L.P.V.) and right portal vein (R.P.V.)). Small venous
tributaries drain the caudate lobe directly into to the I.V.C. On its medial surface, the caudate lobe is attached to the
right liver by the caudate process.
After arising from the celiac axis, the common hepatic artery turns upward and runs lateral
and adjacent to the common bile duct. The gastroduodenal artery that supplies the proximal
duodenum and pancreas is typically the first branch of the common hepatic artery. The right
gastric artery takes off shortly thereafter and continues within the lesser omentum along the
lesser curve of the stomach. At this point the common hepatic artery is referred to as the proper
hepatic artery. The proper hepatic artery courses towards the hilum, and soon divides into the
right and left hepatic arteries. Prior to the bifurcation, a small cystic artery branches off to
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3. Hepatic veins (Outflow)
The three major hepatic veins (the right, middle and left) comprise the main outflow tract for
the liver, although additional veins (5 – 20) of varying size are always present as direct
communications between the vena cava and the posterior surface of the right lobe. Uniquely,
the caudate lobe (segment I) drains principally through direct communications with the
retrohepatic cava.
The hepatic veins lie within the three major scissura of the liver dividing the parenchyma into
the right anterior and posterior sectors, and the right and left lobes. (Fig 2 and 3) The right
hepatic vein lies within the right scissura (or segmental fissure) and divides the right lobe into
a posterior (segments VI and VII) and anterior (segments V and VIII) sector. The middle hepatic
veins lies within the main hepatic scissura (or main lobar fissure) separating the right anterior
sector (segments V and VIII) from the quadrate lobe (segment IV). Anatomically, the main
scissura separates the liver into right and left lobes. The left hepatic vein lies within the left
scissura (or the left segmental fissure) in line with or just to the right of the falciform ligament.
The right hepatic vein drains directly into the suprahepatic cava, while the middle and left
hepatic vein coalesce to form a short common trunk prior to entry. The umbilical vein
represents an additional alternative site of venous efflux. It is located beneath the falciform
ligament and eventually terminates in the left hepatic vein, or less commonly in the confluence
of the middle and left hepatic veins.
4. Hepatic venous anomalies
Although the outline above should suffice as cursory knowledge of hepatic venous anatomy,
it is far from exhaustive. For example, large accessory right hepatic veins are commonly found,
and an appreciation of these structures on axial imaging can be important to operative
planning. If a large accessory right hepatic vein is present, it may be possible to divide all three
major hepatic veins in the performance of an extended left hepatectomy. Most importantly,
the surgeon embarking on hepatic resection should have a thorough knowledge of the internal
course of the hepatic veins, as the danger posed by hepatic venous bleeding cannot be
overestimated.
5. Hepatic arteries (Inflow)
5.1. Extrahepatic arterial anatomy
“Normal” hepatic arterial anatomy is anything but normal. Indeed standard celiac arterial
anatomy as described in most major anatomic treatise is found in only 60% of cases. An
accessory hepatic artery refers to a vessel that supplies a segment of liver that also receives
blood supply from a normal hepatic artery. An aberrant hepatic artery is called a replaced
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 hepatic artery as it represents the only blood supply to a specific hepatic segment. Precise
knowledge of normal hepatic arterial anatomy is necessary to appreciate abnormal anatomy
and will be the focus of this section.
The celiac artery arises from the aorta shortly after it emerges through the diaphragmatic
hiatus. The celiac trunk itself is typically very short and divides into the left gastric, splenic,
and common hepatic artery shortly after its origin. (Figure 5). The common hepatic artery
typically passes forward for a short distance in the retroperitoneum where it them emerges at
the superior border of the pancreas and left side of the common hepatic duct. The common
hepatic artery supplies 25% of the liver’s blood supply, with the portal vein supplying the
remaining 75%.
Figure 4. Caudate lobe anatomy. The caudate lobe is situated to the left of the inferior vena cava (I.V.C). Superiorly
the caudate lobe is covered by segments II and III which are reflected laterally in this diagram. The ligamentum ve‐
nousm, a remnant of the fetal umbilical vein, courses across the anterior surface of the caudate lobe to enter the left
hepatic vein. The caudate lobe runs along the retrohepatic vena cava from the common trunk of the middle and left
hepatic veins (M.H.V., L.H.V.) to the portal vein (P.V.) inferiorly. (Left (L.P.V.) and right portal vein (R.P.V.)). Small venous
tributaries drain the caudate lobe directly into to the I.V.C. On its medial surface, the caudate lobe is attached to the
right liver by the caudate process.
After arising from the celiac axis, the common hepatic artery turns upward and runs lateral
and adjacent to the common bile duct. The gastroduodenal artery that supplies the proximal
duodenum and pancreas is typically the first branch of the common hepatic artery. The right
gastric artery takes off shortly thereafter and continues within the lesser omentum along the
lesser curve of the stomach. At this point the common hepatic artery is referred to as the proper
hepatic artery. The proper hepatic artery courses towards the hilum, and soon divides into the
right and left hepatic arteries. Prior to the bifurcation, a small cystic artery branches off to
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provide blood supply to the gallbladder. While coursing through the hepatoduodenal
ligament, the proper hepatic artery, common bile duct, and portal vein are enveloped in a
peritoneal sheath within the hepatoduodenal ligament. The proper hepatic artery bifurcates
earlier than the common bile duct and portal vein. In 80% of cases the right hepatic artery
courses posterior to the common hepatic duct before entering the hepatic parenchyma. In 20%
of cases, the right hepatic artery may lie anterior to the common hepatic duct. Upon reaching
the hepatic parenchyma, the right hepatic artery branches into right anterior (Segments V and
VIII), and right posterior sectoral branches (Segments VI and VII). The posterior sectoral branch
initially runs horizontally through the hilar transverse fissure (of Gunz), normally present at
the base of Segment V and adjacent to the caudate process. The left hepatic artery runs
vertically towards the umbilical fissure where it gives off a small branch (often called the
middle hepatic artery) to segment IV, before continuing on to supply Segments II and III.
Additional small branches of the left hepatic artery supply the caudate lobe (segment I),
although caudate arterial branches may also arise from the right hepatic artery. The sectoral
and segmental bile ducts and portal veins follow the course of the hepatic artery branches.
Intrahepatic branching of these structures will be discussed in more detail below.
The blood supply to the common bile duct is varied and multiple. Branches of the common
hepatic, gastroduodenal, and pancreaticoduodenal arteries have all been shown to provide
arterial supply at various levels.
5.2. Hepatic arterial anomalies
Variations in the arterial blood supply to the liver are common. Although the hepatic artery
typically arises from the celiac axis, complete replacement of the main hepatic artery or its’
Figure 5. Normal celiac axis anatomy. The presence of the right hepatic (R.H.), middle hepatic (M.H.) to segment IV,
and left hepatic (L.H.) artery are demonstrated.
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branches occur with variable frequency. Similarly, duplication or accessory hepatic arterial
branches, particularly an accessory left hepatic artery, may be more the norm than an anomaly.
The most common hepatic arterial anomaly involving a replaced vessel is a replaced right
hepatic artery (25%). In this situation, the replaced right hepatic artery usually arises from the
superior mesenteric artery and runs lateral and posterior to the portal vein within the hepa‐
toduodenal ligament. (Figure 6). In rare instances, the entire common hepatic artery, or its’
individual branches may arise directly off the celiac trunk or aorta.
6. Portal venous anatomy
The portal vein is formed by a union of the superior mesenteric vein (SMV) and splenic vein
behind the neck and body of the pancreas. In up to one third of all individuals, the inferior
mesenteric vein may also join this confluence. Venous tributaries from the pancreas may also
drain directly into the portal vein, and generally correspond to the arterial supply. More
precisely, there are anterior, posterior, superior and inferior pancreatic vessels. In addition,
the left gastric vein and inferior mesenteric vein typically drain into the splenic vein, but in
rare instances these vessels may enter the portal vein directly. Surgical dogma states that there
are no venous branches on the anterior surface of the portal vein and, for the most part this is
true – most veins enter the portal vein tangentially from the side. However, having paid
homage to surgical dogma, the reality is that small anterior venous branches may exist, and
any manipulation posterior to the pancreatic neck and anterior to the portal vein should be
performed with maximum operative exposure and care.
Access to the portal vein is typically obtained by identifying the superior mesenteric vein on
the inferior surface of the pancreas. In some circumstances it is necessary to first locate the
middle colic vein within the transverse mesocolon and follow it inferiorly to the SMV. The
length of the SMV is highly variable, and may range from only a few millimeters up to 4 cm.
In many circumstances the SMV is made up of 2 to 4 venous branches that coalesce shortly
before joining the portal vein rather than a single dominant vein. The inferior pancreatico‐
duodenal vein, which can be quite prominent, is the only vein that normally enters the SMV
directly. Proper identification of this vein is necessary to avoid injury (and often substantial
blood loss). All other pancreatic venous tributaries enter the portal vein, rather than the SMV.
In the performance of a pancreaticoduodenal resection, early division of the common bile duct
(CBD) provides great exposure to the right lateral side of the portal vein, and facilitates the
creation of a “tunnel” above the portal vein, and beneath the pancreas. Once a determination
has been made regarding the resectability of the pancreatic lesion, we favor early transection
of the common bile duct. If the tumor later proves unresectable, a palliative end to side
bilioenteric bypass can be performed.
In addition to those variants described above, there are additional (but rare) congenital
anomalies of the portal vein with which the surgeon should be aware. The two most common
are an anterior portal vein that lies above the pancreas and duodenum, and a direct entry of
the portal vein into the inferior vena cava-- a congenital “portocaval” shunt. The importance
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provide blood supply to the gallbladder. While coursing through the hepatoduodenal
ligament, the proper hepatic artery, common bile duct, and portal vein are enveloped in a
peritoneal sheath within the hepatoduodenal ligament. The proper hepatic artery bifurcates
earlier than the common bile duct and portal vein. In 80% of cases the right hepatic artery
courses posterior to the common hepatic duct before entering the hepatic parenchyma. In 20%
of cases, the right hepatic artery may lie anterior to the common hepatic duct. Upon reaching
the hepatic parenchyma, the right hepatic artery branches into right anterior (Segments V and
VIII), and right posterior sectoral branches (Segments VI and VII). The posterior sectoral branch
initially runs horizontally through the hilar transverse fissure (of Gunz), normally present at
the base of Segment V and adjacent to the caudate process. The left hepatic artery runs
vertically towards the umbilical fissure where it gives off a small branch (often called the
middle hepatic artery) to segment IV, before continuing on to supply Segments II and III.
Additional small branches of the left hepatic artery supply the caudate lobe (segment I),
although caudate arterial branches may also arise from the right hepatic artery. The sectoral
and segmental bile ducts and portal veins follow the course of the hepatic artery branches.
Intrahepatic branching of these structures will be discussed in more detail below.
The blood supply to the common bile duct is varied and multiple. Branches of the common
hepatic, gastroduodenal, and pancreaticoduodenal arteries have all been shown to provide
arterial supply at various levels.
5.2. Hepatic arterial anomalies
Variations in the arterial blood supply to the liver are common. Although the hepatic artery
typically arises from the celiac axis, complete replacement of the main hepatic artery or its’
Figure 5. Normal celiac axis anatomy. The presence of the right hepatic (R.H.), middle hepatic (M.H.) to segment IV,
and left hepatic (L.H.) artery are demonstrated.
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branches occur with variable frequency. Similarly, duplication or accessory hepatic arterial
branches, particularly an accessory left hepatic artery, may be more the norm than an anomaly.
The most common hepatic arterial anomaly involving a replaced vessel is a replaced right
hepatic artery (25%). In this situation, the replaced right hepatic artery usually arises from the
superior mesenteric artery and runs lateral and posterior to the portal vein within the hepa‐
toduodenal ligament. (Figure 6). In rare instances, the entire common hepatic artery, or its’
individual branches may arise directly off the celiac trunk or aorta.
6. Portal venous anatomy
The portal vein is formed by a union of the superior mesenteric vein (SMV) and splenic vein
behind the neck and body of the pancreas. In up to one third of all individuals, the inferior
mesenteric vein may also join this confluence. Venous tributaries from the pancreas may also
drain directly into the portal vein, and generally correspond to the arterial supply. More
precisely, there are anterior, posterior, superior and inferior pancreatic vessels. In addition,
the left gastric vein and inferior mesenteric vein typically drain into the splenic vein, but in
rare instances these vessels may enter the portal vein directly. Surgical dogma states that there
are no venous branches on the anterior surface of the portal vein and, for the most part this is
true – most veins enter the portal vein tangentially from the side. However, having paid
homage to surgical dogma, the reality is that small anterior venous branches may exist, and
any manipulation posterior to the pancreatic neck and anterior to the portal vein should be
performed with maximum operative exposure and care.
Access to the portal vein is typically obtained by identifying the superior mesenteric vein on
the inferior surface of the pancreas. In some circumstances it is necessary to first locate the
middle colic vein within the transverse mesocolon and follow it inferiorly to the SMV. The
length of the SMV is highly variable, and may range from only a few millimeters up to 4 cm.
In many circumstances the SMV is made up of 2 to 4 venous branches that coalesce shortly
before joining the portal vein rather than a single dominant vein. The inferior pancreatico‐
duodenal vein, which can be quite prominent, is the only vein that normally enters the SMV
directly. Proper identification of this vein is necessary to avoid injury (and often substantial
blood loss). All other pancreatic venous tributaries enter the portal vein, rather than the SMV.
In the performance of a pancreaticoduodenal resection, early division of the common bile duct
(CBD) provides great exposure to the right lateral side of the portal vein, and facilitates the
creation of a “tunnel” above the portal vein, and beneath the pancreas. Once a determination
has been made regarding the resectability of the pancreatic lesion, we favor early transection
of the common bile duct. If the tumor later proves unresectable, a palliative end to side
bilioenteric bypass can be performed.
In addition to those variants described above, there are additional (but rare) congenital
anomalies of the portal vein with which the surgeon should be aware. The two most common
are an anterior portal vein that lies above the pancreas and duodenum, and a direct entry of
the portal vein into the inferior vena cava-- a congenital “portocaval” shunt. The importance
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Figure 6. Hepatic arterial anomalies. (a) Replaced main hepatic artery arising from the superior mesenteric artery
(SMA), (b) Independent origin of the right and left hepatic artery from the celiac axis, (c) Replaced right hepatic artery
arising from the SMA, (d) Replaced left hepatic artery arising from the left gastric artery (LGA), (e) Accessory right hep‐
atic artery arising from the SMA, (f) Accessory left hepatic artery arising from the LGA.
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of careful dissection around the portal vein cannot be overemphasized. Inadvertent injury or
transection of the portal vein or a main tributary is difficult to correct, and remains among the
most lethal of surgical errors.
7. Intrahepatic arterial and portal venous anatomy
Throughout the course of the liver, the sectoral and segmental bile ducts, hepatic arteries and
portal venous branches run together. (Figure 7) Whereas knowledge of precise intrahepatic
biliary anatomy is of most practical value to the operating surgeon, further detail about
intrahepatic anatomy will be discussed in that section below.
8. The biliary tract
Extrahepatic hepatic biliary anatomy
The extrahepatic biliary system consists of the extrahepatic portions of the right and left bile
ducts that join to form a single biliary channel coursing through the posterior head of the
pancreas to enter the medial wall of the second portion of the duodenum. The gallbladder and
cystic duct form an additional portion of this extrahepatic biliary system that typically joins
with the terminal portion of the common hepatic duct to form the common bile duct. In most
instances, the confluence of the right and left bile ducts lies to the right of the umbilical fissure
and anterior to the right branch of the portal vein. The right hepatic duct is typically short (<
1cm) and branches into a right posterior sectoral duct (segments VI/VII) and a right anterior
sectoral duct (segments V/VIII) shortly after entering the hepatic parenchyma. In contrast, the
left hepatic duct has a relatively long extrahepatic course (2- 3 cm) along the base of the
quadrate lobe (segment IV) and enters the hepatic parenchyma at the umbilical fissure.
Lowering the hilar plate (i.e., connective tissue enclosing the left hepatic elements and Glisson’s
capsule) at the base of the quadrate lobe provides great exposure to both the biliary hilum and
the extrahepatic portion of the left hepatic duct. (Figure 8)
9. The common bile duct
By convention, the entry point of the cystic duct divides the main extrahepatic biliary channel
into the common hepatic duct (above) and the common bile duct (below). The common bile
duct continues inferiorly positioned anterior to the portal vein, and lateral to the common
hepatic artery. If the hepatic artery bifurcates early, the right hepatic artery may be seen
coursing below (80% of the time) the common bile duct (see details above). At the junction of
the 1st and 2nd portion of the duodenum, the common bile duct ducks behind the duodenum
posterior to the pancreatic head, in order to enter the medial wall of the duodenum (2nd portion)
at the sphincter of Oddi.
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Figure 6. Hepatic arterial anomalies. (a) Replaced main hepatic artery arising from the superior mesenteric artery
(SMA), (b) Independent origin of the right and left hepatic artery from the celiac axis, (c) Replaced right hepatic artery
arising from the SMA, (d) Replaced left hepatic artery arising from the left gastric artery (LGA), (e) Accessory right hep‐
atic artery arising from the SMA, (f) Accessory left hepatic artery arising from the LGA.
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of careful dissection around the portal vein cannot be overemphasized. Inadvertent injury or
transection of the portal vein or a main tributary is difficult to correct, and remains among the
most lethal of surgical errors.
7. Intrahepatic arterial and portal venous anatomy
Throughout the course of the liver, the sectoral and segmental bile ducts, hepatic arteries and
portal venous branches run together. (Figure 7) Whereas knowledge of precise intrahepatic
biliary anatomy is of most practical value to the operating surgeon, further detail about
intrahepatic anatomy will be discussed in that section below.
8. The biliary tract
Extrahepatic hepatic biliary anatomy
The extrahepatic biliary system consists of the extrahepatic portions of the right and left bile
ducts that join to form a single biliary channel coursing through the posterior head of the
pancreas to enter the medial wall of the second portion of the duodenum. The gallbladder and
cystic duct form an additional portion of this extrahepatic biliary system that typically joins
with the terminal portion of the common hepatic duct to form the common bile duct. In most
instances, the confluence of the right and left bile ducts lies to the right of the umbilical fissure
and anterior to the right branch of the portal vein. The right hepatic duct is typically short (<
1cm) and branches into a right posterior sectoral duct (segments VI/VII) and a right anterior
sectoral duct (segments V/VIII) shortly after entering the hepatic parenchyma. In contrast, the
left hepatic duct has a relatively long extrahepatic course (2- 3 cm) along the base of the
quadrate lobe (segment IV) and enters the hepatic parenchyma at the umbilical fissure.
Lowering the hilar plate (i.e., connective tissue enclosing the left hepatic elements and Glisson’s
capsule) at the base of the quadrate lobe provides great exposure to both the biliary hilum and
the extrahepatic portion of the left hepatic duct. (Figure 8)
9. The common bile duct
By convention, the entry point of the cystic duct divides the main extrahepatic biliary channel
into the common hepatic duct (above) and the common bile duct (below). The common bile
duct continues inferiorly positioned anterior to the portal vein, and lateral to the common
hepatic artery. If the hepatic artery bifurcates early, the right hepatic artery may be seen
coursing below (80% of the time) the common bile duct (see details above). At the junction of
the 1st and 2nd portion of the duodenum, the common bile duct ducks behind the duodenum
posterior to the pancreatic head, in order to enter the medial wall of the duodenum (2nd portion)
at the sphincter of Oddi.
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Figure 7. Portal pedicles. This cutaway view of the right and left portal pedicles demonstrate the course of the right
and left portal veins, hepatic ducts, and hepatic arteries as they enter the hepatic parenchyma
Figure 8. Lowering of the hilar plate and exposure of the left hepatic duct. The left hepatic duct runs at the base of
the quadrate lobe (segment 4) and is covered by the hilar plate (a layer of connective tissue running between the hep‐
atoduodenal ligament and the Glissonian capsule of the liver. Dividing this layer demonstrates the extrahepatic por‐
tion of the left hepatic duct arising from the umbilical fissure. (Numbers 2,3,4 and refer to segmental liver anatomy).
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10. Gallbladder and cystic duct
The gallbladder is situated on the undersurface of the anterior inferior sector (segment V) of
the right lobe of the liver. Though often densely adherent, it is separated from the liver
parenchyma by the cystic plate, a layer of connective tissue arising from Glisson’s capsule and
in continuity with the hilar plate at the base of segment IV. In rare instances, the gallbladder
is only loosely attached to the undersurface of the liver by a thinly veiled mesentery and may
be prone to volvulus. Variations in gallbladder anatomy are rare. These variations include (a)
bilobed or double gallbladders, (b) septated gallbladders, or (c) gallbladder diverticulums.
The cystic duct arises from the infindibulum of the gallbladder and runs medial and inferior
to join the common hepatic duct. The cystic duct is typically 1-3 mm in diameter, and can range
from 1 mm to 6 cm in length depending upon its union with the common hepatic duct. Spiral
mucosal folds, referred to as valves of Heister, are present in the mucosa of the cystic duct.
Cystic duct abnormalities are uncommon and include (a) double cystic ducts (very rare), (b)
aberrant cystic duct entry sites, and (c) aberrant cystic duct union with the common hepatic
duct. Aberrant entry points for the cystic duct include a low entry into the common hepatic
duct retroduodenal or retropancreatic, and anomalous entry into the main right hepatic duct
or sectoral duct. Aberrant union of the cystic duct and common hepatic duct can take multiple
forms including (a) absence of a cystic duct (< 1%), (b) parallel course of the cystic duct and
common hepatic artery with a shared septum (20%), and (c) an anomalous passage of the cystic
duct posterior to the common hepatic duct with entry on the medial wall (5%). (Figure 9)
Figure 9. Variations in cystic ductal anatomy.
Typically, the cystic artery is a single vessel that courses lateral and posterior to the cystic duct.
However, variations in the anatomy of the cystic artery are common. (Figure 10) Multiple cystic
arteries, origin of the cystic artery from a segmental or lobar hepatic artery, aberrant course of
the cystic artery over the cystic duct, and various other anomalies have been reported. A careful
intra-operative determination of cystic artery anatomy is important to prevent unnecessary
hemorrhage during cholecystectomy.
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Figure 7. Portal pedicles. This cutaway view of the right and left portal pedicles demonstrate the course of the right
and left portal veins, hepatic ducts, and hepatic arteries as they enter the hepatic parenchyma
Figure 8. Lowering of the hilar plate and exposure of the left hepatic duct. The left hepatic duct runs at the base of
the quadrate lobe (segment 4) and is covered by the hilar plate (a layer of connective tissue running between the hep‐
atoduodenal ligament and the Glissonian capsule of the liver. Dividing this layer demonstrates the extrahepatic por‐
tion of the left hepatic duct arising from the umbilical fissure. (Numbers 2,3,4 and refer to segmental liver anatomy).
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10. Gallbladder and cystic duct
The gallbladder is situated on the undersurface of the anterior inferior sector (segment V) of
the right lobe of the liver. Though often densely adherent, it is separated from the liver
parenchyma by the cystic plate, a layer of connective tissue arising from Glisson’s capsule and
in continuity with the hilar plate at the base of segment IV. In rare instances, the gallbladder
is only loosely attached to the undersurface of the liver by a thinly veiled mesentery and may
be prone to volvulus. Variations in gallbladder anatomy are rare. These variations include (a)
bilobed or double gallbladders, (b) septated gallbladders, or (c) gallbladder diverticulums.
The cystic duct arises from the infindibulum of the gallbladder and runs medial and inferior
to join the common hepatic duct. The cystic duct is typically 1-3 mm in diameter, and can range
from 1 mm to 6 cm in length depending upon its union with the common hepatic duct. Spiral
mucosal folds, referred to as valves of Heister, are present in the mucosa of the cystic duct.
Cystic duct abnormalities are uncommon and include (a) double cystic ducts (very rare), (b)
aberrant cystic duct entry sites, and (c) aberrant cystic duct union with the common hepatic
duct. Aberrant entry points for the cystic duct include a low entry into the common hepatic
duct retroduodenal or retropancreatic, and anomalous entry into the main right hepatic duct
or sectoral duct. Aberrant union of the cystic duct and common hepatic duct can take multiple
forms including (a) absence of a cystic duct (< 1%), (b) parallel course of the cystic duct and
common hepatic artery with a shared septum (20%), and (c) an anomalous passage of the cystic
duct posterior to the common hepatic duct with entry on the medial wall (5%). (Figure 9)
Figure 9. Variations in cystic ductal anatomy.
Typically, the cystic artery is a single vessel that courses lateral and posterior to the cystic duct.
However, variations in the anatomy of the cystic artery are common. (Figure 10) Multiple cystic
arteries, origin of the cystic artery from a segmental or lobar hepatic artery, aberrant course of
the cystic artery over the cystic duct, and various other anomalies have been reported. A careful
intra-operative determination of cystic artery anatomy is important to prevent unnecessary
hemorrhage during cholecystectomy.
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Figure 10. Cystic artery anomalies. (A) Typical course, (B) Double cystic artery, (C) cystic artery crossing anterior to the
main bile duct, (D) cystic artery originating from the right branch of the hepatic artery and crossing the common hep‐
atic duct anteriorly, (E) cystic artery originating from the left branch of the hepatic artery, (F) cystic artery originating
from the gastroduodenal artery, (G) the cystic artery may arise from the celiac axis, (H) cystic artery originating from a
replaced right hepatic artery.
10. Intrahepatic bile duct anatomy
An understanding of intrahepatic ductal anatomy is obviously important and vital to the
performance of a high biliary anastomoses for cholangiocarcinoma (Klatskin tumors), an
intrahepatic bilioenteric bypass, and complex hepatic resections such as caudate lobectomy,
and left and right trisegmentectomy. The right and left lobes of the liver are drained separately
by the right and left hepatic ducts. In contrast, 1 – 4 smaller ducts from either the right or left
hepatic ducts drain the caudate lobe. Within the liver parenchyma, the intrahepatic biliary
radicals parallel the major portal triad tributaries directed toward each hepatic segment of the
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liver. More specifically, bile ducts are usually situated superior to its complementary portal
vein branch, while the hepatic artery lies inferiorly.
The left hepatic duct drains all 3 segments of the left liver. (Segment II, III, and IV). In some
textbooks, segment IV, the quadrate lobe, is futher sub-divided into sub-segments (4A,
superior, and 4B, inferior). So conceptually, both the right and left hepatic ducts each drains 4
segments. Although the left hepatic duct originates within the liver and terminates in the
common hepatic duct, it is easier to describe its’ path in reverse since the extrahepatic areas
are readily visible to the operating surgeon. After the bifurcation into the right and left hepatic
ducts, the left duct courses towards the umbilical fissure along the under surface of segment
IVB above and behind the left branch of the portal vein. Access to this area can be gained by
lowering the hilar plate (described above). Several small branches from the quadrate lobe
(Segment 4) and the caudate lobe (Segment 1) may enter the left duct at this location. The left
hepatic duct is formed within the umbilical fissure by the segment III (lateral), and segment
IVB (medial) ducts. Following the course of the umbilical fissure vertically towards the
falciform ligament, the segment II (lateral), and segment IVA (medial) branches are formed.
Although a careful and tedious dissection is required to access the segmental biliary ducts for
anastomoses, (e.g., a segment III bypass), control of the segmental portal triads to all areas of
left lobe is readily achievable within the umbilical fissure. (see Figure 11)
Figure 11. Left portal vein pedicle. The union of the segment IV, II, and III portal veins within the umbilical fissure
forms the left portal vein. A separate segment I portal vein also enters the left portal vein before it coalesces with the
right portal vein at the hilus. Lines A, B, C, D demonstrate various lines of portal vein transection which are required to
complete various hepatic resections. Line A is the line of transection for completion of a left hepectecomy and caudate
lobectomy. Line B is the line of transection for completion of a left hepatectomy. Line C is the line of transection for a
segment II resection. Line D is the line of transection for a segment III resection.
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Figure 10. Cystic artery anomalies. (A) Typical course, (B) Double cystic artery, (C) cystic artery crossing anterior to the
main bile duct, (D) cystic artery originating from the right branch of the hepatic artery and crossing the common hep‐
atic duct anteriorly, (E) cystic artery originating from the left branch of the hepatic artery, (F) cystic artery originating
from the gastroduodenal artery, (G) the cystic artery may arise from the celiac axis, (H) cystic artery originating from a
replaced right hepatic artery.
10. Intrahepatic bile duct anatomy
An understanding of intrahepatic ductal anatomy is obviously important and vital to the
performance of a high biliary anastomoses for cholangiocarcinoma (Klatskin tumors), an
intrahepatic bilioenteric bypass, and complex hepatic resections such as caudate lobectomy,
and left and right trisegmentectomy. The right and left lobes of the liver are drained separately
by the right and left hepatic ducts. In contrast, 1 – 4 smaller ducts from either the right or left
hepatic ducts drain the caudate lobe. Within the liver parenchyma, the intrahepatic biliary
radicals parallel the major portal triad tributaries directed toward each hepatic segment of the
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liver. More specifically, bile ducts are usually situated superior to its complementary portal
vein branch, while the hepatic artery lies inferiorly.
The left hepatic duct drains all 3 segments of the left liver. (Segment II, III, and IV). In some
textbooks, segment IV, the quadrate lobe, is futher sub-divided into sub-segments (4A,
superior, and 4B, inferior). So conceptually, both the right and left hepatic ducts each drains 4
segments. Although the left hepatic duct originates within the liver and terminates in the
common hepatic duct, it is easier to describe its’ path in reverse since the extrahepatic areas
are readily visible to the operating surgeon. After the bifurcation into the right and left hepatic
ducts, the left duct courses towards the umbilical fissure along the under surface of segment
IVB above and behind the left branch of the portal vein. Access to this area can be gained by
lowering the hilar plate (described above). Several small branches from the quadrate lobe
(Segment 4) and the caudate lobe (Segment 1) may enter the left duct at this location. The left
hepatic duct is formed within the umbilical fissure by the segment III (lateral), and segment
IVB (medial) ducts. Following the course of the umbilical fissure vertically towards the
falciform ligament, the segment II (lateral), and segment IVA (medial) branches are formed.
Although a careful and tedious dissection is required to access the segmental biliary ducts for
anastomoses, (e.g., a segment III bypass), control of the segmental portal triads to all areas of
left lobe is readily achievable within the umbilical fissure. (see Figure 11)
Figure 11. Left portal vein pedicle. The union of the segment IV, II, and III portal veins within the umbilical fissure
forms the left portal vein. A separate segment I portal vein also enters the left portal vein before it coalesces with the
right portal vein at the hilus. Lines A, B, C, D demonstrate various lines of portal vein transection which are required to
complete various hepatic resections. Line A is the line of transection for completion of a left hepectecomy and caudate
lobectomy. Line B is the line of transection for completion of a left hepatectomy. Line C is the line of transection for a
segment II resection. Line D is the line of transection for a segment III resection.
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The right hepatic duct emerges from the liver at the base of segment V just to right of the
caudate process. This duct drains segments V, VI, VII, and VIII and originates at the junction
of the right posterior (segments VI and VII), and anterior (segments V and VIII) sectoral ducts.
The right posterior sectoral duct follows an almost horizontal course at the base of segments
V and VI that can often been seen lying within a transverse fissure on the superficial surface
of the liver. Segmental biliary branches from segments VI (inferior) and VII (superior) converge
to form the main right posterior sectoral duct. Segmental branches from segments V and VIII
form the right anterior sectoral duct. While the right posterior sectoral duct follows a horizontal
course, the right anterior sectoral duct runs almost vertical within segment V, and receives
branches from both segment V (inferior) and VIII (superior).
Biliary drainage of the caudate lobe is less predictable. Conceptually, the caudate lobe has three
distinct areas -- a right part, a left part, and the caudate process. In some instances three separate
bile ducts may be present. The caudate process represents a narrow bridge of tissue that
connects the caudate to the right lobe (segment V). In more than 75% of cases the caudate drains
into both the right and left hepatic ductal system, but isolated drainage into the right (< 10%),
or left hepatic duct (~15%) can occur.
11. Anomalous biliary drainage
Normal intra- and extrahepatic biliary anatomy is present in approximately 75 percent of cases.
(Figure 12) Every effort should be made to define existing intrahepatic anatomy based on pre-
operative imaging, since failure to do so may result in devastating complications. Anomalies
in both sectoral and segmental anatomy may exist together or separately. The more common
type of each of the anomalies will be described in more detail below.
Anomalous sectoral biliary anatomy
Although the union of the right and left hepatic duct typically occurs at the hilum, a triple
confluence of the right posterior and anterior sectoral ducts with the left hepatic duct may,
exist in up to ~15% of cases. (Figure 12) In 20% of cases, one of the right sectoral ducts, more
commonly the anterior sectoral duct, may enter the common hepatic duct distal to the
confluence. If this situation is not recognized it can be very dangerous, and represents a
common cause of injury during laparoscopic cholecystectomy. Less commonly (~5%), the right
posterior sectoral duct (and rarely the right anterior sectoral duct) may cross to enter the
intrahepatic portion of the left hepatic duct. Failure to appreciate this anomaly prior to right
or left hepatectomy, can lead to significant post-operative problems. Note some authorities
believe that this anomaly represents the most common intrahepatic biliary variations.
Anomalous segmental biliary anatomy
A large number of segmental biliary anomalies have been reported. Most are unimportant to
the surgeon and of anatomical interest only. Figure 13 illustrates the more common anomalies
that have been reported within the right lobe and the medial segment of the left lobe.
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Figure 12. Normal and aberrant sectoral ductal anatomy. (A) Typical ductal anatomy, (B) triple confluence, (C) Ectopic
drainage of a right sectoral duct into the common hepatic duct (C1, right anterior duct draining into the common
hepatic duct; C2, right posterior duct draining into the common hepatic duct), (D) ectopic drainage of a right sectoral
duct into the left hepatic ductal system (D1, right posterior sectoral duct draining into the left hepatic ductal system;
D2, right anterior sectoral duct draining into the left hepatic ductal system, (E) absence of the hepatic duct confluence,
(F) absence of right hepatic duct and ectopic drainage of the right posterior duct into the cystic duct.
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Figure 12. Normal and aberrant sectoral ductal anatomy. (A) Typical ductal anatomy, (B) triple confluence, (C) Ectopic
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Figure 13. Normal and aberrant segmental ductal anatomy. (A), variations of segment V, (B) variations of segment VI,




A comprehensive understanding of normal and aberrant anatomy is the cornerstone of
surgery. The truth of this statement is nowhere more apparent than in the performance of
complex hepatobiliary surgery. Mastery of the segmental anatomy of the liver, as well as a
comprehensive understanding of both normal and anomalous arterial, venous and biliary
anatomy, are the sine qua non for performing safe hepatic resections. Recent advances in peri-
operative management of patients with hepatobiliary diseases (detailed elsewhere in this
book), permit the surgeon to perform increasingly radical hepatic procedures (upon sicker
patients.) Although the expertise offered by our radiology and anesthesiology colleagues is
important, it is incumbent upon every surgeon who performs liver resection to be well
prepared. An age-old surgical axiom states “98% of the surgical outcome is determined in the
operating room.” A good outcome in the performance of hepatic resections requires one to
become a student of the game.
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1. Introduction
The liver is the largest gland in the body. The average human liver weighs approximately
1.5-1.7 kg, and holds a blood volume of approximately 500 ml. It receives approximately
25% of the cardiac output, of which 75% is supplied by the portal vein and the other 25% by
the hepatic artery. Its venous drainage is to the inferior vena cava via the hepatic veins. The
hepatic ductal system produces the bile which is then stored in the gall bladder.
The liver synthesizes most proteins, with the exception of gamma globulins and factor VIII.
It is also responsible for protein degradation, glucose homeostasis, fatty acid β-oxidation, bi‐
lirubin production and excretion. Hepatocytes are embryologically less differentiated; hence
the liver is the only organ capable of regeneration after surgical resection or trauma.
Hepatic blood flow is predominantly dependent upon systemic blood flow and pressure-
based on pressure flow regulation and hepatic arterial buffer response. There is also central
nervous system control of the hepatic blood flow via the thoracic sympathetic fibers. Sympa‐
thetic stimulation may cause the blood volume which is present in the liver to be expelled
into the circulation, thus providing additional circulatory volume if needed.
Hepatic blood flow is reduced by all anesthetic agents and techniques via reductions in hep‐
atic blood flow and hepatic oxygen uptake. The volatile agents, desflurane and sevoflurane
have the least significant effect on total hepatic blood flow. Other perioperative causes of a
reduction of hepatic blood flow include mechanical ventilation, hypercarbia, positive end-
expiratory pressure, hypotension, hemorrhage, hypoxemia and surgery. A significant de‐
crease in hepatic blood flow can result in parenchymal centrilobular necrosis when extreme
resulting in further worsening of perioperative liver dysfunction.
© 2013 Dalal and Lang; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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In liver disease, anesthetic drug distribution, metabolism and elimination may be altered.
Uptake and onset of anesthetic drug action is usually unaffected. Hepatic clearance of an
agent is dependent upon volume of distribution, functional hepatic blood flow, hepatic ex‐
traction ratio and hepatic microsomal activity. As a result, opioids may accumulate and the
pharmacological actions of drugs such as benzodiazepines maybe prolonged. In extreme sit‐
uations, actions of non-depolarizing muscle relaxants such as vecuronium and rocuronium
maybe also be prolonged.
The liver plays a critical role in coagulation as it is the principal site of synthesis for the ma‐
jority of clotting factors: II, V, VII, IX, X, XI, and XII. All coagulation factors except for VIII,
which is mainly produced by the endothelium, are markedly reduced in patients with liver
disease. Patients with chronic liver disease may also develop thrombocytopenia secondary
to splenomegaly caused by prolonged portal hypertension. Additionally, reduced levels of
thrombopoietin, which regulates platelet production in the liver, may also further contribute
to platelet counts in more advanced disease. Also, antithrombin-III (AT-III) levels fall due to
reduced synthesis and/or increased consumption due to fibrinolysis. All of the proteins in‐
volved in fibrinolysis except for tissue plasminogen activator (tPA) and plasminogen activa‐
tor inhibitor (PAI-1) are synthesized in the liver. However, tPA levels can be increased due
to decreased clearance by the liver predisposing patients to further risks of intra- and perio‐
perative hemorrhage. Hemostatic changes associated with surgical bleeding are thrombocy‐
topenia, platelet function defects, inhibition of platelet aggregation and adhesion by nitric
oxide and prostacyclin, decreased levels of coagulation factors: II, V, VII, IX, X, XI, quantita‐
tive and qualitative abnormalities of fibrinogen, low levels of α2-antiplasmin, Factor XIII
and thrombin activatable fibrinolysis inhibitor, and elevated tPA. Hemostatic changes asso‐
ciated with thrombosis are elevated vWF, decreased levels of ADAMTS-13 (a vWF cleaving
protease), and decreased levels of anti-coagulants: ATIII, Protein C and S, α2 macroglobulin,
elevated levels of heparin cofactor II, elevated VIII, decreased levels of plasminogen, normal
or increased PAI-1. Hypercoagulability can occur in patients with liver disease, especially
those with cholestatic disease.
In  the  setting  of  acute  liver  failure  (ALF),  the  coagulopathy  encountered  can  be  much
more severe.  Plasma concentrations of  coagulation factors  with the shortest  half-life  fall
first;  factors  V and VII  (12  hrs  and 4-6hrs  respectively)  and factors  II,VII  and X subse‐
quently. In a review of over 1000 patients with ALF by the US Acute Liver Failure Study
Group,  the  mean  international  normalization  ratio  (INR)  in  ALF was  3.8  +/-  4.0  (range
1.5 - >10) with most having a moderately prolonged INR (1.5 to 5) and only 19% with an
INR  >5.  Moreover,  thrombocytopenia  is  common  with  40%  of  patients  having  platelet
counts < 90,000 on admission. [1]
2. Pathophysiology of End Stage Liver Disease
Liver disease can be acute or chronic. Common causes of chronic liver disease are viral hep‐
atitis (B & C), autoimmune hepatitis, non-alcoholic steatohepatitis (NASH), Laennec’s cir‐
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rhosis, cryptogenic cirrhosis, and metabolic diseases such as hemachromatosis and Wilson’s
disease. Cholestatic causes of liver disease include primary biliary cirrhosis and primary
sclerosing cholangitis.
Predominant pathophysiological manifestation of liver disease is portal hypertension. There
is increased resistance to portal blood flow due to hepatic parenchymal scarring and fibro‐
sis, and splanchnic hyperemic resulting in hypersplenism, thrombocytopenia and the pro‐
gression formation of varices. Normal portal pressures are usually in the range of 5-12
mmHg. Portal hypertension is generally defined when any 2 of the following 3 criteria are
met: splenomegaly, ascites or bleeding esophageal varices. Portal pressures at this time are
usually > 20 mmHg.
The combination of decreased production of albumin and portal hypertension results in the
accumulation of ascites. It also occurs due to renal retention of sodium and water, and local‐
ization of this excess fluid in the peritoneal cavity. Tense ascites may decrease functional re‐
sidual capacity (FRC), adversely affect pulmonary gas exchange and increase risk of
aspiration. Hydrothorax or pleural effusions may produce atelectasis. Secondary hyperal‐
dosteronism may manifest as hypokalemic metabolic alkalosis. Additionally, there is intra-
and extra-pulmonary shunting, elevated mixed venous oxygen saturation (SvO2), altered
lactate metabolism. The hyperdynamic circulation is a result of decreased systemic vascular
resistance (SVR) and compensatory increased cardiac output to maintain tissue perfusion.
Inadequate synthesis of coagulation factors produces coagulopathy. There is delayed gastric
emptying creating putting the patient at-risk for aspiration. Increased ammonia levels (hy‐
perammonemia) can result in hepatic encephalopathy.
3. Other clinically relevant associations with patients with liver disease
includes
Portopulmonary hypertension (POPH) is a pulmonary hypertension syndrome with vascu‐
lar obstruction and increased resistance to pulmonary arterial flow due to varying degrees
of pulmonary endothelial/smooth muscle proliferation, vasoconstriction and in-situ throm‐
bosis. The development of POPH has not been demonstrated to correlate with the severity
of liver disease.
Hepatopulmonary syndrome (HPS) is characterized by arterial hypoxemia caused by intra-
pulmonary vascular dilatations. The clinical triad of 1) portal hypertension; 2) hypoxemia;
and 3) pulmonary vascular dilatations characterizes the clinical presentation of HPS [2].
Hepatorenal syndrome is a form of pre-renal acute kidney injury that occurs in decompen‐
sated cirrhosis. The syndrome is classified into two types: Type 1 is characterized by a dou‐
bling of the serum creatinine level to greater than 2.5 mg/dl in less than 2 weeks while Type
2 is characterized by a stable or slower progressive course of renal failure [3].
Hepatic encephalopathy occurs due to accumulation of circulating neurotoxins such as un‐
metabolized ammonia, gamma aminobutyric acid, gut-derived false neurotransmitters lead‐
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In liver disease, anesthetic drug distribution, metabolism and elimination may be altered.
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Hepatic Surgery62
rhosis, cryptogenic cirrhosis, and metabolic diseases such as hemachromatosis and Wilson’s
disease. Cholestatic causes of liver disease include primary biliary cirrhosis and primary
sclerosing cholangitis.
Predominant pathophysiological manifestation of liver disease is portal hypertension. There
is increased resistance to portal blood flow due to hepatic parenchymal scarring and fibro‐
sis, and splanchnic hyperemic resulting in hypersplenism, thrombocytopenia and the pro‐
gression formation of varices. Normal portal pressures are usually in the range of 5-12
mmHg. Portal hypertension is generally defined when any 2 of the following 3 criteria are
met: splenomegaly, ascites or bleeding esophageal varices. Portal pressures at this time are
usually > 20 mmHg.
The combination of decreased production of albumin and portal hypertension results in the
accumulation of ascites. It also occurs due to renal retention of sodium and water, and local‐
ization of this excess fluid in the peritoneal cavity. Tense ascites may decrease functional re‐
sidual capacity (FRC), adversely affect pulmonary gas exchange and increase risk of
aspiration. Hydrothorax or pleural effusions may produce atelectasis. Secondary hyperal‐
dosteronism may manifest as hypokalemic metabolic alkalosis. Additionally, there is intra-
and extra-pulmonary shunting, elevated mixed venous oxygen saturation (SvO2), altered
lactate metabolism. The hyperdynamic circulation is a result of decreased systemic vascular
resistance (SVR) and compensatory increased cardiac output to maintain tissue perfusion.
Inadequate synthesis of coagulation factors produces coagulopathy. There is delayed gastric
emptying creating putting the patient at-risk for aspiration. Increased ammonia levels (hy‐
perammonemia) can result in hepatic encephalopathy.
3. Other clinically relevant associations with patients with liver disease
includes
Portopulmonary hypertension (POPH) is a pulmonary hypertension syndrome with vascu‐
lar obstruction and increased resistance to pulmonary arterial flow due to varying degrees
of pulmonary endothelial/smooth muscle proliferation, vasoconstriction and in-situ throm‐
bosis. The development of POPH has not been demonstrated to correlate with the severity
of liver disease.
Hepatopulmonary syndrome (HPS) is characterized by arterial hypoxemia caused by intra-
pulmonary vascular dilatations. The clinical triad of 1) portal hypertension; 2) hypoxemia;
and 3) pulmonary vascular dilatations characterizes the clinical presentation of HPS [2].
Hepatorenal syndrome is a form of pre-renal acute kidney injury that occurs in decompen‐
sated cirrhosis. The syndrome is classified into two types: Type 1 is characterized by a dou‐
bling of the serum creatinine level to greater than 2.5 mg/dl in less than 2 weeks while Type
2 is characterized by a stable or slower progressive course of renal failure [3].
Hepatic encephalopathy occurs due to accumulation of circulating neurotoxins such as un‐
metabolized ammonia, gamma aminobutyric acid, gut-derived false neurotransmitters lead‐
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ing to altered neurotransmission by glutamate or altered cerebral energy homeostatsis. [4]
Clinically, it is manifested by neuropsychiatric abnormalities and generalized clonus on clin‐
ical examination.
4. Assessing perioperative risk
Patient operative risk is dictated by severity of liver disease, co-existing medical diseases
and type of surgery (i.e., upper abdominal, emergent, cardiac etc.) It may also be dependent
on s on the anesthetic conducted and ability to maintain of hepatic blood flow.
An important measure for assessing mortality risk is the Child-Pugh Classification. Though this
was first used to stratify risk for surgical correction of portal hypertension, it is also found to be
predictive of survival in cirrhosis. The score is assigned based upon bilirubin, albumin, pro‐
thrombin time (PT), ascites and encephalopathy. One point is given for each of the following: al‐
bumin > 3.5 g/dl, INR < 1.7, bilirubin <2mg/dl, no ascites, no encephalopathy. 2 points are given
for each of the following: Albumin 1.8- 3.5 g/dl, INR between1.7-2.3, bilirubin 2-3 mg/dl, slight to
moderate ascites, grade 1-2 encephalopathy. 3 points are given for each of the following: albu‐
min < 1.8 g/dl, INR >2.3, bilirubin > 3 mg/dl, tense ascites, grade 3-4 encephalopathy. Class A = 5-6
points, Class B = 7-9 points, Class C = 10-15 points. [5] Child Pugh A, B, C predicts a perioperative
mortality risk of 10, 30 and 80 % respectively. [6]
Other measures for predicting mortality include ascites, increased serum creatinine, preop‐
erative GI bleed, high ASA physical status score and previous abdominal surgery. Steatosis
and steatohepatitis may also be considered as risk factors for postoperative complications,
especially after abdominal procedures. The Model of End Liver Disease (MELD) score pre‐
dicts severity based upon serum creatinine, total bilirubin, and PT INR. It is used to estimate
long term survival, as well as list patients for liver transplantation with the United network
of Organ Sharing (UNOS). (need a reference here)
Elective surgery is contraindicated when the patient has acute viral hepatitis, alcoholic hepa‐
titis, fulminant hepatic failure, severe chronic hepatitis, is a Child Pugh C patient or has oth‐
er manifestations of end stage liver disease.
Patients with advanced liver disease should be effectively managed so that hepatic perfusion
and hepatic oxygen delivery are maximized l and sequelae of their liver disease such as hepatic
encephalopathy, cerebral edema, coagulopathy, hepatopulmonary syndrome, portopulmona‐
ry hypertension and portal hypertension has been identified and treated accordingly if possible.
5. Preoperative evaluation of patients with liver disease
Assessment of hepatic function includes evaluating risks for aggravating underlying liver
disease, extra-hepatic complications, alterations of hepatic synthetic function and altered
drug disposition.
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Liver function tests do not measure hepatic function. They represent release of damaged or
dead hepatocyte intracellular contents into the systemic circulation, hence provide a snap‐
shot at that point in time only. Actual liver function is represented by albumin, prothrombin
time and pseudocholinesterase concentrations. Obtaining liver function tests in healthy pa‐
tients is not recommended as abnormal liver function tests (LFTs) exist in about 1 in 700 pa‐
tients, and a vast majority of these patients do not have advanced liver disease. Thus,
patients with asymptomatic elevations in serum transaminase levels (less than two times
normal values) may undergo anesthesia and surgery with good outcomes.
Patients with chronic hepatitis should be screened prior to elective surgery even if they are
asymptomatic. The INR is the most sensitive indicator of hepatocellular dysfunction. At
present, though it is accepted that abnormal hemostasis is a result of liver disease, it is de‐
batable whether the abnormal tests really predict bleeding risk [7]. Moreover, the relation‐
ship of coagulation profiles to the risk of bleeding with chronic as well as acute liver disease
is uncertain [8]. Low platelet count may not be solely responsible for an increased risk of
bleeding as the platelet function is also important. Bleeding time is no longer recommended
as a test of platelet function. The current consensus is for a pre-procedure platelet count >
50,000, since it appears that a platelet count above 50,000 is likely to be adequate based on
previous studies [9].
It is also important to assess the patient for extra-hepatic pathophysiology related to liver
disease. The diagnostic criteria for POPH include a mean pulmonary artery pressure
(mPAP) greater than 25 mmHg at rest and a pulmonary vascular resistance (PVR) of > 240
dynes.s.cm-5 [10]. A better measure is a transpulmonary gradient > 12 mmHg (mPAP-PAOP)
as this reflects the obstruction to flow (PVR) and also distinguishes the contribution of intra‐
vascular volume and flow to the mPAP [11].
The European Respiratory Society (ERS)/European Association for Study of the Liver
(EASL) Task Force have certain set diagnostic criteria for hepatopulmonary syndrome
(HPS). These include diagnosis of liver disease, an A-a oxygen gradient > 15 mmHg, pulmo‐
nary vascular dilatation documented by “positive" delayed, contrast-enhanced echocardiog‐
raphy with left heart, detection of microbubbles for > 4 cardiac cycles after right heart
opacification of microbubbles and brain uptake > 6% following 99mTc macroaggregated al‐
bumin (MAA) lung perfusion scanning. HPS can be diagnosed when there is a cirrhosis
with ascites, serum creatinine of >1.5 mg/dL, no improvement of serum creatinine after at
least 2 days with diuretic withdrawal and volume expansion with albumin, absence of
shock, no current or recent treatment with nephrotoxic drugs and absence of parenchymal
kidney disease as indicated by proteinuria > 500 mg/day, microhematuria, and/or abnormal
renal ultrasonography. [12]
6. Cardiac assessment of End Stage Liver Disease (ESLD) patients
Cirrhotic patients with ESLD may suffer from cirrhotic cardiomyopathy. This is comprised
of increased cardiac output and compromised ventricular response to stress. This entity is
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and steatohepatitis may also be considered as risk factors for postoperative complications,
especially after abdominal procedures. The Model of End Liver Disease (MELD) score pre‐
dicts severity based upon serum creatinine, total bilirubin, and PT INR. It is used to estimate
long term survival, as well as list patients for liver transplantation with the United network
of Organ Sharing (UNOS). (need a reference here)
Elective surgery is contraindicated when the patient has acute viral hepatitis, alcoholic hepa‐
titis, fulminant hepatic failure, severe chronic hepatitis, is a Child Pugh C patient or has oth‐
er manifestations of end stage liver disease.
Patients with advanced liver disease should be effectively managed so that hepatic perfusion
and hepatic oxygen delivery are maximized l and sequelae of their liver disease such as hepatic
encephalopathy, cerebral edema, coagulopathy, hepatopulmonary syndrome, portopulmona‐
ry hypertension and portal hypertension has been identified and treated accordingly if possible.
5. Preoperative evaluation of patients with liver disease
Assessment of hepatic function includes evaluating risks for aggravating underlying liver
disease, extra-hepatic complications, alterations of hepatic synthetic function and altered
drug disposition.
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nary vascular dilatation documented by “positive" delayed, contrast-enhanced echocardiog‐
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with ascites, serum creatinine of >1.5 mg/dL, no improvement of serum creatinine after at
least 2 days with diuretic withdrawal and volume expansion with albumin, absence of
shock, no current or recent treatment with nephrotoxic drugs and absence of parenchymal
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6. Cardiac assessment of End Stage Liver Disease (ESLD) patients
Cirrhotic patients with ESLD may suffer from cirrhotic cardiomyopathy. This is comprised
of increased cardiac output and compromised ventricular response to stress. This entity is
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likely mediated by decreased beta-agonist transduction, increased circulating inflammatory
mediators resulting in cardiac depression, and accompanying repolarization abnormalities
[13-18]. Low systemic vascular resistance and bradycardia are also commonly seen in ESLD.
Patients with ESLD may also demonstrate diastolic dysfunction. [19]. The electrophysiologic
abnormalities found in cirrhotic cardiomyopathy include QT-interval prolongation, electri‐
cal and mechanical dyssynchrony and chronotropic incompetence [20-22]. Carvedilol ad‐
ministered to patients with ESLD has been demonstrated to reduce portal pressures by
decreasing net splanchnic blood flow. [23].
Additionally,  ESLD  are  also  at  risk  for  the  development  of  coronary  artery  disease
(CAD),  however  the  liver  itself  has  not  been  implicated.  Approximately  25  %  of  these
patients have at  least  one moderate or severe coronary artery with critical  stenosis.  Ob‐
structive CAD was most  common among patients with 2 traditional  cardiac risk factors
such as smoking, diabetes mellitus ( DM),and/or hyperlipidemia [24]. Left ventricular hy‐
pertrophy and hyperdynamic systolic  function in ESLD may result  in hemodynamically
significant  left  ventricular  outflow tract  obstruction  (LVOTO).  One  retrospective  review
of 106 transplant recipients found inducible LVOTO on pre-operative dobutamine stress
echocardiography (DSE) in 40% of patients [25]. In this study, an outflow gradient of 36
mm  Hg  was  significantly  associated  with  intraoperative  hypotension.  Many  ESLD  pa‐
tients  also  have  prolonged  corrected  QT  interval  (QTc)  on  an  electrocardiogram  which
can be  associated with  an increased risk  of  ventricular  arrhythmias.  Though it  is  not  a
contraindication to  surgery  and anesthesia,  one  should look for  electrolyte  disturbances
or  the  use  of  QT  interval-prolonging  drugs.  All  patients  with  ESLD  should  undergo  a
preoperative  echocardiography  to  assess  ventricular  function,  ventricular  size,  valvular
function, pulmonary artery pressure, and to exclude the presence of a significant LVOTO
or pericardial  effusion.  Pre-operative  echocardiography is  useful  to  calculate  pulmonary
artery  systolic  pressure.  Pulmonary  artery  systolic  pressures  (PASP)  values  of  45-50
mmHg and /or right ventricular dysfunction are usually used for screening POPH. Right
heart catheterization should be performed to gauge the mean pulmonary artery pressure
(PAP), pulmonary capillary wedge pressure (PCWP) and transpulmonary gradient (TPG)
as  5% to  10% of  ESLD candidates  have  POPH [26],.  A preoperative  mPAP of  35  to  50
mm Hg has  been  associated  with  a  50% risk  of  mortality  after  liver  transplantation  in
patients  with  POPH  [26],  and  mortality  approached  100%  among  patients  with  POPH
and mPAP ≥50 mm Hg [27]. Thus, POPH warrants perioperative treatment with vasodi‐
lators  such  as  epoprosterenol,  sildenafil  or  nitric  oxide.  Stress  testing  of  ESLD patients
can  be  done  to  detect  CAD.  Dobutamine  stress  echocardiography  has  been  found  to
have a negative predictive value in ESLD patients to be 85%.[28,29]. The predictive value
of nuclear single-photon emission computed tomography (SPECT) stress imaging is limit‐
ed by the chronic vasodilatory state exhibited by patients with ESLD [30]. The specificity
of abnormal SPECT findings for obstructive CAD by coronary angiography is  only 61%
[31]. Coronary angiography is the gold standard for detecting CAD. When possible, it is
important make an assessment of CAD risk in the ESLD patient before revascularization
becomes contraindicated (usually an excessive bleeding risk due to coagulopathy and/or
thrombocytopenia).  Transesophageal  echocardiography  (TEE)  and/or  pulmonary  artery
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catheterization may be used intraoperatively to  allow for  real-time hemodynamic moni‐
toring and volume management..
7. Anesthetic agents
All volatile anesthetics decrease the mean arterial pressure and portal blood flow. Halothane
has consistently the most dramatic effect in reducing hepatic arterial blood flow. [32,33]. On
the other hand, sevoflurane, desflurane and isoflurane have been consistently shown to bet‐
ter preserve hepatic blood flow and function. Intravenous anesthetics have a modest impact
on hepatic blood flow, and no meaningful adverse impact on postoperative liver function if
the mean arterial pressure is adequately maintained throughout the time anesthetized. In‐
duction agents such as etomidate and thiopental decrease hepatic blood flow, either from
increased hepatic arterial vascular resistance or from reduced cardiac output and/or blood
pressure. [34]. Ketamine has little impact on hepatic blood flow. [35] Propofol increases total
hepatic blood flow in both hepatic arterial and portal venous circulation, suggesting a signif‐
icant vasodilator effect. [36,37].
Opioids such as morphine have significantly reduced metabolism in patients with advanced
cirrhosis. The elimination half-life of morphine is prolonged, potentially exaggerating seda‐
tive and respiratory depressant effects. Fentanyl is highly lipid soluble with a short duration
of action, which is also metabolized in the liver. Fentanyl elimination is not appreciably al‐
tered in patients with cirrhosis. [38,39]. However, unlike fentanyl, the half-life of alfentanil is
almost doubled in patients with cirrhosis. [40]. Remifentanil is a synthetic opioid with an es‐
ter linkage that allows for rapid hydrolysis by blood and tissue esterases. It elimination is
unaltered in patients with severe liver disease. [41].
Thiopental has a small hepatic extraction ratio. However, its elimination half-life is un‐
changed in cirrhotics, as it has a large volume of distribution. The clearance of etomidate is
unchanged in cirrhotic patients, but its clinical recovery time maybe unpredictable due to
increased volumes of distribution [42]. The elimination kinetic profile of propofol is similar
in cirrhotic patients as well as normal patients, but the mean clinical recovery times maybe
longer after discontinuation of infusions. [43]. The half-life of midazolam is prolonged due
to reduced clearance, reduced protein binding, resulting in a prolonged duration of action
and an enhanced sedative effect, especially after multiple doses or prolonged infusions. [44]
Dexmedetomidine, an α2-adrenergic agonist, with sedative and analgesic properties, is pri‐
marily metabolized in the liver. Dose adjustments are therefore indicated when used in pa‐
tients with significant hepatic dysfunction. [45].
Vecuronium and rocuronium are steroidal muscle relaxants which undergo hepatic metabo‐
lism, hence have decreased clearance, prolonged half-lives, and prolonged neuromuscular
blockade in patients with cirrhosis. [46,47]. Atracurium and cisatracurium which undergo
Hofmann elimination and ester hydrolysis respectively, have clinical duration of actions
similar to those in normal patients. [48,49]
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For liver surgery where major bleeding is anticipated, it is prudent to secure intravenous
access  using  large  bore  peripheral  catheters  as  well  as  central  venous  access  catheters.
Rapid sequence induction is recommended in patients with tense ascites to minimize the
risk  of  aspiration.  Circulatory  collapse  should be  prevented by concomitant  administra‐
tion of  intravenous colloid solutions because intravascular volume re-equilibrium occurs
6 to 8 hrs after removal of larger volumes of ascitic fluid. [50]. Large volumes of colloids
and crystalloids maybe given within a few minutes with the assistance of  commercially
available  rapid infusion devices.  Red cell  salvage should be  facilitated with  use  of  Cell
savers  with/without  leukocyte  filters.  Blood  administration  may  be  associated  with  hy‐
perkalemia and hypocalcemia.
Bleeding during liver surgery could be either surgical, due to previous or acquired coag‐
ulation disturbances, or both. The preoperative INR has no predictive value in relation to
intraoperative  blood  loss  and  the  value  of  fresh  frozen  plasma (FFP)  administration  to
correct  abnormal  INR  values  is  debatable  and  may  even  increase  bleeding  due  to  the
volume load [51]. Intraoperative hemostasis panels consisting of INR, fibrinogen and pla‐
telet count, and platelet function assays for both platelet count and function, may help to
differentiate  between the  above.  A very useful  intraoperative  test  for  coagulation is  the
thromboelastograph  (TEG).  This  test  denotes  the  net  effect  of  pro  and  anti-coagulants
and pro and anti-fibrinolytic factors and the resulting clot tensile strength. It provides in‐
formation  on  the  rate  and  strength  of  clot  formation  and  also  clot  stability/fibrinolysis.
(Table 1)
Parameter Interpretation Preferred therapy for
abnormal values
R R is the time of latency from the time that the blood was
placed in the TEG® analyzer until the initial fibrin formation.
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α The α-value measures the rapidity (kinetics) of fibrin build-up
and cross-linking and the speed of clot strengthening.
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K K time is a measure of the rapidity to reach a certain level of
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FFP
MA MA, or Maximum Amplitude, is a direct function of the
maximum dynamic properties of fibrin and platelet bonding
and represents the ultimate strength of the fibrin clot.
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In addition, it is possible to detect heparin-like activity and to measure functional fibrino‐
gen.(Figure 1-5,) Moreover, the only way to currently detect intraoperative hypercoagubility
is via TEG. (Figure 6) Thus, TEG may act to facilitate specific goal directed therapy. If fibri‐
nolysis is diagnosed on the TEG and it is causing clinically significant microvascular ooze,
small doses of epsilon aminocaproic acid (EACA) or tranexamic acid (TA) are suitable anti-
fibrinolytics. Factor VII has been used to control massive bleeding during liver surgery;
however, it has not proved to be consistently effective to control bleeding and is associated
with significant side effects. [52]
Transesophageal echocardiography (TEE) is a very useful cardiac monitoring tool to moni‐
tor function of the ventricles and assess intraoperative regional wall motion abnormalities
(RWMAs), especially in patients with CAD. The monitoring of right heart systolic function
is essential in patients with POPH. Moreover, it can be used effectively to assess volume sta‐
tus and guide fluid therapy.
9. Post-operative considerations
Surgery and anesthesia can further worsen hepatic function. Moreover, undiagnosed pre-
existing liver  disease is  often the cause of  hepatic  dysfunction postoperatively.  Depend‐
ing  upon  the  surgical  procedure,  one  may  observe  continued  “third  space“  losses..
Potential for renal dysfunction or failure as a result of surgery is exacerbated with preex‐
isting  liver  disease.  As  well,  preoperative  or  intraoperative  coagulopathy  can  continue
postoperatively or can develop during first 24-48 hrs after surgery secondary to worsen‐
ing hepatic dysfunction.
Postoperative jaundice occurs as a result of overproduction and under excretion of bilirubin,
direct hepatocellular injury, or extra-hepatic obstruction. [53] Multiple blood transfusions
can increase the levels of unconjugated bilirubin because approximately 10 % of stored
whole blood undergoes hemolysis within 24 hours of transfusion. Each 0.5 – 1 unit of blood
stored in CPDA-1 yields 7.5 g of hemoglobin, which is then converted to approximately 250
mg of bilirubin. [54] This may overwhelm the liver’s ability to conjugate and excrete biliru‐
bin. Immediate postoperative jaundice (< 3wks) can also occur due for multiple reasons in‐
cluding but not exclusive to hemolysis, anesthesia, hypotension, hypovolemia, drugs,
infection, sepsis, bleeding, resorption of hematoma, bile duct ligation or injury, hepatic ar‐
tery ligation, retained common bile duct stone, postoperative pancreatitis, Gilbert’s syn‐
drome, Dubin-Johnson Syndrome, inflammatory bowel syndrome, heart failure. [53]
Delayed postoperative jaundice (>3 wks) can be a result of drugs, blood transfusion, post-
intestinal bypass status and total parenteral nutrition. [53]
10. Postoperative pain relief role of epidural analgesia
Thoracic epidural analgesia provides excellent analgesia for liver resections. [55] The cathe‐
ter is usually inserted at the T6-T9 space. Ropivacaine or bupivacaine are common local an‐
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esthetics used with or without the addition of small amounts of opioids such as fentanyl,
sufentanil, hydromorphone or morphine. It also reduces the gastrointestinal paralysis com‐
pared with systemic opioids. [56]. There is benefit of using combined general and epidural
anesthesia in patients with high-risk surgery, but this has not been extensively studied in
hepatic surgery. The reasons are probably associated with the concerns with coagulation is‐
sues in this group. Additional concerns maybe harbored as neuroaxial blocks themselves are
associated with risks. Estimated risk of having serious neurological injury may be as high as
0.08 %.[57, 58]. Moreover, direct spinal cord injury can occur without paraesthesias, whereas
pain is more common in lesions affecting nerve roots. [59]. The incidence of persistent neu‐
rological deficit has been reported as 0.005-0.07 %. [60,61]. At our institution, we follow a
practice where time from anticoagulant drug administration to epidural catheter placement
is 3-5 days for warfarin, INR < 1.5, 4 hrs for heparin low dose subcutaneously, 12 hrs for low
molecular weight heparin (LMWH), 5 days for clopidogrel and zero for aspirin. The time
from epidural catheter removal to anticoagulant drug administration is at least 24 hrs for
warfarin, 2 hrs for low dose heparin and 6-8 hrs for LMWH.
It is essential to understand that the degree of underlying parenchymal disease is not the
only factor which is  responsible for perioperative coagulopathy. Other important factors
include amount of blood loss, dilution coagulopathy, amount and quality of residual liv‐
er parenchyma, its exposure to ischemia to name a few. [62-64]. Persistent pain or transi‐
ent  coagulopathy  may  cause  delayed  epidural  catheter  removal  in  patients  undergoing
partial  hepatectomy  [65].  The  risk  of  meningitis  or  epidural  abscess  is  in  the  range  of
0.0004-0.05% [66,67].
11. Liver – specific surgical procedures
Transjugular Intrahepatic Portosystemic Shunt Procedure (TIPS)
TIPS is a procedure used in patients with end stage liver disease to decrease portal pressure
and attenuate complications related to portal hypertension. It is usually done in the inter‐
ventional radiology suite. The goal of this procedure is diversion of portal blood flow into
the hepatic vein. The stent is passed through the internal jugular vein over a wire into the
hepatic vein, which is located using fluoroscopic guidance. This stent is then advanced
through the hepatic parenchyma into the portal vein. This will decompress the portal circu‐
lation. Usually, general anesthesia is requested for this procedure, as the radiologists prefer
that the patients do not move during this procedure and it may be prolonged. Sedation is
usually not preferred as there maybe potential respiratory depression in cirrhotic patients
with underlying pulmonary dysfunction or hypoxemia from hepatopulmonary syndrome.
Additionally, the presence of ascites may produce risk of aspiration. For this procedure, the
central venous pressure (CVP) is monitored. After the stent is placed, the portal pressures
are measured. Reduction of the difference between the two reflects the effectiveness of TIPS.
Potential complications of this procedure include pneumothorax with internal jugular vein
(IJV) cannulation, hematoma formation, inadvertent carotid puncture, cardiac arrhythmia
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with intracardiac catheter passage, acute life threatening hemorrhage with hepatic artery
puncture, hepatic capsular tear, extrahepatic portal venous puncture, development of pul‐
monary edema and congestive cardiac failure.
12. Radiofrequency Ablation (RFA) of hepatic tumors
Radiofrequency ablation of tumors up to 3 cm in size is currently used to treat non-resecta‐
ble malignant tumors. During this procedure, a high-frequency, alternating current is deliv‐
ered through a needle-like probe into the tumor, which induces coagulative necrosis of the
tumor and surrounding tissue.[68,69]. PFA is done either percutaneously or laparoscopical‐
ly. In a study which analyzed nationwide RFAs, it was found that procedure-specific com‐
plications were frequent (18.2 %), with transfusion requirements (10.7 %), intraoperative
bleeding (4.3 %), and hepatic failure (2.8 %) being the most common. Postoperative compli‐
cations were also common (12.0 %), with arrhythmias, heart failure, coagulopathy, and open
surgical approach acting as significant predictors. [70]
Transarterial Chemoembolization (TACE)
Usually,  an  adequate  amount  of  emulsion  containing  oil-based  contrast  agent  Lipiodol
and anticancer agents is injected through a catheter then the selected arteries are embol‐
ized  by  embolic  agents.  Superselective  TACE is  generally  used to  minimize  damage  to
non-tumorous  areas  by  using  a  microcatheter  to  embolize  only  the  cancerous  subseg‐
ment.[71-73] Epirubicin and cisplatin are commonly used as anticancer agents, and miri‐
platin,  a  new  platinum  drug,  came  into  use  in  2010.[74,75].  Indications  for  TACE  are
wide-ranging,  and the  procedure  is  generally  performed in  patients  with  hypervascular
hepatocellular cancer (HCC) who are not indicated for surgery or local  therapy for rea‐
sons  such  as  multiple  bilobar  HCC,  liver  dysfunction,  old  age  or  co-morbidity,  and  in
whom the first branch from the main portal vein is not occluded. In practice, this techni‐
que is commonly indicated for patients who are Child–Pugh class A or B with multiple
tumors  with  a  diameter  of  3  cm  or  more  or  with  four  or  more  HCC.  [76,77].  When
TACE is combined with RFA, there may be several advantages. For example, TACE de‐
creases  the  blood flow which  in  turn  reduces  the  heat  loss,  thus  increasing  the  size  of
the RFA ablative zone. In addition, the inclusion of TACE makes the evaluation of abla‐
tive margins easier, and enhances the control of satellite lesions.
Hepatic Resections
Liver resections can be done either open or robotic/laparoscopic. Hepatic resection proce‐
dures include partial resection, subsegmental resection, segmental resection, two segment
resection, extended two-segment resection or three-segment resections. Pre-operative assess‐
ment should include the evaluation of the risk assessment using the CTP or MELD score,
hepatic parenchymal function, and correction of severe anemia or coagulopathy, manage‐
ment of severe esophageal varices. The choice of anesthetic drugs as well as their doses
should be based on the above assessment. There is a risk of significant blood loss. Therefore,
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it may be prudent to secure large bore intravenous access and be prepared for rapid infusion
of colloids and crystalloids. Blood and blood products should be made available for perio‐
perative use. Control of bleeding during resection is usually done with pressure, coagula‐
tion and hilar clamping or via the Pringle maneuver. Hilar occlusion produces a minimal
increase in systemic arterial pressure, increase in systemic vascular resistance and a minimal
decrease in cardiac index. There may be risk of air embolism with extensive resection and
disruption of hepatic veins. Most surgeons request a low central venous pressure to facili‐
tate dissection and minimize blood loss from the hepatic vessels and vena cava. Postopera‐
tive concerns are similar to those in major abdominal surgery. Central neuroaxial analgesia
is not recommended if there is risk of coagulopathy which may result in hematoma forma‐
tion in the epidural or spinal space.
Donor Liver Hepatectomy
One method of expanding donor pool for liver transplantation is the use of living donor
grafts. Adult-to-adult living donor liver transplantation (LDLT) is a complex procedure that
poses serious health risks to and provides no direct health benefit for the donor. Because of
this uneven risk-benefit ratio, ensuring donor autonomy through informed consent is criti‐
cal. However, informed consent for LDLT is sub-optimal as donors do not adequately ap‐
preciate disclosed information during the informed consent process, despite United
Network for Organ Sharing/CMS regulations requiring formal psychological evaluation of
donor candidates. [78] Types of donor liver grafts can be left lobe, left lobe and caudate,
right lobe, extended right lobe and right lateral sector. After preoperative evaluation and
screening, a virtual resection and volume analysis is done using contrast enhanced comput‐
ed tomography (CT). These not only estimate SLV but can also determine segmental vol‐
ume, delineate surgical planes, define anatomical landmarks of hepatic vasculature and
biliary structures and calculate anticipated graft and remnant liver volumes post resection.
It is essential that the minimal donor remnant volume be at least 30% of the original volume.
Additionally, when right-lobe LDLT is planned, whether the middle hepatic vein (MHV)
should remain in the donor or be resected is controversial. The MHV primarily provides
various drainage of the right anterior lobe and segment IV. Most transplant surgeons prefer
to leave the MHV in the donor to avoid congestion of segment IV and reduce the risk of liv‐
er failure in the donor.[79] The anesthesia management is similar to that of hepatectomy. In
donors, several complications have been reported. In one study, right hepatectomy (resec‐
tion of segments 5–8) was done in 101 donors, left lobectomy (resection of segments 2–3) in
11 donors, and left hepatectomy (resection of segments 2–4) in one donor. Minor anesthetic
complications were shoulder pain, pruritus and urinary retention related to epidural mor‐
phine, and major morbidity included central venous catheter-induced thrombosis of the bra‐
chial and subclavian vein, neuropraxia, foot drop and prolonged postdural puncture
headache. One of 113 donors died from pulmonary embolism on the 11th postoperative day.
[80]. It was also observed that donor patients experienced significant postoperative pain de‐
spite the use of thoracic patient-controlled epidural analgesia (PCEA) infusion catheters as
compared to patients who had undergone major hepatic resection. This was attributed to the
longer surgical duration for donor hepatectomy and neuroplasticity which may play a role
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in exaggerated postoperative pain perception along with various psychological factors.[81].
It is also interesting to note that approximately 10% of donors had a platelet count < 150,000
x 109/liter, 2 to 3 years post-donation. [82]
13. Conclusion
Patients  with  liver  disease  are  at  increased  risk  for  both  perioperative  morbidity  and
mortality. They require delineation of the degree of liver dysfunction present prior to un‐
dergoing surgery and have outcomes that are primarily dictated by the degree of hepatic
dysfunction and type of surgery performed. They can certainly pose significant challeng‐
es for perioperative care.
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in exaggerated postoperative pain perception along with various psychological factors.[81].
It is also interesting to note that approximately 10% of donors had a platelet count < 150,000
x 109/liter, 2 to 3 years post-donation. [82]
13. Conclusion
Patients  with  liver  disease  are  at  increased  risk  for  both  perioperative  morbidity  and
mortality. They require delineation of the degree of liver dysfunction present prior to un‐
dergoing surgery and have outcomes that are primarily dictated by the degree of hepatic
dysfunction and type of surgery performed. They can certainly pose significant challeng‐
es for perioperative care.
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1. Introduction
Major hepatic resections have become the routine aspect of managing certain liver condi‐
tions  such  as  primary  liver  malignancies  and  certain  secondaries.  Five-year  survival  is
negligible in un-treated patients compared with around 30% in those receiving hepatic re‐
section [1]. Patients with liver disease who require surgery are at greater risk for surgical
and anesthesia related complications than those with a healthy liver [2, 3, 4]. The magni‐
tude of the risk depends upon the type of liver disease and its severity, the surgical pro‐
cedure, and the type of anesthesia.
The first few days after major hepatic surgery are critical to successful outcome of the proce‐
dure. Metabolic and functional changes after hepatic resection are unique and cause signifi‐
cant challenges in management. A multidisciplinary approach is required along with
effective communication among all caregivers. With attentive, anticipatory care, many po‐
tential problems can be averted and new problems can be detected early and treated appro‐
priately. Contemporary critical care management after major hepatic surgery doesn’t differ
from standard intensive care which includes invasive hemodynamic monitoring, mechani‐
cal ventilation, vital parameter monitoring, strict antisepsis measures, metabolic control
with due attention to the glycemic control and nutritional aspect which more or less always
affected in the patients with cirrhosis.
The post-operative management after hepatic surgery is greatly influenced by hemodynam‐
ic monitoring intraoperatively. Patient’s intra-operative course, blood loss, requirement of
blood products during surgery largely defines the outcome in post-operative period along
with patient’s nutritional status, liver functions and associated comorbidities. Hence close
co-operation with the anesthesiologist and surgeon is necessary.
Majority of postoperative management issues after liver resection are unique and require a
thorough understanding of liver metabolism and the pathophysiology of liver disease. The
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purpose of this review is to elaborate on specific early postoperative management issues af‐
ter liver resection, examine current evidence and present the management options.
2. Hepatic resections and general considerations
Through the recent surgical advances, hepatic resection could be carried out under the con‐
dition of liver cirrhosis or obstructive jaundice, but there are many complications and associ‐
ated mortality in these cases. Hepatic cirrhosis limits the ability of the liver to regenerate.
Fortunately, it appears that most of the advanced cirrhotic livers can tolerate even major re‐
sections, and the presence of cirrhosis should not preclude potentially curative or life-pro‐
longing surgery [5]. Careful patient selection based on preoperative Child-Pugh score and
ICG test, resections can be limited leaving behind enough liver parenchyma to avoid post-
operative liver dysfunction. But such patients are more vulnerable to perioperative insults
secondary to ischemia and hypoperfusion, which is reflected in perioperative morbidity and
mortality [6]. The Child-Pugh clinical scoring system has been used as a reliable, validated
prognostic tool for patients with chronic liver disease undergoing general or porto-caval
shunt surgery and has gained widespread use in hepato-biliary surgery. It has recently been
suggested that patients with scores of B or C should not receive liver resection surgery [7].
The associated cirrhosis greatly increases the risk for partial hepatectomy. In normal liver.
even up to 70% of resection of liver is well tolerated. With underlying liver cirrhosis, partial
hepatectomy is only offered to patients who are Pugh-Child's A and the most favorable class B
patients [8]. While in Child C patients even minor hepatic surgery or even locoregional thera‐
py can cause hepatic dysfunction. Post-operative outcome and level of post-operative care
largely influenced by the underlying cirrhosis and post cirrhotic complications present at the
time of surgery. Hence, even enucleation of hepatocellular carcinoma in Child C patients is a
major surgery and procedure related mortality is present in one-third of patients [9].
3. Post-operative care
Variables such as severity of underlying cirrhosis, degree of debility before surgery, associ‐
ated co-morbid diseases and operative complexity appear to have a significant influence on
the rapidity at which patients progress through their early postoperative recovery phase.
Attributed to regenerating capacity of the liver, most of the major liver resections are well tol‐
erated and seldom patients have significant biochemical abnormalities. Patients with compen‐
sated liver cirrhosis and its complications are more prone for intraoperative blood loss causing
deterioration of organ functions and loss of reserve capacity to withstand even minor stress
causing  life-threatening  complications.  The  disturbances  in  cardio-respiratory  function
should be carefully monitored in high Dependency unit. The complications are more in elderly
patients. The condition of older patients can change rapidly and therapy may need to be ad‐
justed every few hours if optimum cardio-respiratory function is to be maintained.
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• Planning of intensive monitoring for high risk patients with associated co-morbidities
should be done during surgery and in postoperative wards
• Diagnose and treat complications quickly
• Institute invasive monitoring and elective ventilation when required
• Continue postoperative care to increase the rate of recovery.
3.1. Immediate post operative
Initial postoperative assessment begins in operating room. Most patients with pre-operative
normal liver functions and child A patients recover without any systemic effects. Such pa‐
tients may not need intensive care unit and can directly be transferred to inpatient wards
after an appropriate period of extremely close observation in recovery unit. Many centers
usually monitor the patients in ICU for 24 hours before being transferred to inpatient setting
after major liver resections.
Most of the patients are awakened in operating room after surgery, and if extubation criteria
are fulfilled, the patient is extubated [10, 11]. It is advised that not all patients are candidates
of early extubation and each case should be judged on its own merits. But prolonged intuba‐
tion and mechanical ventilation in postoperative period associated with more pulmonary
complications that further prolongs patient’s recovery and increases the mortality & mor‐
bidity [12]. In addition, Mandell et al. demonstrated that immediately extubated patients ex‐
perienced a shorter stay in the ICU, resulting in a significant reduction in ICU services and
associated costs for extubated patients [13].
After arrival in ICU, initial vital assessment should be done. Most centers follow more or
less same protocol. Fluid management is strictly based on patient’s present hemodynamic
conditions and blood products are administered as per the present condition requires. Input
and output fluid charts are maintained with due attention to hourly urine output which
should be minimum 0.5 ml/kg/min. Any renal dysfunction in the form of oliguria should be
treated immediately because optimum renal function is of paramount importance as a deter‐
minant of good outcome [14].
Routine blood investigations, coagulation profile and organ specific tests are ordered. Pa‐
tients still on ventilatory support, baseline arterial blood gas estimation is done at the arriv‐
al. Serum lactate level is determined as it depicts the imbalance between tissue oxygen
supply and consumption, thus an indirect measure of tissue perfusion and cardiac output
[15]. Postoperative aminotransferase and alanine aminotransferase and total bilirubin levels
are not routinely measured after trauma-related surgery. However, in postoperative liver re‐
section and living donor hepatectomy, these values are to be followed to ensure recovery of
liver function [16]. A transient early increase in serum hepatic transaminase and alkaline
phosphatase levels as a result of hepatocellular damage is common, but a persisting eleva‐
tion suggests ongoing hepatic ischemia.
Hypothermia in postoperative period is prevented and core body temperature is maintained
above 37oC. Hypothermia can cause vaso-constriction and coagulopathy. Core temperature
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should be monitored and normothermia maintained using warmed fluids and forced warm
air blankets. The abdominal drains are examined for the color and content as postoperative
hemorrhage is not uncommon after major liver resections and may require re-exploration. In
liver transplant setting, due to underlying coagulopathy, ongoing hemorrhage must be de‐
tected at earliest. Gross blood stained drain fluid with acute fall in hemoglobin level should
alarm surgeon and patient should be re-explored at earliest.
All patients receive broad spectrum antibiotics. The choice of antibiotics is usually center de‐
pendent. In our center, we usually administer single broad spectrum antibiotic, mostly third
generation cephalosporin in stable patients with Child A score. But in high risk patients, de‐
fined by Child score & nutritional status, and patients who are on ventilator support postop‐
eratively, we prefer to use combination broad spectrum antibiotics. In presence of fever,
blood culture and antibiotics sensitivity defines the course of antibiotics administered.
3.2. Monitoring of vital parameters
Monitoring the vital parameters like pulse, blood pressure, respiratory rate, ECG, oxygen
saturation and the urine output and immediate intervention are instituted to prevent post‐
operative complications. Vital organ functioning is monitored as follow:
1. Blood pressure, temperature, pulse, respiratory rate.
2. Electrolytes, glycemic control, liver and renal functions
3. Fluid balance and urine output
4. Drain and wound status and appropriate care
5. Medication for pain relief
6. Neurological and cardiac functions
7. Good nutritional intake and bowel movement
3.2.1. Cardiac Monitoring
Central venous line, arterial blood pressure monitoring, continuous record of pulse rate and
heart rate are routine standards for monitoring the patients after major hepatic surgery. Arteri‐
al blood pressure monitoring accurately measures blood pressure even in presence of hypoten‐
sion and hypovolemia. In addition, repeated blood sampling can be obtained for routine
laboratory investigations and arterial blood gas monitoring. Patients are usually tachycardic
postoperatively. But heart rate >100/min should be thoroughly checked for ongoing insults
such as persistent hypovolemia, pain, ongoing hemorrhage (drain fluid & falling HB level are
indicators) or cardiac arrhythmias. Sinus tachycardia is common after major surgery and
should revert without any complications. If tachycardia increases, persistent infection, hypo‐
volemia, pain or presence of cardiac arrhythmia are detected and treated promptly.
At least two large-bore intravenous cannulas are inserted. Although rapid infusion devices
are seldom needed, they are available and primed in the ICU at all times. Pulmonary artery
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catheterization is reserved for patients with known preoperative left-ventricular dysfunc‐
tion. This allows continuous measurement of cardiac output and instantaneous calculation
of systemic vascular resistance. Real-time ECG monitoring is carried out routinely on most
critically ill patients. Changes in rate, rhythm, and character can be identified rapidly by
physicians and nurses and acted on immediately.
Monitoring of central venous pressure (CVP) is an important aspect in patients after major liv‐
er resections. Measurement of CVP acts as guide for fluid management and hemodynamic ma‐
nipulation. Liver resections usually carried out under low CVP, usually between 2-5 mm of
Hg, to prevent blood loss. This especially an important strategy in patients with underlying
liver cirrhosis with child score B & C. CVP is usually kept in same range after surgery and ex‐
cess fluid administration is restricted. If patient is normotensive and urine output is adequate
(>0.5 mL/kg/hr), any attempt to administer extra fluid to elevate CVP is avoided especially in
first 48 hours. But after major liver resection, a hyperdynamic state with increased cardiac in‐
dex and augmented splanchnic blood flow persists for at least 3 days postoperatively [17]. This
increased blood supply to the residual liver parenchyma ensures rapid growth.
Signs and symptoms of the heart failure can easily be overlooked as they mimic those of cirrho‐
sis and liver failure. Transthoracic echocardiography is a useful modality in such patients
which can measure right ventricular systolic pressure and also shows the cardiac changes.
3.2.2. Pulmonary monitoring
Pulmonary  functions  are  assessed  by  continuous  pulse  oximetry,  intermittent  arterial
blood gas analysis, respiratory rate and if patient is on ventilator support, patients are ob‐
served  via  end-tidal  carbon  dioxide  monitoring  in  addition  to  the  standard  ventilatory
monitoring and alarm systems.
The course of extubated patients is fairly predictable and most of them recover without any
complications. However, after major resections pulmonary complications such as pleural ef‐
fusion, right sub-diaphragmatic collection causing right lung collapse and pulmonary ede‐
ma are frequent. edema. These complications range from 50% to over 80% according to
literature [18, 19]. Atelectasis is most common amongst these. Atelectasis can be reduced by
early mobilization, aggressive chest physiotherapy, adequate pain control and incentive spi‐
rometry. Extubated patients should be given chest physiotherapy and incentive spirometry
exercises as early as 8 hours post operatively. This will help the expansion of lung and pre‐
vent accumulation of the secretions causing atelectasis. Nebulisation with saline with or
without anti-cholinergics is given daily 2-3 times and continued till patients are ambulatory.
If the patient is admitted to the ICU while intubated after reversal of the paralytic agents,
the ventilatory settings are adjusted according to the patient’s respiratory status and arte‐
rial blood gases. Patients with good cough and gag reflex, respiratory rate <30 breaths per
minute,  tidal volume >5ml/kg and aterial  PO2 >70mmHg can be extubated. But in pres‐
ence  of  pulmonary  complications  (described  later),  in  very  ill,  malnourished  patients
weaning is  not possible and may require prolonged ventilation.  Metabolic abnormalities
such as hypophosphatemia,  hypomagnesemia,  hypocalcemia and hypokalemia may lead
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to  respiratory  muscle  dysfunction  and  inability  to  wean  from  ventilator  [20].  Such  pa‐
tients in whom prolonged mechanical ventilation is needed for more than 1 week, trache‐
ostomy  should  be  considered  to  clear  airway  secretions  and  reduce  the  resistance  that
accompanies the use of standard long endotracheal tubes.
Extubated patients with postoperative hypoxemia are benefited by continuous positive air‐
way pressure (CPAP) that increases the lung expansion and improves fair gas exchange across
alveolar capillary membrane. Appropriate analgesia is essential to prevent pulmonary compli‐
cations, but oversedation needs to be carefully avoided. In absence of coagulopathy and other
contraindications, epidural analgesia should be considered and it has been shown to reduce
the pulmonary complications [21]. Deep vein thrombosis prophylaxis is strongly encouraged
after major liver surgery to prevent any thromboembolic complications.
However, in absence of complications in relatively stable postoperative patients, recovery is
smooth and extubation is possible within 12 hours.
3.2.3. Renal function monitoring
Maintenance of effective renal function is a critical factor after major hepatic surgery includ‐
ing liver transplantation [22]. 3% of patients experience permanent and 10% transient renal
dysfunction following major liver surgery [23]. Hence every attempt must be made to pre‐
vent and control renal failure in perioperative period.
Renal autoregulation effectively ceases below renal perfusion pressures of 70 mmHg to 75
mmHg, below which flow becomes pressure dependent. In cirrhotic patients, the concomi‐
tant sympathetic activation results in a rightward shift of the autoregulation curve; thus
these patients have even less tolerance of reductions in renal perfusion pressure [24]. Ade‐
quate fluid management is imperative for both adequate renal perfusion pressure and flow
throughout the entire post-operative period to prevent renal impairment.
Hourly monitoring of urine output and laboratory values such as blood urea and serum
creatinine  are  good measures  of  adequate  renal  functioning.  Urine  output  is  monitored
with as indwelling catheter and urine output is maintained at more than 1-2 ml/kg. Any
decrease in urinary output should be assessed for the intravascular volume and hypovole‐
mia if any should be corrected.
In presence of normal blood pressure and satisfactory intravascular volume, diuretics are
used to improve the urine output. 1 to 2 mg/kg furosemide is given intravenously as bolus
followed by a furosemide infusion of 0.2-0.4 mg/kg/hr titrated to maintain adequate urine
flow. Continuous infusion results in increased urine output without much alteration in vol‐
ume status often seen with intermittent bolus therapy.
Intraoperative hemodynamic instability and clamping of major vessels during major liver
resections are the main causes of postoperative renal failure. Intraoperative blood loss can
lead to renal perfusion problems leading to acute tubular necrosis (ATN) especially in cir‐
rhotic patients with marginal renal functions from the outset. Drug induced nephrotoxicity
is another cause of post-operative renal insufficiency.
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Renal insufficiency, probably the most ominous perioperative complication in patients with
liver disease, is usually a predictor of markedly reduced survival and a sign that hepatore‐
nal syndrome may have developed.
3.2.4. Neurological assessment
Postoperative drowsiness and confusion are commonly caused by neuraxial or systemic
opioid administration, which responds to simple changes in administration. However, these
patients should be carefully assessed for more serious pathology. Most of the patients show
normal neurological recovery. The patients who are extubated immediately after surgery,
neurological recovery is complete and not associated with any morbidity. The intubated pa‐
tients who require mechanical ventilation are usually sedated and neurological assessment
in such patients is difficult and usually misleading.
Assessment of the patient’s neurological status is done by Glasgow coma scale (GCS) scor‐
ing system that records the conscious state of the patient. Patients with GCS score 12 or
more are fully conscious and if with endotracheal tube, can be extubated if other pulmonary
criteria for extubation are met. Mechanically ventilated patients with sedation and under ef‐
fect of paralyzing drugs are difficult to assess neurologically and assessment should be per‐
formed after wearing of effects of these drugs.
In patients undergoing liver transplantation, the marginal metabolism of anesthetic agents
can cause  delayed emergence  from surgery,  as  well  as  residual  hepatic  encephalopathy
[9]. Many patients usually resolve without any neurological aftereffects after major hepat‐
ic  resections,  but  prolonged  ICU  stay  due  to  postoperative  complications  can  result  in
neurological  dysfunction  that  range  from  anxiety,  depression  and  sleep  deprivation  to
frank hallucinations and delusional states.  ICU psychosis is not uncommon. Patients de‐
veloping  postoperative  hepatic  dysfunction  may develop  hepatic  encephalopathy  which
reflects  a  spectrum of  neuropsychiatric  abnormalities  seen in  patients  with  altered liver
functions  after  exclusion  of  other  known  central  nervous  system  disorders  [25].  Drugs
such as narcotics and sedatives should be avoided in patients with postoperative impair‐
ment of liver functions and used cautiously with underlying liver cirrhosis as they may
cause prolonged depression of consciousness and precipitate hepatic encephalopathy [4].
Encephalopathy must be considered in a patient with deteriorating liver function and un-
explained neurological symptoms. Measurement of blood ammonia may be useful if  the
diagnosis is unclear. Encephalopathy is treated with cardio-respiratory optimization, fur‐
ther lactulose and may require invasive ventilation.
3.3. Fluid and electrolyte management
Optimizing perioperative fluid management is essential in reducing the risk of postopera‐
tive complications and mortality as the cirrhotic patients tend to have limited physiologic
reserve. Adequate fluid administration may reduce the stress response to surgical trauma
and support recovery [26].
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The immediate postoperative period after hepatic resection is characterized by fluid and
electrolyte imbalances that are further accentuated by derangements of liver function. Main‐
tenance of adequate fluid balance and normal renal function is critical. Cirrhotics are prone
to fluid shifts, vasodilation and resultant hypotension. In this setting, colloids rather than
crystalloids should be administered to restore intravascular volume. 50% of patients will al‐
so develop significant but self-limiting ascites during the first 48 h, which can cause hypovo‐
lemia. Management with sodium restriction and judicious use of diuretic therapy is
recommended. Paracentesis may be necessary to prevent tense ascites [27].
At present, no widely accepted recommendations are available for the optimal peri-opera‐
tive fluid regimen to be used in major non-thoracic surgery. The exact balance of fluid trans‐
fusion will be determined by the size of resection, plasma electrolytes and glucose
measurements, and volaemic status of the patient. In liver transplantation, fluid overload
has been shown to be a predictor of poor graft function and increased postoperative morbid‐
ity [28]. In liver resection it has been shown repeatedly that keeping the CVP low results in
reduced blood loss and blood transfusion requirements [29-33].
Crystalloids mainly, 0.9% saline and lactated ringer, usually are used postoperatively as re‐
placement and maintenance fluid. Colloids act as plasma expander and can be added as
maintenance fluid, but should not be used as resuscitation fluid in case of shock.
Electrolyte abnormalities are common after major hepatic resections, especially beyond
Child A patients. Hyponatremia is often seen in patients with cirrhosis and ascites. Howev‐
er, asymptomatic patients treated with normal saline and serum sodium is monitored. So‐
dium deficit is corrected gradually. In symptomatic patients, a goal increase of sodium with
1.5-2 mEq/L/hr for 3-4 hours until symptoms resolve appears to be safe. But it should not
exceed 10 mEq/L in first 24 hours [34]. Rapid correction in any patients is avoided as it may
result in central pontine myelinosis.
Hyperlactemia and hypophosphatemia are common derangements in patients undergoing
liver resection. Due to the additive effects of lactate-containing intravenous solution, non-
lactate containing solutions are recommended for postoperative use [35]. Hypophosphate‐
mia is encountered in nearly all patients after major hepatic resection is believed to be due to
increased phosphate uptake by regenerating hepatocytes. It may cause impaired energy me‐
tabolism in many organs and may lead to respiratory failure, cardiac arrhythmias, hemato‐
logic dysfunction, insulin resistance, and neuromuscular dysfunction [36, 37]. Standard liver
resection management includes adequate replacement of phosphate with supplementation
of maintenance fluids with potassium phosphate and oral/parenteral replacement.
Correction of potassium is an ongoing process after major liver resections. Patients with
high urine output may have hypokalemia which should be corrected. In most cases supple‐
mentation is administered by the intravenous route, but it can also be given orally via naso‐
gastric tube. Patients who have received multiple transfusions tend to have hyperkalemia.
Before potassium correction underlying metabolic acidosis must be treated first. Severe hy‐
perkalemia in patients with renal dysfunction or failure requires urgent treatment with
pharmacological agents or early dialysis. In presence electrocardiographic changes, intrave‐
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nous calcium to stabilize the cardiac membrane, intravenous insulin and glucose can be giv‐
en to decrease serum potassium levels. However associated hypomagnesemia should be
corrected as it is commonly seen in association with hypokalemia and hypercalcemia.
3.4. Glycemic control
Strict control of blood glucose in surgical patients admitted to intensive care unit has been
shown to reduce morbidity and mortality [38]. Hyperglycemia may be induced by surgical
stress causing dysregulation of liver metabolism and immune function, resulting in adverse
postoperative outcomes [39]. Insulin therapy is particularly important and blood glucose
levels are monitored serially to keep glucose levels in target range of 90-120 mg/dl. But de‐
velopment of insulin resistance after the liver resection makes adequate blood glucose con‐
trol challenging. Some centers use insulin-sliding scale to keep blood glucose in target
range, in which blood glucose levels are monitored at regular intervals and doses of insulin
changed accordingly while some centers use continuous insulin infusion to control glucose
levels. The doses of insulin are to be modified depending on the blood sugar levels.
Okabayashi et al. [40] examined the safety and effectiveness of closed loop insulin adminis‐
tration system, a type of artificial pancreas (STG-22, Nikkiso, Tokyo, Japan) in patients un‐
dergoing hepatic resection, but the mean sugar level was above the target levels 90-120
mg/dl. Hypoglycemia after insulin therapy is not uncommon. Hypoglycaemia may as well
occur in postoperative due to result of impaired hepatic mobilization of glucose is in high-
risk patients or large resections and may necessitate glucose infusion. Dextrose solutions are
used to restore normal sugar level. If patients can take orally, or no contraindications for en‐
teral feeding, oral or nasogastric feeding is always preferred.
3.5. Nutrition
Malnutrition is common in patients with liver disease and it may increase risk of postopera‐
tive complications after major liver surgeries [41].
The post-hepatic resection period the high demand of the regenerating liver is characterized by
a catabolic state and often has glucose and electrolyte imbalances. Nutritional support during
this critical period is of paramount importance to ensure adequate hepatic regeneration and
postoperative-recovery. Non-cirrhotic patients with adequate preoperative nutritional status
may not require any special intervention and should be started on early oral/enteral diet.
But patients who have poor nutritional intake, with or without compromised liver functions
(cirrhosis or steatosis), after major liver resections the short-term outcome in such patients
may be improved with the use of supplemental enteral nutrition. This may as well improve
the child class of patients and reduce the mortality in patients with cirrhosis and malnutri‐
tion. If oral feeding can be tolerated, enteral feeding is always preferred over parenteral as it
also maintains the intestinal integrity.
Richter, et al. [42] evaluated five randomized controlled studies that compared enteral ver‐
sus parenteral nutrition in the post-hepatic resection patients [43-45] and concluded that the
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postoperative complications were significantly low in patients with enteral feeding. In addi‐
tion, supplementation of branched chain amino acids has got immunomodulating role. Liv‐
er disease alters the metabolism of amino acids resulting in low levels of branched chain
amino acids such as leucine, isoleucine and valine. Branched chain amino acids (BCAA)
supplementation in patients with advanced cirrhosis is associated with improved nutritional
status and decreased frequency of complications of cirrhosis. Okabayashi et al. showed im‐
proved quality of life in patients supplemented with BCAA after they underwent major hep‐
atic resections [46]. Ishikawa et al. demonstrated increased levels of erythropoietin after
short term supplementation with BCAA in non-hepatitis patients undergoing curative resec‐
tion [47]. Erythropoietin has got protective effects on liver cells from ischemic injury.
Thus, adequate perioperative nutritional support and institution of early enteral nutrition
are  crucial.  Protein  restriction is  advised only in  presence of  neurological  complications
like encephalopathy.
3.6. Correction of coagulopathy
Derangements in conventional markers of coagulation such as prothrombin time/ interna‐
tional ratio (PT/INR), partial thromboplastin time (PTT) and platelet count are common post
hepatectomy and correlates with the extent of resection. Postoperative coagulopathy peaks
2-5 days post surgery. Decreased synthetic functions of the liver remnant and consumption
of coagulation factors postoperatively can cause increase in INR postoperatively between 1
to 5 days with corresponding decrease in platelets and fibrinogen [48, 49].
Prolongation of PT/INR is often self-limited and usually resolves without the need for trans‐
fusion of fresh frozen plasma (FFP) in non-cirrhotics. In patients with cirrhosis, decreased
hepatic protein synthesis contributes to a prolonged prothrombin time and partial thrombo‐
plastin time, both of which are prolonged usually in direct proportion to the impairment of
hepatic reserve. Administration of fresh frozen plasma provides all necessary clotting fac‐
tors and can correct underlying coagulopathy.
Patients having preoperative obstructive jaundice should receive vitamin K injection both
before and after surgery. Sometimes determination of the precise cause of coagulopathy
may be difficult in some patients with advanced liver disease, both vitamin K and fresh fro‐
zen plasma given together in such patients. In case of postoperative drop in hemoglobin and
hematocrit, fresh whole blood transfusion is ideal replacement. A platelet count of 50,000/μl
is acceptable. Administration of platelets in the absence of bleeding often results in platelet
antibodies, even if type-specific platelets are used. Thrombocytopenia should be treated
with platelet transfusion only if platelet count is less than 10,000/ μl or between
10,000-30,000/ μl in presence of active bleeding.
Currently, there is no consensus regarding the criteria for prophylactic FFP transfusion after
hepatic resection. Cirrhotics are at increased risk of bleeding after resection. A combination
of FFP transfusions, vitamin K, octreotide and human r-FVIIa may be utilized to correct coa‐
gulopathy and prevent bleeding.
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4. Pain management
Postoperative pain following liver surgery is significant, and adequate analgesia remains a
challenge for the caregivers. It helps in early mobilization, improves respiratory functions,
permits smooth extubation and decreases systemic blood pressure [50]. Opioids are main‐
stay of postoperative pain management, morphine and fentanyl being most commonly used
analgesics. However, opioids can certainly cause sedation, respiratory depression and exac‐
erbation of hepatic encephalopathy. Due to decreased metabolism of opioids in cirrhotic pa‐
tients, the bioavailability of these drugs is increased. Size of liver resection has been
correlated with impaired opioid metabolism, larger volume resections result in greater im‐
pairment of opioid metabolism [51]. Hence, patients should be closely monitored for any
signs of respiratory depression. In presence of renal dysfunction, fentanyl is better choice as
it is less affected by renal impairment [52].
Epidural analgesia has emerged as an important pain management option in major surger‐
ies and with adjunct to intravenous analgesics provides better pain control & less sedation.
But many patients presenting for hepatic surgery have a coagulopathy or thrombocytopenia
that makes them ineligible for an epidural or intrathecal therapy. The prolonged prothrom‐
bin time potentially predisposes these patients to spinal hematoma and cord compression.
In our institute we use epidural analgesia only in patients with normal coagulation profile
and good hepatic functions. Intrathecal morphine in doses of 0.5 mg to 0.7 mg can be used
as an alternative in patients without coagulopathy. This significantly reduces systemic mor‐
phine requirements postoperatively.
Patient controlled analgesia (PCA) is newly emerged concept of self administration of anal‐
gesics in controlled doses by patient himself with a pump. This is preferred mode of admin‐
istrating opioids for moderate to severe pain. Randomized controlled trials have shown the
effectiveness of PCA over conventional parenteral analgesia in providing better pain control
and increased patient satisfaction [53].
The use of NSAIDs is not recommended post hepatectomy in cirrhotic patients and in re‐
nal insufficiency due to risk of hemorrhage and hepatorenal syndrome. However, intrave‐
nous acetaminophen can be used in doses not  exceeding more than 2 g/day in patients
with liver impairment [54].
5. Postoperative complications
Approximately 20% of otherwise healthy patients may experience postoperative complica‐
tions after elective liver resections [6]. Postoperative complications included surgical compli‐
cations (bleeding from the surgical site and bile leak), hepatic dysfunction, cardiovascular,
respiratory, and renal system dysfunction, and infection. Preoperative American Society of
Anesthesiologists (ASA) classification [55], presence of steatosis, extent of resection, simulta‐
neous extrahepatic resection, and perioperative blood transfusion [56] have been found to
be independent predictors for the development of postoperative complications.
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and increased patient satisfaction [53].
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nous acetaminophen can be used in doses not  exceeding more than 2 g/day in patients
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5. Postoperative complications
Approximately 20% of otherwise healthy patients may experience postoperative complica‐
tions after elective liver resections [6]. Postoperative complications included surgical compli‐
cations (bleeding from the surgical site and bile leak), hepatic dysfunction, cardiovascular,
respiratory, and renal system dysfunction, and infection. Preoperative American Society of
Anesthesiologists (ASA) classification [55], presence of steatosis, extent of resection, simulta‐
neous extrahepatic resection, and perioperative blood transfusion [56] have been found to
be independent predictors for the development of postoperative complications.




Infection after hepatic resection is a major contributor of postoperative morbidity and mor‐
tality and might be predictive of long-term outcomes [57]. Obesity, preoperative biliary
drainage, extent of hepatic resection, operative blood loss, comorbid conditions and postop‐
erative bile leak are the risk factors predictive of postoperative infectious complications [58,
59]. Standard measures to reduce the incidence of postoperative infectious complications
such as early mobilization, strict antiseptic measures during patient care, changing or re‐
moving the urinary catheters within 10 days, removal of central venous catheters earliest
possible and aggressive chest physiotherapy should be routine in the postoperative period.
Most frequent complications are pulmonary infection and intra-abdominal infections with
abscess formation. Both of these complications are well responsive to the antibiotics. Intra-
abdominal collections either biloma or frank abscesses should be drained under radiologic
guidance. Septic shock is rare and associated mortality is high if develops. Early recognition
of postoperative infection, prompt institution of broad-spectrum antibiotics and aggressive
source control is of utmost importance.
Early enteral feeding has protective role in maintaining gut mucosal barrier function. Dis‐
ruption of this barrier results in translocation of intestinal organisms that is the source of
postoperative infections especially in malnourished patients. Strategies such as early enteral
nutrition are aimed to protect the gut-barrier function and reduce infectious complication.
5.2. Post operative hemorrhage
Less frequent complications include post-operative hemorrhage that is associated with in‐
creased  mortality.  Underlying  coagulopathy  is  the  main  reason.  Patients  with  cirrhosis,
steatosis,  and  after  chemotherapy  are  at  especially  increased  risk  of  coagulopathy  and
bleeding. Postoperative coagulopathy is at its peak 2-5 days post surgery may act as an‐
other contributory factor. Immediate re-exploration and hemostasis is the treatment. This
may necessitate the blood transfusion.
5.3. Pulmonary complications
Pulmonary complications are not uncommon after major hepatic resections. Pulmonary
complications are a major cause of morbidity and mortality during the postoperative period
[60]. Common pulmonary complications occurring in the postoperative period include pul‐
monary atelectasis, pleural effusion, pulmonary edema and pneumonia.
5.3.1. Atelectasis
Atelectasis is one of the most common postoperative pulmonary complications, particularly
following abdominal and thoraco-abdominal procedures [(61). Postoperative atelectasis is
usually caused by decreased compliance of lung tissue, impaired regional ventilation, re‐
tained airway secretions, and/or postoperative pain that interferes with spontaneous deep
breathing and coughing [62]. After major hepatic resections right sub-diaphragmatic collec‐
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tions and postoperative pain are the major causes. Continuous positive airway pressure
(CPAP) is beneficial to patients who develop hypoxemia and/or increased respiratory effort
due to postoperative atelectasis in the setting of few secretions. Patients with abundant res‐
piratory secretions receive frequent chest physiotherapy such as postural drainage & per‐
cussion and oral suctioning. Flexible bronchoscopy should be performed for the patients
who are unresponsive to chest physiotherapy and oral suctioning.
Any accumulation in right sub-diaphragmatic space should be drained under radiologic
guidance. Atelectasis can be reduced by early mobilization, incentive spirometry, aggressive
chest physiotherapy and adequate postoperative analgesia.
5.3.2. Pneumonia
Pneumonia is uncommon complication but may prove life threatening. It usually tends to
occur  within  first  five  postoperative  days  [63].  It  presents  with  fever,  leukocytosis,  in‐
creased secretions, and pulmonary infiltrates on chest radiographs. Patients develop hypo‐
xemia and eventually respiratory distress. Postoperative pneumonia should be suspected
in presence of fever, leukocytosis and development of new pulmonary infiltrates on chest
radiographs. Empiric antibiotic treatment must be started and tailored as per the micro‐
biological analysis of sputum samples.
5.3.3. Pleural effusion
Pleural effusion occurs mostly on right side and related to surgical manipulation or hepatic
hydrothorax. Minimal pleural effusion is common during the immediate postoperative peri‐
od and disappears within few days. However, larger collections and persistent pleural effu‐
sion affecting respiratory functions must be drained.
Subphrenic abscess is a complication of surgery that may induce pleural effusions; however,
the effusions associated with a subphrenic abscess are distinct from the usual postoperative
pleural effusion in that they usually become apparent about 10 days after surgery and are
typically associated with signs and symptoms of systemic infection [64]. Subphrenic abscess
must be drained and appropriate antibiotic treatment should be started.
5.3.4. Pulmonary edema
Extravascular lung-water accumulation, indicating mild to moderate pulmonary edema fol‐
lowing liver resection, has been reported; however, this does not appear to affect oxygena‐
tion significantly in the postoperative period [65]. Early onset may be related to transfusion-
related acute lung injury or overzealous fluid administration. It is due to increased
permeability across alveolar capillary membrane [66]. Other causes include sepsis and acute
respiratory distress syndrome. Treatment of pulmonary edema includes fluid restriction, di‐
uretics and continuous positive airway pressure. Most cases resolve spontaneously in a rela‐
tively short period of time with no long-term sequelae [67]
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Postoperative hepatic failure remains a significant challenge. Liver dysfunction is common
after liver surgery and anesthesia. It can range from mild enzyme elevations to fulminant
hepatic failure. The abnormalities of liver functions noted postoperatively are mostly due to
surgery itself or anaesthetic agents used. Although increased serum bilirubin is common
postoperatively especially in cirrhotic patients (upto 20%), jaundice is infrequent (<1%) and
its presence should prompt a thorough evaluation of the cause.
Although low residual liver volume was found to be associated with postoperative liver fail‐
ure, the regenerative ability of the liver is remarkable, and the residual, otherwise healthy liver
is expected to double in size within the first week following the resection. Increase in hepatic
parenchymal mass does not necessarily result in full restoration of functional ability. Pre-exist‐
ing cirrhosis or positive virus carrier status limits liver regeneration, and these patients are
more susceptible to developing postoperative hepatic failure. Liver regenerating is also re‐
duced in diabetic patients predisposing them for the liver failure after major resections [68].
But liver dysfunction can also occur in absence of any pre-existing liver disease. The hep‐
atocellular  dysfunction  may  occur  due  to  drugs  including  anaesthetic  agents,  ischemia,
shock,  iatrogenic  injury  or  viral  hepatitis.  Known  causes  of  cholestatic  dysfunction  in‐
clude sepsis, prolonged blood transfusions, drugs, biliary tract injury, choledocholithiasis
and total  parenteral  nutrition  [4].  Even if  abnormalities  are  not  noted on computed to‐
mography  or  ultrasonography,  choalngiographic  studies  are  warranted  in  presence  of
strong suspicion of biliary obstruction.
Most cases of benign postoperative jaundice (without any obvious cause) eventually resolve
spontaneously with supportive treatment only. Usually all cases of hepatic dysfunction are
managed in ICU and liver functions are monitored serially along with the coagulation pa‐
rameters. Hepatic failure is a life threatening complications. Presence of hepatic encephalop‐
athy increases mortality. Increased ammonia due to underlying hepatic failure is a key
element in the pathogenesis of encephalopathy. Coagulation parameters are often deranged
with underlying liver failure and should be corrected with blood transfusion and fresh fro‐
zen plasma transfusion. If patient doesn’t respond to the supportive medical management,
liver transplantation must be considered. However, hepatic failure is rare complication after
major resection and presence of underlying liver dysfunction should prompt specialized
management of underlying cause to prevent progression of liver failure.
5.3.6. Other complications
In-hospital mortality following liver resection has been associated with perioperative myo‐
cardial infarction, sepsis with multiple organ failure and pulmonary embolism. After major
abdominal surgeries, the risk of deep venous thrombosis and pulmonary embolism is
15-40% that increases the mortality, morbidity and length of hospital stay significantly [69].
Early mobilization, intermittent pneumatic compression devices and pharmacologic agents
have important role in prevention of venous thromboembolism (VTE). While pharmacologic
thromboprophylaxis is widely accepted for most general surgery procedures, the fear of
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bleeding after major hepatectomy has limited its use. But venous thromboembolism can still
occur even in presence of deranged coagulation parameters (prolonged INR & aPTT [70]. A
higher incidence of VTE has been noted in patients not receiving thromboprophylaxis and
should be administered starting the day of surgery unless high risk of bleeding exists.
6. Summary
The expansion of major liver surgery as a treatment option for various liver tumours has
presented  new  challenges  to  surgeons  and  physicians  in  terms  of  the  assessment  and
management of  postoperative complications,  particularly those involving hepatic  insuffi‐
ciency and susceptibility to infection. Understanding of hepatic pathophysiology is impor‐
tant  for  optimal  perioperative care.  Multiple  factors  contribute  to  increased mortality  in
patients with underlying liver disease. But due to advances in surgery, anesthesia and im‐
proved critical  care  management,  there  is  progressive  improvement  in  survival  even in
complex  situations.  Patient  selection  with  evaluation  of  the  risk  factors  in  various  liver
conditions is needed. Reduction in mortality in patients with liver disease undergoing re‐
section  depends  on  close  attention  to  coagulation,  intravascular  volume,  renal  function,
electrolyte levels, cardiovascular status and nutrition. patient selection, appropriate moni‐
toring,  and  multidisciplinary  postoperative  management  are  the  key  elements  in  im‐
proved survival among patients undergoing liver resections.
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1. Introduction
In-hospital mortality rates after hepatectomy for HCC have been greatly improved due to
advances in surgical techniques and perioperative management [1-4]. However, relatively
high morbidity rates remain problematic, and bile leakage and organ/space surgical site in‐
fection (SSI) are still common causes of major morbidity after hepatectomy for HCC [5-13].
Various types of hepatectomy in many centres have recently been performed based on the
degree of hepatic functional reserve and the location of the HCC. Anatomic hepatectomy for
HCC, including subsegmentectomy, reportedly contributes to the prognosis for patients
with HCC [14-16]. In addition, the rate of repeat hepatectomy for recurrent HCC has recent‐
ly increased from 10% to 31% as the prognosis for patients with HCC has improved [17-22].
In our institution, anatomic and repeat hepatectomies for HCC have been performed aggres‐
sively [12, 16, 22]. We investigated risk factors for bile leakage and organ/space SSI follow‐
ing hepatectomies for HCC in the present series, which included a large number of patients
with a high proportion of anatomic or repeat hepatectomy. Furthermore, causes, manage‐
ment and outcomes of intractable bile leakage and organ/space SSI were investigated and
strategies to reduce major morbidity were considered.
2. Methods
2.1. Patients
Medical records of 359 patients who underwent hepatectomy without biliary reconstruction
for HCC in our department between January 1, 2001 and March 31, 2010 were studied retro‐
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1. Introduction
In-hospital mortality rates after hepatectomy for HCC have been greatly improved due to
advances in surgical techniques and perioperative management [1-4]. However, relatively
high morbidity rates remain problematic, and bile leakage and organ/space surgical site in‐
fection (SSI) are still common causes of major morbidity after hepatectomy for HCC [5-13].
Various types of hepatectomy in many centres have recently been performed based on the
degree of hepatic functional reserve and the location of the HCC. Anatomic hepatectomy for
HCC, including subsegmentectomy, reportedly contributes to the prognosis for patients
with HCC [14-16]. In addition, the rate of repeat hepatectomy for recurrent HCC has recent‐
ly increased from 10% to 31% as the prognosis for patients with HCC has improved [17-22].
In our institution, anatomic and repeat hepatectomies for HCC have been performed aggres‐
sively [12, 16, 22]. We investigated risk factors for bile leakage and organ/space SSI follow‐
ing hepatectomies for HCC in the present series, which included a large number of patients
with a high proportion of anatomic or repeat hepatectomy. Furthermore, causes, manage‐
ment and outcomes of intractable bile leakage and organ/space SSI were investigated and
strategies to reduce major morbidity were considered.
2. Methods
2.1. Patients
Medical records of 359 patients who underwent hepatectomy without biliary reconstruction
for HCC in our department between January 1, 2001 and March 31, 2010 were studied retro‐
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spectively. Patients comprised 292 men and 67 women, with a mean age of 65 years (range,
32-89 years). The aetiology of liver disease was hepatitis C virus in 163 patients, hepatitis B
virus in 122 patients, both hepatitis C virus and hepatitis B virus in 31 patients, and alcoholic
liver disease in 16 patients. Child-Pugh class was A in 332 patients and B in 27 patients. A
total of 296 patients (82.5%) underwent anatomic hepatectomy including subsegmentecto‐
my. Repeat hepatectomy was performed for 59 patients (16.4%). Repeat hepatectomy was
indicated when all tumours detected on preoperative imaging could be resected within the
hepatic functional reserve. When recurrent HCC tumours were 2 cm in maximum diameter
and 3 were present, percutaneous ablation therapies were selected despite the feasibility of
repeat hepatectomy, depending on tumour location in the liver.
2.2. Surgical procedure
Laparotomy was performed through a J incision in 287 patients, a Mercedes incision in 33
patients, a midline incision in 23 patients, and a thoraco-abdominal incision in 16 patients.
Preoperative cholangiography was not usually performed. Intraoperative ultrasonography
was performed to determine the extent of HCC and the line of parenchymal transection. Pa‐
renchymal transection was performed using an ultrasonic dissector (Sonop 5000; Aloka, To‐
kyo, Japan) combined with bipolar electrocautery. Glisson’s pedicles in livers dissected by
the ultrasonic dissector were ligated and small pedicles were resected using metallic surgi‐
cal clips. For hemihepatectomies or extended operations, hilar dissection was performed to
divide the ipsilateral branches of the hepatic artery and portal vein. The hepatic duct was
exposed inside the liver during parenchymal transection and was ligated or oversewn using
fine non-absorbable sutures. Parenchymal transection in hemihepatectomy or extended op‐
erations was performed largely without occlusion of vascular inflow. For segmentectomies
or subsegmentectomies, Glisson’s pedicle was transected at the hepatic hilus and an inter‐
mittent Pringle manoeuvre was applied during parenchymal transection.
Intraoperative cholangiography was undertaken for selected patients when the integrity of
the bile duct was in doubt. A bile leakage test using a cholangiography catheter was also
performed for selected patients when many Glisson’s pedicles were exposed in the plane of
hepatic resection. In principle, two abdominal drainage tubes were systematically posi‐
tioned and the method of placing the drainage tubes was changed according to the type of
hepatectomy. In hemihepatectomy, one drainage tube was placed on the cut surface of the
liver and another was positioned at the Winslow hiatus. In subsegmentectomy and segmen‐
tectomy, one drainage tube was placed on the cut surface of the liver and another was posi‐
tioned in the right subphrenic space. From 2001 to 2005, an open drainage system was
employed using 12-mm silicone Penrose drains (Kaneka, Osaka, Japan). From 2006 to 2010,
a closed drainage system was used with 24-Fr BLAKE silicone drains (Johnson & Johnson,
Somerville, NJ, USA). Drains were removed when the drainage was serous and contained
no bile, usually around postoperative day (POD) 5.
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2.3. Definition of bile leakage
Postoperative bile leakage was defined as the drainage of macroscopic bile from surgical
drains for more than 7 days after surgery. Major bile leakage was defined as macroscopic bile
discharge >100 ml/day that did not decrease from one day to the next. Minor bile leakage was
defined as bile leakage that did not fulfil the definition for major bile leakage. Intractable bile
leakage was defined as bile leakage requiring endoscopic retrograde biliary drainage (ERBD)
or percutaneous transhepatic biliary drainage (PTBD) during postoperative management.
2.4. Definition of SSIs
SSIs were defined according to the National Infections Surveillance system [23]. Using these
criteria, SSIs are classified as either incisional (superficial or deep) or organ/space. Criteria
for superficial incisional SSI included infection occurring at the incision site within 30 days
after surgery that involved only the skin and subcutaneous tissue and at least one of the fol‐
lowing: 1) pus discharge from the incision; 2) bacteria isolated from a sample culture from
the superficial incision; 3) localized pain, tenderness, swelling, redness, or heat; and 4)
wound dehiscence. Criteria for deep incisional SSI included infection of the fascia or muscle
related to the surgical procedure occurring within 30 days after surgery and at least one of
the following: 1) pus discharge from the deep incision; 2) spontaneous dehiscence of the in‐
cision; or 3) deliberate opening of the incision when the patient displayed the previously de‐
scribed signs and symptoms of infection. The definition of organ/space SSI was based on
postoperative findings of at least one of the following: 1) purulent drainage from a drain
without macroscopic bile discharge; or 2) intra-abdominal collection of purulent fluid con‐
firmed at the time of reoperation or percutaneous drainage. If intra-abdominal collection at
the time of reoperation or percutaneous drainage contained macroscopic bile discharge, bile
leakage was considered present. If purulent fluid was drained first and macroscopic bile
leakage subsequently became apparent, this was defined as bile leakage. In contrast, if
drainage of purulent fluid was still observed after the cessation of macroscopic bile leakage,
this was defined as organ/space SSI.
2.5. Antimicrobial prophylaxis
Prophylactic antibiotics regimens were as follows. With initial hepatectomy, a first-genera‐
tion cephalosporin was injected intravenously within 30 min prior to skin incision. In pa‐
tients who underwent operations lasting longer than 3 h, additional antimicrobial agents
were injected intravenously every 3 h, as recommended by the Center for Disease Control
guidelines [23]. These agents were also administered up to POD 2. In repeat hepatectomy,
second-generation cephalosporin was injected intravenously in the same manner as in the
initial hepatectomy and continued until POD 3.
2.6. Intervention for methicillin-resistant Staphylococcus aureus (MRSA)
With the exception of two emergency cases, all  patients underwent preoperative evalua‐
tion for MRSA, including nasal culture. As a result,  9 of the 359 patients (2.5%) showed
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spectively. Patients comprised 292 men and 67 women, with a mean age of 65 years (range,
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the ultrasonic dissector were ligated and small pedicles were resected using metallic surgi‐
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divide the ipsilateral branches of the hepatic artery and portal vein. The hepatic duct was
exposed inside the liver during parenchymal transection and was ligated or oversewn using
fine non-absorbable sutures. Parenchymal transection in hemihepatectomy or extended op‐
erations was performed largely without occlusion of vascular inflow. For segmentectomies
or subsegmentectomies, Glisson’s pedicle was transected at the hepatic hilus and an inter‐
mittent Pringle manoeuvre was applied during parenchymal transection.
Intraoperative cholangiography was undertaken for selected patients when the integrity of
the bile duct was in doubt. A bile leakage test using a cholangiography catheter was also
performed for selected patients when many Glisson’s pedicles were exposed in the plane of
hepatic resection. In principle, two abdominal drainage tubes were systematically posi‐
tioned and the method of placing the drainage tubes was changed according to the type of
hepatectomy. In hemihepatectomy, one drainage tube was placed on the cut surface of the
liver and another was positioned at the Winslow hiatus. In subsegmentectomy and segmen‐
tectomy, one drainage tube was placed on the cut surface of the liver and another was posi‐
tioned in the right subphrenic space. From 2001 to 2005, an open drainage system was
employed using 12-mm silicone Penrose drains (Kaneka, Osaka, Japan). From 2006 to 2010,
a closed drainage system was used with 24-Fr BLAKE silicone drains (Johnson & Johnson,
Somerville, NJ, USA). Drains were removed when the drainage was serous and contained
no bile, usually around postoperative day (POD) 5.
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defined as bile leakage that did not fulfil the definition for major bile leakage. Intractable bile
leakage was defined as bile leakage requiring endoscopic retrograde biliary drainage (ERBD)
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2.4. Definition of SSIs
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after surgery that involved only the skin and subcutaneous tissue and at least one of the fol‐
lowing: 1) pus discharge from the incision; 2) bacteria isolated from a sample culture from
the superficial incision; 3) localized pain, tenderness, swelling, redness, or heat; and 4)
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related to the surgical procedure occurring within 30 days after surgery and at least one of
the following: 1) pus discharge from the deep incision; 2) spontaneous dehiscence of the in‐
cision; or 3) deliberate opening of the incision when the patient displayed the previously de‐
scribed signs and symptoms of infection. The definition of organ/space SSI was based on
postoperative findings of at least one of the following: 1) purulent drainage from a drain
without macroscopic bile discharge; or 2) intra-abdominal collection of purulent fluid con‐
firmed at the time of reoperation or percutaneous drainage. If intra-abdominal collection at
the time of reoperation or percutaneous drainage contained macroscopic bile discharge, bile
leakage was considered present. If purulent fluid was drained first and macroscopic bile
leakage subsequently became apparent, this was defined as bile leakage. In contrast, if
drainage of purulent fluid was still observed after the cessation of macroscopic bile leakage,
this was defined as organ/space SSI.
2.5. Antimicrobial prophylaxis
Prophylactic antibiotics regimens were as follows. With initial hepatectomy, a first-genera‐
tion cephalosporin was injected intravenously within 30 min prior to skin incision. In pa‐
tients who underwent operations lasting longer than 3 h, additional antimicrobial agents
were injected intravenously every 3 h, as recommended by the Center for Disease Control
guidelines [23]. These agents were also administered up to POD 2. In repeat hepatectomy,
second-generation cephalosporin was injected intravenously in the same manner as in the
initial hepatectomy and continued until POD 3.
2.6. Intervention for methicillin-resistant Staphylococcus aureus (MRSA)
With the exception of two emergency cases, all  patients underwent preoperative evalua‐
tion for MRSA, including nasal culture. As a result,  9 of the 359 patients (2.5%) showed
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colonisation with MRSA on admission to our institution. In those 9 patients with detec‐
tion  of  MRSA  colonisation  from  preoperative  nasal  cultures,  decolonisation  was  per‐
formed  using  intranasal  mupirocin  therapy  (administered  twice  daily  for  3-5  days
preoperatively). Prophylactic intravenous infusion of vancomycin was not applied in the 9
patients with intranasal MRSA colonisation.
2.7. Analysis of risk factors for bile leakage and SSIs
Patient demographics, operative and tumour factors, and preoperative liver function were
evaluated to determine impacts on the occurrence of bile leakage and organ/space SSI. Pre‐
operative factors included patient age, sex, aetiology of liver disease, Child-Pugh classifica‐
tion, indocyanine green dye retention rate at 15 min (ICG-R15), serum albumin, history of
diabetes mellitus, previous radiofrequency ablation (RFA) and previous transarterial che‐
moembolisation (TACE). The cut-off level for ICG-R15 was set at 20%, because ICG-R15
<20% has been reported as the safe range for bisegmentectomy [3,5,9]. Surgical factors were
evaluated for the type of skin incision, type of hepatectomy, number of hepatectomies,
blood loss, operative time, blood transfusion, and method of abdominal drainage. With re‐
gard to the type of hepatectomy, anterior segmentectomies and medial (S4) segmentecto‐
mies were sub-grouped for analysis. The cut-off point for operative time was determined by
an analysis of the receiver operating characteristics curve for bile leakage. The optimal cut-
off for operative time was 306 min; sensitivity and specificity were 0.696 and 0.728, respec‐
tively. We thus set 300 min as the cut-off level for operative time. Tumour factors included
the number of HCC lesions and the maximum diameter of HCC. Cut-off level for HCC di‐
ameter was determined according to results from previous reports that analysed risk factors
for morbidity after hepatectomy for HCC [3,5,9,12].
2.8. Investigation of intractable bile leakage
Management and outcomes were investigated for 46 patients with postoperative bile leakage.
Indications for ERBD to treat postoperative bile leakage were based on postoperative findings
of at least one of the following: 1) amount of macroscopic bile discharge from surgical drains
>200 ml/day at 2 weeks after surgery; 2) amount of macroscopic bile discharge from surgical
drains >100 ml/day at 4 weeks after surgery; or 3) macroscopic bile discharge from surgical
drains still continuing at 6 weeks after surgery. PTBD was indicated when postoperative chol‐
angiography and biliary drainage by ERBD were considered impractical. Intractable bile leak‐
age necessitating ERBD or PTBD was encountered in 8 patients. The operative procedure,
number of hepatectomies, timing of biliary procedures, sites of bile leakage and possible caus‐
es of bile leakage were evaluated in these 8 patients with intractable bile leakage.
2.9. Investigation of characteristics in organ/space SSI
Organ/space SSI was classified according to the modified Clavien system [24]: grade I, minor
risk events not requiring special treatment; grade II, potentially life-threatening complications
requiring pharmacological treatment; grade III, complications requiring surgical, endoscopic
or radiological intervention, either with (III-b) or without (III-a) general anaesthesia; grade IV,
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life-threatening complications involving dysfunction of one (IV-a) or multiple (IV-b) major or‐
gans; and grade V, complications resulting in the death of the patient. Management and out‐
comes were investigated for 31 patients with organ/space SSI.  In addition,  the causative
bacterium was identified for both incisional and organ/space SSIs. Furthermore, pre- and in‐
traoperative  parameters,  causative  bacteria  and  hospitalisation  were  compared  between
groups classified by the number of hepatectomies in patients with organ/space SSI.
2.10. Statistical analysis
Operative time, blood loss and postoperative hospital stay are presented as mean ± standard
error of the mean. Differences in qualitative variables were assessed using Fisher's exact test or
the 2 test, while differences in quantitative variables were analysed using the Mann-Whitney
test. Uni- and multivariate logistic regression analyses were used to identify risk factors for bile
leakage and organ/space SSI based on the 18 above-mentioned clinical factors. Relative risk
was described by the estimated odds ratio (OR) with a 95% confidence interval. Two-sided P-
values were computed and an effect was considered significant at the level of P 0.05. All statis‐
tical analyses were performed using SPSS II statistical software (SPSS, Tokyo, Japan).
3. Results
3.1. Risk factors for bile leakage (Tables 1, 3)
Univariate logistic regression analysis revealed several factors associated with increased risk
of developing bile leakage. Repeat hepatectomy influenced the risk of developing bile leak‐
age, with an OR of 3.78 compared to the initial hepatectomy. In contrast, neither previous
RFA nor TACE had any significant impact on the occurrence of bile leakage. Operative time
300 min was associated with increased risk (OR, 5.32; P< 0.001), as was blood loss 2 000 ml
(OR, 4.12; P< 0.001). Multivariate analysis regarding bile leakage confirmed operative time
300 min as an independent risk factor.
Table 1. Univariate analysis of risk factors for bile leakage.
3.2. Risk factors for SSIs (Tables 2, 3)
SSIs developed in 14.5% of patients (n=52), and 3 patients showed both incisional and organ/
space SSIs. Univariate logistic regression analysis revealed several factors associated with
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colonisation with MRSA on admission to our institution. In those 9 patients with detec‐
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<20% has been reported as the safe range for bisegmentectomy [3,5,9]. Surgical factors were
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blood loss, operative time, blood transfusion, and method of abdominal drainage. With re‐
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mies were sub-grouped for analysis. The cut-off point for operative time was determined by
an analysis of the receiver operating characteristics curve for bile leakage. The optimal cut-
off for operative time was 306 min; sensitivity and specificity were 0.696 and 0.728, respec‐
tively. We thus set 300 min as the cut-off level for operative time. Tumour factors included
the number of HCC lesions and the maximum diameter of HCC. Cut-off level for HCC di‐
ameter was determined according to results from previous reports that analysed risk factors
for morbidity after hepatectomy for HCC [3,5,9,12].
2.8. Investigation of intractable bile leakage
Management and outcomes were investigated for 46 patients with postoperative bile leakage.
Indications for ERBD to treat postoperative bile leakage were based on postoperative findings
of at least one of the following: 1) amount of macroscopic bile discharge from surgical drains
>200 ml/day at 2 weeks after surgery; 2) amount of macroscopic bile discharge from surgical
drains >100 ml/day at 4 weeks after surgery; or 3) macroscopic bile discharge from surgical
drains still continuing at 6 weeks after surgery. PTBD was indicated when postoperative chol‐
angiography and biliary drainage by ERBD were considered impractical. Intractable bile leak‐
age necessitating ERBD or PTBD was encountered in 8 patients. The operative procedure,
number of hepatectomies, timing of biliary procedures, sites of bile leakage and possible caus‐
es of bile leakage were evaluated in these 8 patients with intractable bile leakage.
2.9. Investigation of characteristics in organ/space SSI
Organ/space SSI was classified according to the modified Clavien system [24]: grade I, minor
risk events not requiring special treatment; grade II, potentially life-threatening complications
requiring pharmacological treatment; grade III, complications requiring surgical, endoscopic
or radiological intervention, either with (III-b) or without (III-a) general anaesthesia; grade IV,
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life-threatening complications involving dysfunction of one (IV-a) or multiple (IV-b) major or‐
gans; and grade V, complications resulting in the death of the patient. Management and out‐
comes were investigated for 31 patients with organ/space SSI.  In addition,  the causative
bacterium was identified for both incisional and organ/space SSIs. Furthermore, pre- and in‐
traoperative  parameters,  causative  bacteria  and  hospitalisation  were  compared  between
groups classified by the number of hepatectomies in patients with organ/space SSI.
2.10. Statistical analysis
Operative time, blood loss and postoperative hospital stay are presented as mean ± standard
error of the mean. Differences in qualitative variables were assessed using Fisher's exact test or
the 2 test, while differences in quantitative variables were analysed using the Mann-Whitney
test. Uni- and multivariate logistic regression analyses were used to identify risk factors for bile
leakage and organ/space SSI based on the 18 above-mentioned clinical factors. Relative risk
was described by the estimated odds ratio (OR) with a 95% confidence interval. Two-sided P-
values were computed and an effect was considered significant at the level of P 0.05. All statis‐
tical analyses were performed using SPSS II statistical software (SPSS, Tokyo, Japan).
3. Results
3.1. Risk factors for bile leakage (Tables 1, 3)
Univariate logistic regression analysis revealed several factors associated with increased risk
of developing bile leakage. Repeat hepatectomy influenced the risk of developing bile leak‐
age, with an OR of 3.78 compared to the initial hepatectomy. In contrast, neither previous
RFA nor TACE had any significant impact on the occurrence of bile leakage. Operative time
300 min was associated with increased risk (OR, 5.32; P< 0.001), as was blood loss 2 000 ml
(OR, 4.12; P< 0.001). Multivariate analysis regarding bile leakage confirmed operative time
300 min as an independent risk factor.
Table 1. Univariate analysis of risk factors for bile leakage.
3.2. Risk factors for SSIs (Tables 2, 3)
SSIs developed in 14.5% of patients (n=52), and 3 patients showed both incisional and organ/
space SSIs. Univariate logistic regression analysis revealed several factors associated with
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increased risk of developing SSIs. Repeat hepatectomy influenced the risk of developing
SSIs, with an OR of 8.27 for initial hepatectomy. Operative time 300 min was associated with
increased risk (OR, 4.46; P<0.001). The presence of blood transfusion influenced the risk of
developing SSIs. Presence of bile leakage was associated with increased risk of SSIs (OR,
6.40; P=0.002). Multivariate analysis regarding SSIs confirmed both repeat hepatectomy and
operative time 300 min as independent risk factors.
3.3. Risk factor for incisional SSI (Tables 2, 3)
Incidence of incisional SSI was 6.7% (n=24). Univariate logistic regression analysis revealed
that the presence of blood transfusion was associated with increased risk of developing inci‐
sional SSI. Type of skin incision classified according to the presence or absence of transverse
incision showed no significant influence on the occurrence of incisional SSI in this series.
Multivariate analysis regarding incisional SSI confirmed the presence of blood transfusion
as an independent risk factor.
3.4. Risk factors for organ/space SSI (Tables 2, 3)
Organ/space SSI developed in 8.6% of patients (n = 31). Univariate logistic regression analy‐
sis revealed several factors associated with increased risk of developing organ/space SSI. Re‐
peat hepatectomy influenced the risk of developing organ/space SSI, with an OR of 4.29
compared to initial hepatectomy. In contrast, neither previous RFA nor TACE exerted any
significant impact on occurrence of organ/space SSI.
Table 2. Univariate analysis of risk factors for SSIs.
The method of abdominal drainage (open Penrose drains or closed suction drains) showed
no significant influence. Operative time 300 min was associated with increased risk of or‐
gan/space SSI (OR, 2.99; P< 0.001). Presence of bile leakage was likewise associated with in‐
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creased risk (OR, 3.16; P = 0.01). Blood loss 2 000 ml was associated with increased risk (OR,
2.63; P< 0.001). Multivariate analysis confirmed both repeat hepatectomies and presence of
bile leakage as independent risk factors for organ/space SSI.
Table 3. Multivariate analysis of risk factors for bile leakage and SSIs.
3.5. Management and outcomes of bile leakage (Figure 1)
Management and outcomes of the 46 patients with bile leakage are shown in Figure 1.
Figure 1. Medical management and outcomes for patients with postoperative bile leakage.
Minor bile leakage in 30 patients (65%) was controllable and cured by conservative therapies
comprising drainage alone in 23 patients and drainage with irrigation in 7 patients. Sixteen pa‐
tients (35%) showed complications of major bile leakage. In 8 of these patients, the major bile
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increased risk of developing SSIs. Repeat hepatectomy influenced the risk of developing
SSIs, with an OR of 8.27 for initial hepatectomy. Operative time 300 min was associated with
increased risk (OR, 4.46; P<0.001). The presence of blood transfusion influenced the risk of
developing SSIs. Presence of bile leakage was associated with increased risk of SSIs (OR,
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operative time 300 min as independent risk factors.
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that the presence of blood transfusion was associated with increased risk of developing inci‐
sional SSI. Type of skin incision classified according to the presence or absence of transverse
incision showed no significant influence on the occurrence of incisional SSI in this series.
Multivariate analysis regarding incisional SSI confirmed the presence of blood transfusion
as an independent risk factor.
3.4. Risk factors for organ/space SSI (Tables 2, 3)
Organ/space SSI developed in 8.6% of patients (n = 31). Univariate logistic regression analy‐
sis revealed several factors associated with increased risk of developing organ/space SSI. Re‐
peat hepatectomy influenced the risk of developing organ/space SSI, with an OR of 4.29
compared to initial hepatectomy. In contrast, neither previous RFA nor TACE exerted any
significant impact on occurrence of organ/space SSI.
Table 2. Univariate analysis of risk factors for SSIs.
The method of abdominal drainage (open Penrose drains or closed suction drains) showed
no significant influence. Operative time 300 min was associated with increased risk of or‐
gan/space SSI (OR, 2.99; P< 0.001). Presence of bile leakage was likewise associated with in‐
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creased risk (OR, 3.16; P = 0.01). Blood loss 2 000 ml was associated with increased risk (OR,
2.63; P< 0.001). Multivariate analysis confirmed both repeat hepatectomies and presence of
bile leakage as independent risk factors for organ/space SSI.
Table 3. Multivariate analysis of risk factors for bile leakage and SSIs.
3.5. Management and outcomes of bile leakage (Figure 1)
Management and outcomes of the 46 patients with bile leakage are shown in Figure 1.
Figure 1. Medical management and outcomes for patients with postoperative bile leakage.
Minor bile leakage in 30 patients (65%) was controllable and cured by conservative therapies
comprising drainage alone in 23 patients and drainage with irrigation in 7 patients. Sixteen pa‐
tients (35%) showed complications of major bile leakage. In 8 of these patients, the major bile
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leakage was treated using drainage with irrigation. One patient died due to subsequent in‐
tractable ascites and liver failure during drainage with irrigation, while the other 7 patients
healed. The remaining 8 patients with major bile leakage needed either ERBD or PTBD.
3.6. Characteristics of 8 patients with intractable bile leakage (Table 4)
We investigated the characteristics of the 8 patients who needed either ERBD or PTBD for bile
leakage. High-risk surgical procedures were performed in most of these cases and repeat hepa‐
tectomy was performed in 6 of the 8 patients. The median timing of biliary procedures was
POD 21.5 (range, POD 2-45). Bile leakage sites identified on postoperative cholangiography in‐
cluded the hepatic duct in 2 patients and the raw surface of the liver in 6 patients. Possible caus‐
es of bile leakage as assessed by postoperative cholangiography were as follows: stricture of
the hepatic duct that existed preoperatively, possibly due to previous treatments for HCC in 4
patients (2 patients due to previous hepatectomies, 1 patient due to previous TACE, 1 patient
due to previous RFA), stricture of the hepato-jejunostomy from previous pancreatoduodenec‐
tomy in 1 patient, dyskinesis of the papilla of Vater in 1 patient and intraoperative injury of the
left hepatic duct related to repeat hepatectomy in 2 patients. Three of these 8 patients subse‐
quently showed complications of intractable ascites. In 2 patients, both bile leakage and in‐
tractable ascites were cured without intra-abdominal septic complications. The other patient
with stricture and injury of the left hepatic duct caused by a previous RFA died due to intracta‐
ble ascites, uncontrollable biliary infection and liver failure. Bile leakage in the other 5 patients
healed after either ERBD or PTBD, with no other major morbidities.
Table 4. Characteristic and management of 8 patients with intractable bile leakage.
Hepatic Surgery112
3.7. Management and outcome of organ/space SSI
Organ/space SSI in 31 patients was classified as follows: abscess on the cut surface of the liv‐
er in 26 patients; right subphrenic abscess in 4 patients; and liver abscess in 1 patient. One of
the 31 patients with organ/space SSI was treated by reoperation due to right subphrenic ab‐
scess, but died due to myocardial infarction. Eleven patients needed percutaneous drainage
of organ/space SSI and all of them were cured. Organ/space SSI in 19 patients healed with
irrigation of the pre-existing drain. As a result, 31 patients with organ/space SSI were strati‐
fied according to the modified Clavien system as follows: grade I, 0 patients; II, 13 patients;
III-a, 15 patients; III-b, 2 patients; IV-a, 1 patient; IV-b, 0 patients; and V, 0 patients. No mor‐
tality was associated with organ/space SSI in this series, but the postoperative hospital stay
was significantly longer for patients with organ/space SSI (53 7.2 days) than for patients
without organ/space SSI (27 0.9 days, P = 0.001).
3.8. Bacteria causing incisional and organ/space SSI (Table 5)
Causative bacteria for incisional and organ/space SSI comprised gram-positive cocci in 17
patients (70.8%) and 19 patients (61.3%), and gram-negative rods in 6 patients (25.0%) and 9
patients (29.0%), respectively, indicating similar proportions of gram-positive cocci and
gram-negative rods in both incisional and organ/space SSI. MRSA was the causative bacteria
in 12 of 19 patients with organ/space SSI caused by gram-positive cocci.
Table 5. Causative bacteria of incisional and organ/space SSI.
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with stricture and injury of the left hepatic duct caused by a previous RFA died due to intracta‐
ble ascites, uncontrollable biliary infection and liver failure. Bile leakage in the other 5 patients
healed after either ERBD or PTBD, with no other major morbidities.
Table 4. Characteristic and management of 8 patients with intractable bile leakage.
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3.7. Management and outcome of organ/space SSI
Organ/space SSI in 31 patients was classified as follows: abscess on the cut surface of the liv‐
er in 26 patients; right subphrenic abscess in 4 patients; and liver abscess in 1 patient. One of
the 31 patients with organ/space SSI was treated by reoperation due to right subphrenic ab‐
scess, but died due to myocardial infarction. Eleven patients needed percutaneous drainage
of organ/space SSI and all of them were cured. Organ/space SSI in 19 patients healed with
irrigation of the pre-existing drain. As a result, 31 patients with organ/space SSI were strati‐
fied according to the modified Clavien system as follows: grade I, 0 patients; II, 13 patients;
III-a, 15 patients; III-b, 2 patients; IV-a, 1 patient; IV-b, 0 patients; and V, 0 patients. No mor‐
tality was associated with organ/space SSI in this series, but the postoperative hospital stay
was significantly longer for patients with organ/space SSI (53 7.2 days) than for patients
without organ/space SSI (27 0.9 days, P = 0.001).
3.8. Bacteria causing incisional and organ/space SSI (Table 5)
Causative bacteria for incisional and organ/space SSI comprised gram-positive cocci in 17
patients (70.8%) and 19 patients (61.3%), and gram-negative rods in 6 patients (25.0%) and 9
patients (29.0%), respectively, indicating similar proportions of gram-positive cocci and
gram-negative rods in both incisional and organ/space SSI. MRSA was the causative bacteria
in 12 of 19 patients with organ/space SSI caused by gram-positive cocci.
Table 5. Causative bacteria of incisional and organ/space SSI.
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3.9. Comparison between initial and repeat hepatectomies in patients with organ/space
SSI (Table 6)
We compared clinical parameters between initial and repeat hepatectomies in patients with
organ/space SSI (Table 6). HCC diameter was significantly larger in patients with organ/
space SSI who underwent initial hepatectomy than in patients who underwent repeat hepa‐
tectomy. No significant differences were seen between groups in any other preoperative pa‐
rameters, including patient demographics and preoperative liver function. No significant
differences were identified between groups in operative parameters, including blood loss,
operative time and blood transfusion. Rates of bile leakage were similar between groups. In
contrast, in terms of bacteria causing organ/space SSI, detection of MRSA was significantly
more frequent in the repeat hepatectomy group than in the initial group.
Table 6. Comparison between initial nad repeat hepatectomies in patients with organ/space SSI.
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4. Discussion
In-hospital mortality rates after hepatectomy for HCC have been greatly improved due to
advances in surgical techniques and perioperative management [1-4]. However, relatively
high morbidity rates  remain problematic.  The overall  morbidity rates  after  hepatectomy
for liver tumors have been reported to be 22.6 – 47.7%, and bile leakage and organ/space
surgical site infection (SSI) are still common causes of major morbidity after hepatectomy
for  HCC [5-13].  Various  types  of  hepatectomy in  many centres  have recently  been per‐
formed based on the degree of hepatic functional reserve and the location of the HCC. In
addition,  the rate of  repeat  hepatectomy for recurrent  HCC has recently increased from
10% to 31% as the prognosis for patients with HCC has improved [17-22]. The characteris‐
tic of our study is that this series consisted of a large number and percentage of both ana‐
tomic and repeat hepatectomies for HCC.
Rates of bile leakage after hepatectomy for liver tumours and benign lesions have been re‐
ported as 3.6%-12.0%, varying widely among different studies [6, 7, 11, 12, 25-30]. However,
no standardised definition of bile leakage after hepatectomy has been established. In previ‐
ous reports [6, 8, 11, 13, 30], the definition based on the drainage of macroscopic bile has
been adopted. Several studies has proposed the definition on quantitative basis using the bi‐
lirubin concentration within the drain [26, 28], but these cut-off values varied. Currently, the
International Study Group of Liver Surgery has proposed a consensus definition of bile leak‐
age based on the postoperative course of bilirubin concentration in serum and drainage flu‐
id [31]. Application of a uniform definition of bile leakage is indispensable to enabling
standardised comparison of the results of different clinical reports and to facilitating objec‐
tive evaluation of therapeutic modalities in the field of hepatectomies.
In the present study, prolonged operative time was identified as an independent risk factor
for bile leakage and the type of hepatectomy had no significant impact on the rate of bile
leakage. Several groups have reported that hepatectomies in which the cut surface exposed
the major Glisson’s sheath (i.e., central bisegmentectomy, S4 segmentectomy, and S8 subseg‐
mentectomy) were independent risk factors for bile leakage [8, 28-30]. However, our results
indicate that the standard types of hepatectomy were not risk factors for bile leakage, even if
a wide cut surface with an exposed major Glisson’s sheath was necessary, when assessment
of liver function was appropriate and surgical procedures were performed carefully during
transection of the liver parenchyma. We assume that the prolongation of operative time in
this study was related to the extended duration of liver parenchymal transection and/or re‐
section for severe intra-abdominal adhesions around the liver.
Our results revealed latent stricture of the biliary anatomy and intraoperative injury of the
hepatic duct related to repeat hepatectomy as the main causes of intractable bile leakage re‐
quiring invasive treatment. Preoperative assessment of the biliary anatomy should therefore
be considered for selected patients at high risk of intractable bile leakage. Various measures
could also be applied during surgery to diminish the incidence of major and intractable bile
leakage. First, intraoperative cholangiography should be used, particularly in repeat hepa‐
tectomies and in patients who have been treated with RFA or TACE for HCC located in the
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hepatic hilar region, as the identification of bile duct injury or stricture could allow immedi‐
ate correction. Second, T-tube drainage or trans-cystic duct drainage of the common bile
duct could be indicated in patients needing decompression of the biliary tree, such as pa‐
tients with dyskinesis of the papilla of Vater. Third, particularly in repeat systematised hep‐
atectomies, division of the bile ducts could be performed inside the liver during
parenchymal transection, as this procedure could decrease the risk of injury to the bile ducts
compared to division of the bile ducts at the liver hilum.
In the 1980s and 1990s, organ/space SSI formation after hepatectomy was reported as a fatal
complication causing liver failure and death [32-34]. Although rates of organ/space SSI after
hepatectomy have been reported as 4.7%-25% [35-42], hospital mortality rates caused by or‐
gan/space SSI have declined [7-10, 36, 40]. Several groups have reported high patient age
and presence of diabetes mellitus as independent risk factors for organ/space SSI [36, 39].
However, these variables were not identified as independent risk factors for organ/space SSI
in the present study. Our key result was the identification of repeat hepatectomy as an inde‐
pendent risk factor for organ/space SSI, suggesting that treatment strategies need to be es‐
tablished to reduce the high rate of organ/space SSI after repeat hepatectomy.
Repeat hepatectomy was identified as an independent risk factor for SSI and organ/space
SSI, but previous RFA and TACE were not. Repeat hepatectomy for recurrent HCC is useful
in establishing the good long-term outcomes. Cumulative 5-year survival rates after second
hepatectomy have been reported as 41-69% [17-22]. RFA has recently been confirmed as a
safe and promising therapy for recurrent HCC after hepatectomy. However, sufficient evi‐
dence does not exist to confirm whether RFA actually improves long-term outcomes. Cumu‐
lative 5-year survival rates after RFA for recurrent HCC after hepatectomy have been
reported as 18-51.6% [43-45]. RFA is sometimes ineffective for HCC on the liver surface or
near large vessels. In addition, postoperative adhesions between the remnant liver and gas‐
trointestinal tract may prevent safe percutaneous RFA in patients with recurrent HCC.
In this study, MRSA was detected more frequently in organ/space SSI after repeat hepa‐
tectomy compared with after initial hepatectomy. We assume that most organ/space SSIs
with MRSA after repeat hepatectomy develop as a result of contamination when the sur‐
gical  procedure comes into contact  with intra-abdominal  colonisation or micro-abscesses
of MRSA that had formed after the initial hepatectomy. This assumption might be partial‐
ly supported by our result that the method of abdominal drainage (open or closed) had
no significant influence on the occurrence of organ/space SSI. If this assumption is valid,
preoperative interventions for MRSA, consisting of nasal culture and decolonisation of na‐
sal MRSA, will not greatly reduce the occurrence of organ/space SSI involving MRSA af‐
ter  repeat  hepatectomy.  Walsh  et  al.  recently  reported  that  an  MRSA  intervention
program, in which all patients received intranasal mupirocin and those patients colonised
with MRSA received prophylactic  intravenous infusion of vancomycin,  resulted in near-
complete  and sustained elimination of  MRSA SSIs  after  cardiac  surgery [46].  Regarding
patients  who  undergo  repeat  hepatectomies,  preoperative  detection  of  intra-abdominal
colonisation or micro-abscess containing MRSA is difficult. MRSA intervention programs
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thus need to be improved, particularly for patients who undergo repeat hepatectomies, by
considering the prophylactic intravenous administration of vancomycin.
In conclusion, our results reveal prolonged operative time as an independent risk factor for bile
leakage, and latent stricture of the biliary anatomy and intraoperative injury of the hepatic
duct related to repeat hepatectomy as the main causes of intractable bile leakage necessitating
invasive treatment. Repeat hepatectomy was also identified as an independent risk factor for
organ/space SSI, with MRSA as the main causative bacteria in organ/space SSI after repeat hep‐
atectomy for HCC. Establishment of treatment strategies is thus important for reducing the
high rate of organ/space SSI after repeat hepatectomy. In addition, preoperative assessment of
the biliary anatomy and surgical procedures to decrease the incidence of major bile leakage
should be considered for selected patients at high risk of intractable bile leakage.
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1. Introduction
Ischemia-Reperfusion (I/R) injury is an important cause of liver damage occurring during
surgical procedures including hepatic resections and liver transplantation (LT) [1-3]. The
shortage of organs has led centers to expand their criteria for the acceptance of marginal
grafts that exhibit poor tolerance to I/R [4]. Some of these include the use of organs from old‐
er donors and grafts such as small-for-size or steatotic livers. However, I/R injury is the un‐
derlying cause of graft dysfunction in marginal organs [4]. Indeed, the use of steatotic livers
for transplantation is associated with an increased risk of primary nonfunction or dysfunc‐
tion after surgery [5]. In addition, the occurrence of postoperative liver failure after hepatic
resection in a steatotic liver exposed to normothermic ischemia has been reported [6]. A
large number of factors and mediators play a part in liver I/R injury. The relationships be‐
tween the signalling pathways involved are highly complex and it is not yet possible to de‐
scribe, with absolute certainty, the events that occur between the beginning of reperfusion
and the final outcome of either poor function or a non-functional liver graft. We will show
that the mechanisms responsible for hepatic I/R injury depends on the experimental model
used, who are valuable tool for understanding the physiopathology of hepatic I/R injury and
discovering novel therapeutic targets and drugs. Several strategies to protect the liver from
I/R injury have been developed in animal models and, some of these, might find their way
into clinical practice. The species used for experimental investigation of hepatic I/R injury
range from mice to pigs. The book chapter will discuss the numerous experimental models
used to study the complexity of hepatic I/R injury, data reported in choice of the animal
model, when selecting an animal species, the age, the sex, the degree of steatosis…etc. Thus,
the different strengths and limitations of the different experimental models will be dis‐
cussed. Also the standardized experimental conditions, such as anesthetic and analgesic
procedures will be described. We also attempt to highlight the fact that the types of ischemia
(cold and warm ischemia) play an important role in experimental liver surgery. The most
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existing reviews concerning about mechanisms responsible of I/R does not make a distinc‐
tion between cold and warm ischemia. We will discuss the different experimental models of
normothermic ischemia including global hepatic ischemia with portocaval decompression,
global liver ischemia with spleen transposition and partial liver ischemia. Among the differ‐
ent experimental models of cold hepatic I/R injury, we will described the different experi‐
mental models used, including a section on orthotopic liver transplantation (OLT) because it
is a common yet and complex microsurgical technique. In an attempt to expand the size of
the donor pool, the different surgical techniques including reduced-size liver transplanta‐
tion (RSLT), split liver transplantation (SLT) and living donor liver transplantation (LDLT)
will be mentioned in the book chapter. In line with this, the optimization of graft function
and survival through the static organ preservation and machine perfusion will also dis‐
cused. Static organ preservation was a breakthrough and remains the conventional method
of preservation. The machine perfusion has emerged as a suitable strategy for preserving
liver grafts with promising data over the past decade, especially when marginal organs such
as steatotic liver are used for transplantation. The strengths and disadvantages of the differ‐
ent types of machine perfusion (normothermic, hypothermic and subnormothermic machine
perfusion) will be discussed. Furthermore some factors, including the duration and extent of
hepatic ischemia, starvation, graft, age, and steatosis-which must be considered before the
selection of an experimental model of hepatic I/R-will be mentioned. All of these factors con‐
tribute to enhancing liver susceptibility to I/R injury. In line with this, we will focused on the
negative effects of ischemia on liver regeneration in both normal and marginal livers when
they are subjected to liver surgery associated with hepatic resections or LT. The different ex‐
perimental models of hepatic I/R in which both conditions-ischemia and resection- are
present will be described.
2. Hepatic ischemia-reperfusion injury
Due to the complexity of hepatic I/R injury, the present review summarizes the established
basic concepts of the mechanisms and cell types involved in this process (Fig. 1). The imbal‐
ance between nitric oxide (NO) and endothelin production, contributes to microcirculatory
diseases associated with I/R. Concomitantly, the activation of Kupffer cells (KC) releases re‐
active oxygen species (ROS) and proinflammatory cytokines, including tumour necrosis fac‐
tor-α (TNF-α) and interleukin-1 (IL-1) [7-9]. ROS can also derive from mitochondria and the
xanthine dehydrogenase/xanthine oxidase (XDH/XOD) pathway in activated SEC and hepa‐
tocytes. Cytokines promote neutrophil activation and accumulation, thereby contributing to
the progression of parenchymal injury by releasing ROS and proteases [7,10]. Capillary nar‐
rowing also contributes to hepatic neutrophil accumulation [11]. Besides, IL-1 and TNF-α re‐
cruit and activate CD4+ T-lymphocytes, which produce granulocyte-macrophage colony-
stimulating factor (GM-CSF), interferon gamma (INF-γ) and TNF-β. These cytokines
amplify KC activation and TNF-α and IL-1 secretion and promote neutrophil recruitment
and adherente into the liver sinusoids [12]. Platelet activating factor can prime neutrophils
for ROS generation, whereas leukotriene B4 (LTB4) contributes to the amplification of the
neutrophil response [7,10]. In addition, I/R initiates protein misfolding in the endoplasmic
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reticulum (ER), which can activate a highly conserved unfolded protein response (UPR) sig‐
nal transduction pathway. The UPR is characterized by coordinated activation of three ER
transmembrane proteins, inositol-requiring enzyme 1 (IRE1), PKR-like ER kinase (PERK)
and activating transcription factor (ATF)-6. If the damage is so severe that homeostasis can‐
not be restored, ER stress signal transduction pathways ultimately initiate apoptosis and ne‐
crosis [9]. In addition to the high ROS level–generating system found in liver grafts shows
low levels of antioxidants such as glutathione (GSH) and superoxide dismutase (SOD) [1,9].
Alterations in the renin-angiotensin system (RAS), retinol binding protein 4 (RBP4), adipo‐
nectin and peroxisome proliferator activated receptor gamma (PPARγ) contribute to oxida‐
tive stress. Toll like receptor (TLR4) signaling pathway is also responsible for the hepatic I/R
damage. Myeloid differentiation primary response gene 88 (MyD88) and TIR-domain-con‐
taining adapter-inducing interferon-β (TRIF) activate intracellular signaling cascades that ul‐
timately trigger an inflammatory response [9,13].
Figure 1. Mechanisms involved in hepatic ischemia-reperfusion injury. ATP, adenosine triphosphate; Cyt c: cytochrome
c; EC, endothelial cell; ET, endothelin; GM-CSF, granulocyte-macrophage colony-stimulating factor; GSH, glutathione;
ICAM, intracellular cell adhesion molecule; IFN α/β, interferon α/β; IL, interleukin; INF, interferon; IRE1, inositol-requir‐
ing enzyme 1; KC, kupffer cell; LTB4, leucotriene B4; MyD88, myeloid differentiation primary response gene 88; NO,
nitric oxide; ONOO-, peroxynitrite; PAF, platelet activating factor; PERK, protein kinase-like endoplasmic reticulum kin‐
ase; PPARγ, peroxisome proliferator-activated receptor γ; RBP4, retinol binding protein 4; Renin-Angiotensin system
(RAS): Ang II and Ang 1-7, angiotensin; ROS, reactive oxygen species; SLP, secretory leukocyte protease inhibitor; SOD,
superoxide dismutase; TLR4, toll-like receptor 4; TNF, tumor necrosis factor; TRAF6, TNF receptor-associated factor 6;
TRIF, TIR-domain-containing adapter-inducing interferon- β; UPR/ER, unfolded protein response/endoplasmic reticu‐
lum; VCAM, vascular cell adhesion molecule; X/XOD, xanthine/xanthine oxidase
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Experimental surgery is an activity within the scientific development, offering a wide range
of possibilities for the progress of medicine. As a discipline can be accessed from various
branches of science and allows testing and development of surgical procedures and learning
the scientific method, so that, working with laboratory animals has been and is required
prelude to innovation and development of advances in clinical surgery. The reproduction
and validation of experimental models has facilitated the extrapolation of the knowledge ac‐
quired to Medicine [16]. The animals used in research models have been divided into four
groups: spontaneous, induced, negative and orphans. 1) The spontaneous or non-manipu‐
lated models are obtained by selection of inbred animals that express a variable or among
populations in which a large number of animals that express variable; 2) Induced or manip‐
ulated models are obtained by an experimental challenge that can be classified into five
groups: A. Administration of biologically active substances, eg., induction of steatosis after
alcohol ingestion. B. Surgical manipulation, such as partial hepatectomy (PH) for the study
of liver regeneration. C. Administration of modified diets, lack or surplus components, e.g.,
in the study of hyperlipidemia. D. Genetic manipulation and transgenic animals which pro‐
duce special models that are being helpful in understanding mechanisms of pathogenesis
and therapy. 3) The negative patterns are those in which a given variable does not develop.
The interest is in studying the mechanisms that provide resistance. 4) Orphan models are
those expressing an unknown variable in humans [16].
The speed of human studies is slow, the majority of human tissues are not routinely accessi‐
ble for research purposes, and there is a very limited opportunity for interventional studies.
Although scientific research has always relied on the use of cell cultures, information that is
obtained through in vitro studies can be extrapolated to biomedical research only when ana‐
lyzed within a complex organism with metabolic functioning. Therefore, one avenue hold‐
ing tremendous potential in the search for therapies against I/R damage is the use of intact
living systems, in which complex biological processes can be examined. There are many ad‐
vantages of animal studies: large numbers of animals (especially rodents) can be bred and
studied, interventional studies can be performed, and established and emerging tools for
targeted manipulation of gene expression levels provide insight into the function of media‐
tors in hepatic I/R injury.
Comparison of the results of animal studies and their extrapolation to human beings is feasi‐
ble, but with limitations. Among the primary obstacles are differences in hypothermia and
ischemia tolerance, differences in the anatomy of the livers of various species and subspe‐
cies, differences between and within the experimental models used, and differences in the
modes of administration, dosage, and metabolic breakdown of the drugs under investiga‐
tion. Thus, it is very important to choose the animal species and the experimental model and
to standardize the protocol according to the clinical question under study.
Small and large animals have their own advantages and disadvantages but the ultimate
choice of animal species depends essentially on the scientific problema in question. Small
animals such as mice and rats are exceptionally useful because they are easy to manage,
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present minimal logistical, financial, or ethical problems, and provide the potential for ge‐
netic alterations (e.g., transgenic and knockout animals). However, an important drawback
is that the results of studies performed in small animals are of limited applicability to hu‐
man beings due to their varying size and anatomy of the liver and their faster metabolism
[17]. Large animals such as pigs, sheep, and dogs exhibit greater similarity in their anatomy
and physiology to human beings. Thus, they are more suited for the study of problems of
direct clinical relevance. However, their use is restricted by serious logistical and financial
difficulties and often by ethical concerns. Furthermore, the technical possibilities of blood
and tissue processing are extremely restricted because of the limited availability of immuno‐
logical tools for use in large animal species [17].
Extensive data exist on liver anatomy in various species of animals, but a few examples of
species variations will suffice to prove that caution is warranted in the extrapolation of this
data to humans. Mice and rats each have 4 liver lobes: median (or middle), left, right, and
caudate and all, except the left, are further subdivided into 2 or more parts. Human liver
lobes can be subdivided into 9 segments based on the vascular and ductal branching pat‐
terns to the right and lefts sides. The hepatic lobes of the rat appear to have similar funda‐
mental portal and hepatic venous systems, and thus segments, comparable to that of human
liver. The vascular systems to or from lobes show individual variations in humans as well as
in rats. In humans and other mammals, sinusoids drain only into the terminal hepatic veins
whereas in the rat sinusoids enter the hepatic venous system at all levels of the hepatic ve‐
nous tree. In rats, unlike humans, the sinusoids are supplied not only by the terminal portal
venules but also directly from larger venous branches. In addition, rat livers lack the septal
vein branches, which are present both in humans and pigs [18]. The presence of arterio-por‐
tal anastomosis is very frecuent in rats but not in hamsters and humans. The rat is unique in
possessing a perihilar biliary plexus, which is present from the large hiliar portal tracts to
smaller portal tracts. An equivalent, less developed structure exists in humans only in large
portal tracts. The biliary system in pigs lacks this plexus altogether, but contains numerous
side pouches throughout the course of the bile duct [18,19]. Mice and humans have a gall
bladder, but not the rat. Significant difference is present among the species with respect to
the extent of hepatic parenchymal innervation and the human has the most abundant sup‐
ply of autonomic nerves in the intraparenchymal region [20]. Differences in hepatic cell
types have been reported depending of species evaluated. For example, regarding to endo‐
thelial cells, rats have relatively higher fenestrae compared to some other species. Defenes‐
tration is though to play a role in some liver diseases [18]. Intrinsic biochemical differences
between the hepatocytes of the various species have been also reported. Rats and mice are
extremely sensitive to the response of peroxisome proliferators, hamsters show a less
marked response while primates and humans are insensitive or non-responsive [21]. There
are two principle hypotheses to explain species differences in response to PPs: quantity of
PPARa and/or the quality of the PPARα-mediated response [22].
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lobes can be subdivided into 9 segments based on the vascular and ductal branching pat‐
terns to the right and lefts sides. The hepatic lobes of the rat appear to have similar funda‐
mental portal and hepatic venous systems, and thus segments, comparable to that of human
liver. The vascular systems to or from lobes show individual variations in humans as well as
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whereas in the rat sinusoids enter the hepatic venous system at all levels of the hepatic ve‐
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possessing a perihilar biliary plexus, which is present from the large hiliar portal tracts to
smaller portal tracts. An equivalent, less developed structure exists in humans only in large
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the extent of hepatic parenchymal innervation and the human has the most abundant sup‐
ply of autonomic nerves in the intraparenchymal region [20]. Differences in hepatic cell
types have been reported depending of species evaluated. For example, regarding to endo‐
thelial cells, rats have relatively higher fenestrae compared to some other species. Defenes‐
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between the hepatocytes of the various species have been also reported. Rats and mice are
extremely sensitive to the response of peroxisome proliferators, hamsters show a less
marked response while primates and humans are insensitive or non-responsive [21]. There
are two principle hypotheses to explain species differences in response to PPs: quantity of
PPARa and/or the quality of the PPARα-mediated response [22].
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When selecting an animal species, the age and sex of the animals should be considered. De‐
pending on the duration of ischemia, young (35–50 g) and older rats (250–400 g) exhibit sig‐
nificant differences in their hepatic microcirculation [23]. A mature rat weighing more than
250 g (14–16 weeks old) is the most suitable because younger rats can present technical
problems, whereas older rats are more prone to respiratory infections and fat accumulation.
Sex selection also affects experimental results, as hormone levels in female animals are de‐
pendent on the estrous cycle, which certainly affects the ischemia tolerance of the liver. For
instance, a study demonstrated that after normothermic liver ischemia, male rats were less
sensitive to reperfusion injury than female rats.
Considering the relevancy of hepatic steatosis in surgery, experimental models of hepatic
I/R injury in the presence of steatosis have been developed. However, the mechanisms in‐
volved in hepatic I/R injury, as it will be described in following sections, are different de‐
pending on the method used to induce steatosis. The different models of steatosis include 1)
induced genetic models; 2) animals fed diets with high levels of saturated fat and/or carbo‐
hydrates and/or proteins; 3) animals fed diets deficient in methyl groups (choline, methio‐
nine, folates); and 4) animals fed modified high-fat diets (lower methionine and choline and
higher-fat content).
The induction of I/R injury must be performed under standardized experimental conditions.
Of primary importance are the conditions under which the animals are kept such as ade‐
quate acclimatization time, maintenance under climatized conditions with 12 hours light / 12
hours darkness, and standardized diets. The anesthetic method and postoperative analgesic
regimen must also be standardized. When choosing the anesthetic and analgesic procedures,
possible interactions with liver metabolism must be considered. Attention must be paid to
adequate monitoring of blood pressure, heart rate, and body temperature.
4. Normothermic hepatic ischemia
4.1. Global hepatic ischemia with portocaval decompression
The model of global liver ischemia with portal decompression ideally simulates the clinical
situation of warm ischemia after the Pringle maneuver for liver resection and LT. The first
successful shunt operation in humans was performed by Vidal in 1903 [24]. Blakemore was
one of the first workers to report successful portal-systemic anastomosis in rats working
principally with endothelium-lined tubes [25]. Burnett et al., modified this technique to form
a portocaval shunt [26]. In 1959 Bernstein and Cheiker developed the portosystemic shunt
that conducted the portal blood after functional hepatectomy into one of the iliac veins [27].
In small animals, in addition to many other shunt techniques such as the portofemoral shunt
and the mesentericocaval shunt via the jugular vein, in 1995, Spiegel et al., developed the
splenocaval shunt [28] (Figure 2).
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Figure 2. Models of global normotermic liver ischemia. A) Pringle-maneuver. B) Splecnocaval shunt. C) Portojugular
shunt. D) Spleen transposition.
4.2. Global liver ischemia with spleen transposition
Bengmark et al., developed this model in 1970 for the surgical treatment of portal hyperten‐
sion [29]. In 1981 Meredith and Wade presented a rat model that by transposition of the
spleen produced a portosystemic shunt in the anhepatic rat [30]. A small incision is made in
the left hypochondrium. After transposition of the spleen into a subcutaneous pouch, ade‐
quate portosystemic anastomoses arise after two to three weeks (Figure 2). Reversal of blood
flow in the splenic vein, induced by the transposition, stimulates angiogenesis. In the second
step 2 weeks later, the surgeon performs a median laparotomy and temporary occlusion of
the hepatoduodenal ligament. This decompression by spleen transposition does not require
microsurgical technique and is therefore easy to perform. Two-to-three weeks postopera‐
tively, the spleen will have been encapsulated without any signs of bleeding or inflamma‐
tion. One disadvantage of this model is the long time lapse (3 weeks) until the formation of
adequate portosystemic collaterals. Not until this point in time are the collaterals sufficiently
large to take over portal vein flow completely. Furthermore, it is uncertain how the changes
in hepatic inflow will react upon the collaterals [31].
4.3. Partial liver ischemia and liver regeneration
In 1982, Yamauchi et al., described a model of hepatic ischemia [32]. In this technique, ische‐
mia is induced by occlusion of the hepatic artery, the portal vein, and the bile duct of the left
and median lobes. An extracorporeal shunt is not necessary because blood flow continues
through the right and caudal liver lobes. This model of 70% partial ischemia has been wide‐
ly used in experimental studies of hepatic I/R [13,33]. Additionally, an experimental model
of 30% partial liver ischemia has been used in which blood supply to the right lobe of the
liver is interrupted by occlusion at the level of the hepatic artery and portal vein [34]. It is
known that, in clinical situations, PH under I/R is usually performed to control bleeding
during parenchymal dissection. In vitro studies, although they have proved helpful in dis‐
closing the signal transmission pathways of various hepatocyte mitogens, need to be supple‐
mented by in vivo studies with experimental animals so as to simulate the interactions
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that conducted the portal blood after functional hepatectomy into one of the iliac veins [27].
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and the mesentericocaval shunt via the jugular vein, in 1995, Spiegel et al., developed the
splenocaval shunt [28] (Figure 2).
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spleen produced a portosystemic shunt in the anhepatic rat [30]. A small incision is made in
the left hypochondrium. After transposition of the spleen into a subcutaneous pouch, ade‐
quate portosystemic anastomoses arise after two to three weeks (Figure 2). Reversal of blood
flow in the splenic vein, induced by the transposition, stimulates angiogenesis. In the second
step 2 weeks later, the surgeon performs a median laparotomy and temporary occlusion of
the hepatoduodenal ligament. This decompression by spleen transposition does not require
microsurgical technique and is therefore easy to perform. Two-to-three weeks postopera‐
tively, the spleen will have been encapsulated without any signs of bleeding or inflamma‐
tion. One disadvantage of this model is the long time lapse (3 weeks) until the formation of
adequate portosystemic collaterals. Not until this point in time are the collaterals sufficiently
large to take over portal vein flow completely. Furthermore, it is uncertain how the changes
in hepatic inflow will react upon the collaterals [31].
4.3. Partial liver ischemia and liver regeneration
In 1982, Yamauchi et al., described a model of hepatic ischemia [32]. In this technique, ische‐
mia is induced by occlusion of the hepatic artery, the portal vein, and the bile duct of the left
and median lobes. An extracorporeal shunt is not necessary because blood flow continues
through the right and caudal liver lobes. This model of 70% partial ischemia has been wide‐
ly used in experimental studies of hepatic I/R [13,33]. Additionally, an experimental model
of 30% partial liver ischemia has been used in which blood supply to the right lobe of the
liver is interrupted by occlusion at the level of the hepatic artery and portal vein [34]. It is
known that, in clinical situations, PH under I/R is usually performed to control bleeding
during parenchymal dissection. In vitro studies, although they have proved helpful in dis‐
closing the signal transmission pathways of various hepatocyte mitogens, need to be supple‐
mented by in vivo studies with experimental animals so as to simulate the interactions
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between the various cell populations of the liver. Different strategies have been adopted for
the experimental induction of liver regeneration as follow below [35]. On the other hand, the
use of an experimental model including both hepatic regeneration and I/R injury is advisa‐
ble to simulate the clinical situation of selective or hemihepatic vascular occlusion for liver
resections. In experimental model, after resection of left hepatic lobe, a microvascular clamp
is placed across the portal triad supplying the median lobe (30%). Congestion of the bowel is
avoided during the clamping period by preserving the portal flow through the right and
caudate lobes. At the end of ischemia time, the right lobe and caudate lobes are resected,
and reperfusion of the median lobe is achieved by releasing the clamp. This model of hepat‐
ic resection does not require any portal decompression and also fulfills certain important cri‐
teria such as reversibility, good reproducibility, and simple performance [36].
4.4. Other experimental models of liver regeneration – Regeneration after liver injury
There are large numbers of toxins that can cause liver damage and cell death in the liver pa‐
renchyma followed by liver regeneration. Carbon tetrachloride, d-galactosamine, ethanol,
thioacetamide and acetaminophen are the hepatotoxins that have been most frequently em‐
ployed to induce experimental liver regeneration in the hope of answering various ques‐
tions [35]. In contrast to PH, these so-called hepatotoxic models of liver regeneration are
easier to perform and of greater clinical relevance. Whereas PH leaves all the remaining hep‐
atic acini intact, hepatotoxins can be used selectively to induce centrilobular or periportal
necrotic lesions and can thus better simulate certain liver diseases. One serious weakness of
toxin-induced liver regeneration is the por reproducibility and standardisability of the mod‐
els, because the local and systemic effects of the toxin depend on the dose, the mode of ad‐
ministration, the species of animals, their age and nutritional status and other factors, and
the extent of the liver injury and the regeneration can vary accordingly. The regenerative re‐
sponse of the liver is often determined by the dose and mode of administration. Further‐
more, the toxins can directly interfere with the cellular and molecular mechanisms of liver
regeneration, e.g., by damaging membranes (interruption of the interaction between growth
factors and membrane receptors), impairment of gene expression and protein synthesis, in‐
flammatory reactions (increased production of cytokines and oxygen radicals) or activation
of nonparenchymal cells [37]. Finally, in these toxic models the processes of liver injury and
repair are closely interwoven, a fact that adds to the difficulties of investigating liver regen‐
eration. It is therefore difficult to predict the extent of liver damage and liver regeneration
and to avoid significant variability between individual experiments [35].
5. Liver transplantation
The development and implementation of different surgical techniques in LT have been
based upon animal experimental studies. LT in larger laboratory animals such as dogs and
pigs is technically easier. However, the rat has become the most important subject for exper‐
imental LT because of, among other factors, the availability of genetically defined animals
[38]. The first experimental liver replacement with OLT was reported by Cannon in 1956,
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but none of those dogs survived [39]. Surgical techniques for experimental OLT on pigs
were started by Garnier et al., in 1965 [40]. OLT in mice is technically very difficult, even
without reconstruction of the hepatic artery. By contrast, OLT in rats is technically accessi‐
ble, producing more clinically relevant and reliable data [41]. The development of clinically
relevant OLT models in rats [41] has advanced clinical knowledge in LT. These experimental
models facilitate the study of new preservation methods, tolerance induction, rejection
mechanisms, and novel immunosuppressor therapies [42].
The first model of OLT in the rat was described by Lee et al., in 1973 using hand-suture tech‐
niques [43]. This technique includes standard microvascular suture technique for venous
anastomoses and a miniaturized extracorporeal portal-tojugular shunt (“microsuture mod‐
el”). Rearterialization of the graft is performed by anastomosing the donor aorta end-to-side
to the host aorta, and the donor bile duct is implanted into the duodenum [43]. Two years
later, in 1975, Lee reported a modified model without hepatic artery reconstruction and tem‐
poral shunt of the portojugular venovenous bypass [44]. However, these models were not
widely used due to the prolonged surgical time and technical demand. In 1979, Zimmer‐
mann introduced a microsuture model [45] that is similar to the simplified model of Lee
[44]. He developed a new technique for bile duct reconstruction that preserves the sphincter
of ampulla “splint technique”. In the same year, Kamada and Calne [46] developed a cuff
technique for anastomoses of portal vein and bile duct to simplify Lee’s model and especial‐
ly to shorten the anhepatic time and reduce biliary complications. With the cuff method be‐
ing introduced by Kamada and Calne [46], OLT in rats without hepatic artery reconstruction
became globally accepted [41]. Other models introduced by later investigators contain for
the most part only a few modifications. In 1980 Miyata introduced the “three-cuff model’’
[47] with cuff technique for the three venous anastomoses. Bile duct anastomosis is per‐
formed by using the splint technique first described by Zimmermann [45], in which reestab‐
lishment of hepatic blood flow is not carried out. Anastomosis of the portal vein is done by
the method of Kamada and Calne [46]. For connecting the bile duct, splint technique was
used [47]. In 1982 Engemann [48] devised a microsuture model that corresponds closely to
the model of Lee [43]. During the anhepatic time he dispensed with portosystemic bypass
and used an aortic-celiac segment for rearterialization. This had been already prepared in
the donor operation, and anastomosed end-toside to the infrarenal aorta of the recipient.
Bile duct anastomosis is performed using the splint technique [48]. Portal vein clamping
causes a rise of endotoxin in the portal vein, which could lead to disturbances in hepatic mi‐
crocirculation. Lee was the first to use a portosystemic shunt, but in further models it has
not been established because the acceleration of the transplantation procedure by improved
anastomotic techniques was expected to preclude the need for this complicated operative
procedure [38]. Kitakado completed the “two-cuff model” in 1992 by developing a bioab‐
sorbable material (synthesis of D, L-lactic acid and glycolic acid). Its in vivo degradation time
is about 4 months when used for cuff anastomosis of portal vein and infrahepatic vein cava
[49]. He established a longterm model in OLT in rat. This surgical procedure is usually per‐
formed according to the procedure described by Kamada and Calne [46]. After arterial and
portal perfusion, the suprahepatic vena cava is dissected free from the diaphragmatic ring,
and the intrathoracic vena cava is transected. The aorta is cut around the celiac axis to form
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sponse of the liver is often determined by the dose and mode of administration. Further‐
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regeneration, e.g., by damaging membranes (interruption of the interaction between growth
factors and membrane receptors), impairment of gene expression and protein synthesis, in‐
flammatory reactions (increased production of cytokines and oxygen radicals) or activation
of nonparenchymal cells [37]. Finally, in these toxic models the processes of liver injury and
repair are closely interwoven, a fact that adds to the difficulties of investigating liver regen‐
eration. It is therefore difficult to predict the extent of liver damage and liver regeneration
and to avoid significant variability between individual experiments [35].
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The development and implementation of different surgical techniques in LT have been
based upon animal experimental studies. LT in larger laboratory animals such as dogs and
pigs is technically easier. However, the rat has become the most important subject for exper‐
imental LT because of, among other factors, the availability of genetically defined animals
[38]. The first experimental liver replacement with OLT was reported by Cannon in 1956,
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anastomoses and a miniaturized extracorporeal portal-tojugular shunt (“microsuture mod‐
el”). Rearterialization of the graft is performed by anastomosing the donor aorta end-to-side
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widely used due to the prolonged surgical time and technical demand. In 1979, Zimmer‐
mann introduced a microsuture model [45] that is similar to the simplified model of Lee
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technique for anastomoses of portal vein and bile duct to simplify Lee’s model and especial‐
ly to shorten the anhepatic time and reduce biliary complications. With the cuff method be‐
ing introduced by Kamada and Calne [46], OLT in rats without hepatic artery reconstruction
became globally accepted [41]. Other models introduced by later investigators contain for
the most part only a few modifications. In 1980 Miyata introduced the “three-cuff model’’
[47] with cuff technique for the three venous anastomoses. Bile duct anastomosis is per‐
formed by using the splint technique first described by Zimmermann [45], in which reestab‐
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and used an aortic-celiac segment for rearterialization. This had been already prepared in
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Bile duct anastomosis is performed using the splint technique [48]. Portal vein clamping
causes a rise of endotoxin in the portal vein, which could lead to disturbances in hepatic mi‐
crocirculation. Lee was the first to use a portosystemic shunt, but in further models it has
not been established because the acceleration of the transplantation procedure by improved
anastomotic techniques was expected to preclude the need for this complicated operative
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sorbable material (synthesis of D, L-lactic acid and glycolic acid). Its in vivo degradation time
is about 4 months when used for cuff anastomosis of portal vein and infrahepatic vein cava
[49]. He established a longterm model in OLT in rat. This surgical procedure is usually per‐
formed according to the procedure described by Kamada and Calne [46]. After arterial and
portal perfusion, the suprahepatic vena cava is dissected free from the diaphragmatic ring,
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Experimental Models in Liver Surgery
http://dx.doi.org/10.5772/51829
129
the aortic patch. Finally, the inferior vena cava, the portal vein, and the bile duct are cut, and
the graft is placed in a cold preservation solution (Figure 3). OLT is then performed by su‐
ture or mechanical microvascular anastomoses. Sutured vascular anastomosis reduces the
incidence of thrombosis but takes a long time to perform. Suprahepatic vena cava anastomo‐
sis is performed by the continuous suturing technique. Then, portal vein and infrahepatic
vena cava anastomosis is performed in the same manner. Hepatic artery reconstruction in
rat LT can prevent bile duct ischemia and preserve the structure of the liver [50]. Several
techniques of rearterialization by suture have been proposed [50], the best being the aortic
segment anastomosis technique. After rearterialization, the common bile duct is anasto‐
mosed. OLT by hand-sewn microanastomosis is a very useful method because this techni‐
que comes closest to the techniques used in human transplantation surgery. Alternatively,
livers can be satisfactorily allografted in rats by using the rapid cuff-ligature technique for
anastomosis [46]. In the simplified technique, the donor hepatic artery can be ligated be‐
cause it will not be anastomosed [42].
Figure 3. Liver transplantation procedure. A) Suprahepatic cava vein prepared for the anastomosis. B) Inferior vein
cava cuff attachment. C) Anhepatic phase in the recipient rat. D) Anastomosis of suprahepatic cava vein by continuous
suture. E) Portal vein anastomosis trhough the cuff method. F) Anastomosis of the bile duct.
6. Strategies to expand the size of the donor pool
In an attempt to expand the size of the donor pool, a number of surgical techniques have
been developed over the past 15 years, including reduced-size liver transplantation (RSLT),
split liver transplantation (SLT) and living donor liver transplantation (LDLT) [51]. For chil‐
dren and small adult recipients, RSLT has been developed to maximize the use of donor or‐
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gans. Bismuth and Houssin in 1984, transplanted the left lateral segment of the left liver lobe
from a cadaveric donor into a small child and discarded the remainder of the donor liver
[52]. Couinaud’s anatomical classification permits the creation of partial liver allografts from
either deceased or living donors. Couinaud’s classification divides the liver into eight inde‐
pendent segments, each of which has its own vascular inflow, outflow, and biliary drainage
[53]. Segments IV to VIII are used for adults, whereas left lateral lobes (Segments II and III)
or left lobes (Segments II, III, and IV) are used for pediatric recipients. Bleeding, bilomas,
and portal vein thrombosis are complications related to the procedure itself, which are asso‐
ciated with an increased number of re-operation. SLT, first performed in 1988, allows the di‐
vision of the adult donor liver, together with its vascular and biliary structures, into two or
more functional grafts, which can be transplanted into two or more recipients [54]. Liver
splitting is performed either ex situ or in situ. So far, there is no consensus on which techni‐
que is superior because both techniques demonstrate similar patient and graft survival rates
compared with whole liver grafting [54]. Biliary complications occur in 22% of recipients. In
1990, Broelsch et al., reported the first 20 series of LDLT in the USA [55]. In 1996, Lo et al.,
[56] performed the first successful LDLT using an extended right lobe from a living donor
for an adult recipient. One of the benefits of reduced-size grafts from living donors is a graft
of good quality with a short ischemic time, this latter being possible because live donor pro‐
curements can be electively timed with the recipient procedure. Conversely, the major con‐
cern over the application of LDLT for adults is graft-size disparity. Small grafts require
posterior regeneration to restore the liver/body ratio. A small graft may result in malfunc‐
tion or the small for size syndrome in which the recipient fails to sustain adequate metabolic
function. It is well known that I/R significantly reduce liver regeneration after hepatectomy.
Thus, the identification and subsequent modulation of mechanism that are involved in liver
injury and regeneration might favor the recovery and functioning of the transplanted organ.
To mimic some of the pathophysiological events that occur during such clinical situations,
several experimental models of RSLT have been developed. For example, OLT with the im‐
plantation of liver grafts that approximated 30%–70% of the normal mass of a rat liver has
been performed. Graft size is important for normal liver function and host survival [51]. It
has been reported that 100% of recipient rats that were implanted with 40%, 50%, 60%, or
70% of the liver survived regardless of the duration of preservation. This suggests that graft
sizes of 40% or greater are sufficient to meet the metabolic demands of the recipients. The
transplantation of a graft of 30% of the normal liver mass provides an extreme model of hep‐
atic reduction that presumably stimulated a maximal regenerative response [51]. Three pos‐
sibilities exist with respect to the timing of the graft reduction: in the donor before
perfusion, in the container (ex situ), or in the recipient after reperfusion. If the reduction is
done in vivo prior to the removal of the donor liver, then two concerns exist: 1) excessive
bleeding might stimulate systemic responses that could alter the liver and 2) the immediate
phase of the regeneration response could be initiated in the donor animal. The second
choice, ex situ reduction, can be done without the risk of damaging the graft by manipula‐
tion or affecting anastomosis after reperfusion. Finally, resection of the graft after implanta‐
tion in the recipient adds surgical stress and the risk of bleeding.
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7. Modes of organ preservation and optimizing the graft
The ideal method of organ preservation should: 1) Reverse injury sustained during donor
death and organ procurement; 2) Provide viability testing; 3) Prolong safe preservation time
and 4) Improve the graft quality [57]. There are currently 2 modes of preservation methods
for livers: static and dynamic (Figure 4). Simple cold storage is the main method for static
storage while hypothermic machine perfusion (HMP) and normothermic machine perfusion
(NMP) comprise some of the methods for dynamic preservation. Of these methods, only
simple cold store is roved clinically for livers. The remaining methods are in various stages
of pre-clinical and early clinical studies. Dynamic preservation methods require some dy‐
namic movement of either fluid or gas to facilitate preservation. The advantage of these
methods over simple cold storage is that they all have been shown to improve recovery of
donor after cardiac death organs. These organs have the potential to increase the donor pool
by 20–40%.
Figure 4. Illustrative modes of organ preservation. Static or dynamic organ preservation.
7.1. Static organ preservation
Static cold storage (SCS) is the most commonly used preservation method used for all or‐
gans. The principles underlying cold preservation are the slowing of metabolism (by cool‐
ing) and the reduction of cell swelling due to the composition of preservation solutions. The
introduction of the University of Wisconsin (UW) solution by Belzer and Southard for SCS
was a breakthrough and remains the conventional method of preservation. Reduction of
metabolic activity (by cooling) is the major principle of organ preservation [57,58]. At the
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moment the flow of oxygenated blood is terminated, the supply of oxygen, cofactors and
nutrients stops and the accumulation of metabolic waste products begins. Although metabo‐
lism is slowed 1.5- to 2-fold for every 10ºC drop in temperature, anaerobic metabolism con‐
tinues, which leads to depletion of energy stores and concomitant build up of an acidotic
milieu. Depletion of ATP causes loss of transcellular electrolyte gradients, influx of free cal‐
cium and the subsequent activation of phospholipases, and therefore is the main contributor
for cell swelling and lysis. Ischaemia creates the basis for the subsequent production of toxic
molecules after reperfusion, particularly reactive oxygen intermediates, the basis of the cas‐
cade of events that characterize the I/R injury. Even with the most effective preservation sol‐
utions, cold storage aggravates graft injury at the time of transplantation. This situation is
due to two processes, one proportional to the duration of ischemia and the other specifically
related to cooling [57]. Using this preservation method, however, organs undergo injury at
several consecutive stages: warm ischemia prior to preservation, cold preservation injury, is‐
chemic rewarming during surgical implantation and reperfusion injury. With the extension
of criteria to include expanded criteria donor and donation after cardiac death organs, static
preservation is associated with increased delayed graft function and graft loss. In organs re‐
trieved from non-heart-beating donors (NHBD) -with an inevitable period of oxygen depri‐
vation between cardiac arrest and organ perfusion – the deleterious effects of cold ischaemia
are superimposed on the injury sustained during warm ischaemia [57]. Only a few studies
have demonstrated the optimization of graft function and survival with modification of stat‐
ic preservation. It is doubtful that considerable improvements in organ preservation and es‐
pecially in the rescue of marginal organs will be possible as long as the strategy is based on
static principles [58]. In 1990s, Minor et al., developed a new method, called venous system‐
ic oxygen persufflation (VSOP) to supply gaseous oxygen to livers during SCS preservation
[59]. The oxygen was introduced into hepatic vasculature via the suprahepatic vena cava.
This technique was employed on steatotic rat livers for 24 h, and resulting in improved pres‐
ervation of mitochondria and sinusoidal endothelial linings, less KC activation and reduced
hepatocellular enzyme release compared to SCS preservation. Recently, by assessing the en‐
zyme release, energy storage, bile production, and cell death during isolated reperfusion, it
was demonstrated that application of VSOP for 90 minutes may rescue the steatotic livers
after extended (18 h) SCS preservation [60].
7.2. Machine perfusion
Machine liver perfusion is an alternative preservation method to SCS which can be further
categorized based on the temperature employed and has emerged with promising data over
the past decade because it has significant potential in graft preservation and optimization
when the use of marginal organs is the objective. Machine perfusion involves pulsatile per‐
fusion of the liver using a machine as opposed to SCS. This can be performed by perfusing
the liver with a hypothermic perfusate or with a normothermic perfusate. There is experi‐
mental evidence in animal models that machine perfusion protects against liver I/R injury
[61]. The safety and efficacy of machine perfusion compared to SCS to decrease liver I/R in‐
jury is yet to be assessed in humans by randomized controlled trials [61,62].
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Compared with simple cold storage, machine perfusion confers many anticipated advantag‐
es such as the following: 1) provision of continuous circulation and better preservation of
the microcirculation; 2) continuous nutrient and oxygen delivery; 3) removal of metabolic
waste products and toxins; 4) opportunity to assess organ viability; 5) improved clinical out‐
comes via improved immediate graft function rates; 6) prolonged preservation time without
increased preservation damage; 7) administration of cytoprotective and immunomodulating
substances; and 8) lower graft dysfunction incidence, shorter hospital stays, and better graft
survival rates [62].
7.3. Normothermic machine perfusion
In the first half of the 20th century, Alexis Carrel perfused different organs with normother‐
mic, oxygenated serum and demonstrated viability for several days [63]. Actually, the first
successful human LT carried out by Starzl [64], were transplanted after liver graft pretreat‐
ment by machine perfusion with diluted, hyperbaric oxygenated blood. Most perfusion cir‐
cuits were assembled from standard cardiopulmonary bypass components. Principle
constituents are a centrifugal pump, a membrane oxygenator and a heat exchanger. Other
critical components of the perfusate include nutrition (glucose, insulin, aminoacids), drugs
to prevent thrombosis or microcirculatory failure (heparin, prostacyclin) and agents to re‐
duce cellular oedema, cholestasis and free radical injury [57]. Normothermic machine perfu‐
sion (NMP) provides a physiologically-relevant environment to the isolated donor organ,
the quality of liver grafts can be manipulated more efficiently than those simply stored in an
ice-box during SCS, because NMP maintains and mimics normal in vivo liver conditions and
function during the entire period of preservation, thus avoiding hypothermia and hypoxia
and minimizing preservation injury [58,62]. In contrast to cold storage preservation the con‐
cept of normothermic preservation is to maintain cellular metabolism. The underlying prin‐
ciple is the combination of continuous circulation of metabolic substrates for ATP
regeneration and removal of waste products. There is accumulating evidence for the superi‐
ority of the more physiological approach of normothermia in association with an oxygenat‐
ed blood-based perfusion solution [57].
Schön et al., [65] studied NMP to preserve pig livers for transplantation and to rescue them
from warm ischemia in a model of donor after cardiac death. Short (5 h) or prolonged (20 h)
NMP preservation is superior to SCS for normal and ischemically damaged livers, respective‐
ly [62]. The longest preservation of steatotic livers was the NMP preservation for 48 hours in a
pig model by Jamisson et al., who employed blood containing additional insulin and vasodila‐
tors as perfusate, and observed a mild reduction of steatosis from 28% to 15%. The NMP cir‐
cuit dually perfuses 1.5 L of autologous heparinized blood at physiological pressures, which
allows hepatic blood flow autoregulation. Prostacyclin, taurocholic acid, and essential amino
acids are infused continuously. Apart from logistics, one potential drawback of NMP is the
mandatory use of oxygen carriers if blood is not available [62]. Perhaps the only weakness is
that SCS prior to NMP revokes its beneficial effect. Therefore, immediately after cardiac asys‐
tole, normothermic perfusion in the donor should be installed, as described by Fondevila et al.,
[66] for the preservation of livers from uncontrolled donation after cardiac death. The use of
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NHBDs as a source of liver grafts for transplantation has long been debated. The concept of
normothermic recirculation in the context of NHBDs was first developed by Garcia-Valdeca‐
sas et al., [67]. With 4 h of NMP, hepatic damage incurred during 90 minutes of cardiac arrest
can be reverted, achieving 100% graft survival after 5 days of postransplant follow-up. These
results offer the hope that NMP will be able to increase the clinical applicability of NHBD LT
over that offered by traditional cold storage [67].
Figure 5. Esquematic illustration for ex-vivo and in-vivo normotermic machine perfusion
7.4. Hypothermic machine perfusion
For decades, cooling down organs to cold temperatures allowed successful organ transplan‐
tation within a limited period. The first and most prominent difference between SCS and
(oxygenated) hypothermic machine perfusion (HMP) is the restoration of the tissue’s energy
charge and glycogen content while preventing ATP depletion [62]. In 1990, Pienaar et al.,
[68] reported that seven of eight dogs survived after LT with HMP preservation for 72 h and
a similar outcome after 48 h of SCS. HMP is increasingly being used as an alternative meth‐
od to SCS for the preservation of grafts obtained from nonoptimal donors. Indeed, several
studies have reported a greater reduction in delayed graft function after HMP preservation
than after SCS. Bessems et al., employed HMP preservation with UW-gluconate solution on
steatotic rat livers for 24 h and alleviated I/R compared to SCS [69]. There is a substantial
body of research, predominantly in rodents, demonstrating improved preservation by pro‐
viding oxygen to livers [70]. Nevertheless, clear guidelines towards target values/ranges for
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oxygen levels regarding the optimal duration of oxygenation during HMP are lacking. HMP
can also be applied at the end of the cold storage period, which is attractive for logistical
reasons. The disadvantage here is the time-dependent increase in vascular resistance, bear‐
ing the risk of damage to the sinusoidal endothelium [58].
7.5. Subnormotermic machine perfusion
Subnormothermic machine perfusion (SNMP) preservation lies between HMP and NMP,
but it remained relatively unexplored until recently despite holding promising applications
[71]. In an isolated rat liver perfusion model, SNMP enhanced the functional integrity of
steatotic livers compared with SCS findings. Organ protecting properties mediated by de‐
creasing the temperature to a 20–28ºC have been observed previously. SNMP avoids some
of the downsides of hypothermia while maintaining mitochondrial function and it may cir‐
cumvent the logistical rest raints of NMP [62]. Vairetti et al., preserved steatotic rat livers by
SNMP (20ºC) with Kreb-Henseleit solution for 6 hours and obtained reduced I/R damage
compared to SCS [71].
8. Factors to be considered before the selection of an experimental model
of hepatic I/R
Many investigators have used rodent models of warm (in situ) liver I/R to mimic some of the
pathophysiological events that occur during LT. Although a great deal of useful information
has been generated from these studies, an overriding question remains: Are the mechanisms
responsible for transplant-mediated liver injury and dysfunction the same as those that have
been reported for warm liver I/R injury? The answer is yes and no; that is, some of the mech‐
anisms are similar, but many are dissimilar. It is important to make a distinction between
the different types of ischemia, because there already is some controversy regarding the
pathophysiological mechanisms depending on the type of ischemia (cold or normothermic),
and it should be considered that the type of ischemia, the extent and time of ischemia, the
type of liver submitted to I/R, and the presence of liver regeneration, all lead to differences
in the pathophysiological mechanisms of hepatic I/R. These are discussed below to provide
the reader with a guide to select the appropriate experimental model of hepatic I/R depend‐
ing on the aims being pursued.
8.1. Relevance of the type of surgical procedure
The mechanisms responsible for hepatic I/R injury as well as the effects of pharmacological
treatments are dependently of the liver surgical procedure. There is a range of potentially
conflicting results with regard to the mechanisms responsible for ROS generation in liver I/R
injury depending of the liver surgical procedure evaluated. XDH/XOD system is the main
ROS generator in hepatocytes and LT-related lung damage [72]. However, results obtained
in experimental models of the isolated perfused liver have underestimated the importance
of the XDH/XOD system, and suggest that mitochondria could be the main source of ROS
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[9]. In addition, studies by Metzger et al., in experimental models of normothermic hepatic
ischemia showed that the increased vascular oxidant stress after 30 and 60 minutes of ische‐
mia was attenuated by inactivation of KC but not by high dose of allopurinol in experimen‐
tal models of normothermic hepatic ischemia [73].
It should be considered that the effectiveness of drugs on hepatic regeneration and damage
could be different depending on the surgical conditions evaluated. Thus, gadolinium chlor‐
ide treatment protected against hepatic damage in conditions of I/R without hepatectomy
and improved liver regeneration after PH without I/R [74]. However, the same drug had in‐
jurious effects on hepatic damage and impaired liver regeneration in conditions of PH under
I/R [75]. It should be also considered that the effectiveness of RAS blockers on hepatic regen‐
eration and damage could be different depending on the surgical conditions evaluated. In
conditions of PH under I/R, the AT1R antagonist for nonsteatotic livers and the AT1R and
AT2R antagonists for steatotic ones improved regeneration in the remnant liver. The combi‐
nation of AT1R and AT2R antagonists in steatotic livers showed stronger liver regeneration
than either antagonist used separately and also provided the same protection against dam‐
age as that afforded by AT1R antagonist alone. However, the loss of protection of Ang II re‐
ceptor antagonists against damage in conditions of PH under I/R (only AT1R antagonist
protected steatotic liver against damage) compared with the study of I/R without hepatecto‐
my (in which both Ang-II receptor antagonists reduced damage in both liver types) could be
explained by the different surgical conditions. In the model of I/R without hepatectomy [33],
the blood supply to the left and median liver lobes (70% hepatic mass) was interrupted, and
the other hepatic lobes remained intact. However, in the conditions evaluated herein, only
blood supply to the remnant liver (30% hepatic mass) was interrupted and the other hepatic
lobes were excised. Compared with the study of I/R without hepatectomy [33], in PH under
I/R, there are two main differences, the percentage of hepatic mass that is deprived of blood
supply and hepatic resection. It is well known that the mechanisms of hepatic damage are
different depending on the percentage of hepatic mass that is deprived of blood supply
[76,77]. In addition, the inherent mechanisms of hepatic damage derived from the massive
removal of hepatic mass should be considered. This may explain, at least partially, why the
same drug, such as an Ang II receptor antagonist, may show differential effect on hepatic
injury depending on surgical conditions [36]. In line with this, clinical and experimental
studies revealed the injurious effects of NO on damage in the remnant liver in conditions of
PH under I/R [36]. However NO protect against hepatic damage in an experimental model
of I/R without PH [11]. In PH under I/R, Ang-II is an appropriate therapeutic target to pro‐
tect steatotic livers against hepatic damage and regenerative failure. However, this target
could be not appropriate in steatotic LT, since the results indicate a novel target for thera‐
peutic interventions in LT within the RAS cascade, based on Ang 1-7, which could be specif‐
ic for this type of liver. Indeed, Ang 1-7 receptor antagonist reduced necrotic cell death and
increased survival in recipients transplanted with steatotic liver grafts [15].
The results, based on isolated perfused liver, indicated that the addition of epidermal
growth factor (EGF) and isulin-like growth factor 1 (IGF-I) separately or in combination to
UW reduced hepatic injury and improved function in both liver types. EGF increased IGF-I,
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oxygen levels regarding the optimal duration of oxygenation during HMP are lacking. HMP
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reasons. The disadvantage here is the time-dependent increase in vascular resistance, bear‐
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pathophysiological events that occur during LT. Although a great deal of useful information
has been generated from these studies, an overriding question remains: Are the mechanisms
responsible for transplant-mediated liver injury and dysfunction the same as those that have
been reported for warm liver I/R injury? The answer is yes and no; that is, some of the mech‐
anisms are similar, but many are dissimilar. It is important to make a distinction between
the different types of ischemia, because there already is some controversy regarding the
pathophysiological mechanisms depending on the type of ischemia (cold or normothermic),
and it should be considered that the type of ischemia, the extent and time of ischemia, the
type of liver submitted to I/R, and the presence of liver regeneration, all lead to differences
in the pathophysiological mechanisms of hepatic I/R. These are discussed below to provide
the reader with a guide to select the appropriate experimental model of hepatic I/R depend‐
ing on the aims being pursued.
8.1. Relevance of the type of surgical procedure
The mechanisms responsible for hepatic I/R injury as well as the effects of pharmacological
treatments are dependently of the liver surgical procedure. There is a range of potentially
conflicting results with regard to the mechanisms responsible for ROS generation in liver I/R
injury depending of the liver surgical procedure evaluated. XDH/XOD system is the main
ROS generator in hepatocytes and LT-related lung damage [72]. However, results obtained
in experimental models of the isolated perfused liver have underestimated the importance
of the XDH/XOD system, and suggest that mitochondria could be the main source of ROS
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[9]. In addition, studies by Metzger et al., in experimental models of normothermic hepatic
ischemia showed that the increased vascular oxidant stress after 30 and 60 minutes of ische‐
mia was attenuated by inactivation of KC but not by high dose of allopurinol in experimen‐
tal models of normothermic hepatic ischemia [73].
It should be considered that the effectiveness of drugs on hepatic regeneration and damage
could be different depending on the surgical conditions evaluated. Thus, gadolinium chlor‐
ide treatment protected against hepatic damage in conditions of I/R without hepatectomy
and improved liver regeneration after PH without I/R [74]. However, the same drug had in‐
jurious effects on hepatic damage and impaired liver regeneration in conditions of PH under
I/R [75]. It should be also considered that the effectiveness of RAS blockers on hepatic regen‐
eration and damage could be different depending on the surgical conditions evaluated. In
conditions of PH under I/R, the AT1R antagonist for nonsteatotic livers and the AT1R and
AT2R antagonists for steatotic ones improved regeneration in the remnant liver. The combi‐
nation of AT1R and AT2R antagonists in steatotic livers showed stronger liver regeneration
than either antagonist used separately and also provided the same protection against dam‐
age as that afforded by AT1R antagonist alone. However, the loss of protection of Ang II re‐
ceptor antagonists against damage in conditions of PH under I/R (only AT1R antagonist
protected steatotic liver against damage) compared with the study of I/R without hepatecto‐
my (in which both Ang-II receptor antagonists reduced damage in both liver types) could be
explained by the different surgical conditions. In the model of I/R without hepatectomy [33],
the blood supply to the left and median liver lobes (70% hepatic mass) was interrupted, and
the other hepatic lobes remained intact. However, in the conditions evaluated herein, only
blood supply to the remnant liver (30% hepatic mass) was interrupted and the other hepatic
lobes were excised. Compared with the study of I/R without hepatectomy [33], in PH under
I/R, there are two main differences, the percentage of hepatic mass that is deprived of blood
supply and hepatic resection. It is well known that the mechanisms of hepatic damage are
different depending on the percentage of hepatic mass that is deprived of blood supply
[76,77]. In addition, the inherent mechanisms of hepatic damage derived from the massive
removal of hepatic mass should be considered. This may explain, at least partially, why the
same drug, such as an Ang II receptor antagonist, may show differential effect on hepatic
injury depending on surgical conditions [36]. In line with this, clinical and experimental
studies revealed the injurious effects of NO on damage in the remnant liver in conditions of
PH under I/R [36]. However NO protect against hepatic damage in an experimental model
of I/R without PH [11]. In PH under I/R, Ang-II is an appropriate therapeutic target to pro‐
tect steatotic livers against hepatic damage and regenerative failure. However, this target
could be not appropriate in steatotic LT, since the results indicate a novel target for thera‐
peutic interventions in LT within the RAS cascade, based on Ang 1-7, which could be specif‐
ic for this type of liver. Indeed, Ang 1-7 receptor antagonist reduced necrotic cell death and
increased survival in recipients transplanted with steatotic liver grafts [15].
The results, based on isolated perfused liver, indicated that the addition of epidermal
growth factor (EGF) and isulin-like growth factor 1 (IGF-I) separately or in combination to
UW reduced hepatic injury and improved function in both liver types. EGF increased IGF-I,
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and both additives up-regulated AKT in both liver types. This was associated with glycogen
synthase kinase-3β (GSK3β) inhibition in non-steatotic livers and PPARγ over-expression in
steatotic livers [78]. The benefits of EGF and IGF-I as additives in UW solution were also
clearly seen in an experimental model of normothermic hepatic ischemia. However, the rela‐
tionship between EGF and IGF-I was different dependently of the surgical procedure. In‐
deed, under these conditions, IGF-I increased EGF, thus protecting steatotic and non-
steatotic livers against I/R damage. The beneficial role of EGF on hepatic I/R damage may be
attributable to p38 inhibition in non-steatotic livers and to PPARγ overexpression in steatot‐
ic livers [79].
PPARα agonists as well as ischemic preconditioning (IP), through PPARα, inhibited mito‐
gen-activated protein kinase expression following I/R in steatotic livers undergoing normo‐
thermic hepatic ischemia. This in turn inhibited the accumulation of adiponectin in steatotic
livers and reduced its negative effects on oxidative stress and hepatic injury [13]. In line
with this, adiponectin silent small interfering RNA (siRNA) treatment decreased oxidative
stress and hepatic injury in steatotic livers. However, another study by Man et al., 2006 [80]
in small fatty grafts, adiponectin treatment exerted anti-inflammatory effects that down-
regulated TNFα mRNA and vasoregulatory effects that improved the microcirculation. Adi‐
ponectin anti-inflammatory effects also include the activation of cell survival signaling via
the phosphorylation of Akt and the stimulation of NO production. Additionally, the studies
by Man et al., [80] showed the anti-obesity and proliferative properties of adiponectin in
small fatty transplants. Taken together, the aforementioned data indicate that the action
mechanisms of adiponectin depend on the surgical conditions. Thus, on the basis of the dif‐
ferent results reported to date in hepatic I/R, it is difficult to discern whether we should aim
to inhibit adiponectin, or administer adiponectin to protect steatotic livers against cold is‐
chemia associated with transplantation. Moreover, the adiponectin data reported for these
experimental models of hepatic I/R [13,80] should not be extrapolated to cadaveric organ
transplantation. For small liver grafts (which are relatively common) and under conditions
of warm ischemia, the periods of ischemia range from 40 to 60 minutes; this range may not
be accurate for cadaveric donor LT.
RBP4 is an adipokine synthesized by the liver, whose known function is to transport retinol
in circulation. However, the role of RBP4 in hepatic I/R could depend on the liver surgical
procedure. Steatotic liver grafts were found to be more vulnerable to the down-regulation of
RBP4. RBP4 treatment-through AMP-activated protein kinase (AMPK) induction- reduced
PPARγ over-expression, thus protecting steatotic liver grafts against I/R injury associated
with transplantation. In terms of clinical application, therapies based on RBP4 treatment and
PPARγ antagonists might open new avenues for steatotic LT and improve the initial condi‐
tions of donor livers with low steatosis that are available for transplantation [81]. On the oth‐
er hand, the effects of RBP4 could depend on the surgical conditions. Indeed, RBP4
administration not only failed to protect both liver types from damage and regenerative fail‐
ure, it exacerbated the negative consequences of liver surgery in PH under I/R [82]. Under
these conditions, RBP4 affected the mobilization of retinol from steatotic livers, revealing ac‐
tions of RBP4 independent of simple retinol transport. The injurious effects of RBP4 were
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not due to changes in retinol levels. Thus, strategies based on modulating RBP4 could be in‐
effective and possibly even harmful in both liver types in PH under I/R or surgical condi‐
tions including small-for-size LT.
8.2. Relevance of the duration of hepatic ischemia
The severity of hepatocyte damage depends on duration of ischemia. Depending on the ob‐
jectives of the research, it is important to consider a specific ischemia duration. In other
words, if you want to study the mechanisms involved in hepatic I/R injury or the protective
mechanisms of a drug, it is more appropriate to use a duration of ischemia associated with
high survival. If the purpose is to study the relevance of a drug in hepatic I/R injury, then it
is advisable to assess survival, and, therefore, it is more adequate to use experimental mod‐
els in which the ischemic period is associated with low survival. These observations are
based on the following data reported in the literature. It appears that short periods (60 mi‐
nutes) of warm ischemia result in reversible cell injury, in which liver oxygen consumption
returns to control levels when oxygen is resupplied after ischemia. Reperfusion after more
prolonged periods of warm ischemia (120-180 minutes) results in irreversible cell damage.
These observations agree with a previous report on rat liver subjected to I/R, indicating a
cellular endpoint for hepatocytes after 90 minutes of ischemia [83]. In human LT, a long is‐
chemic period is a predicting factor for posttransplantation graft dysfunction, and some
transplantation groups hesitate to transplant liver grafts preserved for more than 10 h. Some
studies in experimental models of LT indicate that cold ischemia for 24 h induces low sur‐
vival. However, LT, following shorter ischemic periods, may also result in primary organ
dysfunction [72].
It is important to distinguish between the types of Ischemia (warm and cold) because there
is already some controversy about the pathophysiological mechanisms of cold ischemia,
which may depend, for example, on the time. The mechanisms of hepatic I/R injury are also
different depending on the duration of hepatic ischemia. Along these lines, in the same ex‐
perimental model of LT, XDH/XOD plays a crucial role in hepatic I/R injury only in condi‐
tions under which significant conversion of XDH to XOD occurs (80–90% of XOD) such as
16 h of cold ischemia. However, this ROS generation system does not appear to be crucial
for shorter ischemic periods such as 6 h of cold ischemia [72]. Similarly, it should also be
noted that oxidative stress in hepatocytes and the stimulatory state of KCs after I/R depend
on the duration of ischemia and may also differ between ischemia at 4ºC and that at 37ºC,
which probably leads to different developmental mechanisms of liver damage.
Our previous results indicate that PPARα does not play a crucial role in I/R injury in non‐
steatotic livers. This contrasts with a study published by Okaya and Lentsch [84], in which
the authors reported the benefits of PPARα agonists on postischemic liver injury. Although
the dose and pretreatment time of the PPARα agonist WY-14643 were similar in both stud‐
ies, Okaya and Lentsch reported an ischemic period of 90 minutes; ours was 60 minutes,
which is the ischemic period currently used in liver surgery [3]. Thus, 60 minutes of ische‐
mia seems to be insufficient to induce changes in PPARα in nonsteatotic livers [13].
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and both additives up-regulated AKT in both liver types. This was associated with glycogen
synthase kinase-3β (GSK3β) inhibition in non-steatotic livers and PPARγ over-expression in
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clearly seen in an experimental model of normothermic hepatic ischemia. However, the rela‐
tionship between EGF and IGF-I was different dependently of the surgical procedure. In‐
deed, under these conditions, IGF-I increased EGF, thus protecting steatotic and non-
steatotic livers against I/R damage. The beneficial role of EGF on hepatic I/R damage may be
attributable to p38 inhibition in non-steatotic livers and to PPARγ overexpression in steatot‐
ic livers [79].
PPARα agonists as well as ischemic preconditioning (IP), through PPARα, inhibited mito‐
gen-activated protein kinase expression following I/R in steatotic livers undergoing normo‐
thermic hepatic ischemia. This in turn inhibited the accumulation of adiponectin in steatotic
livers and reduced its negative effects on oxidative stress and hepatic injury [13]. In line
with this, adiponectin silent small interfering RNA (siRNA) treatment decreased oxidative
stress and hepatic injury in steatotic livers. However, another study by Man et al., 2006 [80]
in small fatty grafts, adiponectin treatment exerted anti-inflammatory effects that down-
regulated TNFα mRNA and vasoregulatory effects that improved the microcirculation. Adi‐
ponectin anti-inflammatory effects also include the activation of cell survival signaling via
the phosphorylation of Akt and the stimulation of NO production. Additionally, the studies
by Man et al., [80] showed the anti-obesity and proliferative properties of adiponectin in
small fatty transplants. Taken together, the aforementioned data indicate that the action
mechanisms of adiponectin depend on the surgical conditions. Thus, on the basis of the dif‐
ferent results reported to date in hepatic I/R, it is difficult to discern whether we should aim
to inhibit adiponectin, or administer adiponectin to protect steatotic livers against cold is‐
chemia associated with transplantation. Moreover, the adiponectin data reported for these
experimental models of hepatic I/R [13,80] should not be extrapolated to cadaveric organ
transplantation. For small liver grafts (which are relatively common) and under conditions
of warm ischemia, the periods of ischemia range from 40 to 60 minutes; this range may not
be accurate for cadaveric donor LT.
RBP4 is an adipokine synthesized by the liver, whose known function is to transport retinol
in circulation. However, the role of RBP4 in hepatic I/R could depend on the liver surgical
procedure. Steatotic liver grafts were found to be more vulnerable to the down-regulation of
RBP4. RBP4 treatment-through AMP-activated protein kinase (AMPK) induction- reduced
PPARγ over-expression, thus protecting steatotic liver grafts against I/R injury associated
with transplantation. In terms of clinical application, therapies based on RBP4 treatment and
PPARγ antagonists might open new avenues for steatotic LT and improve the initial condi‐
tions of donor livers with low steatosis that are available for transplantation [81]. On the oth‐
er hand, the effects of RBP4 could depend on the surgical conditions. Indeed, RBP4
administration not only failed to protect both liver types from damage and regenerative fail‐
ure, it exacerbated the negative consequences of liver surgery in PH under I/R [82]. Under
these conditions, RBP4 affected the mobilization of retinol from steatotic livers, revealing ac‐
tions of RBP4 independent of simple retinol transport. The injurious effects of RBP4 were
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not due to changes in retinol levels. Thus, strategies based on modulating RBP4 could be in‐
effective and possibly even harmful in both liver types in PH under I/R or surgical condi‐
tions including small-for-size LT.
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The severity of hepatocyte damage depends on duration of ischemia. Depending on the ob‐
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words, if you want to study the mechanisms involved in hepatic I/R injury or the protective
mechanisms of a drug, it is more appropriate to use a duration of ischemia associated with
high survival. If the purpose is to study the relevance of a drug in hepatic I/R injury, then it
is advisable to assess survival, and, therefore, it is more adequate to use experimental mod‐
els in which the ischemic period is associated with low survival. These observations are
based on the following data reported in the literature. It appears that short periods (60 mi‐
nutes) of warm ischemia result in reversible cell injury, in which liver oxygen consumption
returns to control levels when oxygen is resupplied after ischemia. Reperfusion after more
prolonged periods of warm ischemia (120-180 minutes) results in irreversible cell damage.
These observations agree with a previous report on rat liver subjected to I/R, indicating a
cellular endpoint for hepatocytes after 90 minutes of ischemia [83]. In human LT, a long is‐
chemic period is a predicting factor for posttransplantation graft dysfunction, and some
transplantation groups hesitate to transplant liver grafts preserved for more than 10 h. Some
studies in experimental models of LT indicate that cold ischemia for 24 h induces low sur‐
vival. However, LT, following shorter ischemic periods, may also result in primary organ
dysfunction [72].
It is important to distinguish between the types of Ischemia (warm and cold) because there
is already some controversy about the pathophysiological mechanisms of cold ischemia,
which may depend, for example, on the time. The mechanisms of hepatic I/R injury are also
different depending on the duration of hepatic ischemia. Along these lines, in the same ex‐
perimental model of LT, XDH/XOD plays a crucial role in hepatic I/R injury only in condi‐
tions under which significant conversion of XDH to XOD occurs (80–90% of XOD) such as
16 h of cold ischemia. However, this ROS generation system does not appear to be crucial
for shorter ischemic periods such as 6 h of cold ischemia [72]. Similarly, it should also be
noted that oxidative stress in hepatocytes and the stimulatory state of KCs after I/R depend
on the duration of ischemia and may also differ between ischemia at 4ºC and that at 37ºC,
which probably leads to different developmental mechanisms of liver damage.
Our previous results indicate that PPARα does not play a crucial role in I/R injury in non‐
steatotic livers. This contrasts with a study published by Okaya and Lentsch [84], in which
the authors reported the benefits of PPARα agonists on postischemic liver injury. Although
the dose and pretreatment time of the PPARα agonist WY-14643 were similar in both stud‐
ies, Okaya and Lentsch reported an ischemic period of 90 minutes; ours was 60 minutes,
which is the ischemic period currently used in liver surgery [3]. Thus, 60 minutes of ische‐
mia seems to be insufficient to induce changes in PPARα in nonsteatotic livers [13].
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8.3. Relevance of the extent of hepatic ischemia
Another factor to consider before selecting the experimental model of hepatic I/R is the per‐
centage of hepatic ischemia applied. The extent of hepatic injury as well as the hepatic I/R
mechanisms, including the recovery of blood flow and energy charge during hepatic reper‐
fusion is dependent on the extent of ischemia-whether total or partial (70%) hepatic ische‐
mia is applied [36]. This fact could be explained by the stealing phenomenon. In contrast to
100% hepatic ischemia, during ischemia in the left and median lobes, the flow is shunted via
the right lobes and following the release of the occlusion of the left and median lobes, a sig‐
nificant amount of shunting via the right lobes will continue during reperfusion until vascu‐
lar resistance in the postischemic lobes decreases. This occurs because blood flows through
the path of least resistance. The reasons for this may be cellular swelling endothelial, stasis,
or other changes. Thus, the recovery of blood flow and hepatic perfusion of the preischemic
lobe is later in the case of 70% hepatic ischemia than in 100% hepatic ischemia [76]. In line
with these observations, the benefits of some drugs such as ATP-MgCl2 were dependent on
the extent of hepatic ischemia used [32,77].
8.4. Relevance of the type of liver submitted to I/R
A variety of clinical factors including starvation, graft age, and steatosis have been studied
in different experimental models of hepatic I/R because of the relevance of these factors in
clinical practice. These factors enhance liver susceptibility to I/R injury, further increasing
the patient risks related to reperfusion injury.
8.4.1. Starvation
The pre-existent nutritional status is a major determinant of the hepatocyte injury associated
with I/R. In clinical LT, starvation of the donor, due to prolonged intensive care unit hospi‐
talization or the lack of adequate nutritional support, increases the incidence of hepatocellu‐
lar injury and primary nonfunction [85]. Based on the nutritional state status, several
experimental and clinical studies support the hypothesis that the availability of glycolytic
substrates is important for maintenance of hepatic ATP levels during I/R. Fasting exacer‐
bates I/R injury because the low content of glycogen stores results in more rapid ATP deple‐
tion during ischemia. In addition, fasting causes alterations in tissue antioxidant defenses,
accelerates the conversion of XDH to XOD during hypoxia and induces mitochondrial alter‐
ations [85]. Caraceni et al., [86] have shown that mitochondrial damage is greatly enhanced
by fasting which decreases the hepatic content of antioxiants and therefore sensitizes the mi‐
tochondrial to the injurious effects of ROS. Considering these observations, an artificial nu‐
tritional support may represent a new approach for the prevention of reperfusion injury in
fasted livers. On the contrary, fasting has been reported to improve organ viability and sur‐
vival [87], as it reduces phagocytosis and the generation of TNF-α [87]. To understand these
apparent contradictory results, it is important to consider the different experimental condi‐
tions in these investigations. A beneficial effect of high glycogen content can mainly be ex‐
pected under conditions of long preservation times and long periods of warm ischemia.
Under these conditions, high metabolic reserves of the liver may attenuate ischemic cell in‐
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jury and preserve defense functions against cytotoxic mediators of KCs. Conversely, short
ischemic periods require lower metabolic reserves, and the extent of KC activation can be
the dominant factor in early graft injury.
8.4.2. Age
A number of distinct age-related alterations have been identified in the hepatic inflammato‐
ry response to hepatic I/R [88]. Under warm hepatic ischemia, mature adult mice had great‐
ly increased neutrophil function, increased intracellular oxidant levels, and decreased
mitochondrial function compared with the findings in young adult mice. These alterations
contributed to the increased liver injury after I/R observed in mature adult mice compared
with that in young adult mice. The results obtained in an experimental model of isolated
perfused liver indicate that, during reperfusion, livers obtained from old rats generate a
lower amount of oxyradicals than livers from young rats. This fact could be explained by the
lower KC activity, the reduction of liver blood flow, and the impaired functions and struc‐
tural alterations observed in the livers of old rats. In fact, in hepatocytes from mature adult
mice, delayed activation of nuclear factor kappa B (NFκB) in response to TNF-α and virtual‐
ly no production of macrophage inflammatory protein 2 have been detected, which may be
due to an agerelated defect in hepatocytes [88].
8.4.3. Steatosis
The first step to minimize the adverse effects of I/R in steatotic livers is a full understanding
of the mechanisms involved in I/R injury in these marginal organs. This can be achieved on‐
ly with the selection of an appropriate method to induce steatosis in livers undergoing I/R. It
is well known that the mechanisms involved in hepatic I/R injury are different depending
on the type of liver (nonsteatotic versus steatotic livers). In addition to the impairment of
microcirculation, mitochondrial ROS generation dramatically increases during reperfusion
in steatotic livers [9,86]. Results obtained under warm hepatic ischemia indicate that apopto‐
sis is the predominant form of hepatocyte death in the ischemic nonsteatotic liver, whereas
the steatotic livers develop massive necrosis after an ischemic insult [9]. Steatotic livers dif‐
fered from nonsteatotic livers in their response to the UPR and ER stress since IRE1 and
PERK were weaker in the presence of steatosis [89]. Decreased ATP production and dys‐
function of regulators of apoptosis, such that Bcl-2, Bcl-xL and Bax have been proposed to
explain the failure of apoptosis in steatotic livers. Differences were also observed when we
analyzed the role of the RAS, as the nonsteatotic grafts exhibited higher Ang-II levels than
steatotic grafts whereas steatotic grafts exhibited higher Ang 1-7 levels [15]. In the context of
I/R injury associated with LT, the axis ACE-Ang II-ATR and ACE2-Ang 1-7-Mas play a ma‐
jor role in nonsteatotic and steatotic grafts, respectively. From the point of view of clinical
application, these findings may open up new possibilities for therapeutic interventions in LT
within the RAS cascade, based on Ang 1-7 for steatotic livers and Ang II for non-steatotic
ones [15]. Moreover, reduced RBP4 and increased PPARγ levels were observed in steatotic
livers compared to non-steatotic livers [81]. The vulnerability of steatotic livers subjected to
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8.3. Relevance of the extent of hepatic ischemia
Another factor to consider before selecting the experimental model of hepatic I/R is the per‐
centage of hepatic ischemia applied. The extent of hepatic injury as well as the hepatic I/R
mechanisms, including the recovery of blood flow and energy charge during hepatic reper‐
fusion is dependent on the extent of ischemia-whether total or partial (70%) hepatic ische‐
mia is applied [36]. This fact could be explained by the stealing phenomenon. In contrast to
100% hepatic ischemia, during ischemia in the left and median lobes, the flow is shunted via
the right lobes and following the release of the occlusion of the left and median lobes, a sig‐
nificant amount of shunting via the right lobes will continue during reperfusion until vascu‐
lar resistance in the postischemic lobes decreases. This occurs because blood flows through
the path of least resistance. The reasons for this may be cellular swelling endothelial, stasis,
or other changes. Thus, the recovery of blood flow and hepatic perfusion of the preischemic
lobe is later in the case of 70% hepatic ischemia than in 100% hepatic ischemia [76]. In line
with these observations, the benefits of some drugs such as ATP-MgCl2 were dependent on
the extent of hepatic ischemia used [32,77].
8.4. Relevance of the type of liver submitted to I/R
A variety of clinical factors including starvation, graft age, and steatosis have been studied
in different experimental models of hepatic I/R because of the relevance of these factors in
clinical practice. These factors enhance liver susceptibility to I/R injury, further increasing
the patient risks related to reperfusion injury.
8.4.1. Starvation
The pre-existent nutritional status is a major determinant of the hepatocyte injury associated
with I/R. In clinical LT, starvation of the donor, due to prolonged intensive care unit hospi‐
talization or the lack of adequate nutritional support, increases the incidence of hepatocellu‐
lar injury and primary nonfunction [85]. Based on the nutritional state status, several
experimental and clinical studies support the hypothesis that the availability of glycolytic
substrates is important for maintenance of hepatic ATP levels during I/R. Fasting exacer‐
bates I/R injury because the low content of glycogen stores results in more rapid ATP deple‐
tion during ischemia. In addition, fasting causes alterations in tissue antioxidant defenses,
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ations [85]. Caraceni et al., [86] have shown that mitochondrial damage is greatly enhanced
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tochondrial to the injurious effects of ROS. Considering these observations, an artificial nu‐
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jury and preserve defense functions against cytotoxic mediators of KCs. Conversely, short
ischemic periods require lower metabolic reserves, and the extent of KC activation can be
the dominant factor in early graft injury.
8.4.2. Age
A number of distinct age-related alterations have been identified in the hepatic inflammato‐
ry response to hepatic I/R [88]. Under warm hepatic ischemia, mature adult mice had great‐
ly increased neutrophil function, increased intracellular oxidant levels, and decreased
mitochondrial function compared with the findings in young adult mice. These alterations
contributed to the increased liver injury after I/R observed in mature adult mice compared
with that in young adult mice. The results obtained in an experimental model of isolated
perfused liver indicate that, during reperfusion, livers obtained from old rats generate a
lower amount of oxyradicals than livers from young rats. This fact could be explained by the
lower KC activity, the reduction of liver blood flow, and the impaired functions and struc‐
tural alterations observed in the livers of old rats. In fact, in hepatocytes from mature adult
mice, delayed activation of nuclear factor kappa B (NFκB) in response to TNF-α and virtual‐
ly no production of macrophage inflammatory protein 2 have been detected, which may be
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The first step to minimize the adverse effects of I/R in steatotic livers is a full understanding
of the mechanisms involved in I/R injury in these marginal organs. This can be achieved on‐
ly with the selection of an appropriate method to induce steatosis in livers undergoing I/R. It
is well known that the mechanisms involved in hepatic I/R injury are different depending
on the type of liver (nonsteatotic versus steatotic livers). In addition to the impairment of
microcirculation, mitochondrial ROS generation dramatically increases during reperfusion
in steatotic livers [9,86]. Results obtained under warm hepatic ischemia indicate that apopto‐
sis is the predominant form of hepatocyte death in the ischemic nonsteatotic liver, whereas
the steatotic livers develop massive necrosis after an ischemic insult [9]. Steatotic livers dif‐
fered from nonsteatotic livers in their response to the UPR and ER stress since IRE1 and
PERK were weaker in the presence of steatosis [89]. Decreased ATP production and dys‐
function of regulators of apoptosis, such that Bcl-2, Bcl-xL and Bax have been proposed to
explain the failure of apoptosis in steatotic livers. Differences were also observed when we
analyzed the role of the RAS, as the nonsteatotic grafts exhibited higher Ang-II levels than
steatotic grafts whereas steatotic grafts exhibited higher Ang 1-7 levels [15]. In the context of
I/R injury associated with LT, the axis ACE-Ang II-ATR and ACE2-Ang 1-7-Mas play a ma‐
jor role in nonsteatotic and steatotic grafts, respectively. From the point of view of clinical
application, these findings may open up new possibilities for therapeutic interventions in LT
within the RAS cascade, based on Ang 1-7 for steatotic livers and Ang II for non-steatotic
ones [15]. Moreover, reduced RBP4 and increased PPARγ levels were observed in steatotic
livers compared to non-steatotic livers [81]. The vulnerability of steatotic livers subjected to
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warm ischemia is also associated with increased adiponectin, oxidative stress, and IL-1 lev‐
els and a reduced ability to generate IL-10 and PPARα [13,90].
It should be considered that there are differences in the mechanisms involved in hepatic I/R
injury depending on the method used to induce steatosis. In contrast with other experimen‐
tal models of steatosis, both dietary high fat and alcohol exposure induced the production of
SOD/catalase-insensitive ROS, which may be involved in the mechanism of steatotic liver
failure after OLT [9]. Neutrophils have been involved in the increased vulnerability of stea‐
totic livers to I/R injury, especially in alcoholic steatotic livers. However, neutrophils do not
account for the differentially greater injury in non-alcoholic steatotic livers during the early
or late hours of reperfusion. Similarly, the role of TNF in the vulnerability of steatotic livers
to I/R injury may be dependent on the type of steatosis [1,9].
8.5. Relevance of regeneration in experimental models of hepatic I/R
It is known that different experimental models trigger different responses when a common
mechanism or the same drug is investigated. This situation is witnessed when analyzing liv‐
er injury in models of I/R with or without hepatectomy. This situation is illustrated by Ram‐
alho et al., [36] regarding the loss of protection of Ang-II receptor antagonists against liver
damage in conditions of PH under I/R compared with the study of I/R without hepatectomy,
in which Ang-II receptor antagonists reduced hepatic damage. These different results could
not be explained by differences in the dose or frequency of drug administration but rather
by differences in surgical conditions (percentage of hepatic ischemia and the presence or ab‐
sence of hepatectomy). In the model of I/R without hepatectomy [33], the blood supply to
the left and median liver lobes (70% hepatic mass) was interrupted, and the other hepatic
lobes remained intact. However, in PH under I/R, only blood supply to the remnant liver
(30% hepatic mass) was interrupted and the other hepatic lobes were excised [36].
According to the cell type and experimental or pathologic conditions, TNF-α may stimu‐
late cell  death or it  may induce hepatoprotective effects  mediated by antioxidant,  antia‐
poptotic,  and  other  anti-stress  mediators  coupled  with  a  pro-proliferative  biologic
response. For example, although the deleterious effect of the TNF-α in local and systemic
damage associated with hepatic I/R in experimental  models of  normothermic hepatic is‐
chemia is well established [91], this mediator is also a key factor in hepatic regeneration
[92], an important process in RSLT and PH associated with hepatic resections [93]. These
differential effects observed for TNF-α can also be extrapolated to transcription factors. It
is  well  known that  NFκB can regulate  various downstream pathways and thus has  the
potential to be both pro- and antiapoptotic [8]. Currently it is not clear whether the bene‐
ficial  effects  of  NFκB activation in protection against  apoptosis  or  its  detrimental  proin‐
flammatory  role  predominate  in  liver  I/R  [8].  Hepatic  neutrophil  recruitment  and
hepatocellular  injury  are  significantly  NFκB  activation  is  suppressed  in  mice  following
partial hepatic I/R. However, NFκB activation is essential for hepatic regeneration after rat
LT, and reduces apoptosis and hepatic I/R injury [94].
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9. Strategies applied in experimental models of hepatic I/R
9.1. Pharmacological treatment and additives in preservation solution
Numerous experimental studies have focused on the developing in vivo  pharmacological
strategies  aimed at  inhibiting the harmful  effects  of  I/R [9,72,89,90,95-99].  Some of  these
studies are summarized in Table 1.  However,  none of  these treatments has managed to
prevent hepatic I/R injury. A large number of ingredients-which have been introduced in‐
to UW solution in experimental models of hepatic cold ischemia [9,95,100-102] (Table 1).
However, none of these modifications to the UW solution composition have found their
way into routine  clinical  practice.  Further  studies  will  be  required to  elucidate  whether
the use of perfluorochemicals (PFC) in preservation solutions might improve the viability
of liver grafts  undergoing transplantation.  PFC are hydrocarbons with high capacity for
dissolving respiratory and other nonpolar gases. A negligible O2-binding constant of PFC
allows them to release O2 more effectively than hemoglobin into the surrounding tissue
(acts as an oxygen-supplying agent). PFC differs from hemoglobin preparations in that it
is  a  totally synthetic  compound formed on a liquid hydrocarbon base.  Unlike hemoglo‐
bin, acidosis, alkalosis, and temperature seem to have no or little effect on the oxygen de‐
livery  of  PFC,  allowing  this  compound  to  be  used  effectively  during  cold  storage  of
organs [103]. A recently study, used Oxycyte, a PFC added to UW solution can be benefi‐
cial  after  cardiac  death liver  graft  preservation in  a  rat  model  [103].  However,  their  ef‐
fects on reperfusion injury were not evaluated in that study. In fact,  the possibility that
preoxygenated  PFC  exacerbates  the  ROS  during  reperfusion  should  not  be  discarded
since the use of gaseous oxygen applied to the livers during the storage period was only
effective in improving hepatic viability upon reperfusion when antioxidants were added
to the UW rinse solution [104].
It should be also considered that the inclusion of some components in the UW solution has
been both advocated and criticized. Indeed, simplified variants of the UW solution in which
some additive were omitted were demonstrated to have similar or even higher protective
potential during cold liver storage. Another limitation of the UW solution is that some of its
constituent compounds, including allopurinol do not offer very good protection because
they are not present at a suitable concentration and encounter problems in reaching their
site of action [9]. The possible side effects of some drugs may frequently limit their use in
human LT. For example, idiosyncratic liver injury in humans is documented for chlorpro‐
mazine, pernicious systemic effects have been described for NO donors, allopurinol therapy
can cause hematological changes and gadolinium can induce coagulation disorders. Some
case reports of acute hepatotoxicity attributed to rosiglitazone have been published [105].
The development of therapeutic strategies that utilize the protective effect of heme oxygen‐
ase-1 induction is hampered by the fact that most pharmacological inducers of this enzyme
perturb organ function by themselves [106].
Pharmacological  treatment-derived  difficulties  must  also  be  considered.  In  this  regard,
SOD and GSH exhibit inadequate delivery to intracellular sites of ROS action [9]. The ad‐
ministration of anti-TNF antibodies does not effectively protect against hepatic I/R injury,
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damage in conditions of PH under I/R compared with the study of I/R without hepatectomy,
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sence of hepatectomy). In the model of I/R without hepatectomy [33], the blood supply to
the left and median liver lobes (70% hepatic mass) was interrupted, and the other hepatic
lobes remained intact. However, in PH under I/R, only blood supply to the remnant liver
(30% hepatic mass) was interrupted and the other hepatic lobes were excised [36].
According to the cell type and experimental or pathologic conditions, TNF-α may stimu‐
late cell  death or it  may induce hepatoprotective effects  mediated by antioxidant,  antia‐
poptotic,  and  other  anti-stress  mediators  coupled  with  a  pro-proliferative  biologic
response. For example, although the deleterious effect of the TNF-α in local and systemic
damage associated with hepatic I/R in experimental  models of  normothermic hepatic is‐
chemia is well established [91], this mediator is also a key factor in hepatic regeneration
[92], an important process in RSLT and PH associated with hepatic resections [93]. These
differential effects observed for TNF-α can also be extrapolated to transcription factors. It
is  well  known that  NFκB can regulate  various downstream pathways and thus has  the
potential to be both pro- and antiapoptotic [8]. Currently it is not clear whether the bene‐
ficial  effects  of  NFκB activation in protection against  apoptosis  or  its  detrimental  proin‐
flammatory  role  predominate  in  liver  I/R  [8].  Hepatic  neutrophil  recruitment  and
hepatocellular  injury  are  significantly  NFκB  activation  is  suppressed  in  mice  following
partial hepatic I/R. However, NFκB activation is essential for hepatic regeneration after rat
LT, and reduces apoptosis and hepatic I/R injury [94].
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and this finding has been related to the failure of complete TNF-α neutralization locally
[11].  Although this  also occurs  in  non-steatotic  livers,  modulating I/R injury in steatotic
livers  poses  a  greater  problem.  Differences  in  the  action  mechanisms  between  steatotic
and non-steatotic livers mean that therapies that are effective in non-steatotic livers may
prove useless in the presence of steatosis, and the effective drug dose may differ between
the two liver types. Findings such as these must be considered when applying pharmaco‐
logical strategies in the same manner to steatotic and non-steatotic livers because the ef‐
fects may be very different. For example, caspase inhibition, a highly protective strategy
in non-steatotic livers, had no effect on hepatocyte injury in steatotic livers [9]. Moreover,
whereas in an LT experimental model, an NO donor reduced oxidative stress in non-stea‐
totic livers, the same dose increased the vulnerability of steatotic grafts to I/R injury. Fur‐
thermore, there may be drugs that would only be effective in steatotic livers. This was the
case of compounds such as cerulenin, which reduce UCP-2 expression in steatotic livers
and carnitine [9].




Mice Cerulenin (Fatty acid synthase
inhibitor)
15 min




Apocynin (NAPH oxidase inhibitor) ↓ Oxidative stress
TBC-1269 (Pan-selectin antagonist) 90 min ↓ Inflammatory response, ERK ½
Rat
Rat
Lisinopril  (ACE inhibitor)
30 min
↓ Oxidative stress
Ascorbate (ROS scavenger) ↓ Apoptosis
Allopurinol (XOD inhibitor) 30 60 min ↓Oxidative stress
Melatonin (Hormone) 40 min ↓ IKK, JNK pathways
SOD (antioxidant)
45 min
↓ Microcirculatory disturbances, leukocyte
acumulation
L-arginine (NO precursor) ↑ NO, ATP ↓ Neutrophil accumulation




↓ IL-1, Oxidative stress
Anti-ICAM-1 ↓ Adherence of leukocytes in postsinusoidal venules
Gabexate mesilate (Protease
inhibitor)
↓ TNF-α, Leukocyte activation
OP-2507 (Analogue of prostacyclin) ↓ Microcirculatory disturbance
WY-14643 (PPARα agonist) ↓ Oxidative stress, Inflammatory cytokines
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n-3 PUFA ↓ Liver injury, Oxidative stress
Glutathione (Antioxidant)
60 90 min
↓ Microcirculatory disturbances ↑ Detoxification of
ROS
Spermine NONOate (NO donor) ↓ IL-1α, Oxidative stress
FK506 (Immunosupressant) ↓ TNF





Anti-TNF antiserum ↓ TNF, Leukocyte accumulation
α-Lipoic acid (Antioxidant) ↑ Liver regeneration, ↓ Apoptosis








↓ Endoplasmic reticulum stress
Sirolimus (Immunossupressant) ↓ Linfocytes
IL-1ra (IL-1 receptor antagonist) 90 min ↓ TNF, Oxidative stress
Dog FK 3311 (Cox-2 inhibitor) 60 min ↓ Neutrophil infiltration, Cox-2





Cerulenin (fatty acid synthase
inhibitor)
80 min
↓ UPC2, ↑ ATP
Rat FK 409 (NO donor) 80 min ↑ HSP, IL-10, ↓ SEC damage, IL-1
CS1 peptides (FN-α4β1 interac
blocker)
4 h
↓ Neutrophil and lymphocyte T infiltration, TNF-α,
iNOS
Tocopherol (antioxidante) 5 h







↓ Macrophages infiltration and T cells
PSGL-1 (P-selectin blocker) ↓ Neutrophil infiltration, TNF-α, INFγ, iNOS
Anti-TNF antiserum 6, 24 h ↓ TNF, Leukocyte accumulation
SOD (antioxidant)
8 h
↓ Microcirculatory disturbance, Leukocyte acumulation
Tauroursodeoxycholate (Bile acid) ↓ Endoplasmic reticulum stress
Allopurinol (XOD inhibitor) 8, 16 h ↓Oxidative stress
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and this finding has been related to the failure of complete TNF-α neutralization locally
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Z-DEVD-FMK (caspase 3 and 7
inhibitor)
16 h
↑ Microvascular perfusión, Bcl-2 ↓ Apoptosis
L-arginine (NO precursor)
18 h
↑ NO, ATP, ↓ Neutrophil accumulation
Treprostinil (Prostacyclin analogue)




↑ PI3K/Akt, ↓ Apoptosis
Bucillamine (antioxidant) ↓Oxidative stress
Chlorpromazine (Ca2 + channel
antagonist)
↑ ATP ↓ Mitocondrial dysfunction, Alterations in lipid
metabolism
sCR1 (complement inhibitor) ↓ Microcirculatory disturbance, Leukocyte adhesion




Anti-ICAM-1 ↓ Adherence of leukocytes in postsinusoidal venules
Glycine (Kupfer cell modulator) ↓ Neutrophil accumulation, TNF-α
GdCl3 (Kupffer cell blocker) ↓ Neutrophil accumulation, TNF-α
Cbz-Val-Phe methyl ester (calpain
inhibitor)
24, 40h ↓ Calpain activation, SEC apoptotic
EHNA (adenosine deaminase
inhibitor)
24, 44 H ↑ Interstitial adenosine ↓ Microcirculatory disturbance,
Leukocytes rolling
CGS-21680 (adenosine A2 receptor
agonist)
30 h ↑ cAMP, ↓ SEC Killing
Sotrastaurin (PKC Inhibitor) ↓ Apoptosis, macrophage/neutrophil accumulation
FR167653 (IL-1β and TNF-α supressor) 48 h ↓ TNF-α, IL-1α, Kupffer cell activation
Doxorubicin (Heat shock proteins
inducer)




8 h ↓ ET-1




Mouse Erythropoietin (EPO) 24 h ↓ Liver injury
Rat Meloxicam (COX-2 Inhibitor) 1 h ↓ Apoptosis, Liver injury, Oxidative stress
Simvastatin (KLF2-inducer) 1, 6, 16 h ↓ Inflammation, Liver injury, Oxidative stress,
Tauroursodeoxycholate (Bile acid) 2 h ↓ Endoplasmic reticulum stress
S-nitroso-N-acetylcysteine 2, 4, 6 h ↓ Liver injury
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↓ TNF-α and neutrophil accumulation
Ruthenium red (mitochondrial Ca2+
uniporter inhibitor)
↓ Mitocondrial dysfunction
Melatonin (Hormone) ↓ Oxidative stress, Liver injury
OP-4183 (PGI2 analogue) ↓ Oxidative stress
SAM (ATP precursor) ↓ Oxidative stress
IDN-1965 (caspase inhibitor) 24, 30 h ↓ Apoptosis
Pifithrin-alpha (p53 inhibitor) 24, 48 h ↓ Apoptosis
Sodium nitroprusside (NO donor) ↓ Microcirculatory dysturbances
FR167653 (p38 inhibitor) 30 h ↓ Microcirculatory dysturbances
GSNO (NO donor) 48 h ↓ SEC damage
Dog Trifluoperazine (calmodulin inhibitor) 24 h ↓ Microcirculatory dysturbances
Pig
E5880 (PAF antagonist) 8 h ↓ Microcirculatory dysturbances
EGF, IGF-1, NGF-α 18 h ↑ ATP
Table 1. In vivo pharmacological therapy and additives in preservation solution in experimental models of warm
hepatic ischemia (with or whithout hepatectomy) and liver transplantation
9.2. Gene therapy
Advances in molecular biology provide new opportunities to reduce liver I/R injury by us‐
ing gene therapy. Genome manipulation can be achieved by: A) germ line manipulation (oo‐
cyte  injections);  B)  stem  cell  transformation  and  reintroduction  into  embryos,  and  C)
targeting specific  cells  or  organs  with  vectors  or  viruses  (gene transfer).  The first  2  ap‐
proaches include germ-line alterations and are neither feasible nor accepted by society. The
third approach would lend to the treatment of individual patients with either acquired or
congenital diseases [12]. In the last years, significant advances in gene therapy vectors have
occurred. Gene transfer can be accomplished by direct injection of DNA into a target or‐
gan or tissue, transduction by recombinant viral vectors carrying a specific gene of inter‐
est,  e.g.,  adenovirus  (Ad)  or  retrovirus,  transfection  of  cells  by  chemical  methods  (e.g.,
cationic liposomes), or stem cell transduction and reintroduction of genetically-altered cells
back into embryos [107] (Table 2). Currently, researchers in gene transfer have focused ef‐
forts toward targeting vectors to specific cells or organs without loss of transduction abili‐
ty  [108,109],  allowing  high  level  gene  transduction  of  the  liver  without  affecting  other
organs [12,107].
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24, 44 H ↑ Interstitial adenosine ↓ Microcirculatory disturbance,
Leukocytes rolling
CGS-21680 (adenosine A2 receptor
agonist)
30 h ↑ cAMP, ↓ SEC Killing
Sotrastaurin (PKC Inhibitor) ↓ Apoptosis, macrophage/neutrophil accumulation
FR167653 (IL-1β and TNF-α supressor) 48 h ↓ TNF-α, IL-1α, Kupffer cell activation
Doxorubicin (Heat shock proteins
inducer)




8 h ↓ ET-1




Mouse Erythropoietin (EPO) 24 h ↓ Liver injury
Rat Meloxicam (COX-2 Inhibitor) 1 h ↓ Apoptosis, Liver injury, Oxidative stress
Simvastatin (KLF2-inducer) 1, 6, 16 h ↓ Inflammation, Liver injury, Oxidative stress,
Tauroursodeoxycholate (Bile acid) 2 h ↓ Endoplasmic reticulum stress
S-nitroso-N-acetylcysteine 2, 4, 6 h ↓ Liver injury
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↓ TNF-α and neutrophil accumulation
Ruthenium red (mitochondrial Ca2+
uniporter inhibitor)
↓ Mitocondrial dysfunction
Melatonin (Hormone) ↓ Oxidative stress, Liver injury
OP-4183 (PGI2 analogue) ↓ Oxidative stress
SAM (ATP precursor) ↓ Oxidative stress
IDN-1965 (caspase inhibitor) 24, 30 h ↓ Apoptosis
Pifithrin-alpha (p53 inhibitor) 24, 48 h ↓ Apoptosis
Sodium nitroprusside (NO donor) ↓ Microcirculatory dysturbances
FR167653 (p38 inhibitor) 30 h ↓ Microcirculatory dysturbances
GSNO (NO donor) 48 h ↓ SEC damage
Dog Trifluoperazine (calmodulin inhibitor) 24 h ↓ Microcirculatory dysturbances
Pig
E5880 (PAF antagonist) 8 h ↓ Microcirculatory dysturbances
EGF, IGF-1, NGF-α 18 h ↑ ATP
Table 1. In vivo pharmacological therapy and additives in preservation solution in experimental models of warm
hepatic ischemia (with or whithout hepatectomy) and liver transplantation
9.2. Gene therapy
Advances in molecular biology provide new opportunities to reduce liver I/R injury by us‐
ing gene therapy. Genome manipulation can be achieved by: A) germ line manipulation (oo‐
cyte  injections);  B)  stem  cell  transformation  and  reintroduction  into  embryos,  and  C)
targeting specific  cells  or  organs  with  vectors  or  viruses  (gene transfer).  The first  2  ap‐
proaches include germ-line alterations and are neither feasible nor accepted by society. The
third approach would lend to the treatment of individual patients with either acquired or
congenital diseases [12]. In the last years, significant advances in gene therapy vectors have
occurred. Gene transfer can be accomplished by direct injection of DNA into a target or‐
gan or tissue, transduction by recombinant viral vectors carrying a specific gene of inter‐
est,  e.g.,  adenovirus  (Ad)  or  retrovirus,  transfection  of  cells  by  chemical  methods  (e.g.,
cationic liposomes), or stem cell transduction and reintroduction of genetically-altered cells
back into embryos [107] (Table 2). Currently, researchers in gene transfer have focused ef‐
forts toward targeting vectors to specific cells or organs without loss of transduction abili‐
ty  [108,109],  allowing  high  level  gene  transduction  of  the  liver  without  affecting  other
organs [12,107].
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ds siRNA RNA No limitation Transient No Zero
DNA injection DNA No limitation Transient No Zero
Cationic liposomes DNA No limitation Transient No Zero
Stem cell
transduction
DNA No limitation Transient No Zero
Table 2. Summary of gene therapy vectors commonly used.
Antiapoptotic Strategies (Bcl-2/Bcl-Xl, Bag-1 and caspases): Bcl-2 blocks apoptosis and necrosis
and has been implicated in the prolongation of cell survival [110]. Given its functional impor‐
tance in the cell death cascade, it constitutes one of the key targets for cytoprotective therapeu‐
tic manipulation for the regulation of apoptosis [110,111]. As demostrated by Bilbao et al., [111]
in a mouse hepatic I/R model, overexpression of Ad-mediated Bcl-2 gene significantly de‐
creased hepatocyte apoptosis and necrosis, improved hepatic function, and prolonged surviv‐
al as compared with controls. In addition, Bag-1 is a Bcl-2 binding protein resulting in a
prolonged and stabilized antiapoptotic activity [112]. In addition, Bag-1 appears to exert an in‐
direct silencing effect on TNF receptor R1 and hence suppresses the death receptor signal. A re‐
cent study by Sawitzki et al., [113] has demonstrated the cytoprotective effect of Ad-mediated
Bag-1 gene transfer in rat liver I/R. Using a model of cold ischemia and OLT, Ad-Bag-1 trans‐
fer improved portal venous blood flow, increased bile production, and improved hepatic func‐
tion with decreased neutrophil accumulation in the graft. Furthermore, Ad-mediated Bag-1
expression preserved hepatic architecture and reduced inflammation. The activation of T cells
infiltrating the graft was inhibited, since decreased expression of TNF-α, CD25, IL-2, and IFNγ
[107]. Caspase-8 is presumed to be the apex of the death-mediated apoptosis pathway, where‐
as caspase-3 belongs to the “effector” proteases in the apoptosis cascade. Contreras et al., dem‐
onstrated that inhibition of caspase-8 and caspase-3 by siRNA provided significant protection
against warm hepatic I/R injury and decreased animal mortality. In addition, animals given
siRNA caspase-8, or more significantly siRNA caspase-3, presented lower neutrophil infiltra‐
tion and better histologic profiles [114].
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Antioxidant therapy (SOD, HO-1, Ferritin): Oxidative stress can activate NF-κB and the AP-1
pathway and induce expression of proinflammatory genes including cytokines, adhesion
molecules, and chemokines leading to neutrophil-mediated inflammation [115-117]. To in‐
hibit the burst of ROS or its effect on hepatocytes, several oxygen stress inhibitory proteins
have been studied, e.g., SOD and catalase have been transfected by either adenovirus, lipo‐
somes or polyethylene-glycol [8,12,118]. Using partial hepatic I/R models, Ad-mediated
MnSOD administration reduced liver tissue damage and activation of both NF-κB and AP1
[119,120] when compared with lacZ-transduced controls. In another study, He et al., [121]
demonstrated that SOD or catalase gene delivery by polylipid nanoparticles injected via the
portal vein 1 day prior to the warm I/R procedure resulted in high levels of the transgene
enzyme activity in the liver, and markedly attenuated hepatic I/R injury [121]. However, re‐
sults with NFκB activation have been conflicting. Takahashi et al. reported that overexpres‐
sion of IκB, an NFκB inhibitor (mediated by Ad-IκB) resulted in partial protection in hepatic
I/R injury [122]. Heme oxygenase 1 (HO-1) is a stress responsive protein and can be induced
by various conditions such as hypoxia [12,107]. Several studies have shown that HO-1 ex‐
hibits potent cytoprotective effects after hepatic I/R [123,124]. In a cold ex-vivo rat liver per‐
fusion model and a syngeneic liver transplant OLT model, treatment of genetically obese
Zucker rats with Ad-HO-1 improved portal venous blood flow, increased bile production,
and decreased hepatocyte injury [123]. Unlike in untreated rats, upregulation of HO-1 corre‐
lated with preserved hepatic architecture, improved liver function, and depressed infiltra‐
tion by T cells and macrophages. Ad-mediated HO-1 gene overexpression increased
survival of recipients from 40% to 80% [12,107]. Ad-HO-1 gene transfer decreased macro‐
phage infiltration in the portal areas and inducible nitric oxide synthetase (iNOs) expres‐
sion; it also increased the expression of antiapoptotic genes Bcl-2/Bcl-xl and Bag-1, as
compared with controls [107]. Iron chelation is another approach to ameliorate the I/R injury
cascade. Free iron has been shown to play a role in the formation of the free radicals through
the Fenton reaction; these contribute to endothelial cell damage. Ferritin induction is a result
of the action of HO-1 on the heme porphyrin causing the release of Fe2+. Ferritin can reduce
the availability of intracellular free Fe2+, which can participate in free radical generation
[125]. Studies by Ke et al., [107] demostrated that overexpression of Ad vector carrying the
ferritin heavy chain (H-ferritin) gene protects rat livers from I/R injury [126]. In these stud‐
ies, the protective effect of H-ferritin was associated with the inhibition of endothelial cell
and hepatocyte apoptosis. Evidence suggested that H-ferritin exerts an antiapoptotic role
and may be used as a therapeutic measure to prevent I/R [107].
Immunoregulatory cytokines (IL-10 and IL-13) and IL-1 receptor antagonist (IL-1R): IL-13 regu‐
lates liver inflammatory I/R injury via the signal transducer and activator of transcription 6
(STAT6) pathway [127]. IL-10 induces antioxidant HO-1 gene expression in murine macro‐
phages and exerts anti-inflammatory effects [128]. In recent studies, Ad-IL-13 gene transfer
in cold ischemia models has shown powerful cytoprotective effects [129]. Gene transfer of
IL-13 improved hepatic function, upregulated HO-1, and prevented hepatic apoptosis
through the upregulation of Bcl-2/Bcl-xl [107]. The beneficial effects of IL-13 correlated with
in vivo cross talk between innate TLR4 and adaptive Stat6 immunity [130]. In fact, using an
experimental model of warm hepatic ischemia, Stat6-deficient mice with Ad-IL-13 failed to
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Table 2. Summary of gene therapy vectors commonly used.
Antiapoptotic Strategies (Bcl-2/Bcl-Xl, Bag-1 and caspases): Bcl-2 blocks apoptosis and necrosis
and has been implicated in the prolongation of cell survival [110]. Given its functional impor‐
tance in the cell death cascade, it constitutes one of the key targets for cytoprotective therapeu‐
tic manipulation for the regulation of apoptosis [110,111]. As demostrated by Bilbao et al., [111]
in a mouse hepatic I/R model, overexpression of Ad-mediated Bcl-2 gene significantly de‐
creased hepatocyte apoptosis and necrosis, improved hepatic function, and prolonged surviv‐
al as compared with controls. In addition, Bag-1 is a Bcl-2 binding protein resulting in a
prolonged and stabilized antiapoptotic activity [112]. In addition, Bag-1 appears to exert an in‐
direct silencing effect on TNF receptor R1 and hence suppresses the death receptor signal. A re‐
cent study by Sawitzki et al., [113] has demonstrated the cytoprotective effect of Ad-mediated
Bag-1 gene transfer in rat liver I/R. Using a model of cold ischemia and OLT, Ad-Bag-1 trans‐
fer improved portal venous blood flow, increased bile production, and improved hepatic func‐
tion with decreased neutrophil accumulation in the graft. Furthermore, Ad-mediated Bag-1
expression preserved hepatic architecture and reduced inflammation. The activation of T cells
infiltrating the graft was inhibited, since decreased expression of TNF-α, CD25, IL-2, and IFNγ
[107]. Caspase-8 is presumed to be the apex of the death-mediated apoptosis pathway, where‐
as caspase-3 belongs to the “effector” proteases in the apoptosis cascade. Contreras et al., dem‐
onstrated that inhibition of caspase-8 and caspase-3 by siRNA provided significant protection
against warm hepatic I/R injury and decreased animal mortality. In addition, animals given
siRNA caspase-8, or more significantly siRNA caspase-3, presented lower neutrophil infiltra‐
tion and better histologic profiles [114].
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Antioxidant therapy (SOD, HO-1, Ferritin): Oxidative stress can activate NF-κB and the AP-1
pathway and induce expression of proinflammatory genes including cytokines, adhesion
molecules, and chemokines leading to neutrophil-mediated inflammation [115-117]. To in‐
hibit the burst of ROS or its effect on hepatocytes, several oxygen stress inhibitory proteins
have been studied, e.g., SOD and catalase have been transfected by either adenovirus, lipo‐
somes or polyethylene-glycol [8,12,118]. Using partial hepatic I/R models, Ad-mediated
MnSOD administration reduced liver tissue damage and activation of both NF-κB and AP1
[119,120] when compared with lacZ-transduced controls. In another study, He et al., [121]
demonstrated that SOD or catalase gene delivery by polylipid nanoparticles injected via the
portal vein 1 day prior to the warm I/R procedure resulted in high levels of the transgene
enzyme activity in the liver, and markedly attenuated hepatic I/R injury [121]. However, re‐
sults with NFκB activation have been conflicting. Takahashi et al. reported that overexpres‐
sion of IκB, an NFκB inhibitor (mediated by Ad-IκB) resulted in partial protection in hepatic
I/R injury [122]. Heme oxygenase 1 (HO-1) is a stress responsive protein and can be induced
by various conditions such as hypoxia [12,107]. Several studies have shown that HO-1 ex‐
hibits potent cytoprotective effects after hepatic I/R [123,124]. In a cold ex-vivo rat liver per‐
fusion model and a syngeneic liver transplant OLT model, treatment of genetically obese
Zucker rats with Ad-HO-1 improved portal venous blood flow, increased bile production,
and decreased hepatocyte injury [123]. Unlike in untreated rats, upregulation of HO-1 corre‐
lated with preserved hepatic architecture, improved liver function, and depressed infiltra‐
tion by T cells and macrophages. Ad-mediated HO-1 gene overexpression increased
survival of recipients from 40% to 80% [12,107]. Ad-HO-1 gene transfer decreased macro‐
phage infiltration in the portal areas and inducible nitric oxide synthetase (iNOs) expres‐
sion; it also increased the expression of antiapoptotic genes Bcl-2/Bcl-xl and Bag-1, as
compared with controls [107]. Iron chelation is another approach to ameliorate the I/R injury
cascade. Free iron has been shown to play a role in the formation of the free radicals through
the Fenton reaction; these contribute to endothelial cell damage. Ferritin induction is a result
of the action of HO-1 on the heme porphyrin causing the release of Fe2+. Ferritin can reduce
the availability of intracellular free Fe2+, which can participate in free radical generation
[125]. Studies by Ke et al., [107] demostrated that overexpression of Ad vector carrying the
ferritin heavy chain (H-ferritin) gene protects rat livers from I/R injury [126]. In these stud‐
ies, the protective effect of H-ferritin was associated with the inhibition of endothelial cell
and hepatocyte apoptosis. Evidence suggested that H-ferritin exerts an antiapoptotic role
and may be used as a therapeutic measure to prevent I/R [107].
Immunoregulatory cytokines (IL-10 and IL-13) and IL-1 receptor antagonist (IL-1R): IL-13 regu‐
lates liver inflammatory I/R injury via the signal transducer and activator of transcription 6
(STAT6) pathway [127]. IL-10 induces antioxidant HO-1 gene expression in murine macro‐
phages and exerts anti-inflammatory effects [128]. In recent studies, Ad-IL-13 gene transfer
in cold ischemia models has shown powerful cytoprotective effects [129]. Gene transfer of
IL-13 improved hepatic function, upregulated HO-1, and prevented hepatic apoptosis
through the upregulation of Bcl-2/Bcl-xl [107]. The beneficial effects of IL-13 correlated with
in vivo cross talk between innate TLR4 and adaptive Stat6 immunity [130]. In fact, using an
experimental model of warm hepatic ischemia, Stat6-deficient mice with Ad-IL-13 failed to
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improve hepatic function and hepatic histological features. Transfer of Ad-IL-13 increased
anti-oxidant HO-1 expression and inhibited TLR4 activation in WT mice, whereas low HO-1
and enhanced TLR4 expression was shown in Stat6-deficient mice [107]. It has been demon‐
strated that the pro-inflammatory cytokine IL-1 plays a critical role in the pathophysiologi‐
cal response to I/R. Experimental results have shown that blockade of the IL-1R reduced
TNF production and liver damage [131]. In a partial hepatic I/R model, gene transfer of Ad-
mediated IL-1R antagonist prolonged animal survival and improved hepatic function while
preserving the histological architecture. In addition, a marked decrease in production of
proinflammatory cytokines such as IL-1, TNF-α, and IL-6 was present [107].
T-cell co-stimulation blockade: CD40-CD154. A number of studies have shown that CD4+ T
lymphocytes play an important role as key cellular mediators in I/R injury mediated inflam‐
matory responses. The CD40–CD154 co-stimulation pathway provides the essential second
signal in the initiation and maintenance of T-cell-dependent immune esponses [132]. Recent
studies have demonstrated that CD40-CD154 is required for the mechanism of hepatic
warm I/R injury [133]. In OLT, prolonged in vivo blockade of the CD40-CD154 interaction
following pretreatment of liver isografts with Ad-CD40Ig exerted potent cytoprotection
against I/R injury. Apoptosis was prevented and neutrophil accumulation was reduced. Evi‐
dence also demonstrated prevention of Th1-type cytokine (interferon γ (IFN-γ) and IL-2)
upregulation and the local expression of antioxidant HO-1 and antiapoptotic Bcl-2/Bcl-xl
genes were triggered [107].
Adipocytokine, sphyngolipid and TLR4 regulation: Massip-Salcedo et al., [13] demostrated
though the systemic delivery of adiponectin in livers treated with adiponectin siRNA that
steatotic livers by themselves can generate adiponectin as a consequence of I/R. This study
reports evidence of the injurious effects of adiponectin in stetatotic livers under warm ische‐
mic conditions, and results suggest the clinical potential of gene therapy for I/R damage in
steatotic livers by siRNA-mediated adiponectin gene silencing [13]. Products of sphingolipid
metabolism are important second messengers that regulate a variety of cell processes includ‐
ing cell death, proliferation, and inflammation. Using a mice warm hepatic I/R model, Shi et
al., demonstrated that SK2 knockdown by siRNA effectively prevented hepatocyte death
[134]. Jiang et al., [135] reported a hepatocyte-specific delivery system for the treatment of
liver I/R, using galactose-conjugated liposome nanoparticles (Gal-LipoNP). Heptocyte-spe‐
cific targeting was validated by selective in vivo delivery as observed by increased Gal-Lip‐
oNP accumulation and gene silencing in the liver. Gal-LipoNP TLR4 siRNA treatment
reduced hepatic damage, neutrophil accumulation and the inflammatory cytokines IL-1 and
TNF-α [135].
Advances in molecular biology have provided new opportunities to reduce liver I/R injury
using gene therapy [9,12,13,96,114] (Table 3). However, the experimental data indicate that
there are a number of problems inherent in gene therapy, such as vector toxicity, difficulties
in increasing transfection efficiencies and protein expression at the appropriate time and
site, and the problem of obtaining adequate mutants (in the case of NFκB) due to the contro‐
versy regarding NFκB activation [136]. Although non-viral vectors (such as naked DNA and
liposomes) are likely to present fewer toxic or immunological problems, they suffer from in‐
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efficient gene transfer [136]. In addition, LT is an emergency procedure in most cases, which
leaves very little time to pre-treat the donor with genetic approaches. Efforts to reduce the
time between gene therapy and LT might open new venues for preventative gene therapy
[12]. Currently, viral vectors hydrodynamic injection and cationic liposomes are the main
methods for delivering siRNA in vivo. While viral vectors are associated with severe side ef‐
fects, other methods require large volume and high injection speed, which are not clinically
applicable [135]. Systemic administration of small interfering RNA (siRNA) may cause glob‐
ally nonspecific targeting of all tissues, which impedes clinical use.
9.3. Cell therapy – Hepatocyte transplantation
The liver was among the first organs considered for strategies based on the transplantation
of isolated cells. The first hepatocyte transplant was performed to treat the Gunn rat, the ani‐
mal model for Crigler-Najjar syndrome, which is congenitally unable to conjugate bilirubin
and consequently exhibits life long hyperbilirubinemia. The transplant resulted in a de‐
creased plasma bilirubin concentration. Later, isolated hepatocytes were transplanted into
rats with liver failure induced by dimethylnitrosamine. These experiments demonstrated
that hepatocyte transplantation could potentially be used for the treatment of liver failure
and innate defects of liver-based metabolism. More than 30 years later, these models are still
used in work to improve hepatocyte engraftment and/or function [137].
Many studies have shown that hepatocytes transplanted into rodents via the spleen or the
portal vasculature enter through portal vein branches and are entrapped in proximal hepatic
sinusoids; consequently, the hepatocytes are distributed predominantly in periportal re‐
gions of the hepatic lobules. Transplanted hepatocytes cause both portal hypertension and
transient I/R injury. The portal hypertension, in experimental animals at least, usually re‐
solves within 2 to 3 hours with no obvious long-term detrimental effects, and microcircula‐
tory abnormalities disappear within 12 hours. Numerous hepatocytes (up to 70% of
transplanted cells) remain trapped in the portal spaces, and most of them are destroyed by
the phagocytic responses of KC, which are activated shortly after deposition of hepatocytes
in liver sinusoids [138]. The remaining cells translocate from sinusoids into the liver plates
through a process involving disruption of the sinusoidal endothelium and release of vascu‐
lar endothelial growth factor by both host and transplanted cells. In rodents, hepatic remod‐
eling is complete within 3 to 7 days, and the engrafted cells become histologically
indistinguishable from host cells. Transplantation of 2 x 107 hepatocytes in rats has led to the
engraftment of about 0.5% of the transplanted cells in the recipient livers [139]. Only hepato‐
cytes harboring a selective advantage for survival/proliferation can efficiently repopulate a
recipient liver, and as a result, many repopulation strategies have been developed using ap‐
proaches involving the induction of acute or chronic liver injury [137]. Despite decades of
research, the processes and factors underlying cell engraftment and in situ proliferation are
only partially understood, and a good understanding of these mechanisms is essential for
the development of new and efficient treatments of human liver diseases. The prevention of
early loss of transplanted cells would undoubtedly improve hepatocyte transplantation.
First, it has been recently shown that cell-cell interactions between transplanted hepatocytes
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improve hepatic function and hepatic histological features. Transfer of Ad-IL-13 increased
anti-oxidant HO-1 expression and inhibited TLR4 activation in WT mice, whereas low HO-1
and enhanced TLR4 expression was shown in Stat6-deficient mice [107]. It has been demon‐
strated that the pro-inflammatory cytokine IL-1 plays a critical role in the pathophysiologi‐
cal response to I/R. Experimental results have shown that blockade of the IL-1R reduced
TNF production and liver damage [131]. In a partial hepatic I/R model, gene transfer of Ad-
mediated IL-1R antagonist prolonged animal survival and improved hepatic function while
preserving the histological architecture. In addition, a marked decrease in production of
proinflammatory cytokines such as IL-1, TNF-α, and IL-6 was present [107].
T-cell co-stimulation blockade: CD40-CD154. A number of studies have shown that CD4+ T
lymphocytes play an important role as key cellular mediators in I/R injury mediated inflam‐
matory responses. The CD40–CD154 co-stimulation pathway provides the essential second
signal in the initiation and maintenance of T-cell-dependent immune esponses [132]. Recent
studies have demonstrated that CD40-CD154 is required for the mechanism of hepatic
warm I/R injury [133]. In OLT, prolonged in vivo blockade of the CD40-CD154 interaction
following pretreatment of liver isografts with Ad-CD40Ig exerted potent cytoprotection
against I/R injury. Apoptosis was prevented and neutrophil accumulation was reduced. Evi‐
dence also demonstrated prevention of Th1-type cytokine (interferon γ (IFN-γ) and IL-2)
upregulation and the local expression of antioxidant HO-1 and antiapoptotic Bcl-2/Bcl-xl
genes were triggered [107].
Adipocytokine, sphyngolipid and TLR4 regulation: Massip-Salcedo et al., [13] demostrated
though the systemic delivery of adiponectin in livers treated with adiponectin siRNA that
steatotic livers by themselves can generate adiponectin as a consequence of I/R. This study
reports evidence of the injurious effects of adiponectin in stetatotic livers under warm ische‐
mic conditions, and results suggest the clinical potential of gene therapy for I/R damage in
steatotic livers by siRNA-mediated adiponectin gene silencing [13]. Products of sphingolipid
metabolism are important second messengers that regulate a variety of cell processes includ‐
ing cell death, proliferation, and inflammation. Using a mice warm hepatic I/R model, Shi et
al., demonstrated that SK2 knockdown by siRNA effectively prevented hepatocyte death
[134]. Jiang et al., [135] reported a hepatocyte-specific delivery system for the treatment of
liver I/R, using galactose-conjugated liposome nanoparticles (Gal-LipoNP). Heptocyte-spe‐
cific targeting was validated by selective in vivo delivery as observed by increased Gal-Lip‐
oNP accumulation and gene silencing in the liver. Gal-LipoNP TLR4 siRNA treatment
reduced hepatic damage, neutrophil accumulation and the inflammatory cytokines IL-1 and
TNF-α [135].
Advances in molecular biology have provided new opportunities to reduce liver I/R injury
using gene therapy [9,12,13,96,114] (Table 3). However, the experimental data indicate that
there are a number of problems inherent in gene therapy, such as vector toxicity, difficulties
in increasing transfection efficiencies and protein expression at the appropriate time and
site, and the problem of obtaining adequate mutants (in the case of NFκB) due to the contro‐
versy regarding NFκB activation [136]. Although non-viral vectors (such as naked DNA and
liposomes) are likely to present fewer toxic or immunological problems, they suffer from in‐
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efficient gene transfer [136]. In addition, LT is an emergency procedure in most cases, which
leaves very little time to pre-treat the donor with genetic approaches. Efforts to reduce the
time between gene therapy and LT might open new venues for preventative gene therapy
[12]. Currently, viral vectors hydrodynamic injection and cationic liposomes are the main
methods for delivering siRNA in vivo. While viral vectors are associated with severe side ef‐
fects, other methods require large volume and high injection speed, which are not clinically
applicable [135]. Systemic administration of small interfering RNA (siRNA) may cause glob‐
ally nonspecific targeting of all tissues, which impedes clinical use.
9.3. Cell therapy – Hepatocyte transplantation
The liver was among the first organs considered for strategies based on the transplantation
of isolated cells. The first hepatocyte transplant was performed to treat the Gunn rat, the ani‐
mal model for Crigler-Najjar syndrome, which is congenitally unable to conjugate bilirubin
and consequently exhibits life long hyperbilirubinemia. The transplant resulted in a de‐
creased plasma bilirubin concentration. Later, isolated hepatocytes were transplanted into
rats with liver failure induced by dimethylnitrosamine. These experiments demonstrated
that hepatocyte transplantation could potentially be used for the treatment of liver failure
and innate defects of liver-based metabolism. More than 30 years later, these models are still
used in work to improve hepatocyte engraftment and/or function [137].
Many studies have shown that hepatocytes transplanted into rodents via the spleen or the
portal vasculature enter through portal vein branches and are entrapped in proximal hepatic
sinusoids; consequently, the hepatocytes are distributed predominantly in periportal re‐
gions of the hepatic lobules. Transplanted hepatocytes cause both portal hypertension and
transient I/R injury. The portal hypertension, in experimental animals at least, usually re‐
solves within 2 to 3 hours with no obvious long-term detrimental effects, and microcircula‐
tory abnormalities disappear within 12 hours. Numerous hepatocytes (up to 70% of
transplanted cells) remain trapped in the portal spaces, and most of them are destroyed by
the phagocytic responses of KC, which are activated shortly after deposition of hepatocytes
in liver sinusoids [138]. The remaining cells translocate from sinusoids into the liver plates
through a process involving disruption of the sinusoidal endothelium and release of vascu‐
lar endothelial growth factor by both host and transplanted cells. In rodents, hepatic remod‐
eling is complete within 3 to 7 days, and the engrafted cells become histologically
indistinguishable from host cells. Transplantation of 2 x 107 hepatocytes in rats has led to the
engraftment of about 0.5% of the transplanted cells in the recipient livers [139]. Only hepato‐
cytes harboring a selective advantage for survival/proliferation can efficiently repopulate a
recipient liver, and as a result, many repopulation strategies have been developed using ap‐
proaches involving the induction of acute or chronic liver injury [137]. Despite decades of
research, the processes and factors underlying cell engraftment and in situ proliferation are
only partially understood, and a good understanding of these mechanisms is essential for
the development of new and efficient treatments of human liver diseases. The prevention of
early loss of transplanted cells would undoubtedly improve hepatocyte transplantation.
First, it has been recently shown that cell-cell interactions between transplanted hepatocytes
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and hepatic stellate cells modulate hepatocyte engraftment in rat livers. After cell transplan‐
tation, soluble signals activating hepatic stellate cells are rapidly induced along with early
up-regulated expression of matrix metalloproteinases and their inhibitors [140]. Second, the
interaction between integrin receptors and the extracellular matrix plays a role in cell en‐
graftment. Third, hepatocytes express soluble and membrane-bound forms of tissue factor–
dependent activation of coagulation and exert tissue factor–dependent hepatocyte-related
procoagulant activity [137].
Gene Specie Ischemia Vector Effect
Bcl-2 Mouse Warm ischemia Adenovirus ↓ Apoptosis and Necrosis ↑ Survival
eNOS Mouse Warm ischemia Adenovirus ↓ Liver injury
SOD Mouse/Rat Warm ischemia Adenovirus ↓ Liver injury
IL-13 Mouse/Rat Cold ischemia Adenovirus
↓ Liver injury, Neutrophil infiltration, TLR4
activation, Apoptosis ↑ HO-1 expression, Survival
Bag-1 Rat Cold ischemia Adenovirus ↓ Liver injury, Neutrophil infiltration
CD40Ig Rat Cold ischemia Adenovirus
↓ Liver injury, Neutrophil accumulation, Apoptosis
and Necrosis
IkB Rat Cold ischemia Adenovirus ↓ Liver injury
HO-1 Rat Cold ischemia Adenovirus
↓ Liver injury, Macrophage infiltration, iNOS ↑
Survival






↓ Liver injury ↑ Survival
SOD Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
Catalase Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
SK2 Mouse Warm ischemia siRNA ↓ Liver injury, Apoptosis ↑ survival
Caspase-3 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
Caspase-8 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
TLR4 Mouse Warm ischemia siRNA
↓ Liver injury, Neutrophil infiltration, ROS,
Inflammation
Adiponectin Rat Warm ischemia siRNA ↓ Liver injury
Table 3. Summary of gene therapy using specific target genes in hepatic ischemia-reperfusion
In recent years, the development of different animal models has allowed significant progress
in hepatocyte transplantation. In rats, the occlusion of portal branches of the two anterior
liver lobes results in a regeneration response in the remaining nonoccluded lobes leading to
their hypertrophy. This procedure, portal branch ligation, favors efficient retroviral trans‐
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duction of hepatocytes in vivo. Furthermore, hepatic tissue engineering using primary hepa‐
tocytes is an emerging therapeutic approach to liver diseases. Two recent studies reported
engraftment of functional hepatocytes in a neovascularized subcutaneous cavity in mice. A
method to manipulate uniform sheets of hepatic tissue allowing the formation, in vivo, of a
3-dimensional miniature liver system that maintained its biological function for several
months has been also described [137,139]. In the view of clinical practice, treatment of fulmi‐
nant hepatic failure patients by hepatocyte transplantation has been attempted by a number
of investigators [141]. In one report, patients who received a hepatocyte transplant, one pa‐
tient fully recovered and three were successfully bridged to OLT [141]. In a prospective
study of five patients who were transplanted with cryopreserved human hepatocytes, three
patients were successfully bridged to OLT [142]. Other reports have described clinical im‐
provement and relatively longer survival in hepatocyte- transplanted patients [143] but poor
final outcome has also been reported, possibly related to immunosuppression, inadequate
number of transplanted cells, and limited engraftment time [137].
Figure 6. Mechanisms of Ischemic preconditioning in hepatic ischemia-reperfusion injury. AMPK, AMP-activated pro‐
tein kinase; ATP, adenosine triphosphate; ET, endothelin; GSH, glutathione; HO-1, heme oxygenase 1; HSP72, heat
shock protein 72; IL, interleukin; JNK, c-Jun N-terminal kinase; NO, nitric oxide; PKC, protein kinase C; PPAR, peroxi‐
some proliferator-activated receptor; RAS, renin-angiotensin system; ROS, reactive oxygen species; SOD, superoxide
dismutase; TNF, tumor necrosis factor; XDH/XOD, xanthine/xanthine oxidase
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and hepatic stellate cells modulate hepatocyte engraftment in rat livers. After cell transplan‐
tation, soluble signals activating hepatic stellate cells are rapidly induced along with early
up-regulated expression of matrix metalloproteinases and their inhibitors [140]. Second, the
interaction between integrin receptors and the extracellular matrix plays a role in cell en‐
graftment. Third, hepatocytes express soluble and membrane-bound forms of tissue factor–
dependent activation of coagulation and exert tissue factor–dependent hepatocyte-related
procoagulant activity [137].
Gene Specie Ischemia Vector Effect
Bcl-2 Mouse Warm ischemia Adenovirus ↓ Apoptosis and Necrosis ↑ Survival
eNOS Mouse Warm ischemia Adenovirus ↓ Liver injury
SOD Mouse/Rat Warm ischemia Adenovirus ↓ Liver injury
IL-13 Mouse/Rat Cold ischemia Adenovirus
↓ Liver injury, Neutrophil infiltration, TLR4
activation, Apoptosis ↑ HO-1 expression, Survival
Bag-1 Rat Cold ischemia Adenovirus ↓ Liver injury, Neutrophil infiltration
CD40Ig Rat Cold ischemia Adenovirus
↓ Liver injury, Neutrophil accumulation, Apoptosis
and Necrosis
IkB Rat Cold ischemia Adenovirus ↓ Liver injury
HO-1 Rat Cold ischemia Adenovirus
↓ Liver injury, Macrophage infiltration, iNOS ↑
Survival






↓ Liver injury ↑ Survival
SOD Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
Catalase Mouse Warm ischemia Polyplexes ↓ Liver injury ↑ Antioxidative enzyme activity
SK2 Mouse Warm ischemia siRNA ↓ Liver injury, Apoptosis ↑ survival
Caspase-3 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
Caspase-8 Mouse Warm ischemia siRNA ↓ Liver injury, Neutrophil infiltration
TLR4 Mouse Warm ischemia siRNA
↓ Liver injury, Neutrophil infiltration, ROS,
Inflammation
Adiponectin Rat Warm ischemia siRNA ↓ Liver injury
Table 3. Summary of gene therapy using specific target genes in hepatic ischemia-reperfusion
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The response of hepatocyte to ischemia never ceases to surprise. In fact, contrary to what
might be expected, the induction of consecutive periods of ischemia in the liver does not in‐
duce an additive effect in terms of hepatocyte lesions. Ischemic preconditioning (IP) based
on brief periods of ischemia followed by a short interval of reperfusion prior to a prolonged
ischemic stress protects the liver against I/R injury by regulating different cell types and
multiple mechanisms such as energy metabolism, microcirculatory disturbances, leukocyte
adhesion, KC activation, proinflammatory cytokine release, oxidative stress, apoptosis and
necrosis [96] (Figure 6). This is an advantage in relation with the use of drugs that exerts its
action on a specific mechanism. The benefits of IP observed in experimental models of hep‐
atic warm and cold ischemia [96] prompted human trials of IP. To date, IP has been success‐
fully applied in human liver resections in both steatotic and non-steatotic livers but
unfortunately, it proved ineffective in elderly patients [144]. Preliminary clinical studies
have reported the benefits of IP in LT [145,146]. IP may also have a role in the transplanta‐
tion of small grafts whose pathophysiology overlaps with I/R injury. Additional random‐
ized clinical studies are necessary to confirm whether this surgical strategy can be
commonly used in clinical liver surgery.
10. Conclusion and perspectives
From the data obtained in experimental models of hepatic I/R, we can state that I/R injury is
a multifaceted and intriguing phenomenon. The increasing use of marginal donors in major
liver surgery and the fact that these organs are more susceptible to ischemia highlight the
need for further research directed at the mechanisms of I/R injury. Machine perfusion has
been criticized for its complicated logistics and for possibly damaging the organ and vital
structures such as the endothelium. On the contrary, NMP fulfils all ideal organ preserva‐
tion criteria by avoiding hypoxia and hypothermia. Responses to the strategies aimed at re‐
ducing hepatic I/R injury might depend on the surgical procedure, type of liver and
percentage of hepatic ischemia. Further research is required to elucidate whether the phar‐
macological approaches presented in this review can be translated into liver surgery associ‐
ated with hepatic resections and LT. Advances in molecular biology have provided new
opportunities to reduce liver I/R injury using gene therapy. However, there are a number of
problems inherent in gene therapy, such as vector toxicity and difficulties in increasing
transfection. Liver-cell transplantation is at an early stage. Numerous approaches to isolat‐
ing stem cells of hepatic or extrahepatic origin, including embryonic stem cells, are being de‐
veloped. However, extensive work is still required to assess the number of cells that need to
be expanded and differentiated, and the functionality of the different cell types needs to be
carefully addressed in animal models. Surgical strategies such as IP affect multiple aspects
of I/R injury, whereas pharmacological approaches often affect only a few mediators and
might have systemic side effects.
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1. Introduction
Liver resection is considered the treatment of choice for liver tumours. Despite standardized
techniques and technological advancing for liver resections, an intra-operative haemorrhage
rate ranging from 700 and 1200 ml is reported with a post-operative morbidity rate ranging
from 23 and 46% and a surgical death rate ranging from 4 and 5% [l],[2],[3],[4],[5],[6].
The parameter "Blood loss" has a central role in liver surgery and different strategies to
minimize it are a key to improve these results. Bleeding has to be considered a major concern
for the hepatic surgeon because of several reasons. At first it is certainly the major intra-
operative surgical complication and cause of death and historically one of the major postop‐
erative complication together with bile leaks and hepatic failure [5],[6],[7],[8],[9].
Besides a high intra-operative blood loss is associated with higher rate of post-operative
complication and shorter long-term survival [10],[ll],[l2],[l3]. Furthermore it is associated with
an extensive use of vessel occlusion techniques, directly correlated with higher risk of post‐
operative hepatic failure. Last, a higher value of intra-operative blood loss is associated with
a higher rate of peri-operative transfusions; host immunosuppression associated with trans‐
fusions with a dose-related relationship is correlated with a higher rate of complication (in
particular infections) and recurrence of malignancies in neoplastic patients [11],[l2],[l4],[l5],
[l6],[17],[18],[19],[20],[21]. In order to reduce transfusions hepatic surgeon has also not to
misinterpret post-operative fluctuations of blood parameter: Torzilli at al. demonstrated that
haemoglobin rate and haematocrit after liver resection show a steady and significant decrease
until the third post-operative day and then an increase; so this situation has to be explained as
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physiological and does not justifies blood administration [22].Although the mechanism of
bleeding in surgical interventions is multifactorial, technical factors may be responsible for a
significant amount of intraoperative and early postoperative bleeding. The main progress in
reducing perioperative blood loss has been made through improved surgical and anesthetic
techniques and through better understanding of hemostatic disorders in patients who have
liver disease. developments in surgical, anesthesiologic, and pharmacologic strategies that
have contributed to a reduction of blood loss during liver surgery in cirrhotic and noncirrhotic
patients. The clinical relevance of different types of strategies may vary, depending on the
stage of the operation. For example, topical hemostatic agents have a role in reducing blood
loss from the hepatic resection surface after partial liver resection, whereas surgical techniques
play a more important role during transection of the liver parenchyma (Fig. 1).
2. How can we reduce bleeding in liver surgery?
Figure 1 shows the amount of blood loss during the different phases of liver surgery. It is clear
that the higher risk for bleeding and the greater amount of blood loss occur during the
parenchymal transection phase of the procedure.
Figure 1. The mechanisms of bleeding and the relative amount of blood loss (dotted line) during the three surgical
stages of partial liver resections. In general, most bleeding can be encountered during transsection of the liver paren‐
chyma. In this stage of the operation, blood loss is mainly caused by bleeding from the resection surface of the liver.
The aim of the study is to investigate the principal solutions to the problem of high blood loss
in hepatic resection, considering the role of surgeons and anestesiologists. Table 1 resume all
the methods to prevent or reduce bleeding during liver surgery. Moreover we focused our
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attention on the technological aspects of liver parenchima transection. We will describe each
technology and instrument discussing the principle of functioning, the technical characteristics
and analysed the advantages (A) and the disadvantages (D) correlated to their employment






Continuous Pringle maneuver after ischemic preconditioning
Intermittent Pringle maneuver
Total vascular occlusion
















If needed, forced diuresis
Blood products
Use of pharmacologic agents
Antifibrinolytics
Recombinant factor VIIa
Table 1. Surgical and anesthesiologic methods used to reduce blood loss in liver surgery
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Intermittent Pringle maneuver
Total vascular occlusion
















If needed, forced diuresis
Blood products
Use of pharmacologic agents
Antifibrinolytics
Recombinant factor VIIa
Table 1. Surgical and anesthesiologic methods used to reduce blood loss in liver surgery
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Moreover we tried to compare the different instruments and technologies basing on literature
data to identify the best instruments for each type of liver resection (open surgery, laparoscopic
surgery, resective surgery, oncologic surgery, liver transplantation).
3. The role of the surgeon
Most blood loss during liver resection occurs during parenchymal transection. Hepatic
surgeon has different ways to control bleeding:
Vessel occlusion techniques: Those technique are based on the idea that to limit the blood
flow through the liver during parenchymal transection can reduce the haemorrhage. Although
various forms and modified techniques of vascular control have been practiced, there are
basically two main strategies; inflow vascular occlusion and total vascular exclusion23-24
Inflow vascular occlusions are techniques that limit anterograde blood flow with the clamping
of all the triad of the hepato-duodenal ligament (Pringle 's manoeuvre, PM), only of the vascular
pedicles (selective clamping of the portal vein and the hepatic artery or Bismuth technique) or
intravascularportal clamping. During Pringle’s manouvre the hepatoduodenal ligament is
encircled with a tape, and then a vascular clamp or tourniquet is applied until the pulse in the
hepatic artery disappears distally. The PM has relatively little general haemodynamic effect
and no specific anaesthetic management is required. However, bleeding can still occur from
the backflow from the hepatic veins and from the liver transection plane during unclamping.
The other concern is the ischaemic-reperfusion injury to the liver parenchyma, especially in
patients with underlying liver diseases25. The continuous Pringle manoeuvre (CPM) can be
safely applied to the normal liver under normothermic conditions for up to 60 minutes and
up to 30 minutes in pathological (fatty or cirrhotic) livers, although much longer durations of
continuous clamping 127 minutes in normal livers and 100 minutes in pathological livers have
been reported to be safe26-27. One way to extend the duration of clamping and to reduce
ischaemia to the remnant liver is by the intermittent Pringle manoeuvre (IPM). It involves
periods of inflow clamping that last for 15-20 minutes followed by periods of unclamping for
five minutes (mode 15/5 or 20/5), or five minutes clamping followed by one minute unclamping
(mode 5/1)28-29 IPM permits a doubling of the ischaemia time, when compared with CPM
and the total clamping time can be extended to 120 minutes in normal livers and 60 minutes
in pathological livers. The disadvantage of IPM is that bleeding occurs from the liver transac‐
tion surface during the unclamping period and, thus, the overall transection time is prolonged
as more time is spent in achieving haemostasis. Belghiti et al (1999) revealed that there was no
significant difference in total blood loss or volume of blood transfusion between CPM and IPM
(mode 15/5). However, they noticed that pathological livers tolerated CPM poorly.
A newer perspective on inflow occlusion comes from the concept of ischaemic preconditioning
(IP). It refers to an endogenous self-protective mechanism by which a short period of ischaemia
followed by a brief period of reperfusion produces a state of protection against subsequent
sustained ischaemia-reperfusion injury [30]-[31]. The IP is performed with ten minutes of
ischaemia followed by ten minutes of reperfusion before liver transaction with CPM [32].
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Hemihepatic clamping (half-Pringle manoeuvre) interrupts the arterial and portal inflow
selectively to the right or left liver lobe that is to be resected [33]-[34]. It can be performed with
or without prior hilar dissection. It can also be combined with simultaneous occlusion of the
ipsilateral major hepatic vein. The advantage of this technique is that it avoids ischaemia in
the remnant liver, avoids visceral congestion and allows clear demarcation of the resection
margin. The disadvantage is that bleeding from the parenchymal cut surface can occur from
the nonoccluded liver lobe.
Segmental vascular clamping entails the occlusion of the ipsilateral hepatic artery branch and
balloon occlusion of the portal branch of a particular segment. The portal branch is identified
by intra-operative ultrasound and puncture with a cholangiography needle through which a
guide wire and balloon catheter is passed [35],[36].
Total vascular exclusion (TVE) combines total inflow and outflow vascular occlusion of the
liver, isolating it completely from the systemic circulation. It is done with complete mobilisa‐
tion of the liver, encircling of the suprahepatic and infrahepatic IVC, application of the Pringle
manoeuvre, and then clamping the infrahepatic IVC followed by clamping of the suprahepatic
IVC. TVE is associated with significant haemodynamic changes and warrants close invasive
and anaesthetic monitoring. Occlusion of the IVC leads to marked reduction of venous return
and cardiac output, with a compensatory 80% increase in systemic vascular resistance and 50%
increase in heart rate and, thus, not every patient can tolerate it. TVE can be applied to a normal
liver for up to 60 minutes and for 30 minutes in a diseased liver. The ischaemic time can be
extended when combined with hypothermic perfusion of the liver [37]-[38]. Apart from the
unpredictable haemodynamic intolerance, post-operative abdominal collections or abscesses
and pulmonary complications are more common in TVE, when compared with CPM.
Inflow occlusion with extraparenchymal control of hepatic veins is a modified way of per‐
forming TVE. The main and any accessory right hepatic vein, the common trunk of the middle
and left hepatic veins, or the separate trunks of the middle and left hepatic veins (15% of cases)
are first dissected free and looped. It has been reported that the trunks of the major hepatic
veins can be safely looped in 90% of patients [39]-[40]. The loops can then be tightened or the
vessels clamped after inflow occlusion is applied, so that the liver lobe is isolated from the
systemic circulation without interrupting the caval flow. It can be applied in a continuous or
intermittent manner. The maximal ischaemia time is up to 58 minutes under continuous
occlusion. This technique is more demanding than TVE, but it can avoid the haemodynamic
drawbacks of TVE while at the same time provide almost a bloodless field for liver transection.
Instruments and technique for resections: Although a large part of improvements of these
last decades in liver surgery can be correlated to a better knowledge of the surgical hepatic
anatomy (Couinaud’s segmentation of liver [41]), better monitoring during anaesthesia and
introduction of intra-operative ultrasonography and of other imaging techniques, the choice
of surgical technique for sectioning the liver has surely important repercussions on the
intervention’s outcome. Furthermore in the last two decades improvements in technology
allowed the development of a large number of instruments with the aim to reduce blood loss
during surgical procedure. The main part of these tools have been developed or applied to
liver surgery. The rationale in liver transection is to employ an instrument that can selectively
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Moreover we tried to compare the different instruments and technologies basing on literature
data to identify the best instruments for each type of liver resection (open surgery, laparoscopic
surgery, resective surgery, oncologic surgery, liver transplantation).
3. The role of the surgeon
Most blood loss during liver resection occurs during parenchymal transection. Hepatic
surgeon has different ways to control bleeding:
Vessel occlusion techniques: Those technique are based on the idea that to limit the blood
flow through the liver during parenchymal transection can reduce the haemorrhage. Although
various forms and modified techniques of vascular control have been practiced, there are
basically two main strategies; inflow vascular occlusion and total vascular exclusion23-24
Inflow vascular occlusions are techniques that limit anterograde blood flow with the clamping
of all the triad of the hepato-duodenal ligament (Pringle 's manoeuvre, PM), only of the vascular
pedicles (selective clamping of the portal vein and the hepatic artery or Bismuth technique) or
intravascularportal clamping. During Pringle’s manouvre the hepatoduodenal ligament is
encircled with a tape, and then a vascular clamp or tourniquet is applied until the pulse in the
hepatic artery disappears distally. The PM has relatively little general haemodynamic effect
and no specific anaesthetic management is required. However, bleeding can still occur from
the backflow from the hepatic veins and from the liver transection plane during unclamping.
The other concern is the ischaemic-reperfusion injury to the liver parenchyma, especially in
patients with underlying liver diseases25. The continuous Pringle manoeuvre (CPM) can be
safely applied to the normal liver under normothermic conditions for up to 60 minutes and
up to 30 minutes in pathological (fatty or cirrhotic) livers, although much longer durations of
continuous clamping 127 minutes in normal livers and 100 minutes in pathological livers have
been reported to be safe26-27. One way to extend the duration of clamping and to reduce
ischaemia to the remnant liver is by the intermittent Pringle manoeuvre (IPM). It involves
periods of inflow clamping that last for 15-20 minutes followed by periods of unclamping for
five minutes (mode 15/5 or 20/5), or five minutes clamping followed by one minute unclamping
(mode 5/1)28-29 IPM permits a doubling of the ischaemia time, when compared with CPM
and the total clamping time can be extended to 120 minutes in normal livers and 60 minutes
in pathological livers. The disadvantage of IPM is that bleeding occurs from the liver transac‐
tion surface during the unclamping period and, thus, the overall transection time is prolonged
as more time is spent in achieving haemostasis. Belghiti et al (1999) revealed that there was no
significant difference in total blood loss or volume of blood transfusion between CPM and IPM
(mode 15/5). However, they noticed that pathological livers tolerated CPM poorly.
A newer perspective on inflow occlusion comes from the concept of ischaemic preconditioning
(IP). It refers to an endogenous self-protective mechanism by which a short period of ischaemia
followed by a brief period of reperfusion produces a state of protection against subsequent
sustained ischaemia-reperfusion injury [30]-[31]. The IP is performed with ten minutes of
ischaemia followed by ten minutes of reperfusion before liver transaction with CPM [32].
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Hemihepatic clamping (half-Pringle manoeuvre) interrupts the arterial and portal inflow
selectively to the right or left liver lobe that is to be resected [33]-[34]. It can be performed with
or without prior hilar dissection. It can also be combined with simultaneous occlusion of the
ipsilateral major hepatic vein. The advantage of this technique is that it avoids ischaemia in
the remnant liver, avoids visceral congestion and allows clear demarcation of the resection
margin. The disadvantage is that bleeding from the parenchymal cut surface can occur from
the nonoccluded liver lobe.
Segmental vascular clamping entails the occlusion of the ipsilateral hepatic artery branch and
balloon occlusion of the portal branch of a particular segment. The portal branch is identified
by intra-operative ultrasound and puncture with a cholangiography needle through which a
guide wire and balloon catheter is passed [35],[36].
Total vascular exclusion (TVE) combines total inflow and outflow vascular occlusion of the
liver, isolating it completely from the systemic circulation. It is done with complete mobilisa‐
tion of the liver, encircling of the suprahepatic and infrahepatic IVC, application of the Pringle
manoeuvre, and then clamping the infrahepatic IVC followed by clamping of the suprahepatic
IVC. TVE is associated with significant haemodynamic changes and warrants close invasive
and anaesthetic monitoring. Occlusion of the IVC leads to marked reduction of venous return
and cardiac output, with a compensatory 80% increase in systemic vascular resistance and 50%
increase in heart rate and, thus, not every patient can tolerate it. TVE can be applied to a normal
liver for up to 60 minutes and for 30 minutes in a diseased liver. The ischaemic time can be
extended when combined with hypothermic perfusion of the liver [37]-[38]. Apart from the
unpredictable haemodynamic intolerance, post-operative abdominal collections or abscesses
and pulmonary complications are more common in TVE, when compared with CPM.
Inflow occlusion with extraparenchymal control of hepatic veins is a modified way of per‐
forming TVE. The main and any accessory right hepatic vein, the common trunk of the middle
and left hepatic veins, or the separate trunks of the middle and left hepatic veins (15% of cases)
are first dissected free and looped. It has been reported that the trunks of the major hepatic
veins can be safely looped in 90% of patients [39]-[40]. The loops can then be tightened or the
vessels clamped after inflow occlusion is applied, so that the liver lobe is isolated from the
systemic circulation without interrupting the caval flow. It can be applied in a continuous or
intermittent manner. The maximal ischaemia time is up to 58 minutes under continuous
occlusion. This technique is more demanding than TVE, but it can avoid the haemodynamic
drawbacks of TVE while at the same time provide almost a bloodless field for liver transection.
Instruments and technique for resections: Although a large part of improvements of these
last decades in liver surgery can be correlated to a better knowledge of the surgical hepatic
anatomy (Couinaud’s segmentation of liver [41]), better monitoring during anaesthesia and
introduction of intra-operative ultrasonography and of other imaging techniques, the choice
of surgical technique for sectioning the liver has surely important repercussions on the
intervention’s outcome. Furthermore in the last two decades improvements in technology
allowed the development of a large number of instruments with the aim to reduce blood loss
during surgical procedure. The main part of these tools have been developed or applied to
liver surgery. The rationale in liver transection is to employ an instrument that can selectively
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eliminate parenchyma leaving vital structures intact. In other words, a resistance modulated
device, able to fragment low-resistance tissue (hepatic parenchyma) preserving fibrous (high-
resistance) components such as vessels and biliary ducts, successively ligated by the surgeon.
To date, no single instrument has been designed to adequately satisfy both of these tasks.
There are two techniques we could define traditional: the finger fracture method and the clamp
crushing method. These are the oldest techniques for hepatic transection and are still employed
especially by long experienced surgeons. Techniques of liver transection gained marked
attention since the introduction of the clamp-crushing technique in the 1970s.10,11 As a
refinement of the finger fracture method, it has served as the reference technique for liver
transection ever since.
The use of traditional techniques to isolate bile ducts and vascular pedicles from the sur‐
rounding parenchyma provides for employment of clips or sutures for sealing bile ducts and
vascular vessels and for other haemostasis techniques to stop haemorrhage from the resection’s
surface. There are several studies those sustain that traditional methods are still competitive
with new technique based on utilization of special devices [1],[42],[96] In a recent Metanalysis
Rahbari and coll concluded that the clamp-crushing technique could be still reccomended as
the reference method for the transection of the parenchyma during liver surgery [12], [4].
Introduction of new devices for liver dissection surely have an important role, in particular
for reduction of intra-operative blood loss. Actually the most important devices useful for liver
resection are the followings, presented as they are from a technical point of view and analysed
to find the advantages (A) and the disadvantages (D) correlated to their employment and
divede according to the source of energy employed. There are two types of transection devices:
those mainly used for dissection (e.g. the haemostatic clamps or ultrasonic dissector) and
mainly used for haemostasis and coagulation (e.g. sutures, endo-staplers, sealers, etc.) (table
2). Moreover the water-jet, the ultrasonic aspirator (CUSA®) and the blunt dissection can be
categorised under selective dissection techniques. Non-selective techniques cannot discrimi‐
nate between duct structures and parenchyma. To mention are finger fracture and mechanical
instruments as the scalpel, the scissors and with reservation the linear stapler as well as thermal
instruments as the high-frequency electrocoagulator, the laser, the bipolar forceps or the




suction knife electrocoagulation (mono/bipolar)





Table 2. Surgical techniques for preparation and tissue transection of the liver
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Furthermore most attempts have involved use of radiofrequency ablation-based instruments
in a “precoagulation strategy” in which the energy device is used to burn and seal the
parenchyma before sharp dissection. In the second strategy, ultrasonic-activated instruments
cut through the liver while sealing the vessels. Both method suffer from the fact that large
vessels are poorly visualized and can bleed on transection. In addition, blood or biliary vessels
from adiacent parts of the liver meant to be salvage can be inadvertently injured by this “blind”
coagulation.
3.1. Tools based on ultrasound technology
Harmonic Scalpel, HS (Johnson and Johnson Medical, Ethicon, Cincinnati, USA): Also known
as "Ultrasonically Activated Scalpel" or "Ultrasonic Coagulation Shears", this instrument was
introduced in the early 1990s. The ultrasound scissors System includes a generator with a foot
switch, the reusable handle for the scalpel and the cutting device with scissors. The scissors
are composed by a moveable blade and by a fixed longitudinal blade that vibrates with a
ultrasonic frequency of 55,5 kHz (55.500 vibrations per second). HS can simultaneously cut
and coagulate causing protein denaturation by destroying the hydrogen bonds in proteins and
by generation of heat in vibrating tissue. This generated heat denatures proteins and forms a
sticky coagulum that covers the edges of dissection. Although the heat produces no smoke
and thermal injury is limited, the depth of marginal necrosis is greater than incurred by either
the water jet or CUSA The lateral spread of the energy is 500 micrometers.
A: HS is the only instrument that can simultaneously cut and coagulate (it can coagulate vessel
until 2-3 mm of diameter [43]); it’s useful on cirrhotic liver [44]; no electricity passes through
the patient and there’s no smoke production (especially useful in laparoscopic surgery); it can
be used in laparoscopic and laparotomic surgery. D: The instrument results in a continuous
bleeding risk related to the blind tissue penetration to coagulate vessels hidden into the hepatic
parenchyma. Studies demonstrate that HS is not capable to reduce blood loss and operating
time compared to traditional techniques [45]-[46], cannot coagulate vessel over 2-3 mm of
diameter which have to be clipped, legated or sealed with other instruments; HS is not easy
to use as a blunt dissector and have substantially demonstrated its usefulness only during the
resection of the superficial part of liver (2, 3 cm) free from large vessels and bile ducts; besides
some studies have demonstrated that HS increases the rate of post-operative bile leaks [47]-
[48] raising concern that HS may not be effective in sealing bile ducts. this postoperative bile
leakage occurred because Glisson’s sheath was not completely sealed when the HA is used
blindly in the deep liver parenchymal layer. It was difficult to seal the sheath precisely in the
deep liver parenchymal layer.
The use of HS in liver cirrhosis is controversial. The greatest concern with the use of the
harmonic scalpel is the risk of shearing [49]. Slight errors of movement can shear parenchyma
without completely coagulating vessels and/or ducts. Moreover it’s expensive (the generator
costs US$ 20.000 and the handle US$ 250). An evolution fo the harmonic Scalpel is the Harmonic
FOCUS. Using this device the liver parenchyma is crushed by the nonactivated HF, which
blades are similar to Kelly forceps, and the tiny areas of residual tissue are checked and
completely sealed with the activated HF without changing to forceps. This device allow, after
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eliminate parenchyma leaving vital structures intact. In other words, a resistance modulated
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To date, no single instrument has been designed to adequately satisfy both of these tasks.
There are two techniques we could define traditional: the finger fracture method and the clamp
crushing method. These are the oldest techniques for hepatic transection and are still employed
especially by long experienced surgeons. Techniques of liver transection gained marked
attention since the introduction of the clamp-crushing technique in the 1970s.10,11 As a
refinement of the finger fracture method, it has served as the reference technique for liver
transection ever since.
The use of traditional techniques to isolate bile ducts and vascular pedicles from the sur‐
rounding parenchyma provides for employment of clips or sutures for sealing bile ducts and
vascular vessels and for other haemostasis techniques to stop haemorrhage from the resection’s
surface. There are several studies those sustain that traditional methods are still competitive
with new technique based on utilization of special devices [1],[42],[96] In a recent Metanalysis
Rahbari and coll concluded that the clamp-crushing technique could be still reccomended as
the reference method for the transection of the parenchyma during liver surgery [12], [4].
Introduction of new devices for liver dissection surely have an important role, in particular
for reduction of intra-operative blood loss. Actually the most important devices useful for liver
resection are the followings, presented as they are from a technical point of view and analysed
to find the advantages (A) and the disadvantages (D) correlated to their employment and
divede according to the source of energy employed. There are two types of transection devices:
those mainly used for dissection (e.g. the haemostatic clamps or ultrasonic dissector) and
mainly used for haemostasis and coagulation (e.g. sutures, endo-staplers, sealers, etc.) (table
2). Moreover the water-jet, the ultrasonic aspirator (CUSA®) and the blunt dissection can be
categorised under selective dissection techniques. Non-selective techniques cannot discrimi‐
nate between duct structures and parenchyma. To mention are finger fracture and mechanical
instruments as the scalpel, the scissors and with reservation the linear stapler as well as thermal
instruments as the high-frequency electrocoagulator, the laser, the bipolar forceps or the
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Furthermore most attempts have involved use of radiofrequency ablation-based instruments
in a “precoagulation strategy” in which the energy device is used to burn and seal the
parenchyma before sharp dissection. In the second strategy, ultrasonic-activated instruments
cut through the liver while sealing the vessels. Both method suffer from the fact that large
vessels are poorly visualized and can bleed on transection. In addition, blood or biliary vessels
from adiacent parts of the liver meant to be salvage can be inadvertently injured by this “blind”
coagulation.
3.1. Tools based on ultrasound technology
Harmonic Scalpel, HS (Johnson and Johnson Medical, Ethicon, Cincinnati, USA): Also known
as "Ultrasonically Activated Scalpel" or "Ultrasonic Coagulation Shears", this instrument was
introduced in the early 1990s. The ultrasound scissors System includes a generator with a foot
switch, the reusable handle for the scalpel and the cutting device with scissors. The scissors
are composed by a moveable blade and by a fixed longitudinal blade that vibrates with a
ultrasonic frequency of 55,5 kHz (55.500 vibrations per second). HS can simultaneously cut
and coagulate causing protein denaturation by destroying the hydrogen bonds in proteins and
by generation of heat in vibrating tissue. This generated heat denatures proteins and forms a
sticky coagulum that covers the edges of dissection. Although the heat produces no smoke
and thermal injury is limited, the depth of marginal necrosis is greater than incurred by either
the water jet or CUSA The lateral spread of the energy is 500 micrometers.
A: HS is the only instrument that can simultaneously cut and coagulate (it can coagulate vessel
until 2-3 mm of diameter [43]); it’s useful on cirrhotic liver [44]; no electricity passes through
the patient and there’s no smoke production (especially useful in laparoscopic surgery); it can
be used in laparoscopic and laparotomic surgery. D: The instrument results in a continuous
bleeding risk related to the blind tissue penetration to coagulate vessels hidden into the hepatic
parenchyma. Studies demonstrate that HS is not capable to reduce blood loss and operating
time compared to traditional techniques [45]-[46], cannot coagulate vessel over 2-3 mm of
diameter which have to be clipped, legated or sealed with other instruments; HS is not easy
to use as a blunt dissector and have substantially demonstrated its usefulness only during the
resection of the superficial part of liver (2, 3 cm) free from large vessels and bile ducts; besides
some studies have demonstrated that HS increases the rate of post-operative bile leaks [47]-
[48] raising concern that HS may not be effective in sealing bile ducts. this postoperative bile
leakage occurred because Glisson’s sheath was not completely sealed when the HA is used
blindly in the deep liver parenchymal layer. It was difficult to seal the sheath precisely in the
deep liver parenchymal layer.
The use of HS in liver cirrhosis is controversial. The greatest concern with the use of the
harmonic scalpel is the risk of shearing [49]. Slight errors of movement can shear parenchyma
without completely coagulating vessels and/or ducts. Moreover it’s expensive (the generator
costs US$ 20.000 and the handle US$ 250). An evolution fo the harmonic Scalpel is the Harmonic
FOCUS. Using this device the liver parenchyma is crushed by the nonactivated HF, which
blades are similar to Kelly forceps, and the tiny areas of residual tissue are checked and
completely sealed with the activated HF without changing to forceps. This device allow, after
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accurate exposure, a sealing “under view” of tiny vasculatures and biliary structures and this
seems to reduce bleeding and postoperative bile leakages. [125-126] This new technique has
been called “fusion technique”.The attempt to accomplish both the task of division and of
hemostasis is provided by a recently introduced device, which intends to crush liver paren‐
chyma simul taneously sealing the vessels without the need to change the instrument, the so
called focus-clysis or ‘fusion technique’
Functionally, the instrument should be compared to a Kelly, in which the surgeon can adjust the
precision and depth of cutting by modulating blade pressure; parenchyma crushing exposes the
tiny vessels that can be coagulated employing the harmonic technology provided in high power
(1–2 mm vessels) and low power (up to 5 mm). Vessels larger than 5 mm in diameter should be
divided and ligated in a traditional fashion. It seems that the ‘fusion technique’ could reduce
blood loss and the incidence of biliary fistula, with a cost comparable to other technologies.
Cavitron Ultrasonic Surgical Aspirator, CUSA (Valleylab) (Fig 2): The use in liver surgery of
this instrument, also known as Ultrasonic Dissector, was described for the first time in
literature in 1979 by Hodgson [50]. CUSA is a surgical system in which a pencil-grip surgical
hand piece contains a transducer that oscillates longitudinally at 23 kHz and to which a hollow
conical titanium tip is attached. The vibrating tip of the instrument causes explosion of cells
with a high water content (just like hepatocytes) and fragmentation of parenchyma sparing
blood and bile vessel because of their walls prevalently composed by connective cells poor of
water but rich of intracellular bonds. This device (together with hydrojet dissector) should be
considered among that tools able to selectively divide parenchyma from vessels according to
their different mechanical resistance (in which hepatocytes contain less fibrous tissue than the
vessel, thus offering less resistance to crushing during parenchymal division), the so called
selective dissection technique.
Figure 2. Parenchima transection using CUSA
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The device  is  equipped by a  saline solution irrigation system that  cools  the hand piece
and wash the transection plane and by a constant suction system that removes fragment‐
ed bits of tissue and permits excellent visualization. A:  CUSA is capable to dissect offer‐
ing excellent visualization resulting useful in particular during non-anatomical resections
and approaching the deeper portion of the transaction plane [51]-[52]. The instrument al‐
lows surgeons to  see  clearly  blood and biliary  vessels  as  they dissect  through the liver
[53], (2) use of the instrument allows them to avoid prolonged extrahepatic vascular con‐
trol,  and (3)  the  operation actually  takes  less  time because the  vessels  are  continuously
controlled during the dissection and there is little need for a prolonged search for bleed‐
ing or biliary vessels after the specimen has been removed.
A previous retrospective study from Fan showed that the ultrasonic dissector resulted in lower
blood loss, lower morbidity, and lower mortality compared with the clamp crushing technique
[54] Furthermore, ultrasonic dissection resulted in a wider tumor-free margin because of a
more precise transection plane.
D: CUSA can‘t coagulate or realize haemostasis so it need to be used in couple with an other
instruments to achieve hemostasis and biliostasis. Even if some studies sustain it to be capable
to reduce intra-operative blood loss, operating time and duration of vessel occlusion [55],
important studies demonstrate that CUSA can’t offer these advantages if compared with
traditional techniques; a prospective trial by Rau et al. showed no statistical difference in
reduction of blood loss with the use of CUSA as compared to conventional methods [56]; and
another trial by Takayama et al. [52], in fact, noted a greater median blood loss. CUSA causes
more frequent tumour exposure at the surgical margin than traditional techhiques[ 1] and it’s
less useful for cirrhotic livers because the associated fibrosis prevents easy removal of
hepatocytes [57]; besides some authors found using CUSA method (compared to clamp
crushing method) an increase of venous air embolism without evidence of hemodynamic
compromise but with increased risk of paradoxical embolism in cirrhotic patients [58].
Moreover CUSA should be used in association with other devices which are able to perform
hemostasis. The instrument seems cumbersome and complicated to inexperienced operating
room personnel. Therefore, it is easy for the instrument to malfunction. The fact that the
instrument works by removing a margin of liver tissue makes it, by nature, less attractive for
harvesting liver for living-donor transplantation.
3.2. Tools based on radiofrequency technology
Tissuelink Monopolar Floating Ball, TMFB (Floating Ball, TissueLink medical, Dover, NH,
USA) (Fig 3): This new instrument put on the market in 2002 is a linear device that employs
Radiofrequency energy focused at the tip to coagulate target tissue. The tip is provided with
a low volume (4-6 ml/min) saline solution irrigation that makes easier the conduction of RF in
surrounding tissue and cools the tip itself avoiding formation of chars. TMFB can seal vascular
and bile structures up to 3 mm in diameter by collagen fusion. These qualities makes this device
an excellent instrument for achieving haemostasis and in particular for pre- coagulating (with
a painting movement) parenchyma and vessels prior to transection, preventing blood loss.
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conical titanium tip is attached. The vibrating tip of the instrument causes explosion of cells
with a high water content (just like hepatocytes) and fragmentation of parenchyma sparing
blood and bile vessel because of their walls prevalently composed by connective cells poor of
water but rich of intracellular bonds. This device (together with hydrojet dissector) should be
considered among that tools able to selectively divide parenchyma from vessels according to
their different mechanical resistance (in which hepatocytes contain less fibrous tissue than the
vessel, thus offering less resistance to crushing during parenchymal division), the so called
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Figure 2. Parenchima transection using CUSA
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The device  is  equipped by a  saline solution irrigation system that  cools  the hand piece
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[53], (2) use of the instrument allows them to avoid prolonged extrahepatic vascular con‐
trol,  and (3)  the  operation actually  takes  less  time because the  vessels  are  continuously
controlled during the dissection and there is little need for a prolonged search for bleed‐
ing or biliary vessels after the specimen has been removed.
A previous retrospective study from Fan showed that the ultrasonic dissector resulted in lower
blood loss, lower morbidity, and lower mortality compared with the clamp crushing technique
[54] Furthermore, ultrasonic dissection resulted in a wider tumor-free margin because of a
more precise transection plane.
D: CUSA can‘t coagulate or realize haemostasis so it need to be used in couple with an other
instruments to achieve hemostasis and biliostasis. Even if some studies sustain it to be capable
to reduce intra-operative blood loss, operating time and duration of vessel occlusion [55],
important studies demonstrate that CUSA can’t offer these advantages if compared with
traditional techniques; a prospective trial by Rau et al. showed no statistical difference in
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instrument works by removing a margin of liver tissue makes it, by nature, less attractive for
harvesting liver for living-donor transplantation.
3.2. Tools based on radiofrequency technology
Tissuelink Monopolar Floating Ball, TMFB (Floating Ball, TissueLink medical, Dover, NH,
USA) (Fig 3): This new instrument put on the market in 2002 is a linear device that employs
Radiofrequency energy focused at the tip to coagulate target tissue. The tip is provided with
a low volume (4-6 ml/min) saline solution irrigation that makes easier the conduction of RF in
surrounding tissue and cools the tip itself avoiding formation of chars. TMFB can seal vascular
and bile structures up to 3 mm in diameter by collagen fusion. These qualities makes this device
an excellent instrument for achieving haemostasis and in particular for pre- coagulating (with
a painting movement) parenchyma and vessels prior to transection, preventing blood loss.
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Figure 3. The Tissue Link working performing a liver resection
Otherwise continuously heating tissue underneath a cool  layer,  however,  causes a build
up  of  steam  that  can  result  in  tissue  destruction.  The  latter  phenomenon  is  known  as
steam popping [59].
There are two models on the market, the DS3.0 with blunt tip that simply coagulates and the
DS3.5-C Dissecting Sealer that is provided with sharp tip that can also dissect. A: The instru‐
ment is, in a sense, “friendlier” to most surgeons. In other words, surgeons, who are usually
adept at using cautery, can easily understand this mechanism of action and use it accordingly.
TMFB can coagulate (and the Dissecting Sealer can also cut) tissues and seals blood and bile
ducts up to 3 mm in diameter, is able to reduce blood loss and the recourse to vessel occlusion
techniques if compared to traditional technique s [60],[61],[62], offers good results also in
cirrhotic livers and cystopericystectomy [63] and has a saline irrigation that avoids production
of smoke, chars and sticky coagulum to which the device could stick causing new bleeding
when it’s moved away. TMFB, used on the cut liver surface after dissection, destroys eventual
additional cancer cells at the margin of resection; in order to assure sterile margins, extra tissue
destruction at the margins of resection may be desirable for tumor excisions. Otherwise this
could be a disadvantage in case of living donor liver transplantation. It’s available for both
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laparotomic and laparoscopic surgery and it’s quite cheap and compatible with most electro‐
surgical generator currently available.
D: TMFB is not able to coagulate vessel over 2-3 mm of diameter which have to be clipped,
legated or sealed with other instruments [64]. So the instrument should be used in combination
with other instruments or clips or ties. Moreover studies do not demonstrate it’s efficacy to
reduce operating time if compared with traditional techniques [65].
Bipolar Vessel Sealing Device, BVSD (LigaSure, Valleylab Inc. Boulder, Colorado, USA)
(fig 4): The use in liver surgery of this instrument was described for the first time in liter‐
ature  in  2001  by  Horgan  [67].  The  LigaSure  System  includes  a  generator  with  a  foot
switch and a clamp-form hand piece that can be used for parenchymal fragmentation and
isolation of blood and bile structures just like in clamp crushing technique before applica‐
tion of energy; it employs RF to realize permanent occlusion of vessels or tissue bundle.
The LigaSure generator has a Valleylab’s Instant Response technology, a feedback-control‐
led response system that diagnoses the tissue type in the instrument jaws and delivers the
appropriate amount of  energy to effectively seal  the vessel:  when the seal  cycle is  com‐
plete,  a  generator  tone sound,  and output  to  the handset  is  automatically  discontinued.
BVSD is capable to obliterate the lumen of veins and arteries up to 7 mm in diameter by
the fusion of elastin and collagen proteins of the vessel walls; that makes BVSB the only
safe and real alternative to sutures and clips for sealing vessel [68],[69],[70].
Figure 4. The Ligasure Atlas during parenchyma transection
A: BVSD coagulates sealing vessels up to 7 mm in diameter with minimal charring, thermal
spread or smoke, it’s capable to reduce blood loss and the need for vessel occlusion techniques if
compared to traditional techniques [8],[71],[72], A recently published randomized controlled
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trial demonstrated that the use of Ligasure in combination with a clamp crushing technique re‐
sulted in lower blood loss and faster transaction speed in minor liver resections compared with
the conventional technique of electric cautery or ligature for controlling vessels in the transec‐
tion plane [73]. Otherwise a more recent randomized trial from the same team was not able to
show a real difference between the traditional techniques and the Ligasure vessel sealing sys‐
tem [74]. The instrument is available for both laparotomic and laparoscopic surgery [75]. Fur‐
thermore the use of Ligasure System is not correlated with an increase of the rate of post-
operative bile leaks and in some study bile leakage was nihill [76]-[127] and that proves his
effectiveness in obliterate also bile vessel. D: after the application the coagulated tissue often
sticks to the instrument’s jaws causing new bleeding when the device is moved away; BVSD
seems to be less effective in presence of cirrhosis for two reasons: first the portal hypertension
correlated with cirrhosis causes thinning of the dilate portal vein’s walls and makes their obliter‐
ation less effective; second cirrhosis makes crushing technique difficult and the hepatic tissue
between the blades may disperse the power applied causing vessel to bleed [128]; moreover it
seems to be ineffective in cystopericystectomy [77] (even if some surgeons sustain his effective‐
ness in this surgery [78]). Ligasure vessels sealing system has been widely use during liver trans‐
ection in a “blind” way [70]-[71], achieving parenchymal fracture and vessel sealing in the same
time without identìfication of tiny vasculatures and bile ducts. This could be considered a limits
of this tools which do not allow the surgeon to clearly check the structures which are going to be
sealed. To overcome this limit a technique similar to the “fusion technique” used with Harmon‐
ic FOCUS has been developed for the Ligasure vessel sealing system [130]., using the Ligasure
precise. With this technique using LigaSure itself, the hepatic parenchyma was widely and gen‐
tly crushed and confirmed that the remnant vessels and tiny vessels ( 2mm in diameter) were
divided by the LigaSure under direct vision. This allow to coagulate only vessels appropriate for
sealing with this instrument and imprtant vascular pedicles to adjacent segments can be visual‐
ized and protected. Larger vessels (3mm in diameter) were tied by absorbable braid. This ap‐
proach seems to reduce transection time and is the so called “postcoagulation technique” [138].
Habib’s technique: This technique, invented by Habib in 2002, is also known as Bloodless
Hepatectomy Technique [10],[88]. Resection is conducted using cooled tip RadioFrequency
probe those contain a 3 cm exposed tip to coagulate liver resection margins. Once a 2 cm-wide
coagulative necrosis zone is created by multiple applications of the probes in adjacent zones
and at different depths, the division of the parenchyma with a surgical scalpel is possible
without any bleeding. Both the remnant liver and the removed specimen have on the margin
of resection a portion of necrotic coagulated liver l cm thick.
A: The primary problem with each of the previous devices is that whilst small vessels can be coa‐
gulated during transection, larger vessels are often left patent and injured, which can result in
considerable blood loss requiring tedious clipping and suturing in order to achieve haemostasis.
Habib’s Technique allows hepatic resections with marginal blood loss, without any vessel oc‐
clusion technique or intra or post-operative transfusions, coagulating each vessel encountered
in the field of energy application; In a preliminary study of 15 cases of mainly segmental or
wedge resection reported by Weber et al., the mean blood loss was only 30±10 ml, and no com‐
plications such as bile leakage were observed [88]. Another group also reported low blood loss
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using this technique in liver resection [89]. Haemostasis is obtained only by RF thermal energy:
no additional devices like stitches, knots, clips or fibrin glue are needed [10],[88],[90],[91]; it’s ef‐
fective also in the cirrhotic liver and the l-cm-thick of burned coagulated surface assures mar‐
gins free from tumour. The technique has the advantage of simplicity compared with the
aforementioned transection techniques. As the RF assisted technique allows parenchymal spar‐
ing during the first resection, this in turn results in more repeat liver resections being possible
for recurrences. It also enables nonanatomical resections during these repeat resections.
D: Habib’s technique cannot be applied near the hilum or the cava vein for fear of dam‐
aging  this  structures  and  because  the  blood  flow  of  large  vessels  subtracts  RF  energy
and involves an incomplete coaugulative necrosis [92],[93] (up to now the technique has
been experienced only for segmental resection); the l-cm-thick of burned coagulated layer
in the surface involves the loss of part of healthy parenchyma and a higher rate of post-
operative  abdominal  abscesses  [91],[94].  Moreover  one  potential  disadvantage  of  this
technique is  the sacrifice of  parenchymal tissue in the liver  remnant,  with a 1  cm wide
necrotic tissue at the transection margin, which may be critical in cirrhotic patients who
require major liver resection or in case of liver resection for living donor liver transplan‐
tation. An evolution of the Habib probe is the Habib 4X [92]which adress the problem of
time consuming and the risk of skin burns from the grounding pad related to previous
device.The device was introduced perpendicularly into the liver, abutting the transection
line (Figure 5).  The generator was programmed to produce an alert  signal when energy
delivery  had  been  automatically  stopped,  thus  avoiding  over  coagulation  and  carbona‐
tion. The probe was gently moved to and fro in its vertical axis for 3e5 mm throughout
the  coagulation  process  to  avoid  adherence  of  the  probe  to  the  liver  parenchyma.  The
probe was then reintroduced adjacent to the last coagulated area in a serial fashion, until
the area to be transected was fully ablated. The number of applications required to cre‐
ate a complete zone of desiccation was related to the size of the cut surface of the resec‐
tion margin.
1. A second line of ablation, parallel to the first line and closer to the tumour edge, was then
done to ensure complete tissue coagulation and perfect haemostasis prior to transection
2. The Habib 4X was then applied perpendicularly to the previous two lines of ablation, so
as to ensure complete coagulation of any residual normal liver parenchyma. This allowed
a margin of coagulated liver parenchyma to remain; ensuring vessels and bile ducts
remained sealed. For deeper tumours the device was applied at an angle of 45 degrees to
the surface. This technique allow to achieve a very low rate of blood transfusion in a very
large series [88]
Gyrus plasmakinetic pulsed bipolar coagulation device: Gyrus /Gyrus medical inc., Maple
Groves, Mn, USA) is a bipolar cautery device which seals the hepatic parenchima using a
combination of pressure and energy that results in the fusion of collagen and elastin in the
walls of the hepatic vasculature and bile ducts [98]. The device can reliably seals vessels up to
7 mm in diameter minimizing the amount of blood loss during the transection of the liver.
Thermal spread and sticking to tissues is reduced by a cooling period after each pulse as the
The Aim of Technology During Liver Resection — A Strategy to Minimize Blood Loss During Liver Surgery
http://dx.doi.org/10.5772/54301
179
trial demonstrated that the use of Ligasure in combination with a clamp crushing technique re‐
sulted in lower blood loss and faster transaction speed in minor liver resections compared with
the conventional technique of electric cautery or ligature for controlling vessels in the transec‐
tion plane [73]. Otherwise a more recent randomized trial from the same team was not able to
show a real difference between the traditional techniques and the Ligasure vessel sealing sys‐
tem [74]. The instrument is available for both laparotomic and laparoscopic surgery [75]. Fur‐
thermore the use of Ligasure System is not correlated with an increase of the rate of post-
operative bile leaks and in some study bile leakage was nihill [76]-[127] and that proves his
effectiveness in obliterate also bile vessel. D: after the application the coagulated tissue often
sticks to the instrument’s jaws causing new bleeding when the device is moved away; BVSD
seems to be less effective in presence of cirrhosis for two reasons: first the portal hypertension
correlated with cirrhosis causes thinning of the dilate portal vein’s walls and makes their obliter‐
ation less effective; second cirrhosis makes crushing technique difficult and the hepatic tissue
between the blades may disperse the power applied causing vessel to bleed [128]; moreover it
seems to be ineffective in cystopericystectomy [77] (even if some surgeons sustain his effective‐
ness in this surgery [78]). Ligasure vessels sealing system has been widely use during liver trans‐
ection in a “blind” way [70]-[71], achieving parenchymal fracture and vessel sealing in the same
time without identìfication of tiny vasculatures and bile ducts. This could be considered a limits
of this tools which do not allow the surgeon to clearly check the structures which are going to be
sealed. To overcome this limit a technique similar to the “fusion technique” used with Harmon‐
ic FOCUS has been developed for the Ligasure vessel sealing system [130]., using the Ligasure
precise. With this technique using LigaSure itself, the hepatic parenchyma was widely and gen‐
tly crushed and confirmed that the remnant vessels and tiny vessels ( 2mm in diameter) were
divided by the LigaSure under direct vision. This allow to coagulate only vessels appropriate for
sealing with this instrument and imprtant vascular pedicles to adjacent segments can be visual‐
ized and protected. Larger vessels (3mm in diameter) were tied by absorbable braid. This ap‐
proach seems to reduce transection time and is the so called “postcoagulation technique” [138].
Habib’s technique: This technique, invented by Habib in 2002, is also known as Bloodless
Hepatectomy Technique [10],[88]. Resection is conducted using cooled tip RadioFrequency
probe those contain a 3 cm exposed tip to coagulate liver resection margins. Once a 2 cm-wide
coagulative necrosis zone is created by multiple applications of the probes in adjacent zones
and at different depths, the division of the parenchyma with a surgical scalpel is possible
without any bleeding. Both the remnant liver and the removed specimen have on the margin
of resection a portion of necrotic coagulated liver l cm thick.
A: The primary problem with each of the previous devices is that whilst small vessels can be coa‐
gulated during transection, larger vessels are often left patent and injured, which can result in
considerable blood loss requiring tedious clipping and suturing in order to achieve haemostasis.
Habib’s Technique allows hepatic resections with marginal blood loss, without any vessel oc‐
clusion technique or intra or post-operative transfusions, coagulating each vessel encountered
in the field of energy application; In a preliminary study of 15 cases of mainly segmental or
wedge resection reported by Weber et al., the mean blood loss was only 30±10 ml, and no com‐
plications such as bile leakage were observed [88]. Another group also reported low blood loss
Hepatic Surgery178
using this technique in liver resection [89]. Haemostasis is obtained only by RF thermal energy:
no additional devices like stitches, knots, clips or fibrin glue are needed [10],[88],[90],[91]; it’s ef‐
fective also in the cirrhotic liver and the l-cm-thick of burned coagulated surface assures mar‐
gins free from tumour. The technique has the advantage of simplicity compared with the
aforementioned transection techniques. As the RF assisted technique allows parenchymal spar‐
ing during the first resection, this in turn results in more repeat liver resections being possible
for recurrences. It also enables nonanatomical resections during these repeat resections.
D: Habib’s technique cannot be applied near the hilum or the cava vein for fear of dam‐
aging  this  structures  and  because  the  blood  flow  of  large  vessels  subtracts  RF  energy
and involves an incomplete coaugulative necrosis [92],[93] (up to now the technique has
been experienced only for segmental resection); the l-cm-thick of burned coagulated layer
in the surface involves the loss of part of healthy parenchyma and a higher rate of post-
operative  abdominal  abscesses  [91],[94].  Moreover  one  potential  disadvantage  of  this
technique is  the sacrifice of  parenchymal tissue in the liver  remnant,  with a 1  cm wide
necrotic tissue at the transection margin, which may be critical in cirrhotic patients who
require major liver resection or in case of liver resection for living donor liver transplan‐
tation. An evolution of the Habib probe is the Habib 4X [92]which adress the problem of
time consuming and the risk of skin burns from the grounding pad related to previous
device.The device was introduced perpendicularly into the liver, abutting the transection
line (Figure 5).  The generator was programmed to produce an alert  signal when energy
delivery  had  been  automatically  stopped,  thus  avoiding  over  coagulation  and  carbona‐
tion. The probe was gently moved to and fro in its vertical axis for 3e5 mm throughout
the  coagulation  process  to  avoid  adherence  of  the  probe  to  the  liver  parenchyma.  The
probe was then reintroduced adjacent to the last coagulated area in a serial fashion, until
the area to be transected was fully ablated. The number of applications required to cre‐
ate a complete zone of desiccation was related to the size of the cut surface of the resec‐
tion margin.
1. A second line of ablation, parallel to the first line and closer to the tumour edge, was then
done to ensure complete tissue coagulation and perfect haemostasis prior to transection
2. The Habib 4X was then applied perpendicularly to the previous two lines of ablation, so
as to ensure complete coagulation of any residual normal liver parenchyma. This allowed
a margin of coagulated liver parenchyma to remain; ensuring vessels and bile ducts
remained sealed. For deeper tumours the device was applied at an angle of 45 degrees to
the surface. This technique allow to achieve a very low rate of blood transfusion in a very
large series [88]
Gyrus plasmakinetic pulsed bipolar coagulation device: Gyrus /Gyrus medical inc., Maple
Groves, Mn, USA) is a bipolar cautery device which seals the hepatic parenchima using a
combination of pressure and energy that results in the fusion of collagen and elastin in the
walls of the hepatic vasculature and bile ducts [98]. The device can reliably seals vessels up to
7 mm in diameter minimizing the amount of blood loss during the transection of the liver.
Thermal spread and sticking to tissues is reduced by a cooling period after each pulse as the
The Aim of Technology During Liver Resection — A Strategy to Minimize Blood Loss During Liver Surgery
http://dx.doi.org/10.5772/54301
179
impedance of the coagulated tissue increased. This instrument has been previously widely
used in gynaecological procedures and it’s use in liver surgery is relatively new.
Figure 5. Habib technique for liver resection
A: It could be used in a similar manner to the clamp-crush technique to transect hepatic
parenchyma. After incising the hepatic capsule with bovie the instrument is inserted into the
liver in an open manner and bipolar energy is applied as the forceps are slowly closed over
the parenchyma. The cauterized liver is subsequently transected with Metzenbaum scissors.
The device was used for the entire hepatic parenchymal transection; only named vascular and
biliary structures required additional attention and were stapled or suture ligated. The device
exhibits a minimal thermal spread of 2–3 mm and was frequently used for parenchymal
transection abutting the hepatic hilum. With the exception of large, named vascular and biliary
structures which were routinely stapled or ligated, excellent haemostasis and biliary duct
fusion were achieved uniformly.
In a recent series median blood loss rate compare favourably with those in several large series
using the traditional clamp-crush technique [99]. Moreover blood loss and transfusion rates
were comparable with those cited in recent report of alternative parenchymal transection, as
showed by results of Tan et Al [100]. In this study Gyrus compared favourably with Harmonic
scalpel in term of Bile leakage and the author underlined the concorrential cost of the device.
Moreover it seems to be useful even in case of cirrhotic patients. Corvera et al. [98] have also
reported the use of the Gyrus device in cirrhotic livers comparing it to the clamp and crush
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technique. They evaluated five patients in each group showing similar results between the two
groups in terms of operating time, blood loss and major post-operative complications.
D: as the ligasure vessel sealing device one of the limit of this device is the “blind” use without
clear identification of vascular and biliary structures before sealing
The Aquamantis System:  The Aquamantys System employs Transcollation ® technology
(fig  6)  to  simultaneously  deliver  RF (radiofrequency)  energy and saline  for  haemostatic
sealing and coagulation of soft tissue and bone at the surgical site. Transcollation technol‐
ogy is used in a wide variety of surgical procedures, including orthopaedic joint replace‐
ment, spinal surgery, orthopaedic trauma and surgical oncology.Transcollation technology
simultaneously  integrates  RF  (radiofrequency)  energy  and  saline  to  deliver  controlled
thermal energy to the tissue. This allows the tissue temperature to stay at or below 100°C,
the boiling point  of  water.  Unlike conventional  electrosurgical  devices  which operate  at
high temperatures, Transcollation technology does not result in smoke or char formation
when put in contact with tissue. Blood vessels contain Type I and Type III collagen with‐
in their walls. Heating these collagen fibers causes radial compression, resulting in a de‐
crease in vessel lumen diameter. Using the Aquamantys generator with patented bipolar
and monopolar sealers, surgeons can achieve broad tissue-surface haemostasis by apply‐
ing Transcollation technology in a painting motion, or it can be used to spot-treat bleed‐
ing vessels.  This is capable of sealing structures 3–6 mm in diameter without producing
high temperature or excessive charring and eschar. Structures more than 6 mm in diame‐
ter should be divided in conventional  manner with clips or ties.  Constant suction is  re‐
quired to clear the saline used for irrigation.
Figure 6. Aquamantys transcollation technology performing liver resection
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A: it’s use is “friendlier” to most surgeons, easy to learn most surgeons are comfortable after
5–6 procedures. It seals blood and bile ducts up to 6 mm in diameter, is able to reduce blood
loss and the recourse to vessel occlusion techniques. Moreover it offers good results also in
cirrhotic livers [66] and destroys eventual additional cancer cells at the margin of resection.
D: it is expensive and pace of liver transection could be low. Moreover there is a lack of data
reported in literature due to the relative novelty of this device.
Coolinside: The new Coolinside® device (Apeiron Medical, Valencia, Spain) is a hand-held
device which simultaneously coagulates (using RF) and cuts (by means of a cold scalpel) the
liver. This device and its manipulation is built for both laparotomic and laparoscopic proce‐
dures.Coagulation is performed by a blunttip metallic electrode positioned at the distal edge,
which is electrically connected to a Cosman CC-1 coagulator system (Radionics, Burlington,
MA, USA) operating at a maximum power of 90W. The liver tissue is cut using a thin blade at
the distal edge. Inside it the active electrode has a closed hydraulic circuit containing saline
solution at a temperature of 0 ºC, which is propelled to the distal edge by a Radionics contin‐
uous perfusion pump (Burlington, MA, USA) at a speed of approximately 130 mL/min. The
cold liquid keeps the surface of the tissue below 100 ºC by refrigerating the active electrode.
The feedback system for the warm saline solution means that it can never come into contact
with the patient (as in the case of the Tissuelink® device).
A: The key to the performance of the device is in the fact that the depth of hepatic parenchymal
transection is adapted to the coagulation effect achieved by the proximal edge of the active
electrode, that part which first comes into contact with the tissue. In this way, every time the
surgeon moves the device over the surface of the liver, the parenchyma is cut and coagulated
simultaneously [132]. In this study 11 hepatic resection were performed entirely with coolin‐
side without the need for ligature or clips or pringle manouver, with no bile leak complication
and high transection speed. This device combines coagulation and transection capacity and it
does not need to be combined with other devices (not even stitches or clips). Moreover, it is
not necessary to perform vascular occlusion, parenchymal coagulation is homogeneous and,
lastly, there is the possibility of using it in laparoscopic surgery.
D:As with other RF devices, tissue pre-coagulation can change structures so that it can be
difficult to identify the main hepatic vessels or conduits. Moreover, the amount of hepatic
tissue that is sacrificed may be greater than in the case of other techniques, given that with this
device the coagulated area may be up to 5 mm, which might limit but not contraindicate this
technique in cirrhotic patients. Moreover this could be considered a disadvantages in case of
liver resection during living donor liver transplantation
3.3. Others source of energy
Water Jet Scalpel, WJS: The WJS was introduced in 1982 by Papachristou [79]. This tools could
achieve, as well as CUSA, a selective dissection.
The dissection modalities which take advantage of the anatomic conditions are called selective.
The water-jet effects hereby like an intelligent knife and separates the more resistant duct- and
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vessel structures automatically from the parenchyma which thus become visible. When visible
they can be closed easily under controlled conditions.
The device consists of a pressure generating pump and a flexible hose connected to the
hand piece. The liquid (saline solution) flows at a steady stream and is projected through
the nozzle at the tip of the hand piece. The jet hits the liver at the desired line of trans‐
ection and washes away the parenchyma, leaving the intra-hepatic ducts and vessel un‐
damaged; then the vascular and bile structures can be legated and the transection plane
coagulated.  The tip is  reinforced by a  suction tube which removes excess  fluid;  besides
splashing is avoided by covering the area of dissection with a transparent sheet or a Pet‐
ri  dish.  Compared  to  the  CUSA,  the  water  jet  leaves  a  smoother  cut  surface  and  little
hepatic degeneration or necrosis at the borders.
A: WJS can dissect offering excellent visualization and is effective also in the cirrhotic liver. In
the only available prospective randomized trial of water jet in the literature, in which 31
patients underwent liver resection using water jet and another 30 patients underwent liver
resection using CUSA, water jet transection reduced blood loss, blood transfusion, and
transection time compared with CUSA [80]. water jet techniques is quite good for dissecting
out major hepatic veins when tumors are in proximity. This allows for delineation of hepatic
veins, particularly at the junction with the inferior vena cava, and prevents positive margin.
It allow the so called selective dissection technique.
D: WJS can’t coagulate or realize haemostasis and some study demonstrate that it cannot
achieve a reduction of intra-operative blood loss and operating time if compared with
traditional techniques [81],[82]; using this technique is possible cancerous seeding of the
healthy abdominal organs and infection of the operators by hepatic viruses. Moreover in
literature some cases of gas embolism are described using this device [83]. Furthermore the
instrument may be more effective than the CUSA with respect to operating in the presence of
cirrhosis. Papachristou and Barters [79] initially reported that the water jet was likely to be
ineffective when there is increased fibrotic tissue. Later papers, however, describe successful
resections with cirrhosis by using higher jet pressures. Une et al. [80] report that one does not
need to use higher water jet pressures to dissect cirrhotic tissue effectively; instead, the same
pressures as for normal parenchyma just need to be applied longer. The major concern of
surgeons using the water jet is the associated splash. The latter effect is caused by solution
bouncing off tissues. Besides the obvious infectious concerns of the possibility of contaminat‐
ing operating room personnel, the splash brings up the notion of the possibility of cancerous
seeding. This possibility must be considered in operations for malignancy and one needs to
take additional care not to expose the gross tumor during the dissection.
Staplers  (fig  7):  Since  the  nineties  vascular  staplers  to  divide  hepatic  veins  and  portal
branches during hemihepatectomy are considered an achievement that  aids in minimiz‐
ing blood loss and thereby reduces the need for inflow occlusion. Further, staplers seem
to be advantageous in the unroofing of hepatic cysts since any inadvertently injured bile
duct or blood vessel is sealed [84].
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Staplers can be used in liver surgery for control of inflow and outflow vessels, or to di‐
vide liver parenchyma [84],[85]. The stapler is rarely used as the principal instrument in
hepatic resection. The device can add speed to the operation in open or laparoscopic sur‐
gery. Its primary use is for achieving control of hepatic vasculature, particularly the hep‐
atic  veins.The  use  of  vascular  staplers  to  divide  hepatic  veins  and  portal  branches  is
considered an achievement that has aided in minimizing blood loss and thereby reduced
the need for inflow occlusion. Recent publications reporting a number of techniques us‐
ing stapling devices in liver surgery showed them to be extraordinarily useful in the safe
ligation of inflow and outflow vessels.
Figure 7. Parenchima transection performed using a Stapler
Biliary radicals can be incorporated efficiently into the staple line. Division of the hepatic veins
with a stapler as opposed to direct ligation proffers several advantages. First, it eliminates the
risk of dissecting the hepatic veins and minimize the risk of slipped ligature. Furthermore the
stapler simultaneously divides multiple venous branches, especially on the right side, that are
too short to allow for a safe and rapid more traditional ligation.
A: It is particularly useful in dividing the major trunk of hepatic veins or the middle hepatic
vein deep in the transaction. Vascular staplers also can be used to divide the hepatic duct
pedicle in right or left hepatectomy [7]. The procedure starts by dividing the liver capsule by
diathermy the use of a stapler for transection of the liver parenchyma following by fracturing
the liver tissue with a vascular clamp in a stepwise manner and subsequently divided with an
EndoGIA vascular stapler. In a large series of 300 stapler hepatectomies, including 193 major
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hepatectomies, mortality of 4% and morbidity of 33% were reported which is comparable with
conventional liver resection techniques. Vascular control was necessary in only 10% of the
series, with an overall median blood loss of 700 mL [86]. The rate of biliary leakage seems to
be very low, with a 8% reported in the largest series [86]. Moreover the trasection speed is the
highest among all the techniques employed. Most recently, an ultrasound-directed transpar‐
enchymal application of vascular staplers to selectively divide major intrahepatic blood vessels
before the parenchymal phase of liver resection has been shown to minimize blood loss, warm
ischemia time, and operative time [131].
More to the point, in cases of difficult parenchymal transection with ongoing bleeding, the
stapler device offers faster specimen removal giving the surgeon the opportunity to control
the loss of blood from the raw liver surface
D:Although the technique appears attractive, the financial cost is a serious drawback. One
problem associated with the use of a stapler for liver transection is increased risk of bile leak,
since the stapler is not very effective in sealing small bile ducts [87]. Otherwise other studies
report a very low rate of biliary injury and leakage. Moreover the surgeon must also be selective
in the use of a stapler for the treatment of tumors particularly near the hilum in order to obtain
sufficient margin. In case of stapler malfunction the surgeon should be ready with a back up
technique to achieve vein control in case of sudden hemorrage. Serious blood loss can
theoretically occur when the stapler has sealed only half the diameter of the vessel or after
misfire of the device.
Chang’s needle technique: This technique presented by Chang in 2001 [95] is based on the
utilization of a special instrument equipped with a 18 cm straight inner needle with an hook
near its top; Chang needle can be applied repeatedly to make overlapping interlocking
mattress sutures with N° l silks along the inner side of the division line. After this phase liver
parenchyma can be divided directly by scissors, electrocautery or traditional resection
methods applying new suture only for tubular structures of significant size.
A: Chang’s needle technique can be performed without application of any vessel occlusion
techniques, without any other haemostatic technique and reducing blood transfusions; this
method seems to be capable to reduce both intra-operative blood loss and resection time;
besides it’s surely cheap and is reported to be simple too [96].
D: It can’t be applied if the lesion is too close to inferior cava vein [97]
3.4. Combined techniques
In the last decades a combined use of the devices previously analyzed has been reported in
literature to increase the efficacy of each device, based on consideration that we have 2 different
kind of instruments (as shown in table 3): those that allow a preparation of vascular structures
achieving a selective dissection and those that allow a non-selective dissection (with a blind
coagulation of the vasculature and biliary structures). Efficient and safe liver parenchymal
transection is dependent on the ability to simultaneously address 2 tasks: parenchymal
division and hemostasis. Because no single instrument has been developed that is adequate
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for both of these tasks, most hepatic parenchymal transections are performed using a combi‐
nation of instruments and techniques.
Aloia e coll developed a 2-surgeons technique which combine saline-linked cautery and
ultrasonic dissection [133]. This techniques allowed a reduction in the operative time when
compared to ultrasonic dissection alone. Moreover blood loss and lenght of operation seems
to be reduced.
a Blood loss is expressed in ml.
b Value refers only to transection time.
c Blood loss is expressed in ml/cm2. The number of patients transfused is expressed as a mean only in the trial Rau et al. [9].
Table 3. Only randomized trials are reported. NA= Not available in the study.
In January 2004, Sakamoto et al retrospectively compared their experience with 16 liver
resections in which SLC was used in combination with a bipolar vessel-sealing device and a
matched set of 16 patients undergoing liver resections in which a crush-clamp technique was
used.[134] They found that fewer patients in the SLC group required inflow occlusion and that
blood loss was reduced. Differences in total operative time were not reported, but liver
transection time was prolonged in the SLC group. Aldrighetti et al. [135] published a relatively
larger series comparing clamp-crushing with ultrasonic plus harmonic scalpel dissection. The
latter resulted in longer operative time, but with a reduced blood loss (and consequently a
lower transfusion rate) and with a lower rate of biliary fistula. However, the retrospective
method of the study, and the relatively long period of inclusion may have biased these results
against the clamp-crush technique. Lesurtel and Tanai combined ultrasonic dissection with
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bipolar coagulation [136-137]. They concluded that UD associated with efficient bipolar forceps
cautery is probably one of the safest and the most efficient device for liver transection, even if
its superiority over the clamp crushing technique has not been well established. In a recent
paper Yokoo et coll [139] combined the use of ultrasonically activated scalpel with a saline
linked radiofrequency dissecting sealer versus bipolar cautery with a saline-irrigation system
and ultrasonically activated. Scalpel. The first technique resulted in shorter operative time and
lower postoperative complication rate. Moreover Gruttadauria and coll developed a combi‐
nation of utrasonic surgical aspirator in association with a monopolar floating ball in elderly
patients. This new technique reduced length of stay, procedure length, and use of perioperative
blood in a cohort of patients [140]. Nagano and coll evaluated the efficacy of combination of
CUSA plus argon beam colagulator in comparison with CUSA plus bipolar coagulation, and
showed that the first approach allowed to a shorter transection time and lower blood loss [141]
Haemostasis techniques: Coagulation of vessels over l mm of diameter can be achieved
positioning clips or sutures before division, or using devices like LigaSure, TMFB or HS for
their target vessels or staplers for the largest veins. Clips and sutures are used especially during
transection through traditional techniques.
During and after liver’s transaction haemostasis of the vascular structures under 1 mm of
diameter is another important concern of the surgeon: first because the continuous bleeding
from the little vessels in the parenchyma represents a considerable part of intra-operative blood
loss, and second because it makes hard for the surgeon the visualization of the surgical field.
The stop of tearing small vessels that causes oozing from the cut surface can be achieved with
normal monopolar or bipolar electrocoagulator, better if equipped with saline irrigation that
makes them less traumatic and avoids formation of sticky coagulum An alternative is repre‐
sented by employment of Argon Beam Coagulator or TMFB that probably is the best device
for stopping tearing of small vessels on the cut surface of the liver.
After the resection other two precautions can be taken: application of mattress sutures for
providing to a mechanical compression of the bare surface and application of biological glue
for realizing complete haemostasis through a chemical/biological action.
Choice of surgical strategy: The choice of surgical strategy is based on the pre-operative
evaluation and on the now indispensable Intra-Operative Ultrasonography (IOUS); in fact
several studies have demonstrated that the IOUS is capable to change surgical strategy in over
40% of cases finding new lesions or diagnosing as inoperable lesions those were thought
operable at the previous evaluation [101-104].The kind of surgical strategy chosen for the
intervention on the base of affects strongly influences the operative outcome and the amount
of operative blood loss. The most considerable aspect is the amplitude of the resection: a large
resection like a right hemi-hepatectomy (or another typical resection) involves a higher
bleeding and risk of complications. From this point of view the choice of segmental or wedge
limited resections, when they are possible in respect of radical oncology standards, has to be
consedered the best option [105,106]. Usual surgical margins for removal of liver tumours are
l cm of healthy parenchyma surrounding the lesion. Kokudo et al. in 2002 demonstrated that
for colorectal metastases the surgical margin can be, in particular situations, lowered to 2 mm
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with increase of the pathology recurrence rate from O% for 5 mm margin to 6% for 2 mm
margin [107].
This finding, combined with a contrast-enhanced IOUS during the resection, could be a
rationale incentive for practising limited resections [108-110], and the possibility of an accurate
investigation of the remnant liver through the IOUS
Drug administration for reducing intra-operative blood loss: Liver resection may cause a
variable degree of hyperfibrinolytic states; this phenomenon occurs in the days immediately
after hepatectomy and is more pronounced in patients with a diseased liver or in patients who
have undergone to a wider hepatectomy extent [111-116]So some authors propose the
utilization of drugs with antifibrinolytic effect like Aprotinin that is reported to be capable to
reduce intra-operative blood loss (especially during liver resection time) and transfusions
[117-119]. Other authors propose utilization of the cheaper Tranexamic acid reporting similar
results [120]. Although a theoretical risk of thromboembolic complications is present, no
adverse drug effects like deep venous thrombosis, pulmonary embolism or other circulatory
disturbances were detected in both these studies.
3.5. Comparison of different liver transection techniques
The choice of transection techniques is currently a matter of preference of surgeons, as there
are few data from prospective randomized trials that compared different techniques. It has
been shown in small prospective randomized trials that clamp crushing or water jet may be
preferable to CUSA in terms of quality of transection or speed of transection [1],[122]. Moreover
Water-jet dissection.
Seems to be considerably faster than CUSA® or blunt dissection and Pringle-time and blood
loss can be reduced by using this device [83]. However, the results of these trials remain to be
validated by larger-scale trials. CUSA dissection is still a widely used technique worldwide.
Several studies have been addressed to clarify these critical points, underlining the advantages
and the drawbacks of each device. One of the first randomized studies [52] comparing the
ultrasonic dissector versus the clamp-crush technique showed that the ultrasonic dissector is
more frequently associated with tumor exposure at the resection margin and with incomplete
appearance of landmark hepatic veins on the cut surface. The authors did not find any
difference in postoperative morbidity and blood loss, concluding that clamp-crushing
technique resulted in a higher quality of hepatectomy, thus being the option of choice.
Aldrighetti et al. [135] published a relatively larger series comparing clamp-crushing with
ultrasonic plus harmonic scalpel dissection. The latter resulted in longer operative time, but
with a reduced blood loss (and consequently a lower transfusion rate) and with a lower rate
of biliary fistula. However, the retrospective method of the study, and the relatively long
period of inclusion may have biased these results against the clamp-crush technique.The study
performed by Takayama and colleagues found no difference in transection speed between the
crush/clamp technique and ultrasonic dissection. This same study also demonstrated that the
crush/clamp technique resulted in increased precision and improved quality of hepatectomy
according to a grading system considering such factors as positive surgical margins, appear‐
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ance of landmark hepatic veins on the cut hepatic surface, and postoperative morbidity. Koo
and colleagues also demonstrated that no difference existed with blood loss, transfusion
requirements, speed of resection, or total operative time between crush/clamp and the
ultrasonic dissector
A randomized study [73] comparing LigaSure with the conventional method, demonstrated
no statistical difference (p = 0.185) in blood loss and mortality rate between the two groups.
But, LigaSure was slightly superior in terms of transection speed, number of ties per cm 2 and
hemostasis time. The resulting total operating time decreased by 27 min, and hospital stay was
shortened by 2 days in the LigaSure group. The authors performed also a cost analysis which
found a highly cost-effective ratio in favor of LigaSure due to shorter operative time, hospital
stay and low capital cost of the disposable device. They considered 3 mm as the range of
maximal effectiveness in sealing portal triads (without increasing the rate of biliary fistula). A
more recent randomized study [74] did not demonstrate this difference in blood loss, operating
time and hospital stay, failing to find a superiority of one technique over the other. In this
particular situation, the cost-effectiveness of LigaSure in the clamp-crush method was not
confirmed, favoring once again the latter. Radiofrequency-assisted hepatic transection has also
been studied in a randomized, controlled fashion. The results of this study indicated that
postoperative morbidity, including abscesses and biliary complications, was significantly
higher with the use of radiofrequency-assisted resection compared to crush/clamp.
As recently described in non-randomized settings [85]-[86], liver transection could be also
performed with the stapling technique. As reported, the technique appears to be safe and
quicker. Commonly, staplers are considered to be expensive tools, but they increase only the
total material cost. However, owing to decreased blood loss, transfusion rate, shorter operative
time and in-hospital stay, the global cost for a hepatectomy (especially for the major ones) has
considerably decreased especially in high-volume centers. It should also be noticed that the
stapling technique [142] can reduce the time of vascular control (i.e. Pringle). This fact turns
out to be relevant when the resection is conducted in injured parenchyma due to prolonged
chemotherapy (hepatic steatosis, sinusoidal obstruction syndrome, steatohepatitis, etc.).
Cataldo et al [143] comparing stapler, crush/clamp and dissecting sealer demostrate that liver
trasnection with stapler was quicker, but mean blood loss and oncological margin were similar
for the three techniques. A recent study of clearly demonstrate that there is no benefit of any
alternative method that has so far been compared with the clamp-crushing technique within
a RCT regarding morbidity, mortality, and transfusion rates. Moreover, available RCTs failed
to show an advantage of these novel devices to reduce blood loss, parenchymal injury,
operation time, and hospital stay.Recently, a randomized trial compared four methods of liver
transection, namely clamp crushing, CUSA, Hydrojet, and dissecting sealer, with 25 patients
in each group [121]. In that study, clamp crushing was associated with the fastest transection
speed, lowest blood loss, and lowest blood transfusion requirement. Furthermore, clamp
crushing was the most cost-effective technique. However, in that study, clamp crushing was
performed with the Pringle maneuver, whereas the other techniques were performed without
the Pringle maneuver. This might have resulted in bias in favor of clamp crushing. An other
recent comparative study between clamp crushing technique (CRUSH), ultrasonic dissection
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postoperative morbidity, including abscesses and biliary complications, was significantly
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alternative method that has so far been compared with the clamp-crushing technique within
a RCT regarding morbidity, mortality, and transfusion rates. Moreover, available RCTs failed
to show an advantage of these novel devices to reduce blood loss, parenchymal injury,
operation time, and hospital stay.Recently, a randomized trial compared four methods of liver
transection, namely clamp crushing, CUSA, Hydrojet, and dissecting sealer, with 25 patients
in each group [121]. In that study, clamp crushing was associated with the fastest transection
speed, lowest blood loss, and lowest blood transfusion requirement. Furthermore, clamp
crushing was the most cost-effective technique. However, in that study, clamp crushing was
performed with the Pringle maneuver, whereas the other techniques were performed without
the Pringle maneuver. This might have resulted in bias in favor of clamp crushing. An other
recent comparative study between clamp crushing technique (CRUSH), ultrasonic dissection
The Aim of Technology During Liver Resection — A Strategy to Minimize Blood Loss During Liver Surgery
http://dx.doi.org/10.5772/54301
189
(CUSA) or bipolar device (LigaSure), failed to show any difference between the three techni‐
ques in terms of intraoperative blood loss, blood transfusion, postoperative complications and
mortality [72]. Further prospective randomized studies are needed to determine which
transection technique is the best. Moreover a recent review of the Cochrane conclude that
Clamp-crush technique is advocated as the method of choice in liver parenchymal transection
because it avoids special equipment, whereas the newer methods do not seem to offer any
benefit in decreasing the morbidity or transfusion requirement. Otherwise in the comparison
of different techniques, apart from the efficacy in transaction with low blood loss, the relative
speed of transection and the potential complications are other parameters to be considered.
[122] Furthermore, the use of special instruments for transection is costly, especially when two
instruments are used in combination for transection and hemostasis. It is difficult to compare
the relative cost of different transection instruments because some are reusable whereas others
are designed for single use, and the cost of the same instrument varies substantially in different
countries. The clamp–crush and sharp dissection techniques do not involve any additional
instruments. A cost comparison between the clamp–crush technique and other techniques
revealed that clamp–crush is two to six times cheaper than other methods, depending on the
number of surgeries performed each year. Nonetheless, the cost of these various techniques
should play a part in the surgeon’s decision as to whether to use them or not.
Besides reduction of blood loss and perioperative complications, radical resection with tumor-
free margins is a major goal in surgery for malignant hepatic lesions. Disease-positive resection
margins are a strong prognostic factor for local tumor recurrence and overall survival.
Unfortunately, pathohistological data on resection margins were only available for two
trials.Takayama et al. demonstrated comparable resection margins in their comparison of the
clamp-crushing to the ultrasonic dissector technique.[52] However, Smyrniotis et al. reported
far greater length of the narrowest tumor-free margin in their sharp transection group. [144]
The question of whether any alternative transection technique provides a benefit in longterm
survival of cancer patients needs further evaluation within clinical trials.
4. The role of the anaesthesiologist
Patients those are subjected to liver surgery are usually pre and intra-operatorially treated with
infusion of liquids, plasma expanders and blood products: normally hepatic resections are in
fact conduced in condition of euvolaemia or hypervolaemia to protect patients from the risk
of consistent haemorrhage and haemodynamic’s instability.
Despite this idea several studies have demonstrated that a condition of Low Central Venous
Pressure (LCVP) can reduce bleeding, recourse to vessel occlusion techniques and transfusions
during resection [111,112,113]. It has been scientifically demonstrated that intra-operative
blood loss is correlated with inferior retro-hepatic vena cava pressure [114].
Mendelez obtained very low blood loss results in major hepatic resections managed keeping
theCVP under 5 mmHg: this is possible with abstention from practising any infusion but intra-
operative liquid infusion at the low speed of 75 ml/h and without any drug administration but
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employing hypotensive effects of normal anaesthetics (like Isoflurane, morphine and Fenta‐
lyn). It’s obvious that LCVP technique needs a strict monitoring of several parameters: in
particular systolic arterial pressure has constantly to be kept over 90 mmHg and diuresis over
25 ml/h. After the specimen is removed and after the realization of complete haemostasis starts
the infusion of liquids, and if necessary of plasma expanders and blood products until
euvolaemia is obtained and haemoglobin value is over 8-10 g/dl [115].
LCVP has to be abandoned in case of uncontrollable haemorrhage (over 25% of total blood
volume) or application of total vascular exclusion technique. Mendelez using LCVP reports a
0,4% rate of gas embolism [116]. This illustrates the importance of collaboration between
surgeons and anaesthetists for a successful hepatectomy.
5. Conclusions
Improvement in the techniques of liver transection is one of the most important factors for
improved safety of hepatectomy in recent years. The use of intraoperative ultrasound aids
delineation of the proper transection plane and allow to transect tumor close to main vessels
without bleeding. Clamp crushing and ultrasonic dissection are currently the two most
popular techniques of liver transection. The role of new instruments such as ultrasonic shear
and RFA devices in liver transection remains unclear, with few data available in the literature.
The role of vascular exclusion including Pringle’s manouver seems to be decreasing with
improved transection technique. However, it remains a useful technique in reducing bleeding
from inflow vessels, especially for surgeons with less experience in liver resection, and recent
results show safety of this technique even for prolonged total time of ischemia. Maintenance
of low central venous pressure remains an important adjunctive measure to reduce blood loss
in liver transection.
As clear data for comparison of various liver transection techniques are lacking, currently the
choice of technique is often based on the individual surgeon’s preference. However, certain
general recommendations can be made based on existing data and the author’s experience.
Clamp crushing is a lowcost technique but it requires substantial experience to be used
effectively for liver transection, especially in the cirrhotic liver. CUSA can be used in both
cirrhotic and non-cirrhotic liver, is associated with low blood loss and it has a well established
safety record, with low risk of bile leak. It is particularly useful in major hepatic resections
when dissection of the major branches of the hepatic veins is required, or in cases where the
tumor is in close proximity to a major hepatic vein, as it allows clear dissection of the hepatic
vein from the tumor. This could be the preferred
5.1. Technique in oncological resection
5.1.1. The main disadvantage of the CUSA technique is slow transection
Newer instruments such as the Harmonic Scalpel, Ligasure and TissueLink Dissector enhance
the capability of hemostasis and allow faster transection. However, they lack the preciseness
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far greater length of the narrowest tumor-free margin in their sharp transection group. [144]
The question of whether any alternative transection technique provides a benefit in longterm
survival of cancer patients needs further evaluation within clinical trials.
4. The role of the anaesthesiologist
Patients those are subjected to liver surgery are usually pre and intra-operatorially treated with
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during resection [111,112,113]. It has been scientifically demonstrated that intra-operative
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results show safety of this technique even for prolonged total time of ischemia. Maintenance
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when dissection of the major branches of the hepatic veins is required, or in cases where the
tumor is in close proximity to a major hepatic vein, as it allows clear dissection of the hepatic
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Newer instruments such as the Harmonic Scalpel, Ligasure and TissueLink Dissector enhance
the capability of hemostasis and allow faster transection. However, they lack the preciseness
The Aim of Technology During Liver Resection — A Strategy to Minimize Blood Loss During Liver Surgery
http://dx.doi.org/10.5772/54301
191
of CUSA in dissection of major hepatic veins, and, HS more than others may be associated
with increased risk of bile leak. Moreover they are particularly useful in laparoscopic liver
resection. They can also be used in combination with CUSA for sealing of vessels, but this
increases the cost substantially. RFA-assisted transection is probably the most speedy liver
transaction technique. However, the risk of thermal injury to major bile duct is a serious
concern and its use is probably restricted to minor resection Gyrus and Aquamantis are
relatively new instrument and literature do not allow to draw any conclusion about their
efficacy and safety.
The experience of the surgeon in practising hepatic surgery, whatever is the method to perform
it, is still a factor of primary importance. In spite of that, the advent of new diagnostic instru‐
ments, new devices for resection and coagulation, a better knowledge of the liver’s anatomy
and pathology and a closer collaboration with the anaesthetist make the hepatic surgery a kind
of surgery more defined and rational. From this point of view new studies based on the use
of different surgical strategies, association of different devices and employment of different
diagnostic and anaesthetic techniques is desirable.
5.2. Summary of advantages and disadvantages of the parenchymal-division instruments
(table 4)
Table.4lists the primary advantages and disadvantages of five instruments used for paren‐
chymal division during liver resection. The CUSA has the principal advantage of precise
identification of both vascular and biliary vessels so that they may be controlled by ligature or
other methods. In addition, the CUSA provides some haptic feedback to the surgeon so that
dissection planes may remain clear. The principal disadvantages of the CUSA are threefold:
(1) While the instrument permits removal of a large margin around tumors, the proof of
adequate margins ends up in the suction container; (2) due to its mechanism of action, the
CUSA is not very good for dissection through the fibrotic tissues found in cirrhotic livers; (3)
without considerable education of the operating room personnel, the complexity of the
mechanism may be cause for delays or malfunctions during procedures. The water jet affords
many of the same advantages as the CUSA. Additionally, it produces minimal marginal
necrosis, making it an ideal instrument in certain scenarios. The most important concern with
this instrument, however, is the splash, for reasons described above. The harmonic scalpel’s
primary advantage is its ability to simultaneously cut and coagulate. The associated coagulum,
however, may cause delayed complications. Originally devised for laparoscopic use, the
harmonic scalpel’s design is not particularly advantageous for open cases. Used as an adjunc‐
tive instrument, the stapler provides the possibility for speedier dissections. On the other hand,
the stapler is a relatively imprecise instrument that also has the potential to malfunction during
procedures. The floating ball is a surgeon-friendly instrument, particularly for the novice liver
resectionist. Its mode of action may be particularly helpful in cirrhosis. The instrument acts by
“controlled” burning and therefore is, by nature, an imprecise instrument; plus, there are
concerns both for delayed complications related to the coagulum and for steam popping.
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5.3. Ranking the clinical usefulness of the five instruments (table 5)
Table 2 subjectively ranks the five instruments according to perceived usefulness in various
clinical scenarios. For resection of malignancies, we rank the CUSA number one because of its
ability to stay within tissue planes during resections while preserving vessels for ligature. The
water jet was second due to concerns about the splash. Third on the list is the floating ball
because of its user friendliness. The harmonic scalpel lands fourth on our list because we expect
laparoscopic liver resections to increase. We find the water jet to be the most useful instrument
for living-donor resections because of the minimal necrotic margin. After the water jet, we
advocate the more traditional, fine instrument (e.g., mosquito clamp) dissections. We rank the
CUSA third because with experience, the surgeon may minimize the disadvantage of tissue
removal.
Table 4. Advantages and disadvantages of most common devices
The  harmonic  scalpel  tops  the  instruments  for  laparoscopic  surgery,  primarily  because
the scalpel is designed for laparoscopic surgery. Another reason the scalpel is particular‐
ly  useful  here  is  that  the  principal  tumors  being removed now via  the  laparoscope are
small benign ones.
Therefore, the imprecision of this instrument is not so much of a disadvantage. The CU‐
SA comes in second primarily because its suction competes with insufflation. Staplers are
number  three  because  of  their  ability  to  gain  quick  control  over  vessels  during  laparo‐
scopic  dissections.  Finally,  because  laparoscopic  hepatic  surgery is  rapidly  evolving,  we
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believe there will  soon be new uses for  old instruments or  development of  new instru‐
ments that will be particularly useful for this approach. For cirrhotic livers, we rank the
floating ball number one due to its effective burning of fibrotic tissue. The harmonic scal‐
pel  may also be effective.  Because of  their  relative precision,  we rank the water jet  and
CUSA lower than the other two. Staplers do also have a role here.
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Habib
Laparoscopic procedures HS and Ligasure
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1. Introduction
The first experiences of ultrasonography (US) during surgical operations dated at the first
years of the sixties, when some surgeons employed ultrasound in order to identify urinary
or biliary stones [1,2]. These experiences gave birth to 2 important areas of application of ul‐
trasound in the surgical field: intra-operative ultrasonography (IOUS) and interventional ul‐
trasonography.
The first reports concerning the usage of IOUS in liver surgery dated at 1980-81 [3,4].
Hepatic surgery became the most important field of development of IOUS and nowadays
the ultrasounds are employed for several goals: the precise localization of lesions and their
relationship with surrounding biliary and vascular structures, the examination of the liver
anatomy in order to plan the surgical strategy in respect of the oncologic principles, the in‐
tra-operative re-staging with identification of new nodules.
In 1968 Gramiak and Shah firstly introduced the ultrasound contrast agents (USCA); later,
the introduction of ultrasound contrast agents for the study of the liver in 1999 [5], and then
the intra-operative contrast enhanced ultrasound (CEIOUS) [6] offered further development
to this important technique.
Nowadays the IOUS is considered an invaluable tool for hepatic surgery and its usage
should be considered mandatory. CEIOUS demonstrates great potentialities but its role has
not been established yet, even considering recent developments of multi-slice computerized
tomography and magnetic resonance with liver-specific contrast agents.
© 2013 Garancini et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
© 2013 Garancini et al.; licensee InTech. This is a paper distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. IOUS and CEIOUS: Technical aspects
If  compared  to  the  trans-abdominal  conventional  US,  IOUS  offers  several  advantages.
First,  the  higher  resolution of  the  ultrasonographyc  images,  because  the  probe  is  in  di‐
rect  contact  with the  liver  avoiding the  absorption of  acoustic  waves  by the  abdominal
wall. Second, during conventional US the liver has to be “spied” within the acoustic win‐
dows (es:  transcostal),  meanwhile during IOUS the proper intra-operative probes [Fig 1]
can  be  placed  in  contact  with  the  anterior,  superior,  inferior  or  posterior  liver  surface
and a lesion can be studied from different point of view; consequently, IOUS performed
after  liver  mobilization offers  much more information.  Third,  during IOUS,  information
obtained with the ultrasound study and information gained by inspection and palpation
can complement each other.
Figure 1. Intra-operative ultrasound probe
The non-panoramic nature of the study represents the main limitation of every US examina‐
tion, included the IOUS. A great attention should be paid to examine the whole liver paren‐
chyma, avoiding to leave some portion of the liver unexplored. For this reason, information
gained by IOUS should always be integrated with the ones obtained from the pre-operative
and panoramic study like computerized tomography (CT) and magnetic resonance (MR).
Before IOUS of the liver, partial hepatic mobilization with section of the round and falciform
ligaments is always suggested.
Firstly, the liver should be explored using a standard convex (frequencies: 3.75-10 MHz) or
micro-convex probe (frequencies: 3.75-10 MHz), in order to obtain a wide ultrasonographyc
imaging. The probe should be initially placed between segment 4a and 4b to visualize the
hepatic hilum, and then moved on the liver surface evaluating presence of eventual anatom‐
ical abnormalities of portal, arterial or biliary pedicles and of sub-hepatic venous system.
Then the liver should be explored and mapped searching for focal lesions; precise localiza‐
tion of the lesions detected at pre-operative staging must be confirmed and new lesions
must be mapped. A standardized sequential study of each segment is suggested for that,
avoiding to leave unexplored portion of liver.
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Afterwards,  when indicated,  the CEIOUS can be performed;  main goals  of  the CEIOUS
are characterization of lesions of uncertain nature and detection of new lesions not previ‐
ously visualized.
The contrast  agent  (example:  4.8  ml  of  Sulfur  Hexafluoride)  has  to  be  injected in  a  pe‐
ripheral vein (cannula of 21 gauge or larger) and the arterial,  portal and late phases are
monitored (CEIOUS phases are reported in Table 1 and Figure 2); if necessary the USCA






Table 1. CEUS and CEIOUS vascular phases
The main advantage of the trans-abdominal contrast enhanced ultrasound (CEUS) and of
the CEIUOS is that they allow a continuous real-time imaging; consequently they offer
much more information for characterization of nodules than contrast-enhanced CT and MR,
whose main limitation is that they are non-continuous techniques.
3. CEIOUS: The contrast agents
The acoustic difference between the intra-vascular gas microbubbles and the surrounding
blood and tissues represents the basis for use of ultrasound contrast agents (USCA). The gas
content of first-generation USCA (eg: Levovist, Schering AG, Berlin, Germany) is air, and
the outward diffusion of air results in a relatively rapid decrease in the acoustic reflection
and hence limited clinical utility. The stability of newer USCA like Optison (GE Healthcare,
Amersham, Buckinghamshire, England), SonoVue (Bracco, Milan, Italy), and Definity (Bris‐
tol-Myers Squibb, Billerica, MA) is achieved by use of highmolecular-weight gases, and the
slower outward diffusion of these gases makes such second generation USCAs more effec‐
tive and long lived in the vascular system.
In recent years microbubbles taken up by Kupffer cells, thus possessing a "post-vascular"
phase, were registered as a new second-generation USCA in Japan (Sonazoid, GE Health‐
care). During the post-vascular Kupffer-phase, the tumour appears as a contrast defect im‐
age due to the lack of Kupffer cells and can consequently be characterized.
The usage of some USCAs is not approved in Italy, and authors’ experience hare reported is
limited to the Sulfur Hexafluoride (SonoVue, Bracco, Milan, Italy).
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Figure 2. This picture shows a colorectal liver metastases (indicated by azure-blu arrows) in the arterial, portal and tardive phases (time passes 
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4. IOUS and CEIOUS: The intra-operative re-staging
Nowadays, IOUS is still considered the most accurate diagnostic technique for detecting fo‐
cal liver lesions [7,8]. Nevertheless, it’s remarkable that recent technical ameliorations in ra‐
diology allowed better outcomes in terms of sensitivity and specificity regarding the
detection of primitive and metastatic liver lesions. In particular, the recent availability of
multidetector-row Computerized Tomography (CT) with more than 64 channels and of liver
specific contrast agents in Magnetic Resonance (MR) represent a great improvement in the
diagnostic accuracy of liver tumours.
Hepatocellular carcinoma (HCC) and colo-rectal liver metastases (CRLM) represent the
most common malignant liver lesions and the most common indication to liver resection
worldwide, and consequently in this chapter the attention will be focused to the staging of
these tumours.
4.1. Colorectal liver metastases
Concerning  the  detection  of  synchronous  liver  metastases,  the  contrast  enhanced  CT is
reported  to  have  a  sensitivity  and  the  specificity  of  respectively  64-72%  and  64-72%
[9,10], although some recent studies conducted on smaller populations showed values of
sensibility of 71.7–92% [11-14]. On the other hand, concerning the detection of metachro‐
nous liver metastases,  the efficacy of contrast  enhanced CT revealed to be unimpressive
in term of sensibility [15].
MR showed sensibility ranging from 42 and 100%; the sensibility of MR with liver-specific
non-superparamagnetic contrast agents ranges between 64 and 98%, resulting generally su‐
perior when compared to the sensibility of CT scan, and a specificity of 75-79% [16-20].
In literature the data regarding the sensibility of the Positron Emission Tomography (PET) –
CT appear contrasting, meanwhile the specificity is considered higher than the ones ob‐
tained by contrast enhanced CT and MR [21-23].
The trans abdominal CEUS showed high values of sensibility (80-98%) and specificity
(66%-98%) for the detection of CRLM; for lesions larger than 20 mm, when sulphur-hexa‐
fluoride microbubbles (SonoVue®, Bracco, Milan, Italy) SonoVue is employed as contrast
agent, the sensibility is 100% and consequently superior to conventional ultrasound and
comparable to contrast enhanced CT [24-29]. It’s remarkable that the studies included in
these reviews regard mostly comparisons between different radiologic techniques without
the anatomo-pathologic or follow up data.
Several studies demonstrated that IOUS of the liver is useful for the intra-operative re-stag‐
ing of patients undergoing to liver resection for CRLM [7,8] and of patients undergoing to
colorectal resection of the primitive neoplasm even in absence of liver lesions detected dur‐
ing pre-operative work-up [30-31]. The superiority of the IOUS compared to pre-operative
studies in terms of sensibility leads to a modification of the surgical strategy [32]. The main
limitation of the IOUS is the difficult characterization of the nodules; it has been ridden out
after the introduction of the USCAs.
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Several studies demonstrated that the CEIOUS is the most accurate diagnostic technique for
detection and characterization of liver nodules; both the sensibility and specificity of CEI‐
OUS in studies based on the comparison with other diagnostic techniques like CT and MR
rises up to 100% and downsize the diagnostic accuracy of the pre-operative staging and
even of the IOUS [33-37].
Preliminary results of a prospective study [59] based on the comparison among CEIOUS,
CEUS, CT and RM with liver-specific contrast agent for the detection of liver metastases in
patients submitted to colorectal resection for cancer, showed that CEIOUS has higher sensi‐
bility and specificity when singularly compared to any other pre-operative technique [Table
2]. These results are consistent with the ones previously published in similar setting of pa‐
tients. In this survey, when the pre-operative work up is analysed on the whole (CT + RM +
CEUS), CEIOUS did not offer an amelioration in terms of sensibility but showed an in‐
creased value of specificity for better characterization of liver lesions. Moreover, the CEI‐
OUS modified the surgical strategy in 44.4% of patients even when the pre-operative work
up is analysed on the whole (CT + RM + CEUS).
TC RM CEUS CEIOUS
Sensibility 80% 90% 80% 100%
Specificity 93% 79% 100% 100%
Table 2. Sensibility and specificity of CT, RM, CEUS and CEIOUS
Consequently, all patients undergoing liver resection for CRLM and all patients undergoing
colorectal resection for cancer should be submitted to IOUS of the liver; moreover, among
these patients, all the ones studied during the pre-operative staging with only one radiologic
technique, all the ones studied with more than one technique reporting contrasting results
and all the ones with new hepatic nodules during IOUS should be submitted to CEIOUS.
4.2. Hepatocellular carcinoma
Studies regarding the accuracy of pre-operative radiologic examinations for HCC assessed
values of sensitivity and specificity of 60-93% and 50-95% for CT and of 52-100% and 42-97%
for MR respectively; regarding the RM the best results have been obtained employing liver-
specific contrast agents [39-40]. On the other side, it’s remarkable that the studies included
in these reviews regard mostly comparisons between different radiologic techniques with‐
out the anatomo-pathologic or follow up data.
Several studies reported that IOUS detects additional nodules in 33-41% of patients under‐
going liver resection for HCC [41-43]. In cirrhotic patients with HCC, IOUS is a useful tool to
detect new nodules but cannot differentiate malignant lesions from other liver nodules
which account for 70–80% [44]. In fact, the risk nowadays is to overestimate the tumour
stage with IOUS or laparoscopic ultrasonography considering that, except for those nodules
with mosaic ultrasonographic pattern which are malignant in 84% of cases, only 24–30% of
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hypoechoic nodules, and 0–18% of those hyperechoic are malignant [45]. To overcome this
problem even biopsy seems not to be adequate. When sulphur-hexafluoride microbubbles
(SonoVue®, Bracco, Milan, Italy), the CEIOUS analysis of nodules vascularization may pro‐
vide crucial information for their differentiation.
In this sense, Torzilli et al proposed in 2007 [41] a classification for the patterns of enhance‐
ment during CEIOUS in 4 categories: A1 (full enhancement in the arterial phase and wash-
out in the delayed phases), A2 (intralesional signs of neovascularization during all phases),
A3 (no nodular enhancement but detectability during the liver enhancement), and B (unde‐
tectability during the liver enhancement). Following this classification, resection is recom‐
mended for A1-3 nodules for high risk of malignancy and no treatment is recommended for
B nodules.
With its intra-operative re-staging, CEIOUS shows sensibility of 100%, specificity of 69-100%
and can modify the surgical strategy up to 79% of patients [41-43]. All patients undergoing
liver resection for HCC should be submitted to IOUS; moreover, all the patients carriers of
liver tumours of uncertain differentiation at pre-operative work up and all patients with
new nodules at IOUS should be submitted to CEIOUS.
5. Echo-guided liver resection
The modern liver surgery is based on two concepts: a liver resection has to be radical follow‐
ing the oncologic principles and has to be conservative in a parenchyma sparing policy [46].
Consequently the exact resection plane should be carefully planned before the resection us‐
ing the invaluable ultrasound guidance.
An ultrasound probe is  placed on the liver surface and the target lesion to be removed
has to be visualized. The surgeon draws on the liver surface the resection plane that in‐
cludes the tumour; this procedure is simplified by the usage of a linear probe, because if
the acoustic waves are parallel, to define the projection of the lesion or of the resection’s
area on the liver surface is easier (Fig). After that, the parenchymal transection can start,
but during the resection the echo-guidance should be used to check if the resection plane
is correct or has to be modified.
It’s remarkable that the oncologic principles those have to be respected can vary depending
on the type of liver tumour.
In presence of CRLM, the most important aspect regards the tumour margin. Positive hepa‐
tectomy margin has been indicated as an independent negative prognostic factor for carriers
of CRLM [47], but the minimum safe width of free margin has to be established yet. Data
regarding the presence of micro-metastases around CRLM are contrasting, reporting rates of
micro-metastases ranging from 2% to 58% of patients; consequently, these authors suggest‐
ed different widths of free margin ranging from 2 to 10 mm [48,49]. If the presence of micro-
metastases around a CRLM could be related to the cytoreduction after some type
chemotherapy has to be clarified yet. The rate of cut edge recurrence is reported to be up to
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tectomy margin has been indicated as an independent negative prognostic factor for carriers
of CRLM [47], but the minimum safe width of free margin has to be established yet. Data
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13.3% for a margin inferior to 2 mm, but if the surgical margin could represents a prognostic
factor for patients survival is still debated [48,49]. Anyway, all the authors agree that micro-
metastases are confined to a short distance from the tumour (mostly less than 5-10 mm) and
that a tumour margin of 10 mm is safe without risk of cut-edge recurrence. The more rea‐
sonable approach for carriers of CRLM should be to guarantee a 10 mm margin when possi‐
ble, so the surgeon during the echo-guided definition of the resection plane should consider
this margin. Anyway, because liver resection plus chemotheraphy provides the best chance
of cure for carriers of CRLM, complete removal of the tumour with a minimum margin
(even less than 2 mm) is justified when technically unavoidable for tumours size, location or
number. This aspect is of paramount importance in presence of tumours next to or in contact
with major vessels; in these cases, in absence of clear signs of vascular invasion at the IOUS,
the vessel resection and consequent major liver resection should be avoided, offering with a
parenchyma sparing policy lower post-operative morbidity and mortality. Moreover the
avoidance of major hepatectomy allows the possibility of further repeated hepatectomies in
patients with disease recurrence, those have shown similar morbidity and mortality com‐
pared to first hepatectomy [50].
In presence of HCC, the most important aspect regards the type of surgical resection to be
performed, anatomic or non-anatomic. Anatomic resection should be considered the gold
standard approach for liver resection in patients with HCC, meanwhile non-anatomic resec‐
tion should be indicated only in selected patients with HCC set on cirrhosis with poor liver
function. Indeed, tumour dissemination from the main lesion through the portal branches
demands an anatomic approach with removal of at least the portal area which includes the
lesion. The surgical margin per se does not represent a main aspect, because an anatomic
resection (segmentectomy or sub-segmentectomy) can be considered adequate even in pres‐
ence of a narrow margin, while a non-anatomic resection of a nodule with a 10 or even 20
mm margin could be inadequate if the portal branch feeding the nodule has not be removed.
HCCs are usually associated with liver cirrhosis, and several series reported that liver resec‐
tion in cirrhotic patients is related to not negligible postoperative mortality and morbidity
[51,52]. The main problem to overcome when planning a surgical approach is to find a bal‐
ance between the liver volume to be resected, which should be drastically reduced, and the
need to perform, if possible, an anatomic resection. The use of IOUS as guidance is indispen‐
sable in this sense, but there are several methods up to now available for this procedure. The
most diffused technique is the puncture technique proposed by Makuuchi et al in 1981
[53,54]. With this technique, the portal branch feeding the tumour to be resected is punc‐
tured under IOUS-guidance, through a free-hand technique or with a proper device, and
then dye (usually indigo-carmine) is injected into the vessel while the hepatic artery at the
hepatic hilum is clamped. The stained area becomes evident on the liver surface, it is
marked with the electrocautery, and hepatic artery clamping is released. The main disad‐
vantage of this technique, other than the quite high skill in puncturing millimetric vessels, is
the fact that if the ink regurgitates or is injected into the wrong portal branch, it could be
difficult to identify the proper area to be removed. Furthermore, clamping of the hepatic ar‐
tery is recommended but not always feasible without the need for a hilar dissection to tape
the vessel to be clamped. Other methods have been proposed such as a balloon catheter in‐
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serted transhepatically to occlude the feeding portal branch [55], or, more recently, through
the mesenteric vein [56]. Mazziotti et al. proposed for segment 8 resection the division of the
liver along the main portal fissure, and subsequently to approach the segment 8 glissonian
pedicle intraparenchymally [57]. Santambrogio et al. have even recently suggested ablation
of the feeding portal and arterial branches [58].
More recently Torzilli et al. proposed the ultrasound-guided finger compression technique,
consisting in the demarcation of the resection area (segmental either subsegmental) by
IOUS-guided finger compression of the vascular pedicle feeding the tumor at the level clos‐
est to the tumour but oncologically suitable. This maneuver is constantly monitored in real-
time by simply using the same IOUS probe and it is maintained until the surface of the
targeted liver area begins to discolor and can be easily marked with the electrocautery [59].
Torzilli’s technique offers several advantages, including the non-invasiveness (no intravas‐
cular catheter) and rapid reversibility, and consequently can be repeated if necessary.
In general, any other type of primitive or metastatic liver tumours, when a surgical treat‐
ment is indicated, can be managed by means of a surgical resection with adequate margins,
but in literature data concerning other specific tumours are still lacking.
One more and recent application of IOUS in hepatic surgery concerns the management of
liver tumours involving an hepatic vein (HV) next to the caval confluence. These lesions tra‐
ditionally require a major hepatectomy, with resection of the involved vein and the portion
of parenchyma drained by that vein. Nevertheless, as previously reported, morbidity and
mortality after major hepatic resections are not negligible, especially in cirrhotic patients
[51,52]. A careful intra-operative study of the liver anatomy can offer alternatives to major
hepatectomy. In 1987 Makuuchi M et al. introduced a new hepatectomy procedure for resec‐
tion of the right hepatic vein (when invaded by a tumour) and preservation of the inferior
right hepatic vein, an accessory hepatic vein draining segment VI present in 20-25% of pa‐
tients [60]. Then, in 2010 Torzilli et al. suggested a set of criteria to be met for a parenchyma-
sparing liver resection in presence of liver tumours invading any HV at its caval confluence
[61]. The criteria are based on the direct or indirect signs of presence of venous anastomoses
connecting adjacent HV, those had been previously highlighted in 1958 by Couinaud C et al.
during studies performed on liver specimens [62] and can now be detected intra-operatively
during IOUS [63].
A segment of a HV can be resected while avoiding the removal of the complete portion of
the liver drained by that vein when, during HV finger compression at the hepatocaval con‐
fluence, at least one of these criteria is satisfied:
1. Reversal flow direction in the peripheral portion of the hepatic vein to be removed,
which suggests drainage through collateral circulation in adjacent HV or inferior cava
vein (IVC)
2. Hepatopetal flow in the portal branch feeding the areas to be spared
3. Detectable connecting veins with adjacent HV or IVC
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demands an anatomic approach with removal of at least the portal area which includes the
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It is remarkable how every surgical procedure performed on the liver is strictly depend‐
ent from the knowledge of the liver anatomy and from the ultrasounds; definitely in liv‐
er  surgery  the  ultrasounds  represent  the  link  between  the  surgical  anatomy  and  the
surgical intervention.
6. Laparoscopic ultrasound
Due to improvements in technologies and increasing surgeon's experiences, the number of
hepatectomy performed laparoscopically increased exponentially around the world in the
recent years, and consequently the usage of laparoscopic ultrasound (LUS) of the liver [64].
Main goals of LUS are the same of ones presented in open liver surgery; anyway LUS has a
few theoretical drawbacks if compared to traditional IOUS, including the difficulty in the ul‐
trasound study of the superior and posterior segments and the limited diffusion of laparo‐
scopic probe equipped for the contrast enhanced study.
Other indications to LUS include the re-staging before laparotomic liver surgery or before
laparoscopic resection of gastrointestinal cancer (more frequently of colorectal cancer). Diag‐
nostic laparoscopy combined with LUS is considered an adequate staging modality for pri‐
mary liver malignancies and permits to avoid unnecessary laparotomies [65]. Nevertheless,
the LUS seems to play a limited role in staging patients with potentially resectable CRLM
candidates for open liver resection; this is owing mainly to the low sensitivity rate of 59%
[66]. Consequently there may be a role for laparoscopy for diagnosing suspected peritoneal
disease, but LUS should not be used routinely in patients with CRLM candidates for open
liver resection.
The LUS of the liver at the time of primary resection of colorectal cancer is reported to yield
more lesions than preoperative contrast-enhanced computerized tomography and could be
considered for routine use during laparoscopic oncologic colorectal surgery [67].
One further indication for LUS is laparoscopic radiofrequency in patients carriers of HCC
and not amenable to liver resection or percutaneous ablation; in these patients, LUS is an in‐
valuable tool, either in the pre-treatment imaging to re-stage the patient, evaluate the rela‐
tionship of the tumour with the surrounding structures and to guide the insertion of the
electrode into the tumour, either for the post-treatment imaging evaluation [68].
7. Conclusions
Ultrasonography is an invaluable tool in hepatic surgery, either for the intra-operative re-
staging, either for the guidance during the surgical procedure. The only major drawback of
this IOUS-guided liver surgery is the need for hepatic surgeons to be trained in the use of
ultrasound. Indeed, to be fully profitable, IOUS and CEIOUS should be carried out by the
surgeon himself who can then use the information obtained by the ultrasound exploration
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in a surgical perspective. Organization of a training program for liver surgeons is far from
being carried out worldwide, but it should be considered a main goal for hepato-biliary sur‐
geons, because the liver surgeons must be equipped with ultrasound skills as like as with
surgical technical skills.
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Segmental Oriented Liver Surgery
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Additional information is available at the end of the chapter
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1. Introduction
Understanding the vascular and biliary anatomy of the liver is mandatory for a successful
anatomical liver resection. It is also extremely important in complex liver operations, althaugh
it might not be in cases of simple wedge resection for benign disease. As the presence of HCC
is usually in the background of liver cirrhosis, the importance of anatomical resection to be
able to clear the tumour and have sufficient amount of liver to avoid post-operative liver
failure. In this chapter we will try to illustrate the importance of anatomical liver resection and
give an idea of the latest liver anatomy with a demonstration on how to identify and resect
each part of the liver.
2. Why anatomical liver resection
As many general surgeons might like to do wedge non anatomical liver resections because it
is less complicated and gets the tumour out. There are several reasons to perform anatomical
resection:
1. In Hepato-Cellular carcinoma (HCC) which is the most common reason to perform liver
resections, were it is the first line of treatment nowadays [1,2]. As the HCC are able to
invade the portal veins and disseminate through its inter segmental branches [3] (cough
reflux), segmentectomy is preferable. Intrahepatic metastasis [4,5] and invasion to the
portal and hepatic venous system will affect the post operative prognosis. To improve the
post surgical outcome the segmental liver resection is indicated. It involves the removal
of the whole segment containing the tumor with its vasculature which might be affected
by the tumor invasion [1,4 - 6]. Satellite micro metastasis will also be removed as their
feeding vessel for that segment [3].
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1. Introduction
Understanding the vascular and biliary anatomy of the liver is mandatory for a successful
anatomical liver resection. It is also extremely important in complex liver operations, althaugh
it might not be in cases of simple wedge resection for benign disease. As the presence of HCC
is usually in the background of liver cirrhosis, the importance of anatomical resection to be
able to clear the tumour and have sufficient amount of liver to avoid post-operative liver
failure. In this chapter we will try to illustrate the importance of anatomical liver resection and
give an idea of the latest liver anatomy with a demonstration on how to identify and resect
each part of the liver.
2. Why anatomical liver resection
As many general surgeons might like to do wedge non anatomical liver resections because it
is less complicated and gets the tumour out. There are several reasons to perform anatomical
resection:
1. In Hepato-Cellular carcinoma (HCC) which is the most common reason to perform liver
resections, were it is the first line of treatment nowadays [1,2]. As the HCC are able to
invade the portal veins and disseminate through its inter segmental branches [3] (cough
reflux), segmentectomy is preferable. Intrahepatic metastasis [4,5] and invasion to the
portal and hepatic venous system will affect the post operative prognosis. To improve the
post surgical outcome the segmental liver resection is indicated. It involves the removal
of the whole segment containing the tumor with its vasculature which might be affected
by the tumor invasion [1,4 - 6]. Satellite micro metastasis will also be removed as their
feeding vessel for that segment [3].
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Anatomic liver resection is superior to non anatomic from the oncologic and anatomic aspects
[7]. Anatomically based hepatectomy is the best means of achieving a negative margin[8].The
recurrence rate within 2 years associated with aggressive tumor biology such as high tumor
grade, satellite lesions and microvascular invasion [7], is higher in non anatomical resection.
In small HCC <4cm anatomic resection achieves better disease-free survival than limited
resection without increasing the postoperative risk [9-10].
The overall survival and the disease-free survival rates were significantly better in the anatomic
resection compared to the non anatomic resection group [1,11-12],as well as the recurrence
disease free survival [10].
A meta-regression analysis was done and published in June 2012 that was conducted on 9036
patients from 1990-2011 and demonstrated that the 5 years disease free survival and the 5 year
survival was significantly better in the anatomic resection group than the non anatomic
resection group with no effect on the post operative mortality and morbidity[13].
2. Less bleeding with almost no need for transfusion in the intra-operative period as there
is no transaction of the vessels. Also there is few vessels present in the inter segmental
planes. Relatively the inter segmental area is a non-vascular plane, so segmental identi‐
fication, control of the feeding vessels and the vascular pedicle will decrease the blood
loss. This is one of the direct causes of decreased post operative morbidities and mortalities
[3,14 - 16].
3. Segmental resection will preserve as much of the liver parenchyma [3] and will enable
sufficient liver volume especially in cirrhotic patients [16] and in patients with multiple
liver lesions [17] or in patients who will need another resection in the future. Also it will
decrease the post operative liver insufficiency from small liver remnant in cirrhotic
patients [3,14,15,16].
4. In colorectal metastasis segmental resection is superior to non anatomical resection as it
results in better tumour clearance and free margins. Multiple studies demonstrated that
it did affect the disease free survival, and the control of micro-metastasis through
segmental portal branches. Segmentectomy offered disease-free and overall survival rates
similar to those after major resection. [3,14]
For metastasis it has been found that with wedge resection the recurrence rate and positive
margins were higher compared to the segmental resection. This resulted in inadequate tumour
resection especially in deep lesions where the incidence of inadvertently cutting into the
tumour is higher. Also the bleeding rate is high due to the difficult control of the venous
branches that will obscure the resection plane.
Wedge resections are usually inadequate and potentially dangerous, especially for large
tumours, and are often associated with greater blood loss and a greater incidence of positive
histological margins.[8,11]. Liver failure due to parynchymal necrosis or small liver remnant
are observed in non anatomical (wedge) liver resection. It also results in higher incidence of
biliary fistula and infection because of the remnant devitalized liver tissue [18].
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Non-anatomical liver resection (Wedge) can be done in certain circumstances; in resections
where the tumour is small (<3cm) and located peripherally at the edge of a cirrhotic liver or
when the tumour is situated at the border of several segments and its resection requires the
removal of large volume which is not possible due to the liver status.
Also, in cases of benign liver resection were no safety margin is required and the surgeon
would like to preserve as much liver volume as possible, so the lesion can be enucleated.
However, care should be taken not to injure nearby vessels or bile ducts.
3. Segmental liver anatomy
3.1. The history
The understanding of liver segments was first established in 1953 by Healy [19] and was further
reinforced by Couinaud in 1957 [20]. When trying to understand their description it might be
somewhat confusing, however we will try to make it as simple as possible.
They both used the new division by Cantlie who disapproved the old terminology of the right
and left liver which was divided by the falciform ligament and used his description of the right
and left liver divided by the midline which is oblique and extended from the gallbladder bed
to the right side of the inferior vena cava. Healy then divided the liver using the arteriobiliary
segmentation. This lead to the division of the right liver into the two segments, the right
anterior and the right posterior segments (called now sections). The left side was divided by
the falciform into the left medial and left lateral segments (called now sections). However,
Couinaud used the hepatic veins and divided the right liver into right anterior and right
posterior sectors. The left side was divided by the left hepatic vein into the left medial and left
lateral sectors, and the middle hepatic vein was running in the midplane of the liver (Cantile
line). Then recently the terminology of segments that was described by Healy was changed to
sections leading the way to the word section and sector that you see in all papers involving
the liver anatomy. They both divided these sectors or sections to segments according to the
portal vein anatomy and we reached to our 8 segments that we know today. Figure.1
When looking at these two description you will find that both agreed on the anatomy of the
right liver cause there was no difference between the right anterior (segment 5&8) and the right
posterior (segments 6&7) section or sector. However, on the left side there was a difference,
because of the anatomical variations and we believe this is what led to this misunderstanding.
The left medial section (segment 4) is not the same as the left medial sector (segment 3&4), and
the left lateral section (segment 2&3) is not the same as the left lateral sector (segment 2). They
also both agreed on the separation of segment 1 (caudate Lobe) as it has its own blood supply
and drains directly to the inferior vena cava.
Another thing when looking to the terminology is the word “Lobe”. Some authors use the term
left lobectomy to describe the resection of segments 2&3, which is the functional left lateral
section. Also the right lobe as segments 4 to 8 were it is an extended right trisectionectomy.
Segmental Oriented Liver Surgery
http://dx.doi.org/10.5772/51775
225
Anatomic liver resection is superior to non anatomic from the oncologic and anatomic aspects
[7]. Anatomically based hepatectomy is the best means of achieving a negative margin[8].The
recurrence rate within 2 years associated with aggressive tumor biology such as high tumor
grade, satellite lesions and microvascular invasion [7], is higher in non anatomical resection.
In small HCC <4cm anatomic resection achieves better disease-free survival than limited
resection without increasing the postoperative risk [9-10].
The overall survival and the disease-free survival rates were significantly better in the anatomic
resection compared to the non anatomic resection group [1,11-12],as well as the recurrence
disease free survival [10].
A meta-regression analysis was done and published in June 2012 that was conducted on 9036
patients from 1990-2011 and demonstrated that the 5 years disease free survival and the 5 year
survival was significantly better in the anatomic resection group than the non anatomic
resection group with no effect on the post operative mortality and morbidity[13].
2. Less bleeding with almost no need for transfusion in the intra-operative period as there
is no transaction of the vessels. Also there is few vessels present in the inter segmental
planes. Relatively the inter segmental area is a non-vascular plane, so segmental identi‐
fication, control of the feeding vessels and the vascular pedicle will decrease the blood
loss. This is one of the direct causes of decreased post operative morbidities and mortalities
[3,14 - 16].
3. Segmental resection will preserve as much of the liver parenchyma [3] and will enable
sufficient liver volume especially in cirrhotic patients [16] and in patients with multiple
liver lesions [17] or in patients who will need another resection in the future. Also it will
decrease the post operative liver insufficiency from small liver remnant in cirrhotic
patients [3,14,15,16].
4. In colorectal metastasis segmental resection is superior to non anatomical resection as it
results in better tumour clearance and free margins. Multiple studies demonstrated that
it did affect the disease free survival, and the control of micro-metastasis through
segmental portal branches. Segmentectomy offered disease-free and overall survival rates
similar to those after major resection. [3,14]
For metastasis it has been found that with wedge resection the recurrence rate and positive
margins were higher compared to the segmental resection. This resulted in inadequate tumour
resection especially in deep lesions where the incidence of inadvertently cutting into the
tumour is higher. Also the bleeding rate is high due to the difficult control of the venous
branches that will obscure the resection plane.
Wedge resections are usually inadequate and potentially dangerous, especially for large
tumours, and are often associated with greater blood loss and a greater incidence of positive
histological margins.[8,11]. Liver failure due to parynchymal necrosis or small liver remnant
are observed in non anatomical (wedge) liver resection. It also results in higher incidence of
biliary fistula and infection because of the remnant devitalized liver tissue [18].
Hepatic Surgery224
Non-anatomical liver resection (Wedge) can be done in certain circumstances; in resections
where the tumour is small (<3cm) and located peripherally at the edge of a cirrhotic liver or
when the tumour is situated at the border of several segments and its resection requires the
removal of large volume which is not possible due to the liver status.
Also, in cases of benign liver resection were no safety margin is required and the surgeon
would like to preserve as much liver volume as possible, so the lesion can be enucleated.
However, care should be taken not to injure nearby vessels or bile ducts.
3. Segmental liver anatomy
3.1. The history
The understanding of liver segments was first established in 1953 by Healy [19] and was further
reinforced by Couinaud in 1957 [20]. When trying to understand their description it might be
somewhat confusing, however we will try to make it as simple as possible.
They both used the new division by Cantlie who disapproved the old terminology of the right
and left liver which was divided by the falciform ligament and used his description of the right
and left liver divided by the midline which is oblique and extended from the gallbladder bed
to the right side of the inferior vena cava. Healy then divided the liver using the arteriobiliary
segmentation. This lead to the division of the right liver into the two segments, the right
anterior and the right posterior segments (called now sections). The left side was divided by
the falciform into the left medial and left lateral segments (called now sections). However,
Couinaud used the hepatic veins and divided the right liver into right anterior and right
posterior sectors. The left side was divided by the left hepatic vein into the left medial and left
lateral sectors, and the middle hepatic vein was running in the midplane of the liver (Cantile
line). Then recently the terminology of segments that was described by Healy was changed to
sections leading the way to the word section and sector that you see in all papers involving
the liver anatomy. They both divided these sectors or sections to segments according to the
portal vein anatomy and we reached to our 8 segments that we know today. Figure.1
When looking at these two description you will find that both agreed on the anatomy of the
right liver cause there was no difference between the right anterior (segment 5&8) and the right
posterior (segments 6&7) section or sector. However, on the left side there was a difference,
because of the anatomical variations and we believe this is what led to this misunderstanding.
The left medial section (segment 4) is not the same as the left medial sector (segment 3&4), and
the left lateral section (segment 2&3) is not the same as the left lateral sector (segment 2). They
also both agreed on the separation of segment 1 (caudate Lobe) as it has its own blood supply
and drains directly to the inferior vena cava.
Another thing when looking to the terminology is the word “Lobe”. Some authors use the term
left lobectomy to describe the resection of segments 2&3, which is the functional left lateral
section. Also the right lobe as segments 4 to 8 were it is an extended right trisectionectomy.
Segmental Oriented Liver Surgery
http://dx.doi.org/10.5772/51775
225
This description was based on the anatomical land mark of the liver using the falciform
ligament and not the functioning liver segments as described above.
3.2. The new terminology
The use of many different terminologies and difficulty in understanding the description
described above, were the European societies adopted Couinaud’s description and the
American societies used the Healy’s description. So the scientific committee of the Interna‐
tional Hepato-Pancreato-Biliary Association with experts around the world came up with the
Brisbane 2000 Terminoloy of Liver Anatomy and resection which we have been using and will
use for our description in this chapter [21].
To understand this terminology, first the liver is divided into two parts, the main liver and the
caudate lobe (called the dorsal sector by Cauinaud). Then the main liver is divided into the
right and left liver.
This part is called the first order division, where the liver is divided into the right liver or right
hemiliver, and the left liver or the left hemiliver. Notice the word lobe has been removed
completely for the confusion we mentioned above, so the resection of the right side is called
right hepatectomy or right hemihepatectomy (segments 5 to 8). The left side is called; left
hepatectomy or left hemihepatectomy (segments 2 to 4). Figure.2
The second order division, where the right liver is divided into two parts. The right anterior
section giving the right anterior sectionectomy (segment 5&8), the right posterior section
leading to the resection of the right posterior sectionectomy (segments 6&7). On the left side
there will be the left medial section giving the left medial sectionectomy (segment 4), and the
left lateral section leading to the resection of the left lateral sectionectomy (segment 2&3).
Figure.3
through segmental portal branches. Segmentectomy offered disease-free and overall survival rates similar to those after major 
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6&7). On the left side there will be the left medial section giving the left medial sectionectomy (segment 4), and the left lateral 
section leading to the resection of the left lateral sectionectomy (segment 2&3). Figure.3  
 
Figure 3. Sections Green: right posterior, orange: right anterior Yellow: left medial, red: left lateral 
The third order division, is the division of each of these sections into segments as we mentioned above. The resection of any of 
these segments is called a segmentectomy and if two or more segments were resected that are not related as described in the 
second order division it is called bisegmentectomy or trisegmentectomy. This should not be coinfused with the trisectionectomy of 
the right or left side were we resect three sections and not segments. Figure.4 
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The third order division, is the division of each of these sections into segments as we mentioned
above. The resection of any of these segments is called a segmentectomy and if two or more
segments were resected that are not related as described in the second order division it is called
bisegmentectomy or trisegmentectomy. This should not be coinfused with the trisectionecto‐
my of the right or left side were we resect three sections and not segments. Figure.4
 
Figure 4. Segments, each with a different color 
An addition was added also if the word sector were to be used instead of section. This is the same on the right side and on the left 
we had a left medial sector with a left medial secterectomy (segment 3&4), and the left lateral sector giving rise to the resection of 
the left lateral secterectomy (segment 2). So the term section or sector has to be used very cautiously on the left side to describe 
exactly what you mean. 
2.3. Clinical applications 
1. As each liver segment can be resected separately, liver resection can be segment based 
2. Segement 4, is divided into 4A and 4B. This was made because of multiple indications were segment 4A is rsected without 
the resection of segment 4B like in cases of gallbladder cancer. Also the resection of segment 4A is counted as the most 
difficult liver resection as it lies between the middle and the left hepatic vein. 
3. This terminology has gained wide acceptance and has removed most of the confusion that use to exist in the past. 
2.4. Intrahepatic glissonian triads 
The extra hepatic portal triad is consisted of the portal vein, the hepatic artery and the common hepatic duct. These structures are 
enclosed in a connective tissue and peritoneum up to the hepatic hilum. The term Glissonian sheath is reserved for the part that 
extendeds into the intrahepatic portion of the liver beyond the hilum. This sheath surrounds the portal triad structure before they 
enter into each section, giving rise to the resection of each segment (liver unit) separately without affecting the other segments [22]. 
This gives rise to the aberrance of the central segments 4, 5 and 8 ramifications like a bush and fan shaped. Consequently, a single 
segment resection will require several Glissonian sheath at various depth and is much more difficult. Were the priphral segments 6, 
7, 2 and 3 have long branches that travels a distance reaching to these segments giving the appearance of tree like making their 
resection less complicated and usually requiring a single Glissonian sheath ligation [23]. 
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3.4. Intrahepatic glissonian triads
The extra hepatic portal triad is consisted of the portal vein, the hepatic artery and the common
hepatic duct. These structures are enclosed in a connective tissue and peritoneum up to the
hepatic hilum. The term Glissonian sheath is reserved for the part that extendeds into the
intrahepatic portion of the liver beyond the hilum. This sheath surrounds the portal triad
structure before they enter into each section, giving rise to the resection of each segment (liver
unit) separately without affecting the other segments [22]. This gives rise to the aberrance of
the central segments 4, 5 and 8 ramifications like a bush and fan shaped. Consequently, a single
segment resection will require several Glissonian sheath at various depth and is much more
difficult. Were the priphral segments 6, 7, 2 and 3 have long branches that travels a distance
reaching to these segments giving the appearance of tree like making their resection less
complicated and usually requiring a single Glissonian sheath ligation [23].
3.5. Portal vein and liver resection
On the right side the portal vein is similar to the arteriobiliary segmentation. On the left side
they differ from each other. The left portal vein consists of a transverse and an umbilical
portion. The transverse portion only sends small branches to segment 4 and one or two
branches to segment 1. All the larger branches arise beyond the attachment of the ligamentum
venosum (umbilical portion of the left portal vein). Figure.5. This part of the vein gives right
branches to segment 4 and on the left side it gives one branch to segment 2 and more than one
to segment 3. The portal vein terminates where it joins the ligamentum teres at the edge of the
liver. This unique structure explains the duael function of the left portal vein during in-utero
and then in-adult life.
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Figure 5. Portal vein with its divisions 
On the right side the portal vein is usually very short and gives rise to the right anterior and right posterior branches. Each of these 
branches gives rise to two main segmental divisions. The right anterior gives both segment 5 and 8, where the right posterior gives 
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On the right side the portal vein is usually very short and gives rise to the right anterior and
right posterior branches. Each of these branches gives rise to two main segmental divisions.
The right anterior gives both segment 5 and 8, where the right posterior gives segment 6 and
7. Figure.6.
 
Figure 6. A) right anterior portal branch (RAP) B) right posterior portal branch (RPP) 
Usually there are very little variations in the portal vein. The commonest one is where the right anterior branch joins the left portal 
vein. This is very important to recognise especially when doing a left hepatectomy causes injury could happen to the right anterior 
section leading to the loss of segments 5 and 8. Another common anomaly is the absence of the main right portal vein giving rise to 
a trifurcation at the hilum of the portal vein to the left main, right anterior and the right posterior branches. This is important when 
doing a right hepatectomy to transect each branch separately not to injure the left portal vein [24-25]. 
3. Clinical identification of the liver segments 
For the clinical description of this part we will try to simulate what happens in clinical practice by dividing it to pre-operative 
radiology and intra-operative by intra-operative ultrasound.  
3.1. Pre-operative 
To try and make this part as simple as possible for the reader we will try to identify land marks that you should look for in the 
ultrasound, CT or MRI. The ultrasound is the usual screening tool used to see the whole liver and identify cystic from solid lesions. 
Then most centres will request a Triphasic CT scan of the liver in the hope to identify the nature of the lesion and the location. A 
physician should not comment on any lesion seen until full examination of all three phases (arterial, venous and delayed) are 
examined and the lesion is seen on all three phases to give the best chance of reaching the right diagnosis.  
As we described the anatomy of the liver by the first order division and its landmark the middle hepatic vein, it is the same here. 
The middle hepatic vein can be seen on any of the above mentioned x-ray investigation. This will lead to the division of the liver to 
the right and left liver and identifying the lesion in which liver it lies. Figure.7.  
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by dividing it to pre-operative radiology and intra-operative by intra-operative ultrasound.
4.1. Pre–operative
To try and make this part as simple as possible for the reader we will try to identify land marks
that you should look for in the ultrasound, CT or MRI. The ultrasound is the usual screening
tool used to see the whole liver and identify cystic from solid lesions. Then most centres will
request a Triphasic CT scan of the liver in the hope to identify the nature of the lesion and the
location. A physician should not comment on any lesion seen until full examination of all three
phases (arterial, venous and delayed) are examined and the lesion is seen on all three phases
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As we described the anatomy of the liver by the first order division and its landmark the middle
hepatic vein, it is the same here. The middle hepatic vein can be seen on any of the above
mentioned x-ray investigation. This will lead to the division of the liver to the right and left
liver and identifying the lesion in which liver it lies. Figure.7.
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Figure 7. Middle hepatic vein (MHV) A) CT B) Ultrasound
The next step is to identify the falciform ligament and the right hepatic vein. This will divide
the left liver to the medial and lateral sections and the right liver to the anterior and posterior
sections alternatively. By this any lesion will be clearly seen in each section of the hemi-liver.
Figure.8.
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Figure 8. A) right hepatic vein (RHV) – with a lesion in seg 7 B) falciform (FL) 
The last step is to identify the main portal vein and follow it till you reach to the bifurcation of the right and left branches which 
corresponds to the line that divides the liver into the upper and lower segments. This will give rise to the division of each section to 
its corresponded segments as described before in the anatomy part Figure.9. 
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7. Figure.6.
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The last step is to identify the main portal vein and follow it till you reach to the bifurcation
of the right and left branches which corresponds to the line that divides the liver into the upper
and lower segments. This will give rise to the division of each section to its corresponded
segments as described before in the anatomy part Figure.9.
 
Figure 9. Main portal vein (MPV), with a lesion seen in the right posterior lower segment (segment6) 
If this simple technique is adopted a full idea of the lesions identity and location could be achieved with a high degree of certainty 
making the surgical planning much more feasible. Figure.10. 
 
Figure 9. Main portal vein (MPV), with a lesion seen in the right posterior lower segment (segment6)
If this simple technique is adopted a full idea of the lesions identity and location could be
achieved with a high degree of certainty making the surgical planning much more feasible.
Figure.10.
 
Figure 9. Main portal vein (MPV), with a lesion seen in the right posterior lower segment (segment6) 
If this simple technique is adopted a full idea of the lesions identity and location could be achieved with a high degree of certainty 
making the surgical planning much more feasible. Figure.10. 
 
Figure 10. All segments identified on CT pre-opretive
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4.2. Intra–operative
This is usually carried out by the intra-operative ultrasound [26-30], which we believe no
liver  resection  should  be  done  without  mastering  its  use  especially  in  malignant  liver
lesions. There are six simple steps that should be followed to get the best results of the
ultrasound. 1)  General  inspection the whole liver as CT is  not  the ideal  tool  to identify
superficial liver lesions. 2) A systemic recognition of all three hepatic veins and the main
portal veins with its branches to identify all the liver segments. 3) Localize the tumour and
determine which segments are involved. 4) Determine which segments needs to be resected
to achieve good margins and balance it with the state of the liver trying at all times to go
thru the anatomical lines to get an anatomical liver resection when possible to achieve the
advantages  mentioned  before.  5)  Mark  the  liver  resection  line  on  the  liver  surface.  6)
Redetermine the distance from the tumour and the resection lines to be certain not to be
close or even worse go thru the lesion.
To identify the segments the same method that was done pre-operative on CT is adopted by
the localisation of the middle hepatic vein and drawing a line on it to get the right and left
livers. Figure.11.
Figure 10. All segments identified on CT pre-opretive 
3.2. Intra-operative 
This is usually carried out by the intra-operative ultrasound [26-30], which we believe no liver resection should be done without 
mastering its use especially in malignant liver lesions. There are six simple steps that should be followed to get the best results of 
the ultrasound. 1) General inspection the whole liver as CT is not the ideal tool to identify superficial liver lesions. 2) A systemic 
recognition of all three hepatic veins and the main portal veins with its branches to identify all the liver segments. 3) Localize the 
tumour and determine which segments are involved. 4) Determine which segments needs to be resected to achieve good margins 
and balance it with the state of the liver trying at all times to go thru the anatomical lines to get an anatomical liver resection when 
possible to achieve the advantages mentioned before. 5) Mark the liver resection line on the liver surface. 6) Redetermine the 
distance from the tumour and the resection lines to be certain not to be close or even worse go thru the lesion. 
To identify the segments the same method that was done pre-operative on CT is adopted by the localisation of the middle hepatic 
vein and drawing a line on it to get the right and left livers. Figure.11. 
 
Figure 11. Intra operative ultrasound middle hepatic vein. A) longitudinal   B) sagetal 
The falciform ligament which divides the left liver to the medial and lateral sections can be seen on the surface. The left hepatic 
vein that divides segment 2 and 3 can be identified. On the right side the right hepatic vein is seen and a line is made to divide the 
right liver to the anterior and posterior sections. Figure.12. Figure 11. Intra operative ultrasound middle hepatic vein. A) longitudinal B) sagetal
The falciform ligament which divides the left liver to the medial and lateral sections can be
seen on the surface. The left hepatic vein that divides segment 2 and 3 can be identified. On
the right side the right hepatic vein is seen and a line is made to divide the right liver to the
anterior and posterior sections. Figure.12.
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The last step is to identify the main portal vein and follow it till you reach to the bifurcation
of the right and left branches which corresponds to the line that divides the liver into the upper
and lower segments. This will give rise to the division of each section to its corresponded
segments as described before in the anatomy part Figure.9.
 
Figure 9. Main portal vein (MPV), with a lesion seen in the right posterior lower segment (segment6) 
If this simple technique is adopted a full idea of the lesions identity and location could be achieved with a high degree of certainty 
making the surgical planning much more feasible. Figure.10. 
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Figure 10. All segments identified on CT pre-opretive
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4.2. Intra–operative
This is usually carried out by the intra-operative ultrasound [26-30], which we believe no
liver  resection  should  be  done  without  mastering  its  use  especially  in  malignant  liver
lesions. There are six simple steps that should be followed to get the best results of the
ultrasound. 1)  General  inspection the whole liver as CT is  not  the ideal  tool  to identify
superficial liver lesions. 2) A systemic recognition of all three hepatic veins and the main
portal veins with its branches to identify all the liver segments. 3) Localize the tumour and
determine which segments are involved. 4) Determine which segments needs to be resected
to achieve good margins and balance it with the state of the liver trying at all times to go
thru the anatomical lines to get an anatomical liver resection when possible to achieve the
advantages  mentioned  before.  5)  Mark  the  liver  resection  line  on  the  liver  surface.  6)
Redetermine the distance from the tumour and the resection lines to be certain not to be
close or even worse go thru the lesion.
To identify the segments the same method that was done pre-operative on CT is adopted by
the localisation of the middle hepatic vein and drawing a line on it to get the right and left
livers. Figure.11.
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Figure 11. Intra operative ultrasound middle hepatic vein. A) longitudinal   B) sagetal 
The falciform ligament which divides the left liver to the medial and lateral sections can be seen on the surface. The left hepatic 
vein that divides segment 2 and 3 can be identified. On the right side the right hepatic vein is seen and a line is made to divide the 
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Figure 12. Intra operative ultrasound right hepatic vein. 
The portal vein is then identified and followed to get all its branches and a line is made horizontally to get the upper and lower 
segments of the liver. Figure.13. After connecting all these lines the liver segments will be seen on the surface with the exception of 
segment 1 which is separate as we indicated before and can be seen over the IVC as the caudate lobe [31]. Figure.14 
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The portal vein is t en id ntified and followed o get all its branches and a line is made
horizontally to get  the upper and lower segments of  the liver.  Figure.13.  After connect‐
ing all  these  lines  the  liver  segments  will  be  seen on the  surface  with  the  exception of
segment 1 which is separate as we indicated before and can be seen over the IVC as the
caudate lobe [31]. Figure.14
 
Figure 13. A) Right Portal veins (RPV) and its bifurcation to right anterior (RAPV) and right posterior (RPPV). B) Left portal vein (LPV) with its 
segmental branches  
 
Figure 13. A) Righ  Portal veins (RPV) and its bifurcation to right anteri r (RAPV) and right posterior (RPPV). B) Left
portal vein (LPV) with its segmental branches
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Figure 14. Liver segments on the liver intra operatively Portal vein (PV) in weight, middle hepatic vein (MHV), falciform
ligament (FL), right hepatic vein (RHV)
5. Liver resection
A full pre-operative evaluation is necessary before embarking on a liver resection especially
that most of the patients with HCC are also cirrhotic. There are multiple models to evaluate
these patients and the most widely used one is the Child-Pugh score. This model stratifies
patients into stage A, B, and C. Also the size of the tumour and the patient’s physiological
function are very important. Therefor most recent staging systems for HCC has included three
important factors to evaluate the patient before any liver resection, the tumour, the liver status
and the patient factor. Although chronic liver disease is not an absolute contraindication to
liver resection, the morbidity and mortality increases prohibitively with increasing hepatic
dysfunction. Childs class C or late B patients are generally excluded from major resections
whereas Childs A or early B patients may be candidates [8,31].
As we mentioned above radiological studies are important in determining the presence of
portal hypertension, ascitis, tumour localization, feasibility of the resection, tumour extension,
distance from the pedicles and segments necessary to be resected as well as extra-hepatic
metastasis [8].
5.1. Position and skin incision
The patient is usually in supine position, with the arms extended 90° when possible [8]. To
minimize risk of air embolism from disrupted hepatic veins[8] and to minimize blood loss
from the resected raw liver surface[3]. The resection is performed with the patient in the
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Trendelenburg position and as recommended by all liver surgeon with a low central venous
pressure of 0-5 mmHg(15°).Figure.15.
 
Figure 15. Skin incisions for liver surgery 
Preparation of the operative field includes the area from the lower abdomen up to and including the chest, extending from axillary 
line to axillary line [8]. The majority of liver resections are performed with either a right subcostal incision with upper midline 
extension (inverted hockey stick) or a chevron (Mercedes) incision [8]. Intra-operative ultrasound is done as described above and 
the necessary ligaments are released according to the segments of the liver that needs to bee resected. Usually the falciform 
ligament is released to allow free mobilization of the liver and a better access for the ultrasound. 
4.2. Approaches to liver resection 
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Preparation of the operative field includes the area from the lower abdomen up to and
including the chest, extending from axillary line to axillary line [8]. The majority of liver
resections are performed with either a right subcostal incision with upper midline extension
(inverted hockey stick) r a ch vron (Merced ) i cision [8]. In ra-operative ultrasound is done
as described above and the necessary ligaments are released according to the segments of the
liver that needs to bee resected. Usually the falciform ligament is released to allow free
mobilization of the liver and a bette  ac ess for the ultrasound.
5.2. Approaches to liver resection
A liver surgeon should be familiar with all the techniques of liver resection because each has
advantages and disadvantages making different resections more feasible.
5.2.1 Anterior approach
This technique is started by dissection of the portal triad and the hilar plate, where the right
and left portal veins are identified.Figure.16. This makes the ligation of each portal branch
more feasible. Then the vascular line of demarcation is seen and with the aid of intra-operative
ultrasound to identify the rest of the vascular structures and the tumour. The liver is then
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mobilized according to the part being resected. Parynchymal transaction is then carried out
followed by ligation of the hepatic veins. This type is usually applied in patients with less liver
fibrosis and a right or left liver resection is needed.
A liver surgeon should be familiar with all the techniques of liver resection because each has advantages and disadvantages 
making different resections more feasible. 
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according to the part being resected. Parynchymal transaction is then carried out followed by ligation of the hepatic veins. This 
type is usually applied in patients with less liver fibrosis and a right or left liver resection is needed. 
 
Figure 16. Anterior Approach. A) the tape is around the main and right hepatic artery. B) The yellow tape is around the left portal vein 
4.2.2 Posterior approach 
The liver is mobilized according to the part being resected. This will give access to the right or left hepatic vein which is usually 
circled and controlled. Then two ways can be done, were some surgeons transect the vein followed by Pringle and transect the liver 
parenchyma by the fast technique in about 10-15 min. This is usually fast and has less bleeding and can be done in patients with 
right, left and both left lateral and right posterior (peripheral sections) liver resections specially if the patient has liver fibrosis 
because of the time and bleeding. However, this technique requires the excellent use of ultrasound to avoid injury to the main 
vascular structures, and prevent a long Pringle time for the unresected part of the liver. 
The other way is to start with the liver transaction. This will not require the routine use of Pringle, however it can be associated 
with more blood lose, and longer transection time to control the bleeding. This is usually done in non cirrhotic patients specially in 
living related liver transplant.  
By using also the posterior approach the portal pedicle will be transacted at the end in the liver. This will decrease the injury or the 
narrowing of the unresected pedicle. 
4.2.3 Hanging technique 
This approach was adopted recently and was mainly applied in the right liver donors for living related liver transplant. This 
technique usually relies on the principle of keeping the liver well vascularised till the last minute to keep the liver viable.  
Figure 16. Anterior Approach. A) the tape is around the main and right hepatic artery. B) The yellow tape is around
the left portal vein
5.2.2 Posterior approach
The liver is mobilized according to the part being resected. This will give access to the right or
left hepatic vein which is usually circled and controlled. Then two ways can be done, were
some surgeon  tran ct the vein f llowed by Pringle and transect t e liv  par nchyma by the
fast technique in about 10-15 min. This is usually fast and has less bleeding and can be done
in patients with right, left and both left lateral and right posterior (peripheral sections) liver
resections specially if the patient has liver fibrosis because of the time and bleeding. However,
this techniq e requires the excell nt us  of u trasound o void injury to the main vascular
structures, and prevent a long Pringle time for the unresected part of the liver.
The other way is to start with the liver transaction. This will not require the routine use of
Pringle, however it can be associated with more blood lose, and longer transection time to
control the bleeding. This is usually done in non cirrhotic patients specially in living related
liver transplant.
By using also the posterior approach the portal pedicle will be transacted at the end in the liver.
This will decrease the injury or the narrowing of the unresected pedicle.
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Trendelenburg position and as recommended by all liver surgeon with a low central venous
pressure of 0-5 mmHg(15°).Figure.15.
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This approach was adopted recently and was mainly applied in the right liver donors for living
related liver transplant. This technique usually relies on the principle of keeping the liver well
vascularised till the last minute to keep the liver viable.
The approach is done by using the avascular plane on the anterior part of the inferior vena
cava and the window between the right and middle hepatic vein. This makes the passage of a
tape from the inferior part of the liver to the superior part over the inferior vena cava. Figure.
17. The live is then transacted over the tape slowly while maintaining good haemostasis. Then
the right hepatic vein and the right pedicle are transacted.The approach is done by using the avascular plane on the anterior part of the inferior vena cava and the window between the right and middle hepatic vein. This makes the passage of a tape from the inferior part of the liver to the superior part over the inferior 
vena cava. Figure.17. The live is then transacted over the tape slowly while maintaining good haemostasis. Then the right hepatic 
vein and the right pedicle are transacted. 
 
Figure 17. Hanging technique 
This method is used mainly in right liver resection, and the tape can be moved in any plane wanted with the aid of the ultrasound. 
It also has a non touch like technique, were the liver is not mobilized till the vascular inflow and outflow are transacted. However, 
it requires time and very experienced surgeon not to injure the inferior vena cava during insertion of the tape. It’s also time 
consuming and not applied in cirrhotic liver because bleeding will be more. 
4.2.4. Hilar plate dissection 
This technique is started by hilar plate dissection and reaching to each sectional branch or even to each segmental branch. Control 
of the inflow is done first followed by mobilization of the part intended to be resected. The liver resection is then carried out and 
the outflow is then transacted. Figure.18 
Figure 17. Hanging technique
This method is used m inly in right liver r ection, and the tape can b  moved in any plane
wanted with the aid of the ultrasound. It also has a non touch like technique, were the liver is
not mobilized till the vascular inflow and outflow are transacted. However, it requires time
and very experienced surgeon not to injure the inferior vena cava during insertion of the tape.
It’s also time consuming and not applied in cirrhotic liver because bleeding will be more.
5.2.4. Hilar plate dissection
This technique is started by hilar plate dissection and reaching to each sectional branch or even
to each segmental branch. Control of the inflow is done first followed by mobilization of the
part intended to be resected. The liver resection is then carried out and the outflow is then
transacted. Figure.18
This method is best for central liver resection, however the hilar dissection requires experience
and cannot be carried out in cirrhotic livers as bleeding will be difficult to control. Intra-
operative ultrasound is very important to locate the portal branches and the outflow veins to
decrease its injury, also the tumor localization is important not to cut through it.
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5.2.5. Intra–hepatic ligation
Peripheral and non anatomical liver resections are usually done by this approach. Intra-
operative ultrasound is done to see the tumour and its blood supply. Mobilization followed
by parenchymal transaction, were the inflow and outflow vessels are transacted in the liver.
5.2.6. Radio–frequency assisted liver resection
The first description of RFA-assisted liver resection was published by Habib’s group [32]. This
technique showed a major improvement of liver surgery with low/no morbidity and mortality
observed [33]. It also showed decrease in the anesthetic time, operative time, hospital stay, and
blood loss. Liver resection became a comparatively safer procedure [34].
Liver resection utilizing radiofrequency-induced resection plane coagulation as a safe alter‐
native to the established resection techniques. The residual zone of coagulation necrosis
remains basically unchanged during a follow up of three years, with a safety margins of 0.5-3.5
cm and Histopathological proof [35].
The RadioFrequency Assisted liver resection has 5 steps [32, 36]:
Step 1: First or inner line is made on the liver capsule with argon diathermy to mark the
periphery of the tumor. This is done by bimanual palpation and intraoperative ultrasound.
 
Figure 18. Hillar dissection. Tapes around the sectional portal branches on the right and the main left portal vein on the left 
This method is best for central liver resection, however the hilar dissection requires experience and cannot be carried out in 
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operative time, hospital stay, and blood loss. Liver resection became a comparatively safer procedure [34]. 
Liver resection util zing radiofrequ ncy-induced resection plane coagulation as a safe alternative to the established resection 
techniques. The residual zone of coagulation necrosis remains basically unchanged during a follow up of three years, with a safety 
margins of 0.5-3.5 cm and Histopathological proof [35]. 
Th  RadioFrequency Assist d liver resection has 5 steps [32, 36]: 
Figure 18. Hillar dissection. Tapes around the sectional portal branches on the right and the main left portal vein on
the left
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Step 2: Second or outer line, again using argon diathermy, is made on the liver capsule 2 cm
outside (away from) the inner line to mark the site where the probe is positioned to achieve
coagulative necrosis.
Step 3: Coagulative necrosis is produced along a line that follows the second or outer line. The
cooled-tip RF probe and a 500-kHz RF Generator, which produces 100 W of power and allows
measurements of the generator output, tissue impedance, and electrode tip temperature. The
probe contains a 3-cm exposed electrode, a thermocouple on the tip to monitor temperature
and impedance. Two coaxial cannulae through which chilled saline is circulated during RF
energy application to prevent tissue boiling and cavitation immediately adjacent to the needle.
Step 4: Further probe applications are deployed to obtain a zone of necrosis according to the
depth of the liver parenchyma to be resected. Application of the RF energy should begin with
the area deepest and farthest from the upper surface of the liver. Once the deepest 3 cm of
tissue is coagulated, the probe is withdrawn by 3 cm to coagulate the next cylinder of tissue,
and so on until the upper surface of the liver is reached. Each application requires about 60
seconds of RF energy.
Before each probe removal, the saline infusion is stopped to increase the temperature close to
the electrode. This results in coagulation of the needle tract during withdrawal and reduces
the possibility of bleeding from the probe tract and the liver capsule.
Step 5: The liver parenchyma is divided using the scalpel. The plane of division should be
situated midway between the first and second line so as to leave a 1-cm resection margin away
from the tumor and leave in situ 1 cm of burned coagulated surface.
5.2.7. Total hepatic vascular exclusion
This method combines total inflow and outflow vascular occlusion of the liver, isolating it
completely from the systemic circulation. It is achieved after complete liver mobilization,
application of inflow occlusion by Pringle manoeuvre, and then placing a clamp across the
infra-hepatic IVC above the renal veins and the right adrenal vein followed by a supra-hepatic
IVC clamp above the opening of the major hepatic veins. After the parenchymal transection
and hemostasis, the clamps are removed in the reverse order[37]. Figure 19.
This results in a significant haemodynamic instability, with a substantial reduction in cardiac
output, though blood pressure is usually maintained [38]. Around 10% of patients cannot
tolerate it haemodynamically[39].
The ischaemic limit is 60-90 mins for patients with normal liver function [40]. In patients with
cirrhosis, the maximal ischaemic time is halved and, in addition, the liver function before
surgery must be at the better end of the spectrum[41]
However this technique is not done nowadays with the advanced surgical techniques except
in rare conditions like tumour thrombus reaching the IVC or the atrium Figure 20. It also
prevents intra-operative thrombus migration, and allows major hepatic veins or IVC recon‐
struction [37].
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Figure 19. Total hepatic vascular occlusion 
This results in a significant haemodynamic instability, with a substantial reduction in cardiac output, though blood pressure is 
usually maintained [38]. Around 10% of patients cannot tolerate it haemodynamically[39]. 
The ischaemic limit is 60-90 mins for patients with normal liver function [40]. In patients with cirrhosis, the maximal ischaemic time 
is halved and, in addition, the liver function before surgery must be at the better end of the spectrum[41] 
However this technique is not done nowadays with the advanced surgical techniques except in rare conditions like tumour 
thrombus reaching the IVC or the atrium Figure 20. It also prevents intra-operative thrombus migration, and  allows major hepatic 
veins or IVC reconstruction [37]. 
 
Figure 20. A case of HCC with atrial thrombus with total vascular occlusion. The thrombus is being removed from the right atrium. 
However, with the development of liver surgery there has been use of some part of vascular occlusion done selectively or in 
compinations: 
1. In-flow control: 
 Pringle manoeuvre; This is done by occluding the total inflow to the liver. This is usually in cases of central liver resection 
or majour resections where a large volume of blood is suspected to be lost. Figure 21 
Figure 20. A case of HCC with atrial thrombus with total vascular occlusion. The thrombus is being removed from the
right atrium.
Step 1: First or inner line is made on the liver capsule with argon diathermy to mark the periphery of the tumor. This is done by 
bimanual palpation and intraoperative ultrasound. 
Step 2: Second or outer line, again using argon diathermy, is made on the liver capsule 2 cm outside (away from) the inner line to 
mark the site where the probe is positioned to achieve coagulative necrosis.  
Step 3: Coagulative necrosis is produced along a line that follows the second or outer line. The cooled-tip RF probe and a 500-kHz 
RF Generator, which produces 100 W of power and allows measurements of the generator output, tissue impedance, and electrode 
tip temperature. The probe contains a 3-cm exposed electrode, a thermocouple on  the tip to monitor temperature and impedance. 
Two coaxial cannulae through which chilled saline is circulated during RF energy application to prevent tissue boiling and 
cavitation immediately adjacent to the needle. 
Step 4: Further probe applications are deployed to obtain a zone of necrosis according to the depth of the liver parenchyma to be 
resected. Application of the RF energy should begin with the area deepest and farthest from the upper surface of the liver. Once the 
deepest 3 cm of tissue is coagulated, the probe is withdrawn by 3 cm to coagulate the next cylinder of tissue, and so on until the 
upper surface of the liver is reached. Each application requires about 60 seconds of RF energy. 
Before each probe removal, the saline infusion is stopped to increase the temperature close to the electrode. This results in 
coagulation of the needle tract during withdrawal and reduces the possibility of bleeding from the probe tract and the liver 
capsule. 
Step 5: The liver parenchyma is divided using the scalpel. The plane of division should be situated midway between the first and 
second line so as to leave a 1-cm resection margin away from the tumor and leave in situ 1 cm of burned coagulated surface. 
4.2.7. Total hepatic vascular exclusion 
This method combines total inflow and outflow vascular occlusion of the liver, isolating it completely from the systemic 
circulation. It is achieved after complete liver mobilization, application of inflow occlusion by Pringle manoeuvre, and then placing 
a clamp across the infra-hepatic IVC above the renal veins and the right adrenal vein followed by a supra-hepatic IVC clamp above 
the opening of the major hepatic veins. After the parenchymal transection and hemostasis, the clamps are removed in the reverse 
order[37]. Figure 19. 
 
Figure 19. Total hepatic vascular occlusion
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Step 2: Second or outer line, again using argon diathermy, is made on the liver capsule 2 cm
outside (away from) the inner line to mark the site where the probe is positioned to achieve
coagulative necrosis.
Step 3: Coagulative necrosis is produced along a line that follows the second or outer line. The
cooled-tip RF probe and a 500-kHz RF Generator, which produces 100 W of power and allows
measurements of the generator output, tissue impedance, and electrode tip temperature. The
probe contains a 3-cm exposed electrode, a thermocouple on the tip to monitor temperature
and impedance. Two coaxial cannulae through which chilled saline is circulated during RF
energy application to prevent tissue boiling and cavitation immediately adjacent to the needle.
Step 4: Further probe applications are deployed to obtain a zone of necrosis according to the
depth of the liver parenchyma to be resected. Application of the RF energy should begin with
the area deepest and farthest from the upper surface of the liver. Once the deepest 3 cm of
tissue is coagulated, the probe is withdrawn by 3 cm to coagulate the next cylinder of tissue,
and so on until the upper surface of the liver is reached. Each application requires about 60
seconds of RF energy.
Before each probe removal, the saline infusion is stopped to increase the temperature close to
the electrode. This results in coagulation of the needle tract during withdrawal and reduces
the possibility of bleeding from the probe tract and the liver capsule.
Step 5: The liver parenchyma is divided using the scalpel. The plane of division should be
situated midway between the first and second line so as to leave a 1-cm resection margin away
from the tumor and leave in situ 1 cm of burned coagulated surface.
5.2.7. Total hepatic vascular exclusion
This method combines total inflow and outflow vascular occlusion of the liver, isolating it
completely from the systemic circulation. It is achieved after complete liver mobilization,
application of inflow occlusion by Pringle manoeuvre, and then placing a clamp across the
infra-hepatic IVC above the renal veins and the right adrenal vein followed by a supra-hepatic
IVC clamp above the opening of the major hepatic veins. After the parenchymal transection
and hemostasis, the clamps are removed in the reverse order[37]. Figure 19.
This results in a significant haemodynamic instability, with a substantial reduction in cardiac
output, though blood pressure is usually maintained [38]. Around 10% of patients cannot
tolerate it haemodynamically[39].
The ischaemic limit is 60-90 mins for patients with normal liver function [40]. In patients with
cirrhosis, the maximal ischaemic time is halved and, in addition, the liver function before
surgery must be at the better end of the spectrum[41]
However this technique is not done nowadays with the advanced surgical techniques except
in rare conditions like tumour thrombus reaching the IVC or the atrium Figure 20. It also
prevents intra-operative thrombus migration, and allows major hepatic veins or IVC recon‐
struction [37].
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Figure 19. Total hepatic vascular occlusion 
This results in a significant haemodynamic instability, with a substantial reduction in cardiac output, though blood pressure is 
usually maintained [38]. Around 10% of patients cannot tolerate it haemodynamically[39]. 
The ischaemic limit is 60-90 mins for patients with normal liver function [40]. In patients with cirrhosis, the maximal ischaemic time 
is halved and, in addition, the liver function before surgery must be at the better end of the spectrum[41] 
However this technique is not done nowadays with the advanced surgical techniques except in rare conditions like tumour 
thrombus reaching the IVC or the atrium Figure 20. It also prevents intra-operative thrombus migration, and  allows major hepatic 
veins or IVC reconstruction [37]. 
 
Figure 20. A case of HCC with atrial thrombus with total vascular occlusion. The thrombus is being removed from the right atrium. 
However, with the development of liver surgery there has been use of some part of vascular occlusion done selectively or in 
compinations: 
1. In-flow control: 
 Pringle manoeuvre; This is done by occluding the total inflow to the liver. This is usually in cases of central liver resection 
or majour resections where a large volume of blood is suspected to be lost. Figure 21 
Figure 20. A case of HCC with atrial thrombus with total vascular occlusion. The thrombus is being removed from the
right atrium.
Step 1: First or inner line is made on the liver capsule with argon diathermy to mark the periphery of the tumor. This is done by 
bimanual palpation and intraoperative ultrasound. 
Step 2: Second or outer line, again using argon diathermy, is made on the liver capsule 2 cm outside (away from) the inner line to 
mark the site where the probe is positioned to achieve coagulative necrosis.  
Step 3: Coagulative necrosis is produced along a line that follows the second or outer line. The cooled-tip RF probe and a 500-kHz 
RF Generator, which produces 100 W of power and allows measurements of the generator output, tissue impedance, and electrode 
tip temperature. The probe contains a 3-cm exposed electrode, a thermocouple on  the tip to monitor temperature and impedance. 
Two coaxial cannulae through which chilled saline is circulated during RF energy application to prevent tissue boiling and 
cavitation immediately adjacent to the needle. 
Step 4: Further probe applications are deployed to obtain a zone of necrosis according to the depth of the liver parenchyma to be 
resected. Application of the RF energy should begin with the area deepest and farthest from the upper surface of the liver. Once the 
deepest 3 cm of tissue is coagulated, the probe is withdrawn by 3 cm to coagulate the next cylinder of tissue, and so on until the 
upper surface of the liver is reached. Each application requires about 60 seconds of RF energy. 
Before each probe removal, the saline infusion is stopped to increase the temperature close to the electrode. This results in 
coagulation of the needle tract during withdrawal and reduces the possibility of bleeding from the probe tract and the liver 
capsule. 
Step 5: The liver parenchyma is divided using the scalpel. The plane of division should be situated midway between the first and 
second line so as to leave a 1-cm resection margin away from the tumor and leave in situ 1 cm of burned coagulated surface. 
4.2.7. Total hepatic vascular exclusion 
This method combines total inflow and outflow vascular occlusion of the liver, isolating it completely from the systemic 
circulation. It is achieved after complete liver mobilization, application of inflow occlusion by Pringle manoeuvre, and then placing 
a clamp across the infra-hepatic IVC above the renal veins and the right adrenal vein followed by a supra-hepatic IVC clamp above 
the opening of the major hepatic veins. After the parenchymal transection and hemostasis, the clamps are removed in the reverse 
order[37]. Figure 19. 
 
Figure 19. Total hepatic vascular occlusion
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However, with the development of liver surgery there has been use of some part of vascular
occlusion done selectively or in compinations:
1. In-flow control:
2. Pringle manoeuvre; This is done by occluding the total inflow to the liver. This is usually
in cases of central liver resection or majour resections where a large volume of blood is
suspected to be lost. Figure 21
 
Figure 21. Pringles manoeuvre 
 Hemi-Hepatic control; This is done as described before in the right or left hemi-hepatectomy by controlling the right or 
left pedicle at the glissonian sheath. Figure 16 
 Sectional control; This is done by isolating and controlling the sectional branches as described in the (Hilar Plate 
Disection) as described above to be able to isolate each section without affecting other parts of the liver. Figure 17 
2. Out-Flow Control: 
 Total hepatic control; this is achieved by either clamping of the IVC above and below or clamping the hepatic veins 
without affecting the flow of the IVC as nowadays done in piggy-back liver transplant. 
 Isolated hepatic vein control; this is done as described in the posterior approach where full mobilization of the liver is 
done and the right or left hepatic vein is isolated and clamped with-out affecting the IVC or the other hepatic veins 
These all can be done separately or combined to achieve a bloodless liver resection and maintain patient stability. 
4.3. Parynchymal transaction 
Meyer-May described the use of Kocher-like clamps to crush liver parenchyma in 1939 [12,42] and haemostatic clamps such as 
Kelly clamps [43] are still used to crush small areas of the parenchyma, leaving the vessels intact.  
Lortat-Jacob used the handle of a scalpel[9] and Lin described the use of finger fracture to remove parenchyma under inflow 
occlusion to isolate vessels and bile ducts for ligation[44,45].  
Ultrasonic dissection has been developed using the CUSA (Cavitron Ultrasonic Surgical Aspirator)[42], this allows for delineation 
of the hepatic veins, particularly at the junction with the inferior vena cava, and prevents positive margin [45]. It has been shown to 
be very effective for division of the parenchyma with low blood losse [46,47].  
Water-jet dissection [48-49] reduced blood loss, blood transfusion, and transaction time compared with CUSA, but there is 
increased risk of venous air embolism [45]. 
Figure 21. Pringles manoeuvre
1. Hemi-Hepatic control; This is done as described before in the right or left hemi-hepatec‐
tomy by con rolling the right or eft pedi le at the glisso ian sheat . Figure 6
2. Sectional control; This is done by isolating and controlling the sectional branches as
described in the (Hilar Plate Disection) as described above to be able to isolate ach section
without affecting other parts of the liver. Figure 17
3. Out-Flow Control:
4. Total hepatic control; this is achieved by either clamping of the IVC above and below or
clamping the hepatic veins without affecting the flow of the IVC as nowadays done in
piggy-back liver transplant.
5. Isolated hepatic vein control; this is done as described in the posterior approach where
full mobilization of the liver is done and the right or left hepatic vein is isolated and
clamped with-out affecting the IVC or the other hepatic veins
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These all can be done separately or combined to achieve a bloodless liver resection and
maintain patient stability.
5.3. Parynchymal transaction
Meyer-May described the use of Kocher-like clamps to crush liver parenchyma in 1939 [12,42]
and haemostatic clamps such as Kelly clamps [43] are still used to crush small areas of the
parenchyma, leaving the vessels intact.
Lortat-Jacob used the handle of a scalpel[9] and Lin described the use of finger fracture to
remove parenchyma under inflow occlusion to isolate vessels and bile ducts for ligation[44,45].
Ultrasonic dissection has been developed using the CUSA (Cavitron Ultrasonic Surgical
Aspirator)[42], this allows for delineation of the hepatic veins, particularly at the junction with
the inferior vena cava, and prevents positive margin [45]. It has been shown to be very effective
for division of the parenchyma with low blood losse [46,47].
Water-jet dissection [48-49] reduced blood loss, blood transfusion, and transaction time
compared with CUSA, but there is increased risk of venous air embolism [45].
Harmonic Scalpel allows sealing of small vessels during the transaction of liver parenchyma.
It can be used alone or in combination with clamp crushing or CUSA. It also have been adopted
for laparoscopic resections [50,51] with limitation in the dissection around the main trunk of
the hepatic veins [52]. Figure.22Harmonic Scalpel allows sealing of small vessels during the transaction of liver parenchyma. It can be used alone or in combination 
with clamp crushing or CUSA. It also have been adopted for laparoscopic resections [50,51] with limitation in the dissection around 
the main trunk of the hepatic veins [52]. Figure.22 
 
Figure 22. Instruments used for liver resection 
Ligasure designed to seal small vessels by a combination of Ultrasonic dissection of liver parenchyma using compression pressure 
and bipolar radiofrequency (RF) energy[45], it was found to be more useful in laparoscopic resection than open. 
Tissue Link dissecting sealer, where saline runs to the tip of the electrode to couple RF energy to the liver surface and achieve 
coagulation[45]. 
All these instruments have been used and according to many authors each has been claimed to be better than the other. Our believe 
is that a surgeon should be familiar with all techniques and instruments as each hospital has its own and when instrument 
malfunction occurs he will have the ability to adopt and rise up to the situation. 
4.4. Specific liver resections 
4.4.1. Right hepatectomy 
Resection of the right hemiliver (segments 5,6,7 &8) is one of the most common types of liver resection. It involves removing all 
hepatic parenchyma to the right of the middle hepatic vein [8]. This can be done by the Anterior, Posterior or the hanging 
techniques described above. However, it is important to see which approach will be better for each patient taking into 
consideration the tumour and the status of the liver. 
This starts with mobilization of the right liver by division of the falciform, coronary and right triangular ligaments. Then vascular 
inflow and outflow control should take place. Three general approaches have been described for achieving vascular inflow control: 
1) extrahepatic dissection within the porta hepatis, with division of the right hepatic artery and right portal vein prior to division of 
the parenchyma (anterior approach) 2) intrahepatic control of the main right pedicle within the substance of the liver prior to 
parenchymal transection (Intra-Hepatic ligation); and 3) intrahepatic control of the pedicle after parenchymal transaction (hanging 
technique or posterior approach) [8]. 
Figure 22. Instruments used for liver resection
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However, with the development of liver surgery there has been use of some part of vascular
occlusion done selectively or in compinations:
1. In-flow control:
2. Pringle manoeuvre; This is done by occluding the total inflow to the liver. This is usually
in cases of central liver resection or majour resections where a large volume of blood is
suspected to be lost. Figure 21
 
Figure 21. Pringles manoeuvre 
 Hemi-Hepatic control; This is done as described before in the right or left hemi-hepatectomy by controlling the right or 
left pedicle at the glissonian sheath. Figure 16 
 Sectional control; This is done by isolating and controlling the sectional branches as described in the (Hilar Plate 
Disection) as described above to be able to isolate each section without affecting other parts of the liver. Figure 17 
2. Out-Flow Control: 
 Total hepatic control; this is achieved by either clamping of the IVC above and below or clamping the hepatic veins 
without affecting the flow of the IVC as nowadays done in piggy-back liver transplant. 
 Isolated hepatic vein control; this is done as described in the posterior approach where full mobilization of the liver is 
done and the right or left hepatic vein is isolated and clamped with-out affecting the IVC or the other hepatic veins 
These all can be done separately or combined to achieve a bloodless liver resection and maintain patient stability. 
4.3. Parynchymal transaction 
Meyer-May described the use of Kocher-like clamps to crush liver parenchyma in 1939 [12,42] and haemostatic clamps such as 
Kelly clamps [43] are still used to crush small areas of the parenchyma, leaving the vessels intact.  
Lortat-Jacob used the handle of a scalpel[9] and Lin described the use of finger fracture to remove parenchyma under inflow 
occlusion to isolate vessels and bile ducts for ligation[44,45].  
Ultrasonic dissection has been developed using the CUSA (Cavitron Ultrasonic Surgical Aspirator)[42], this allows for delineation 
of the hepatic veins, particularly at the junction with the inferior vena cava, and prevents positive margin [45]. It has been shown to 
be very effective for division of the parenchyma with low blood losse [46,47].  
Water-jet dissection [48-49] reduced blood loss, blood transfusion, and transaction time compared with CUSA, but there is 
increased risk of venous air embolism [45]. 
Figure 21. Pringles manoeuvre
1. Hemi-Hepatic control; This is done as described before in the right or left hemi-hepatec‐
tomy by con rolling the right or eft pedi le at the glisso ian sheat . Figure 6
2. Sectional control; This is done by isolating and controlling the sectional branches as
described in the (Hilar Plate Disection) as described above to be able to isolate ach section
without affecting other parts of the liver. Figure 17
3. Out-Flow Control:
4. Total hepatic control; this is achieved by either clamping of the IVC above and below or
clamping the hepatic veins without affecting the flow of the IVC as nowadays done in
piggy-back liver transplant.
5. Isolated hepatic vein control; this is done as described in the posterior approach where
full mobilization of the liver is done and the right or left hepatic vein is isolated and
clamped with-out affecting the IVC or the other hepatic veins
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These all can be done separately or combined to achieve a bloodless liver resection and
maintain patient stability.
5.3. Parynchymal transaction
Meyer-May described the use of Kocher-like clamps to crush liver parenchyma in 1939 [12,42]
and haemostatic clamps such as Kelly clamps [43] are still used to crush small areas of the
parenchyma, leaving the vessels intact.
Lortat-Jacob used the handle of a scalpel[9] and Lin described the use of finger fracture to
remove parenchyma under inflow occlusion to isolate vessels and bile ducts for ligation[44,45].
Ultrasonic dissection has been developed using the CUSA (Cavitron Ultrasonic Surgical
Aspirator)[42], this allows for delineation of the hepatic veins, particularly at the junction with
the inferior vena cava, and prevents positive margin [45]. It has been shown to be very effective
for division of the parenchyma with low blood losse [46,47].
Water-jet dissection [48-49] reduced blood loss, blood transfusion, and transaction time
compared with CUSA, but there is increased risk of venous air embolism [45].
Harmonic Scalpel allows sealing of small vessels during the transaction of liver parenchyma.
It can be used alone or in combination with clamp crushing or CUSA. It also have been adopted
for laparoscopic resections [50,51] with limitation in the dissection around the main trunk of
the hepatic veins [52]. Figure.22Harmonic Scalpel allows sealing of small vessels during the transaction of liver parenchyma. It can be used alone or in combination 
with clamp crushing or CUSA. It also have been adopted for laparoscopic resections [50,51] with limitation in the dissection around 
the main trunk of the hepatic veins [52]. Figure.22 
 
Figure 22. Instruments used for liver resection 
Ligasure designed to seal small vessels by a combination of Ultrasonic dissection of liver parenchyma using compression pressure 
and bipolar radiofrequency (RF) energy[45], it was found to be more useful in laparoscopic resection than open. 
Tissue Link dissecting sealer, where saline runs to the tip of the electrode to couple RF energy to the liver surface and achieve 
coagulation[45]. 
All these instruments have been used and according to many authors each has been claimed to be better than the other. Our believe 
is that a surgeon should be familiar with all techniques and instruments as each hospital has its own and when instrument 
malfunction occurs he will have the ability to adopt and rise up to the situation. 
4.4. Specific liver resections 
4.4.1. Right hepatectomy 
Resection of the right hemiliver (segments 5,6,7 &8) is one of the most common types of liver resection. It involves removing all 
hepatic parenchyma to the right of the middle hepatic vein [8]. This can be done by the Anterior, Posterior or the hanging 
techniques described above. However, it is important to see which approach will be better for each patient taking into 
consideration the tumour and the status of the liver. 
This starts with mobilization of the right liver by division of the falciform, coronary and right triangular ligaments. Then vascular 
inflow and outflow control should take place. Three general approaches have been described for achieving vascular inflow control: 
1) extrahepatic dissection within the porta hepatis, with division of the right hepatic artery and right portal vein prior to division of 
the parenchyma (anterior approach) 2) intrahepatic control of the main right pedicle within the substance of the liver prior to 
parenchymal transection (Intra-Hepatic ligation); and 3) intrahepatic control of the pedicle after parenchymal transaction (hanging 
technique or posterior approach) [8]. 
Figure 22. Instruments used for liver resection
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Ligasure designed to seal small vessels by a combination of Ultrasonic dissection of liver
parenchyma using compression pressure and bipolar radiofrequency (RF) energy [45], it was
found to be more useful in laparoscopic resection than open.
Tissue Link dissecting sealer, where saline runs to the tip of the electrode to couple RF energy
to the liver surface and achieve coagulation [45].
All these instruments have been used and according to many authors each has been claimed
to be better than the other. Our believe is that a surgeon should be familiar with all techniques
and instruments as each hospital has its own and when instrument malfunction occurs he will
have the ability to adopt and rise up to the situation.
5.4. Specific liver resections
5.4.1. Right hepatectomy
Resection of the right hemiliver (segments 5, 6, 7 & 8) is one of the most common types of liver
resection. It involves removing all hepatic parenchyma to the right of the middle hepatic vein
[8]. This can be done by the Anterior, Posterior or the hanging techniques described above.
However, it is important to see which approach will be better for each patient taking into
consideration the tumour and the status of the liver.
This starts with mobilization of the right liver by division of the falciform, coronary and right
triangular ligaments. Then vascular inflow and outflow control should take place. Three
general approaches have been described for achieving vascular inflow control: 1) extrahepatic
dissection within the porta hepatis, with division of the right hepatic artery and right portal
vein prior to division of the parenchyma (anterior approach) 2) intrahepatic control of the main
right pedicle within the substance of the liver prior to parenchymal transection (Intra-Hepatic
ligation); and 3) intrahepatic control of the pedicle after parenchymal transaction (hanging
technique or posterior approach) [8].
Then the right hepatic artery, right portal vein and the right hepatic duct are lighted and
divided extrahepatic. The right liver is then dissected from the inferior vena cava either before
or after according to which approach is being adopted. The short hepatic veins that drain from
the right hemi liver to the inferior vena cava should be ligated and divided as well as the
Hepato-caval ligament. The right hepatic vein is then dissected extrahepatic and ligated. After
this step a clear line of demarcation will appear as the right hemi liver will became darker and
ischemic. Liver parenchyma transaction will be done on the right border of the middle hepatic
vein. Some vascular anomalies can cause the demarcation line of a right hepatectomy to be
along the left border of the middle hepatic vein so care must tacked to preserve segment 4
branches or it will become congested. Blood loss control can be achieved by pringle's maneu‐
ver, using of low central pressure or extrahepatic clamping of the middle and left hepatic
veins.Figure.23
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Then the right hepatic artery, right portal vein and the right hepatic duct are lighted and divided extrahepatic. The right liver is 
then dissected from the inferior vena cava either before or after according to which approach is being adopted. The short hepatic 
veins that drains from the right hemi liver to the inferior vena cava should be ligated and divided as well as the Hepato-caval 
ligament. The right hepatic vein is then dissected extrahepatic and ligated. After this step a clear line of demarcation will appear as 
the right hemi liver will became darker and ischemic. Liver parenchyma transaction will be done on the right border of the middle 
hepatic vein. Some vascular anomalies can cause the demarcation line of a right hepatectomy to be along the left border of the 
middle hepatic vein so care must tacked to preserve segment 4 branches or it will become congested. Blood loss control can be 
achieved by pringle's maneuver, using of low central pressure or extrahepatic clamping of the middle and left hepatic 
veins.Figure.23 
 
Figure 23. Right Hepatectomy; a right liver specimen with tumor invasion in the right hepatic vein 
4.4.2. Extended right hepatectomy (Right trisectionectomy) 
Right hepatectomy + extrahepatic ligation and division of the branches of the hepatic artery, portal vein and bile ducts to segment 4 
with the division of the right and middle hepatic veins leaving the left hepatic vein and portal triad supplying the left lateral 
section intact [18]. 
The left triangular ligament may be preserved to prevent liver rotation and venous outflow occlusion post resection [42].Figure.24 
Figure 23. Right Hepatectomy; a right liver specimen with tumor invasion in the right hepatic vein
5.4.2. Extended right hepatectomy (Right trisectionectomy)
Right hepatectomy + extrahepatic ligation and division of the branches of the hepatic artery,
portal vein and bile ducts to segment 4 with the division of the right and middle hepatic veins
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The left triangular ligament may be preserved to prevent liver rotation and venous outflow
occlusion post resection [42].Figure.24
 
Figure 24. Right extended tri-sectionectomy;  a CT scan of a liver tumor that was resected as shown in the drawing  
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This can be done in the same manner as the right liver resection, however it will require the identification of the left portal triad. 
Starting with mobilization of the left liver by division of the falciform and the left triangular ligaments. Extrahepatic division of the 
extrahepatic branches of the left hepatic artery, left portal vein and left hepatic duct. Isolation of the trunk of the middle and left 
hepatic vein. Parynchymal transaction done along the plane demarcated by the ischemic left liver along a plan on the left side of 
the middle hepatic vein. The same should be considered as the line of demarcation can be on the right of the middle hepatic vein. 
The left hepatic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's maneuver plus either low central 
venous pressure or selective hepatic vascular occlusion by clamping the right hepatic vein. Figure 25 
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Ligasure designed to seal small vessels by a combination of Ultrasonic dissection of liver
parenchyma using compression pressure and bipolar radiofrequency (RF) energy [45], it was
found to be more useful in laparoscopic resection than open.
Tissue Link dissecting sealer, where saline runs to the tip of the electrode to couple RF energy
to the liver surface and achieve coagulation [45].
All these instruments have been used and according to many authors each has been claimed
to be better than the other. Our believe is that a surgeon should be familiar with all techniques
and instruments as each hospital has its own and when instrument malfunction occurs he will
have the ability to adopt and rise up to the situation.
5.4. Specific liver resections
5.4.1. Right hepatectomy
Resection of the right hemiliver (segments 5, 6, 7 & 8) is one of the most common types of liver
resection. It involves removing all hepatic parenchyma to the right of the middle hepatic vein
[8]. This can be done by the Anterior, Posterior or the hanging techniques described above.
However, it is important to see which approach will be better for each patient taking into
consideration the tumour and the status of the liver.
This starts with mobilization of the right liver by division of the falciform, coronary and right
triangular ligaments. Then vascular inflow and outflow control should take place. Three
general approaches have been described for achieving vascular inflow control: 1) extrahepatic
dissection within the porta hepatis, with division of the right hepatic artery and right portal
vein prior to division of the parenchyma (anterior approach) 2) intrahepatic control of the main
right pedicle within the substance of the liver prior to parenchymal transection (Intra-Hepatic
ligation); and 3) intrahepatic control of the pedicle after parenchymal transaction (hanging
technique or posterior approach) [8].
Then the right hepatic artery, right portal vein and the right hepatic duct are lighted and
divided extrahepatic. The right liver is then dissected from the inferior vena cava either before
or after according to which approach is being adopted. The short hepatic veins that drain from
the right hemi liver to the inferior vena cava should be ligated and divided as well as the
Hepato-caval ligament. The right hepatic vein is then dissected extrahepatic and ligated. After
this step a clear line of demarcation will appear as the right hemi liver will became darker and
ischemic. Liver parenchyma transaction will be done on the right border of the middle hepatic
vein. Some vascular anomalies can cause the demarcation line of a right hepatectomy to be
along the left border of the middle hepatic vein so care must tacked to preserve segment 4
branches or it will become congested. Blood loss control can be achieved by pringle's maneu‐
ver, using of low central pressure or extrahepatic clamping of the middle and left hepatic
veins.Figure.23
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4.4.2. Extended right hepatectomy (Right trisectionectomy) 
Right hepatectomy + extrahepatic ligation and division of the branches of the hepatic artery, portal vein and bile ducts to segment 4 
with the division of the right and middle hepatic veins leaving the left hepatic vein and portal triad supplying the left lateral 
section intact [18]. 
The left triangular ligament may be preserved to prevent liver rotation and venous outflow occlusion post resection [42].Figure.24 
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Figure 24. Right extended tri-sectionectomy;  a CT scan of a liver tumor that was resected as shown in the drawing  
4.4.3. Left hepatectomy 
This can be done in the same manner as the right liver resection, however it will require the identification of the left portal triad. 
Starting with mobilization of the left liver by division of the falciform and the left triangular ligaments. Extrahepatic division of the 
extrahepatic branches of the left hepatic artery, left portal vein and left hepatic duct. Isolation of the trunk of the middle and left 
hepatic vein. Parynchymal transaction done along the plane demarcated by the ischemic left liver along a plan on the left side of 
the middle hepatic vein. The same should be considered as the line of demarcation can be on the right of the middle hepatic vein. 
The left hepatic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's maneuver plus either low central 
venous pressure or selective hepatic vascular occlusion by clamping the right hepatic vein. Figure 25 
 
Figure 25. A case of Left Liver resection;  the middle hepatic vein seen in the remnant liver with a schematic demonstration 
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the falciform and the left triangular ligaments. Extrahepatic division of the extrahepatic
branches of the left hepatic artery, left portal vein and left hepatic duct. Isolation of the trunk
of the middle and left hepatic vein. Parynchymal transaction done along the plane demarcated
by the ischemic left liver along a plan on the left side of the middle hepatic vein. The same
should be considered as the line of demarcation can be on the right of the middle hepatic vein.
The left hepatic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's
maneuver plus either low central venous pressure or selective hepatic vascular occlusion by
clamping the right hepatic vein. Figure 25
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hepatic vein. Parynchymal transaction done along the plane demarcated by the ischemic left liver along a plan on the left side of 
the middle hepatic vein. The same should be considered as the line of demarcation can be on the right of the middle hepatic vein. 
The left h patic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's maneuver plus either low central 
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Figure 25. A case of Left Liver resection;  the middle hepatic vein seen in the remnant liver with a schematic demonstration 
Figure  25.  A  case  of  Left  Liver  resection;  the  middle  hepatic  vein  seen  in  the  remnant  liver  with  a  schematic
demonstration
5.4.4. Extended left hepatectomy (Left trisectionectomy)
Similar to left hepatectomy in addition of the right anterior section. Care should be done to
preserve the hepatic arterial, portal venous and bile duct branches to the right posterior section
and the right hepatic vein. If the right inferior hepatic vein is large it should be preserved so
the venous drainage to segment 6 will not be affected [18].
5.4.5. Left lateral sectionectomy
Isolated segment II or III resection is uncommonly performed because of the ease of combined
segment II and III (left lateral section) and the small volume of each segment. In the presence
of cirrhosis or when multiple segmental resections are performed, isolated resection may be
necessary. The left hepatic vein is identified extrahepaticaly and the left lateral sectional portal
triad is ligated at the umbilical vein and the falciform ligament.Figure.26. Then the hepatic
transaction is carried out with very minimal blood lose.
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Figure 26. A) left lateral section as seen on intra-operaive ultrasound. B) the specimen with tumour to check for margins 
4.4.6. Right posterior sectionectomy (Segment VI and VII) 
This can be achieved by most techniques described above depending on the tumour size and the status of the Liver. Full 
mobilization of the right liver with division of the posterior draining veins. The right portal pedicle is exposed, and the anterior 
and posterior branches are identified (Hilar plate approach). The posterior pedicle is clamped, and the line of demarcation is 
evident. The pedicle may be divided, and parenchymal dissection may be performed in standard fashion. The line of transection is 
horizontal and posterior to the right hepatic vein. However, the right vein may be sacrificed during this procedure since the 
anterior section will be adequately drained by the middle hepatic vein[8].  If the liver is cirrhotic we would advise the use of an 
extrahepatic approach like the posterior approach to minimize the blood lose and injury to the right anterior portal triad.  
4.4.7. Right anterior sectionectomy (Segment V and VIII) 
This is extreamly rare and very difficult because of its location between both the right and middle hepatic veins with the 
importance of not injuring any of them. This is why if it is done it is combined with segment IV (Central liver resection) to remove 
the middle hepatic vein and have a safe distance from the right hepatic vein. The approach is similar to the right posterior 
sectionectomy were the right anterior portal triad is seen and ligated to stop the inflow and get the line of demarcation.  
4.4.8. Isolated segment II or III resection 
Figure 26. A) left lateral section as seen on intra-operaive ultrasound. B) the specimen with tumour to check for
margins
5.4.6. Right posterior sectionectomy (Segment VI and VII)
This can be achieved by most techniques described above depending on the tumour size and
the status of the Liver. Full m biliz ti n of the right liver with div sio  of the posterior draining
veins. The right portal pedicle is exposed, and the anterior and posterior branches are identified
(Hilar plate approach). The posterior pedicle is clamped, and the line of demarcation is evident.
The pedicle may be i ided, and parenchymal dissection m y be performed in standard
fashion. The line of tra section is horizontal and posterior to the right hepatic vein. However,
the right vein may be sacrificed during this procedure since the anterior section will be
adequately drained by the middle hepatic vein[8]. If the liver is cirrhotic we would advise the
use of an extrahepatic approach like the posterior approach to minimize the blood lose and
injury to the right anterior portal triad.
5.4.7. Right anterior sectionectomy (Segment V and VIII)
This is extreamly rare and very difficult because of its location between both the right and
middle hepatic veins with the importance of not injuring any of them. This is why if it is done
it is combined with segment IV (Central liver resection) to remove the middle hepatic vein and
have a safe distance from the right hepatic vein. The approach is similar to the right posterior
sectionectomy were the right anterior portal triad is seen and ligated to stop the inflow and
get the line of demarcation.
5.4.8. Isolated segment II or III resection
For removal of either segment II or III, the inflow pedicle is ligated, but the main left hepatic
vein is preserved because it provides the only venous drainage to the remaining segment. The
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the falciform and the left triangular ligaments. Extrahepatic division of the extrahepatic
branches of the left hepatic artery, left portal vein and left hepatic duct. Isolation of the trunk
of the middle and left hepatic vein. Parynchymal transaction done along the plane demarcated
by the ischemic left liver along a plan on the left side of the middle hepatic vein. The same
should be considered as the line of demarcation can be on the right of the middle hepatic vein.
The left hepatic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's
maneuver plus either low central venous pressure or selective hepatic vascular occlusion by
clamping the right hepatic vein. Figure 25
 
Figure 24. Right extended tri-sectionectomy;  a CT scan of a liver tumor that was resected as shown in the drawing  
4.4.3. Left hepatectomy 
This can be done in the same manner as the right liver resection, however it will require the identification of the left portal triad. 
Starting with mobilization of the left liver by division of the falciform and the left triangular ligaments. Extrahepatic division of the 
extrahepatic branches of the left hepatic artery, left portal vein and left hepatic duct. Isolation of the trunk of the middle and left 
hepatic vein. Parynchymal transaction done along the plane demarcated by the ischemic left liver along a plan on the left side of 
the middle hepatic vein. The same should be considered as the line of demarcation can be on the right of the middle hepatic vein. 
The left h patic vein is ligated intrahepaticly. Blood Loss can be reduced by using Pringle's maneuver plus either low central 
venous pressure or selective hepatic vascular occlusion by clamping the right hepatic vein. Figure 25 
 
Figure 25. A case of Left Liver resection;  the middle hepatic vein seen in the remnant liver with a schematic demonstration 
Figure  25.  A  case  of  Left  Liver  resection;  the  middle  hepatic  vein  seen  in  the  remnant  liver  with  a  schematic
demonstration
5.4.4. Extended left hepatectomy (Left trisectionectomy)
Similar to left hepatectomy in addition of the right anterior section. Care should be done to
preserve the hepatic arterial, portal venous and bile duct branches to the right posterior section
and the right hepatic vein. If the right inferior hepatic vein is large it should be preserved so
the venous drainage to segment 6 will not be affected [18].
5.4.5. Left lateral sectionectomy
Isolated segment II or III resection is uncommonly performed because of the ease of combined
segment II and III (left lateral section) and the small volume of each segment. In the presence
of cirrhosis or when multiple segmental resections are performed, isolated resection may be
necessary. The left hepatic vein is identified extrahepaticaly and the left lateral sectional portal
triad is ligated at the umbilical vein and the falciform ligament.Figure.26. Then the hepatic
transaction is carried out with very minimal blood lose.
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5.4.6. Right posterior sectionectomy (Segment VI and VII)
This can be achieved by most techniques described above depending on the tumour size and
the status of the Liver. Full m biliz ti n of the right liver with div sio  of the posterior draining
veins. The right portal pedicle is exposed, and the anterior and posterior branches are identified
(Hilar plate approach). The posterior pedicle is clamped, and the line of demarcation is evident.
The pedicle may be i ided, and parenchymal dissection m y be performed in standard
fashion. The line of tra section is horizontal and posterior to the right hepatic vein. However,
the right vein may be sacrificed during this procedure since the anterior section will be
adequately drained by the middle hepatic vein[8]. If the liver is cirrhotic we would advise the
use of an extrahepatic approach like the posterior approach to minimize the blood lose and
injury to the right anterior portal triad.
5.4.7. Right anterior sectionectomy (Segment V and VIII)
This is extreamly rare and very difficult because of its location between both the right and
middle hepatic veins with the importance of not injuring any of them. This is why if it is done
it is combined with segment IV (Central liver resection) to remove the middle hepatic vein and
have a safe distance from the right hepatic vein. The approach is similar to the right posterior
sectionectomy were the right anterior portal triad is seen and ligated to stop the inflow and
get the line of demarcation.
5.4.8. Isolated segment II or III resection
For removal of either segment II or III, the inflow pedicle is ligated, but the main left hepatic
vein is preserved because it provides the only venous drainage to the remaining segment. The
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inflow pedicles to segments II and III branches directly from the umbilical portion of the left
main portal vein. To isolate these pedicles, the left lateral section is shifted cephalad using
traction on the divided falciform ligament. If present, the parenchymal bridge between
segment III and IV is divided with electrocautery. Dissection of the umbilical fissure to the left
of the portal vein is performed. Ligation of either segment II or III pedicles demarcates the
boundary between them. The left hepatic vein may be clamped to reduce blood loss, but
clamping is generally unnecessary if the central venous pressure is low. Liver transection then
proceeds in an oblique antero-cranial plane with attention to preserve the left hepatic vein [3].
5.4.9. Isolated segment VII
To expose this segment dissection of the right triangular ligament is necessary. The vascular
pedicle of segment VII originate from the right lateral glissoian pedicle and enters the paren‐
chyma in a common trunk at segment VI, this will run deep and divide to two branches anterior
to segment VI and posterior to segment VII.
After mobilizing the infindibulum of the gall bladder and dividing the lateral peritoneum of
the hepato-duodenal ligament the lateral pedicle can be easily freed as well as the artery. Once
this is identified with the bile duct, the right branch of the portal vein is freed. The bile ducts
will never be dissected outside the parenchyma but only transparenchymaly at the end of the
resection to prevent damage to the adjacent hepatic ducts. Clamping of the arterial branch will
lead to blanching of the entire right anterior section. The fissure of the right hepatic vein will
indicate the upper resection margin. The vein could be left in place or removed in case of
neoplasm infiltration, also isolated resection of segment VII with ligation of the right hepatic
vein can be safely performed, venous out flow of segment VI should be insured by preserving
the accessory hepatic veins and the right inferior hepatic vein(present in 25%) to prevent the
transitory venous congestion of segment VI with hemorrhage from the resection margins after
isolated removal of segment VII. After clamping of the lateral glissonian pedicle the trunk of
the right hepatic vein will be clamped and divided. Parenchymal dissection will follow the
appearing ischemic demarcation line and the dissection plane will start from the top down‐
ward between segment VII and VIII. The pedicle will be exposed with the dissection once it
have been divided the arterial and portal branches at the hilum can be unclamped, segment
VI returns to its normal color and the inferior demarcation line will become evident.
5.4.10. Isolated segment VI
Similar to segment VII, after mobilization of the right liver, ligation of the inferior or accessory
suprahepatic vein if present and clamping of the arterial and portal brances which will produce
the ischemic demarcation line.
The parenchyma is divided starting from the lower margin of the liver proceeding along an
oblique plane from the right to the left and from the front to back. Deep in the parenchyma the
lateral pedicle is ligated. The glissonian pedicle is then unclamped at the hilum and segment
VII will return to the normal colour, the upper dissection margin will follow the ischemic line
between the two segments VI and VII.
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5.4.11. Isolated segment IV
Segment IV is divided into two subsegments, IVA and IVB, based on the inflow pedicles. Isolated
resection of IVB is usually done in a intra-hepatic ligation method and most often with seg‐
ment V in cases of gallbladder carcinoma. Were outflow control for segment IV resection is
usually not obtained until the liver is divided. After dissection of the hepatoduodenal liga‐
ment the left branches of the hepatic artery are identified and then the middle branch is ligated
and divided. Dissection will be carried out along the gall bladder-inferior vena cava plane.
Glissonian capsule divided above the hilar plate. The portal branch is usually seen with the hilar
plate and dissection with control by Bull-dog clamps to see the line of demarcation. At this point
segment IV will only be attached to the Middle Hepatic vein which will be transfixed.
5.4.12. Isolated segment I ''Caudate lobe''
This is the least popular liver resection as all the other segments can be done in an intra-hepatic
ligation method or in a non-anatomical approach. However, the Caudate liver resection has
its own unique location above the inferior vena cava and its own blood supply giving it the
excellent challenge for any liver surgeon. There are 5 approaches:
1. Bilateral approach: For isolated caudate lobectomy, the caudate lobe is approached from
both right and left side after complete mobilization of the liver with controll of the
suprahepatic and intrahepatic inferior vena cava as well as the right hepatic vein and the
common trunk of the middle and left hepatic veins. Then the caudate lobe is detached
from the inferior vena cava along the anterior surface of the retro-haptic IVC and the short
hepatic veins are identified and divided. The hepatogastric ligament is detached from the
undersurface of the liver and the fibrous hepatocaval ligament need to be divided to free
the spieglian lobe from the IVC and the diaphragm. All short hepatic veins are ligated and
divided. So the caudate lobe is free from the inferior vera cava. The branches of the to the
para caval portion of the caudate lobe from the right portal vein, right hepatic artery and
duct, branches to the spiegelian lobe from the left portal vein, left hepatic artery and duct
are ligated and divided. By carefull dissection the liver is detached from the surroundings
and the right, middle and left hepatic veins. In this step; 2 important land marks for this
dissection : A) the angle between the right hepatic vein and the inferior vans cava i.e the
top of the caudate lobe. B) the meeting point between the caudate process and the right
liver. An imaginary line joining these two points is considered as the caudate boundary
for the liver transection. Meticulous care should be applied not to injure the major vessels
or induce bleeding which will be difficult to control.
2. Left sided approach: Similar to the bilateral approach whit the exception that the dissec‐
tion is mainly from the left side of the liver. In small tumours <3cm, if an isolated partial
caudate lobecetomy or left hepatectomy combined with complete caudate lobecetomy is
carried out. Figure 27
3. Right sided approach: Similar to the bilateral approach whit the exception that the
dissection is mainly from the right side of the liver. In thin patients with right hepatectomy
combined with caudate lobecetomy.
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inflow pedicles to segments II and III branches directly from the umbilical portion of the left
main portal vein. To isolate these pedicles, the left lateral section is shifted cephalad using
traction on the divided falciform ligament. If present, the parenchymal bridge between
segment III and IV is divided with electrocautery. Dissection of the umbilical fissure to the left
of the portal vein is performed. Ligation of either segment II or III pedicles demarcates the
boundary between them. The left hepatic vein may be clamped to reduce blood loss, but
clamping is generally unnecessary if the central venous pressure is low. Liver transection then
proceeds in an oblique antero-cranial plane with attention to preserve the left hepatic vein [3].
5.4.9. Isolated segment VII
To expose this segment dissection of the right triangular ligament is necessary. The vascular
pedicle of segment VII originate from the right lateral glissoian pedicle and enters the paren‐
chyma in a common trunk at segment VI, this will run deep and divide to two branches anterior
to segment VI and posterior to segment VII.
After mobilizing the infindibulum of the gall bladder and dividing the lateral peritoneum of
the hepato-duodenal ligament the lateral pedicle can be easily freed as well as the artery. Once
this is identified with the bile duct, the right branch of the portal vein is freed. The bile ducts
will never be dissected outside the parenchyma but only transparenchymaly at the end of the
resection to prevent damage to the adjacent hepatic ducts. Clamping of the arterial branch will
lead to blanching of the entire right anterior section. The fissure of the right hepatic vein will
indicate the upper resection margin. The vein could be left in place or removed in case of
neoplasm infiltration, also isolated resection of segment VII with ligation of the right hepatic
vein can be safely performed, venous out flow of segment VI should be insured by preserving
the accessory hepatic veins and the right inferior hepatic vein(present in 25%) to prevent the
transitory venous congestion of segment VI with hemorrhage from the resection margins after
isolated removal of segment VII. After clamping of the lateral glissonian pedicle the trunk of
the right hepatic vein will be clamped and divided. Parenchymal dissection will follow the
appearing ischemic demarcation line and the dissection plane will start from the top down‐
ward between segment VII and VIII. The pedicle will be exposed with the dissection once it
have been divided the arterial and portal branches at the hilum can be unclamped, segment
VI returns to its normal color and the inferior demarcation line will become evident.
5.4.10. Isolated segment VI
Similar to segment VII, after mobilization of the right liver, ligation of the inferior or accessory
suprahepatic vein if present and clamping of the arterial and portal brances which will produce
the ischemic demarcation line.
The parenchyma is divided starting from the lower margin of the liver proceeding along an
oblique plane from the right to the left and from the front to back. Deep in the parenchyma the
lateral pedicle is ligated. The glissonian pedicle is then unclamped at the hilum and segment
VII will return to the normal colour, the upper dissection margin will follow the ischemic line
between the two segments VI and VII.
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5.4.11. Isolated segment IV
Segment IV is divided into two subsegments, IVA and IVB, based on the inflow pedicles. Isolated
resection of IVB is usually done in a intra-hepatic ligation method and most often with seg‐
ment V in cases of gallbladder carcinoma. Were outflow control for segment IV resection is
usually not obtained until the liver is divided. After dissection of the hepatoduodenal liga‐
ment the left branches of the hepatic artery are identified and then the middle branch is ligated
and divided. Dissection will be carried out along the gall bladder-inferior vena cava plane.
Glissonian capsule divided above the hilar plate. The portal branch is usually seen with the hilar
plate and dissection with control by Bull-dog clamps to see the line of demarcation. At this point
segment IV will only be attached to the Middle Hepatic vein which will be transfixed.
5.4.12. Isolated segment I ''Caudate lobe''
This is the least popular liver resection as all the other segments can be done in an intra-hepatic
ligation method or in a non-anatomical approach. However, the Caudate liver resection has
its own unique location above the inferior vena cava and its own blood supply giving it the
excellent challenge for any liver surgeon. There are 5 approaches:
1. Bilateral approach: For isolated caudate lobectomy, the caudate lobe is approached from
both right and left side after complete mobilization of the liver with controll of the
suprahepatic and intrahepatic inferior vena cava as well as the right hepatic vein and the
common trunk of the middle and left hepatic veins. Then the caudate lobe is detached
from the inferior vena cava along the anterior surface of the retro-haptic IVC and the short
hepatic veins are identified and divided. The hepatogastric ligament is detached from the
undersurface of the liver and the fibrous hepatocaval ligament need to be divided to free
the spieglian lobe from the IVC and the diaphragm. All short hepatic veins are ligated and
divided. So the caudate lobe is free from the inferior vera cava. The branches of the to the
para caval portion of the caudate lobe from the right portal vein, right hepatic artery and
duct, branches to the spiegelian lobe from the left portal vein, left hepatic artery and duct
are ligated and divided. By carefull dissection the liver is detached from the surroundings
and the right, middle and left hepatic veins. In this step; 2 important land marks for this
dissection : A) the angle between the right hepatic vein and the inferior vans cava i.e the
top of the caudate lobe. B) the meeting point between the caudate process and the right
liver. An imaginary line joining these two points is considered as the caudate boundary
for the liver transection. Meticulous care should be applied not to injure the major vessels
or induce bleeding which will be difficult to control.
2. Left sided approach: Similar to the bilateral approach whit the exception that the dissec‐
tion is mainly from the left side of the liver. In small tumours <3cm, if an isolated partial
caudate lobecetomy or left hepatectomy combined with complete caudate lobecetomy is
carried out. Figure 27
3. Right sided approach: Similar to the bilateral approach whit the exception that the
dissection is mainly from the right side of the liver. In thin patients with right hepatectomy
combined with caudate lobecetomy.
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4. Anterior approach: This approach provides a better operative field by opening the mid
plane of the liver widely so the major hepatic veins and the Hilar plate will be exposed to
direct vision thus will facilitate tumour resection from the main vessels. For tumours >4cm
especially when the tumour is located in the paracaval portion or in close contact with the
major hepatic veins. With tha same technique of the bilateral approach. After freeing the
caudate lobe from the reto-hepatic inferior vena cava, pringle's meneuver is then applied.
The liver is transacted through the mid plane starting from the point between the root of
the right and middle hepatic veins to the fossa of the gall bladder. This is better done using
the hanging technique. When the transection reaches the Hilar plate at the hilum, the
portal triade of the caudate lobe is isolated and divided. The caudate lobes then separated
from the major hepatic veins in one block with the tumour. After removal of the specimen
all bleeding points and bile leak should be controlled individually.
5. Retrograde caudate lobectommy: Used if the tumour is closely adherent to or infiltrating
the inferior vena cava, or if the tumour is too large in size to be turned from one side to
the other. Mobilization of the liver by the division of all the ligaments, control of the
hepatoduodenal ligament, suprahepatic and intrahepatic inferior vena cava for possible
occlusion if necessary. The liver is transected along the mid plane 1cm from the tumour,
the hepatic veins are exposed under direct vision and carefully dissected from the
specimen, ligation and division of the caudate portal triad from the right/left hepatic
arteries and veins. In combined Left/right hepatectomy with caudate lobecetomy the
hepatic pedicel can be transected accordingly. The specimen will be attached only to the
inferior vena cava. The last step here will be the division of the short hepatic veins, and if
the tumour is attached to the IVC part of it could be resected with the tumour and then
it'll be repaired or reconstructed.
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Figure 27. Caudate liver resection, A) the lobe is removed from the IVC and lifted up (left approach). B) The specimen of the caudate with the left 
liver and the CBD for cholangiocarcinoma 
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the liver. In thin patients with right hepatectomy combined with caudate lobecetomy. 
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specimen will be attached only to the inferior vena cava. The last step here will be the division of the short hepatic veins, and if 
the tumour is attached to the IVC part of it could be resected with the tumour and then it'll be repaired or reconstructed. 
4.4.13. Central liver resection 
Segments IV, V, and VIII (also known as mesohepatectomy) is rarely performed. This resection involves ligation of inflow vessels 
from both the right and left portal pedicles. The resection is performed by combining the techniques of segment IV resection and 
right anterior secti nectomy. Dissection begins at the hilum and the umbilical fissure with the goal of inflow contr l. The right 
Figu e 27. audate liver resection, A) the lobe is removed from the IVC and lifted up (left approach). B) The specimen
of the caudate with the left liver and the CBD for cholangiocarcinoma
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5.4.13. Central liver resection
Segments IV, V, and VIII (also known as mesohepatectomy) is rarely performed. This resection
involves ligation of inflow vessels from both the right and left portal pedicles. The resection is
performed by combining the techniques of segment IV resection and right anterior sectionec‐
tomy. Dissection begins at the hilum and the umbilical fissure with the goal of inflow control.
The right anterior sectional pedicle is isolated, as are the segment IV pedicles. The division of
the liver parenchyma begins to the right of the umbilical fissure (or within it if the tumor is
nearby). Figure.28.Care should be given to avoid ligating the left main portal umbilical branch.
Dissection is continued upward to the main trunk of middle hepatic vein. The right anterior
sectional pedicle is ligated to demarcate the boundary of the liver resection on the right side.
Liver transection proceeds in the plane of the right hepatic vein until it meets the left resection
plane. At this point, one should be cautious with handling the freely dangling central lobe.
Excessive traction may tear the thin-walled middle hepatic vein, resulting in massive hemor‐
rhage. Gently hold the lobe and divide the base of the middle hepatic vein. This procedure
removes the gallbladder, central lobe, and middle hepatic vein en bloc, leaving the caudate,
right posterior section, and left lateral section intact. The raw liver surface may be covered with
a flap of omentum.
anterior sectional pedicle is isolated, as are the segment IV pedicles. The division of the liver parenchyma begins to the right of the 
umbilical fissure (or within it if the tumor is nearby). Figure.28.Care should be given to avoid ligating the left main portal umbilical 
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demarcate the boundary of the liver resection on the right side. Liver transection proceeds in the plane of the right hepatic vein 
until it meets the left resection plane. At this point, one should be cautious with handling the freely dangling central lobe. Excessive 
traction may tear the thin-walled middle hepatic vein, resulting in massive hemorrhage. Gently hold the lobe and divide the base 
of the middle hepatic vein. This procedure removes the gallbladder, central lobe, and middle hepatic vein en bloc, leaving the 
caudate, right posterior section, and left lateral section intact. The raw liver surface may be covered with a flap of omentum. 
 
Figure 28. Central liver lesion as seen on CT scan and the same patient intra-operatively after resection  
4.5. Control of bleeding 
To minimize blood loss from the resected raw liver surface the patient is placed 15 degres in the Trendelenburg position [3]. Low 
venous pressure is maintained by minimizing fluid infusion and restricting intraoperative blood transfusion unless more than 25% 
of the blood volume is lost [53,54]. Systolic blood pressure is kept above 90 mm Hg, and intraoperative urine output is maintained 
at about 25 mL/hour [3]. 
Dissection and control of the hepatic veins performed prior to parenchymal transaction.[8].  
Venous outflow draining is divided after dividing the inflow vessels[8], unless the posterior approach is adopted with a Pringles 
manoeuvre to prevent liver congestion. 
Control of the suprahepatic and intrahepatic inferior vena cava [18], pringle's maneuver[3,18], and mobilization with parenchymal 
transection performed with a low central venous pressure < 5 mm Hg [3,11] can decrease the bleeding amount significantly.  
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Figure 28. Central liver lesion as seen on CT scan and the same patient intra-operatively after resection
5.5. Control of bleeding
To minimize blood loss from the resected raw liver surface the patient is placed 15 degres in
the Trendelenburg position [3]. Low venous pressure is maintained by minimizing fluid
infusion and restricting intraoperative blood transfusion unless more than 25% of the blood
volume is lost [53,54]. Systolic blood pressure is kept above 90 mm Hg, and intraoperative
urine output is maintained at about 25 mL/hour [3].
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4. Anterior approach: This approach provides a better operative field by opening the mid
plane of the liver widely so the major hepatic veins and the Hilar plate will be exposed to
direct vision thus will facilitate tumour resection from the main vessels. For tumours >4cm
especially when the tumour is located in the paracaval portion or in close contact with the
major hepatic veins. With tha same technique of the bilateral approach. After freeing the
caudate lobe from the reto-hepatic inferior vena cava, pringle's meneuver is then applied.
The liver is transacted through the mid plane starting from the point between the root of
the right and middle hepatic veins to the fossa of the gall bladder. This is better done using
the hanging technique. When the transection reaches the Hilar plate at the hilum, the
portal triade of the caudate lobe is isolated and divided. The caudate lobes then separated
from the major hepatic veins in one block with the tumour. After removal of the specimen
all bleeding points and bile leak should be controlled individually.
5. Retrograde caudate lobectommy: Used if the tumour is closely adherent to or infiltrating
the inferior vena cava, or if the tumour is too large in size to be turned from one side to
the other. Mobilization of the liver by the division of all the ligaments, control of the
hepatoduodenal ligament, suprahepatic and intrahepatic inferior vena cava for possible
occlusion if necessary. The liver is transected along the mid plane 1cm from the tumour,
the hepatic veins are exposed under direct vision and carefully dissected from the
specimen, ligation and division of the caudate portal triad from the right/left hepatic
arteries and veins. In combined Left/right hepatectomy with caudate lobecetomy the
hepatic pedicel can be transected accordingly. The specimen will be attached only to the
inferior vena cava. The last step here will be the division of the short hepatic veins, and if
the tumour is attached to the IVC part of it could be resected with the tumour and then
it'll be repaired or reconstructed.
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Figure 27. Caudate liver resection, A) the lobe is removed from the IVC and lifted up (left approach). B) The specimen of the caudate with the left 
liver and the CBD for cholangiocarcinoma 
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specimen will be attached only to the inferior vena cava. The last step here will be the division of the short hepatic veins, and if 
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4.4.13. Central liver resection 
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5.4.13. Central liver resection
Segments IV, V, and VIII (also known as mesohepatectomy) is rarely performed. This resection
involves ligation of inflow vessels from both the right and left portal pedicles. The resection is
performed by combining the techniques of segment IV resection and right anterior sectionec‐
tomy. Dissection begins at the hilum and the umbilical fissure with the goal of inflow control.
The right anterior sectional pedicle is isolated, as are the segment IV pedicles. The division of
the liver parenchyma begins to the right of the umbilical fissure (or within it if the tumor is
nearby). Figure.28.Care should be given to avoid ligating the left main portal umbilical branch.
Dissection is continued upward to the main trunk of middle hepatic vein. The right anterior
sectional pedicle is ligated to demarcate the boundary of the liver resection on the right side.
Liver transection proceeds in the plane of the right hepatic vein until it meets the left resection
plane. At this point, one should be cautious with handling the freely dangling central lobe.
Excessive traction may tear the thin-walled middle hepatic vein, resulting in massive hemor‐
rhage. Gently hold the lobe and divide the base of the middle hepatic vein. This procedure
removes the gallbladder, central lobe, and middle hepatic vein en bloc, leaving the caudate,
right posterior section, and left lateral section intact. The raw liver surface may be covered with
a flap of omentum.
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Figure 28. Central liver lesion as seen on CT scan and the same patient intra-operatively after resection  
4.5. Control of bleeding 
To minimize blood loss from the resected raw liver surface the patient is placed 15 degres in the Trendelenburg position [3]. Low 
venous pressure is maintained by minimizing fluid infusion and restricting intraoperative blood transfusion unless more than 25% 
of the blood volume is lost [53,54]. Systolic blood pressure is kept above 90 mm Hg, and intraoperative urine output is maintained 
at about 25 mL/hour [3]. 
Dissection and control of the hepatic veins performed prior to parenchymal transaction.[8].  
Venous outflow draining is divided after dividing the inflow vessels[8], unless the posterior approach is adopted with a Pringles 
manoeuvre to prevent liver congestion. 
Control of the suprahepatic and intrahepatic inferior vena cava [18], pringle's maneuver[3,18], and mobilization with parenchymal 
transection performed with a low central venous pressure < 5 mm Hg [3,11] can decrease the bleeding amount significantly.  
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Figure 28. Central liver lesion as seen on CT scan and the same patient intra-operatively after resection
5.5. Control of bleeding
To minimize blood loss from the resected raw liver surface the patient is placed 15 degres in
the Trendelenburg position [3]. Low venous pressure is maintained by minimizing fluid
infusion and restricting intraoperative blood transfusion unless more than 25% of the blood
volume is lost [53,54]. Systolic blood pressure is kept above 90 mm Hg, and intraoperative
urine output is maintained at about 25 mL/hour [3].
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Dissection and control of the hepatic veins performed prior to parenchymal transaction.[8].
Venous outflow draining is divided after dividing the inflow vessels[8], unless the posterior
approach is adopted with a Pringles manoeuvre to prevent liver congestion.
Control of the suprahepatic and intrahepatic inferior vena cava [18], pringle's maneuver[3,18],
and mobilization with parenchymal transection performed with a low central venous pressure
< 5 mm Hg [3,11] can decrease the bleeding amount significantly.
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Dissection and control of the hepatic veins performed prior to parenchymal transaction.[8].
Venous outflow draining is divided after dividing the inflow vessels[8], unless the posterior
approach is adopted with a Pringles manoeuvre to prevent liver congestion.
Control of the suprahepatic and intrahepatic inferior vena cava [18], pringle's maneuver[3,18],
and mobilization with parenchymal transection performed with a low central venous pressure
< 5 mm Hg [3,11] can decrease the bleeding amount significantly.
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1. Introduction
Resection of malignant lesions arising in the dorsal sector of the liver is a challenging procedure
because the sector is located deep in the abdominal cavity and surrounded by the inferior vena
cava (IVC) and the major hepatic veins [1 – 9]. A hanging maneuver is an innovative procedure
in hepatic surgeries, in which the liver parenchyma is hung by a tape, thereby making a straight
cutting line [10 – 14]. This technique was applied in two patients who had a hepatocellular
carcinoma (HCC) in the dorsal sector. Patient 1 was a 46-year-old female, who was found to
have an HCC, approximately 3 cm in diameter, located just above the IVC. The patient had a
large inferior right hepatic vein (IRHV). The superior right hepatic vein (SRHV) and the IRHV
were individually controlled with a tape after dividing several short hepatic veins from the
right side of the IVC. A cotton tape was introduced from the groove between the SRHV and
the middle hepatic vein (MHV) to the right and left Glisson sheaths via the space just next to
the left side of the IRHV. The liver was split into the right and left hemilivers by pulling the
tape upwards. Next, the tape was introduced from the space behind the confluence of the MHV
and the left hepatic vein (LHV) to the space behind the left Glisson sheath via the fissure of
the ligamentum venosum after dividing a few small Glisson branches into the caudate lobe
from the left Glisson sheath. The liver parenchyma was divided between the medial sector and
the dorsal sector by pulling the tape medially, Finally, the dorsal sector including the tumor
was resected by dividing the short hepatic veins from the left side of the IVC. Patient 2 was a
59-year-old male, who was found to have an HCC, approximately 3 cm in diameter, located
in the Spiegel lobe (a part of the dorsal sector) during a follow-up for chronic hepatitis B. The
tumor compressed the left side of the IVC and protruded inferomedially. Cotton tape was
introduced from the groove between the MHV and the LHV to the groove between the right
and left Glisson sheaths via the posterior surface of the liver after dividing all the short hepatic
© 2013 Uchiyama et al.; licensee InTech. This is an open access article distributed under the terms of the
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veins from the right side of the IVC. The liver was split into the right and left hemilivers by
pulling the tape upwards. The liver parenchyma was divided between the medial sector and
the dorsal sector as in Patient 1. The operation time was 623 and 435 minutes and the intrao‐
perative blood loss was 834 and 1320 grams, respectively. No complications occurred in the
two patients. The application of hanging maneuvers enables surgeons to safely resect tumors
located deep in the dorsal sector of the liver.
This surgical technique requires a lot of indispensable procedures for hepatic surgeries. This
chapter presents the step-by-step surgical procedures regarding hanging maneuvers for an
isolated resection of the dorsal sector.
2. Patients
The patients’ characteristics and preoperative laboratory data are summarized in Table 1.
Patient 1 had a cirrhotic liver caused by hepatitis B and had undergone laparoscopic splenec‐
tomy approximately two months before hepatectomy to control intractable ascites caused by
splenomegaly accompanied with cirrhosis. Patient 2 had a fibrotic liver caused by chronic
hepatitis B. Both patients had a solitary HCC in the dorsal sector.
Patient 1 Patient 2
age 46 59
gender female male
native liver disease cirrhosis caused by hepatitis B chronic hepatitis B
white blood cell (/μl) 4900 5400
hemoglobin (g/dl) 7.9 14.7
platelet (× 103 /μl) 235 171
total bilirubin (mg/dl) 0.49 0.42
albumin (g/dl) 3.2 4.6
prothrombin time – international
normalized ratio
1.05 0.95
indocyanine green dye retention at 15
minutes (%)
27 13
tumor diameter (cm) 3 3
Table 1. Patient characteristics and preoperative laboratory data
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3. Surgical procedures in patient 1
The HCC, approximately 3 cm in diameter, was located just above the IVC (Figure 1). A limited
hepatectomy was selected because the patient had a relatively advanced cirrhotic liver and the
preoperative evaluations predicted that an extended hepatectomy would have led to postop‐
erative liver failure.
Figure 1. Hepatocellular carcinoma in Patient 1 located just above the inferior vena cava
Figure 2 shows a schematic diagram of the surgical procedure. Patient 1 had a relatively large
IRHV. This vein was kept intact because its division could have caused congestion of the
posterior sector. The liver was split into the right and left hemilivers by dividing the liver
parenchyma along the right side of the middle hepatic vein using a hanging maneuver with a
cotton tape introduced into the space between the posterior surface of the liver and the anterior
surface of the IVC. The liver parenchyma was divided between the medial sector and the dorsal
sector using a hanging maneuver with a cotton tape placed in the fissure of the ligamentum
venosum.
The patient was placed in the supine position. The abdomen was opened by bilateral subcostal
incisions with an upper midline extension. There was a small amount of ascites and the liver
had a cirrhotic appearance. Cholecystectomy was performed and a tube was inserted into the
cystic duct for cholangiography. The right lobe was mobilized clockwise by dividing the right
triangular ligament. The IVC ligament was divided, and the SRHV and the IRHV were
individually encircled with a tape. A thin cotton tape was introduced from the groove between
the SRHV and the confluence of the MHV and the LHV to the left-side space of the IRHV
(Figure 3).
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The procedure moved on to the hepatic hilum. The right Glisson sheath was encircled with a
tape. A small notch was made on the lowest part of the dividing plane as a hook for the hanging
tape (Figure 4).
The left lateral lobe was mobilized counterclockwise by dividing the left triangular ligament.
The ligamentum venosum was divided near the LHV (Figure 5). Thereafter, the confluence of
the MHV and the LHV was encircled with a tape.
Figure 2. Schematic diagram of the hanging maneuvers for the isolated resection of the dorsal sector used in Patient
1 IRHV, the inferior right hepatic vein; IVC, the inferior vena cava; MHV, the middle hepatic vein; T, tumor
Figure 3. Introducing a cotton tape along the left-side spaces of the superior and the inferior hepatic veins SRHV, the
superior right hepatic vein; IRHV, the inferior right hepatic vein
Hepatic Surgery260
Figure 5. Division of the ligamentum venosum
The tail of the cotton tape was introduced into the groove between the right and the left Glisson
sheath. The liver was split into the right and the left hemilivers by pulling up the cotton tape
upwards (Figure 6, 7).
Figure 4. Taping of the right Glisson sheath
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The procedure moved on to the hepatic hilum. The right Glisson sheath was encircled with a
tape. A small notch was made on the lowest part of the dividing plane as a hook for the hanging
tape (Figure 4).
The left lateral lobe was mobilized counterclockwise by dividing the left triangular ligament.
The ligamentum venosum was divided near the LHV (Figure 5). Thereafter, the confluence of
the MHV and the LHV was encircled with a tape.
Figure 2. Schematic diagram of the hanging maneuvers for the isolated resection of the dorsal sector used in Patient
1 IRHV, the inferior right hepatic vein; IVC, the inferior vena cava; MHV, the middle hepatic vein; T, tumor
Figure 3. Introducing a cotton tape along the left-side spaces of the superior and the inferior hepatic veins SRHV, the
superior right hepatic vein; IRHV, the inferior right hepatic vein
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Figure 6. Splitting of the liver into the right and left hemilivers using a hanging maneuver (schematic diagram) LHV,
the left hepatic vein; MHV, the middle hepatic vein; SRHV, the superior right hepatic vein
Figure 7. Splitting of the liver into the right and left hemilivers using a hanging maneuver (photograph)
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Splitting the liver into the two hemilivers revealed a few caudate branches from the left Glisson
sheath (Figure 8). These branches were divided to make a space behind the left Glisson sheath
(Figure 9). A cotton tape was introduced from the space behind the confluence of the MHV
and the LHV to the space behind the left Glisson sheath via the fissure of the ligamentum
venosum. The liver parenchyma was transected between the medial sector and the dorsal
sector by medially lifting the cotton tape (Figure 10).
Figure 8. Division of the caudate branch from the left Glisson sheath (left) and a hanging maneuver for transecting
the liver parenchyma between the medial sector and the dorsal sector (right) Green arrows indicate the caudate
branch from the left Glisson sheath. LHV, the left hepatic vein; MHV, the middle hepatic vein
Figure 9. Division of the caudate branch from the left Glisson sheath
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Figure 10. A hanging maneuver for transecting the liver parenchyma between the medial sector and the dorsal sector
All the short hepatic veins from the dorsal sector were divided from the left side of the IVC
(Figure 11, 12). The IVC ligament was divided, and the dorsal sector including the tumor was
retrieved from the surgical field (Figure 13).
Figure 11. Division of the short hepatic veins from the left side of the inferior vena cava (schematic diagram) Green
arrows indicate the short hepatic veins to be divided.
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Figure 13. Completion of the isolated resection of the dorsal sector IVC, the inferior vena cava 
4. Surgical procedures in patient 2 
The surgical procedures in Patient 2 were reported previously [15]. The procedures differed in two points from the procedures 
used in Patient 1: All the short hepatic veins were divided from the right side of the IVC and the liver was split into hemilivers 
along the left side of the MHV by introducing cotton tape through the groove between the MHV and the LHV. 
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Figure 10. A hanging maneuver for transecting the liver parenchyma between the medial sector and the dorsal sector
All the short hepatic veins from the dorsal sector were divided from the left side of the IVC
(Figure 11, 12). The IVC ligament was divided, and the dorsal sector including the tumor was
retrieved from the surgical field (Figure 13).
Figure 11. Division of the short hepatic veins from the left side of the inferior vena cava (schematic diagram) Green
arrows indicate the short hepatic veins to be divided.
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The surgical results are summarized in Table 2. Patient 1 required transfusion of two units of
red blood cell because of pre-existing anemia. The resected specimens had an acceptable
tumor-free surgical margin. Kinetics of the laboratory data are shown in Figure 14 and 15. Both
patients exhibited rapid recovery of laboratory data. Follow-up CT after the surgeries dem‐
onstrated that there were no perfusion abnormalities in the livers (Figure 16).
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operation time (minutes) 623 435
intraoperative blood loss (grams) 834 1320
blood transfusion two units of concentrated red blood
cell
none
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Figure 16. Follow-up CT of Patient 1 two months after the surgery Yellow arrows indicate the dividing plane between the right and left hemilivers. 
6. Conclusion 
Livers with malignant lesions to be resected are often cirrhotic. Parenchymal transection of cirrhotic liver from the dorsal direction 
may cause uncontrollable bleeding. The application of hanging maneuvers to an isolated resection of the dorsal sector enables 
surgeons to safely transect the liver parenchyma only via an anterior approach.  
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1. Introduction
Hepatectomy is an established first-line therapeutic option for hepatocellular carcinoma. Be‐
cause there is high likelihood of cancer cells from hepatocellular carcinoma spreading
throughout the portal venous system, anatomical hepatectomy is effective for eradication of
the intrahepatic metastases of hepatocellular carcinoma [1, 2].
Figure 1. The hepatocellular carcinomais located in segment 8 of the liver (A) and close to the root of the right anteri‐
or Glissonean pedicle (B).
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For patients with hepatocellular carcinomalocated in the right anterior section or close to the
root of the right anterior Glissonean pedicle (Figure 1A, 1B), right anterior sectionectomy
has an important advantage, i.e., preservation of nontumorous parenchyma, over conven‐
tional hemihepatectomy. Although right anterior sectionectomy is a difficult hepatic resec‐
tion because of the danger of intraoperative bleeding from the middle and right hepatic
veins and risk factor of postoperative bile leakage [3, 4], this surgical procedure is safe and
effective in selected patients [5, 6]. Laparoscopic mesohepatectomy is performed at limited
institutions [7, 8]; however, the use of this procedure is limited and controversial to date be‐
cause of the high degree of proficiency required. Herein, we describe techniques of right an‐
terior sectionectomy using theGlissonean pedicle transection method via a conventional
open laparotomy approach. The Brisbane 2000 terminology of liver anatomy andresections
is used in this manuscript.
2. Surgical technique
Laparotomy is performed through an upper midline incision with right lateral subcostal ex‐
tension (reversed L-shaped incision). The xiphoid process is excised, the round ligament is
ligated and divided, and the falciform ligament is divided along the surface of the liver. We
routinely conduct an intraoperative ultrasonography for hepatectomy to define the tumor
location and vessels to be manipulated for resection.The right hemiliver is mobilized by di‐
viding the coronary and right triangular ligaments; however, the right adrenal gland is not
dissected from the right hemiliver. The ventral surfaces of the root ofthe right and middle
hepatic veins are exposed. A cholecystectomy is performed and a 4-Fr. biliary tube is insert‐
ed through the cystic duct for a bile leakage test after removing the specimen.
The hepatoduodenal ligament is encircled and taped. The peritoneum of the hepatoduode‐
nal ligament is dissected at the ventral and dorsal sides of the hepatic hilum, the hilar plate
is detached blindly and bluntly from the liver parenchyma, and then, the right Glissonean
pedicle is encircled extrahepatically using Kelly forceps.To avoid injury to the elements of
the caudate lobe, the right Glissonean pedicle should be encircled on the right side of the
caudate process branch. After the cystic plate is dissected, the right anterior Glissonean
pedicle is identified and encircled extrahepatically[9, 10] (Figure 2). If a large liver tumor is
located near the root of the right Glissonean pedicle, it is difficult to approach the Glisso‐
nean pedicle extrahepatically; therefore, the anterior branches of the right hepatic artery and
right portal vein are encircled separately [11].
After the right anterior Glissonean pedicle is clamped,discoloration of the right anterior sec‐
tion is confirmed, and the demarcation line is then marked by electrocautery (Figure 3).
Using the Pringle maneuver, a parenchymal dissection between the left medial and right an‐
terior sections is performed along the demarcation line from the caudal towardthe cranial
direction using an ultrasonic surgical aspirator and the right side of the middle hepatic vein
is exposed on the raw surface of the liver. The branches of the middle hepatic vein originat‐
ing from the anterior section are ligated and divided, and the thick branches should be
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clamped with vascular clamp forceps, divided and sewn with a continuous suture (Figure
4). At the cranial and caudal ends of the parenchymal dissection, the right side of the middle
hepatic vein root and the left side of the right anterior Glissonean pedicle are identified, re‐
spectively. The dorsal end point of the parenchymal dissection is the line which connects the
root of the middle hepatic vein and the hilar plate.
Using right hemihepatic vascular occlusion [12], a parenchymal dissection between the right
anterior and posterior sections is performed along the demarcation line from the caudal to‐
ward the cranial direction using anultrasonic surgical aspirator and the left side of the right
hepatic vein is exposed on the raw surface of the liver. After the parenchymal dissection is
progressed toward the right anterior Glissonean pedicle, the anterior Glissonean pedicle is
exposed as distally as possible to avoid biliary injury of the right posterior section (Figure 5)
and divided using the stapler or double transfixing sutures (Figure 6). At the cranial end of
parenchymal dissection, the left side of the right hepatic vein root is identified.
By retracting the anterior section upward, the parenchymal dissection between the right an‐
terior section and caudate lobe is advanced from the caudal to the cranial direction (Figure
7). Then, the right anterior section is removed (Figure 8).
Hemostasis of the raw surface of the liver is confirmed and the bile leakage test performed.
Then, the biliary tube is extracted, and the stump of the cystic duct is ligated.
A closed drain is placed in the raw surface of the liver.
Figure 2. The right and right anterior Glissonean pedicles are encircled extrahepatically.
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Figure 3. The right anterior section is marked by electrocautery.
Figure 4. The branch of the middle hepatic vein originating from the anterior section (V8) is clamped with vascular
clamp forceps.
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Figure 5. The anterior Glissonean pedicle is exposed as distally as possible.
Figure 6. The anterior Glissonean pedicle isdivided using the stapler.
Right Anterior Sectionectomy for Hepatocellular Carcinoma
http://dx.doi.org/10.5772/51029
275
Figure 3. The right anterior section is marked by electrocautery.
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Figure 5. The anterior Glissonean pedicle is exposed as distally as possible.
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Figure 7. By retracting the anterior section upward, the parenchymal dissection between the right anterior section
and caudate lobe is advanced from the caudal to the cranial direction.
Figure 8. After the right anterior section is removed, the right side of the middle hepatic vein and the left side of the
right hepatic vein are exposed on the raw surface of the liver.
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3. Comments
Between April 2010 and May 2012, 8 patients underwent a right anterior sectionectomyus‐
ing the Glissonean pedicle transection method for hepatocellular carcinoma at our institu‐
tion. The median surgical time was 323 minutes (range: 227-468 minutes)and the median
surgical blood loss was 830.5 ml (range: 180-2009 ml). There was one postoperative compli‐
cation, i.e., bile leakage, and no mortality.
TheextrahepaticGlissonean pedicle approach is preferable to avoid postoperative lymphatic
leakage than separately dividing the arterial and portal branches of the right anterior sec‐
tion. It is important to divide the right anterior Glissonean pedicle as distally as possibleto
avoid biliary injury of the right posterior section.
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Figure 7. By retracting the anterior section upward, the parenchymal dissection between the right anterior section
and caudate lobe is advanced from the caudal to the cranial direction.
Figure 8. After the right anterior section is removed, the right side of the middle hepatic vein and the left side of the
right hepatic vein are exposed on the raw surface of the liver.
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1. Introduction
Historically benign liver tumors were encountered incidentally during laparotomy or more re‐
cently during laparoscopy at which time definitive histological diagnosis can be established.
However, with the utilization of advanced imaging modalities hepatic neoplasms have been in‐
creasingly identified, with a prevalence rate of up to 50% reported among the general popula‐
tion [1]. Among these incidental lesions, 83% were characterized as benign neoplasms, as
outlined in Table 1 [1-3]. Benign hepatic neoplasms represent a diverse group of tumors that de‐
velop from either epithelial or mesenchymal cell lines (Table 2), and while the frequency of such
lesions is not well documented, more than 50% are classified as hemangiomas [1]. Focal nodu‐
lar hyperplasia (FNH) and hepatic adenomas represent the next most frequently diagnosed be‐
nign tumors. A variety of additional exceedingly rare benign lesions have also been described
most of which are sufficiently infrequent enough to be classified as “fascinomas” [1].
Neoplasm Relative frequency
Hemangioma 52%
Focal nodular hyperplasia 11%
Metastatic tumor (TxNxM1) 11%
Hepatocellular adenoma 8%





Other benign hepatic process 1%
Table 1. Diagnostic frequency of incidentally identified solid liver neoplasms1,2,9
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Table 2. Benign solid liver neoplasms1,9
Most benign tumors are asymptomatic which makes standardizing the work-up difficult. The
evaluation of incidental solid hepatic tumors should be individualized based upon the
patient’s age, sex, past medical history, medications, and associated clinical signs. Although
physical examination of the abdomen is typically unremarkable it may rarely reveal localized
tenderness and/or a palpable mass. Liver function tests are indicated though are seldom
abnormal in asymptomatic patients. Additional laboratory testing such as alpha-fetoprotein
(AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 19-9 and, lactate dehy‐
drogenases may also be ordered depending on the clinical scenario.
Substantial advancements and the widespread availability and use of modern imaging
modalities to diagnose and treat abdominal pain, has led to a marked increase in the identifi‐
cation of benign liver tumors. A full discussion of the advantages and disadvantages of
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individual imaging techniques is beyond the scope of this chapter but is outlined in Table 3.
Briefly, B-mode ultrasonography (US) can effectively differentiate cystic and solid neoplasms
and is usually the initial study of choice [4,5]. Contrast-enhanced computed tomography (CT)
provides greater sensitivity than US for determination of lesion number, size, and location [5,
6]. Magnetic resonance imaging (MRI) represents the most sensitive and specific study to
discriminate between various benign liver lesions, particularly when contrast agents are used
[5-7]. Finally, fluorodeoxyglucose positron emission tomography (18FDG-PET) can aid in the
differentiation of benign versus malignant tumors based on the metabolic activity of the lesion
[8]. Although modern imaging techniques can precisely diagnose the vast majority of inci‐
dental benign tumors, laparoscopic or open biopsy is necessary to exclude malignancy when
precise diagnosis remains elusive.
US = ultrasonography; CT = computed tomography; MRI = magnetic resonance imaging; T1 = T1-weighted MRI; T2 = T2-
weighted MRI; Tc-99m RBC = technetium-99m-labeled red blood cell; Tc-99m SC = technetium-99m sulfur colloid.
Table 3. Radiographic appearance of benign liver neoplasms1,9
Accurate diagnosis is essential to the appropriate management of hepatic neoplasms. Al‐
though patients may require surgical intervention for diagnostic purposes, few benign tumors
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on autopsy studies with 60%-80% identified in individuals in their 4th- 6th decade of life
[12-16].The precise etiology of hemangiomas is poorly understood but they are generally
considered to be benign congenital hamartomas composed of disorganized venous vascula‐
ture separated by intervening fibrous tissue [17]. Hemangiomas vary greatly in size from a
few millimeters to over 50 cm, with the majority (up to 80%) less than 4 cm [1,12,18]. Although
most commonly solitary, up to 40% of patients with hemangiomas have multiple tumors [19].
Capillary hemangiomas are more prevalent than are cavernous hemangiomas [1,20]. However,
these hypervascular lesions are typically small (2 cm) and are rarely clinically significant [1].
As such, the management of capillary hemangiomas requires the exclusion of malignancy and
patient reassurance that routine surveillance is not necessary in the absence of symptoms [9].
Cavernous hemangiomas are far more often clinically relevant than capillary hemangiomas.
The incidence of cavernous hemangiomas is 3 times greater among women than men, with a
mean age of 45 years [12,16]. Whether this reflects a true increase in incidence or a result of
more frequent imaging amongst females remains unclear as evident by one autopsy series in
which there was a nearly equal sex incidence [1,21]. Although no link between oral contra‐
ceptive pill (OCP) use and hemangioma incidence has been established, early studies suggest
a link between OCP use and increased hemangioma size at initial presentation [18].
3. Clinical presentation
The most frequently reported symptoms of liver hemangiomas include abdominal pain, nau‐
sea, vomiting, early satiety, and prolonged fever [1,22]. Most symptoms of hepatic hemangio‐
ma are attributable to rapid expansion, thrombosis, or infarction, resulting in inflammation or
stretching of Glisson’s capsule [1]. Large hemangiomas (> 10 cm) may occasionally present as a
non-tender palpable mass in the right upper quadrant, however physical exam more often re‐
veals only vague abdominal tenderness without a mass [1,23]. Occasionally, a bruit maybe de‐
tected over the liver. Evidence of intratumoral or intraperitoneal rupture may be reflected by
hemoperitoneum and subsequent shock, which requires emergent surgical intervention. Rare‐
ly biliary colic, obstructive jaundice, gastric obstruction, torsion of a pedunculated lesion, pul‐
monary embolism, spontaneous intraperitoneal hemorrhage, and consumptive coagulopathy
have been reported [22,24,25]. Kasabach-Merritt syndrome, which was originally used to de‐
scribe thrombocytopenia and afibrinogenemia associated with hemangiomas on the skin and
spleen of infants, is frequently used to define hepatic hemangioma patients with severe throm‐
bocytopenia and concomitant consumptive coagulopathy [26].
4. Pathology
Hemangiomas are typically well demarcated from surrounding hepatic tissue, which often
permits surgical enucleation [27]. In tumors not well demarcated, the tumor-parenchymal
interface defines the ease with which enucleation versus formal resection is required. Four
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interface variants between the hemangioma and hepatic parenchyma have been described.
The “fibrolamellar” interface is characterized by a capsule-like fibrous ring of various thickness
and is the most common [9]. The involved veins parallel the periphery of the hemangioma or
traverse the fibrous lamella. The healthy hepatic parenchyma is often atrophic and a plane
between the hemangioma and uninvolved liver tissue is well defined. A second variant, the
“compression” interface consists of a hemangioma in which the periphery of the neoplasm is
well demarcated despite the absence of a fibrous lamella [1]. An “interdigiting” pattern lacks
a fibrous lamella and instead is replaced by an ill-defined plane between the vascular channels
of the hemangioma and uninvolved hepatic parenchyma [1]. Finally, an “irregular” or
“spongy” interface occur when the hemangioma appears to intercalate into the surrounding
hepatic parenchyma [1]. Despite the invasive appearance of this variant, hemangiomas do not
possess any malignant potential.
The diagnosis of cavernous hemangioma is generally easy to establish with modern imaging
techniques. However, in some instances atypical hemangiomas may be confused for other
pathology, including but not limited to, hemorrhagic telangiectasia (Osler-Rendu-Weber),
hemangioendothelioma, and peliosis hepatis [9]. When diagnosis remains unclear, indeter‐
minate lesions should be managed surgically as percutaneous biopsy may result in uncon‐
trollable hemorrhage [1].
5. Radiographic evaluation
Accurate radiographic diagnosis of hepatic hemangioma is essential since once definitive
diagnosis is established no additional intervention is typically required [9]. Radiographic
evaluation is largely dictated by clinical presentation as most hemangiomas are discovered
incidentally on imaging studies completed for unrelated symptomology and/or pathology.
Depending on the initial degree of diagnostic certainty additional imaging maybe superfluous.
B-mode ultrasonography is typically the initial imaging study performed [1]. On US heman‐
giomas appear as a homogenous hyperechoic mass that is well demarcated from surrounding
liver parenchyma [1,28,29]. The addition of duplex US provides additional information
regarding peripheral blood flow and central pooling of venous blood [1,28]. As malignant
lesions may demonstrate similar acoustic patterns, additional imaging modalities are often
required for definitive confirmation. On contrast enhanced compute tomography (CE-CT)
hemangiomas initially appear as hypodense masses with a pattern of irregular peripheral
nodular enhancement following initial injection of contrast [30,31]. Delayed venous images
subsequently demonstrate characteristic central venous filling of the hypodense mass [30,31].
Magnetic resonance imagining (MRI), though rarely needed for diagnosis of most hemangio‐
mas, is the most sensitive and specific modality for the detection and diagnosis of hemangioma
[6,32]. T-1 weighted images reveal a smooth well-demarcated homogenous isodense mass,
whereas T-2 weighted studies demonstrate a hyperdense pattern [33,34]. The administration
of intravenous gadolinium diethylenetriaminepentaacetic acid (Gd-DTPA) contrast results in
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images [1,35,36]. This enhancement pattern is typical of most hemangiomas > 2 cm [37].
Hemangiomas < 2 cm may demonstrate rapid uniform enhancement which is indistinguish‐
able from hypervascular hepatocellular carcinoma (HCC) [37]. 18F-FDG PET scan may be useful
for differentiation between benign and malignant hepatic tumors [38]. Studies have shown
that the activity of both glucose-6-phosphatase and glucose transporters are increased in HCC
resulting in decreased uptake of 18F-FDG in hemangiomas as compared to HCC [8]. Histori‐
cally, technetium-99 labeled red blood cells scintigram (Tc-99 RBC scan) was the gold standard
for the diagnostic evaluation of hemangiomas, but technological advancements in axial
imaging has led to a decline in the reliance on RBC scintigraphy [31,39]. Finally, selective
hepatic angiography typically yields a characteristic neovascular “corkscrewing” appearance
with rapid central filling from the neovascular periphery described as “cottonwool” [1].
Despite these characteristic findings, the high diagnostic yield of less invasive modalities
makes arteriography rarely necessary.
6. Diagnosis & treatment
The majority of hemangiomas are asymptomatic, particularly those lesions < 1.5 cm in size [1].
Although hemangiomas can grow to great sizes, they generally do not compromise liver
function and as such liver function tests are often normal. In rare instances thrombosis or
intraparenchymal hemorrhage may occur acutely affecting liver function tests. Spontaneous
rupture of hepatic hemangiomas is an exceptionally rare event with a review of the literature
revealing less than 30 cases of spontaneous rupture since 1898. Given the low yet significant
risk of bleeding, fine needle aspiration (FNA) should be avoided [1]. As a rule, biopsy is only
indicated if a histologic diagnosis is unclear or will alter planned treatment, thus in the absence
of clinical symptoms the most appropriate treatment strategy is careful observation [1].
Surgical resection should be considered in patients with disabling pressure or pain suggestive
of extrinsic compression of adjacent structures, in those experiencing acute symptoms related
to rupture, or when malignancy cannot be ruled out [22,40]. In general clinical symptoms
increase concurrently with tumor size, with most symptomatic tumors having a mean size of
10 ± 8 cm as compared with 6.8 ± 5.8 cm for asymptomatic lesions [41].
Surgical intervention should be approached no differently than for treatment of other hepatic
tumors. It is essential that surgeons possess an extensive knowledge of the anatomy and
vascular supply of the liver. The extent of hepatic resection required is directly related to the
anatomic location of the lesion and its proximity to surrounding vasculature. Thus, the location
of the lesion will largely dictate the operative approach hence a full evaluation of the tumor’s
extent is critical. Large central lesions which border the inferior vena cava, hepatic outflow
tract, or the portal vein, may pose an exorbitant surgical risk and as such may not allow for
resection [1].
While enucleation is often indicated, formal resection is required in certain instances. Recall it
is the histological features of the tumor-parenchymal interface which defines how easily a
parenchymal-sparing technique may be utilized. Unlike malignant lesions, resection of
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hemangiomas does not necessitate removal of a margin of normal tissue with the tumor.
Enucleation is carried out by careful dissection within the proper plane between the hepatic
parenchyma and tumor. Division and ligation of the principal hepatic artery should be
completed early in the operation as this often results in significant tumor decompression
thereby facilitating resection [1]. The majority of hemangiomas are contained within a tough
fibrous capsule which can be clamped and used for retraction purposes [1]. As hepatic venous
branches are encountered extending from the lesion they should be controlled with clips or
ties [1]. Presently, mortality outcomes for resection and enucleation are comparable [42].
Hepatic artery ligation for treatment of hemangioma has also been described anecdotally [9].
Although its benefits are likely transient, hepatic artery embolization and/or ligation play a
pivotal role only in the temporary management of uncontrolled hemorrhage from rupture
[43,44]. Finally, radiation therapy for symptomatic hemangiomas has also been reported.
Though data validating the use of radiotherapy is limited, it seems a reasonable approach for
symptomatic hemangioma where surgical intervention is clearly contraindicated.
7. Special issue: Hemangioma in children
Hepatic  hemangiomas of  infancy and childhood differ  substantially in their  appearance,
presentation, and progression than those in adults [1]. These lesions are frequently large
and symptomatic.  In contrast to adult  hemangiomas, the risk of spontaneous rupture in
infancy is  greater [1].  Similarly,  Kasabach-Merritt  syndrome occurs more frequently and
results more often in death among affected infants.  As a result of the numerous venous
lakes within these lesions, which serve as siphons for a large proportion of the total car‐
diac  output,  severe  congestive  heart  failure  and  death  may  result.  Initial  treatment  of
high  output  cardiac  failure  in  children  includes  oxygen,  diuretics,  digitalis,  corticoste‐
roids,  hepatic artery ligation, and radiation therapy [2,  45-48].  Contrary to the conserva‐
tive  management  of  adult  hemangiomas,  hemangiomas  of  infancy  and childhood more
frequently require life-saving surgical intervention.
8. Focal nodular hyperplasia
Focal nodular hyperplasia (FNH) is the second most common benign hepatic lesion [20]. FNH
is found predominately in women (in a ratio of 8-9:1) between the ages of 20-50 years, and has
a prevalence of 4 - 8% in the general population [49,50]. Similar to hemangiomas, the prevalence
of FNH has markedly increased over the past several decades, which likely reflects the
proficiency and widespread use of advanced imaging modalities [1].
Although Klatskin (1977) and Vana (1979) each reported an association between OCP use and
the development of FNH, the high frequency of FNH in the absence of OCP use suggests no
causal relationship [32,51]. However, enlargement of FNH lesions has been described in the
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yet been clearly delineated, it has been suggested that FNH is a hyperplastic polyclonal
response of normal hepatic parenchyma to localized areas of increased arterial perfusion [53].
Expectantly, FNH has been found in association with vascular disorders and malformations
including hereditary hemorrhagic telangiectasia, hemihypertrophy Klippel-Trenaunay-
Weber syndrome, and congenital absence of the portal vein [49,54-57].
While typically small (< 5 cm), FNH lesions have been reported as large as 19 cm [48,50]. The
majority of FNH lesions are solitary in nature (80%-95%), although up to 20% of individuals
are reported to have multiple lesions [1, 48, 50]. When multifocal, FNH often occurs in
conjuncture with other benign hepatic lesions including hemangiomas [58].
9. Clinical presentation
FNH is frequently asymptomatic with up to 75% of lesions discovered incidentally dur‐
ing radiologic workup, laparotomy, or laparoscopy for unrelated pathology [59].  Similar
to hepatic  hemangiomas,  spontaneous rupture is  extremely rare as illustrated by Cham‐
berlain et.  al  (2003)  management of  33 patients  with FNH where no ruptures were evi‐
dent  [9].  Large,  peripheral,  pedunculated  lesions  may  result  in  a  palpable  mass
associated with abdominal pain and/or fullness, but acute symptoms associated with rup‐
ture, necrosis, or infarction are a rarity.
10. Pathology
Macroscopically FNH is a firm pale to red colored lesion with sharp margins. Lesions are
typically small, pedunculated, and peripherally located. Unlike hemangiomas and hepatic
adenomas, FNH lack a capsule. Histologically FNH appears as regenerative nodules making
histopathological differentiation from cirrhosis difficult. Lesions contain normal hepatic
elements with a haphazard arrangement of cords and sinusoids [5]. Proliferating bile ducts,
fibrous septae, Kupffer cells, and sinusoids are typically present in FNH, and are characteris‐
tically absent in hepatocellular adenomas [13,50,59]. Generally FNH contain a large artery with
multiple branches radiating through disorganized fibrous septa to the periphery. This
radiating arterial pattern produces a spoke and wheel image on angiography and is responsible
for the central scar appearance on radiographic imaging studies [60,61].
11. Radiographic imaging
Definitive diagnosis of FNH can be challenging. FNH lesions are well visualized on US but
are highly variable and exhibit no distinct characteristic features. Helical CE-CT reveals a well-
demarcated lesion that is often isodense [29]. However, during the portal venous phase the
pathognomonic central scar may be appreciated. Distinguishing FNH on standard MRI can
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prove challenging as the lesion is composed of the similar elements as the normal liver
parenchyma. FNH may appear isointense with a central scar on T-1 and T-2 weighted imaging
[62]. MRI with Gd-DTPA demonstrates a hyperintense lesion early, which becomes isointense
with central scar enhancement on delayed imaging [63-65]. The use of reticuloendothelial
agents including Ferridex, which is taken up selectively by Kupffer cells, increases the
specificity of both CT and MRI imaging [1]. Technetium-99-labeled sulfur colloid scintigraphy
may prove helpful in demonstrating the presence of Kupffer cells within the FNH lesion,
however this finding is not specific enough for definitive diagnosis [1,66,67]. Angiography,
though rarely indicated for the diagnosis of FNH, usually demonstrates a hypervascular mass
with a single central artery and enlarged peripheral vessels in a “spoken wheel” appearance
[66-68]. Finally, 18F-FDG PET can aid in the differentiation between benign and malignant
lesions, but it is neither sensitive nor specific enough for diagnosis of FNH [8,38].
12. Diagnosis & treatment
The natural  course of an FNH lesion is generally indolent with minimal risk of rupture
or complication.  Laboratory testing generally  reveals  normal  liver  function tests  and al‐
pha-fetoprotein levels, although minor elevations in aspartate and alanine aminotransfer‐
ase, alkaline phosphatase, and gamma glutamyl transpeptidase may occasionally be seen.
Definitive diagnosis  of  FNH in an asymptomatic  patient  warrants conservative manage‐
ment  and includes  close  observation with  repeat  imaging every  four  to  six  months  [9].
When radiology is equivocal, most surgeons still choose close observation with follow-up
studies  preformed every three  to  four  months.  Biopsy is  generally  not  indicated,  as  re‐
sults are seldom diagnostic [69].
Although it may be impossible to distinguish FNH from a well-differentiated HCC without
surgical excision, FNH tumors do not undergo malignant transformation. Thus indications for
surgical intervention should be limited to those situations where there is a change in the size
or number of lesion(s), a change in the intensity of symptoms, or where classic imaging
characteristics are absent and diagnostic dilemma remains [70]. Hence, the role of the surgeon
is typically limited to patient reassurance and close observation [9].
13. Hepatic adenoma
Hepatic adenomas are identified predominately in women of reproductive age [49]. The
estimated prevalence of hepatic adenomas within the general population on postmortem
exams is approximately 1% [10]. Etiologically, hepatic adenomas are of epithelial origin. Unlike
hepatic hemangiomas and FNH, a clear association between the use of OCPs and hepatic
adenomas has been established. First described in 1973, multiple studies have documented a
reciprocal relationship between OCP use and adenoma incidence based on estrogen dose and
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dent  [9].  Large,  peripheral,  pedunculated  lesions  may  result  in  a  palpable  mass
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histopathological differentiation from cirrhosis difficult. Lesions contain normal hepatic
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radiating arterial pattern produces a spoke and wheel image on angiography and is responsible
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demarcated lesion that is often isodense [29]. However, during the portal venous phase the
pathognomonic central scar may be appreciated. Distinguishing FNH on standard MRI can
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prove challenging as the lesion is composed of the similar elements as the normal liver
parenchyma. FNH may appear isointense with a central scar on T-1 and T-2 weighted imaging
[62]. MRI with Gd-DTPA demonstrates a hyperintense lesion early, which becomes isointense
with central scar enhancement on delayed imaging [63-65]. The use of reticuloendothelial
agents including Ferridex, which is taken up selectively by Kupffer cells, increases the
specificity of both CT and MRI imaging [1]. Technetium-99-labeled sulfur colloid scintigraphy
may prove helpful in demonstrating the presence of Kupffer cells within the FNH lesion,
however this finding is not specific enough for definitive diagnosis [1,66,67]. Angiography,
though rarely indicated for the diagnosis of FNH, usually demonstrates a hypervascular mass
with a single central artery and enlarged peripheral vessels in a “spoken wheel” appearance
[66-68]. Finally, 18F-FDG PET can aid in the differentiation between benign and malignant
lesions, but it is neither sensitive nor specific enough for diagnosis of FNH [8,38].
12. Diagnosis & treatment
The natural  course of an FNH lesion is generally indolent with minimal risk of rupture
or complication.  Laboratory testing generally  reveals  normal  liver  function tests  and al‐
pha-fetoprotein levels, although minor elevations in aspartate and alanine aminotransfer‐
ase, alkaline phosphatase, and gamma glutamyl transpeptidase may occasionally be seen.
Definitive diagnosis  of  FNH in an asymptomatic  patient  warrants conservative manage‐
ment  and includes  close  observation with  repeat  imaging every  four  to  six  months  [9].
When radiology is equivocal, most surgeons still choose close observation with follow-up
studies  preformed every three  to  four  months.  Biopsy is  generally  not  indicated,  as  re‐
sults are seldom diagnostic [69].
Although it may be impossible to distinguish FNH from a well-differentiated HCC without
surgical excision, FNH tumors do not undergo malignant transformation. Thus indications for
surgical intervention should be limited to those situations where there is a change in the size
or number of lesion(s), a change in the intensity of symptoms, or where classic imaging
characteristics are absent and diagnostic dilemma remains [70]. Hence, the role of the surgeon
is typically limited to patient reassurance and close observation [9].
13. Hepatic adenoma
Hepatic adenomas are identified predominately in women of reproductive age [49]. The
estimated prevalence of hepatic adenomas within the general population on postmortem
exams is approximately 1% [10]. Etiologically, hepatic adenomas are of epithelial origin. Unlike
hepatic hemangiomas and FNH, a clear association between the use of OCPs and hepatic
adenomas has been established. First described in 1973, multiple studies have documented a
reciprocal relationship between OCP use and adenoma incidence based on estrogen dose and




exposure [1]. The prevalence of hepatic adenomas is estimated at 1 per 1,000,000 among women
who have never used OCP as compared with 30-40 per 1,000,000 amongst long-term OCP users
[72,76]. OCPs also affect the course of disease progression as lesions are generally larger, more
numerous, and more likely to bleed than tumors in OCP-naïve individuals [32,75,77,78].
Adenoma regression has been observed in patients after discontinuation of OCP with recur‐
rence ensuing during pregnancy and/or OCP re-administration [72,79,-82]. Despite these
findings, the mechanism by which estrogen therapy affects the development and course of
hepatic adenomas has yet to be clearly elucidated.
Hepatic adenomas are typically small (< 5 cm), soft, solitary lesions but may be multiple in up
to 30% of cases [9]. Of note, hepatic adenomatosis disease, defined as the presence of >10
lesions, is a distinct disease entity from that of hepatic adenoma and as such will not be
described in further detail [83]. Hepatic adenomas have been associated with type I glycogen
storage disease, galactosemia, Klienfelter’s syndrome, and Turner’s syndrome as well as with
androgen, domiphene, danazol and growth hormone use [1,84-86]. Although hepatic adeno‐
mas are benign, these lesions have been associated with spontaneous hemorrhage, rupture,
and malignant transformation, making prognosis more grave than that of other benign hepatic
tumors [5,87].
14. Clinical presentation
Since  adenoma and FNH both present  in  women of  reproductive  age and have similar
radiographic  appearances  they  are  frequently  confused.  Differential  diagnosis  is  critical
given that the recommended treatment of each respective lesions differs. Hepatic adeno‐
mas are most often diagnosed as a result of imaging done for unrelated pathology or fol‐
lowing workup of a palpable abdominal mass (30% patients)  [88].  Occasionally episodic
pain  may be  evident  as  a  result  of  an  enlarged liver,  intratumoral  bleed,  or  tumor  ne‐
crosis [9].  Up to 33% of patients with hepatic adenomas present with acute rupture and
concomitant intraperitoneal bleeding [1].  The development of acute severe pain associat‐
ed with hypotension reflects spontaneous rupture and carries a 20% mortality rate if not
appropriately identified and treated [32,89-91].
15. Pathology
Grossly hepatic adenomas appear as smooth, soft, and pale yellow tumor on cut surface [1].
These lesions often contain prominent blood vessels that have a high potential for rupture and
hemorrhage [1]. As adenomas lack a fibrous capsule intraparenchymal bleeding may occur,
which frequently results in a variegated appearance.
Microscopically hepatic adenomas appear as well circumscribed lesions composed of monot‐
onous sheets of hepatocytes laden with glycogen and lipids [5]. These lesions lack normal
hepatic architecture and demonstrate thickened trabeculae interspersed with sinusoids and
Hepatic Surgery288
prominent thin walled vessels [1,5]. Biliary ducts and portal tracts are distinctly absent from
adenomas.
While the malignant potential of adenomas remains controversial, several authors have
reported a low (5%) yet consistent risk of transformation [87]. Histological differentiation
between well differentiated HCC and adenoma can be difficult, especially in the presence of
fibrolamellar HCC which is also more common in women of reproductive age. This issue is
further explained in situations in which HCC and hepatic adenoma have been found adjacent
to one another [61,50,89,92,93].
16. Radiological imaging
Although radiographic evaluation is important for complete workup of hepatic adenoma
radiographic features are often nonspecific [94]. As such, despite the use of multiple imaging
techniques, diagnosis often remains equivocal. Ultrasound exhibits a mixed echogenic pattern
with an overall heterogeneous appearance [1,29]. Lesions appear hyperechoic as a result of
their high lipid content with a heterogeneous pattern reflecting intratumoral hemorrhage and
necrosis [95]. CE-CT imaging is frequently utilized for adenoma visualization and typically
demonstrates a hypo- to isodense lesion as a result of low attenuation on non-contrast phase
[1]. A variegated appearance with peripheral enhancement during the early contrast phase
with subsequent centripetal flow during the venous phase may be apparent, however CT can
demonstrate a spectrum of disparate findings [96]. MRI findings for hepatic adenoma are
similar to those on CT. Due to the high fat and glycogen content, adenomas are usually well
demarcated on MRI imaging [29]. While most adenomas appear iso- to hyperintense on both
T-1 and T-2 weighted images, findings are highly variable [1,97]. The administration of contrast
agents including gadolinium or gabodenate dimeglumine (Gd-BOPTA) results in early
markedly uniform enhancement on arterial phase, which subsequently becomes isodense on
the portal venous phase [98]. The use of 18FDG PET scan may also aid in the differentiation of
benign versus malignant disease in which where adenomas demonstrate poor uptake of 18FDG
as compared to HCC [8,38].
Additional  imaging  modalities  infrequently  used  include  technetium-99  sulfur  colloid
scanning. This imaging modality is particularly useful in differentiating between hepatic
adenoma and FNH, as  hepatic  adenomas lack bile  duct  components  and frequently ap‐
pear as a “cold nodules” on imaging [99]. Occasionally however, a minority of lesions do
take  up  the  sulfur  colloid,  rendering  them  indistinguishable  from  FNH  [99].  Although
rarely utilized, angiography typically reveals hypervascular lesions with areas of hemor‐
rhage and necrosis [1,28].
17. Diagnosis & treatment
In the absence of acute hemorrhage, serological tests rarely assist in diagnosis. Liver function
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Hepatic adenomas pose a greater risk for rupture (33%) and malignant transformation (5%)
than do other benign hepatic lesions [9,87]. As such all patients with suspected or confirmed
hepatic adenoma > 3 cm should undergo enucleation or surgical resection [1,100]. The
approach to surgical excision should be as previously described. Since all adenomas are
suspected to harbor malignancy an adequate margin of normal parenchyma should be taken
[1]. When surgical exploration is not feasible angiographic embolization or ligation can provide
temporary yet life saving relief.
As a result of the relationship between OCP and adenoma incidence, it is recommended that
all individuals suspected of having an adenoma discontinue the use of OCP immediately and
indefinitely [1,61]. Patients should also be advised against pregnancy until after adenoma
resection, as the growth and rupture risk of hepatic adenomas is highly unpredictable during
gestation [101]. Yearly follow-up with imaging is advised among all patients where a causal
link between OCP use and adenoma is absent [9]. As a result of improved safety of hepatic
resection and the use of minimally invasive techniques in hepatectomy it is suggested that all
hepatic adenomas > 3 cm be resected [1,100]. In patients with significant contraindications to
surgical intervention, OCP should be discontinued and the patient enrolled in an ongoing
surveillance program [9].
18. Additional liver tumors
18.1. Epithelial tumor
Biliary hamartomas
Bile duct adenomas and hamartomas are common tumors. Bile duct adenomas appear as small,
white, solitary, subcapsular masses [1]. They are defined histologically by narrow lumen bile
ducts surrounded by fibrosis. Hamartomas appear as small gray-white nodules that lie just
beneath the capsule of the liver [102]. Biliary hamartomas are frequently multifocal and are
characterized microscopically by the presence of dilated mature bile ducts surrounded by
fibrous tissue [1]. These lesions are especially important as they are frequently misinterpreted
as metastatic tumor by the operating surgeon. This notion heightens the importance of
confirmatory diagnosis to rule out malignancy for all hepatic lesions. Precise diagnosis is most
important in situations in which the presence of a metastatic liver disease will alter the
proceedings of a planned operation.
18.2. Mesenchymal tumors
Solitary fibrous tumor (other names include benign mesothelioma or fibroma)
Solitary fibrous tumors (SFT) are rare mesenchymal tumors that are frequently mistaken for
metastatic lesions as a result of their radiographic and intra-operative appearance. Grossly
SFT’s appear as white-to-gray lesions and can vary greatly in size ranging from 2 – 20 cm in
diameter [1]. Despite their large size, most SFT’s remain asymptomatic. Histologically, most
have a classic short storiform pattern and display an absence of cellular atypia, mitoses,
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and/or necrosis [1]. However when malignant, SFTs frequently possess a high mitotic rate and
marked cellular atypia. Immunohistochemically SFTs display a strong positive staining for
vimentin and CD-34 [1]. Since definitive histologic examination is required for diagnosis of
either a benign or malignant SFT, surgical resection is indicated in nearly all circumstances.
Lipoma, myelolipoma, or angiomyelipoma
Similar to several other benign hepatic lesions, most benign fatty hepatic tumors are identified
at the time of autopsy with only isolated reports of histological diagnosis following operative
resection [13]. Multiple variants including angiolipoma, myelolipoma, and angiomyolipoma
have been described [13,103]. Additionally, “pseudolipomas” have been described as lesions
in which there is an extracapsular fatty tumor with involutional changes. It is probable that
this lesion results when a free-floating piece of fat becomes entrapped between diaphragm and
liver surface [1,10]. In most situations definitive diagnosis requires surgical resection to exclude
malignancy.
Mesenchymal Hamartomas
Mesenchymal hamartomas are exceedingly rare congenital liver tumors which occur most
frequently in infants under 1 year of age [9,104]. Microscopically these lesions demonstrate a
myxoid background of highly cellular embryonal mesenchyme with haphazard groupings of
bile ducts, cysts, and hepatic cells [105]. Generally, the cystic element is the most prominent
feature resulting in a characteristic “honeycomb” appearance [106]. In contrast to biliary
hamartomas, which are clinically insignificant, mesenchymal hamartomas can significantly
impair hepatic function as a result of their large size [106]. Although benign, these lesions can
result in death due to mass effect and/or hepatic insufficiency [1]. Thus, all suspected mesen‐
chymal hamartomas should be completely excised when possible. If complete surgical excision
cannot be achieved surgical debulking may be sufficient as there have been no reports of
recurrence after an incomplete surgical resection to date [107].
Myxoma
Myxomas are exceptionally uncommon benign lesions of the liver. To date fewer than five
cases have been reported [9,58,108]. These lesions arise from primitive connective tissue.
Histologically myxomas demonstrate a myxoid matrix with scattered proliferation of connec‐
tive tissue cells [108]. Similar to other types of hepatic tumors described above, surgical
resection is generally indicated to exclude malignancy.
Teratoma
Primary teratomas are remarkably rare benign hepatic lesions. A review of the literature
revealed only 7 reports to date, with the majority of lesions occurring in children [109].
Secondary hepatic teratomas have been observed following systemic chemotherapy adminis‐
tration for treatment of testicular cancer [1]. Teratomas arise from pluripotent cells and
frequently contain components from all three germ layers. Teratomas are typically encapsu‐
lated cystic lesions that are easily resectable [1,110]. Imaging characteristics reflect tissue
heterogeneity and are often non-specific [110]. Surgical resection of hepatic teratomas is
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A thorough understanding of the natural history and accurate histologic diagnosis are
fundamental to appropriate management of patients with benign liver tumors. Although
advancements in imaging have drastically improved the detection and characterization of both
benign and malignant liver neoplasms, the ultimate burden of responsibility for diagnosis and
treatment remains that of the surgeon. Ongoing improvements in perioperative care and
surgical techniques, coupled with increased surgical experience presently permit hepatic
resection to be performed with a high level of safety. Despite these developments, a conser‐
vative approach including close observation with serial examination and imaging seems most
appropriate for asymptomatic patients in which malignancy is not suspected.
Symptomatic patients without medical or anatomic contraindication to a major hepatic
resection, as well as patients in whom a malignancy cannot be excluded (including individuals
with adenomas > 3 cm), should be considered for surgical intervention. Preoperative needle
biopsy is frequently contraindicated due to a high risk of rupture and hemorrhage, and
therefore should only be considered after exclusion of hemangioma. Additionally, it is
important to note that distinguishing particular lesions (especially adenoma and FNH) on
needle biopsy is exceedingly difficult. As such caution should exercised when using this
information to make clinical evaluations. Excisional biopsy of small and peripheral lesions and
adequate wedge incision biopsy of large lesions should permit the pathologist to make an
accurate histologic diagnosis and exclude a malignancy. If doubt remains, formal hepatic
resection is indicated.
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vative approach including close observation with serial examination and imaging seems most
appropriate for asymptomatic patients in which malignancy is not suspected.
Symptomatic patients without medical or anatomic contraindication to a major hepatic
resection, as well as patients in whom a malignancy cannot be excluded (including individuals
with adenomas > 3 cm), should be considered for surgical intervention. Preoperative needle
biopsy is frequently contraindicated due to a high risk of rupture and hemorrhage, and
therefore should only be considered after exclusion of hemangioma. Additionally, it is
important to note that distinguishing particular lesions (especially adenoma and FNH) on
needle biopsy is exceedingly difficult. As such caution should exercised when using this
information to make clinical evaluations. Excisional biopsy of small and peripheral lesions and
adequate wedge incision biopsy of large lesions should permit the pathologist to make an
accurate histologic diagnosis and exclude a malignancy. If doubt remains, formal hepatic
resection is indicated.
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1. Introduction
Hepatocellular carcinoma (HCC) is among the most common malignancy and cause of can‐
cer related death worldwide, with a high prevalence in Asia and south Africa as well as an
increasing incidence in the western country. Patients with liver cirrhosis are at highest risk
of developing this malignant disease, and the majority of HCC patients will develop the dis‐
ease on the background of preexisting hepatitis virus infection. It is estimated 50–70% asso‐
ciated with hepatitis C virus in North America and Europe and 70% associated with
hepatitis B virus in Asia and Africa [1], and the incidence of HCC is significantly higher in
men than in women. However, surveillance programs for HCC in patients with cirrhosis
and chronic hepatitis, and the advancement of diagnostic tools are likely to further increase
the incidence of HCC and the detection of small lesions in the liver that prompted the pro‐
portion of patients diagnosed at a potentially curative stage of disease.
Several staging systems have so far been proposed for aiding assessment of treatment plan‐
ning for HCC patients, but an overall consensus remains not exist for any of these staging
systems.The Tumor-Node-Metastasis staging (TNM) system of the American Joint Commit‐
tee on Cancer/Committee of the International Union Against Cancer (AJCC/UICC) has been
widely used for numerous cancer staging in order to stratify patients into prognostic groups
[2], but it is not perfectly applicable for HCC in terms of treatment assessment as the TNM
staging does not consider the underlying liver functional reserve and seems only applicable
to patients undergoing liver resection or liver transplantation. The Cancer of the Liver Ital‐
ian Program (CLIP) classifications and the Okuda staging system were introduced not only
considering tumor features but also liver functional reserve.The CLIP scoring system con‐
siders cirrhotic status in terms of Child-Turcotte-Pugh (CTP) class and several factors relat‐
ed to tumor features including tumor morphology, Alphafeto protein (AFP) level, and
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portal vein thrombosis [3]. Although the CLIP scoring system is probably helpful to identify
patients with a poor prognosis, it might be inadequate to identify patients at early stages of
disease. The Okuda system has also been found unsuitable for prognostic stratification of
patients at an early stage of disease [4]. Therefore, the Japan Integrated Staging score that
combines the CTP class with the Liver Cancer Study Group of Japan TNM stage was formu‐
lated to provide better stratification of patients with early HCC than that achieved by the
CLIP score and Okuda system [5]. Additionally, the Barcelona Clinic Liver Cancer(BCLC)
staging system was suggested as a modification of the Okuda system, and has been validat‐
ed superior for prognostic stratification of patients with HCC than other staging systems
[6-8]. The BCLC staging system involves factors related to underlying liver function, tumor
characteristics, and patients' performance status, and was proposed as a means of predicting
prognosis and as a guide to selecting appropriate therapy for HCC patients.
Generally, these staging systems was developed aiming to stratify patients into groups with
similar prognoses and to serve as a guiding choice of therapy. Current popular treatments
for HCC include liver resection, percutaneous ethanol injection (PEI) or radiofrequency
ablation (RFA), transcatheter arterial chemoembolization (TACE), liver transplantation, and
targeted therapy with novel biologic agent such as sorafenib. The selection of treatment mo‐
dality for HCC patients should be based on the patient's prognosis, which is complex to as‐
sess, as it depends on three factors, namely, the tumor characteristics, the underlying liver
functional reserve and the patient’s physical condition. At present, only liver resection and
liver transplantation are considered the best potential curative therapies. Nonetheless, be‐
cause of underlying liver dysfunction, lack of liver donor availability, and/or late detection
at advanced cancerous stage, only a small proportion of patients are eligible for these cura‐
tive treatments. This chapter reviews the importance and clinical impact of surgical manage‐
ment in terms of liver resection and transplantation for patients with primary HCC and
highlights their relative strengths and weakness.
2. Liver Resection
Liver resection remains the mainstay curative treatment for patients with HCC. However,
the majority of HCC patients are often associated with liver cirrhosis due to hepatitis B or C
viral infection, which might prohibit from liver resection because of impaired liver function.
Moreover, many HCC patients present with advanced tumor stage and only approximately
20–30% of patients are candidates for liver resection on presentation [9-11]. In spite of this
situation, the advancement in anesthetic and surgical techniques, as well as a thorough un‐
derstanding of the liver anatomy, and better perioperative care, have contributed dramati‐
cally to the safety and effectiveness of liver resection for HCC.
Since the proposal of the finger fracture technique for hepatic lobectomy in 1953, transection
of the hepatic parenchyma has evolved during the last 50 years. By finger fracture techni‐
que, the liver tissue is fractured and crushed by the thumb and index finger followed by
isolating and ligating the resistant intrahepatic vascular and ductal structures [12]. Howev‐
Hepatic Surgery302
er, there is some troublesome bleeding from the resection line which makes the surgeons fear
for the safety of the finger fracture technique. To overcome this short coming of the finger
fracture technique, many special instruments were invented to increase the successful rate and
safety of liver resection ever since (Figure 1). Currently, Kelly clamp crushing technique is still
one of the most widely used techniques for liver resection. However, in many centers, includ‐
ing the author’s center, ultrasonic dissection using the Cavitron Ultrasonic Surgical Aspira‐
tor (CUSA) has become the standard technique of liver resection. Today, laparoscopic liver
resection has become feasible in experienced centers due to improvement in instruments
[13-15]. Additionally, modern concepts including the use of vascular inflow occlusion, ana‐
tomic resection, and low central venous pressure anesthesia, and surgical approaches such as
the anterior approach and liver hanging maneuver have been developed along with using
more effective instruments for transection of hepatic parenchyma [16-18]. As a result, liver
resections are increasingly being performed and accepted as a safety procedure.
Figure 1. Liver resection instruments. (a). Lin’s clamp designed by T.Y. Lin. (b). Kelly clamp. (c). Cavitron Ultrasonic Sur‐
gical Aspirator (CUSA). (d). Harmonic scalpel for laparoscopic liver resection.
2.1. Preoperative assessment
The major concern of liver resection in HCC patients is postoperative liver failure, which is
particularly worrisome in patients requiring major resections and/or diseased background
of cirrhotic liver. Therefore, a thorough evaluating of patients in terms of tumor features of
radiologic examination, underlying liver function, and the patient’s physical status is very
important. Theoretically, a successful liver resection for HCC patients should be weighed
against the balance of these three factors.
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2.1.1. Evaluation of tumor status
The assessment of tumor status is the essential step for determining resectability and the ap‐
propriate type of liver resection. The routine radiologic imaging examination prior to liver
resection should include a dynamic liver computed tomography (CT) scan, hepatic angiog‐
raphy, and/or magnetic resonance imaging (MRI) to confirm the diagnosis of HCC as well as
tumor status in terms of size, number and location. Additionally, a chest X-ray or contrast
CT scan of chest and abdomen could be performed to exclude lung or other extrahepatic
metastasis. The CT scan provides important information not only on the tumor size, num‐
ber, location, and any vascular invasion but also on the relationship between the tumor and
major vasculature. Generally, pre-operative biopsy is not necessary as may risk needle track
related tumor seeding.
Large HCC—Solitary HCC with diameter of less than 5 cm is the best candidate for liver re‐
section because of favorable patients’ outcome in terms of HCC recurrent-free survival [19,
20]. However, numerous patients continue to be diagnosed HCC at an advanced stage that
sometimes presented with large tumor with diameter exceed 10 cm. Although liver resec‐
tion for patients with large tumor can be a great challenge for liver surgeons, liver resection
for large HCCs has been shown to be safe and reasonable long-term survival results can be
achieved that appear to be much better than any other nonsurgical treatments [21-23]. The 5-
year survival rate in patients with tumors larger than 10 cm after liver resection is approxi‐
mately 21–27.5% [23-25]. Additionally, since liver transplantation and local ablation are not
indicated for these patients, surgical resection remains the only treatment of choice that pro‐
vides potential cure of patients with large HCC.
Multiple HCCs—Multiple HCCs may represent as a manifestation of advanced disease with
intrahepatic metastasis or independent tumors that derived from multiple foci of hepatocar‐
cinogenesis, which could be an event associated with a poor prognosis. Patients with multi‐
ple HCCs more than 3 nodules have been considered unsuitable for resection. However, it
had been shown that liver resection still can provide survival benefits even for patients with
multiple tumors in a background of CTP class A cirrhosis, and the overall survival rates can
up to 58% at 5 years [26]. Additionally, combined resection and radiofrequency ablation is
considered a new strategy to increase the chance of curative treatment for patients with bilo‐
bar multiple HCCs. For example, resection of the large tumor in one lobe and ablation of
smaller tumors in the other lobe can be performed, or resection of peripheral lesions and
ablation of central lesions for patients with multifocal tumors associated with cirrhosis and
borderline liver function can be performed [27, 28]. The results showed patients who under‐
went surgical resection for multiple HCCs had better survival outcomes as compared with
those who received nonsurgical therapy. Hence, when clearance of all tumor nodules is fea‐
sible and liver function permits, surgical resection or plus effective local ablative therapy
should be considered for patients with bilobar or multiple HCCs.
HCC involving major portal and hepatic veins—HCCs with major portal or hepatic veins in‐
volvement represent an aggressive tumor behavior and frequently associated with multifo‐
cal tumors. Although HCCs with vascular invasion are not considered as favorable surgical
candidates, studies from experienced liver surgical groups have shown that surgical resec‐
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tion for such tumors seems justified as it still results in better survival rates as compared
with that of nonsurgical treatment [29, 30]. The overall survival rates at 5 years were ranged
from 23% to 42% in selected patient who has no liver cirrhosis or impaired liver function.
2.1.2. Evaluation of liver function
Preoperative proper assessment of liver function is fundamental to the safe of liver resection
for HCC patients, but there is no individual test accurately predicting liver function.The
CTP classification is the most common measure to assess liver function, and it combines dif‐
ferent parameters and provides a rough evaluation of the gross synthetic and excretory ca‐
pacity of the liver. Generally, patients with CTP class A are considered good candidates for
liver resection. Patients with CTP class B may be only suitable for minor liver resection such
as wedge resection or single segmentectomy [31], whereas patients with CTP class C are
contraindicated for resection. The risk of death after liver resection increases with each CTP
class. However, this classification is a crude measure and has proven insufficient to stratify
the surgical risk of patient with liver cirrhosis.
Portal hypertension is usually defined by that the portal venous pressure is greater than 10
mmHg, in which the normal value ranges from 5 to 8 mmHg. Patients with portal hyperten‐
sion undergoing liver resection may lead to severe complications, such as variceal bleeding,
endotoxemia, and even hepatic failure in the postoperative period [32]. However, measure‐
ment of portal venous pressure prior to liver resection is difficult, and portal hypertension
could only be roughly assessed by clinical and radiologic signs including splenomegaly, ab‐
dominal collaterals, thrombocytopenia with platelet count less than 100,000/mm3, or esopha‐
gogastric varices. Although portal hypertension is considered a relatively contraindication
of liver resection, study had shown that liver resection is also capable of providing survival
benefits to patients with a background of portal hypertension [26]. Additionally, patients
with abnormal elevation of liver function tests in terms of serum aspartate and alanine ami‐
notransferase levels might have a higher risk of postoperative complication and mortality
rates, and are considered to be poor candidates for major liver resection [33, 34]. Therefore,
patients with abnormal liver function tests should be carefully assessed and selected prior to
liver resection.
Additionally, several hepatobiliary centers have employed more sophisticated quantitative
liver function tests, such as the lidocaine monoethylglycinexylidide test, aminopyrine breath
test, galactose elimination capacity, and indocyanine green (ICG) clearance test to evaluate
the hepatic metabolic function and to predict the risk of postoperative liver failure [35-37].
However, these specific tests reflect the function of the whole liver, whereas the risk of post‐
operative liver failure relies on the liver function reserve of the remnant liver. Among the
various methods, the ICG test is the most widely used to assess liver function prior to liver
resection. The ICG is an organic dye that is taken up by the hepatocytes and excreted via the
bile in an adenosine triphosphate (ATP) dependent manner without been metabolized and
undergoing enterohepatic circulation. Thus, the clearance of ICG from systemic circulation
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tion for such tumors seems justified as it still results in better survival rates as compared
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is merely a measure of hepatic blood flow and function. This test evaluates the retention ra‐
tio of ICG from the peripheral blood at definitive time point after injection of 0.5 mg ICG/kg
(usually 15 minutes, ICG-15), and Makuuchi et al. have incorporated the ICG-15 and two
clinical features in terms of serum bilirubin level and the presence of ascites into an algo‐
rithm of liver resection (Figure 2) [38]. In patients with bilirubin levels less than 1.0mg/dL
and the absence of ascites, ICG-15 is used to predict the extent of liver segments that can be
safely removed. In general, an ICG-15 of 10–20% is usually considered a safety upper limit
for major liver resection. Accordingly, the algorithm has been validated toward zero surgi‐
cal mortality after liver resection by several hepatobiliary centers [39, 40].
Figure 2. Makuuchi’s algorithm for liver resection in patients with HCC [38]. Limited resection means enucleation of
the tumor (usually ≤ 5cm) and less than 1 cm of liver tissue surrounding the tumor was removed.
ICG-15 (%) Safe resection ratio of liver volume
0 < 63.3%







Table 1. The safe resection ratio of liver volume based on the ICG test [43].
Although the assessment of hepatic function and liver volume to be resected is crucial for a
safe liver resection, volumetric analysis of the future liver remnant (FLR) has also been sug‐
gested. The FLR can be measured directly by computer-assisted models of contrast-en‐
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hanced spiral CT. However, it remains controversial regarding which index of the FLR
volume should be used. Some surgeons use the actual total liver volume minus liver volume
to be removed on CT images as the FLR volume, while others use the estimated ideal liver
volume that is calculated by a formula based on body surface area as a standard for calcula‐
tion of the FLR. Nonetheless, the exactly number of the adequate FLR volume in cirrhotic
patients is also no consensus, and at least an FLR of 40% is recommended in patients with
chronic liver disease [41, 42]. In the authors’ center, we have established an equation to re‐
veal the relationship between the ratio of FLR volume and ICG-15 values as well as referen‐
ces for determining a safe resection ratio of the liver volume (Table 1)[43].
2.2. Preoperative therapy
Since not all patients with HCC are amenable to surgical resection, several strategies such as
preoperative TACE that might be used to downsize large HCC or portal vein embolization
(PVE) to increase the FLR have been suggested. However, the efficacy of these preoperative
approaches in terms of HCC oncologic viewpoint remains the subject of debate.
2.2.1. Portal vein embolization
The concept of PVE was introduced on the basis of the idea that an increase in the FLR will
reduce the risk of liver failure after major liver resection for hilar bile duct carcinoma in 1982
[44]. By occluding portal venous branch of the tumor-bearing liver, PVE induces atrophy of
the resection part and hypertrophy of the FLR. Although the ability of liver regeneration in
cirrhotic liver is impaired, PVE may induce clinically sufficient hypertrophy in these pa‐
tients as well.Currently, PVE could be considered for patients with liver cirrhosis when the
FLR is expected less than 40% of the total liver volume [45, 46]. PVE may also be used as a
dynamic liver function test, in which inadequate hypertrophy of the FLR or intolerance of
the patient after PVE indicate that major liver resection is contraindicated. In general, PVE is
a relatively safe procedure, and it may increase the resectability of initial unresectable HCC
and reduce the risk of post hepatectomy liver failure. Additionally, it seems no adverse ef‐
fect on the oncologic outcome of HCC patients undergoing major liver resection [47, 48].
However, the potential for progression of the primary tumor after PVE remains a major con‐
cern, whereas a combination of TACE as a complementary procedure to PVE could be con‐
sidered in order to improve the outcome of HCC patients [49].
2.2.2. Preoperative transcatheter arterial chemoembolization (TACE)
The use of TACE as a neoadjuvant treatment for HCC was proposed in a variety of settings
such as palliative treatment for unresectable HCC, to improve the resectability of intial unre‐
sectable HCC, to downstage the primary tumor for liver transplantation or for delay sur‐
gery. The major goal of TACE is aimed at inducing tumor necrosis and shrinkage as well as
preventing the dissemination of the primary tumor (Figure 3). Theroretically, the use of neo‐
adjuvant TACE in the setting of resectable HCC might be capable of improving survival by
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reducing tummor recurrences. Nonethelesss, the fact is that most studies show conflict out‐
comes of TACE as a neoadjuvant therapy and do not support routine use of preoperative
TACE before liver resection [50-53]. Moreover, preoperative TACE for resectable large HCC
is not recommended because it does not provide complete necrosis of the large tumor and‐
may actually result in progression of the primary tumor owing to delay surgery and compli‐
cate the operation during the process of liver mobilization due to the presence of perihepatic
adhesions after TACE.
Figure 3. TACE induces remarkable shrinkage of tumor mass. (a) A huge liver tumor around 15 cm in size located at
right lobe liver. (b) The tumor was decreased by half in size after three courses of TACE. (4 months after HCC diag‐
nosed)
Clinically, spontaneous tumor rupture accompanied by hemorrhaging has been seen in
small portion of patients with HCC at initial presentation, which might lead to a life-threat‐
ening condition depending on the severity of hemorrhage. Transcatheter arterial emboliza‐
tion (TAE) should be performed for ruptured HCC to control tumor bleeding as well as
stabilizing clinical condition of patients. Liver resection then can be evaluated after the pa‐
tient has recovery from shock status and post-TAE damage of the liver according to the cri‐
teria of liver resection. Generally, TAE followed by staged liver resection of tumor seems to
be a rational treatment strategy for patients with ruptured HCC and hemorrhage if the le‐
sion is resectable, and long-term survival could be expected [54, 55].
2.3. Outcome of liver resection
The operative mortality of liver resection has been reduced to less than 5% with some cen‐
ters approaching to zero mortality in recent years [39, 40, 56]. The improvement is primarily
resulting from advances in surgical techniques, perioperative management, and more cau‐
tious patient selection. However, the postoperative morbidity rate remains high that ranges
from 25 to 50% even in experienced centers [11, 57, 58]. Ascites and pulmonary complica‐
tions are the most common complications, but serious complications such as liver failure,
postoperative hemorrhage, bile leakage, and intra-abdominal sepsis are less frequent nowa‐
days. Apart from that, the long-term survival after resection of HCC have much improved‐
lately, but HCC recurrence remains a major concern for patients undergoing liver resection.
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2.3.1. HCC recurrence
The high incidence of postoperative recurrence, estimated excess of 70% at 5 years, is the
greatest frustration in treating patient with HCC. Recurrent HCCs are mostly intrahepatic
that accounts for approximately 80–90% of cases after liver resection. There are two peaks of
HCC recurrence after liver resection:The first peak occurs at approximately 1 year posthepa‐
tectomy and about 40% of recurrence within the period, in which metastatic dissemination
of the primary tumor is mainly responsible for this early peak. The second peak is observed
at the 4th postoperative year with a 35% of recurrent rate per year, and the majority of the
second peak is more likely attributable to new tumors development related to the carcino‐
genic effect of underlying chronic liver disease [59].
Currently, there is no well-established adjuvant therapy to reduce the risk of recurrence af‐
ter curative liver resection. Although numerous studies have demonstrated the efficacy of
some new modalities including acyclic retinoid, polyprenoic acid [60], intra-arterial io‐
dine-131-labelled lipiodol [61], and adoptive immunotherapy [62] as adjuvant therapy in the
prevention of HCC recurrence after liver resection, the sample size of these individual stud‐
ies was rather small and further validated by randomized trials with large sample size is re‐
quired. Additionally, interferon has been proposed as adjuvant therapy in patients with
HCC and viral hepatitis after liver resection and shown beneficial for reducing recurrence
and prolonging survival [63, 64]. Nonetheless, a more recent cohort study based on a phase
III randomized trial of adjuvant interferon alfa-2b in HCC after curative resection does not
support the benefit of interferon in reducing postoperative recurrence of viral hepatitis-re‐
lated HCC [65]. Apart from that, another potential approach is to use molecular targeted
therapy such as sorafenib that is applied for advanced HCC and may inhibit HCC cell pro‐
liferation and angiogenesis. However, further trial is indicated to test the efficacy of these
targeting drugs as adjuvant therapy after resection of HCC.
Compared with the development of  postoperative adjuvant  therapy,  the risk factors  for
HCC recurrence after liver resection have been extensively explored and established. The
risk factors for tumor recurrence can be categorized into three core groups, related to host
factors, tumor factors, and surgical factors [66].  The tumor factors including vascular in‐
vasion,  satellite  nodules,  large  tumor,  elevation  of  AFP,  poor  differentiated  histologic
grade,  tumor rupture,  and advanced tumor stage are frequently reported risk factor  for
HCC recurrence after liver resection. The host factors are the patient’s characteristics and
underlying liver diseases such as cirrhosis and viral  hepatitis.  Both tumor and host fac‐
tors  are  determined before  operation,  and the  surgeon can only  control  surgical  factors
including  negative  resection  margin,  anatomic  resection,  meticulous  liver  mobilization,
and less blood transfusion.
The treatment strategy for HCC recurrence after liver resection should be the same as that
for primary HCC. Although repeat hepatectomy could be a difficulty owing to perihepatic
adhesion related to first operation, surgical resection remains a preferred treatment whenev‐
er the tumor is considered to be resectable [67-69].
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2.3.2. Survival of patients
Despite the high incidence of postoperative HCC recurrence, current strategy of aggressive
multimodality treatments for recurrent tumors using TACE, RFA, or liver transplantation
has largely improved the overall outcomes of patients even after the development of recur‐
rent HCC. Moreover, surgical resection of recurrent HCC presenting as extrahepatic meta‐
stases could be considered in selected patients who are with isolated extrahepatic metastases
and has otherwise good performance status, good hepatic functional reserve, and well-treat‐
ed intrahepatic HCC, and a survival benefit can be expected from this aggressive approach
[70]. Generally, the overall 5-year survival after resection of HCC reported in the literature
from large series is mostly near 50% or even better in recent years (Table 2).
Authors (Years) Study period Subgroups No. of patients 5-year RFS/OS
Hanazaki et al. (2000) [71] 1983–1997 386 23.3%/34.4%






Wang et al. (2010) [72] 1991–2004 438 ─/43.3%





















Chan et al. (2012) [76] 2001–2005 651 33.9%/51.7%
Giuliante et al. (2012) [77] 1992–2008 Tumor ≤3cm 588 32.4%/52.8%






Altekruse et al. (2012) [79] 1998–2008 SEER–13 1348 ─/47%
Table 2. Long-term survival of patients undergoing liver resection for HCC reported from large series in recent years.
RFS, recurrence-free survival; OS, overall survival; SM, surgical margin; SEER-13, Surveillance Epidemiology and End
Results of USA.
3. Liver transplantation
Recurrence remains a major problem after liver resection for HCC even after margin-nega‐
tive resection. Most of the patients with HCC have underlying cirrhosis that provides poten‐
tial field for development of hepatocellular carcinoma. Since majority hepatic malignancies
are HCC and almost 80% of them have underlying cirrhosis, resection is option in only
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small number of patients and in such patients, recurrence rate is high after resection. Liver
transplantation practically offers greater chance of cure by removing underlying liver cir‐
rhosis and HCC. Also, HCC is multifocal especially with hepatitis C, and total hepatectomy
removes the source of potential possibility of later-developing tumors whereas partial hep‐
atic resection does not.
However, liver transplantation for HCC did not yield satisfactory results initially. Recur‐
rence rates were up to 80% and long term survival rates were unacceptably below that of
patients who underwent liver transplantation for non-malignant causes. These recurrences
usually appeared within 2 years of transplant, most common site being liver allograft that
led to a decline in enthusiasm and a serious concern about using precious donor livers for
treatment [80].It was Bismuth who initially reported good outcomes with liver transplanta‐
tion for small HCC [81] and subsequently, Mazzaferro et al introduced the Milan criteria re‐
porting liver transplantation for HCC with equivalent outcomes to non-HCC patients[82].
Liver transplantation has become now potential curative treatment and it is presently the
treatment of choice for patients with CTP class B or C cirrhosis and early hepatocellular car‐
cinoma. Compared with surgical resection, liver transplantation is associated with better
overall and recurrence-free survival in well selected patients [83-85]. The improved overall‐
results after liver transplantation are thought to be due to better patient selection and the
emergence of various locoregional therapies for HCC that prevent tumor progression while
patient is waitlisted for liver transplantation, thus preventing drop out.
3.1. Patient selection criteria
A major goal of liver transplant team is to select the patients with HCC and cirrhosis at earli‐
er stage of their disease in order to achieve survival duration comparable with that of other
patients with benign liver disease receiving transplants, so as to justify or prioritize the allo‐
cation of a liver graft. Liver transplant candidates with HCC must meet the Milan criteria to
qualify for exceptional HCC waiting list consideration. Also, several other extended criteria
such as UCSF (University of California at San Francisco) criteria are used for patient selec‐
tion in highly specialized transplant centres.
3.1.1. Milan’s criteria
In 1996, a prospective cohort study defined restrictive selection criteria that led to superior
survival for transplant patients in comparison with any other previous experience with
transplantation or other options for HCC. Since then, these selection criteria have become
universally known as the Milan criteria in recognition of their origin (Table 3) [82]. These
criteria have been widely applied in the selection of patients with HCC for liver transplanta‐
tion.In North America as well as in many other world regions, patients within Milan criteria
HCC are given priority to liver transplantation. Generally, a 4-year overall and recurrence-
free survival rates of 85% and 92%, respectively, can be achieved using this selection criteria.
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Hanazaki et al. (2000) [71] 1983–1997 386 23.3%/34.4%






Wang et al. (2010) [72] 1991–2004 438 ─/43.3%





















Chan et al. (2012) [76] 2001–2005 651 33.9%/51.7%
Giuliante et al. (2012) [77] 1992–2008 Tumor ≤3cm 588 32.4%/52.8%






Altekruse et al. (2012) [79] 1998–2008 SEER–13 1348 ─/47%
Table 2. Long-term survival of patients undergoing liver resection for HCC reported from large series in recent years.
RFS, recurrence-free survival; OS, overall survival; SM, surgical margin; SEER-13, Surveillance Epidemiology and End
Results of USA.
3. Liver transplantation
Recurrence remains a major problem after liver resection for HCC even after margin-nega‐
tive resection. Most of the patients with HCC have underlying cirrhosis that provides poten‐
tial field for development of hepatocellular carcinoma. Since majority hepatic malignancies
are HCC and almost 80% of them have underlying cirrhosis, resection is option in only
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small number of patients and in such patients, recurrence rate is high after resection. Liver
transplantation practically offers greater chance of cure by removing underlying liver cir‐
rhosis and HCC. Also, HCC is multifocal especially with hepatitis C, and total hepatectomy
removes the source of potential possibility of later-developing tumors whereas partial hep‐
atic resection does not.
However, liver transplantation for HCC did not yield satisfactory results initially. Recur‐
rence rates were up to 80% and long term survival rates were unacceptably below that of
patients who underwent liver transplantation for non-malignant causes. These recurrences
usually appeared within 2 years of transplant, most common site being liver allograft that
led to a decline in enthusiasm and a serious concern about using precious donor livers for
treatment [80].It was Bismuth who initially reported good outcomes with liver transplanta‐
tion for small HCC [81] and subsequently, Mazzaferro et al introduced the Milan criteria re‐
porting liver transplantation for HCC with equivalent outcomes to non-HCC patients[82].
Liver transplantation has become now potential curative treatment and it is presently the
treatment of choice for patients with CTP class B or C cirrhosis and early hepatocellular car‐
cinoma. Compared with surgical resection, liver transplantation is associated with better
overall and recurrence-free survival in well selected patients [83-85]. The improved overall‐
results after liver transplantation are thought to be due to better patient selection and the
emergence of various locoregional therapies for HCC that prevent tumor progression while
patient is waitlisted for liver transplantation, thus preventing drop out.
3.1. Patient selection criteria
A major goal of liver transplant team is to select the patients with HCC and cirrhosis at earli‐
er stage of their disease in order to achieve survival duration comparable with that of other
patients with benign liver disease receiving transplants, so as to justify or prioritize the allo‐
cation of a liver graft. Liver transplant candidates with HCC must meet the Milan criteria to
qualify for exceptional HCC waiting list consideration. Also, several other extended criteria
such as UCSF (University of California at San Francisco) criteria are used for patient selec‐
tion in highly specialized transplant centres.
3.1.1. Milan’s criteria
In 1996, a prospective cohort study defined restrictive selection criteria that led to superior
survival for transplant patients in comparison with any other previous experience with
transplantation or other options for HCC. Since then, these selection criteria have become
universally known as the Milan criteria in recognition of their origin (Table 3) [82]. These
criteria have been widely applied in the selection of patients with HCC for liver transplanta‐
tion.In North America as well as in many other world regions, patients within Milan criteria
HCC are given priority to liver transplantation. Generally, a 4-year overall and recurrence-
free survival rates of 85% and 92%, respectively, can be achieved using this selection criteria.
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Criteria of liver transplantation for patients with HCC
Single lesion ≤5 cm.
Up to three separate lesions, none larger than 3 cm.
No evidence of gross vascular invasion.
No regional nodal or distant metastases.
Table 3. Milan’s criteria for liver transplantation.
3.1.2. Extended Criteria
Considerable interest has arisen in expansion of usual transplant criteria in highly special‐
ized centres to offer liver transplantation to broader group of patients with HCC as investi‐
gators argued that Milan’s criteria are too restrictive and limit liver transplantation at the
time when incidence of HCC is on the rise. Using explant pathologic data, Yao and co-work‐
ers at the University of California, San Francisco (UCSF) reported 5-year post-transplanta‐
tion survival of 75% in patients with tumors as large as 6.5 cm and cumulative tumor
burden ≤8 cm (Table 4)[86].
Extended criteria of liver transplantation for patients with HCC
Solitary tumor up to 6.5 cm.
A maximum of 3 tumor nodules each up to 4.5 cm.
A total tumor diameter not exceeding 8 cm.
No regional nodal or distant metastases.
Table 4. UCSF criteria for liver transplantation.
The UCSF criteria have been shown to be associated with long -term survival similar to Mi‐
lan criteria when based on explant pathology [87, 88]. However, because of the small sample
size and use of retrospective explant tumor pathology, the results of these studies were chal‐
lenged and also several groups advised caution in expanding the criteria.
Additionally, a recent multicentre study led by the Milan’s group had retrospectively re‐
viewed patients who underwent transplantation for HCC in order to explore the survival of
patients with tumors that exceed the Milan criteria. Accordingly, a prognostic model of
overall survival based on tumor characteristics in terms of size and number was derived,
and an expanded criterion termed “up-to-seven criteria” was introduced [89]. Patients who
fell within the criteria that the sum of the largest tumor size and the number of tumors does
not exceed seven could achieve a 5-year overall survival of 71.2% after liver transplantation
enabling more patients to qualify as transplant candidates.
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3.2. Prognostic Indicators
Several studies have identified patient and tumor-related variables associated with progno‐
sis following liver transplantation for HCC. The majority of prognostic factors are similar to
that of liver resection for patients with HCC.
3.2.1. Tumor related factors
Important prognostic factors in most of scientific studies include tumor number, size, and
location (especially bilobar distribution). The most consistent association is with tumor size.
Other factors are histologic grade of differentiation, stage of disease according to the Ameri‐
can Liver Tumor Study Group (ALTSG) modification of the TNM staging criteria, the pres‐
ence of macrovascular and microvascular invasion, absolute level of serum AFP, and
extrahepatic spread. Tumor size predicts both the likelihood of vascular invasion and tumor
grade, but the relationship is nonlinear and a significant proportion of small tumors have
unfavourable histology, whereas some larger ones do not [90, 91].
3.2.2. Patient related factors
Patients with HCV infection tend to have severe underlying liver disease and more ad‐
vanced HCC at presentation as compared to HBV infection and underlying alcoholic cirrho‐
sis. Hence, the recurrence of HCC is more common among the HCV recipients and thus
reduced survival [92]. The immunosuppressive treatment after liver transplantation is asso‐
ciated with increased risk of tumor recurrence. Thus, immunosuppressant should be re‐
duced to minimum effective levels. Several studies have shown lower recurrence with
sirolimus which is attributed to its anti-proliferative effects on HCC [93-95]. But there is
need for large randomized controlled trials to conclude sirolimus as most appropriate im‐
munosuppressant for patients undergoing liver transplantation for HCC.
3.3. Deceased Donor Liver Transplantation (DDLT)
3.3.1. Graft Allocation
The shortage of donor livers has necessitated the development of allocation system, where‐
by priority for donor organs is given to the most severely ill patients. The prolonged waiting
period frequently results in tumor progression to an extent beyond the transplantable crite‐
ria, leading to a patient's removal or dropout from the waiting list [96]. Allocation of de‐
ceased donor livers for both adults and children is based upon the "model for end stage liver
disease" or MELD score, a statistical model based upon predicted survival in patients with
cirrhosis.As a result of the high dropout rate for patients with HCC, the Organ Procurement
and Transplantation Network (OPTN) of the U.S. has reconsidered the priority of liver graft
allocation. While waiting list priority was determined primarily by liver disease severity
based on the Model for End-Stage Liver Disease (MELD) score, patients with HCC that ful‐
filled the Milan criteria were registered with an adjusted score and were subsequently as‐
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Criteria of liver transplantation for patients with HCC
Single lesion ≤5 cm.
Up to three separate lesions, none larger than 3 cm.
No evidence of gross vascular invasion.
No regional nodal or distant metastases.
Table 3. Milan’s criteria for liver transplantation.
3.1.2. Extended Criteria
Considerable interest has arisen in expansion of usual transplant criteria in highly special‐
ized centres to offer liver transplantation to broader group of patients with HCC as investi‐
gators argued that Milan’s criteria are too restrictive and limit liver transplantation at the
time when incidence of HCC is on the rise. Using explant pathologic data, Yao and co-work‐
ers at the University of California, San Francisco (UCSF) reported 5-year post-transplanta‐
tion survival of 75% in patients with tumors as large as 6.5 cm and cumulative tumor
burden ≤8 cm (Table 4)[86].
Extended criteria of liver transplantation for patients with HCC
Solitary tumor up to 6.5 cm.
A maximum of 3 tumor nodules each up to 4.5 cm.
A total tumor diameter not exceeding 8 cm.
No regional nodal or distant metastases.
Table 4. UCSF criteria for liver transplantation.
The UCSF criteria have been shown to be associated with long -term survival similar to Mi‐
lan criteria when based on explant pathology [87, 88]. However, because of the small sample
size and use of retrospective explant tumor pathology, the results of these studies were chal‐
lenged and also several groups advised caution in expanding the criteria.
Additionally, a recent multicentre study led by the Milan’s group had retrospectively re‐
viewed patients who underwent transplantation for HCC in order to explore the survival of
patients with tumors that exceed the Milan criteria. Accordingly, a prognostic model of
overall survival based on tumor characteristics in terms of size and number was derived,
and an expanded criterion termed “up-to-seven criteria” was introduced [89]. Patients who
fell within the criteria that the sum of the largest tumor size and the number of tumors does
not exceed seven could achieve a 5-year overall survival of 71.2% after liver transplantation
enabling more patients to qualify as transplant candidates.
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location (especially bilobar distribution). The most consistent association is with tumor size.
Other factors are histologic grade of differentiation, stage of disease according to the Ameri‐
can Liver Tumor Study Group (ALTSG) modification of the TNM staging criteria, the pres‐
ence of macrovascular and microvascular invasion, absolute level of serum AFP, and
extrahepatic spread. Tumor size predicts both the likelihood of vascular invasion and tumor
grade, but the relationship is nonlinear and a significant proportion of small tumors have
unfavourable histology, whereas some larger ones do not [90, 91].
3.2.2. Patient related factors
Patients with HCV infection tend to have severe underlying liver disease and more ad‐
vanced HCC at presentation as compared to HBV infection and underlying alcoholic cirrho‐
sis. Hence, the recurrence of HCC is more common among the HCV recipients and thus
reduced survival [92]. The immunosuppressive treatment after liver transplantation is asso‐
ciated with increased risk of tumor recurrence. Thus, immunosuppressant should be re‐
duced to minimum effective levels. Several studies have shown lower recurrence with
sirolimus which is attributed to its anti-proliferative effects on HCC [93-95]. But there is
need for large randomized controlled trials to conclude sirolimus as most appropriate im‐
munosuppressant for patients undergoing liver transplantation for HCC.
3.3. Deceased Donor Liver Transplantation (DDLT)
3.3.1. Graft Allocation
The shortage of donor livers has necessitated the development of allocation system, where‐
by priority for donor organs is given to the most severely ill patients. The prolonged waiting
period frequently results in tumor progression to an extent beyond the transplantable crite‐
ria, leading to a patient's removal or dropout from the waiting list [96]. Allocation of de‐
ceased donor livers for both adults and children is based upon the "model for end stage liver
disease" or MELD score, a statistical model based upon predicted survival in patients with
cirrhosis.As a result of the high dropout rate for patients with HCC, the Organ Procurement
and Transplantation Network (OPTN) of the U.S. has reconsidered the priority of liver graft
allocation. While waiting list priority was determined primarily by liver disease severity
based on the Model for End-Stage Liver Disease (MELD) score, patients with HCC that ful‐
filled the Milan criteria were registered with an adjusted score and were subsequently as‐
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signed additional scores at regular intervals to reflect their risk for dropout as a result of
tumor progression.
3.3.2. Listing Criteria of transplantation candidates
In an attempt to ensure that preoperative assessment is as accurate as possible, UNOS pro‐
vides a set of specific requirements for listing patients with HCC for orthotopic liver trans‐
plantation.
I. The diagnosis must be confirmed by thorough assessment by imaging modalities
such as ultrasound, dynamic CT and /or MRI. Tumor numbers, size, presence or
absence of extrahepatic disease and major vascular disease must be documented.
II. Patient must have one of the following:
1. An Alfa fetoprotein level > 200 ng/mL.
2. Celiac angiography showing tumor blush corresponding to the site shown by
CT/MRI/ultrasonography.
3. A biopsy confirming HCC
4. History of RFA, TACE or other locoregional therapy.
III. Must be within Milan’s criteria.
IV. Continued documentation of the tumor is required every three months by CT or
MRI to ensure continued eligibility for liver transplantation.
Patients will be given priority MELD score depending upon the state of underlying disease.
Prioritization scores for patients with HCC are based upon tumor size and number. With
this new organ allocation policy, waiting time for the patients with HCC to receive a de‐
ceased-donor liver has decreased significantly.
3.4. Living Donor Liver Transplantation (LDLT)
The shortage of organs from deceased donors has curtailed the adoption of living donor liv‐
er transplantation. Living donors can potentially provide an essentially unlimited source of
liver grafts for a planned transplant operation as soon as the diagnosis of HCC is made, thus
decreasing the uncertainty of long waiting periods and reducing possibility of tumor pro‐
gression [97]. The living donor can be from adult-to-adult or adult-to-child. In children
mostly left lateral segment of the liver harvested and donors are usually ABO-compatible
parents. While in adult-to-adult, right or left liver can be harvested that depends upon pre‐
transplant evaluation of donor and CT volumetry of liver. The GRWR (graft to recipient
weight ratio) must be more than 0.8%. Donor not meeting these criteria is rejected for the
fear of small-for-size syndrome and subsequent graft failure [98, 99].
Because a live donor graft is a dedicated gift that is directed exclusively to a particular recip‐
ient, there is no need for an objective allocation system based on a prioritization scheme.
Presently LDLT comprises almost >90% of liver transplants in Asia as compared to <5% in
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US. Unlike in the U.S., where recipients with malignancies receive extra prioritization in the
deceased donor organ allocation scheme, HCC patients in Asia do not. HCC patients in Asia
have a dismal chance of receiving a deceased donor graft and LDLT is often the only option.
3.5. Pretransplant locoregional therapies
Pretransplant locoregional therapy has been adopted by the liver transplant community
worldwide. This concept, known as “bridging therapy” is meant to limit tumor progression
and dropout rate while patients are on the transplant wait list. The most popular techniques
include TACE, transarterial drug-eluting beads, transarterial radio-embolizationand RFA.In
the transplant setting, TACE is currently the most popular neo-adjuvant treatment. It is indi‐
cated in Child–Pugh A or B cirrhotic patients to downstage tumors into the Milan criteria or
to prevent tumor progression. For patients with small HCC confined to the liver, recent data
also indicate that transplantation when used with multimodal therapy using locoregional
procedures and neoadjuvant systemic chemotherapy, results in improved recurrence-free
survival [100, 101]. Apart from that, it is also important to know the wait list dropout rate
and bridging therapy-associated complication rate, because the benefit of preventing wait
list dropout should outweigh the risk of bridging therapy.Patient-individualized treatment
strategy should be based on the performance status, hepatic reserve, tumor burden, and tu‐
mor vascularity pattern.
3.6. Outcome of liver transplantation
To date, orthotopic liver transplantation is no doubt the best therapeutic option for early,
unresectable HCC, although it is limited by graft shortage and the need for appropriate pa‐
tient selection. Since the introduction of the milan’s criteria, the liver transplantation for pri‐
mary HCC is on rise with promising recurrence-free survival and overall survival. Excellent
5-year post-transplant patient survival of at least 70% has been reported from many centers
[102]. Furthermore, better definition of the prognostic factors and more rigorous patient se‐
lection have resulted in significant improvement in 5-year survival for patients receiving
transplants for HCC in the past decade.
However, a tendency for higher HCC recurrence has been reported for patients who under‐
went LDLT than patients who underwent DDLT [103, 104]. The reasons for this difference
are not completely answered by current studies. Possible explanations can be related to the
selection bias for clinical characteristics associated with aggressive tumor behavior, elimina‐
tion of natural selection during the waiting period, and enhancement of tumor growth and
invasiveness by small-for-size graft injury and regeneration [105, 106]. Additionally, more
clinical studies with long-term follow-up are needed to evaluate the role of LDLT for early
HCC. At present, if a suitable and willing donor is identified, LDLT is a reasonable alterna‐
tive to waiting 6 to 12 months for a deceased donor graft in patients with HCC who are oth‐
erwise eligible for liver transplantation.
Although liver transplantation is the only option for the cure in majority of the patients with
HCC complicated by underlying cirrhosis precluding resection, identification of prognostic
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signed additional scores at regular intervals to reflect their risk for dropout as a result of
tumor progression.
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In an attempt to ensure that preoperative assessment is as accurate as possible, UNOS pro‐
vides a set of specific requirements for listing patients with HCC for orthotopic liver trans‐
plantation.
I. The diagnosis must be confirmed by thorough assessment by imaging modalities
such as ultrasound, dynamic CT and /or MRI. Tumor numbers, size, presence or
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II. Patient must have one of the following:
1. An Alfa fetoprotein level > 200 ng/mL.
2. Celiac angiography showing tumor blush corresponding to the site shown by
CT/MRI/ultrasonography.
3. A biopsy confirming HCC
4. History of RFA, TACE or other locoregional therapy.
III. Must be within Milan’s criteria.
IV. Continued documentation of the tumor is required every three months by CT or
MRI to ensure continued eligibility for liver transplantation.
Patients will be given priority MELD score depending upon the state of underlying disease.
Prioritization scores for patients with HCC are based upon tumor size and number. With
this new organ allocation policy, waiting time for the patients with HCC to receive a de‐
ceased-donor liver has decreased significantly.
3.4. Living Donor Liver Transplantation (LDLT)
The shortage of organs from deceased donors has curtailed the adoption of living donor liv‐
er transplantation. Living donors can potentially provide an essentially unlimited source of
liver grafts for a planned transplant operation as soon as the diagnosis of HCC is made, thus
decreasing the uncertainty of long waiting periods and reducing possibility of tumor pro‐
gression [97]. The living donor can be from adult-to-adult or adult-to-child. In children
mostly left lateral segment of the liver harvested and donors are usually ABO-compatible
parents. While in adult-to-adult, right or left liver can be harvested that depends upon pre‐
transplant evaluation of donor and CT volumetry of liver. The GRWR (graft to recipient
weight ratio) must be more than 0.8%. Donor not meeting these criteria is rejected for the
fear of small-for-size syndrome and subsequent graft failure [98, 99].
Because a live donor graft is a dedicated gift that is directed exclusively to a particular recip‐
ient, there is no need for an objective allocation system based on a prioritization scheme.
Presently LDLT comprises almost >90% of liver transplants in Asia as compared to <5% in
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US. Unlike in the U.S., where recipients with malignancies receive extra prioritization in the
deceased donor organ allocation scheme, HCC patients in Asia do not. HCC patients in Asia
have a dismal chance of receiving a deceased donor graft and LDLT is often the only option.
3.5. Pretransplant locoregional therapies
Pretransplant locoregional therapy has been adopted by the liver transplant community
worldwide. This concept, known as “bridging therapy” is meant to limit tumor progression
and dropout rate while patients are on the transplant wait list. The most popular techniques
include TACE, transarterial drug-eluting beads, transarterial radio-embolizationand RFA.In
the transplant setting, TACE is currently the most popular neo-adjuvant treatment. It is indi‐
cated in Child–Pugh A or B cirrhotic patients to downstage tumors into the Milan criteria or
to prevent tumor progression. For patients with small HCC confined to the liver, recent data
also indicate that transplantation when used with multimodal therapy using locoregional
procedures and neoadjuvant systemic chemotherapy, results in improved recurrence-free
survival [100, 101]. Apart from that, it is also important to know the wait list dropout rate
and bridging therapy-associated complication rate, because the benefit of preventing wait
list dropout should outweigh the risk of bridging therapy.Patient-individualized treatment
strategy should be based on the performance status, hepatic reserve, tumor burden, and tu‐
mor vascularity pattern.
3.6. Outcome of liver transplantation
To date, orthotopic liver transplantation is no doubt the best therapeutic option for early,
unresectable HCC, although it is limited by graft shortage and the need for appropriate pa‐
tient selection. Since the introduction of the milan’s criteria, the liver transplantation for pri‐
mary HCC is on rise with promising recurrence-free survival and overall survival. Excellent
5-year post-transplant patient survival of at least 70% has been reported from many centers
[102]. Furthermore, better definition of the prognostic factors and more rigorous patient se‐
lection have resulted in significant improvement in 5-year survival for patients receiving
transplants for HCC in the past decade.
However, a tendency for higher HCC recurrence has been reported for patients who under‐
went LDLT than patients who underwent DDLT [103, 104]. The reasons for this difference
are not completely answered by current studies. Possible explanations can be related to the
selection bias for clinical characteristics associated with aggressive tumor behavior, elimina‐
tion of natural selection during the waiting period, and enhancement of tumor growth and
invasiveness by small-for-size graft injury and regeneration [105, 106]. Additionally, more
clinical studies with long-term follow-up are needed to evaluate the role of LDLT for early
HCC. At present, if a suitable and willing donor is identified, LDLT is a reasonable alterna‐
tive to waiting 6 to 12 months for a deceased donor graft in patients with HCC who are oth‐
erwise eligible for liver transplantation.
Although liver transplantation is the only option for the cure in majority of the patients with
HCC complicated by underlying cirrhosis precluding resection, identification of prognostic
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factors and refinement of selection criteria will improve the outcomes of liver transplanta‐
tion for this otherwise fatal disease. Nonetheless, liver transplantation may also pose a risk
of post transplant lymphoproliferative disorders and other de novo malignacy associated
with long term immunosuppression.
4. Conclusion
The management of patients with HCC remains complex and challenging. Although liver
resection and liver transplantation are the curative treatments for HCC at present, there is
considerable controversy as to whether patients with HCC are better served with liver trans‐
plantation versus liver resection. Liver transplantation removes HCC with underlying cir‐
rhosis and thus sounds best option; however, technical challenges associated with
transplantation and/or immunosuppression should be taken into consideration for selecting
transplant cadidates. Currently, most studies suggest that liver resection should be a priori‐
ty in patients who are candidates for either liver resection or transplantation [102, 107]. De‐
spite a better cancer cure rate for liver transplatation, liver resection remains superior for
patients in terms of limited organ availability and transplantation-associated morbidity and
mortality. Therefore, the optimal treatment for patients with preservd liver function should
always be resection whenever the tumor is resectable, and liver transplantation could be re‐
served as a salvage therapy for patients who encounter HCC recurrence after primary liver
resection. Theoretically, this strategy will not only improve patient survival but relieve the
growing demand of available donor livers.
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1. Introduction
Hepatocellular carcinoma (HCC), an epithelial tumor derived from hepatocytes, accounts for
80% of all primary liver cancers and ranks globally as the fourth leading cause of cancer-related
deaths. Annual mortality rates of HCC remain comparable to its yearly incidence, making it
one of the most lethal varieties of solid-organ cancer. Well-established risk factors for the
development of HCC include hepatitis B carrier state, chronic hepatitis C infection, hereditary
hemochromatosis, and cirrhosis of any etiology, as well as certain environmental toxins. HCC
treatment is a multidisciplinary and a multimodal task with surgery in the form of liver
resection and liver transplantation representing the only potentially curative modalities. Here
we going to discuss the liver resection as treatment modality for HCC in detail.
1.1. Pathology of HCC
Three gross morphologic types of HCC have been identified: nodular, massive and diffuse.
Nodular HCC is often associated with cirrhosis and is characterized by well-circumscribed
nodules. The massive type of HCC, usually associated with a non-cirrhotic liver, occupies a
large area with or without satellite nodules in the surrounding liver. The less common diffuse
type is characterized by diffuse involvement of many small indistinct tumor nodules through‐
out the liver. Histologically, six growth forms of HCC can be differentiated. The most common
form is the trabecular type, usually comprising highly differentiated carcinomas with polyg‐
onal tumor cells similar to hepatocytes; they grow in multilayered trabeculae and enclose blood
spaces lined with endothelium (usually without Kupffer cells). The pseudoglandular type is
generally found in combination with the trabecular form. It is characterized by the formation
of gland-like structures containing detritus and bile or liquid material. The scirrhous type
shows excessive deposits of sclerosed connective tissue, which is relatively low in cells. The
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moderately differentiated tumor cells lie between the septa, which resemble connective tissue.
This type is mostly found after chemotherapy or radiation therapy. The solid type is an
undifferentiated HCC, with the tumor cells displaying considerable cellular polymorphism;
the trabecular tissue pattern has disappeared. The tumor is compact due to compression of the
sinusoids. Differentiation is, however, only possible in rare cases, since there is often consid‐
erable heterogenicity within the tumor, i.e. different tissue types may be found in the same
HCC. Fibrolamellar HCC is rare; it consists of solid cell trabeculae with connective-tissue
septation and a capsule. Spindle cell-like differentiated HCC is likewise a very rare histological
form with a fascicular-sarcomatous growth pattern. Prognosis is significantly poorer than with
other forms of HCC.
1.2. Preoperative evaluation
The preoperative evaluation for resection of HCC should focus on the likelihood of disease
being confined to the liver, and whether the anatomical location of the tumor and the under‐
lying liver function will permit resection (table 2).
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CBC Platelet level is an indirect reflection of portal
hypertension in cirrhosis.
LFT Bilirubin level for synthetic liver function and for Child
Pugh score
Coagulation PT/INR for synthetic liver function and for Child Pugh score
Chemistry For electrolyte imbalance in cirrhotic patient and
assessment of renal function
Albumin Liver synthetic function, nutritional status and Child Pugh
score
AFP Tumor marker for HCC
Hepatitis screen HBV and HCV
Radiology:
US Screening image for high risk patient
It evaluate liver lesion and liver parenchyma
CT and /or MRI - Number and size of lesion and it’s relation to major
vessel
- If it is classic HCC appearance by one image no need to
be supported by another imaging.
- Assessment of future liver remnant
- Role out metastasis
Portal Portal vein pressure If patient cirrhotic and he is candidate for surgery with
questionable portal hypertension
Portal vein embolization If future liver remnant small
Biopsy:
Core biopsy (tumor) If CT and /or MRI are not classical for HCC
Liver biopsy If cirrhosis is not clear and sometime to know the cause of
cirrhosis
Others:
Child Pugh score If patient cirrhotic
ICG For assessment of adequate liver reserve before major
resection (in some centers)
Pre anesthesia evaluation
Table 2. Preoperative checklist for HCC patient
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1.3. Determining the extent of tumor involvement
Anatomic delineation of tumor extent is best achieved with dynamic multiphase CT or MRI
scanning. Arterial phase imaging detects 30 -40 % more tumor nodules than conventional CT
and may be the only phase to demonstrate the tumor in 7 -10 % of cases. Typical picture of
HCC on CT will be an enhanced lesion on arterial phase (figure 1(a)) and early washout of
contrast on venous phase (figure 1(b)).
(a) 
(b) 
Figure 1. (a) Enhanced lesion on arterial phase in HCC (b) Early washout of contrast on venous phase in HCC
There is no general rule regarding tumor size for selection of patients for resection. Certainly,
patients with smaller tumors are less likely to harbor occult vascular invasion and have a better
outcome after therapy. Size alone is not a contraindication for resection of multinodular HCC.
Lymph node metastases are uncommon overall (between 1 - 8 %), but their presence portends
a worse outcome. Preoperative detection of nodal metastases is limited by the frequent
Hepatic Surgery330
presence of benign nodal enlargement, most often involving the porta hepatis and portacaval
space, in patients with cirrhosis. Highly suspicious nodes based on enhancement similar to
the intrahepatic HCC lesions indicate the need for biopsy in a patient being considered for
resection. However, involved nodes are not a contraindication to surgery for fibrolamellar
HCC; these patients should have a formal lymph node dissection.
A chest CT is recommended to complete the staging evaluation and bone scan if suspicious
bone pain or hypercalcemia. HCC has lower FDG accumulation in well-differentiated and low-
grade tumors than in high-grade tumors. In a study by Khan et al, the sensitivity of PET in
diagnosis of HCC was 55% compared with 90% for CT scanning, although some tumors (15
%) were detected by PET only (including distant metastases). So, PET imaging may help assess
tumor differentiation and may be useful in the diagnosis, staging and prognostication of HCC
as an adjunct to CT. However, the utility of PET scanning for detection primary and occult
distant metastatic disease is uncertain, need to be explored further and not recommended in
guidelines from the National Comprehensive Cancer Network (NCCN).
1.4. Assessment of hepatic reserve
Operative mortality is related to the severity of the underlying liver disease; it is 7- 25% in
cirrhotic and less than 3% in non-cirrhotic patients. In patients with cirrhosis, surgical resection
is most safely performed in those with Child-Pugh class A (table 3) disease who has a normal
bilirubin and well preserved liver function. However, even Child-Pugh class A patients may
develop rapid hepatic decompensation following surgery due to limited functional hepatic
reserve.
CHILD – PUGH SCORE
Clinical and laboratory parameter Scores
1 2 3
Encephalopathy (grade) None 1-2 3-4
Ascites None Slight Moderate
Albumin (g/dL) > 3.5 2.8-3.5 < 2.8
Prothrombin time prolonged (sec) 1-4 4-6 6
Bilirubin (mg/dL) < 2 2-3 > 3
For primary biliary cirrhosis < 4 4-10 > 10
Class A = 5–6 points; Class B = 7–9 points; Class C = 10–15 points.
Class A: Good operative risk
Class B: Moderate operative risk
Class C: Poor operative risk
Table 3. Child Pugh score
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Although helpful, the Child-Pugh classification and other tools for assessing underlying liver
disease, such as the Model for End-stage Liver Disease (MELD) score, are not adequate to select
patients with sufficient hepatic reserve for major resection.
Multiple studies have demonstrated that a normal serum bilirubin level and the absence of
clinically significant portal hypertension (i.e., hepatic venous pressure gradient <10 mm Hg)
are the best available indicators of acceptably low risk of postoperative liver failure after liver
resection. In the absence of an elevated serum bilirubin and portal hypertension, survival after
PH can exceed 70% at 5 years. Survival after liver resection in patients with significant portal
hypertension alone decreases to < 50% at 5 years. However, in patients with both an elevated
serum bilirubin and significant portal hypertension, survival drops to < 30% at 5 years,
regardless of Child-Pugh score. Direct measurement of portal pressure is not necessary in
patients with clinical signs of severe portal hypertension, including esophageal varices, ascites,
or splenomegaly associated with a platelet count less than 100,000/mL.
In many centers the Child-Pugh score may be supplemented by specialized investigations such
as the indocyaninegreen (ICG) retention test, especially in marginal cases (e.g. Child-Pugh B,
possible mild portal hypertension). ICG retention of 14% at 15 min is widely accepted (in Asia
Pacific area) as a reflection of adequate functional reserves for major resection (defined as
resection of > 2 Couinaud segments) (figure 2).
Figure 2. Couinaud liver segments
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Assessment of the volume and function of residual liver should also be addressed by CT
volumetry, particularly since portal vein embolization can be a valuable tool to increase the
liver remnant volume and function prior to major hepatic resection, particularly for right sided
tumors.
1.5. Portal vein embolization
Preoperative portal vein embolization (PVE) is a valuable adjunct to major liver resection. PVE
can initiate hypertrophy of the anticipated future liver remnant to enable an extended resection
in a patient with normal liver or major resection in a well compensated cirrhotic patient that
would otherwise leave a remnant liver insufficient to support life following partial hepatec‐
tomy.
There are potential benefits to use of PVE:
• Reduce post-operative morbidity and mortality,
• Convert unresectable tumor due insufficient future liver remnant to resectable for potential
cure.
• Subclinical disease or rapid progression may be detected prior to definitive surgery on post-
embolization imaging studies, thus sparing the patient an unnecessary operation.
• The absence of compensatory hypertrophy identify patient with impaired liver regenera‐
tion,for that decrease post liver resection failure by preclude them from major liver resection.
The success of PVE was addressed by Abulkhir A et al, in a meta-analysis of data from 37
published series of PVE prior to liver resection. Four weeks after PVE, there was an overall
increase in liver volume of between 10 and 12 % that was independent of technique, and 85 %
of patients underwent planned laparotomy for attempted major hepatectomy. Following
resection, only 23 patients had transient liver failure (2.5 %), and seven patients died of acute
liver failure (0.8 %).
Liver regeneration usually peaks within the first 2 weeks after PVE. Studies in swine have
shown that regeneration peaks within 7 days of PVE, with 14% of hepatocytes undergoing
replication. Regeneration rates reported for humans are comparable to those found in animals.
Non-cirrhotic livers demonstrate the fastest regeneration: 12–21 cm3 /day at 2 weeks after PVE,
approximately 11 cm3 /day at 4 weeks, and 6 cm3 /day at 32 days. Livers in patients with
cirrhosis or diabetes regenerate more slowly (approximately 9 cm3 /day at 2 weeks). Biliary
obstruction, diabetes, chronic ethanol consumption, nutritional status, male gender, old age,
and hepatitis all limit regeneration. Controlling these factors where possible is essential to
maximize liver hypertrophy.
Two techniques can be utilized for PVE:
• The TIPE procedure is performed via a minilaparotomy and requires general anesthesia.
• The percutaneous approach (PTPE), which is more commonly used, can be performed in
the radiology suite with local anesthesia and conscious sedation.
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disease, such as the Model for End-stage Liver Disease (MELD) score, are not adequate to select
patients with sufficient hepatic reserve for major resection.
Multiple studies have demonstrated that a normal serum bilirubin level and the absence of
clinically significant portal hypertension (i.e., hepatic venous pressure gradient <10 mm Hg)
are the best available indicators of acceptably low risk of postoperative liver failure after liver
resection. In the absence of an elevated serum bilirubin and portal hypertension, survival after
PH can exceed 70% at 5 years. Survival after liver resection in patients with significant portal
hypertension alone decreases to < 50% at 5 years. However, in patients with both an elevated
serum bilirubin and significant portal hypertension, survival drops to < 30% at 5 years,
regardless of Child-Pugh score. Direct measurement of portal pressure is not necessary in
patients with clinical signs of severe portal hypertension, including esophageal varices, ascites,
or splenomegaly associated with a platelet count less than 100,000/mL.
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as the indocyaninegreen (ICG) retention test, especially in marginal cases (e.g. Child-Pugh B,
possible mild portal hypertension). ICG retention of 14% at 15 min is widely accepted (in Asia
Pacific area) as a reflection of adequate functional reserves for major resection (defined as
resection of > 2 Couinaud segments) (figure 2).
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would otherwise leave a remnant liver insufficient to support life following partial hepatec‐
tomy.
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• Reduce post-operative morbidity and mortality,
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cure.
• Subclinical disease or rapid progression may be detected prior to definitive surgery on post-
embolization imaging studies, thus sparing the patient an unnecessary operation.
• The absence of compensatory hypertrophy identify patient with impaired liver regenera‐
tion,for that decrease post liver resection failure by preclude them from major liver resection.
The success of PVE was addressed by Abulkhir A et al, in a meta-analysis of data from 37
published series of PVE prior to liver resection. Four weeks after PVE, there was an overall
increase in liver volume of between 10 and 12 % that was independent of technique, and 85 %
of patients underwent planned laparotomy for attempted major hepatectomy. Following
resection, only 23 patients had transient liver failure (2.5 %), and seven patients died of acute
liver failure (0.8 %).
Liver regeneration usually peaks within the first 2 weeks after PVE. Studies in swine have
shown that regeneration peaks within 7 days of PVE, with 14% of hepatocytes undergoing
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cirrhosis or diabetes regenerate more slowly (approximately 9 cm3 /day at 2 weeks). Biliary
obstruction, diabetes, chronic ethanol consumption, nutritional status, male gender, old age,
and hepatitis all limit regeneration. Controlling these factors where possible is essential to
maximize liver hypertrophy.
Two techniques can be utilized for PVE:
• The TIPE procedure is performed via a minilaparotomy and requires general anesthesia.
• The percutaneous approach (PTPE), which is more commonly used, can be performed in
the radiology suite with local anesthesia and conscious sedation.
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Volumetric assessment of the liver volume with CT imaging should be done before PVE and
again before surgery. A standardized technique for measuring the future liver remnant, to
select patients for PVE prior to a planned extended hepatectomy (trisegmentectomy) or
hemihepatectomy in the setting of underlying liver disease, is strongly recommended. In
considering the need for PVE, the ratio of future liver remnant and total estimated liver volume
should be calculated. If the future liver remnant is < 20% in a patient with a normal liver or
40% in a patient with a cirrhotic liver, PVE should be considered.
Some reports have shown accelerated tumor growth in the liver after PVE. Problems with
tumor growth are not seen when all of the tumor-bearing areas of the liver are embolized.
Transarterial chemoembolization (TACE) has been proposed as a complementary procedure
prior to PVE in patients with HCC. TACE not only eliminates the arterial blood supply to the
tumor, but it also embolizes potential arterioportal shunts in cirrhotic livers that attenuate the
effects of PVE. Most reserve the "double embolization" procedure for patients with HCC in
patients with liver disease who require right hepatectomy.
2. Surgery
Liver resection is a potentially curative therapy for patients with early-stage HCC (solitary
tumor ≤5 cm in size, or ≤3 tumors each ≤3 cm in size and no evidence of gross vascular invasion)
in a Child-Pugh class A score and no evidence of portal hypertension (although a minor
resection could be considered in some patients with portal hypertension) Table 4. However, in
highly selected cases, patients with a Child-Pugh class B score may be considered for limited
liver resection, particularly if liver function tests are normal and no portal hypertension.
Optimal tumor characteristics for liver resection are solitary tumors without major vascular
invasion. Although no limitation on the size of the tumor is specified for liver resection, the
risk of vascular invasion and dissemination increases with size. However, in one study by
Pawlik TM, no evidence of vascular invasion was seen in approximately one-third of patients
with single HCC tumors of 10 cm or larger. Nevertheless, the presence of macro- or microscopic
vascular invasion is considered to be a strong predictor of HCC recurrence.
Liver resection is controversial in patients with limited and multifocal disease as well as those
with major vascular invasion. Multifocality is associated with lower survival, but does not
exclude a good outcome in selected patients. In several studies, resection of multifocal HCC
is associated with five-year survival rates of approximately 24 %. Patients with multinodular
HCC who appear to benefit from resection are those with sufficient liver reserve to tolerate
resection, without extrahepatic disease and without major vascular invasion. Liver resection
in patients with major vascular invasion should only be performed in highly selected situations
by experienced teams.
Despite even aggressive surgical approaches, most patients have HCC or liver disease too
advance to permit treatment with "curative" intent. In high-incidence regions of the world,
only 10 to 15 % of newly diagnosed patients are candidates for standard resection, whereas in
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low incidence areas, between 15 and 30 % of patients are potentially resectable. Furthermore,
only one-half of patients referred for surgery actually have resectable tumors. Among the
reasons for unresectability are the extent of intrahepatic disease, extrahepatic extension,
inadequate functional hepatic reserve, and involvement of the confluence of the portal or
hepatic veins.
Indication for liver resection:
Indicated:
- Solitary tumor ≤5 cm in size or ≤3 tumors each ≤3 cm in size and no evidence of gross
vascular invasion.
- Solitary tumors (any size) without major vascular invasion.
Patient should be in a Child-Pugh class A and no evidence of portal hypertension
Controversial:
- Multifocal disease
- Major vascular invasion
- Child-Pugh class B score and no portal hypertension
Table 4. Indications for liver resection in hepatocellular carcinoma
2.1. Intraoperative staging
Laparoscopy and intraoperative ultrasound (IOUS) may improve the selection of patients for
potentially curative resection. IOUS can accurately determine the size of the primary tumor
and detect portal or hepatic vein involvement, which precludes curative resection. Another
benefit of IOUS is the identification of major intrahepatic vascular structures, which can be
used to guide segmental or non-anatomic resections.
2.2. Technique
In non-cirrhotic liver, an anatomical resection should be performed. Up to two-thirds of the
functional parenchyma can be removed safely depending upon the age of the patient and his
liver's regenerative capacity. However, for cirrhotic patients, because the capacity for liver
regeneration is impaired in these patients, resection is generally limited to less than 25% of
functional parenchyma. to maintain postoperative liver function. However, some patients
maintain adequate functional hepatic reserve even after a formal hemi-hepatectomy, particu‐
larly if preoperative portal vein embolization (PVE) is used to induce compensatory hyper‐
trophy in the future liver remnant. Both anatomic and wedge resection are acceptable, though
some studies suggest portal-oriented resections enable longer overall and disease-free survival
when feasible which might be because of the pattern of intrahepatic spread of liver cancer cells
along segmental portal vein pedicle, so segmental resection may improve the chance of tumor
clearance compared with a non-anatomical wedge resection.
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Volumetric assessment of the liver volume with CT imaging should be done before PVE and
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liver resection, particularly if liver function tests are normal and no portal hypertension.
Optimal tumor characteristics for liver resection are solitary tumors without major vascular
invasion. Although no limitation on the size of the tumor is specified for liver resection, the
risk of vascular invasion and dissemination increases with size. However, in one study by
Pawlik TM, no evidence of vascular invasion was seen in approximately one-third of patients
with single HCC tumors of 10 cm or larger. Nevertheless, the presence of macro- or microscopic
vascular invasion is considered to be a strong predictor of HCC recurrence.
Liver resection is controversial in patients with limited and multifocal disease as well as those
with major vascular invasion. Multifocality is associated with lower survival, but does not
exclude a good outcome in selected patients. In several studies, resection of multifocal HCC
is associated with five-year survival rates of approximately 24 %. Patients with multinodular
HCC who appear to benefit from resection are those with sufficient liver reserve to tolerate
resection, without extrahepatic disease and without major vascular invasion. Liver resection
in patients with major vascular invasion should only be performed in highly selected situations
by experienced teams.
Despite even aggressive surgical approaches, most patients have HCC or liver disease too
advance to permit treatment with "curative" intent. In high-incidence regions of the world,
only 10 to 15 % of newly diagnosed patients are candidates for standard resection, whereas in
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low incidence areas, between 15 and 30 % of patients are potentially resectable. Furthermore,
only one-half of patients referred for surgery actually have resectable tumors. Among the
reasons for unresectability are the extent of intrahepatic disease, extrahepatic extension,
inadequate functional hepatic reserve, and involvement of the confluence of the portal or
hepatic veins.
Indication for liver resection:
Indicated:
- Solitary tumor ≤5 cm in size or ≤3 tumors each ≤3 cm in size and no evidence of gross
vascular invasion.
- Solitary tumors (any size) without major vascular invasion.
Patient should be in a Child-Pugh class A and no evidence of portal hypertension
Controversial:
- Multifocal disease
- Major vascular invasion
- Child-Pugh class B score and no portal hypertension
Table 4. Indications for liver resection in hepatocellular carcinoma
2.1. Intraoperative staging
Laparoscopy and intraoperative ultrasound (IOUS) may improve the selection of patients for
potentially curative resection. IOUS can accurately determine the size of the primary tumor
and detect portal or hepatic vein involvement, which precludes curative resection. Another
benefit of IOUS is the identification of major intrahepatic vascular structures, which can be
used to guide segmental or non-anatomic resections.
2.2. Technique
In non-cirrhotic liver, an anatomical resection should be performed. Up to two-thirds of the
functional parenchyma can be removed safely depending upon the age of the patient and his
liver's regenerative capacity. However, for cirrhotic patients, because the capacity for liver
regeneration is impaired in these patients, resection is generally limited to less than 25% of
functional parenchyma. to maintain postoperative liver function. However, some patients
maintain adequate functional hepatic reserve even after a formal hemi-hepatectomy, particu‐
larly if preoperative portal vein embolization (PVE) is used to induce compensatory hyper‐
trophy in the future liver remnant. Both anatomic and wedge resection are acceptable, though
some studies suggest portal-oriented resections enable longer overall and disease-free survival
when feasible which might be because of the pattern of intrahepatic spread of liver cancer cells
along segmental portal vein pedicle, so segmental resection may improve the chance of tumor
clearance compared with a non-anatomical wedge resection.
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Surgical outcomes in cirrhotic patients have improved over the past decade as a result of
advances in surgical techniques, in particular the techniques that help to reduce bleeding
during liver parenchyma transection and perioperative support. One of the most important
advances is the thorough understanding of the segmental anatomy of the liver, which can be
delineated using intraoperative ultrasound during operation. The delineation of a proper
transaction plane is important not only for adequate tumor-free margin in resection of liver
tumors but also to avoid inadvertent injuries to major intrahepatic vessels or bile duct pedicles.
Use of the Pringle maneuver for vascular inflow occlusion as an alternative to total vascular
occlusion has decrease deleterious effect on liver. Intermittent Pringle occlusion is well
tolerated by cirrhotic patients for up to 60 minutes and is better tolerated than continuous
clamping. The use of low CVP (less than 5mm Hg) anesthesia and newer instruments such as
the ultrasonic dissector, hydrojet and vascular stapling devices has also significantly improved
visualization, limited blood loss and decreased operative times.
2.3. Anterior technique
Some surgeons have advocated an anterior or "no touch" technique to resection of these tumors.
This approach utilizes initial transection of the liver parenchyma to the inferior vena cava
(IVC), and ligation of the inflow and outflow vessels before mobilization of the right liver lobe.
The advocates of this technique hypothesize that separation of the right liver and the tumor
from the IVC before mobilization avoids prolonged rotation and displacement of the hepatic
lobes, therefore reducing the risk of vascular rupture. In addition, division of the vessels before
tumor manipulation theoretically minimizes the potential for tumor cell dissemination caused
by tumor compression.
2.4. Centrally located tumors
Surgical management of centrally located tumors (i.e., those in segments IV, V, and VIII) is
especially problematic. Extended right or left hemi-hepatectomy is the treatment of choice if
potentially curative surgery can be undertaken safely. An alternative segment-oriented
approach, meso-hepatectomy (also called central hepatectomy), has been proposed in which
the central liver segments IV and/or V, and VIII (with or without segment I) are removed and
the lateral sectors remain intact.
While randomized trials have not been conducted, the available data suggest that meso-
hepatectomy is a reasonable alternative to extended resection for centrally located tumors,
providing acceptable oncologic outcomes with less hepatic parenchymal loss. However, in
some centers, meso-hepatectomy is seldom used, partly because it is a complex and technically
demanding procedure that requires two hepatic resection planes and bilateral biliary recon‐
struction. This results in a higher risk of bile leak and bleeding as well as long-term biliary
stricture and biliary dysfunction. In addition, some data suggest that portal vein embolization
followed by major hepatectomy might be safer.
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2.5. Minimally invasive surgery
The success of minimally invasive resection of benign hepatic tumors has led to interest in
laparoscopic approaches to surgery for HCC. The available literature is limited by the lack of
prospective trials and the paucity of information on long-term oncologic outcomes.
Looking to the available literature, laparoscopic resection is feasible and safe in experienced
hands. It is also highly technically demanding and should be undertaken only in high volume
centers.
2.6. Tumor rupture
Approximately 10% of HCC spontaneously rupture. The clinical picture is that of acute
abdominal pain and distension with drop in the hematocrit and hypotension. Initially, these
patients' hemodynamic should be stabilized followed by trans-arterial embolization for control
of bleeding. If unsuccessful, emergency surgery may be required.
Although the presence of a tumor rupture suggests a high likelihood of peritoneal seeding and
usually a poor outcome from resection, this is not inevitable. If bleeding can be controlled
(arterial embolization is recommended), a formal staging evaluation should be undertaken,
followed by laparoscopic exploration and a subsequent attempt at resection, if feasible. Several
retrospective series suggest a low, but defined long-term survival rate following resection in
such situations.
In the largest series from Hong Kong by Liu CL et al, 154 of 1716 patients who were newly
diagnosed with HCC between 1989 and 1998 presented with spontaneous rupture. The 30-day
mortality rate following tumor rupture was 38 %. After initial stabilization and clinical
evaluation, 33 underwent hepatic resection. Although the median survival after hepatectomy
was worse in ruptured as compared to non-ruptured cases (26 versus 49 months) and the rate
of extra-hepatic recurrence was higher (46 versus 26 %), 8 patients (24 %) remained alive
without recurrent disease after a median follow-up period of 45 months.
2.7. Postoperative management
Postoperative management is primarily supportive. Those patients should be monitored in
ICU with great attention to hydration status, not over or under hydrated with CVP monitor.
The extent of postoperative morbidity is related to the extent of operative resection. Major
postoperative complications include bile leak in 8% and pleural effusion in 7%, which are
usually treated conservatively.
2.8. Perioperative mortality
The 30-day operative mortality rate in modern series of HCC resection ranges widely from 1
-24 %. Fewer than 10 % of perioperative deaths are due to uncontrolled intraoperative
hemorrhage; most are due to postoperative liver failure. The presence of cirrhosis is the most
important predictor of post-resection liver failure and death. The 30-day postoperative
mortality for cirrhotic patients ranges from 14 -24 %, compared to 0.8 -7 % for non-cirrhotics.
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stricture and biliary dysfunction. In addition, some data suggest that portal vein embolization
followed by major hepatectomy might be safer.
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2.6. Tumor rupture
Approximately 10% of HCC spontaneously rupture. The clinical picture is that of acute
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ICU with great attention to hydration status, not over or under hydrated with CVP monitor.
The extent of postoperative morbidity is related to the extent of operative resection. Major
postoperative complications include bile leak in 8% and pleural effusion in 7%, which are
usually treated conservatively.
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The 30-day operative mortality rate in modern series of HCC resection ranges widely from 1
-24 %. Fewer than 10 % of perioperative deaths are due to uncontrolled intraoperative
hemorrhage; most are due to postoperative liver failure. The presence of cirrhosis is the most
important predictor of post-resection liver failure and death. The 30-day postoperative
mortality for cirrhotic patients ranges from 14 -24 %, compared to 0.8 -7 % for non-cirrhotics.
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Two additional factors influence the development of postoperative liver failure in cirrhotic
patients are intraoperative blood loss of >1500 ml and postoperative infection of any type.
Mortality can also be reduced by appropriate selection of patients and meticulous surgical
technique, with the inclusion of preoperative volumetry and portal vein embolization when
appropriate.
Consensus is growing that 30-day operative mortality is an inadequate indicator of risk,
particularly of postoperative hepatic insufficiency and failure. Using an approach similar to
liver transplantation reporting, 90-day mortality reporting appears to be a more valuable
indicator of outcome of liver resection, especially in the cases of extended resection and
resection in patients with diseased livers. This relates to the late development of slowly
progressive jaundice, ascites, and eventual death, which typically occurs outside the hospital
and well after 30 postoperative days in patients with marginal or inadequate liver remnants
(post resection liver failure will be discussed in detail at end of this chapter).
2.9. Fast track surgery
Surgical pathway and ‘fast-track’ (FT) programs are structured interdisciplinary strategies that
have been introduced to optimize perioperative care and accelerate post-operative recovery.
The main aim of the FT protocol is to reduce the metabolic and inflammatory response to
surgical stress and preserve vital functions. A review done by Lidewij et al showed primary
hospital stay was significantly reduced after FT care in two out of the three studies. In one
study, median hospital stay was 6 days in the FT group compared with 8 days in the control
group (P < 0.001). In the other study, primary hospital stay was reduced from 11 days to 7 days
(P < 0.01). There were no significant differences in rates of readmission, morbidity and mortality
between FT and control groups. One trial found a significantly shorter time to successful
resumption of a normal diet in the FT group (1 post-operative day for FT patients vs. 3 days
for the control group).
3. Long-term outcomes
Results of large retrospective studies have shown 5-year survival rates of over 50% for patients
undergoing liver resection for HCC, and some studies suggest that in carefully selected
patients having no vascular invasion by tumor, solitary lesions without intrahepatic metasta‐
sis, tumor diameter ≤5 cm, and a negative surgical margin of >1 cm, five-year survival rates
up to 78 %. However, HCC tumor recurrence rates at 5 years following liver resection have
been reported up to 70%.
Palavecino M et al reported series of 54 patients with advanced HCC and significant tumor
burden who were treated with PVE plus major hepatectomy, the five-year overall survival was
72 % and the five-year disease-free survival was 56 %.
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3.1. Tumor-related prognostic factors
The most important tumor-related prognostic factors are presence and degree of vascular
invasion, tumor number and size, and surgical margin status. Other poor prognostic indicators
are absence of a tumor capsule, preoperative alpha fetoprotein (AFP) levels >10,000 ng/ml, and
poor histologic grade of differentiation.
Both intrahepatic and extra-hepatic spread of HCC is more common with tumors >5 cm,
particularly when associated with venous invasion. In a report by Zhou XD compared 1000
patients with tumors ≤5 cm and 1366 patients having tumors >5 cm, all of whom underwent
hepatectomy over the same period, five-year survival rates were significantly better for
patients with smaller tumors (63 %versus 37 %, respectively). Nevertheless, several series
indicate five year survival rates ranging from 25 to 35 percent in selected patients undergoing
resection for single HCC ≥10 cm. However, although increasing tumor size is associated with
increased risk for vascular invasion, large, solitary tumors without vascular invasion have the
same prognosis as small solitary tumors without vascular invasion.
The importance of wide resection margins is debated. In study by Ozawa K of 225 patients with
HCC who underwent resection, three-year survival was significantly better when a >1 cm
tumor-free margin was achieved (77 % versus 21%, respectively). However, larger series by
Poon RT suggest that a negative margin of <1 cm is acceptable.
Gross or microscopic invasion of branches of the portal or hepatic veins is associated with a
lower probability of survival following resection.
3.2. Underlying liver dysfunction
Preoperative liver dysfunction and cirrhosis are important negative prognostic factors.
Yamanaka N reported a series of 295 patients undergoing resection of HCC, the four-year
survival was more than twofold higher for non-cirrhotic compared to cirrhotic patients (81%
versus 35 %). This difference in outcome may be related in part to the higher frequency of
multicentric HCC in cirrhotic patients.
In patients with cirrhosis related to HBV infection, active hepatitis is also a poor prognostic
factor. As a general rule, the severity of cirrhosis, rather than the presence of a small, early
stage HCC, limits long-term survival in cirrhotic patients with HCC. Chronic liver disease
provides a field that contributes to the development of second primary HCCs and a persisting
risk of HCC-related death beyond five years.
3.3. Recurrences
Treatment of recurrence is a poorly investigated area. Solitary recurrence might benefit from
repeat resection, but in most patients recurrence will be multifocal.It has been suggested,
retrospective analyses, that patients with recurrence might be candidates for salvage trans‐
plantation.. Most of the recurrences and specially those that appear early during follow-up are
due to tumor dissemination and have a more aggressive biological pattern as compared to
primary tumors. Hence, only those patients in whom recurrence is due to de novo oncogenesis
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Two additional factors influence the development of postoperative liver failure in cirrhotic
patients are intraoperative blood loss of >1500 ml and postoperative infection of any type.
Mortality can also be reduced by appropriate selection of patients and meticulous surgical
technique, with the inclusion of preoperative volumetry and portal vein embolization when
appropriate.
Consensus is growing that 30-day operative mortality is an inadequate indicator of risk,
particularly of postoperative hepatic insufficiency and failure. Using an approach similar to
liver transplantation reporting, 90-day mortality reporting appears to be a more valuable
indicator of outcome of liver resection, especially in the cases of extended resection and
resection in patients with diseased livers. This relates to the late development of slowly
progressive jaundice, ascites, and eventual death, which typically occurs outside the hospital
and well after 30 postoperative days in patients with marginal or inadequate liver remnants
(post resection liver failure will be discussed in detail at end of this chapter).
2.9. Fast track surgery
Surgical pathway and ‘fast-track’ (FT) programs are structured interdisciplinary strategies that
have been introduced to optimize perioperative care and accelerate post-operative recovery.
The main aim of the FT protocol is to reduce the metabolic and inflammatory response to
surgical stress and preserve vital functions. A review done by Lidewij et al showed primary
hospital stay was significantly reduced after FT care in two out of the three studies. In one
study, median hospital stay was 6 days in the FT group compared with 8 days in the control
group (P < 0.001). In the other study, primary hospital stay was reduced from 11 days to 7 days
(P < 0.01). There were no significant differences in rates of readmission, morbidity and mortality
between FT and control groups. One trial found a significantly shorter time to successful
resumption of a normal diet in the FT group (1 post-operative day for FT patients vs. 3 days
for the control group).
3. Long-term outcomes
Results of large retrospective studies have shown 5-year survival rates of over 50% for patients
undergoing liver resection for HCC, and some studies suggest that in carefully selected
patients having no vascular invasion by tumor, solitary lesions without intrahepatic metasta‐
sis, tumor diameter ≤5 cm, and a negative surgical margin of >1 cm, five-year survival rates
up to 78 %. However, HCC tumor recurrence rates at 5 years following liver resection have
been reported up to 70%.
Palavecino M et al reported series of 54 patients with advanced HCC and significant tumor
burden who were treated with PVE plus major hepatectomy, the five-year overall survival was
72 % and the five-year disease-free survival was 56 %.
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3.1. Tumor-related prognostic factors
The most important tumor-related prognostic factors are presence and degree of vascular
invasion, tumor number and size, and surgical margin status. Other poor prognostic indicators
are absence of a tumor capsule, preoperative alpha fetoprotein (AFP) levels >10,000 ng/ml, and
poor histologic grade of differentiation.
Both intrahepatic and extra-hepatic spread of HCC is more common with tumors >5 cm,
particularly when associated with venous invasion. In a report by Zhou XD compared 1000
patients with tumors ≤5 cm and 1366 patients having tumors >5 cm, all of whom underwent
hepatectomy over the same period, five-year survival rates were significantly better for
patients with smaller tumors (63 %versus 37 %, respectively). Nevertheless, several series
indicate five year survival rates ranging from 25 to 35 percent in selected patients undergoing
resection for single HCC ≥10 cm. However, although increasing tumor size is associated with
increased risk for vascular invasion, large, solitary tumors without vascular invasion have the
same prognosis as small solitary tumors without vascular invasion.
The importance of wide resection margins is debated. In study by Ozawa K of 225 patients with
HCC who underwent resection, three-year survival was significantly better when a >1 cm
tumor-free margin was achieved (77 % versus 21%, respectively). However, larger series by
Poon RT suggest that a negative margin of <1 cm is acceptable.
Gross or microscopic invasion of branches of the portal or hepatic veins is associated with a
lower probability of survival following resection.
3.2. Underlying liver dysfunction
Preoperative liver dysfunction and cirrhosis are important negative prognostic factors.
Yamanaka N reported a series of 295 patients undergoing resection of HCC, the four-year
survival was more than twofold higher for non-cirrhotic compared to cirrhotic patients (81%
versus 35 %). This difference in outcome may be related in part to the higher frequency of
multicentric HCC in cirrhotic patients.
In patients with cirrhosis related to HBV infection, active hepatitis is also a poor prognostic
factor. As a general rule, the severity of cirrhosis, rather than the presence of a small, early
stage HCC, limits long-term survival in cirrhotic patients with HCC. Chronic liver disease
provides a field that contributes to the development of second primary HCCs and a persisting
risk of HCC-related death beyond five years.
3.3. Recurrences
Treatment of recurrence is a poorly investigated area. Solitary recurrence might benefit from
repeat resection, but in most patients recurrence will be multifocal.It has been suggested,
retrospective analyses, that patients with recurrence might be candidates for salvage trans‐
plantation.. Most of the recurrences and specially those that appear early during follow-up are
due to tumor dissemination and have a more aggressive biological pattern as compared to
primary tumors. Hence, only those patients in whom recurrence is due to de novo oncogenesis
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can be expected to benefit from salvage transplantation or repeated resection. While the most
accurate predictors of recurrence due to dissemination (vascular invasion, satellites) may be
identified on pathology, and since the results of transplantation in these patients is good, some
authors have proposed that this category of patients should be listed immediately after
resection. This might be more effective than waiting for recurrence to develop with excessive
tumor burden possibly excluding liver transplantation. Organ allocation policies might have
to be modified to take these findings into account. Other treatment modalities can provide
disease control (i.e., trans-arterial arterial embolization of chemoembolization, radiofrequency
ablations, sorafenib).
Fewer than 20 % of disease recurrences have an extra-hepatic with overall poor prognosis, and
the benefit of systemic therapy is modest, at best.
3.4. Surveillance
Although data on the role of surveillance in patients with resected HCC are very limited,
recommendations are based on the consensus that earlier identification of disease may
facilitate patient eligibility for investigational studies or other forms of treatment. The NCCN
panel recommends high-quality cross-sectional imaging every 3-6 months for 2 years, then
every 6-12 months. AFP levels, if initially elevated, should be measured every 3 months for 2
years, then every 6-12 months. Re-evaluation according to the initial work-up should be
considered in the event of disease recurrence.
3.5. Survival
Liver resection is a potentially curative therapy for patients with early-stage HCC (solitary
tumor ≤5 cm in size, or ≤3 tumors each ≤3 cm in size and no evidence of gross vascular invasion).
5-year survival rates of over 50% for patients undergoing liver resection for HCC, and some
studies suggest that for selected patients with preserved liver function and early stage HCC,
liver resection can achieve a 5-year survival rate of about 70%. However, HCC tumor recur‐
rence rates at 5 years following liver resection have been reported to exceed 70%.
3.6. Post-Resection Liver Failure (PRLF)
PRLF is a devastating complication that is resource intensive and carries with it considerable
morbidity and mortality. The reported incidence of PRLF ranges between 0.7 - 9.1%. An
inadequate quantity and/or quality of residual liver mass are key events in its pathogenesis.
Major risk factors are the presence of comorbid conditions, pre-existent liver disease and small
Remnant Liver Volume (RLV). It is essential to identify these risk factors during the pre-
operative assessment that includes evaluation of liver volume, anatomy and function.
There is no uniformity concerning the definition of PRLF. In general, PRLF is characterized as
failure of one or more of the hepatic synthetic and excretory functions that include hyper-
bilirubinemia, hypo-albuminemia, prolonged prothrombin time, elevated serum lactate
and/or different grades of hepatic encephalopathy (HE). PRLF is defined by the so-called 50–
50 criteria, which describe PRLF as prothrombin index less than 50% (equal to an international
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standardized ratio more than1.7) and serum bilirubin more than 50 mmol/L (2.9 mg/dL) on
post-operative day 5. When these 50–50 criteria were fulfilled, patients had a 59% risk of
mortality compared with 1.2% when they were not met (sensitivity 69.6% and specificity
98.5%). This rarely occurs in isolation and is often coupled with failure of multiple organs and/
or features of sepsis.
3.7. Pathophysiology of PRLF
After resection of various amounts of functional liver mass, both death and regeneration of
the remaining hepatocytes occur. Physiologically, regeneration outweighs hepatocyte death
and both liver mass and function are restored rapidly. For example, during the first 10 days
after right hepatectomy for living donor liver transplantation, restoration of liver mass up to
74% of the initial volume has been reported. This regeneration is triggered by an increased
metabolic demand placed upon remnant hepatocytes. The ability of the liver remnant to
surmount the effect of surgical resection depends on its capacity to limit hepatocyte death, to
resist metabolic stress, to preserve or recover an adequate synthetic function and to enhance
its regenerative power. These factors rely on both the quality and the quantity of remaining
liver parenchyma. A variety of intraoperative as well as post-operative hits identified that may
attribute to the development of PRLF. These include hepatic parenchymal congestion,
ischemia–reperfusion injury (IRI) and reduced phagocytosis capacity. Liver failure could be
defined as either ‘‘cholestatic’’ (characterized by regeneration of hepatocytes and fibrosis) or
‘‘non-regenerative’’ (characterized by pronounced apoptosis of hepatocytes).
3.8. Hepatic parenchymal congestion
Partial liver resection leads to a relatively augmented sinusoidal perfusion, leading to shear–
stress and congestion of hepatic parenchyma and resulting in vascular and parenchymal
damage similar to small-for-size syndrome after liver transplantation, although less severe.
Moreover, inadequate venous drainage of the liver remnant induces hepatic venous conges‐
tion and functional hepatic volume loss. Hepatic parenchymal congestion may be less severe
in patients with cirrhosis of the liver with preexisting portacaval collaterals.
3.9. Hepatic ischemia–reperfusion injury
Hepatic ischemia–reperfusion injury follows massive bleeding or hepatic in- or outflow
occlusion during liver surgery. Although the resistance of the liver to warm ischemia is
relatively high, hepatic ischemia and reperfusion activate a complex cascade that triggers the
innate immune response by recruitment and activation of Kupffer cells, endothelial cells and
the complement system. These express pro-inflammatory proteins [nuclear factor kB, tumour
necrosis factor-a, interleukin-6], reactive oxygen species, chemokines, complement factors and
vascular cell adhesion molecules. Subsequently, polymorphonuclear neutrophils are activat‐
ed, which aggravate hepatic injury. Although these processes are primarily intended to
maintain homoeostasis, unrestrained activation may become destructive.
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can be expected to benefit from salvage transplantation or repeated resection. While the most
accurate predictors of recurrence due to dissemination (vascular invasion, satellites) may be
identified on pathology, and since the results of transplantation in these patients is good, some
authors have proposed that this category of patients should be listed immediately after
resection. This might be more effective than waiting for recurrence to develop with excessive
tumor burden possibly excluding liver transplantation. Organ allocation policies might have
to be modified to take these findings into account. Other treatment modalities can provide
disease control (i.e., trans-arterial arterial embolization of chemoembolization, radiofrequency
ablations, sorafenib).
Fewer than 20 % of disease recurrences have an extra-hepatic with overall poor prognosis, and
the benefit of systemic therapy is modest, at best.
3.4. Surveillance
Although data on the role of surveillance in patients with resected HCC are very limited,
recommendations are based on the consensus that earlier identification of disease may
facilitate patient eligibility for investigational studies or other forms of treatment. The NCCN
panel recommends high-quality cross-sectional imaging every 3-6 months for 2 years, then
every 6-12 months. AFP levels, if initially elevated, should be measured every 3 months for 2
years, then every 6-12 months. Re-evaluation according to the initial work-up should be
considered in the event of disease recurrence.
3.5. Survival
Liver resection is a potentially curative therapy for patients with early-stage HCC (solitary
tumor ≤5 cm in size, or ≤3 tumors each ≤3 cm in size and no evidence of gross vascular invasion).
5-year survival rates of over 50% for patients undergoing liver resection for HCC, and some
studies suggest that for selected patients with preserved liver function and early stage HCC,
liver resection can achieve a 5-year survival rate of about 70%. However, HCC tumor recur‐
rence rates at 5 years following liver resection have been reported to exceed 70%.
3.6. Post-Resection Liver Failure (PRLF)
PRLF is a devastating complication that is resource intensive and carries with it considerable
morbidity and mortality. The reported incidence of PRLF ranges between 0.7 - 9.1%. An
inadequate quantity and/or quality of residual liver mass are key events in its pathogenesis.
Major risk factors are the presence of comorbid conditions, pre-existent liver disease and small
Remnant Liver Volume (RLV). It is essential to identify these risk factors during the pre-
operative assessment that includes evaluation of liver volume, anatomy and function.
There is no uniformity concerning the definition of PRLF. In general, PRLF is characterized as
failure of one or more of the hepatic synthetic and excretory functions that include hyper-
bilirubinemia, hypo-albuminemia, prolonged prothrombin time, elevated serum lactate
and/or different grades of hepatic encephalopathy (HE). PRLF is defined by the so-called 50–
50 criteria, which describe PRLF as prothrombin index less than 50% (equal to an international
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standardized ratio more than1.7) and serum bilirubin more than 50 mmol/L (2.9 mg/dL) on
post-operative day 5. When these 50–50 criteria were fulfilled, patients had a 59% risk of
mortality compared with 1.2% when they were not met (sensitivity 69.6% and specificity
98.5%). This rarely occurs in isolation and is often coupled with failure of multiple organs and/
or features of sepsis.
3.7. Pathophysiology of PRLF
After resection of various amounts of functional liver mass, both death and regeneration of
the remaining hepatocytes occur. Physiologically, regeneration outweighs hepatocyte death
and both liver mass and function are restored rapidly. For example, during the first 10 days
after right hepatectomy for living donor liver transplantation, restoration of liver mass up to
74% of the initial volume has been reported. This regeneration is triggered by an increased
metabolic demand placed upon remnant hepatocytes. The ability of the liver remnant to
surmount the effect of surgical resection depends on its capacity to limit hepatocyte death, to
resist metabolic stress, to preserve or recover an adequate synthetic function and to enhance
its regenerative power. These factors rely on both the quality and the quantity of remaining
liver parenchyma. A variety of intraoperative as well as post-operative hits identified that may
attribute to the development of PRLF. These include hepatic parenchymal congestion,
ischemia–reperfusion injury (IRI) and reduced phagocytosis capacity. Liver failure could be
defined as either ‘‘cholestatic’’ (characterized by regeneration of hepatocytes and fibrosis) or
‘‘non-regenerative’’ (characterized by pronounced apoptosis of hepatocytes).
3.8. Hepatic parenchymal congestion
Partial liver resection leads to a relatively augmented sinusoidal perfusion, leading to shear–
stress and congestion of hepatic parenchyma and resulting in vascular and parenchymal
damage similar to small-for-size syndrome after liver transplantation, although less severe.
Moreover, inadequate venous drainage of the liver remnant induces hepatic venous conges‐
tion and functional hepatic volume loss. Hepatic parenchymal congestion may be less severe
in patients with cirrhosis of the liver with preexisting portacaval collaterals.
3.9. Hepatic ischemia–reperfusion injury
Hepatic ischemia–reperfusion injury follows massive bleeding or hepatic in- or outflow
occlusion during liver surgery. Although the resistance of the liver to warm ischemia is
relatively high, hepatic ischemia and reperfusion activate a complex cascade that triggers the
innate immune response by recruitment and activation of Kupffer cells, endothelial cells and
the complement system. These express pro-inflammatory proteins [nuclear factor kB, tumour
necrosis factor-a, interleukin-6], reactive oxygen species, chemokines, complement factors and
vascular cell adhesion molecules. Subsequently, polymorphonuclear neutrophils are activat‐
ed, which aggravate hepatic injury. Although these processes are primarily intended to
maintain homoeostasis, unrestrained activation may become destructive.
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3.10. Reduced phagocytosis capacity
Infection complicates the course of PLF either as a precipitant or during later stages. Partial
hepatectomy reduced the phagocytosis capacity of the hepatic reticuloendothelial system.
Nevertheless, the liver remnant has to clear bacteria and their products following bacterial
translocation or intra-abdominal infection. Diminished hepatic clearance of bacteria might
enhance the susceptibility for the development infections and PRLF.
3.11. Risk factors of PRLF
The extent of resection correlates most closely with rates of PRLF and death; and the incidence
increases with the number of segments resected. The incidence of PLF is < 1 % in patients with
no underlying parenchymal disease when 1-2 segments are resected, around 10 % when 4
segments are resected, and 30 % when5 segments or more are resected. However, the exact
amount of residual liver mass required to preserve sufficient liver function is unknown. In
general, an RLV ≥ 25–30% in otherwise healthy livers is consistent with a good post-resectional
outcome. RLV below 25% in normal livers predicted PRLF with a positive predictive value of
90% (95% CI 68–99%) and a specificity of 98% (95% CI 92–100%). When liver function is
restricted, RLV should be as high as 40% to guarantee adequate remnant liver function.
The use of vascular occlusive techniques and significant intraoperative blood loss can exacer‐
bate the level of dysfunction. Vascular occlusive techniques induce ischemia in the liver
remnant. These effects are greatest following total vascular exclusion (inflow + outflow
occlusion), but also occur after prolonged intermittent inflow occlusion.
Intraoperative blood loss (> 1–1.2 liters) and the need for blood transfusion increase the risk of
PLF and sepsis. This may relate to the immunosuppressive effects of blood transfusion or the
initiation of the inflammatory response that accompanies significant hemorrhage.
Vascular reconstruction following in situ en bloc liver and inferior vena cava resection or ex
vivo liver resection is associated with increased rates of PRLF. Ex vivo resection and reimplan‐
tation is associated with an unacceptably high mortality rate. Biliary reconstruction is associ‐
ated with increased morbidity and mortality after liver resection but does not independently
predict PRLF.
Underlying parenchymal disease reduces the functional and regenerative capacity of the liver
remnant. In patients with cirrhosis but no functional impairment or portal hypertension,
resection of up to 50 % is safe. In patients with Child–Pugh grade B or C disease, even small
resections can result in PRLF. The high risk of developing PLF in patients with cirrhosis can
be explained by the wide range of comorbid conditions like portal hypertension, diabetes
mellitus, jaundice, malnutrition, hypersplenism and coagulopathy as well as frequent im‐
paired preoperative liver function and hepatic functional reserve. Furthermore, patients with
cirrhosis have an impaired hepatic regenerative capacity. NAFLD (non alcoholic fatty liver
disease) represents a spectrum of disease ranging from steatosis to steatohepatitis (non-
alcoholic steatohepatitis, NASH), fibrosis and cirrhosis. The grade of steatosis, correlates with
rates of PRLF and death following major Resection. The presence of steatosis is hypothesized
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to be associated with impaired hepatic microcirculation, decreased resistance to ischemia–
reperfusion injury, increased intrahepatic oxidative stress and dysfunction in mitochondrial
adenosine triphosphate synthesis. Chemotherapy-induced liver injury is increasingly preva‐
lent as more patients receive chemotherapy for colorectal liver metastases before liver
resection. Cholestasis reduces both hepatic metabolic and regenerative capacities, and
increases rates of liver dysfunction after major resection.
Other patient-based factors that predict PRLF are age, malnutrition, diabetes mellitus and male
sex. Elderly patients (≥65) suffer frequently from comorbid conditions and have reduced
regenerative capacity of hepatocytes. Approximately 65–90% of patients with advanced liver
disease suffer from protein–calorie malnutrition. Malnutrition is associated with an altered
immune response, reduced hepatic protein synthesis and a reduction in hepatocyte regener‐
ative capacity. Diabetes mellitus is associated with increased morbidity and mortality after
liver resection. This may be due to immune dysfunction or because insulin absence or
resistance reduces regenerative capacity. PRLF is more common in males as testosterone may
have immune-inhibitory effects, predisposing to septic complications.
3.12. Prevention of PRLF
Diabetes mellitus should be screened for and treated before surgery. Nutrition should be
evaluated and consideration given to preoperative oral carbohydrate loading in order to
reduce postoperative insulin resistance. There is no evidence to support delaying liver
resection for a period of nutritional optimization, unless the patient is severely malnourished.
It has been hypothesized that the nutritional status of depleted patients should be corrected
via oral, enteral or parenteral methods before surgery. A meta-analysis on the effect of total
parenteral nutrition compared with enteral nutrition on morbidity and mortality after liver
resection revealed no superiority of either form of nutrition. However, a beneficial effect of
additional parenteral nutrition has been demonstrated in a subgroup of patients who had
cirrhosis and underwent major hepatectomy.
The risk of PRLF may be reduced by strategies to increase parenchymal volume and protect
against parenchymal damage. Strategies available for volume manipulation for HCC patients
include portal vein embolization alone or in combined with locoregional treatment (RFA or
TAE). Portal vein embolization induces apoptosis in the ipsilateral lobe, and proliferation and
growth of the contralateral lobe. This increases the functional capacity of the liver remnant,
limits the effects of hepatic hyperperfusion that may occur in a small-for-size remnant, and
predicts the regenerative response in the future remnant. Failure to proliferate after portal vein
embolization can be used to select patients with impaired regenerative capacity in which major
resection would not be tolerated. The primary concern over portal vein embolization is that it
may increase tumor growth owing to an ipsilateral surge in hepatic arterial flow. Locoregional
treatment can be used in combination with Portal vein embolization to control tumor load
before resection.
In order to limit parenchymal damage and optimize regenerative capacity, a series of hepato‐
protective measures may be employed (intermittent portal clamping, ischemic precondition‐
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3.10. Reduced phagocytosis capacity
Infection complicates the course of PLF either as a precipitant or during later stages. Partial
hepatectomy reduced the phagocytosis capacity of the hepatic reticuloendothelial system.
Nevertheless, the liver remnant has to clear bacteria and their products following bacterial
translocation or intra-abdominal infection. Diminished hepatic clearance of bacteria might
enhance the susceptibility for the development infections and PRLF.
3.11. Risk factors of PRLF
The extent of resection correlates most closely with rates of PRLF and death; and the incidence
increases with the number of segments resected. The incidence of PLF is < 1 % in patients with
no underlying parenchymal disease when 1-2 segments are resected, around 10 % when 4
segments are resected, and 30 % when5 segments or more are resected. However, the exact
amount of residual liver mass required to preserve sufficient liver function is unknown. In
general, an RLV ≥ 25–30% in otherwise healthy livers is consistent with a good post-resectional
outcome. RLV below 25% in normal livers predicted PRLF with a positive predictive value of
90% (95% CI 68–99%) and a specificity of 98% (95% CI 92–100%). When liver function is
restricted, RLV should be as high as 40% to guarantee adequate remnant liver function.
The use of vascular occlusive techniques and significant intraoperative blood loss can exacer‐
bate the level of dysfunction. Vascular occlusive techniques induce ischemia in the liver
remnant. These effects are greatest following total vascular exclusion (inflow + outflow
occlusion), but also occur after prolonged intermittent inflow occlusion.
Intraoperative blood loss (> 1–1.2 liters) and the need for blood transfusion increase the risk of
PLF and sepsis. This may relate to the immunosuppressive effects of blood transfusion or the
initiation of the inflammatory response that accompanies significant hemorrhage.
Vascular reconstruction following in situ en bloc liver and inferior vena cava resection or ex
vivo liver resection is associated with increased rates of PRLF. Ex vivo resection and reimplan‐
tation is associated with an unacceptably high mortality rate. Biliary reconstruction is associ‐
ated with increased morbidity and mortality after liver resection but does not independently
predict PRLF.
Underlying parenchymal disease reduces the functional and regenerative capacity of the liver
remnant. In patients with cirrhosis but no functional impairment or portal hypertension,
resection of up to 50 % is safe. In patients with Child–Pugh grade B or C disease, even small
resections can result in PRLF. The high risk of developing PLF in patients with cirrhosis can
be explained by the wide range of comorbid conditions like portal hypertension, diabetes
mellitus, jaundice, malnutrition, hypersplenism and coagulopathy as well as frequent im‐
paired preoperative liver function and hepatic functional reserve. Furthermore, patients with
cirrhosis have an impaired hepatic regenerative capacity. NAFLD (non alcoholic fatty liver
disease) represents a spectrum of disease ranging from steatosis to steatohepatitis (non-
alcoholic steatohepatitis, NASH), fibrosis and cirrhosis. The grade of steatosis, correlates with
rates of PRLF and death following major Resection. The presence of steatosis is hypothesized
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to be associated with impaired hepatic microcirculation, decreased resistance to ischemia–
reperfusion injury, increased intrahepatic oxidative stress and dysfunction in mitochondrial
adenosine triphosphate synthesis. Chemotherapy-induced liver injury is increasingly preva‐
lent as more patients receive chemotherapy for colorectal liver metastases before liver
resection. Cholestasis reduces both hepatic metabolic and regenerative capacities, and
increases rates of liver dysfunction after major resection.
Other patient-based factors that predict PRLF are age, malnutrition, diabetes mellitus and male
sex. Elderly patients (≥65) suffer frequently from comorbid conditions and have reduced
regenerative capacity of hepatocytes. Approximately 65–90% of patients with advanced liver
disease suffer from protein–calorie malnutrition. Malnutrition is associated with an altered
immune response, reduced hepatic protein synthesis and a reduction in hepatocyte regener‐
ative capacity. Diabetes mellitus is associated with increased morbidity and mortality after
liver resection. This may be due to immune dysfunction or because insulin absence or
resistance reduces regenerative capacity. PRLF is more common in males as testosterone may
have immune-inhibitory effects, predisposing to septic complications.
3.12. Prevention of PRLF
Diabetes mellitus should be screened for and treated before surgery. Nutrition should be
evaluated and consideration given to preoperative oral carbohydrate loading in order to
reduce postoperative insulin resistance. There is no evidence to support delaying liver
resection for a period of nutritional optimization, unless the patient is severely malnourished.
It has been hypothesized that the nutritional status of depleted patients should be corrected
via oral, enteral or parenteral methods before surgery. A meta-analysis on the effect of total
parenteral nutrition compared with enteral nutrition on morbidity and mortality after liver
resection revealed no superiority of either form of nutrition. However, a beneficial effect of
additional parenteral nutrition has been demonstrated in a subgroup of patients who had
cirrhosis and underwent major hepatectomy.
The risk of PRLF may be reduced by strategies to increase parenchymal volume and protect
against parenchymal damage. Strategies available for volume manipulation for HCC patients
include portal vein embolization alone or in combined with locoregional treatment (RFA or
TAE). Portal vein embolization induces apoptosis in the ipsilateral lobe, and proliferation and
growth of the contralateral lobe. This increases the functional capacity of the liver remnant,
limits the effects of hepatic hyperperfusion that may occur in a small-for-size remnant, and
predicts the regenerative response in the future remnant. Failure to proliferate after portal vein
embolization can be used to select patients with impaired regenerative capacity in which major
resection would not be tolerated. The primary concern over portal vein embolization is that it
may increase tumor growth owing to an ipsilateral surge in hepatic arterial flow. Locoregional
treatment can be used in combination with Portal vein embolization to control tumor load
before resection.
In order to limit parenchymal damage and optimize regenerative capacity, a series of hepato‐
protective measures may be employed (intermittent portal clamping, ischemic precondition‐
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ing and hypothermic liver preservation). Total vascular occlusion should be avoided unless
resection cannot be undertaken without it (for example a tumor at the cavohepatic intersec‐
tion). If resection without vascular occlusion is not possible, inflow occlusion is preferable to
total vascular exclusion. Intermittent portal clamping with intervals allowed for reperfusion
is preferred to continuous clamping, usually applying a 15-min clamp–5-min release regimen.
Ischemic preconditioning increases tolerance to prolonged hepatic ischemia and adenosine 5
-triphosphate depletion by exposing the parenchyma to short intervals of ischemia and
reperfusion intraoperatively before resection. This downregulates ischemia–reperfusion
injury and results in less hepatic injury. Ischemic preconditioning reduces the histological
effects of ischemia–reperfusion injury, however, without improving clinical outcome. Hypo‐
thermic liver preservation in conjunction with total vascular exclusion attenuates ischemia–
reperfusion injury. The future remnant is infused with a preservative fluid and surrounded by
crushed ice to maintain the liver at 4 °C.
Data from living liver donors suffering from biopsy proven moderate steatosis revealed that
a body weight reduction of 5% or intervention with a low-fat, high protein diet and exercise
significantly improved hepatic steatosis. However, weight reduction before surgery may not
be feasible because of time deficit and the often pre-existent malnutrition.
Patients with cirrhosis of the liver are more susceptible to the development of PRLF in case of
resection of comparable tumor volumes. However, cirrhosis of the liver cannot be prevented
and, therefore, prevention of PRLF in these patients can only be achieved by careful patient
selection, adequate nutritional support and the use of an appropriate surgical technique.
3.13. Manifestation
PRLF reflects deregulation of the synthetic, excretory and detoxifying capacities of the liver
remnant. In addition, the majority of patients suffering from PRLF will also meet the criteria
of the systemic inflammatory response syndrome and experience multiple organ failure.
Unfortunately, a substantial number of patients suffering from PRLF deteriorate, leading to a
fatal outcome in approximately 80%. However, PRLF is a potentially reversible disorder
because of the regenerative capacity of the liver remnant.
3.13.1. Liver
The clinical consequences of PRLF are jaundice, coagulopathy, ascites, edema and/or HE.
Ascites occurs as a result of surgery (portal hypertension, dissection, gross fluid overload), and
may be difficult to assess it in the immediate postoperative period.
Data from Suc et al. and Balzan et al. concerning liver function on different days after uncom‐
plicated hepatic resection showed an initial increase of serum bilirubin and a decrease of
prothrombin time before normalization of these values on the seventh post-operative day.
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3.13.2. Circulation
Circulatory failure occurring during PRLF resembles the circulatory failure of patients with
sepsis. The pathophysiological changes usually observed are enhanced vascular permeability,
diffuse intravascular coagulation and peripheral vasodilatation that are clinically represented
by reduced peripheral resistance and hemodynamic instability.
3.13.3. Kidneys
Post-hepatic resection renal dysfunction can either result from perioperative disturbances in
renal circulation inducing acute tubular necrosis or accompany PRLF. It is characterized by
azotemia or oliguria and may cause ascites formation; pleural effusion and fluid overload
requiring diuretics or hemofiltration. There is a distinct chance of reversibility of renal failure
when there is recovery of PRLF. Furthermore, it can be hypothesized that the pivotal role of
the kidney in ammonia excretion is impaired, leading to hyperammonemia and HE in patients
suffering from PRLF.
3.13.4. Lung
Although moderate pulmonary edema seems to be a normal finding after partial hepatic
resection owing to general hemodynamic alterations, this usually does not impair oxygen
exchange. Severe remote lung injury, pulmonary edema and acute respiratory distress
syndrome can develop as part of the multiple organ dysfunction syndromes that accompanies
PRLF.
3.13.5. Hepatic encephalopathy
Hepatic encephalopathy is a potentially reversible neuropsychiatric disorder, characterized
by varying degrees of confusion and disorientation. Hyperammonemia plays a central role in
its development and has a direct toxic effect on neurotransmission and astrocyte function.
Although hepatic encephalopathy are important markers for liver failure, altered mental state
may occur in response to drugs such as opiates and may be difficult to assess it in the immediate
postoperative period.
3.13.6. Treatment of PRLF
Large,  randomized  trials  concerning  the  treatment  of  PRLF  are  lacking,  and  therefore,
recommendations for  treatment modalities  are difficult  to  make.  Management principles
resemble those applied to patients with acute liver failure, acute-on-chronic liver failure or
sepsis and focus on support of liver and end-organ function. Goal-directed therapy should
be provided for circulatory disturbances, renal and ventilatory dysfunction, coagulopathy,
malnutrition and HE (table 5). Patients should undergo clinical and laboratory assessment
after liver resection, with the frequency of monitoring and level of care stratified according
to risk.
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ing and hypothermic liver preservation). Total vascular occlusion should be avoided unless
resection cannot be undertaken without it (for example a tumor at the cavohepatic intersec‐
tion). If resection without vascular occlusion is not possible, inflow occlusion is preferable to
total vascular exclusion. Intermittent portal clamping with intervals allowed for reperfusion
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effects of ischemia–reperfusion injury, however, without improving clinical outcome. Hypo‐
thermic liver preservation in conjunction with total vascular exclusion attenuates ischemia–
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crushed ice to maintain the liver at 4 °C.
Data from living liver donors suffering from biopsy proven moderate steatosis revealed that
a body weight reduction of 5% or intervention with a low-fat, high protein diet and exercise
significantly improved hepatic steatosis. However, weight reduction before surgery may not
be feasible because of time deficit and the often pre-existent malnutrition.
Patients with cirrhosis of the liver are more susceptible to the development of PRLF in case of
resection of comparable tumor volumes. However, cirrhosis of the liver cannot be prevented
and, therefore, prevention of PRLF in these patients can only be achieved by careful patient
selection, adequate nutritional support and the use of an appropriate surgical technique.
3.13. Manifestation
PRLF reflects deregulation of the synthetic, excretory and detoxifying capacities of the liver
remnant. In addition, the majority of patients suffering from PRLF will also meet the criteria
of the systemic inflammatory response syndrome and experience multiple organ failure.
Unfortunately, a substantial number of patients suffering from PRLF deteriorate, leading to a
fatal outcome in approximately 80%. However, PRLF is a potentially reversible disorder
because of the regenerative capacity of the liver remnant.
3.13.1. Liver
The clinical consequences of PRLF are jaundice, coagulopathy, ascites, edema and/or HE.
Ascites occurs as a result of surgery (portal hypertension, dissection, gross fluid overload), and
may be difficult to assess it in the immediate postoperative period.
Data from Suc et al. and Balzan et al. concerning liver function on different days after uncom‐
plicated hepatic resection showed an initial increase of serum bilirubin and a decrease of
prothrombin time before normalization of these values on the seventh post-operative day.
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3.13.2. Circulation
Circulatory failure occurring during PRLF resembles the circulatory failure of patients with
sepsis. The pathophysiological changes usually observed are enhanced vascular permeability,
diffuse intravascular coagulation and peripheral vasodilatation that are clinically represented
by reduced peripheral resistance and hemodynamic instability.
3.13.3. Kidneys
Post-hepatic resection renal dysfunction can either result from perioperative disturbances in
renal circulation inducing acute tubular necrosis or accompany PRLF. It is characterized by
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requiring diuretics or hemofiltration. There is a distinct chance of reversibility of renal failure
when there is recovery of PRLF. Furthermore, it can be hypothesized that the pivotal role of
the kidney in ammonia excretion is impaired, leading to hyperammonemia and HE in patients
suffering from PRLF.
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exchange. Severe remote lung injury, pulmonary edema and acute respiratory distress
syndrome can develop as part of the multiple organ dysfunction syndromes that accompanies
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postoperative period.
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recommendations for  treatment modalities  are difficult  to  make.  Management principles
resemble those applied to patients with acute liver failure, acute-on-chronic liver failure or
sepsis and focus on support of liver and end-organ function. Goal-directed therapy should
be provided for circulatory disturbances, renal and ventilatory dysfunction, coagulopathy,
malnutrition and HE (table 5). Patients should undergo clinical and laboratory assessment
after liver resection, with the frequency of monitoring and level of care stratified according
to risk.
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It is normal for serum bilirubin levels and INR to rise in the first 48–72 h postresection.
However, bilirubin concentration above 50 μmol/l (3 mg/dl) or INR greater than 1 7 beyond 5
days is unusual and usually reflects liver dysfunction. Serum bilirubin remains the most
sensitive predictor of outcome in PLF. PT and INR are also valuable, but interpretation may
be compromised if the patient has received clotting factors. Serum albumin, although an
indicator of hepatic synthetic function, will vary in response to inflammation and administra‐
tion of intravenous fluids. Increased levels of liver enzymes are common after liver resection
and do not predict outcome. C-reactive protein levels are dampened after major liver resection,
and day 1 levels inversely correlate with PRLF indices. Serum lactate has a prognostic value
in severe sepsis and ALF, with a serum lactate level above 3 0 mmol/l after fluid resuscitation
predicting death in ALF.
The systemic inflammatory response syndrome (SIRS) is present in more than 50 % of patients
with ALF and predicts a negative outcome.The incidence of SIRS in patients with PLF has not
been evaluated formally, but as in ALF it is likely to be implicated in sepsis, encephalopathy
and end-organ dysfunction. Several studies have examined the role of postoperative functional
assessment of the liver. The ICG15 predicts PRLF, but its value diminishes once liver failure
is established because changes in hepatic blood flow also influence ICG15. Although PRLF is
a potentially reversible condition, mortality rates remain high and currently there is little scope
for therapeutic intervention.
Management of  PRLF must  be undertaken in conjunction with critical  care,  hepatology,
infectious disease and radiology services. The pattern of organ dysfunction that occurs as
a  result  of  PRLF  is  similar  to  that  in  sepsis.  Cardiovascular  failure  is  characterized  by
reduced  systemic  vascular  resistance  and  capillary  leak.  Acute  lung  injury,  pulmonary
oedema  and  acute  respiratory  distress  syndrome  may  ensue.  Acute  kidney  injury  can
progress rapidly in PRLF. Fluid balance should be managed judiciously with avoidance of
salt and water overload. Identifying and treating underlying sepsis is a key in managing
patients with PRLF. Sepsis may exacerbate PRLF, and bacterial infection is present in 80 %
of patients with PRLF and in 90 % of those with ALF. Any acute deterioration should be
attributed to sepsis until proven otherwise. Management of sepsis should be in accordance
with the surviving sepsis guidelines. A trial of prophylactic antibiotics after liver resection
failed to show a reduction in liver dysfunction or infective complications.  However,  the
administration of antibiotics in patients suffering from acute liver failure is associated with
a significant  decrease  in  infectious  complications  and this  may also  be  advantageous in
patients suffering from PRLF. In critically ill  patients with PRLF, chest radiography and
cultures of blood, urine, sputum and drain site/ascetic fluid should be performed. Current
guidelines  for  ALF  propose  that  broad  spectrum  antibiotics  should  be  administered
empirically to patients with progression to grade 3 or 4 hepatic encephalopathy, renal failure
and/or worsening SIRS parameters.
Coagulopathy may occur transiently after major resections and is found in all patients with
PRLF.  As  in  ALF,  coagulation  parameters  can  be  used  to  chart  the  progress  of  PRLF,
provided blood products have not been given. In a multinational review of fresh frozen
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plasma given for transient coagulopathy after resection, there was no consensus for its use.
In the absence of bleeding it is not necessary to correct clotting abnormalities, except for
invasive procedures or when coagulopathy is profound. The level at which a coagulopathy
should be corrected before an interventional procedure in ALF has yet to be defined (the
commonly used threshold for correction is an INR above 1 5). Vitamin K may be given, but
this  is  not  supported  by  clinical  trials.  Thrombocytopenia  may  complicate  liver  failure.
Indications for platelet transfusion in ALF include bleeding, profound thrombocytopenia (<
20 × 10 6 /L), or when an invasive procedure is planned. A platelet count above 70 × 10 6 /
L is deemed safe for interventional Procedures. Recombinant factor VIIa (rFVIIa) has been
used  to  treat  coagulopathy  in  patients  with  ALF.In  a  large  controlled  trial  of  rFVIIa
following major liver resection, no reduction in bleeding events was observed. Its role in
PRLF is yet to be defined.
Gastrointestinal  hemorrhage  is  a  recognized  complication  of  liver  failure.  In  ALF,  H2-
receptor blockers and proton pump inhibitors (PPIs) reduce gastrointestinal hemorrhage in
mechanically ventilated patients. In the non-ventilated patient an oral or sublingual PPI or
oral H2 -receptor blocker is likely to protect against gastrointestinal hemorrhage. High risk
patients  or  patients  with  established PRLF should  therefore  receive  prophylaxis.  Large-
volume ascites may also complicate PRLF. As in ALF, when this causes severe abdominal
discomfort  and/or respiratory compromise,  consideration should be given to therapeutic
paracentesis with simultaneous volume replacement with a plasma expander (ideally 20 %
salt-poor albumin solution). The ratio for replacement is 6-8 gram 20% albumin per liter
ascites drained. Nutrition is important and supplementation should be established early in
patients with liver failure. Enteral nutrition is the preferred route as it improves gut function
and restores normal intestinal flora. Parenteral nutrition can be used when enteral feeding
is not tolerated, but should be introduced with caution owing to the risk of infection. In
critically ill patients ensuring euglycemia improves survival and reduces morbidity.
The role of imaging in PRLF is to assess hepatic blood flow, identify reversible causes of
liver failure and locate sites of infection. Hepatic blood flow can be evaluated using non-
invasive imaging.  Doppler ultrasonography may identify portal  vein,  hepatic  artery and
hepatic vein thrombosis. Contrast CT or MRI can be used to establish hepatic blood flow,
provide more details of vascular abnormalities and identify sites of infection. If patency of
hepatic  vessels  is  still  in  doubt  on  cross-sectional  imaging,  angiography  is  the  ‘gold
standard’. Vascular disorders may complicate liver resection and induce PRLF, but are rare.
Longitudinal exposure of hepatic veins and the use of ultrasonic dissection may lead to
hepatic vein thrombosis. Portal vein thrombosis has also been implicated in the development
of PRLF. In these rare cases of inflow and outflow thrombosis with PRLF, a decision must
be made regarding the benefit of surgical or radiological thrombectomy or dissolution versus
anticoagulation.
Cerebral  edema and intracranial  hypertension  may occur  as  a  result  of  PRLF.  Cerebral
edema is unlikely in patients with grade 1 or 2 hepatic encephalopathy. With progression
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ascites drained. Nutrition is important and supplementation should be established early in
patients with liver failure. Enteral nutrition is the preferred route as it improves gut function
and restores normal intestinal flora. Parenteral nutrition can be used when enteral feeding
is not tolerated, but should be introduced with caution owing to the risk of infection. In
critically ill patients ensuring euglycemia improves survival and reduces morbidity.
The role of imaging in PRLF is to assess hepatic blood flow, identify reversible causes of
liver failure and locate sites of infection. Hepatic blood flow can be evaluated using non-
invasive imaging.  Doppler ultrasonography may identify portal  vein,  hepatic  artery and
hepatic vein thrombosis. Contrast CT or MRI can be used to establish hepatic blood flow,
provide more details of vascular abnormalities and identify sites of infection. If patency of
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of PRLF. In these rare cases of inflow and outflow thrombosis with PRLF, a decision must
be made regarding the benefit of surgical or radiological thrombectomy or dissolution versus
anticoagulation.
Cerebral  edema and intracranial  hypertension  may occur  as  a  result  of  PRLF.  Cerebral
edema is unlikely in patients with grade 1 or 2 hepatic encephalopathy. With progression
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to grade 3, a head CT should be performed to exclude intracranial hemorrhage or other
causes of declining mental status.  In patients with established ALF and encephalopathy,
enteral  lactulose  might  prevent  or  treat  cerebral  edema,  although  the  benefits  remain
unproven. Progression to grade 3/4 encephalopathy warrants ventilation and may require
intracranial pressure monitoring.
Stress ulcer Proton pump inhibitor
Nutrition Enteral energy supply of 2000 kcal/day
Enteral preferred over total parenteral nutrition
Maintain euglycemia
Sepsis Serial chest X-ray, sputum, urine and blood culture
Ascetic fluid from drain site
Consider CT abdomen
Broad spectrum antibiotic if progression of encephalopathy, renal failure or
worsening SIRS parameters
Circulatory disturbances CVP 8–12 mmHg
MAP 70 mmHg
Hematocrit >30%
Pulmonary capillary wedge pressure ≤ 12–15 mmHg
Ventilatory dysfunction Arterial oxygen saturation > 93%
Central venous oxygen saturation > 70%
Renal dysfunction Urine output > 0.5 mL/kg/hour
Coagulopathy Correct if bleeding or interventional procedure (INR<1.5)
Thrombocytopenia Correct if bleeding, profound thrombocytopenia (<20 × 10 6/L) or interventional





If evidence of inflow/outflow occlusion consider anticoagulation/revascularization
Ascites Paracentesis if severe pain/respiratory impairment
Encephalopathy Lactulose
If progression to grade 3–4 encephalopathy, CT head, ventilate and consider ICP
monitoring
** ICP: IntraCranial Pressure, INR: International Normalized Ratio, MAP: Mean Arterial Pressure MR: Magnetic Resonance
CT: Computed Tomography, CVP: Central Venous Pressure, SIRS: Systemic Inflammatory Response Syndrome
Table 5. Management of post resection liver failure.
The concept of hepatocyte transplantation has been investigated as a strategy to boost residual
liver function. Intrahepatic hepatocyte transplantation has been used successfully to treat
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patients with metabolic disorders of the liver. The efficacy of orthotopic liver transplantation
for PRLF has only recently been reported. However, no criteria are available for the selection
of patients who will benefit from emergency liver transplantation for PRLF. Patient who have
favorable tumor characteristics (i.e. R0 resection, low T and negative N status, HCC within
Milan criteria and absence of extra-hepatic disease), without comorbid conditions and without
a limited life expectancy because of other medical conditions considered to be good candidate
for emergency transplantation.
Extracorporeal liver support (ELS) devices fall into two categories: artificial and bioartificial
systems. Artificial devices use combinations of hemodialysis and adsorption over charcoal or
albumin to detoxify plasma. Bioartificial devices use human or xenogenic hepatocytes main‐
tained within a bioreactor to detoxify and provide synthetic function. These systems have not
been evaluated extensively in patients with PRLF. A recent meta-analysis and systematic
review showed that ELS might improve survival in patients with ALF, but not acute-on-
chronic liver failure, in comparison with standard medical therapy.
Abbreviation





PEI Percutaneous ethanol injection
SIRS Systemic Inflammatory Response Syndrome
PLRF Post-resection liver failure
TACE Transarterial chemoembolization
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1. Introduction
Hepatocellular  carcinoma  (HCC)  is  the  third  leading  cause  of  cancer  mortality  world‐
wide, accounting for more than 500,000 deaths annually. Major risk factors include chronic
liver disease and liver cirrhosis  due to hepatitis  B and C viral  infections,  alcoholic  liver
disease and non-alcoholic steatohepatitis (NASH). Surgical resection and liver transplanta‐
tion are the only potentially curable options for patients with HCC. While surgical resection
is the treatment of choice in patients with good hepatic function, it  is contraindicated in
those with moderate to severe cirrhosis (Child class B or C),  leaving these patients with
liver  transplantation  as  the  only  option.  Moreover,  transplantation  is  the  optimal  treat‐
ment even for small, otherwise resectable disease. This is a reflection of a number of factors.
Liver transplantation will most likely result in a microscopically negative resection, which
is  the  most  effective  oncologic  treatment.  Most  HCCs  are  multifocal  especially  in  the
background of  cirrhosis,  though pre-neoplastic  lesions may not  be  visible  on periopera‐
tive  evaluation;  they are  likely  to  continue  to  evolve  into  new primary HCCs.  Further‐
more, transplantation eliminates cirrhosis and restores normal hepatic function. However,
limited organ availability mandates the restriction of liver transplantation to patients with
early stage tumors who are not candidates for resection.
2. Organ allocation
In an effort to prioritize liver transplant candidates according to the highest short-term risk
of mortality from end stage cirrhosis, the model for end-stage liver disease (MELD) scoring
system was implemented in 2002 (table 1). To impart more urgent access to liver transplan‐
tation  for  patients  with  small  HCCs,  additional  points  within  the  scoring  system  were
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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allotted to these patients. This is done to equilibrate their risk of death in comparison with
the mortality of end-stage cirrhosis. The original scoring exception included lesions smaller
than 2 cm, which resulted in an over distribution of  donor livers to patients with HCC
(with many expected small tumors turning out not to be HCC on explanted pathology).
Therefore, the scoring exception was modified later by reducing the upgrade for Stage II
tumors  and  eliminating  it  for  Stage  I  tumors.  Using  the  American  Liver  Tumor  Study
Group Modified TNM staging system, current UNOS guidelines do not allow upgrading
of  candidates  with  Stage  I  disease,  irrespective  of  biopsy  confirmation;  only  candidates
with  Stage  II  HCC  disease  are  upgraded  on  the  waiting  list  to  a  MELD  score  of  22
(equivalent to a 15% probability of candidate death within 3 months) with the intent to
shorten  their  waiting  time.  From 2002-2007  in  UNOS database,  patients  with  an  “HCC
MELD-exception” had similar survival to patients without HCC.




MELD = 3.8[Ln serum bilirubin (mg/dL)] + 11.2[Ln INR] + 9.6[Ln serum creatinine (mg/dL)] + 6.4
* If a patient has had 2 or more hemodialysis treatments or 24 hours of CVVHD in the week prior to the time of the













Table 1. MELD score component, calculation and mortality prediction
3. Criteria for transplantation
Retrospective study by Mazzaferro and colleagues established that favorable results could be
achieved in patients with cirrhosis with either a solitary HCC ≤5 cm or with up to 3 nodules
≤3 cm, criteria that came to be called ‘‘the Milan criteria (Table3).’’ The 5-year survival of these
early-stage patients exceeded 70%. Recipient age, gender, type of viral infection, or Child-Pugh
score (table 2) did not affect survival after transplantation. In a multivariate analysis by Marsh
JW and colleagues, found that independent predictors of tumor-free survival included lymph
node status, depth of vascular invasion, greatest tumor dimension, lobar distribution, and
tumor number.
The strict application of the Milan criteria by UNOS for MELD upgrades allocation disadvan‐
tages patients with HCC with tumor profiles exceeding the criteria’s maximal size or multifocal
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parameters but in whom favorable outcomes after liver transplantation have been demon‐
strated. There is an ongoing debate within the liver transplantation community regarding
whether to expand indications for liver transplantation as primary therapy for HCC. For
patients with HCC disease beyond Milan criteria in whom there is no macroscopic evidence
of vascular invasion or extrahepatic spread, the survival rates after liver transplantation are
generally comparable with patients transplanted for disease within the criteria. Most groups
report a 5-year survival of more than 50% in patients transplanted for HCC beyond Milan,
which many investigators have argued is the minimum acceptable survival rate. In 2001Yao
and colleagues at the University of California, San Francisco (UCSF) defined an expanded set
of HCC criteria (solitary tumor ≤ 6.5 cm, or ≤ 3 nodules with the largest tumor ≤ 4.5 cm and
total tumor diameter ≤ 8 cm)(table3) for which 1 and 5-year survival rates after LT were 90%
and 75%, respectively. Retrospectively evaluating post- liver transplantation survival for
patients with tumors beyond Milan criteria but within ‘‘UCSF’’ expanded criteria by pre-
transplantation imaging and explant pathology, the group at the University of California, Los
Angeles (UCLA) confirmed acceptable 1,3-, and 5-year survival rates of 82%, 65%, and 52%,
respectively. Moreover, the difference in 5-year recurrence-free survival after liver transplan‐
tation for HCC in the UCLA study did not reach statistical significance between Milan criteria
and UCSF expanded criteria tumor groups (74% vs 65%, P =.09). Liver transplantation in such
candidates is controversial and widely adopted. The short-term outcomes are similar to those
who are transplanted within the Milan criteria.





Encephalopathy (grade) None 1-2 3-4
Ascites None Slight Moderate













Class A = 5–6 points; Class
B = 7–9 points; Class C =
10–15 points.




Class C: Poor operative risk
Table 2. Child Pugh score
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Group from Edmonton have study Total Tumor Volume (TTV) in patients with HCC who had
liver transplant based on Milan or UCSF criteria in 3 centers and they found TTV < 115 cm3
has lower recurrence rate than TTV > 115 cm3. In same study they also found that patients
beyond Milan but within TTV < 115 cm3 had survivals similar to those of patients within Milan.
On the contrary, patients with TTV >115 cm3 demonstrated lower survival than those within
TTV <115 cm3 when pathology (5-year: 47% versus 79%, P < 0.001) and radiology staging (5-
year: 53% versus 76%, P < 0.1) was used.
Milan criteria:
- Single lesion ≤ 5 cm or
- ≤3 nodules each ≤ 3 cm
Without vascular invasion.
"UCSF’’ expanded criteria:
- Single lesion ≤ 6.5 cm or
- ≤ 3 nodules with the largest tumor ≤ 4.5 cm and total tumor diameter ≤ 8 cm
Without vascular invasion.
Table 3. Criteria for liver transplantation
4. Pre-transplant treatment for HCC
The major limitation for liver transplantation as therapy for early-stage HCC is the insufficient
number of donor livers. There is always a waiting period between candidate listing and
transplantation. If the waiting period extends over a sufficient length of time, the tumor will
grow and eventually hinders transplantation. In a study by Yao and colleagues of patients with
HCC on the waiting list, a 6-month waiting period for liver transplantation was associated
with a 7.2% cumulative dropout probability, increasing to 37.8% and 55.1% at 12 and 18
months, respectively. In this setting the treatment of HCC prior to liver transplantation has
three potential goals: (a) controlling tumor growth and vascular invasion during the waiting
time and therefore decrease dropouts from the waiting list; (b) carrying out neoadjuvant
therapy to improve the post-transplant outcome by reducing the risk of postoperative
recurrence, and (c) downstaging the HCC burden to make a patient eligible for transplantation.
Followups for patients on waiting list are required every three months by CT or MRI to ensure
continued eligibility for liver transplantation.
5. Percutaneous ablation therapy
5.1. Bridging therapy
Bridge therapy is used to decrease tumor progression and the dropout rate from the liver
transplantation waiting list. It is considered for patients who meet the transplant criteria. A
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number of studies have investigated the role of locoregional treatment as a bridge to liver
transplantation in patients on a waiting list. These studies included radiofrequency ablation
(RFA), transarterial chemoembolization (TACE), surgical resection, conformal radiation
therapy, and sorafenib as “bridge” therapies.
5.1.1. TACE
The rationale for using TACE as a bridge therapy prior to OLT is to control tumor growth
while the patient awaits an organ. In addition, TACE could cause significant tumor necrosis,
which may reduce tumor dissemination, making it a potential neoadjuvant therapy. TACE can
also be used to learn more about the natural history and behavior of a particular tumor prior
to liver transplantation. Decaens et al. failed to demonstrate survival benefit in a retrospective
case-control study comparing 100 patients who underwent TACE prior to liver transplantation
(median 1 session/patient) versus 100 matched controls without prior treatment. Mean waiting
time was 4.2 months, and 5-year post-LT survival rates were 69% versus 63% (p = ns); dropout
was not analyzed. Yao et al. retrospectively studied 168 HCC patients who underwent liver
transplantation, 88 of whom received TACE (in most cases immediately prior to LT). For
patients with HCC within the Milan criteria, 5-year recurrence-free survival was 96% for the
TACE group versus 87% for controls (p = 0.12), but for HCC beyond the Milan criteria the
difference was statistically significant (86% vs. 51%, p = 0.05). Roayaie et al. reported a 46%
dropout rate, but only advanced HCC (>5 cm) were included in this study. Graziadei et al. found
no dropout from the waiting list in patients treated wit TACE meeting Milan criteria and the
mean waiting time was only 178 days. Furthermore, the monitoring protocol of repeat staging
and the criteria for dropout was not specified. In view of this study and others, the dropout
rate ranged from 15 to 46%. The rate of dropout was related to the tumor state and to the
duration in the waiting list, the higher rate (46%) being observed in more advanced HCC and
when the mean waiting time was 340 days. A systematic review of bridging therapy with TACE
by Lesurtel et al. concluded that there was insufficient good quality evidence to demonstrate
that TACE either improved post-LT survival, altered post-LT complication rates, or impacted
on waitlist drop out.
Although pre-liver transplantation TACE does not influence post-LT overall survival and
disease-free survival, it remains indicated in context of clinical trial when the period on the
waiting list is more than 6 months.
5.1.2. Percutaneous ablation therapy
Patients with small tumors can have ablation either by percutaneous ethanol injection,
radiofrequency or any other technique. Pre-transplant RFA ablation for HCC as a strategy to
reduce dropout has been addressed in view studies. More than 80% of patients were in the
Milan criteria with approximately 1 year on the waiting list. The dropout rate ranged from 0
to 14%. In a nonrandomized series from Toronto of 74 patients bridged using ablation
compared with 79 non-bridged patients, the analysis of dropout for tumor progression
identified a difference (p < 0.005) that became apparent only with prolonged waiting time
superior to 300 days.
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The main concern with this approach is seeding due to tumor puncture as has been reported
for diagnostic biopsy. However, puncture-related seeding is usually a case of poorly differ‐
entiated tumors and to peripheral tumors that cannot be approached through a rim of non-
tumoral liver.
In conclusion, due to small size of these studies and the heterogeneous nature of the study
populations, as well as the absence of randomized clinical trials evaluating the utility of bridge
therapy for reducing the liver transplantation waiting list dropout rate, limit the conclusions
that can be drawn. Therefore, if liver transplantation can be done without significant delay
(i.e. within 6 month) would the optimum. However, in patients whose waiting time is
predicted to be prolonged, an RCT of TACE and/or ablation as bridging therapy to decrease
dropout of transplantation could be justified.
5.2. Liver resection
Advances in liver surgery have significantly improved the safety of resection. Resection can
be used as a treatment for HCC prior to liver transplantation in three different settings. First,
resection can be used as a primary therapy, and liver transplantation reserved as a ‘‘salvage’’
therapy for patients who develop recurrence or liver failure. A second justification for resection
prior to transplantation is that it helps refine the selection process. Resection, indeed, gives
access to detailed pathological examination of the tumor and the surrounding liver parenchy‐
ma. Important prognostic information can be obtained from the entire resected tumor,
including differentiation (which proved to be heterogeneous within the tumor), satellite
nodules, microvascular invasion, and capsular effraction. As a result, resection may help deny
transplantation in patients with tumors apparently within the Milano criteria but with
histological features of especially poor prognosis (undetected macrovascular invasion in
particular). On the other hand, resection may help decide transplantation in patients with
tumors slightly outside the Milano criteria but with histological features of good prognosis.
Third, resection can be used as a ‘‘bridge’’ therapy for patients who have already been enlisted
for liver transplantation. Resection as the first line treatment for patients with small HCC with
preserved liver function, followed by salvage transplantation only for recurrence or liver
failure is an attractive option. Initial resection with negative margins, gives rapid access to an
effective therapy, without the need for a donor, and offers 5-year survival rates exceeding 50%
with a good quality of life. The main obstacle to this strategy is the risk of ‘‘loss of chance’’ in
case of rapid and extensive recurrence not amendable to salvage liver transplantation. At the
time of recurrence, salvage liver transplantation is only applicable in patients with a tumor
within the Milan criteria. Initial data showed that patients with HCV infection who developed
recurrence after partial resection had multifocal tumors and/or vascular invasion at the time
of recurrence.
Although limited resection appears to be sufficient in this setting, it is associated with increased
risk of post resection liver failure and is only appropriate for patients with peripheral tumors and
Child A cirrhosis and no portal hypertension. As disadvantage for this approach the subse‐
quent liver transplantation would be more difficult due to increase operative time and blood loss.
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The use of laparoscopic approaches for peripheral tumors may further contribute to expand this
strategy by minimizing technical difficulties during the transplant procedure.
5.3. Tumor dowenstaging
The role of downstaging of tumors before liver transplantation has been explored. Downstag‐
ing is done using HCC directed therapy that aims at reducing the size and/or number of HCC
lesions. Graziadei et al. achieved downstaging to within Milan using TACE in 15/36 patients
(41%). Among those downstaged, four dropped out prior to LT, one remained waiting, and
10 underwent LT; there were six deaths including three HCC recurrences, and 4- year post-
transplant survival of 41%. Yao et al. reports successful downstaging in 21/30 patients with
HCC beyond UCSF using a multimodality approach including resection in four cases. There
were two deaths related to downstaging treatment (one postresection). Among 16 patients
transplanted there was one death and no recurrence, but follow-up was limited (median 16
months). Recent prospective studies have demonstrated that downstaging (prior to transplant)
with percutaneous ethanol injection (PEI), RFA, TACE and transarterial radioembolization
(TARE) with yttrium 90 microspheres improves disease-free survival following transplant.
However, such studies have used different selection criteria for the downstaging therapy and
different transplant criteria after successful downstaging. In some studies response to locore‐
gional therapy has been associated with good outcomes after transplantation. Further valida‐
tion is needed to define the end-points for successful downstaging prior to transplant.
6. Living donor transplantation
Efforts to address the large waiting list of liver transplantation candidates and to decrease the
dropout rate have included several strategies such as living donor LT, domino LT, split LT,
the use of extended criteria donors, and donors after cardiac death. Living donor LT appears
to be an effective option for patients with HCC within the Milan criteria, essentially equivalent
in terms of survival to OLT, and it is cost effective if waiting times exceed 7 months. There are
few data to support the use of living donor LT for patients with HCC who exceed the Milan
criteria, although its use for this purpose is becoming increasingly common.
7. Immunsupression
Immunsupresion is used post liver transplantation to reduce graft rejection but, especial‐
ly in transplantation for HCC, is associated with a risk of tumor growth. While results of
liver  transplantation  including  survival  and  rates  of  rejection  were  dramatically  im‐
proved  in  cyclosporine  treated  patients  compared  with  "historical  controls",  a  high
incidence of neoplasm and its aggressive phenotype were found to be due to cyclospor‐
ine and its activation of transforming growth factor-beta (TGFβ). Vivarelli  and colleagues
reported  an  increase  in  5-year  recurrence  free  survival  in  patients  treated  with  smaller
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The main concern with this approach is seeding due to tumor puncture as has been reported
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Although limited resection appears to be sufficient in this setting, it is associated with increased
risk of post resection liver failure and is only appropriate for patients with peripheral tumors and
Child A cirrhosis and no portal hypertension. As disadvantage for this approach the subse‐
quent liver transplantation would be more difficult due to increase operative time and blood loss.
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The use of laparoscopic approaches for peripheral tumors may further contribute to expand this
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cumulative doses of cyclosporine in the first year following liver transplantation for HCC.
Furthermore, they observed a significantly higher mean cyclosporine level in patients with
HCC recurrence. Tacrolimus, another calcineurin inhibitor was also found to promote cell
cycle progression by an increase in cdk4 kinase activity and thus was linked to increased
tumor recurrence.
On the other hand, the calcineurin-independent immunosuppressive agent sirolimus, a binder
of mTOR, inhibits tumor growth in cell lines, and it inhibits primary and metastatic tumor
growth in vivo. In a study by Wang Z et al, looking at HCC in mouse model of human HCC,
they identify that sirolimus induces cell cycle arrest and blocke proliferation of an HCC cell
line, also sirolimus found to prevent tumor growth and metastatic progression by down-
regulating the mRNA expression of VEGF and HIF-1α.
Several retrospective reports suggest a lower risk of post-transplant tumor recurrence in
patients with HCC with the use of sirolimus as compared to other types of immunosuppressive
agents (such as the calcineurin inhibitors tacrolimus and cyclosporine). However, these reports
are limited by small size and uncertainty as to whether the observed benefits were due to a
specific antitumor effect or an impact on liver transplant in general.
8. Surveillance
There is no consensus as to the optimal approach for post-transplant surveillance. Guidelines
from the National Comprehensive Cancer Network (NCCN) suggest the follow up after liver
transplant with triphasic CT every 3-6 months for 2 years, then every 6-12 months. AFP levels
every 3 months for 2 years, if initially elevated, then every 6-12 months.
9. Survival
There is a clear survival benefit and low recurrence rate after transplantation for hepatocellular
carcinoma. When surgeons adhere to Milan criteria, 5-year survival rates after transplantation
range from 70% to 80%, and tumor recurrence rates are approximately 10%. Since the initial
report by Yao and colleagues that demonstrated acceptable survival rates using the UCSF
criteria (90% 1-year survival rates and 75% 5-year survival rates) and showed no survival
deference from Milan criteria in 1,3 and 5 years, long-term survival need to be further identi‐
fied.
10. Recurrence
Tumor recurrence remains a main limitation to the long-term survival of patients following
liver transplantation for HCC. While the majority of patients recur in the first two years after
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transplantation, late recurrence is not infrequent. Most common sites of recurrence are liver
graft, lung, bone, abdominal lymph nodes, adrenal glands and peritoneum. The incidence of
recurrent HCC following transplantation has been reported to vary, ranging from 6-56%.
However, in cases in which the Milan selection criteria were adopted, risk of recurrence
decreased to 10–15% at 5 years. While several recipient and tumor specific factors are prog‐
nostically important, primary tumor size, number of lesions, grade of tumor and presence of
vascular invasion have been noted to be the most significan clinical risk factors for both
recurrence and survival. De-novo tumor development from recurrent hepatitis and cirrhosis
in the liver graft can occur, however presence of microscopic foci of disease in lymph nodes
or distant organs at the time of transplantation, as well as hematogenous or peritoneal tumor
dissemination during transplantation, are mechanisms attributed to disease recurrence.
Recurrent disease following liver transplantation for HCC may involve an extrahepatic site in
10-43% of patients.
Successful surgical salvage has been reported for intrahepatic and/or confined extrahepatic
HCC metastases. In a study by Regalia et al, involving several Italian centers, 7 out of 21 patients
(30%) underwent salvage resection of recurrent HCC of the liver (2), lung (2), bone (1), skin or
other sites (2). Surgical resection was associated with a survival of 15.5 months, which was
better than the 5.5 months noted among patients treated with a non-surgical approach. Schlitt
et al. reported on 39 patients with recurrent disease, 9 intrahepatic recurrences, 15 extrahepatic
disease and 15 had both intra and extrahepatic recurrence. Eleven of these patients were able
to undergo complete removal of the recurrent disease, including 5 patients with an intrahepatic
recurrence; 7 (63%) were alive at 4.3 years of follow-up. As with HCC of the native liver, the
utilization of resection versus ablation to treat recurrence in the allograft is dependent on
surgical judgment, as well as the size and location of the tumor. While resection may be more
applicable to more superficial and larger tumors, ablative techniques may be sufficient and
appropriate in the setting of smaller and more deeply situated tumors. Although liver resection
for intrahepatic HCC recurrence has been reported by several centers, most series are limited
by a small sample size.
Reports of repeat liver transplantation as a treatment of recurrent intrahepatic HCC are limited
to a few very select case series and is not the standard of care.
Another potential approach to intrahepatic HCC recurrence is the utilization with TACE and
RFA. Ko et al, reported on 28 patients with recurrent HCC who underwent one or more cycles
of TACE after transplantation (mean, 2.5 cycles). In this study, the targeted tumor reduced in
size by ≥25% in 19 of the 28 study patients (68%). However, intrahepatic or extrahepatic
metastasis occurred in 21 of the 28 patients (75%) during the 3-month follow-up period and
mean survival was only 9 months.
Systemic therapeutic options for recurrent HCC are limited. While cytotoxic agents have
traditionally had marginal effect in the treatment of HCC, systemic therapy with molecular
targeted therapy has been shown to prolong survival in recent trials. Sorafenib, a multi-
targeted kinase inhibitor, demonstrated a significant overall survival benefit in patients with
advanced or metastatic HCC when compared with placebo in two separate Phase 3 trials. These
studies were carried out in patients who presented initially with advanced disease (mostly
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recurrent HCC following transplantation has been reported to vary, ranging from 6-56%.
However, in cases in which the Milan selection criteria were adopted, risk of recurrence
decreased to 10–15% at 5 years. While several recipient and tumor specific factors are prog‐
nostically important, primary tumor size, number of lesions, grade of tumor and presence of
vascular invasion have been noted to be the most significan clinical risk factors for both
recurrence and survival. De-novo tumor development from recurrent hepatitis and cirrhosis
in the liver graft can occur, however presence of microscopic foci of disease in lymph nodes
or distant organs at the time of transplantation, as well as hematogenous or peritoneal tumor
dissemination during transplantation, are mechanisms attributed to disease recurrence.
Recurrent disease following liver transplantation for HCC may involve an extrahepatic site in
10-43% of patients.
Successful surgical salvage has been reported for intrahepatic and/or confined extrahepatic
HCC metastases. In a study by Regalia et al, involving several Italian centers, 7 out of 21 patients
(30%) underwent salvage resection of recurrent HCC of the liver (2), lung (2), bone (1), skin or
other sites (2). Surgical resection was associated with a survival of 15.5 months, which was
better than the 5.5 months noted among patients treated with a non-surgical approach. Schlitt
et al. reported on 39 patients with recurrent disease, 9 intrahepatic recurrences, 15 extrahepatic
disease and 15 had both intra and extrahepatic recurrence. Eleven of these patients were able
to undergo complete removal of the recurrent disease, including 5 patients with an intrahepatic
recurrence; 7 (63%) were alive at 4.3 years of follow-up. As with HCC of the native liver, the
utilization of resection versus ablation to treat recurrence in the allograft is dependent on
surgical judgment, as well as the size and location of the tumor. While resection may be more
applicable to more superficial and larger tumors, ablative techniques may be sufficient and
appropriate in the setting of smaller and more deeply situated tumors. Although liver resection
for intrahepatic HCC recurrence has been reported by several centers, most series are limited
by a small sample size.
Reports of repeat liver transplantation as a treatment of recurrent intrahepatic HCC are limited
to a few very select case series and is not the standard of care.
Another potential approach to intrahepatic HCC recurrence is the utilization with TACE and
RFA. Ko et al, reported on 28 patients with recurrent HCC who underwent one or more cycles
of TACE after transplantation (mean, 2.5 cycles). In this study, the targeted tumor reduced in
size by ≥25% in 19 of the 28 study patients (68%). However, intrahepatic or extrahepatic
metastasis occurred in 21 of the 28 patients (75%) during the 3-month follow-up period and
mean survival was only 9 months.
Systemic therapeutic options for recurrent HCC are limited. While cytotoxic agents have
traditionally had marginal effect in the treatment of HCC, systemic therapy with molecular
targeted therapy has been shown to prolong survival in recent trials. Sorafenib, a multi-
targeted kinase inhibitor, demonstrated a significant overall survival benefit in patients with
advanced or metastatic HCC when compared with placebo in two separate Phase 3 trials. These
studies were carried out in patients who presented initially with advanced disease (mostly
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liver confined disease), and did not include patients who had previously undergone curative-
intent therapy, such as surgical resection or liver transplantation. A number of retrospective
studies have reported acceptable safety data for sorafenib in liver transplant patients, with
very few unexpected toxicities or interaction with immunosuppressive medications. The
numbers in these studies are small, and there is clearly a need for a prospective trial to fully
assess the potential survival benefit of sorafenib in this setting.
Radiation therapy is another option for patients with recurrent unresectable HCC. Three
dimensional conformal radiation, as well as stereotactic body radiation therapy and radioem‐
bolization, have been utilized in the treatment of primary unresectable HCC. In addition,
radiation therapy is a treatment option for symptomatic palliation of extrahepatic disease.
Yamashi et al, reported on 28 patients with metastatic HCC involving the portal and/or
peripancreatic lymph nodes who were treated with radiation therapy. A total of 18 (64%) and
five (18%) patients achieved partial responses and complete responses, respectively. The 1-
and 2-year overall survival rates were 53% and 33%, respectively. In one study, Seong et al.
investigated the effectiveness of palliative radiation therapy for HCC bone metastasis. In this
study, 51 patients received radiation therapy for 77 bony metastatic lesions, with a median
total dose of 30 Gy. There was pain relief in 56 lesions (73%), however, median and 1 year
survival were only 5 months and 15%, respectively. In aggregate, these studies suggest that
recurrent metastatic HCC may be sensitive to palliative radiation therapy. Therefore, radiation
therapy should be considered for palliation of metastatic HCC lesions.
Abbreviation
HCC Hepatocellular carcinoma
HIF-1α Hypoxia-inducible factor 1, alpha
MELD Model for end-stage liver disease
RFA Radiofrequency ablation
PEI Percutaneous ethanol injection
TACE Transarterial chemoembolization
TGFβ Transforming growth factor-beta
TNM Classification of Malignant Tumors (Tumor, lymph Node, Metastasis)
VEGF Vascular endothelial growth factor
UNOS United Network for Organ Sharing
UCSF University of California, San Francisco
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1. Introduction
The liver is a common site of metastases. The most relevant metastatic tumor of the liver to
the surgeon is colorectal cancer because of the well-documented potential for long-term sur‐
vival after complete resection. However, a large number of other tumors commonly meta‐
stasize to the liver, including cancers of the upper gastrointestinal system (stomach,
pancreas, biliary), genitourinary system (renal, prostate), neuroendocrine system, breast, eye
(melanoma), skin (melanoma), soft tissue (retroperitoneal sarcoma), and gynecologic system
(ovarian, endometrial, cervix). [1]
The high frequency of liver metastases is caused by: [2]
1. The liver's vast blood supply, which originates from portal and systemic systems.
2. The fenestrations of the hepatic sinusoidal endothelium may facilitate penetration of
malignant cells into the hepatic parenchyma.
3. Humoral factors that promote cell growth and cellular factors, such as adhesion mole‐
cules, favor metastatic spread to the liver.
4. The liver's geographic proximity to other intra-abdominal organs may allow malignant
infiltration by direct extension.
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Not so long ago, oncologists were so pessimistic about the appearance of hepatic metasta‐
ses  that  “no treatment”  was  often  the  recommendation.  Advancing technology and im‐
proved surgical techniques now offer potential therapeutic options for patients with such
lesions.  Patient  selection is  the  most  important  aspect  of  surgical  therapy for  metastatic
disease in the liver and clinical  follow-up of  resected patients  has identified those most
and least likely to benefit. Therefore, realistic expectations and honest patient education is
an important aspect of treatment. [1]
1.1. Clinical presentation
The clinical presentation of patients with liver metastases is variable and subtle. Most pa‐
tients are asymptomatic; a minority may report abdominal pain, jaundice, or pruritus. Hep‐
atic metastases from gastrointestinal carcinoid tumors are associated with release of
vasoactive peptides and serotonin into the systemic circulation. Symptoms of the carcinoid
syndrome, specifically flushing, sweats, and diarrhea, frequently occur in this setting. Liver
metastases from neuroendocrine tumors can lead to significant symptoms caused by the
production of functioning hormones. [1]
Physical examination may reveal hepatomegaly, a friction rub over hepatic metastases, or
ascites caused by hepatic venous obstruction or peritoneal carcinomatosis. [2]
1.2. Histopathology
The histologic appearances of metastatic deposits in the liver may resemble those of the pri‐
mary tumors; however, there can be marked differences. These differences exist because
metastatic foci are derived from a select subpopulation of tumor cells. Cells that are capable
of successful metastasis are believed to have specific characteristics, such as high motility,
resistance to immune-mediated destruction, and a high concentration of matrix receptors or
matrix-degrading enzymes.
Because the metastatic cell population may not be representative of the primary tumor, it
can be difficult to determine the site of origin based on the histologic appearance of the
metastases alone.
The  initial  light-microscopic  findings  can  be  used  to  categorize  the  tissue  into  one  of
three groups:
1. poorly differentiated carcinoma or adenocarcinoma,
2. well-differentiated adenocarcinoma, and
3. squamous carcinoma.




Pancreatic carcinoma CEA, pancreatic carcinoma-associated antigen
Lung carcinoma CEA, cytokeratin, neuron-specific enolase
Breast carcinoma CEA, milk-fat globulin, hCG
Thyroid carcinoma Thyroglobulin
Prostate carcinoma Prostate-specific acid phosphatase, PSA
Melanoma S-100, vimentin, neuron-specific enolase
Carcinoid Chromogranin, neuron-specific enolase
Lymphoma and leukemia CLA
Sarcoma
     Smooth muscle
     Skeletal muscle
     Neurogenic
     Cartilage
     Bone
Type IV collagen, vimentin, desmin
Myoglobin, vimentin, desmin
S-100, myelin basic protein
S-100, vimentin
Vimentin
Germ cell tumors α-fetoprotien, α1-antitrypsin
Trophoblastic tumors hCG, α-Fetoprotein
Table 1. Immunohistochemical antigens for the identification of primary tumors.
Abbreviations: CEA, carcinoembryonic antigen; CLA, common leukocyte antigen; hCG, hu‐
man chorionic gonadotropin; PSA, prostate-specific antigen.
1.3. Biochemical Laboratory Tests
The laboratory tests that are available for liver function assessment are not very sensitive.
CEA remains the most sensitive test for metastatic colon cancer, but even this test can be
normal in the presence of liver metastases, especially with minimal hepatic disease.
1.4. Imaging Techniques
The choice among the various techniques, and the sequence with which they are used,
should be guided primarily by the clinical indication, taking into account the primary type
and the different possible treatments, which also depend on the general status of clinical his‐
tory of the patient. Dedicated liver imaging is not needed in patients diagnosed with disse‐
minated, inoperable disease. [4]
1.4.1. Ultrasonography
1.4.1.1. Transabdominal ultrasonography (US)
US presents several advantages, including low cost, absence of irradiation, wide availability,
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tion than does CT scan or MR imaging, especially for lesions less than 2 cm in size. US is most
commonly used for screening for metastases because of its wide availability. Hepatic metasta‐
ses may be hypoechoic, hyperechoic, cystic, or of mixed echogenicity on ultrasound. Hypere‐
choic masses are observed more commonly in vascular tumors, such as renal cell and islet cell
tumors. Hypovascular lesions, such as lymphoma, appear as hypoechoic masses. [5]
1.4.1.2. Contrast-enhanced US
Contrast-enhanced US, using intravascular microbubble contrast agents, has shown similar
accuracy compared to CT and MR. An advantage of contrast-enhanced US is the potential
for characterization of liver lesions based on morphologic evaluation as well as temporal
vascular enhancement pattern. During the portal venous phase, benign lesions typically en‐
hance more than the liver, whereas malignant lesions enhance less. [6]
1.4.1.3. Endoscopic ultrasound (EUS)
EUS is a well-established tool for diagnosing and staging various gastrointestinal tumors,
especially pancreatic cancer; however, it is not used often for hepatic imaging. A few reports
in the literature address the use of EUS in the evaluation of hepatic metastases. EUS can de‐
tect lesions that are not seen on conventional CT scanning and allows for tissue sampling
using fine-needle aspiration. [4]
Figure 1. Computed tomography of hypervascular liver metastases from a renal primary tumor at the arterial phase.
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1.4.1.4. Intraoperative US (IOUS)
IOUS involves a direct scan of the liver, allowing the use of higher-frequency transducers
with higher resolution. IOUS can also be useful at detecting small, deep hepatic metasta‐
ses not palpable.  IOUS is more accurate than conventional CT scanning or MR imaging
for delineating liver lesions and is regarded as an important tool in determining resecta‐
bility and prognosis. [7]
1.4.2. Computed Tomography
1.4.2.1. Noncontrast Computed Tomography
Contrast CT is sometimes not possible because of contrast allergic reactions or renal impair‐
ment. Although the sensitivity and specificity of noncontrast CT is far reduced as compared
to contrast CT, it may help in identifying hypervascular metastases (especially carcinoid tu‐
mors, islet cell tumors, and renal cell carcinomas) or visualizing calcifications or hemor‐
rhage. Noncontrast CT often fails to distinguish hypovascular tumors from the liver
parenchyma. Nonenhanced blood vessels may also appear as low-attenuation masses and
be confused with metastases. [4]
Figure 2. Computed tomography 3-D reconstruction before surgical showing liver metastases (http://c2i2.digithala‐
mus.com/winter2003/Imaging%20update%20in%20metastatic%20liver%20disease.asp).
1.4.2.2. Contrast Computed Tomography
The CT appearance of liver metastases varies according to the pathologic type of the pri‐
mary tumor. Most lesions are seen best in the portal venous phase, and some lesions are best
seen in delayed venous and occasionally arterial phases. Metastases from melanomas, sarco‐
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fore better visualized during the hepatic arterial phase. Metastases from colorectal cancer
are hypovascular and therefore better visualized during the portal venous phase. [8]
1.4.3. Magnetic Resonance Imaging (MRI)
T1-weighted images generally show hepatic metastases as low-intensity lesions, whereas
T2-weighted images show these lesions to be areas of increased signal intensity. Dynamic,
breath-hold MR imaging with a gadolinium-based contrast material is considered to be the
most sensitive MR technique for detection of hepatic metastases (fig. 3). Similar to CT, MR
angiography can be used as a noninvasive method to evaluate hepatic vasculature. Novel
MR contrast agents have the potential for improving detection of liver metastases. [8, 9]
1.4.4. Positron Emission Tomography (PET)
PET, in which a radioactively labeled tracer is administered to the patient and the scanner
collects the emitted positron radioactivity to generate an image, allows imaging of cellular
processes (such as cellular proliferation (18F-labeled thymidine), hypoxia (18F-labeled Mi‐
so), and blood flow ([15O]water) to be visualized. The majority of clinical experience relies
on the uptake and use of glucose in human cells. 18F-Fluorodeoxyglucose 18FDG, the most
commonly used marker in PET imaging, is an analogue of glucose in which a carbon atom is
replaced by a radioactive fluorine isotope. 18FDG is transported into cells, where it accumu‐
lates to create an intense signal on PET imaging. Malignant lesions typically have increased
18FDG uptake because of the increased expression of glucose transporter proteins and ele‐
vated levels of glycolysis. [10, 11]
Figure 3. Liver metastases after Mn DPPD or mangafodipir injection.
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1.4.5. PET/CT (fig. 4)
Despite excellent clinical results with FDG PET, the technique is intrinsically limited by the
lack of precise and reliable anatomic information. Foci of increased uptake that are clearly lo‐
cated in the liver parenchyma are readily identified and usually correspond to metastases, but
the bowel uptake is highly variable and may be focally increased in regions close to the liver,
and therefore be mistaken with peripheral liver lesions. Combined PET/CT scanners allow the
precise localization of the abnormal areas of uptake. Modern PET/CT devices are equipped
with high-end CT scanners, fully capable of performing full diagnostic CT studies. [11]
2. Colorectal Liver Metastases (CLM)
The liver is the most common site for hematogenous metastasis from colorectal cancers
(CRC). A quarter of patients with primary colorectal carcinoma are found to have synchro‐
nous hepatic metastasis. Nearly half of patients who undergo resection of the colorectal pri‐
mary eventually develop metachronous liver metastasis. [2]
CRC principally spreads through two mechanisms:
1. Via portal venous drainage.
2. To regional lymph nodes and then through central lymphatics into the systemic cir‐
culation or
2.1. Prognostic Variables and Staging Systems
All patients with colorectal metastases by definition are grouped as stage IV in the TNM
staging system, but considerable diversity exists within this group. The prognosis of a pa‐
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tient with a solitary liver metastasis found years after resection of a node-negative right co‐
lon cancer is different from the prognosis of a patient with synchronously discovered diffuse
bilateral liver metastases at the time of operation for a perforated node- positive colon can‐
cer. A classification system that can discriminate between these patients and provide mean‐
ingful prognostic information is essential. This classification system must enable the
comparison of patients from diverse publications and facilitate patient selection for adjuvant
therapy or clinical trials. [2, 12]
2.1.1. Independent predictors of prognosis include [2]
1. the presence of extrahepatic disease,
2. a positive resection margin,
3. nodal metastases from primary cancer,
4. a short disease-free interval,
5. largest tumor greater than 5 cm,
6. more than one liver metastasis, and
7. CEA greater than 200 ng/mL.
• The first two parameters are data that are determined intraoperatively only because preop‐
erative evidence of extrahepatic disease and inability to obtain negative margins would be
relative contraindications to surgery. There is no role for surgical debulking in this setting.
• Using the last five criteria, a preoperative clinical risk score (CRS) system was created
with each positive criterion counting as 1 point.
• This CRS is a simple, easily remembered staging system for classifying patients with liv‐
er-exclusive metastatic colorectal cancer
2.1.2. Prognostic Scoring System for Hepatic Colorectal Metastases: Clinical risk score (CRS)
• Node-positive primary tumor
• Disease-free interval <12 mo between colon resection and appearance of metastases
• Size of largest lesion >5 cm
• >1 tumor
• CEA >200 ng/dL
Sum of points with 1 point assigned for each positive criterion
• The presence of any one of these characteristics still was associated with a 5-year survival.
• No single criterion can be considered a contraindication to resection.
• The total score out of 5 is highly predictive of outcome.
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• A score of 2 or less places a patient in a good prognostic group, for whom resection is ideal.
• For scores of 3 or 4, outcome is less favorable, and patients should be considered for ag‐
gressive trials of adjuvant therapy.
• For a score of 5, long-term disease-free survivors rarely are encountered, and resections in
this high-risk group should be accompanied by trials of adjuvant therapy.
• This CRS proved useful in selection of patients for neoadjuvant therapy and ablative
therapies and in stratification of patients enrolled in clinical trials
• A high CRS has been associated with sufficiently high incidence of occult metastatic dis‐
ease that fluorodeoxyglucose positron emission tomography (FDG PET) can be justified
as a preoperative test
• The yield from laparoscopy in the preoperative staging of patients with hepatic colorectal
metastases also has been correlated with the CRS.
• For patients with a high CRS, a laparoscopy can save patients with disseminated disease
from having a laparotomy, minimizing morbidity and hospital stay, whereas patients
with a low CRS can avoid the added anesthesia and operating room time associated with
a negative laparoscopy. [2, 12]
2.1.3. Molecular Determinants of Outcome
There are reports that molecular characteristics that predict response to chemotherapy, such
as tumor thymidylate synthase levels or levels of the transcription factor E2F-1, are impor‐
tant in predicting the outcome It is likely that these and other molecular determinants will
be incorporated into postoperative prognostic scales in the future. [2]
2.2. Medical Treatment
Over the past 3 decades, the most widely used chemotherapeutic agent in the treatment
of  metastatic  CRC  has  been  5-fluorouracil  (5-FU),  used  either  alone  or  in  combination
with other chemotherapies. [13]
Now, the most commonly used regimens are: FOLFOX, FOLFIRI, and FOLFOXIRI.
2.2.1. FOLFOX is a made up of the drugs
• FOL – Folinic acid (leucovorin), a vitamin B derivative used as a "rescue" drug for high
doses of the drug methotrexate and that modulates/potentiates/reduces the side effects
of fluorouracil;
• F – Fluorouracil (5-FU) fluorouracil (5-FU), a pyrimidine analog and antimetabolite which
incorporates into the DNA molecule and stops synthesis; and
• OX – Oxaliplatin (Eloxatin) A platinum-based drug, usually classified as alkylating




tient with a solitary liver metastasis found years after resection of a node-negative right co‐
lon cancer is different from the prognosis of a patient with synchronously discovered diffuse
bilateral liver metastases at the time of operation for a perforated node- positive colon can‐
cer. A classification system that can discriminate between these patients and provide mean‐
ingful prognostic information is essential. This classification system must enable the
comparison of patients from diverse publications and facilitate patient selection for adjuvant
therapy or clinical trials. [2, 12]
2.1.1. Independent predictors of prognosis include [2]
1. the presence of extrahepatic disease,
2. a positive resection margin,
3. nodal metastases from primary cancer,
4. a short disease-free interval,
5. largest tumor greater than 5 cm,
6. more than one liver metastasis, and
7. CEA greater than 200 ng/mL.
• The first two parameters are data that are determined intraoperatively only because preop‐
erative evidence of extrahepatic disease and inability to obtain negative margins would be
relative contraindications to surgery. There is no role for surgical debulking in this setting.
• Using the last five criteria, a preoperative clinical risk score (CRS) system was created
with each positive criterion counting as 1 point.
• This CRS is a simple, easily remembered staging system for classifying patients with liv‐
er-exclusive metastatic colorectal cancer
2.1.2. Prognostic Scoring System for Hepatic Colorectal Metastases: Clinical risk score (CRS)
• Node-positive primary tumor
• Disease-free interval <12 mo between colon resection and appearance of metastases
• Size of largest lesion >5 cm
• >1 tumor
• CEA >200 ng/dL
Sum of points with 1 point assigned for each positive criterion
• The presence of any one of these characteristics still was associated with a 5-year survival.
• No single criterion can be considered a contraindication to resection.
• The total score out of 5 is highly predictive of outcome.
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This regimen is recommended for 12 cycles, every 2 weeks. The recommended dose sched‐
ule given every two weeks is as follows:
• Day 1: Oxaliplatin 85 mg/m² IV infusion in 250-500 mL D5W and leucovorin 200 mg/m²
IV infusion in D5W both given over 120 minutes at the same time in separate bags using a
Y-line, followed by 5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by 5-FU
600 mg/m² IV infusion in 500 mL D5W (recommended) as a 22-hour continuous infusion.
• Day 2: Leucovorin 200 mg/m² IV infusion over 120 minutes, followed by 5-FU 400 mg/m²
IV bolus given over 2-4 minutes, followed by 5-FU 600 mg/m² IV infusion in 500 mL D5W
(recommended) as a 22-hour continuous infusion.FOLFOX4 regime.
Premedication with antiemetics, including 5-HT3 blockers with or without dexamethasone,
is recommended.
FOLFOX4
drug dose administration time term
Oxaliplatin 85 mg/m² IV infusion 2 h day 1
Folinic acid 200 mg/m² IV infusion 2 h day 1 + 2
Fluorouracil 400 mg/m² IV bolus 2 min day 1 + 2
Fluorouracil 600 mg/m² IV infusion 22 h day 1 + 2
Table 2.
2.2.2. FOLFIRI is is made up of the following drugs:
• FOL – folinic acid (leucovorin).
• F – fluorouracil (5-FU); and
• IRI – irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from un‐
coiling and duplicating.
The dosage consists of: Irinotecan (180 mg/m² IV over 90 minutes) concurrently with folinic
acid (400 mg/m² [or 2 x 250 mg/m²] IV over 120 minutes).
Followed by fluorouracil (400-500 mg/m² IV bolus) then fluorouracil (2400-3000 mg/m² intra‐
venous infusion over 46 hours).
This cycle is typically repeated every two weeks. The dosages shown above may vary from
cycle to cycle.
FOLFOX and FOLFIRI are widely considered to be equivelent in the metastatic setting and
are generally selected according to the toxicity profile. The FOLFOX regimen is character‐
ized by a higher rate of grade 3 and 4 neurotoxicity and neutropenia. The FOLFIRI is associ‐
ated with more nasuea and vomiting, mucositis, and alopecia.
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2.2.3. Folfoxiri
• irinotecan, oxaliplatin, fluorouracil, and folinate
FOLFOXIRI has been shown to have better results than FOLFIRI and FOLFOX in sever‐
al studies.
2.2.4. Cetuximab (Erbitux) and panitumumab (Vectibix)
Both are monoclonal antibodies against the epidermal growth factor receptor (EGFR) and
are now an important part of the treatment algorithm for unresectable colorectal metastases.
Cetuximab is a chimeric monoclonal antibody approved for treatment of metastatic CRC in
combination with irinotecan in patients with disease refractory to irinotecan or as a single
agent in patients who cannot tolerate irinotecan or oxaliplatin. Panitumumab is a fully
humanized monoclonal antibody and therefore appears to have a lower rate of serious infu‐
sion reactions compared with cetuximab. Like cetuximab, panitumumab is approved for sin‐
gle-agent therapy in patients who have progressed on standard chemotherapy. [2]
2.3. Regional treatment for metastatic colorectal cancer
The rationale for a regional approach to what normally would be thought of as a systemic proc‐
ess is based on the concept that tumor cells from gastrointestinal malignancies, especially col‐
orectal cancer, spread hematogenously via the portal circulation, making the liver the first site
of metastasis in most patients. This stepwise spread of cancer from primary site to liver and
from there to other organs provides an opportunity to prevent dissemination of tumor to other
sites by direct treatment of hepatic metastases. In this way, metastatic colorectal cancer differs
from most other metastatic malignancies. In addition, the remarkable ability of the liver to re‐
generate after hepatic resection has enabled aggressive surgical options for hepatic metastases.
There is no doubt that surgery alone can cure a subset of patients. [14]
Liver resection has become the standard treatment for metastatic lesions from colorectal pri‐
maries. With many series reporting long-term survival for these patients, even before the era
of modern chemotherapy, 5-year, 10-year, and 20-year survivals with hepatic resection can
be expected to reach 40%, 25%, and 20%. [2]
2.3.1. Preoperative evaluation
All patients with CLM benefit from evaluation by a multidisciplinary team comprising
physicians (surgeons, medical oncologists, radiologists, pathologists), nurses, social work‐
ers, and research coordinators. The central tenets in the preoperative evaluation of patients
for potential surgical resection of CLM are:
1. establishing the diagnosis,
2. anatomically defining the liver lesion for diagnosis and surgical planning, and
3. staging to rule out extrahepatic disease.
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5. estimation of an individual's tumor biology.
Preoperative biopsy of CLM is rarely indicated or beneficial for assessment of CLM, and has
been associated with tumor dissemination and decreased survival. Preoperative biopsy may
have usefulness for confirmation of extrahepatic disease when a change in therapy is plan‐
ned based on the biopsy results. [1]
2.3.1.1. Evaluation of Fitness for Operation
A careful evaluation of a patient's physiologic capability to tolerate hepatic resection is neces‐
sary to ensure favorable outcomes after hepatectomy. History, physical examination, and rou‐
tine laboratory studies (complete blood count, liver function testing, and coagulation studies)
are relied on to screen for underlying liver dysfunction.The criteria for patient operability are
similar to the criteria considered for any major laparotomy. A history of cardiac and pulmona‐
ry disease must be investigated because these patients are at significant risk for perioperative
complications. Any previous liver disease that might have impaired hepatic function should
be evaluated because this determines the volume of liver than can be resected safely. [2, 14]
2.3.1.2. Anatomic and Functional parameters
Determination of resectability is primarily based on preoperative imaging. High-quality cross-
sectional imaging is critical for gauging the extent of disease, response to preoperative thera‐
py, and for operative planning (The role of preoperative imaging was discussed above). [14]
Patients should be routinely reimaged after any course of systemic therapy; preferably with‐
in 4 weeks of planned resection. Meticulous preoperative attention to the relationships of
CLM to arterioportal inflow, biliary drainage, and hepatic venous outflow is necessary and
allows for an informed and efficient hepatectomy. Preoperative imaging may also help to
identify the presence of concomitant parenchymal disease (eg, fibrosis/cirrhosis, portal hy‐
pertension, steatohepatitis) or extrahepatic disease. [2]
Resectability of CLM has been well defined by the American Hepato-Pancreato-Biliary As‐
sociation (AHPBA)/Society of Surgery of the Alimentary Tract (SSAT)/Society of Surgical
Oncology (SSO) in a 2006 consensus statement as an expected margin-negative (R-0) resec‐
tion resulting in preservation of at least 2 contiguous hepatic segments with adequate in‐
flow, outflow, and biliary drainage with a functional liver remnant (FLR) volume of more
than 20% (for healthy liver). [1, 14]
2.3.1.3. Tumor biology
Careful evaluation of all patients in a multidisciplinary setting allows for better identifica‐
tion of those patients most likely to benefit from surgical resection as opposed to those who
would benefit more from nonoperative therapies, given their particularly aggressive dis‐
ease. Consideration of this question is far from an exact science, but valuable information
can be gleaned from factors such as [1]
1. the stage of primary disease,
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2. number and distribution of CLM,
3. tumor histology,
4. response to chemotherapy,
5. rate of growth of CLM on serial imaging,
6. rate of increase in serum carcinoembryonic antigen (CEA).
2.3.1.4. Diagnostic laparoscopy
Diagnostic laparoscopy has a role in staging those patients in whom preoperative imaging
or high-risk scores suggest a high likelihood for finding intra-abdominal extrahepatic dis‐
ease or for patients with indeterminate intrahepatic lesions that may be best characterized
by IOUS. Laparoscopy is useful at identifying peritoneal disease or the involvement of peri‐
portal lymph nodes not apparent on preoperative imaging. When laparoscopy is employed,
laparotomy can be avoided in patients with unresectable disease. [1, 2]
2.3.2. Operative technique
The goal should be a safe R-0 hepatectomy allowing for preservation of adequate FLR vol‐
ume to avoid hepatic insufficiency. Given the significant decrease in survival between R-0
and R-1/2 resections, the ability to achieve R-0 resection, is paramount. The optimal width of
resection margin is unclear, with no clear minimum margin established. A predicted margin
width of less than 1 cm should not be used as an exclusion to resection. The extent of resec‐
tion depends on the number and location of metastases relative to the portal triads and hep‐
atic veins. Anatomic resections, which are facilitated by intraoperative ultrasound, are
preferred to wedge resections. Anatomic resections permit excision of parenchymal areas
distal to the tumor, where vascular micrometastases tend to occur, and, most importantly
they are less likely to have positive margins. [14, 15]
The principles of hepatic resection are no different for colorectal metastases than for any
other hepatic surgery. Technical details of liver mobilization and various anatomic hepatec‐
tomies have been well described elsewhere in this book. Most procedures can be divided in‐
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7. hemo- and biliostasis.
The abdomen must be explored thoroughly for evidence of extrahepatic metastases. In par‐
ticular, the celiac axis and portocaval and hilar lymph nodes must be palpated, and any sus‐
picious nodes should be removed and examined by frozen section.
Most surgeons routinely use intraoperative ultrasound after mobilization of the liver. IOUS
can delineate better the interior anatomy of the liver, including intrahepatic vessels, and hepat‐
ic resection can be performed more safely and in a more anatomically oriented fashion. In ad‐
dition to the initial planning, the operation can be monitored by the repeated use of IOUS
because the resection line is displayed in relation to the lesion and blood vessels. [14, 15]
2.3.3. Follow-up
Patients after hepatic resection usually are monitored in an attempt to identify early recur‐
rence that may be amenable to further resection. Currently, most patients undergo serial
physical examination, serum CEA level, annual chest x-ray, and CT of the abdomen and pel‐
vis every 3 to 4 months for the first 2 years and then every 6 months for the next 5 years. [16]
2.3.3.1. Adjuvant Chemotherapy
1- Adjuvant Systemic Chemotherapy
Although the use of oxaliplatin-based or irinotecan-based chemotherapies in this setting is
common, there are no clear data from comparative studies supporting such practice. [17]
2- Adjuvant Hepatic Arterial Infusion Chemotherapy
Regional chemotherapy, via the hepatic artery, is a theoretically attractive mode of adjuvant
therapy, because the liver is the most common site for tumor recurrence after liver resection
and is the sole site of recurrence in 40% of patients.
The rationale for HAI of chemotherapy is based on the concept that most metastatic liver
tumors preferentially derive their blood supply from the hepatic artery, whereas normal
hepatic tissue relies on the portal venous blood supply.
The ability of the hepatic parenchyma to extract and metabolize chemotherapy drugs to
nontoxic metabolites offers a unique opportunity to administer highly toxic drug levels to
tumor cells, while minimizing systemic toxicity. The most extensively studied agent is 5-flu‐
orouracil-2-deoxyuridine (FUDR), an analogue of 5-FU that can be concentrated 100-fold to
400-fold in the liver because of a 95% hepatic extraction ratio. [17, 18, 19, 20]
2.4. Controversial issues
2.4.1. Downstaging of unresectable tumor and neoadjuvant chemotherapy.
Potential benefits of prehepatectomy chemotherapy include [2, 20]
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1. the potential to render formerly unresectable patients resectable i.e. the possibility for
downstaging liver metastases,
2. in vivo testing of chemotherapeutic efficacy,
3. identification of occult intra- or extrahepatic metastases, and
4. early exposure of subclinical microscopic metastases to systemic therapy.
5. with  prudent  monitoring  and  attention  to  comorbidities,  allows  for  improved  pa‐
tient selection
Patients with tumor progression during preoperative chemotherapy have a significantly
worse outcome CLM. Potential downsides of preoperative chemotherapy are largely related
to hepatic toxicities that may be clinically relevant. Oxaliplatin has been linked to steatohe‐
patitis and sinusoidal obstruction; irinotecan has been associated with steatohepatitis and
periportal inflammation. A preoperatively treated liver is more fibrotic, often with perivas‐
cular adhesions. The planes of resection are difficult to dissect, making the procedure more
challenging overall. Despite the operative complexity, the perioperative morbidity and mor‐
tality in the trials of resection after neoadjuvant chemotherapy do not seem to be higher
than series of de novo hepatic resection. [1, 2]
One controversial issue is the treatment of a patient with a complete clinical response to neoad‐
juvant chemotherapy. When there is no visible tumor left to resect, should a blind resection,
based on the site of previous metastasis, be undertaken? Suggested practice is to use intrao‐
perative ultrasound to attempt to identify the lesion, and if this is not possible a hepatic re‐
section of the area previously involved with tumor is performed. This is not, however, a
universally accepted practice. [1, 2, 20]
Patients who present with liver lesions that are potentially resectable for cure should be of‐
fered a surgical resection because there are no definite data supporting a neoadjuvant che‐
motherapeutic approach.
2.4.2. Repeated resection for recurrent tumor
In the absence of extrahepatic disease and in a patient with a good performance status and
adequate hepatic reserve, a repeat hepatectomy may be considered. Approximately one
third of recurrence is amenable to further resection The presence of adhesions and the al‐
tered anatomy of the liver, particularly the position of the vasculature and biliary system,
make this technically challenging.
There is a higher likelihood of further recurrence, however, and the study of adjuvant thera‐
py should be encouraged in these patients. [21]
2.4.3. Synchronous Metastases
Synchronous CLM are noted in 20% to 30% of patients at the time of initial colorectal cancer
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2.4.3. Synchronous Metastases
Synchronous CLM are noted in 20% to 30% of patients at the time of initial colorectal cancer




of disease biology, operative approach (staged vs. simultaneous colorectal and liver resec‐
tion), the order of resection, and timing of chemotherapy. [2, 22]
Some suggests that synchronous diagnosis of metastases portends a worse prognosis, per‐
haps as a result of a failure to detect micrometastatic foci in the liver. Delaying hepatic resec‐
tion may increase survival in the surgically resected group by selecting out the patients with
aggressive tumor biology who would be unlikely to derive a survival benefit from resection.
Although delayed resection does not seem to impair survival, it does increase the volume of
resected liver, a factor that is predictive of postoperative complications. [22]
Potential benefits of simultaneous CLM resection include [2]
1. avoidance of morbidity of a second laparotomy and anesthesia, and
2. decreased time to initiation of chemotherapy.
Risks of simultaneous resection are related to the magnitude and complexity of the com‐
bined operation.
A selective approach to synchronous CLM should be based on careful consideration of the
technical complexity and risks for the colorectal and liver resections, as well as judicious in‐
traoperative decision making. Good judgment is required in selection of patients for a simul‐
taneous or a staged resection in close coordination with medical oncologists and
collaborating surgeons. [1]
2.4.4. Bilobar Metastases




3. Combined hepatic resection and ablation.
4. For patients with insufficient FLR, portal vein embolization (PVE) may be a useful ad‐
junct to increase the size of the FLR and allow for safe extended hepatectomy.
Two-stage hepatectomy for patients with bilobar metastases involves an initial hepatectomy
with contralateral portal vein ligation or postoperative PVE, followed by chemotherapy. Af‐
ter restaging, a second hepatectomy is performed based on response to PVE/chemotherapy
and ability to achieve resection with an adequate FLR. A proportion of patients will not be
eligible for second hepatectomy because of disease progression, inadequate FLR, or perio‐
perative or chemotherapy-associated complications. [23, 24]
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2.4.5. Extrahepatic Colorectal Metastases
In the past, extrahepatic disease has been labeled an absolute contraindication to resection of
CLM. However, with the advent of more effective systemic therapies, a growing body of lit‐
erature supports R-0 resection of CLM and extrahepatic metastases. [25]
• An assessment of tumor biology is critical to selecting patients for resection of CLM as
well as extrahepatic metastases. For patients found to have extrahepatic metastases pre‐
operatively, a short course of preoperative chemotherapy followed by reimaging is pru‐
dent to better define the disease biology.
• Intraoperative decision for previously unrecognized intra-abdominal extrahepatic meta‐
stases is difficult. The following should be considered:
1. the complexity and extent of the R-0 hepatic resection,
2. the complexity of resection of the R-0 extrahepatic metastases,
3. the physiologic age of the patient,
4. availability of postoperative chemotherapeutic options, and
5. the  patient's  risk  of  rapid  progression  with  the  additional  finding  of  extrahepatic
metastases.
3. Neuroendocrine Liver Metastases (NLMs)
The liver is the most common site of metastatic disease for neuroendocrine tumors. Nonop‐
erative therapies for advanced neuroendocrine malignancies are associated with minimal re‐
sponse rates, short durations of disease stability, and no clear survival benefit. [26]
3.1. Pathology and Classification
Most NLMs are of gastrointestinal or pancreatic origin, or so-called gastroenteropancreatic
(GEP) tumors GEP neuroendocrine tumors historically are divided into two broad types:
carcinoid and noncarcinoid. Either type may or may not be associated with hormone pro‐
duction causing a clinical endocrinopathy (functional or nonfunctional). [26, 27]
Traditionally, gastrointestinal carcinoids have been classified by their site of origin—foregut
(lung, thymus, stomach, duodenum, pancreas, bile duct, gallbladder, and liver), midgut
(small intestine, appendix, and proximal colon), and hindgut (distal colon and rectum)—be‐
cause of the various biologic and biochemical features shown within these groups. Pancreat‐
ic neuroendocrine tumors have been classified by whether they are functional or not. [26, 28]
Regardless of origin, neuroendocrine tumors are similar histopathologically. Many histolog‐
ic and morphologic features may be shared by benign and malignant tumors. Histologically,
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Neuroendocrine tumors stain positive for chromogranin A, neuron-specific enolase, and
synaptophysin, which confirms neuroendocrine cell origin. Neuroendocrine tumors also
stain positively for one or more endocrine hormones immunohistochemically. [27]
Morphologically, neuroendocrine tumors can be solitary or multiple and solid or cystic. Tu‐
mor size alone is not a reliable indicator of malignancy. Neuroendocrine tumors greater than 2
cm throughout the GEP tract have a greater probability of malignant behavior, however, than
tumors less than 2 cm. Gross or microscopic vascular invasion may occur for any GEP neuroen‐
docrine tumors, although major vascular invasion is most typical of pancreatic NECs. Only the
confirmed presence of metastases confers an unequivocal diagnosis of malignancy. [28]
Regardless of whether NECs are classified as carcinoid or noncarcinoid, the natural history
of patients with unresected or unresectable hepatic metastases generally has been similar.
Overall, patients with unresected hepatic metastases from NEC have an approximately 30%
5-year survival The presence of liver metastases alone is the most significant factor adverse‐
ly affecting outcome Five-year survival with and without liver metastases from NECs is ap‐
proximately 30% to 40% and 90% to 100%. [26]
3.2. Treatment of NLMs
3.2.1. Liver resection
The treatment of hepatic metastases from NECs is aimed at reduction of the mass of malig‐
nant tissue (cytoreduction) chiefly for two reasons. [29]
First, metastatic gastrointestinal neuroendocrine tumors are usually indolent and slow
growing because most are low-grade malignancies (WHO classification). Chemotherapeutic
and radiotherapeutic regimens targeted at rapidly dividing cells are relatively ineffective,
targeting only a paucity of the total population of malignant cells.
Second, symptoms secondary to expression and secretion of biologically active peptides by
these tumors are directly related to overall mass of tumor, although production of peptides
may be heterogeneous among individual metastases. Similarly, pain and debilitating de‐
crease in performance status may have a negative impact on quality of life for nonfunctional
NECs metastatic to the liver. Cytoreduction of the tumor is the most direct and immediately
effective method to provide symptomatic relief.
These reasons, coupled with improved safety for hepatic resection, have prompted hepatic
resection as a primary therapeutic option for patients with functional and nonfunctional
metastatic GEP NECs. Currently, hepatic resection of NLMs is recommended if the primary
tumor and regional disease are resectable or resected, and greater than 90% of hepatic meta‐
stases are resectable or ablatable.
The concept  of  hepatic  resection for  NLMs has grown because of  several  clinical  obser‐
vations: [30]
1. the protracted natural history of NECs compared with other gastrointestinal tract cancers,
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2. the often prolonged duration of intrahepatic disease before evidence of extrahepatic
progression,
3. the clinical impression that the severity of clinical endocrinopathies correlates with the
intrahepatic volume of metastatic disease,
4. the frequent resectability of the primary and regional neuroendocrine tumors despite
metastatic disease, and
5. the rarity of underlying concomitant hepatic disease (fibrosis or cirrhosis).
3.2.1.1. Debulking strategy
When complete resection of gross liver disease is not feasible or in the presence of unresecta‐
ble extrahepatic disease, resection as a tumor debulking strategy should be considered in
patients with extreme hormonal symptoms refractory to other treatments or with tumors in
locations that would affect short-term quality of life, such as large lesions abutting the hep‐
atic hilum (resulting in biliary obstruction) or the colon/duodenum (resulting in gastrointes‐
tinal obstruction). [31, 32]
3.2.1.2. Subsequent plan for treatment of recurrence. [26, 33]
1. For solitary recurrences, either resection or ablation is appropriate. Percutaneous abla‐
tive approaches often are preferable.
2. Repeat  hepatic  resection  is  advised  for  lesions  in  sites  that  preclude  safe  radiofre‐
quency ablation (RFA) (i.e.,  surface metastases adjacent to bowel, near bile ducts, or
near diaphragm).
3. Sequential ablation or resection is undertaken as recurrence is recognized until preclud‐
ed by extent of recurrence within the liver.
4. Extensive recurrent intrahepatic metastases are treated by embolization or chemoembo‐
lization with or without systemic chemotherapy in the absence of extrahepatic disease
and chemotherapy in the presence of extrahepatic disease.
3.2.2. Liver transplantation
Liver  transplantation  (OLT)  has  been  employed  increasingly  to  treat  metastatic  NEC.
OLT  may  be  indicated  if  the  primary  and  regional  NEC  has  been  resected,  and  distal
metastases  have  been  excluded.  While  transplantation  has  the  benefits  of  removing  all
hepatic  disease  burden,  rapid  disease  recurrence  is  near  universal.  Long-term  actuarial
survival  among  patients  transplanted  for  NLM  is  poor  compared  with  overall  patient
and  graft  survival  rates  for  all  indications.  At  present,  liver  transplantation  cannot  be
considered a viable option for unresectable NLM. OLT should be considered as an inves‐




Neuroendocrine tumors stain positive for chromogranin A, neuron-specific enolase, and
synaptophysin, which confirms neuroendocrine cell origin. Neuroendocrine tumors also
stain positively for one or more endocrine hormones immunohistochemically. [27]
Morphologically, neuroendocrine tumors can be solitary or multiple and solid or cystic. Tu‐
mor size alone is not a reliable indicator of malignancy. Neuroendocrine tumors greater than 2
cm throughout the GEP tract have a greater probability of malignant behavior, however, than
tumors less than 2 cm. Gross or microscopic vascular invasion may occur for any GEP neuroen‐
docrine tumors, although major vascular invasion is most typical of pancreatic NECs. Only the
confirmed presence of metastases confers an unequivocal diagnosis of malignancy. [28]
Regardless of whether NECs are classified as carcinoid or noncarcinoid, the natural history
of patients with unresected or unresectable hepatic metastases generally has been similar.
Overall, patients with unresected hepatic metastases from NEC have an approximately 30%
5-year survival The presence of liver metastases alone is the most significant factor adverse‐
ly affecting outcome Five-year survival with and without liver metastases from NECs is ap‐
proximately 30% to 40% and 90% to 100%. [26]
3.2. Treatment of NLMs
3.2.1. Liver resection
The treatment of hepatic metastases from NECs is aimed at reduction of the mass of malig‐
nant tissue (cytoreduction) chiefly for two reasons. [29]
First, metastatic gastrointestinal neuroendocrine tumors are usually indolent and slow
growing because most are low-grade malignancies (WHO classification). Chemotherapeutic
and radiotherapeutic regimens targeted at rapidly dividing cells are relatively ineffective,
targeting only a paucity of the total population of malignant cells.
Second, symptoms secondary to expression and secretion of biologically active peptides by
these tumors are directly related to overall mass of tumor, although production of peptides
may be heterogeneous among individual metastases. Similarly, pain and debilitating de‐
crease in performance status may have a negative impact on quality of life for nonfunctional
NECs metastatic to the liver. Cytoreduction of the tumor is the most direct and immediately
effective method to provide symptomatic relief.
These reasons, coupled with improved safety for hepatic resection, have prompted hepatic
resection as a primary therapeutic option for patients with functional and nonfunctional
metastatic GEP NECs. Currently, hepatic resection of NLMs is recommended if the primary
tumor and regional disease are resectable or resected, and greater than 90% of hepatic meta‐
stases are resectable or ablatable.
The concept  of  hepatic  resection for  NLMs has grown because of  several  clinical  obser‐
vations: [30]
1. the protracted natural history of NECs compared with other gastrointestinal tract cancers,
Hepatic Surgery384
2. the often prolonged duration of intrahepatic disease before evidence of extrahepatic
progression,
3. the clinical impression that the severity of clinical endocrinopathies correlates with the
intrahepatic volume of metastatic disease,
4. the frequent resectability of the primary and regional neuroendocrine tumors despite
metastatic disease, and
5. the rarity of underlying concomitant hepatic disease (fibrosis or cirrhosis).
3.2.1.1. Debulking strategy
When complete resection of gross liver disease is not feasible or in the presence of unresecta‐
ble extrahepatic disease, resection as a tumor debulking strategy should be considered in
patients with extreme hormonal symptoms refractory to other treatments or with tumors in
locations that would affect short-term quality of life, such as large lesions abutting the hep‐
atic hilum (resulting in biliary obstruction) or the colon/duodenum (resulting in gastrointes‐
tinal obstruction). [31, 32]
3.2.1.2. Subsequent plan for treatment of recurrence. [26, 33]
1. For solitary recurrences, either resection or ablation is appropriate. Percutaneous abla‐
tive approaches often are preferable.
2. Repeat  hepatic  resection  is  advised  for  lesions  in  sites  that  preclude  safe  radiofre‐
quency ablation (RFA) (i.e.,  surface metastases adjacent to bowel, near bile ducts, or
near diaphragm).
3. Sequential ablation or resection is undertaken as recurrence is recognized until preclud‐
ed by extent of recurrence within the liver.
4. Extensive recurrent intrahepatic metastases are treated by embolization or chemoembo‐
lization with or without systemic chemotherapy in the absence of extrahepatic disease
and chemotherapy in the presence of extrahepatic disease.
3.2.2. Liver transplantation
Liver  transplantation  (OLT)  has  been  employed  increasingly  to  treat  metastatic  NEC.
OLT  may  be  indicated  if  the  primary  and  regional  NEC  has  been  resected,  and  distal
metastases  have  been  excluded.  While  transplantation  has  the  benefits  of  removing  all
hepatic  disease  burden,  rapid  disease  recurrence  is  near  universal.  Long-term  actuarial
survival  among  patients  transplanted  for  NLM  is  poor  compared  with  overall  patient
and  graft  survival  rates  for  all  indications.  At  present,  liver  transplantation  cannot  be
considered a viable option for unresectable NLM. OLT should be considered as an inves‐





Radiofrequency ablation (RFA) can provide local control and short-term symptomatic relief
from NLM when resection is not possible. Successful ablation typically occur in the treat‐
ment of small metastases (<5 cm). [35-38]
3.2.4. Ethanol Ablation
Percutaneous ethanol injection permits ablation of metastases located adjacent to structures at
risk of damage by RFA. It can be performed on metastases located adjacent to vital structures
(e.g., the hepatic flexure of the colon); adjacent to large vessels vulnerable to the heat-sink ef‐
fect; and adjacent to central bile ducts, where subsequent biliary stricture may occur. [61]
3.2.4.1. Guidelines for Ablation
General guidelines in the ablation of liver metastases are analogous to the treatment of hep‐
atocellular carcinoma and colorectal metastases. [35-38]
There are three clinical scenarios for ablation of neuroendocrine hepatic metastases:
1. adjunct to concurrent surgical resection of hepatic metastases,
2. treatment of limited hepatic metastases in patients unfit for operation, and
3. primary  therapy  when  clinical  expertise  or  intraoperative  circumstances  preclude
safe resection.
3.2.5. Hepatic arterial therapy
Because neuroendocrine tumors usually are highly vascular lesions that predominantly de‐
rive blood supply from the hepatic artery (as opposed to the normal hepatic parenchyma
that derive the majority of blood supply from the portal vein), opportunities exist for select‐
ed ischemia of NLM and/or delivery of directed chemotherapy via hepatic artery therapy.
Hepatic arterial embolization with cyanoacrylate, gel foam particles, polyvinyl alcohol, and
microspheres have all been used to achieve distal embolization without surgical ligation of
the hepatic artery. Chemoembolization provides an intratumoral concentration of chemo‐
therapy that is 10 to 20 times higher than systemic administration.
Complete response and long-term survival are not common after hepatic arterial therapy, as
the periphery of the tumor is spared from ischemia or chemotherapy. Thus, embolization of
lesions close to the hepatic hilum is generally unsuccessful, as the periphery of the tumor
will still cause mass-effect associated symptoms. [39, 40]
The  morbidity  of  embolization  approaches  include  liver  abscess,  transient  liver  failure,
pleural effusion, and postembolization syndrome, the latter consisting of fever, abdominal
pain,  leukocytosis,  and  a  transient  increase  in  liver  enzymes  and/or  bilirubin.  Multiple
sessions of therapy are often needed with varying intervals between sessions. Contraindi‐
cations to hepatic arterial therapy include hepatic failure, portal vein occlusion, uncorrect‐




Short-acting somatostatin analogue therapy is used to prevent or to treat the carcinoid crisis
periprocedurally for any intervention, including resection, transplantation, ablation, or em‐
bolization. Somatostatin analogue treatment generally is well tolerated. Steatorrhea, diar‐
rhea, abdominal discomfort, and biliary sludge or gallstones can develop, but rarely
preclude continued use. [41]
B- Chemotherapy
Systemic chemotherapy generally is reserved for patients with advanced or progressive dis‐
ease in whom other treatment efforts have failed Streptozocin-based combinations with 5-
FU and doxorubicin have resulted in objective responses. Carcinoid tumors may be less
sensitive to cytotoxic agents because of the preponderance of low-grade malignant (well-dif‐
ferentiated) histology and low proliferation index. [24]
C- Interferon Alfa
Systemic interferon alfa may be used to treat advanced NEC. The mechanism of interferon
alfa is mediated through direct inhibitors of the cell cycle (G1/S phase) and of protein and
hormone production, through antiangiogenesis, and indirectly through increased immune
stimulation. Adverse reactions to interferon alfa are common. Chronic fatigue and hemato‐
logic cytopenias are the most common side effects. [42]
3.3. Primary hepatic neuroendocrine tumors
NECs may arise primarily within the liver. The diagnosis presumes a thorough search and
exclusion of an extrahepatic NEC. The cell of origin is unknown. Pancreatic heterotopia has
been postulated as a source of these tumors. Some tumors may arise from intrahepatic bili‐
ary tract radicles because carcinoids of the extrahepatic biliary tract are more common. Pri‐
mary hepatic neuroendocrine tumors may be metastases from an occult primary NEC or a
primary NEC that had spontaneously regressed. [24]
4. Non-colorectal Non-neuroendocrine Liver Metastases (NCNNLM)
Except for gastrointestinal primaries, the liver is not the primary filter for venous blood. In
other words, liver metastases from nongastrointestinal cancers indicate systemic tumor
spread; this makes selection of patients a crucial factor to offer hepatic resection to patients
who may benefit the most.
Tumor biologies  among NCNNLM vary widely,  and their  treatment  requires  dedicated
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The potential utility of surgery in NCNNLM relates to several factors:
1. advances in chemotherapy have led to effective control of extra hepatic disease for cer‐
tain tumor types, supporting a rationale for surgical resection of LM in the presence of
presumed or de facto systemic disease;
2. improvements in patient preparation for surgery, surgical technique and perioperative
care have reduced the perioperative risk of hepatic resection, tipping the risk–benefit
ratio in favor of surgical resection in selected cases;
3. the increased emphasis on multimodality treatment approaches has improved patient
selection and strengthened the role of hepatic resection as a key component of integrat‐
ed multidisciplinary care in selected patients with NCNNLM.
Although it might appear that patients with isolated liver metastases can benefit from hepat‐
ic resection, the proper selection of patients that may potentially benefit from treatment re‐
mains the most critical issue. Patient selection criteria depend on the primary tumor type.
After selection based on patient performance status and evaluation of comorbidities, staging
studies are required not only to assess the overall disease status of the patient but also to
characterize liver lesions and their precise location relative to intrahepatic vascular struc‐
tures. Assessment of the liver volume that will remain after resection is an equally impor‐
tant component of surgical planning for extensive hepatectomy. [43, 45]
Patient selection and oncologic outcome of metastasectomy depends fundamentally on com‐
plete resection of all disease. Preoperative studies are essential in defining both the extent
and the limits of surgical resection. Hepatic volumetry to assess the planned future liver
remnant (FLR) volume is a critical tool for the selection of patients who will undergo major
hepatic resection If the future liver remnant is of inadequate volume, preoperative portal
vein embolization can be used to induce hypertrophy of the future liver remnant to allow
safe resection. Liver tumors are deemed resectable if preoperative evaluation shows that
complete resection of the tumor-bearing liver leaves an adequate remnant volume with ade‐
quate vascular inflow, outflow, and biliary drainage. The treatment of each individual tu‐
mor type requires expertise in staging, systemic therapy, and hepatic surgery. [43, 45]
4.1.2. Nonresectional treatment
Percutaneous and intraoperative ablative techniques may play a role in the treatment of
many types of liver tumors because the therapy
1. can be performed percutaneously or with minimally invasive approaches,
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2. is associated with low morbidity and mortality, and
3. can help preserve liver parenchyma in selected patients.
The role of nonresectional ablative approaches for NCNNLM is not well defined. Data and
experience are still accruing, and for now such treatment should be considered only in those
centers that can provide the full spectrum of therapies for liver metastases. [43]
4.1.3. Hepatic arterial therapies
The utility of hepatic arterial therapies in the treatment of NCNNLM is not well understood.
TACE, TAE, and hepatic artery infusion are not considered standard therapy for NCNNLM.
For certain tumor subtypes, including unresectable soft tissue sarcomas (STS) and gastroin‐
testinal stromal tumors (GIST), these approaches hold promise. [43, 45]
4.2. Specific tumor types
4.2.1. Gastrointestinal tumors
Overall reported survival rates for patients with NCNNLM from gastrointestinal tumors
(esophageal, stomach, duodenum, pancreas, and small bowel) are worse than for those with
nongastrointestinal LM.
4.2.1.1. Esophagus and stomach
Currently, there are no accepted indications for resection of esophageal cancer LM, either for
palliation or cure. The justification for resection of gastric cancer liver metastases remains
controversial. A few published series from Japan and Korea, where the incidence of gastric
cancer is high, specifically address gastric cancer LM. Currently, hepatic resection for gastric
adenocarcinoma cannot be recommended as standard of care. Data supporting hepatic re‐
section in highly selected patients need confirmation by additional clinical studies. [43]
4.2.1.2. Small bowel
Metastases from small bowel adenocarcinoma are most often widespread and associated
with a dismal outcome regardless of treatment. There currently are no data to support resec‐
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2. is associated with low morbidity and mortality, and
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4.2.2. Bile ducts and pancreas
4.2.2.1. Gallbladder, hilar bile ducts, and ampulla
There currently are no generally accepted indications for hepatic resection in patients with
gallbladder cancer, cholangiocarcinoma, or ampullary carcinoma. Judicious recommenda‐
tions should be made on a case-by-case basis. [43, 45]
4.2.2.2. Pancreas
Even for pancreatic carcinoma patients without LM, the overall survival is poor. LM from
pancreatic adenocarcinoma occurs nearly always in the setting of disseminated systemic dis‐
ease.. In the majority of cases, benefit cannot be expected from hepatic resection for this dis‐
ease. [43, 45]
4.2.3. Breast
Although it has not been formally proven that liver resection prolongs survival for selected
patients with liver metastases of breast cancer, recent studies suggest that with careful pa‐
tient selection, resection of breast LM can produce long-term survival. Some authors also
suggest that patients first should undergo systemic chemotherapy, and that only patients
who do not progress should undergo liver resection. [45]
4.2.4. Genitourinary
4.2.4.1. Kidney
In patients with hepatic metastases of renal tumors in whom a complete resection seems
possible, surgical exploration may be justified. The number of studies evaluating renal tu‐
mors including Wilms' tumors, renal cell adenocarcinomas, and nephroblastomas are few,
and the cohorts of patients are small. [43, 45]
4.2.4.2. Testicle
Effective chemotherapeutic regimens are available for most reproductive tumors. Treatment
with chemotherapy can lead to complete responses. Surgical resection is considered a neces‐
sary salvage treatment in the absence of complete radiographic response to systemic thera‐
py, because residual teratomas have been known to degenerate into invasive carcinoma. [43]
“Salvage” hepatic resection may be considered because
1. resection is the only way to confirm a complete response in the residual liver masses,
2. teratomas may progress to malignant transformation in 30% of cases,
3. mortality and morbidity from hepatic resection is low, and
4. if feasible, concomitant resection of liver metastases and residual retroperitoneal dis‐
ease is associated with favorable outcome.
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Because of the small number of published cases, however, no general conclusions can be
drawn.
4.2.4.3. Uterus and ovary
The concept of hepatic resection for LM from ovarian cancer has evolved from the fact that cy‐
toreductive surgery can significantly alter the natural history of ovarian cancer metastatic to
the peritoneum. Resection of ovarian LM may be considered in carefully selected patients that
are candidates for complete cytoreduction after evaluation by a multidisciplinary team. [43]
4.2.5. Melanoma
Most patients with liver metastases of melanoma have unresectable disease owing to extra‐
hepatic disease or disseminated hepatic metastases. Isolated liver metastasis from cutaneous
melanoma is uncommon. Uveal melanoma is a distinct entity that seems to have a different
tumor biology, and it commonly spreads to the liver.. Hepatic resection has been performed
in both populations, although outcomes differ based on the primary site of origin. Hepatic
resection for uveal or cutaneous melanoma should only be considered in a multidisciplinary
setting and by experienced hepatic surgeons. [43, 45]
4.2.6. Adrenal
Hepatic resection can provide acceptable results in selected patients with limited adrenal
metastases, particularly for palliation of symptoms in patients with secreting hepatic tu‐
mors. For patients with symptomatic disease who are not candidates for surgery, ablative
therapy such as RFA may be an effective alternative therapy for symptom control. [43]
4.2.7. Soft tissue sarcoma and gastrointestinal stromal tumor
Hepatic resection for STS metastases is indicated for disease confined to the liver. Patients with
retroperitoneal and intra-abdominal visceral STS and those with leiomyosarcomas are more
likely to have liver-only metastatic disease than are patients with extra-abdominal STS.
The treatment strategy for patients with liver metastases from gastrointestinal stromal tumors
has changed since the development of the targeted agent imatinib mesylate, which achieves
dramatic tumor response rates. Imatinib is now the first-line treatment. Therapy with imatinib
has revolutionized the treatment of patients with GIST and has been used alone and in con‐
junction with hepatic resection for GIST LM. “Complete” radiographic response assessed by
CT or PET, including cystic changes after imatinib treatment of GIST, are not necessarily equiv‐
alent to complete pathologic response. Because hepatic lesions contain viable tumor in >85% of
cases after chemotherapy and biologic therapy, the goal of surgical treatment is complete re‐
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4.2.8. Squamous cell carcinoma
Because the dataset is so heterogeneous, standard recommendations cannot be made, except
that careful patient selection for hepatic resection is mandatory. [43]
4.2.9. Lung cancer
Resection of liver metastases of lung cancer has been reported, and in selected patients long-
term survival has been achieved. [43]
4.2.10. Unknown primary cancer
Patients presenting with liver metastases from an unknown primary tumor are a challenge to
manage because median overall survival is approximately 5 months. The treatment plan for
these patients should be individualized and discussed in a multidisciplinary team. [43, 45]
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1. Introduction
Historically chemotherapy for the treatment of colorectal cancer consisted of the thymidy‐
late synthase inhibitor 5-FU (Adrucil®, Fluouracil®, Efudex®, Fluoroplex®), or more recently
it’s oral pro-drug Capecitabine (Xeloda®), in combination with Folinic acid. Alone these
agents were associated with overall tumour response rates in the order of 20%.[10] In the
last decade newer agents such as Oxaliplatin and Irinotecan have emerged on the market.
These agents are not administered alone but normally in combination with a thymidylate
synthase inhibitor. These combinations have seen the reported objective response to chemo‐
therapy rise to typical rates of 50%.[11-13]
In parallel with the development of these conventional chemotherapeutics a new class of bi‐
ological agents, i.e. antibody based therapies, have emerged. These agents are used to tackle
specific pathways in tumour growth and development such as angiogenesis (e.g. anti-VEG‐
FA antibody Bevacizumab) or cellular proliferation (e.g. the anti-epidermal growth factor
antibodies Cetuximab and Panitumumab). When these agents are added to Oxaliplatin or
Irinotecan based chemotherapy a further 10-15% increase in overall tumour response rate
can be obtained.[14-17]
This improvement in response rates has led to a resurgence of interest in utilising chemo‐
therapy as a means of down-sizing metastatic disease to enable subsequent surgical resec‐
tion – so called conversion chemotherapy.[18] This approach was initially described in 1996
in a series of 330 patients with inoperable colorectal liver metastases of whom 53 (16%) were
able to undergo a subsequent liver resection with curative intent after receiving systemic
chemotherapy. The five year survival for these patients was 40% which compared favoura‐
bly to patients with operable disease treated with surgery alone during the same period.[19]
In 2004 the same group reported the outcome of 1104 patients with initially unresectable col‐
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orectal liver metastases who were treated primarily with systemic chemotherapy over an 11
year period from 1988 – 1999. Of this cohort 138 patients had a sufficient response to chemo‐
therapy to permit subsequent curative intent surgery with an overall 5 year survival of 33%
being achieved.[20]
In a small phase II trial of 42 patients with inoperable colorectal liver metastases Alberts et al
reported that systemic treatment with 5-FU/Oxaliplatin was associated with a tumour re‐
sponse rate of around 60% with 14 patients (33%) having a sufficient response to permit a
liver resection with curative intent.[21] Similar results have been reported with a 5-FU/Irino‐
tecan regimen by Nuzzo et al with 15 out of 42 patients (36%) with inoperable disease being
able to undergo subsequent surgical treatment.[22] In an attempt to determine the most ap‐
propriate regimen for use as conversion chemotherapy the GERCOR trial randomised pa‐
tients with inoperable metastatic colorectal cancer to receive either 5-FU/Irinotecan until
disease progression or unacceptable toxicity and then 5-FU/Oxaliplatin or the reverse se‐
quence (n=113 per arm). Those patients receiving first line Oxaliplatin demonstrated a high‐
er resection rate (n=24; 22%) than those receiving first line Irinotecan (n=10; 9%) and as such
this is the approach most commonly applied in UK practice.[23]
More recently studies have been designed to determine the role of the biological agents in
conversion therapy. In the phase II uncontrolled BOXER trial 46 patients with inoperable
colorectal liver metastases were treated with Capecitabine/Oxaliplatin in combination with
Bevacizumab. 35 of these patients experienced an objective tumour response with 18 (40%)
able to undergo a liver resection with curative intent. In addition 5 patients (11%) experi‐
enced a complete radiological response to systemic therapy.[24] The CRYSTAL trial rando‐
mised patients with inoperable metastatic disease to Irinotecan/5-FU either alone or in
combination with Cetuximab and found that the addition of Cetuxmiab was more likely to
result in patients undergoing subsequent R0 liver resection with curative intent (Odds Ratio
3.02; p=0.002).[17] It is important to note that the response to Cetuximab is primarily deter‐
mined by KRAS mutation status. In the Crystal trial there was no evidence of benefit in pa‐
tients with mutant KRAS who received Cetuximab as compared to those who received 5-
FU/Irinotecan alone.[25]
For those patients who receive successful conversion chemotherapy and are subsequently
considered for liver resection with curative intent it is important to be aware of what the
likely long term outcome will be. Adam et al. reported a series of 184 patients with initially
inoperable disease who underwent hepatectomy after systemic therapy. In these patients a 5
year overall survival rate of 33% was obtained although it is important to note that a signifi‐
cant proportion of patients in this study underwent 2 or more surgical procedures, often in‐
terspersed with further chemotherapy, before long lasting disease control was obtained.[26]
Whilst the role of conversion chemotherapy is widely accepted in the HPB community more
recently the question has been asked about what role systemic therapy may play in the man‐
agement of patients presenting with operable disease from the outset i.e. true neoadjuvant
chemotherapy. The EPOC trial was a multicentre randomised controlled trial which allocat‐
ed such patients to receive either surgery alone or 6 cycles of 5-FU/Oxaliplatin prior to sur‐
gery followed by a further 6 cycles of therapy after surgery (n=182 per arm). Of those
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patients randomised just over 80% of patients in both arms underwent a curative intent liver
resection. When the results of this study were analysed on an intention to treat basis there
was a non-significant trend to improved 3 year overall survival in the chemotherapy arm
(35.4% vs. 28.1%; p=0.058) although statistical significance was only achieved when the anal‐
ysis was limited to only those who underwent resection (42.4% vs. 33.2%; p=0.025).[27] The
difficulty in interpretation of the EPOC trial is that it is impossible to know whether the ben‐
efits of peri-operative chemotherapy were primarily a result of the neoadjuvant or adjuvant
treatment or if both are required. This important question remains, at present, unanswered.
At present most authors would agree that there is insufficient evidence to consider all pa‐
tients with operable disease candidates for systemic therapy prior to surgery although it
may play a role in those with poor prognostic features such as multiple tumour deposits, a
large tumour size or extra-hepatic disease.[28, 29] What is clear however is that an ever in‐
creasing number of patients are presenting for surgical resection on the background of mul‐
tiple cycles of chemotherapy.[30] As experience of managing this patient cohort has
increased there has been a growing recognition that the use of chemotherapy can be associ‐
ated with a toxic injury to the liver parenchyma.[31] The nature of this liver injury and its
implication for the surgical approach to these patients will form the subject of the remainder
of this chapter.
2. Chemotherapy associated liver injury
2.1. Steatosis/steatohepatitis
The presence of fatty change within the liver is increasingly prevalent in the general adult
population where it is commonly associated with the presence of obesity and insulin resist‐
ance (i.e. the metabolic syndrome). Fatty liver disease represents a spectrum of changes
within the liver ranging from simple steatosis through to steatohepatitis and in extreme cas‐
es cirrhosis.[32] Steatohepatitis differs from simple steatosis in that significant inflammatory
infiltrates are present in the liver commonly in association with ballooning degeneration of
hepatocytes.[33]
The link between chemotherapy use and fatty liver disease was first reported in the litera‐
ture in 1998. In a series of 21 patients with colorectal liver metastases treated with systemic
5-FU Peppercorn et al. reported that 48% (n=10) of patients had developed radiological evi‐
dence of steatosis on follow-up imaging.[34] In a later series Pawlik et al. reported the histo‐
logical findings in the liver parenchyma of 334 patients who had undergone resection of
colorectal liver metastases, 153 of whom had received pre-operative chemotherapy. In this
study steatosis ≥ 30% (i.e. steatosis affecting more than 30% of hepatocytes) was present in
18.4% of patients who received pre-operative chemotherapy as compared to only 3.4% of pa‐
tients who were chemotherapy naive (p=0.004). In particular the authors observed that stea‐
tosis was most strongly associated with Irinotecan based chemotherapy (27.3% of patients;
p<0.001) than 5-FU monotherapy (14.9%; p=0.03) and lastly Oxaliplatin based chemotherapy
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(9.6%; p=0.04) suggesting that the nature of the chemotherapy regimen may be important in
determining liver toxicity.[35]
In contrast however a separate series of 406 patients who underwent resection of colorec‐
tal  liver  metastases  failed to  demonstrate  any association between the administration of
pre-operative chemotherapy and the subsequent development of steatosis ≥ 30%. In those
receiving Irinotecan based chemotherapy (n=94)  there  was  however  a  dramatic  increase
in the incidence of steatohepatitis as compared to those patients who were chemotherapy
naive (20.2% vs. 4.4%; p=0.001), a finding which was in contrast to the smaller study de‐
scribed above.[35, 36]
To more accurately determine the nature of the association between chemotherapy use and
the development of fatty change within the liver our group undertook a systematic review
and meta-analysis of the published literature. In this analysis it was not possible to demon‐
strate any association with chemotherapy use overall (Relative Risk 1.25; 95% confidence in‐
terval 0.99 – 1.57; p=0.15) or Oxaliplatin based chemotherapy (Relative Risk 0.98; 95%
confidence interval 0.59 – 1.63; p=0.95) and the development of steatosis ≥ 30%. In the case of
Irinotecan based chemotherapy there was a strong trend to an increased risk of steatosis >
30% (Relative Risk 2.51; 95% Confidence Interval 0.79 – 7.90; p=0.12) which was not statisti‐
cally significant as a consequence of the heterogeneity within the included studies. In con‐
trast there was a strong association between Irinotecan based chemotherapy and
steatohepatitis (Relative Risk 3.45; 95% Confidence Interval 1.12 – 10.62; p=0.03) which was
not demonstrated with other regimens.[37]
2.2. Sinusoidal obstruction syndrome
Sinusoidal obstruction syndrome (SOS; previously known as hepatic veno-occlusive dis‐
ease) represents a microvascular injury to the liver characterised by the histological findings
of dilatation of the hepatic sinusoids and associated atrophy of the surrounding hepatocytes.
In more advanced SOS these changes are accompanied by the development of regenerative
nodules within the liver and ultimately peri-sinusoidal liver fibrosis.[38] Historically SOS
was described as a condition occurring after ingestion of pyrrolizidine alkaloids, a group of
compounds found in plants used in traditional African herbal remedies.[39, 40] Furthermore
SOS has been reported to occur in up to 50% of patients receiving myeloablative chemother‐
apy prior to bone marrow transplantation.[41, 42]
In a seminal paper in 2004 Rubbia-Brandt published a report of histological changes in the
liver parenchyma of 153 patients who had undergone resection of colorectal liver metasta‐
ses. In this study it was reported that 44 out of 87 patients treated with pre-operative chemo‐
therapy had histological features of SOS, the majority of whom had received treatment with
Oxaliplatin based regimens.[38] Similar results were reported by Vauthey et al who demon‐
strated a significantly increased incidence of SOS in patients receiving Oxaliplatin based
chemotherapy as compared to those who were chemotherapy naive (18.9% vs. 1.9%;
p<0.001) where as no such association was demonstrated with other chemotherapy regi‐
mens.[36] In our systematic review of the published literature we demonstrated a strong as‐
sociation between Oxaliplatin based chemotherapy and SOS (Relative Risk 2.78; 95%
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Confidence Interval 1.35 – 5.69; p=0.0007) which again was not replicated in patients receiv‐
ing alternative chemotherapy regimens.[37] The typical appearances of an Oxaliplatin in‐
jured liver, as encountered at laparotomy, are shown in Figure 1.
Figure 1. The classical appearance of the Oxaliplatin injured liver with SOS – commonly described as a “blue liver”
It is therefore clear from this discussion that the nature of liver injury following administra‐
tion of chemotherapy to patients with colorectal liver metastases is dependent on the nature
of the regimen administered. Irinotecan based regimens are primarily associated with the
development of hepatic steatosis/steatohepatitis whereas Oxaliplatin based regimens are as‐
sociated with the development of SOS. The assessment of the severity of this liver injury and
its implications for the surgical management of these patients forms the discussion in the re‐
mainder of this chapter.
3. Assessment of the post-chemotherapy liver
Post hepatectomy liver failure (PHLF) is a feared complication of major liver resection and
was recently defined as “a postoperatively acquired deterioration in the ability of the liver to
maintain its synthetic, excretory and detoxifying functions”[43] whose presence is associat‐
ed with a dramatic increase in the risk of post-operative mortality.[44, 45]
A key risk factor for the development of PHLF is the presence of background liver disease or
injury. Belghiti et al reported, in a series of 747 patients undergoing liver resection, that the
presence of either cirrhosis or steatosis affecting more than 30% of hepatocytes (n=253) was
associated with a post-operative mortality of 9.5% as compared to only 1% in those with a
normal liver parenchyma.[46] In a series of 406 patients undergoing resection of colorectal
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strate any association with chemotherapy use overall (Relative Risk 1.25; 95% confidence in‐
terval 0.99 – 1.57; p=0.15) or Oxaliplatin based chemotherapy (Relative Risk 0.98; 95%
confidence interval 0.59 – 1.63; p=0.95) and the development of steatosis ≥ 30%. In the case of
Irinotecan based chemotherapy there was a strong trend to an increased risk of steatosis >
30% (Relative Risk 2.51; 95% Confidence Interval 0.79 – 7.90; p=0.12) which was not statisti‐
cally significant as a consequence of the heterogeneity within the included studies. In con‐
trast there was a strong association between Irinotecan based chemotherapy and
steatohepatitis (Relative Risk 3.45; 95% Confidence Interval 1.12 – 10.62; p=0.03) which was
not demonstrated with other regimens.[37]
2.2. Sinusoidal obstruction syndrome
Sinusoidal obstruction syndrome (SOS; previously known as hepatic veno-occlusive dis‐
ease) represents a microvascular injury to the liver characterised by the histological findings
of dilatation of the hepatic sinusoids and associated atrophy of the surrounding hepatocytes.
In more advanced SOS these changes are accompanied by the development of regenerative
nodules within the liver and ultimately peri-sinusoidal liver fibrosis.[38] Historically SOS
was described as a condition occurring after ingestion of pyrrolizidine alkaloids, a group of
compounds found in plants used in traditional African herbal remedies.[39, 40] Furthermore
SOS has been reported to occur in up to 50% of patients receiving myeloablative chemother‐
apy prior to bone marrow transplantation.[41, 42]
In a seminal paper in 2004 Rubbia-Brandt published a report of histological changes in the
liver parenchyma of 153 patients who had undergone resection of colorectal liver metasta‐
ses. In this study it was reported that 44 out of 87 patients treated with pre-operative chemo‐
therapy had histological features of SOS, the majority of whom had received treatment with
Oxaliplatin based regimens.[38] Similar results were reported by Vauthey et al who demon‐
strated a significantly increased incidence of SOS in patients receiving Oxaliplatin based
chemotherapy as compared to those who were chemotherapy naive (18.9% vs. 1.9%;
p<0.001) where as no such association was demonstrated with other chemotherapy regi‐
mens.[36] In our systematic review of the published literature we demonstrated a strong as‐
sociation between Oxaliplatin based chemotherapy and SOS (Relative Risk 2.78; 95%
Hepatic Surgery400
Confidence Interval 1.35 – 5.69; p=0.0007) which again was not replicated in patients receiv‐
ing alternative chemotherapy regimens.[37] The typical appearances of an Oxaliplatin in‐
jured liver, as encountered at laparotomy, are shown in Figure 1.
Figure 1. The classical appearance of the Oxaliplatin injured liver with SOS – commonly described as a “blue liver”
It is therefore clear from this discussion that the nature of liver injury following administra‐
tion of chemotherapy to patients with colorectal liver metastases is dependent on the nature
of the regimen administered. Irinotecan based regimens are primarily associated with the
development of hepatic steatosis/steatohepatitis whereas Oxaliplatin based regimens are as‐
sociated with the development of SOS. The assessment of the severity of this liver injury and
its implications for the surgical management of these patients forms the discussion in the re‐
mainder of this chapter.
3. Assessment of the post-chemotherapy liver
Post hepatectomy liver failure (PHLF) is a feared complication of major liver resection and
was recently defined as “a postoperatively acquired deterioration in the ability of the liver to
maintain its synthetic, excretory and detoxifying functions”[43] whose presence is associat‐
ed with a dramatic increase in the risk of post-operative mortality.[44, 45]
A key risk factor for the development of PHLF is the presence of background liver disease or
injury. Belghiti et al reported, in a series of 747 patients undergoing liver resection, that the
presence of either cirrhosis or steatosis affecting more than 30% of hepatocytes (n=253) was
associated with a post-operative mortality of 9.5% as compared to only 1% in those with a
normal liver parenchyma.[46] In a series of 406 patients undergoing resection of colorectal
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liver metastases Vauthey et al reported that those patients with steatohepatitis (n=34) experi‐
enced an increase in both 90 day mortality (14.7% vs. 1.6% p = 0.001) and post hepatectomy
liver failure (5.8% vs. 0.8%; p=0.01).[36] The findings from these case series have been sup‐
ported by a meta-analysis of the published literature which demonstrated that the presence
of hepatic steatosis > 30% was associated with an increased risk of peri-operative complica‐
tions (risk ratio 2.01; p<0.0001) and mortality (risk ratio 2.79; p=0.02).[47] Similarly the pres‐
ence of SOS has been associated with an increased incidence of PHLF in a series of 51
patients undergoing resection of CRLM, 38 of whom had histologically proven SOS (68% vs.
23%; p=0.004)[48]
The other factor that is pivotal in determining the risk of PHLF is the volume of liver which
will remain following surgery, commonly referred to as the future liver remnant or FLR,
which can often be estimated pre-operatively by CT volumetry.[49] In 2003 Shoup et al re‐
ported a series of 126 patients who had undergone a liver resection to treat colorectal liver
metastases. In those patients with a FLR of ≤ 25% (n=20) 90% developed PHLF as compared
to 19% of those with an FLR > 25%. Logistic regression analysis demonstrated that the pres‐
ence of an FLR<25% tripled the risk of PHLF (Odds Ratio 3.09; p<0.0001). Similarly in a
study of 119 patients with a normal liver parenchyma undergoing major liver resection (i.e.
resection of 3 or more Couinaud segments) the median FLR in the 7 patients who developed
PHLF was 29.6% as compared to 42.5% in those who did not (p=0.009).[50] As a conse‐
quence of this evidence the minimum safe FLR in patients with an otherwise normal liver
undergoing resection of CRLM is 25%.[51]
In those patients presenting for surgery on the background of multiple cycles of pre-opera‐
tive chemotherapy it is pivotal, particularly when an extensive liver resection is planned, to
minimise the risk of PHLF. When significant parenchymal injury is present it may be neces‐
sary for the FLR to be as high as 40% and this may have a significant impact on the surgical
strategy employed.[52] Careful pre-operative assessment of the liver is therefore essential in
these patients and the techniques which can be employed for doing this are discussed in
more detail below.
3.1. Clinical/biochemical markers of chemotherapy induced liver injury
Identifying those patients at risk of steatohepatitis following Irinotecan based chemotherapy
is particularly difficult not least because a significant proportion of patients in the back‐
ground community will have a fatty liver as a consequence of either the metabolic syn‐
drome, other underlying liver disease or lifestyle. This is reflected in the study of Ryan et al.
which analysed histological changes in the liver of 334 patients undergoing resection of col‐
orectal metastases. Only 8 patients in this study had histologically defined steatohepatitis
the presence of which, on multivariate analysis, was found to be independently associated
with a BMI > 30kg/m2 but not the use of chemotherapy.[53] The study of Vauthey et al. re‐
ported that, in 94 patients treated with Irinotecan, the incidence of steatohepatitis was 12.1%
in those with a BMI of < 25kg/m2 but 24.6% in those with a BMI of ≥ 25kg/m2. This study did
not however undertake a multivariate analysis to identify independent risk factors associat‐
ed with the presence of steatohepatitis.[36] It has been proposed that elevated serum transa‐
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minases may be of use in determining simple steatosis from steatohepatitis in patients with
non-alcoholic fatty liver disease but it is not know whether this observation also holds true
in those with chemotherapy associated steatohepatitis.[54-56]
Whilst one might intuitively expect that there would be a direct correlation between the
number of cycles of chemotherapy received and the presence of liver injury this relationship
is in fact less than clear cut. In the study of Vauthey et al. which reported the presence of
liver injury in 406 patients undergoing resection of colorectal metastases there was no asso‐
ciation between the number of cycles of chemotherapy administered and the incidence of
steatohepatitis or SOS.[36] On the other hand Kishi et al., in a series of 219 patients who
were treated pre-operatively with Oxaliplatin based chemotherapy, reported that SOS was
present more frequently in those who received 9 or more cycles of chemotherapy than those
who did not (42% vs. 26%; p=0.017).[57] Similarly the study of Aloia et al. reported that the
incidence of SOS in those receiving greater than 12 cycles of chemotherapy was 50% as com‐
pared to 25% in those receiving 6-12 cycles and 10% in those who received less than 6 cycles
(p=0.01).[58] Several studies have undertaken multivariate analysis to identify independent
risk factors associated with the development of chemotherapy induced liver injury. Nakano
et al demonstrated that the presence of SOS was independently associated with receiving 6
or more cycles of Oxaliplatin based chemotherapy (Relative Risk 3.2; p=0.048).[59] In con‐
trast however 3 other studies have failed to demonstrate any such independent association
between the number of cycles of Oxaliplatin administered and the development of SOS.[48,
60, 61] This raises the question of whether other variables, such as the presence of underly‐
ing liver disease, also make a significant contribution to the development of chemotherapy
induced liver injury.
Some authors have suggested that tumour related factors may play a role in determining the
development of SOS. On a univariate analysis of 78 patients treated with pre-operative Oxa‐
liplatin based chemotherapy Soubrane et al. reported that those with SOS tended to have a
larger tumour size (7.8cm vs. 5.2cm; p = 0.004) although this was not identified as an inde‐
pendent risk factor on multivariate analysis.[48] Tamandl et al. were able to confirm this ob‐
servation in a separate study and on this occasion they were able to demonstrate that a
tumour size > 5cm was independently associated with the development of SOS on multi‐
variate analysis (Hazard Ratio 4.42; p = 0.012).[61] This clinical data is supported by experi‐
mental data from our group which suggests that the presence of tumour within the liver of
mice treated with Oxaliplatin based chemotherapy accelerates changes in gene expression
associated with the development of SOS.[62]
The role of various haematological and biochemical parameters to predict the presence of
SOS has also been explored in several studies. Soubrane et al. reported on univariate analy‐
sis that an elevated AST (p=0.0009), ALT (p=0.02) and a low platelet count (p<0.0001) were
all suggestive of the presence of SOS. On multivariate analysis they demonstrated that a
high AST to platelet count ratio (APRI score) was an independent predictor for the presence
of SOS (Odds Ratio 5; p<0.005).[48] Similarly a multivariate analysis from Nakano et al.
demonstrated an independent association between an elevated AST and the presence of SOS
(Relative Risk 3.86; p=0.044). [59] Tamandl et al. reported that on multivariate analysis on
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liver metastases Vauthey et al reported that those patients with steatohepatitis (n=34) experi‐
enced an increase in both 90 day mortality (14.7% vs. 1.6% p = 0.001) and post hepatectomy
liver failure (5.8% vs. 0.8%; p=0.01).[36] The findings from these case series have been sup‐
ported by a meta-analysis of the published literature which demonstrated that the presence
of hepatic steatosis > 30% was associated with an increased risk of peri-operative complica‐
tions (risk ratio 2.01; p<0.0001) and mortality (risk ratio 2.79; p=0.02).[47] Similarly the pres‐
ence of SOS has been associated with an increased incidence of PHLF in a series of 51
patients undergoing resection of CRLM, 38 of whom had histologically proven SOS (68% vs.
23%; p=0.004)[48]
The other factor that is pivotal in determining the risk of PHLF is the volume of liver which
will remain following surgery, commonly referred to as the future liver remnant or FLR,
which can often be estimated pre-operatively by CT volumetry.[49] In 2003 Shoup et al re‐
ported a series of 126 patients who had undergone a liver resection to treat colorectal liver
metastases. In those patients with a FLR of ≤ 25% (n=20) 90% developed PHLF as compared
to 19% of those with an FLR > 25%. Logistic regression analysis demonstrated that the pres‐
ence of an FLR<25% tripled the risk of PHLF (Odds Ratio 3.09; p<0.0001). Similarly in a
study of 119 patients with a normal liver parenchyma undergoing major liver resection (i.e.
resection of 3 or more Couinaud segments) the median FLR in the 7 patients who developed
PHLF was 29.6% as compared to 42.5% in those who did not (p=0.009).[50] As a conse‐
quence of this evidence the minimum safe FLR in patients with an otherwise normal liver
undergoing resection of CRLM is 25%.[51]
In those patients presenting for surgery on the background of multiple cycles of pre-opera‐
tive chemotherapy it is pivotal, particularly when an extensive liver resection is planned, to
minimise the risk of PHLF. When significant parenchymal injury is present it may be neces‐
sary for the FLR to be as high as 40% and this may have a significant impact on the surgical
strategy employed.[52] Careful pre-operative assessment of the liver is therefore essential in
these patients and the techniques which can be employed for doing this are discussed in
more detail below.
3.1. Clinical/biochemical markers of chemotherapy induced liver injury
Identifying those patients at risk of steatohepatitis following Irinotecan based chemotherapy
is particularly difficult not least because a significant proportion of patients in the back‐
ground community will have a fatty liver as a consequence of either the metabolic syn‐
drome, other underlying liver disease or lifestyle. This is reflected in the study of Ryan et al.
which analysed histological changes in the liver of 334 patients undergoing resection of col‐
orectal metastases. Only 8 patients in this study had histologically defined steatohepatitis
the presence of which, on multivariate analysis, was found to be independently associated
with a BMI > 30kg/m2 but not the use of chemotherapy.[53] The study of Vauthey et al. re‐
ported that, in 94 patients treated with Irinotecan, the incidence of steatohepatitis was 12.1%
in those with a BMI of < 25kg/m2 but 24.6% in those with a BMI of ≥ 25kg/m2. This study did
not however undertake a multivariate analysis to identify independent risk factors associat‐
ed with the presence of steatohepatitis.[36] It has been proposed that elevated serum transa‐
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minases may be of use in determining simple steatosis from steatohepatitis in patients with
non-alcoholic fatty liver disease but it is not know whether this observation also holds true
in those with chemotherapy associated steatohepatitis.[54-56]
Whilst one might intuitively expect that there would be a direct correlation between the
number of cycles of chemotherapy received and the presence of liver injury this relationship
is in fact less than clear cut. In the study of Vauthey et al. which reported the presence of
liver injury in 406 patients undergoing resection of colorectal metastases there was no asso‐
ciation between the number of cycles of chemotherapy administered and the incidence of
steatohepatitis or SOS.[36] On the other hand Kishi et al., in a series of 219 patients who
were treated pre-operatively with Oxaliplatin based chemotherapy, reported that SOS was
present more frequently in those who received 9 or more cycles of chemotherapy than those
who did not (42% vs. 26%; p=0.017).[57] Similarly the study of Aloia et al. reported that the
incidence of SOS in those receiving greater than 12 cycles of chemotherapy was 50% as com‐
pared to 25% in those receiving 6-12 cycles and 10% in those who received less than 6 cycles
(p=0.01).[58] Several studies have undertaken multivariate analysis to identify independent
risk factors associated with the development of chemotherapy induced liver injury. Nakano
et al demonstrated that the presence of SOS was independently associated with receiving 6
or more cycles of Oxaliplatin based chemotherapy (Relative Risk 3.2; p=0.048).[59] In con‐
trast however 3 other studies have failed to demonstrate any such independent association
between the number of cycles of Oxaliplatin administered and the development of SOS.[48,
60, 61] This raises the question of whether other variables, such as the presence of underly‐
ing liver disease, also make a significant contribution to the development of chemotherapy
induced liver injury.
Some authors have suggested that tumour related factors may play a role in determining the
development of SOS. On a univariate analysis of 78 patients treated with pre-operative Oxa‐
liplatin based chemotherapy Soubrane et al. reported that those with SOS tended to have a
larger tumour size (7.8cm vs. 5.2cm; p = 0.004) although this was not identified as an inde‐
pendent risk factor on multivariate analysis.[48] Tamandl et al. were able to confirm this ob‐
servation in a separate study and on this occasion they were able to demonstrate that a
tumour size > 5cm was independently associated with the development of SOS on multi‐
variate analysis (Hazard Ratio 4.42; p = 0.012).[61] This clinical data is supported by experi‐
mental data from our group which suggests that the presence of tumour within the liver of
mice treated with Oxaliplatin based chemotherapy accelerates changes in gene expression
associated with the development of SOS.[62]
The role of various haematological and biochemical parameters to predict the presence of
SOS has also been explored in several studies. Soubrane et al. reported on univariate analy‐
sis that an elevated AST (p=0.0009), ALT (p=0.02) and a low platelet count (p<0.0001) were
all suggestive of the presence of SOS. On multivariate analysis they demonstrated that a
high AST to platelet count ratio (APRI score) was an independent predictor for the presence
of SOS (Odds Ratio 5; p<0.005).[48] Similarly a multivariate analysis from Nakano et al.
demonstrated an independent association between an elevated AST and the presence of SOS
(Relative Risk 3.86; p=0.044). [59] Tamandl et al. reported that on multivariate analysis on
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multivariate analysis an elevated alkaline phosphatase or γGT was an independent predic‐
tor of SOS (Hazard Ratio 4; p=0.038) although this was not true for AST or ALT.[61]
Whilst none of these studies have demonstrated a single factor that is reliably able to predict
the presence of chemotherapy induced liver injury it is possible to begin to develop a picture
of the patient characteristics which may lead to a raised index of suspicion and prompt a
more thorough assessment of the liver parenchyma prior to surgery.
3.2. Radiological assessment of chemotherapy induced liver injury
The volume of data on the radiological assessment of fatty liver disease is vast and this is a
reflection of the high incidence of non-alcoholic fatty liver disease in the general population.
The consequence of this is that the appearances of fatty liver disease on each of the 3 main
imaging modalities of the liver have been well described and is summarised in Table 1. It
should be pointed out that on CT scanning hepatic steatosis is best detected on unenhanced
images which are often not performed routinely in most imaging protocols in order to mini‐
mise patient radiation exposure.[63] A recent systematic review and meta-analysis of the
published literature concluded that MRI represented the most accurate method for deter‐
mining the extent of hepatic steatosis with a reported sensitivity of 97.4% and specificity of
76.1% for the detection of steatosis >30%.[64]
Imaging Modality Characteristic features hepatic steatosis
Ultrasound Intracellular fat accumulation leads to an increase in liver echogenicity [63]
Computed Tomography Steatosis leads to a decrease in attenuation of the liver parenchyma [63, 65]
Magnetic Resonance Imaging A loss of liver signal intensity occurs on T1 weighted gradient echo (GRE) opposed
images[63, 65]
Table 1. Appearances of hepatic steatosis on the main liver imaging modalities
Several studies have attempted to identify the utility of pre-operative cross sectional imag‐
ing to identify hepatic steatosis specifically in patients undergoing liver resection. The first
of these was published in 2008 by Cho et al. who conducted a retrospective analysis of 131
patients undergoing partial hepatectomy over a 4 year period who had one of either a non-
contrast CT scan (n=26), contrast enhanced CT scan (n=74) or a gradient opposed MRI (n=32)
with a median interval between imaging and surgery of 17 Days. The ability of these imag‐
ing modalities to predict histologically defined steatosis > 30% was determined. The authors
demonstrated that of the two CT methods studied only non-contrast CT was of any utility in
determining the presence of hepatic steatosis with a high degree of specificity (100%) but
had low sensitivity (33%) with a corresponding positive predictive value (PPV) of 100% and
negative predictive value (NPV) of 83%. In contrast MRI fared much better in excluding the
presence of hepatic steatosis with an NPV of 94% but a PPV of only 44% with a sensitivity of
88% and specificity of 63%. The conclusion of this study was that cross-sectional imaging
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alone was not consistently able to determine the presence of hepatic steatosis and was there‐
fore of limited utility for this purpose.[66]
In 2009 O’Rourke et al. reported a prospective study of n=37 patients undergoing resection
of colorectal liver metastases who received pre-operative liver specific MRI. Again this
study demonstrated a much better performance for MRI in determining the presence of hep‐
atic steatosis > 30% with a PPV of 100%, NPV of 87% a sensitivity of 63% and a specificity of
100%.[67] A subsequent retrospective study by Marsman et al compared the ability of non-
contrast enhanced CT (n=32) and MRI (n=36) to detect the presence of histologically defined
steatosis > 33% in patients undergoing resection of colorectal liver metastases after receiving
pre-operative chemotherapy. In this study MRI by far out performed CT in terms of sensi‐
tivity (78% vs. 70%), specificity (100% vs. 86.4%); PPV (100% vs. 70%) and NPV (93.1% vs.
86.4%) suggesting that this is the imaging modality of choice.[68]
On the basis of the currently available evidence it appears that MRI is the imaging modality
of choice to assess the extent of hepatic steatosis in patients with colorectal liver metastases
prior to surgery. It must be highlighted that cross-sectional imaging is not able to differenti‐
ate between simple steatosis and steatohepatitis which can only be achieved with histologi‐
cal assessment of the liver. Furthermore a ‘normal’ imaging study does not exclude the
presence of hepatic steatosis and in those cases where there is a high level of clinical suspi‐
cion a further evaluation of the liver must be undertaken.
The role of cross-sectional imaging in detecting the presence of SOS is much less clear cut as
compared to hepatic steatosis. It has been proposed that the development of splenomegaly
on post-chemotherapy imaging may serve as a surrogate marker for the presence of SOS.
Overman et al conducted a study in patients who received either 5-FU/Oxaliplatin (n=96) or
5-FU alone (n=40) as adjuvant therapy following resection of a colonic primary and com‐
pared spleen size on pre-operative imaging to that 6 weeks after the final cycle of chemo‐
therapy. They demonstrated that the median increase in spleen size was 22% for those
patients receiving 5-FU/Oxaliplatin whereas there was no increase in size in those receiving
5-FU alone (p<0.001). The authors went on to look at a subgroup of patients (n=63) who un‐
derwent a liver resection after 5-FU/Oxaliplatin and demonstrated, on multivariate analysis,
that a greater than 50% increase in spleen size following chemotherapy was independently
able to predict the presence of SOS (Odds Ratio 2.34; p=0.02) with a sensitivity of 43%, and
specificity of 90%.[60]
Several authors have explored the utility of various MRI protocols to predict the presence of
SOS. Ward et al. reported a study of 60 patients with colorectal liver metastases who under‐
went superparamagnetic iron oxide (SPIO) enhanced MRI prior to liver resection. Following
SPIO administration SOS is characterised by reticular hyperintensity on T2*-gradient re‐
sponse echo weighted MRI images the presence of which the authors graded on a scale of 0
– 3 (summarised in Table 2) with a score of 2 or greater indicating the presence of SOS. Us‐
ing this technique 24 of the 60 patients were thought to have SOS on the basis of MRI the
presence of which was subsequently confirmed histologically in 20 patients. Of the 36 pa‐
tients thought not to have SOS on the basis of MRI 3 were subsequently found to have histo‐
logical features of SOS. This means that SPIO enhanced MRI, in this study, had a sensitivity
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multivariate analysis an elevated alkaline phosphatase or γGT was an independent predic‐
tor of SOS (Hazard Ratio 4; p=0.038) although this was not true for AST or ALT.[61]
Whilst none of these studies have demonstrated a single factor that is reliably able to predict
the presence of chemotherapy induced liver injury it is possible to begin to develop a picture
of the patient characteristics which may lead to a raised index of suspicion and prompt a
more thorough assessment of the liver parenchyma prior to surgery.
3.2. Radiological assessment of chemotherapy induced liver injury
The volume of data on the radiological assessment of fatty liver disease is vast and this is a
reflection of the high incidence of non-alcoholic fatty liver disease in the general population.
The consequence of this is that the appearances of fatty liver disease on each of the 3 main
imaging modalities of the liver have been well described and is summarised in Table 1. It
should be pointed out that on CT scanning hepatic steatosis is best detected on unenhanced
images which are often not performed routinely in most imaging protocols in order to mini‐
mise patient radiation exposure.[63] A recent systematic review and meta-analysis of the
published literature concluded that MRI represented the most accurate method for deter‐
mining the extent of hepatic steatosis with a reported sensitivity of 97.4% and specificity of
76.1% for the detection of steatosis >30%.[64]
Imaging Modality Characteristic features hepatic steatosis
Ultrasound Intracellular fat accumulation leads to an increase in liver echogenicity [63]
Computed Tomography Steatosis leads to a decrease in attenuation of the liver parenchyma [63, 65]
Magnetic Resonance Imaging A loss of liver signal intensity occurs on T1 weighted gradient echo (GRE) opposed
images[63, 65]
Table 1. Appearances of hepatic steatosis on the main liver imaging modalities
Several studies have attempted to identify the utility of pre-operative cross sectional imag‐
ing to identify hepatic steatosis specifically in patients undergoing liver resection. The first
of these was published in 2008 by Cho et al. who conducted a retrospective analysis of 131
patients undergoing partial hepatectomy over a 4 year period who had one of either a non-
contrast CT scan (n=26), contrast enhanced CT scan (n=74) or a gradient opposed MRI (n=32)
with a median interval between imaging and surgery of 17 Days. The ability of these imag‐
ing modalities to predict histologically defined steatosis > 30% was determined. The authors
demonstrated that of the two CT methods studied only non-contrast CT was of any utility in
determining the presence of hepatic steatosis with a high degree of specificity (100%) but
had low sensitivity (33%) with a corresponding positive predictive value (PPV) of 100% and
negative predictive value (NPV) of 83%. In contrast MRI fared much better in excluding the
presence of hepatic steatosis with an NPV of 94% but a PPV of only 44% with a sensitivity of
88% and specificity of 63%. The conclusion of this study was that cross-sectional imaging
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alone was not consistently able to determine the presence of hepatic steatosis and was there‐
fore of limited utility for this purpose.[66]
In 2009 O’Rourke et al. reported a prospective study of n=37 patients undergoing resection
of colorectal liver metastases who received pre-operative liver specific MRI. Again this
study demonstrated a much better performance for MRI in determining the presence of hep‐
atic steatosis > 30% with a PPV of 100%, NPV of 87% a sensitivity of 63% and a specificity of
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contrast enhanced CT (n=32) and MRI (n=36) to detect the presence of histologically defined
steatosis > 33% in patients undergoing resection of colorectal liver metastases after receiving
pre-operative chemotherapy. In this study MRI by far out performed CT in terms of sensi‐
tivity (78% vs. 70%), specificity (100% vs. 86.4%); PPV (100% vs. 70%) and NPV (93.1% vs.
86.4%) suggesting that this is the imaging modality of choice.[68]
On the basis of the currently available evidence it appears that MRI is the imaging modality
of choice to assess the extent of hepatic steatosis in patients with colorectal liver metastases
prior to surgery. It must be highlighted that cross-sectional imaging is not able to differenti‐
ate between simple steatosis and steatohepatitis which can only be achieved with histologi‐
cal assessment of the liver. Furthermore a ‘normal’ imaging study does not exclude the
presence of hepatic steatosis and in those cases where there is a high level of clinical suspi‐
cion a further evaluation of the liver must be undertaken.
The role of cross-sectional imaging in detecting the presence of SOS is much less clear cut as
compared to hepatic steatosis. It has been proposed that the development of splenomegaly
on post-chemotherapy imaging may serve as a surrogate marker for the presence of SOS.
Overman et al conducted a study in patients who received either 5-FU/Oxaliplatin (n=96) or
5-FU alone (n=40) as adjuvant therapy following resection of a colonic primary and com‐
pared spleen size on pre-operative imaging to that 6 weeks after the final cycle of chemo‐
therapy. They demonstrated that the median increase in spleen size was 22% for those
patients receiving 5-FU/Oxaliplatin whereas there was no increase in size in those receiving
5-FU alone (p<0.001). The authors went on to look at a subgroup of patients (n=63) who un‐
derwent a liver resection after 5-FU/Oxaliplatin and demonstrated, on multivariate analysis,
that a greater than 50% increase in spleen size following chemotherapy was independently
able to predict the presence of SOS (Odds Ratio 2.34; p=0.02) with a sensitivity of 43%, and
specificity of 90%.[60]
Several authors have explored the utility of various MRI protocols to predict the presence of
SOS. Ward et al. reported a study of 60 patients with colorectal liver metastases who under‐
went superparamagnetic iron oxide (SPIO) enhanced MRI prior to liver resection. Following
SPIO administration SOS is characterised by reticular hyperintensity on T2*-gradient re‐
sponse echo weighted MRI images the presence of which the authors graded on a scale of 0
– 3 (summarised in Table 2) with a score of 2 or greater indicating the presence of SOS. Us‐
ing this technique 24 of the 60 patients were thought to have SOS on the basis of MRI the
presence of which was subsequently confirmed histologically in 20 patients. Of the 36 pa‐
tients thought not to have SOS on the basis of MRI 3 were subsequently found to have histo‐
logical features of SOS. This means that SPIO enhanced MRI, in this study, had a sensitivity
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of 87%, specificity of 89%, PPV of 83% and NPV of 92% for the presence of SOS.[69] In con‐
trast to these findings however O’Rourke et al. in their study of 37 patients found that SPIO
enhanced MRI had a high specificity (100%) and PPV (100%) for the presence of severe SOS
but a low sensitivity (11%) with a NPV of 78% suggesting that this technique may fail to
identify a significant proportion of patients with SOS.[67]
Grade Description
0 Absent
1 Fine reticulations on a minority of sections
2 Diffuse reticulations or localised coalescent areas of high signal
3 Diffuse reticulations present on all sections or densely coalescent areas of high signal on multiple
sections
Table 2. Grading of reticular hyperintensity on SPIO enhanced MRI to determine the presence of SOS[69]
Shin et al. explored the ability of Gadoxetic acid disodium (EOB-MRI; Primavist®) enhanced
MRI to detect the presence of SOS prior to resection of colorectal metastases. On EOB-MRI
the presence of SOS appears as reticular hypointensity which the authors graded on a scale
of 1-5 with a score of 4 (probably present) or 5 (definitely present) being considered diagnos‐
tic of SOS. Of the 42 patients included in this study all 12 MRI identified cases of SOS had
the diagnosis confirmed histologically and of the 30 MRI negative cases 4 had histological
evidence of SOS. This resulted in a sensitivity of 75%, specificity of 100%, PPV of 100% and a
NPV of 87%. The images in this study were independently reviewed by a radiological resi‐
dent with a good level of agreement (weighted kappa 0.765) suggesting that this technique
is subject to minimal interobserver variability.[70]
The small number of patients in these studies make it difficult to recommend the routine use
of any of these MRI protocols for the sole purpose of detecting pre-operative SOS. The pres‐
ence of splenomegaly on pre-operative imaging, particularly in patients who have received
multiple cycles of Oxaliplatin based chemotherapy, should raise suspicion about the pres‐
ence of SOS and prompt a thorough assessment of the liver parenchyma if extended resec‐
tion is to be performed.
3.3. Functional assessment of the future liver remnant
A variety of techniques have been described which aim to quantitatively assess the function‐
al reserve of the liver and thereby provide a means to determine the minimum safe FLR that
is required to avoid the risk of PHLF. Perhaps the most widely described of these techniques
is the Indocyanine Green (ICG) retention test. Following injection ICG is transported in the
systemic circulation bound to albumin and does not leave the serum until it reaches the liver
where it is taken up by hepatocytes. These hepatocytes then clear ICG by excreting the com‐
pound into the biliary system in an ATP dependent manner. ICG does not enter the portal
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circulation nor is it metabolised by hepatocytes prior to its excretion and therefore the clear‐
ance of ICG provides a direct measure of hepatocyte function.[71]
Typically the retention of ICG at 15 minutes is measured in a serum sample (ICGR-15) and
this value is used as a measure of hepatic functional reserve with a value of <10% being con‐
sidered normal. Based on their experience of using this test in a series of 1429 patients Ima‐
mura et al. described the maximum extent of liver resection they thought could be safely
performed according to the ICGR-15 value (see Table 3).[72] Others however view this
ICGR-15 value as too conservative and state that a cut off of <14% should be used to identify
those patients in whom it is safe to perform major liver resection.[73] The use of ICG reten‐
tion as a pre-operative assessment of liver function is however predominantly limited to
Asia where the majority of liver resections are performed for hepatocellular carcinoma and
therefore the data regarding the validity of this test in patients with colorectal liver metasta‐
ses is limited.
ICGR-15 Value Typical Safe Liver Resection
<10% Right/Left Trisectionectomy
10 – 19% Left hepatectomy / Right sectorectomy
20 – 29% Segmentectomy
≥ 30% Limited non-anatomical resection
Table 3. Typical safe liver resection volumes as recommended by Imamura et al based on ICGR-15 values[72]
Nakano et al reported the outcome of 36 patients who underwent major hepatectomy (>3
Couinaud segments) 20 of whom had histologically proven SOS and 16 who had a normal
liver parenchyma. The presence of SOS in these patients was independently associated with
an ICGR-15 of >10%. It is of note that these patients experienced an increased risk of peri-
operative complications (40% vs. 6.3%; p=0.026) and a longer mean hospital stay (17 days vs.
11 days; p = 0.006).[59] Experimental studies have also suggested that ICGR-15 may be a
useful measure of hepatocyte function in the context of hepatic steatosis.[74] In a series of
101 patients undergoing liver resection for colorectal metastases Klinger et al reported that
the use of preoperative chemotherapy (n=83; all regimens) was associated with a longer
ICGR-15 (7.3% vs. 3.5%; p = 0.005). Similarly those who had received pre-operative chemo‐
therapy were more likely to have an ICGR-15 ≥ 10% (27.7% vs. 0%; p=0.011) and this was
associated with an increased rate of post-operative complications (39.1% vs. 12.8%; p=0.005).
No attempt was made in this study to correlate ICGR-15 values with histological changes
within the liver parenchyma.[75]
The LiMAx test has recently been described as an alternative means of assessing the hepatic
functional reserve. This test measures the cytochrome P450 mediated metabolism of 13C la‐
belled methacetin into acetaminophen and 13CO2 which is exhaled. The test measures
changes in the ratio of exhaled 13CO2 : 12CO2 over a 60 minute period – the greater the 13CO2
excretion the greater the functional reserve of the liver.[76] The authors have demonstrated
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of 87%, specificity of 89%, PPV of 83% and NPV of 92% for the presence of SOS.[69] In con‐
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enhanced MRI had a high specificity (100%) and PPV (100%) for the presence of severe SOS
but a low sensitivity (11%) with a NPV of 78% suggesting that this technique may fail to
identify a significant proportion of patients with SOS.[67]
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tion is to be performed.
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A variety of techniques have been described which aim to quantitatively assess the function‐
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tion as a pre-operative assessment of liver function is however predominantly limited to
Asia where the majority of liver resections are performed for hepatocellular carcinoma and
therefore the data regarding the validity of this test in patients with colorectal liver metasta‐
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20 – 29% Segmentectomy
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liver parenchyma. The presence of SOS in these patients was independently associated with
an ICGR-15 of >10%. It is of note that these patients experienced an increased risk of peri-
operative complications (40% vs. 6.3%; p=0.026) and a longer mean hospital stay (17 days vs.
11 days; p = 0.006).[59] Experimental studies have also suggested that ICGR-15 may be a
useful measure of hepatocyte function in the context of hepatic steatosis.[74] In a series of
101 patients undergoing liver resection for colorectal metastases Klinger et al reported that
the use of preoperative chemotherapy (n=83; all regimens) was associated with a longer
ICGR-15 (7.3% vs. 3.5%; p = 0.005). Similarly those who had received pre-operative chemo‐
therapy were more likely to have an ICGR-15 ≥ 10% (27.7% vs. 0%; p=0.011) and this was
associated with an increased rate of post-operative complications (39.1% vs. 12.8%; p=0.005).
No attempt was made in this study to correlate ICGR-15 values with histological changes
within the liver parenchyma.[75]
The LiMAx test has recently been described as an alternative means of assessing the hepatic
functional reserve. This test measures the cytochrome P450 mediated metabolism of 13C la‐
belled methacetin into acetaminophen and 13CO2 which is exhaled. The test measures
changes in the ratio of exhaled 13CO2 : 12CO2 over a 60 minute period – the greater the 13CO2
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that low post-operative LiMAx values (<80μg/kg/h) are correlated with an unacceptable risk
of post-operative morbidity. On the basis of this they have proposed an algorithm to deter‐
mine the safety of liver surgery based upon pre-operative measurement of the LiMAx to cal‐
culate the likely post-operative LiMAx using CT volumetric calculations of the FLR. This
strategy has not however been proven in an independent prospective cohort and therefore
cannot currently be recommended for routine clinical use.[77]
A final technique for assessing the functional reserve of the liver is hepatobiliary scintigra‐
phy using 99mTc-mebrofenin. Following injection 99mTc-mebrofenin is taken up by hepato‐
cytes and excreted directly into the biliary system without prior intracellular metabolism in
a similar manner to ICG. The hepatic uptake and excretion of 99mTc-mebrofenin is deter‐
mined using images obtained with a gamma camera and from this it is possible to determine
the total liver uptake, corrected for body surface area, as a %/min/m2 of the total injected
dose (referred to as the total liver function or TL-F). In addition the FLR uptake function
(FLR-F) can be calculated as a function of the TL-F based on uptake in the calculated.[78]
De Graaf et al. reported a series 55 patients judged to be at high risk of post-operative com‐
plications following liver resection assessed with 99mTc-mebrofenin scintigraphy prior to liv‐
er resection. They demonstrated that TL-F was significantly reduced in those patients with
background parenchymal disease (7.4 vs. 8.5 %/min/m2; p=0.007). In addition the FLR-F was
significantly lower in those patients who developed PHLF as compared to those who did
not (2.2 vs. 4.3%/min/m2; p=0.001).[79] Whilst this technology needs further evaluation in
prospective studies it is likely that the emerging ability to perform single photon emission
computed tomography (SPECT) thereby enabling quantification of tracer compound activity
in combination with standard CT will lead to renewed interest in the technique.
At present none of these technologies have been adequately characterised in patients with
colorectal metastases undergoing liver resection. Whilst they undoubtedly have potential
merit in identifying those patients with an impaired hepatocyte mass it is not known wheth‐
er the information they add is superior to that obtained standard clinical and radiological
assessment. This must be established before the routine integration of these technologies in‐
to the assessment of this cohort of patients can be recommended.
4. Surgical management of the chemotherapy injured liver
When either clinical suspicion or pre-operative imaging suggest the presence of a chemo‐
therapy induced injury to the liver it may no longer be possible to resect all metastatic dis‐
ease whilst maintaining an adequate FLR to avoid the risk of liver failure. In this situation
two key surgical strategies have been described to reduce the risk of surgery i.e. pre-opera‐
tive portal vein embolisation and two-stage hepatectomy and these are discussed in more
detail below.
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4.1. Pre-operative portal vein embolisation
Portal vein embolisation (PVE) is a particularly useful technique in patients who have dis‐
ease which is technically resectable in a single operation but where so doing would lead to a
compromised FLR. As early as 1920 Rous and Larimore observed that if they ligated a single
branch of the portal vein in a rabbit there was atrophy of the ipsilateral lobe and hypertro‐
phy of the contralateral lobe.[80] As a clinical technique PVE was initially described by Ki‐
noshita et al. in 1986 as a means of limiting the extension of tumour thrombus in patients
with hepatocellular carcinoma.[81] Subsequently in 1990 Makuuchi et al. demonstrated the
safety and efficacy of this technique as a means of increasing the FLR in a series of 14 pa‐
tients undergoing resection of hilar cholangiocarcinoma.[82] In a prospective study Farges et
al. performed CT volumetry on patients undergoing pre-operative PVE and demonstrated
that in those patients with no underlying parenchymal disease the typical increase in FLR
was 16% whereas in those with chronic liver disease the typical increase in FLR was 9%.[83]
In 2010 Wicherts et al. reported a retrospective series of 67 patients who underwent liver re‐
section for colorectal metastases after pre-operative PVE with a cohort of 297 patients who
did not receive PVE. The authors observed that those patients treated with pre-operative
PVE demonstrated a significantly higher complication rate (55.5% vs. 41.1%; p = 0.035) al‐
though there was no difference in surgical mortality between groups. Whilst this difference
in morbidity is striking it is difficult to interpret since whilst all patients in the study under‐
went a major hepatectomy (≥3 Couinaud segments) 54% of those in the PVE group under‐
went a right trisectionectomy as compared to only 28% in the control group. What was
striking in this study however was that 32 of the patients treated with PVE did not proceed
to surgery and amongst these patients there were no 3 year survivors as compared to a 3
year survival rate of 44% in those who did undergo surgery.[84]
A similarly designed study by Pamecha et al. compared the outcome of 36 patients treated
with pre-operative PVE with 65 patients who did not receive PVE all of whom had a diagno‐
sis of colorectal metastases. Of the 36 patients treated with PVE 12 did not progress to sur‐
gery and had a median survival of 14 months as compared to 42 months in those who did
progress to surgery (p<0.0001). Again there was a tendency to higher morbidity in the PVE
group (36% vs. 20%) but in a similar manner to the study of Wicherts et al. more of these
patients had undergone a right trisectionectomy (22% vs. 11%).[85]
The most important finding in both of these series is that nearly a third of all patients select‐
ed to undergo pre-operative portal vein embolisation do not undergo subsequent surgery
and this is primarily a consequence of disease progression.[84, 85] It is likely that the most
important factor driving this disease progression is the compensatory increase in arterial
blood flow which occurs in the embolised lobe.[86] The blood supply of colorectal metasta‐
ses is predominantly derived from the hepatic artery[87] and it is probable that the increase
in arterial flow results in increased oxygen and nutrient supply to the tumour. In addition
following PVE there is an increase in the hepatic production of a wide variety of cytokines,
growth factors and other humoral factors that mediate liver regeneration and it may be that
these also contribute to the progression of metastatic disease.[88, 89]
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computed tomography (SPECT) thereby enabling quantification of tracer compound activity
in combination with standard CT will lead to renewed interest in the technique.
At present none of these technologies have been adequately characterised in patients with
colorectal metastases undergoing liver resection. Whilst they undoubtedly have potential
merit in identifying those patients with an impaired hepatocyte mass it is not known wheth‐
er the information they add is superior to that obtained standard clinical and radiological
assessment. This must be established before the routine integration of these technologies in‐
to the assessment of this cohort of patients can be recommended.
4. Surgical management of the chemotherapy injured liver
When either clinical suspicion or pre-operative imaging suggest the presence of a chemo‐
therapy induced injury to the liver it may no longer be possible to resect all metastatic dis‐
ease whilst maintaining an adequate FLR to avoid the risk of liver failure. In this situation
two key surgical strategies have been described to reduce the risk of surgery i.e. pre-opera‐
tive portal vein embolisation and two-stage hepatectomy and these are discussed in more
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safety and efficacy of this technique as a means of increasing the FLR in a series of 14 pa‐
tients undergoing resection of hilar cholangiocarcinoma.[82] In a prospective study Farges et
al. performed CT volumetry on patients undergoing pre-operative PVE and demonstrated
that in those patients with no underlying parenchymal disease the typical increase in FLR
was 16% whereas in those with chronic liver disease the typical increase in FLR was 9%.[83]
In 2010 Wicherts et al. reported a retrospective series of 67 patients who underwent liver re‐
section for colorectal metastases after pre-operative PVE with a cohort of 297 patients who
did not receive PVE. The authors observed that those patients treated with pre-operative
PVE demonstrated a significantly higher complication rate (55.5% vs. 41.1%; p = 0.035) al‐
though there was no difference in surgical mortality between groups. Whilst this difference
in morbidity is striking it is difficult to interpret since whilst all patients in the study under‐
went a major hepatectomy (≥3 Couinaud segments) 54% of those in the PVE group under‐
went a right trisectionectomy as compared to only 28% in the control group. What was
striking in this study however was that 32 of the patients treated with PVE did not proceed
to surgery and amongst these patients there were no 3 year survivors as compared to a 3
year survival rate of 44% in those who did undergo surgery.[84]
A similarly designed study by Pamecha et al. compared the outcome of 36 patients treated
with pre-operative PVE with 65 patients who did not receive PVE all of whom had a diagno‐
sis of colorectal metastases. Of the 36 patients treated with PVE 12 did not progress to sur‐
gery and had a median survival of 14 months as compared to 42 months in those who did
progress to surgery (p<0.0001). Again there was a tendency to higher morbidity in the PVE
group (36% vs. 20%) but in a similar manner to the study of Wicherts et al. more of these
patients had undergone a right trisectionectomy (22% vs. 11%).[85]
The most important finding in both of these series is that nearly a third of all patients select‐
ed to undergo pre-operative portal vein embolisation do not undergo subsequent surgery
and this is primarily a consequence of disease progression.[84, 85] It is likely that the most
important factor driving this disease progression is the compensatory increase in arterial
blood flow which occurs in the embolised lobe.[86] The blood supply of colorectal metasta‐
ses is predominantly derived from the hepatic artery[87] and it is probable that the increase
in arterial flow results in increased oxygen and nutrient supply to the tumour. In addition
following PVE there is an increase in the hepatic production of a wide variety of cytokines,
growth factors and other humoral factors that mediate liver regeneration and it may be that
these also contribute to the progression of metastatic disease.[88, 89]
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In summary PVE is a potentially useful technique for increasing the FLR in patients in
whom this is likely to be compromised there is a significant risk that the procedure will re‐
sult in disease progression rendering the patient inoperable and therefore must not be em‐
barked upon lightly.
4.2. Two-stage hepatectomy
For a proportion of patients presenting with bilobar disease it is not possible to clear the en‐
tire tumour burden by an extended resection alone (e.g. right trisectionectomy) but rather it
is necessary to combine an anatomical resection (e.g. or the right lobe) with multiple meta‐
stectomies from the contralateral lobe potentially resulting in an insufficient FLR, particular‐
ly in patients with a background liver injury (Figure 2). In such circumstances a PVE alone
would not be appropriate because of the significant risk of tumour progression in the FLR
and therefore a two stage resection should be considered. In the scenario described above
this would typically consist of an initial operation to clear the left liver of tumour using mul‐
tiple metastectomies followed several weeks later by a right hepatectomy. If it was felt at the
time of the primary operation that the hypertrophy induced by surgery alone would not
leave an adequate FLR for the second operation then it may be desirable to perform either
intra-operative ligation of the right portal vein or post-operative percutaneous portal vein
embolisation.[90] In this situation it is the authors preference to perform the latter procedure
thereby avoiding unnecessary dissection of the hilum prior to right hepatectomy.
Wicherts et al. reported the outcomes of 59 patients considered to be inoperable using a sin‐
gle stage procedure who were selected for a two stage approach. All of these patients under‐
went a primary surgical procedure which in the majority of cases consisted of a minor
hepatectomy (<3 Couinaud segments resected) the aim of which was to clear the left liver of
tumour. Subsequently 42 patients underwent a second procedure which was typically a ma‐
jor hepatic resection (≥3 Couinaud segments) and typically this took place 3 months after the
initial surgical procedure. It is of note that 17 patients selected for this approach did not un‐
dergo a second procedure primarily as a consequence of disease progression. The overall 5
year survival in this series was 31% when analysed on an intention to treat basis and this
did not differ, in a statistically significantly manner, from patients undergoing a single stage
hepatectomy over the same period in the authors unit.[91]
More recently Narita et al. reported the outcome of 79 patients treated using a two stage ap‐
proach. After the initial surgical procedure 75 of these patients were considered appropriate
to proceed to the second operation although the majority (92%) were thought to require por‐
tal vein embolisation to facilitate this. Of that cohort of patients 61 (78% of the original co‐
hort) eventually underwent a successful second operation. The main reasons for patients not
proceeding to a second procedure were tumour progression in 10 cases and insufficient re‐
generation of the FLR in a further 5 cases. It is of note that almost 1:6 of the patients who
underwent a second surgical procedure were found to have new disease in the previously
cleared FLR although this was dealt with at the time of surgery in all cases. In those patients
who underwent a successful two stage resection the overall 5 year survival was 32%. Of the
61 patients who were treated successfully by a two stage approach 11 went on to have a sub‐
Hepatic Surgery410
sequent resection of lung metastases although this had no effect on overall survival when
compared to the 50 patients who did not.[92]
Figure 2. Typical MRI scan of patient with bilobar disease who would be considered suitable for a two staged ap‐
proach to liver resection. With this distribution of disease a one stage approach would not leave an adequate FLR.
In a similar manner to PVE alone a two stage hepatectomy is a major undertaking and be‐
fore embarking on this both surgeon and patient should be aware that there is a significant
risk of not being able to complete the planned course of treatment. Despite this it does pro‐
vide an opportunity to achieve a meaningful long term survival in selected patients with ad‐
vanced disease.
5. The long term consequences of chemotherapy associated liver injury
Whilst the primary focus of this chapter is on the effects of chemotherapy associated liver
injury on the surgical management of patients with colorectal liver metastases it would not
be complete without some mention of the emerging evidence that this injury may have an
effect on long term disease specific outcomes. Tamandl et al. have suggested that the pres‐
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proach to liver resection. With this distribution of disease a one stage approach would not leave an adequate FLR.
In a similar manner to PVE alone a two stage hepatectomy is a major undertaking and be‐
fore embarking on this both surgeon and patient should be aware that there is a significant
risk of not being able to complete the planned course of treatment. Despite this it does pro‐
vide an opportunity to achieve a meaningful long term survival in selected patients with ad‐
vanced disease.
5. The long term consequences of chemotherapy associated liver injury
Whilst the primary focus of this chapter is on the effects of chemotherapy associated liver
injury on the surgical management of patients with colorectal liver metastases it would not
be complete without some mention of the emerging evidence that this injury may have an
effect on long term disease specific outcomes. Tamandl et al. have suggested that the pres‐
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ence of the histological features of SOS within the resected liver of patients with colorectal
liver metastases may have a negative impact on long term disease specific survival. In par‐
ticular patients with SOS demonstrated a significantly poorer 3 year progression free surviv‐
al (6.7% vs. 22.7%; p=0.006) a finding which was upheld on multivariate analysis (Hazard
Ratio 2.20; p=0.006). Specifically patients with SOS demonstrated a higher rate of intra-hep‐
atic recurrence following surgery (66.7% vs. 30.5%; p=0.003) and not surprisingly this was
associated with an increased risk of early all cause mortality on multivariate analysis (Haz‐
ard Ratio 2.90; p<0.001).[61]
A major criticism of the study of Tamandl et al. is that it includes only small numbers of pa‐
tients (n=20 with SOS) and therefore it is difficult to draw definitive conclusions.[61] None
the less a recent paper by Vreuls et al. has reported that the development of SOS may be
associated with a poorer tumour response to Oxaliplatin based chemotherapy which the au‐
thors propose may be a consequence of tissue hypoperfusion leading to diminished leading
to impaired delivery of chemotherapy to the tumour.[93] An alternative explanation may be
that SOS is associated with increased expression of the chemokine CCL20 within the liver
which is known to act as a chemo-attractant for colorectal cancer cells.[94] At the same time
as this is occurring within the liver Oxaliplatin chemotherapy also results in increased ex‐
pression of the CCL20 receptor CCR6 within colorectal liver metastases thereby increasing
the migration and proliferation of tumour cells in response to CCL20.[95, 96] It may there‐
fore be that the presence of SOS leads to the establishment of an autocrine signalling loop
which favours the further growth and development of colorectal liver metastases.[97]
This emerging evidence is clearly a cause for concern and, if proven to be true, would add
further impetus to the drive to develop strategies for the prevention of liver injury in pa‐
tients being treated with systemic chemotherapy.
6. Conclusion
Advances in chemotherapy over the last decade or so have revolutionised the care for pa‐
tients with colorectal liver metastases with the end result that patients who historically
would have been considered inoperable are now able to undergo potentially curative surgi‐
cal resection. The pay off for this advance has been the development of a chemotherapy as‐
sociated injury to the liver the nature of which is determined the specific regimens used.
There is no specific test that is able to reliably detect the presence of an injured liver paren‐
chyma and ultimately surgeons must maintain a high index of suspicion for its presence
particularly in patients who have received multiple cycles of chemotherapy over a pro‐
longed period of time. When a liver injury is present it is important that the surgical ap‐
proach is considered carefully and makes allowances for the possibility of an impaired FLR
with a subsequent risk of post operative liver failure. In those situations where there is a
high risk of an insufficient FLR it may be appropriate to utilise techniques such as PVE or
two stage hepatectomy although there is a risk with both these techniques of treatment fail‐
ure as a consequence of disease progression.
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1. Introduction
Hepatic tumors in children are relatively rare, accounting for 1 to 4% of all pediatric solid tu‐
mors. [1] Primary liver masses constitute the third most common group of solid abdominal tu‐
mors of childhood [2] with an incidence of 0.4 to 1.9 per million children each year. [3,4]
Liver masses in children can be malignant, benign, or indeterminate and they are a diverse
group of epithelial and mesenchymal tumors whose incidence can vary considerably with
patient age. [5] Two thirds of liver tumors in children are malignant. [6] Unlike liver tumors
in adults, in which the predominant histology is hepatocellular carcinoma, hepatoblastoma
accounts for two thirds of liver tumors in children. [7] Other liver malignancies in children
include sarcomas, germ cell tumors, and rhabdoid tumors, as well as the more familiar hep‐
atocellular carcinoma. Benign tumors of the liver in children include vascular tumors, ha‐
martomas, adenomas, and focal nodular hyperplasia. The histology and anatomy of a
pediatric liver tumor guides the treatment and prognosis. [8]
In this chapter we outline the epidemiology, etiology, pathology, clinical presentation, diag‐
nosis and management of each of the most important types of liver tumor. Also aspects of
the surgical anatomy and resection techniques and other ways to improve ressecability in
liver tumors in childhood will be described such as portal vein thrombosis, chemotherapy
and transarterial chemoembolization (TACE).
2. Epidemiology
The incidence of hepatic tumors in childhood is consistently quoted from many series as be‐
ing in the region of 0.5-2.5 per million population [9] and approximately 100–150 new cases
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unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
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of liver tumors are diagnosed in the U.S. annually. [7] Two thirds of liver tumors in children
are malignant. [6] acounting for slightly more than 1% of all pediatric malignancies and
among those there is a male preponderance of 1.8 : 1. [7,10]
Hepatoblastoma presents in a younger age group, being a uncommon diagnosis over the
age of 4 years. Hepatocellular carcinoma has its peak onset in early adolescence, although
the range is wide. The older age at onset for hepatocarcinoma may well reflect its close asso‐
ciation with other underlying disease processes. [10]
There are several suggestions that the incidence of malignant liver tumors is increasing in
the U.S. Surveillance, Epidemiology, and End Results data from 1972–1992 showed a 5% an‐
nual increase. [7] Liver cancer represented 2% of all malignancies in infants in the early
1980s with the incidence doubling to 4% 10 years later. [11]
At a population level, there has been a dramatic increase in survival in countries in which a
modern health system has been implemented, although the increased survival is lower for
hepatocarcinoma in comparison with hepatoblastomas. [10] According to Litten & Tomlin‐
son [8], it has been suggested that the improvements in technology, care, and outcomes for
premature infants have been driving forces in the increase of the incidence in hepatic tu‐
mors. Hepatoblastoma is more commonly diagnosed in children with a history of prematur‐
ity than in full-term infants. Interestingly, those tumors that arise in ex-premature infants do
not present at a younger age than those of term infants. [8]
3. Hepatoblastoma
Hepatoblastoma is the most common malignant tumor of the liver in children and is an em‐
bryonal tumor in the classic sense of incomplete differentiation; [12] accounts for 1% of all
pediatric malignancies and for 79% of all liver cancers in children under age. [13] Its overall
incidence is 0.5–1.5 per million, however the incidence in children under the age of 18
months is 11.2 cases per million. [14]
Hepatoblastoma is diagnosed in very young children with a peak in the newborn period re‐
flecting those tumors that developed prenatally, and an overall median age at diagnosis of
18 months; 90 percent of cases are manifest by the fourth birthday, several have been
present at birth, and there is an hypothesized association with prematurity. [15] Only 5% of
new hepatoblastoma cases are diagnosed in children >4 years of age. [8]
The increased incidence of HB in children born before 28 weeks gestation (with birth weight
<1500 g) compared with term gestations, may be explained by the exposure of rapidly divid‐
ing hepatoblasts to endogenous metabolites and hormones as well as exogenous chemicals
that would normally be eliminated via the placenta. Inefficiency and compromise of the im‐
mature detoxification mechanisms could produce multiple somatic mutations and epigenet‐
ic (ie, methylation) modifications of the genome. [16, 17]
For poorly understood reasons, hepatoblastoma occurs in males significantly more frequent‐
ly than it does in females with a male:female ratio that ranges from 1.2 to 3.6:1. [14] Most
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commonly, these tumors present in the right lobe of the liver. [18] There is an increased inci‐
dence of hepatoblastoma in Beckwith-Wiedemann Syndrome, which has a relative risk of
2280 suggesting a role for genetic aberrations of chromosome 11 in the pathogenesis of hep‐
atoblastoma,[19, 20] hemihypertrophy, and familial adenomatous polyposis (FAP) witch has
a relative risk of 1220 suggesting a role for aberrations of chromosome 5 in the pathogenesis.
[21] Screening for cases in FAP kindred families is recommended by testing for germline
mutations in the APC tumor suppressor gene. [22, 23] Inactivation of the APC tumor-sup‐
pressor gene (found on chromosome 5) is found in 67–89% of sporadic hepatoblastoma [24,
25] This gene is known to regulate B-catenin and modulate the wnt signaling pathway, sug-
gesting a role for this signaling pathway in the development of hepatoblastoma. [26] Addi‐
tional biologic markers may include Trisomy 2, 8, and 20 and translocation of the NOTCH2
gene on chromosome 1. [27]
Many etiological factors have been linked with the development of malignant hepatic tu‐
mors in childhood (Table 1). Broadly speaking, genetic influences are particularly important
in the development of hepatoblastoma, whereas environmental factors and coexisting liver
disease are strongly associated with hepatocellular carcinoma. [10]
Hepatoblastoma Hepatocellular carcinoma
Beckwith-Wiedemann Syndrome Hepatitis B
Hemihypertrophy Hepatitis C
Familial adenomatous polyposis (FAP) Hereditary tyrosinemia
α1-Antitrypsin deficiency
Gardner syndrome Cirrhosis secondary to biliary atresia
Glycogen storage disease type I Glycogen storage disease type I
Trisomy 18 Neurofibromatosis
Fetal alcohol syndrome
Prematurity and low birth weight Familial adenomatous polyposis






Paternal exposure to: Fanconi anemia
Metals
Meckel diverticulum
Table 1. Conditions associated with hepatoblastoma and hepatocellular carcinoma.
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Hepatoblastomas are composed of cells resembling the developing fetal and embryonic liv‐
er, hence the classification as an embryonal tumor. Indeed, the cells comprising hepatoblas‐
toma mark similarly to hepatic stem cells, defined as pluripotent hepatoblasts capable of
differentiating into hepatocytes or cholangiocytes. [28, 29]
According to the Childhood Epithelial Liver Tumors – International Criteria (CELTIC) group,
the pathology of hepatoblastoma is classified into four groups based on the work of Weinberg
and Finegold: fetal, embryonal, macrotrabecular and small-cell undifferentiated. [10]
Histologically,  these  tumors  can  be  divided  into  epithelial  (56%)  or  mixed  epithelial/
mesenchymal tissue.  The epithelial  group is  further  subdivided into fetal  (31%),  embry‐
onal  (19%),  macrotrabecular  (3%)  and small-cell  undifferentiated subtypes  (3%).  Thema‐
jority  of  hepatoblastomas  is  epithelial  and  consist  of  a  mixture  of  embryonal  and  fetal
cell types (Fig. 1). [8, 30]
Figure 1. Distribution of histologic subtypes of hepatoblastoma. The majority are epithelial and consist of embryonal
and fetal cell types. Pure fetal histology accounts for approximately 7% of hepatoblastomas and is associated with a
favorable prognosis. Small cell undifferentiated hepatoblastoma accounts for 5% of hepatoblastoma cases and is as‐
sociated with a poor prognosis. [8]
Of the five histologic subtypes—pure fetal, embryonal, mixed epithelial, mesenchymal/
macrotrabecular, and small cell undifferentiated—fetal carries the most favorable prognosis.
[31] Approximately 5% of hepatoblastomas are of the small cell undifferentiated subtype.
This subtype is associated with a worse prognosis. [32] In the mixed epithelial/ mesenchy‐
mal type, the presence of mesenchymal elements is associated with improved prognosis and
the most common mesenchymal elements are cartilage and osteoid. [33]
Hepatoblastomas usually presents as a palpable asymptomatic mass with abdominal disten‐
sion. [10] Less common presentations include weight loss, anorexia, emesis and abdominal
pain and usually indicate advanced disease. [34] One of the more unusual presenting features
of hepatoblastoma is its association with sexual precocity due to the release of human chorion‐
ic gonadotropic hormone (β-HCG) by the tumor. Osteoporosis is said to occur in up to 20% of
the cases and when severe can lead to bone fractures and vertebral compression. [35] The tu‐
mor may rupture spontaneously, producing an acute abdomen and hemoperitoneum. [10]
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Approximately 90% of patients demonstrate elevated serum AFP levels and there is a corre‐
lation between AFP levels and extent of disease. [36]
The right lobe of the liver is most commonly involved with disease but in 35% of patients
there is bilateral disease. [37] Distant metastasis are present in 20% of patients at the time of
diagnosis with the lung being the most common site of metastasis; other common sites are
the brain and bone and metastasis occur more commonly with disease relapse. [38]
Hepatoblastoma (%) Hepatocellular carcinoma (%)
Abdominal mass 71 58





Table 2. Signs and symptoms of liver tumors in children. [10]
Overall, the diagnosis is based on laboratory tests (such as full blood count, liver function
tests, α-Fetoprotein – AFP and other markers), imaging (abdominal radiography, ultraso‐
nography, computer tomography, magnetic resonance imaging, hepatic angiography, chest
radiography and positron-emission tomography – PET) and biopsy.
The full blood count can reveal anemia (usually normocytic, normochromic) in at least 50% of
children with hepatoblastoma. [13, 39] The platelet count is also often abnormal with up to one-
third of patients demonstrating thrombocytosis and fewer patients having thrombocytopenia.
Thrombocytosis is thought to be related to increased levels of circulating thrombopoietin. [40]
Liver function tests are commonly normal in hepatoblastoma. [10] The serum alpha-fetopro‐
tein (AFP) level is elevated in 90% of children with hepatoblastoma and tumors that fail to
express AFP at diagnosis are felt to be biologically more aggressive. [41, 42] AFP levels must
be interpreted with caution because AFP is commonly elevated in normal neonates up to 6
months of age and may be slightly elevated in other tumors, as well as after hepatic damage
or during regeneration of liver parenchyma.
The imaging study is important in evaluation liver neoplasms. CT, MRI and ultrasound are
the most commonly used modalities for pediatric doctors in their medical researches as well
as their clinical practice. Ultrasound is accepted as a first-line imaging method because of its
less irradiation, greater convenience and better real-time. [43] Ultrasound is extremely val‐
uable in detecting much smaller lesions, especially in detecting fluid and blood-flow in a le‐
sion, and it also can evaluate the hepatic vascular anatomy.[44] As a rule, the initial
diagnosis of live tumor is usually made by the abdominal ultrasound examination, which
will identify the liver as the organ of origin. Hepatoblastoma are seen as a hyperechoic, sol‐
id, intrahepatic mass on US. [45]
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Both CT and MRI define the extent of tumor involvement showing its segmental extension
and its proximity to the portal vein, to help determine the resectability. Evaluation with CT
demonstrates a delineated hypoattentuated mass compared with the surrounding normal
tissue and allows identification of calcifications. [46] The use of contrast allows assessment
of vascular involvement by the tumor. Combined MRI and contrast enhanced MR-angiogra‐
phy gives the best evaluation of the vascular structures and the tumor blood supply, and
this best enables the planning of a resection. A diagnostic biopsy is recommended in all chil‐
dren with a suspected hepatoblastoma. Given the potential side effects of chemotherapy, it
is not a good clinical practice to start therapy in a patient in the absence of a tissue diagnosis.
Additionally, it is necessary to rule out HCC. Although it is rare, HCC have been reported in
children under the age of three and they carry a worse prognosis. [47]
Figure 2. CT scan of an infant with a large central hepatoblastoma.
Large multinodular expansile masses, hepatoblastomas radiographically appear well de‐
marcated from the normal liver but are not encapsulated. They may invade hepatic veins,
disseminate to the lungs, or penetrate the liver capsule to reach contiguous tissues. [12]
Historically, North Americans have staged liver tumors similar to other solid tumors, stag‐
ing system continues to be used by the children’s oncology group (COG) and depends upon
extent of surgery at the time of initial diagnosis.
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Relative number of patients presenting in each stage in the COG trial 9645 (1999–2003) is as
follows: Stage I (22%) indicates complete resection at diagnosis, Stage II (0.5%) microscopic
residual after attempted complete resection at diagnosis, Stage III (53%) biopsy at diagnosis
with gross residual tumor, and Stage IV (23%) metastatic disease at diagnosis.[48, 49] The
traditional COG staging system has been criticized for being rather subjective, depending to
a large extent on the surgeon rather than the tumor.[12, 50] To address this concern specific
surgical guidelines have been proposed by the COG liver tumor committee which define the
anatomic and biologic characteristics of a tumor for which resection at diagnosis is recom‐
mended. In addition the upcoming COG hepatoblastoma (AHEP 0731) protocol will add a
risk-based stratification of treatment as follows: low risk (Stage I/II lacking any unfavorable
biologic feature); intermediate risk (Stage III or Stage I/II with small cell undifferentiated his‐
tology); and high risk (Stage IV or Stage I/II/III with AFP <100 at diagnosis). [12]
3.1. Stage Information
There  are  two  standard  surgical  staging  systems  for  pediatric  liver  tumors.  The  Child‐
hood  Liver  Tumour  Strategy  Group  (SIOPEL)  uses  a  presurgical-based  staging  system,
while  the  Children's  Oncology  Group  (COG)  uses  a  postsurgical-based  staging  system.
The staging systems support different treatment strategies. The presurgical staging system
is  used with neoadjuvant chemotherapy followed by definitive surgery (with the excep‐
tion of Pretreatment Extent of Disease [PRETEXT] stage 1), while the postsurgical staging
system has surgery as the initial strategy.
Both systems are used in the United States. In a retrospective comparison of the two stag‐
ing systems at diagnosis using data from patients entered on a North American random‐
ized  trial,  both  staging  systems  predicted  outcome.  The  presurgical  PRETEXT  staging
system may add prognostic information for patients staged postsurgically at stage 3. [51]
The COG is investigating the use of PRETEXT stage before and after chemotherapy to de‐
termine the optimal surgical approach. [52]
3.2. Presurgical Staging for Hepatoblastoma and Hepatocellular Carcinoma
The PRETEXT staging system for hepatoblastoma categorizes the primary tumor based on
extent of liver involvement at diagnosis. The staging system was devised for use in an inter‐
national hepatoblastoma treatment program in which only children with PRETEXT stage 1
hepatoblastoma undergo initial resection of tumor. All others are treated with chemothera‐
py prior to attempted resection of the primary tumor. The liver tumors are staged by inter‐
pretation of computerized tomography or ultrasound with or without additional imaging
by magnetic resonance. The presence or absence of metastases is noted in addition to the
PRETEXT stage, but does not alter the PRETEXT stage. Tumor involvement of the vena
cava, hepatic veins, and portal vein, and extrahepatic extension are also noted.
The imaged liver is divided into four quadrants and involvement of each quadrant with tumor
is determined. Stage increases and prognosis decreases as the number of quadrants radiologi‐
cally involved with tumor increases from one to four. [53, 50] Experienced radiologist review is
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important because it may be difficult to discriminate between real invasion beyond the ana‐
tomic border of a given sector and displacement of the anatomic border. [50, 43]
Figure 3. Pretext stage 1 - Tumor involves only one quadrant; three adjoining liver quadrants are free of tumor.
[http://www.cancer.gov/PublishedContent/MediaLinks/308970.html]
Figure 4. Pretext stage 2 - Tumor involves one or two quadrants; two adjoining quadrants are free of tumor. [http://
www.cancer.gov/PublishedContent/MediaLinks/308970.html]
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Figure 5. Pretext stage 3 - Tumor involves three quadrants and one quadrant is free of tumor or tumor involves two
quadrants and two nonadjoining quadrants are free of tumor. [http://www.cancer.gov/PublishedContent/Medi‐
aLinks/308970.html]
Figure 6. Pretext stage 4 - Tumor involves all four quadrants; there is no quadrant free of tumor. [http://
www.cancer.gov/PublishedContent/MediaLinks/308970.html]
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3.3. Treatment - Chemotherapy
During the past 30 years, there has been an improved survival for patients with HB based
on refinements in surgical techniques, a better understanding of the hepatic segmental anat‐
omy, advances in chemotherapy, and the advent of liver transplantation as a therapeutic
modality for patients with unresectable disease. HB is a surgical neoplasm and only com‐
plete tumor resection results in a realistic hope for cure. Long-term disappearance of tumor
with complete remission with chemotherapy alone has been anecdotally observed. Howev‐
er, chemotherapy is a cornerstone in the management of HB. [55]
Although chemosensitivity varies between patients, it is an essential component of the man‐
agement and complementary to radical surgical resection to affect a cure. In general, surgeons
agree that preoperative chemotherapy helps to reduce the size of most tumors and obtains bet‐
ter demarcation between the tumor and surrounding liver tissue. [56, 57, 58] Consequently, tu‐
mors are more likely to be completely resected without increasing perioperative morbidity or
mortality. It is also speculated that residual microscopic disease may behave more aggressive‐
ly under the influence of hepatotrophic factors stimulating liver regeneration if preoperative
chemotherapy has not been used. [58] On the other hand, von Schweinitz et al. [59] have shown
that there is little to be gained from prolonging chemotherapy beyond the planned treatment
regimen, which incurs the risk of developing chemoresistance. [55]
Even if unresectable at diagnosis, most hepatoblastomas are unifocal and chemosensitive,
especially to ‘‘platinum’’ derivative chemotherapeutic agents. With the routine addition of
cisplatin to the chemotherapy in the late 1980s, overall survival in hepatoblastoma increased
from 30% to 70%. [60, 61] Twenty years later, cisplatin remains the backbone of the chemo‐
therapy regimen. In current trials by COG (America), SIOPEL (Europe, South America),
GPOH (German), and JPLT (Japan) chemotherapeutic agents used in combination with cis‐
platin have differed slightly. Although most use some form of doxorubicin, COG currently
recommends Cisplatin/5FU/Vincristin (C5V) for low-risk tumors, C5V+Doxorubicin for in‐
termediate risk, and hopes to investigate new agents with up-front window therapy in high-
risk tumors. [48, 49] Irinotectan, with or without doxorubicin, has been used in both
America and Europe for patients with relapse. [62] Because tumor cells may become resist‐
ant to chemotherapy over prolonged exposure [63] and because cumulative chemotherapy
toxicity may be unwarranted, prolonged (44 cycles) courses of neoadjuvant chemotherapy
are discouraged by all study groups. Early referral for complex surgical planning may be in‐
dicated for large invasive tumors potentially requiring transplantation. [12]
Two principle strategies exist. In the United States, tumor resection at diagnosis, whenever
prudently possible, has been advocated with the argument that toxicity of chemotherapy
can be reduced by avoidance of unnecessary neoadjuvant chemotherapy, that some tumors
may become resistant to prolonged courses of chemotherapy [64] and the highest survival
rates have historically been observed in patients with initially resected tumors—although
these tumors also tend to be the smaller more favorable tumors. Proposed COG Surgical
guidelines advocate definitive surgical resection at diagnosis for localized, unifocal PRE‐
TEXT I and II tumors followed by chemotherapy. When the tumor is large (PRETEXT III or
IV), multicentric, shows radiographic evidence of portal or hepatic venous invasion, or pul‐
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monary metastatic lesions the chance of curative resection may be improved neoadjuvant
chemotherapy and delayed primary resection. Alternatively, the SIOPEL study group dis‐
courages resection of hepatoblastoma at diagnosis favoring neoadjuvant chemotherapy in
all patients with the argument that the chemotherapy renders most tumors smaller, better
demarcated, and more likely to be completely resected, and that the toxicity of neoadjuvant
chemotherapy is offset by the increased rates of surgical resectability. Both COG and SIO‐
PEL have invested considerable effort in attempts to decrease the significant ototoxiciy at‐
tendant to the use of cisplatin based chemotherapy in young infants and toddlers. [12]
In the Intergroup Hepatoblastoma/ Hepatocellular Carcinoma Study, 28% of HB tumors were
completely resected at diagnosis (Stage I) and 4% (Stage II) were incompletely excised. These
patients had a 91% and 100% 5-year survival, respectively. However, the surgical guidelines of
the protocol lacked clear recommendations regarding which tumor should or should not be re‐
sected at diagnosis. The study compared the use of cisplatin and doxorubicin in one treatment
arm to cisplatin, vincristine, and 5-fluorouracil (5-FU) in the other arm. The overall 3- year sur‐
vival rates were 63% and 71%, respectively. [65] Although the difference between the groups
was not significant, the cisplatin/ doxorubicin group had a higher toxicity rate. A significant re‐
sponse to preoperative chemotherapy was observed in Stage III patients allowing complete tu‐
mor resection in 70–80% of these cases. Pre-operative chemotherapy had no effect on operative
mortality; however, increased transfusion requirement and a higher operative morbidity was
observed in patients that received chemotherapy preoperatively. [55]
The studies coordinated by the SIOPEL group have concentrated on using preoperative che‐
motherapy. [56, 66] In SIOPEL-1, all patients were treated preoperatively with four courses
of cisplatin and doxorubicin (PLADO); surgical resection was followed by two more courses
of chemotherapy. If the tumor was judged unresectable by imaging after four courses of che‐
motherapy, attempting surgical resection was delayed until after the sixth course. If the tu‐
mor remained localized to the liver but was still unresectable, liver transplantation was
recommended as the primary operative procedure if some response to chemotherapy had
been obtained in the absence of extrahepatic tumor extent or metastatic disease. The SIO‐
PEL-2 pilot study [67]was designed to test the efficacy and toxicity of two chemotherapy
regimens, one for patients with HB confined to the liver and involving no more then three
hepatic sections ‘‘standard-risk (SR) HB”, and one for instances of HB extending into all four
sections and/or with lung metastases or intra-abdominal extrahepatic spread or tumor rup‐
ture at presentation or with serum AFP < 100 units at presentation ‘‘high-risk (HR) HB”.
Those with SR-HB were treated with four courses of cisplatin monotherapy, delayed sur‐
gery, and then two more courses of cisplatin. Patients with HR-HB were given cisplatin al‐
ternating with carboplatin and doxorubicin, pre- and postoperatively. For SR-HB patients (n
= 77), and HR-HB patients (n = 58), the 3-year progression-free survival rates were 89% and
48%, respectively. For SR-HB patients, the efficacy of cisplatin monotherapy and the cispla‐
tin/doxorubicin combination are now being compared in a prospective randomized trial
(SIOPEL-3 study). For HR-HB patients, intensified chemotherapy with cisplatin, doxorubi‐
cin, and carboplatin is being investigated in a SIOPEL-4 study. [55]
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In unifocal HB, PRETEXT grouping based on imaging studies at diagnosis in some cases
may lead to overstaging the tumor from PRETEXT III to PRETEXT IV when the anatomic
border separating a lateral section from the sections of the liver harboring the bulging mass
is simply displaced (due to compression) but not invaded. [56, 68] Indeed, repeat imaging
studies after chemotherapy, when the tumor has shrunken, can demonstrate that the ana‐
tomic border is free from invasion and allow for correct staging and performance of a partial
hepatectomy (right or left trisegmentectomy). In multifocal HB with lesions scattered in the
different sections of the liver, clearance of one section, (e.g. the left lateral section) [69] can
apparently be achieved by chemotherapy in some cases, tempting the surgeon to perform a
partial rather than a total hepatectomy. However, this strategy is not recommended because
of the high-risk of leaving viable malignant tumor cells in the remaining section. Therefore,
in multifocal hepatoblastoma, liver transplantation is the best treatment option, whatever
the apparent result of chemotherapy. Further intensification of chemotherapy when the re‐
sponse to completion of full courses of chemotherapy according to protocol is considered
unsatisfactory, and hazardous attempts at partial liver resection in order to avoid liver trans‐
plantation ‘‘at any cost” are no longer justified since the efficacy of primary liver transplan‐
tation for unresectable HB has been validated during the last decade. [55]
Even patients presenting with metastatic disease are potentially curable with a combination of
chemotherapy, complete tumor resection by partial hepatectomy or transplantation, and pul‐
monary metastasectomy. The role of pulmonary metastasectomy has yet to be clearly defined,
although it appears that surgical resection of lung deposits may be more likely to cure patients
with disease present at diagnosis but persistent after neoadjuvant therapy rather than patients
with pulmonary relapse. [12] Data from the most recent COG study, 9645, show 3-year event-
free survival of 90% for Stage I–II, 50% for Stage III, and only 20% for Stage IV (Malogolowkin
et al., 2007). In the European SIOPEL II 3-year survival for standard risk tumors was 90% and
for high-risk tumors was 50%. Cure from hepatoblastoma mandates a complete gross resection
of the primary tumor at some point during the treatment regimen. [12]
3.4. Surgical resection
The objective of the surgical procedure is to obtain a complete resection of the tumor, both
macro- and microscopically, which is paramount for cure of HB (and other liver cancers).
The surgical strategy should be based on a sound knowledge of segmental liver anatomy as
described by Couinaud, [70] vascular occlusion techniques and expertise in performing the
different types of liver resections, including the most extensive procedures (left or right tri‐
segmentectomies). Intraoperative ultrasound is useful in confirming the location of major
vessels and other structures. Nonanatomical, atypical resections are best avoided, except in
rare cases (i.e., pedunculated tumor), because of an increased risk of incomplete tumor re‐
moval and a higher incidence of postoperative complications. [58] Very extensive liver re‐
sections (up to 80% of the liver mass) can be tolerated by young children with HB and
hepatic regeneration can be complete within 3 months, despite the administration of toxic
agents since they usually have no underlying liver disease and excellent hepatic reserve. [71]
Liver function rapidly returns to normal without long-term sequelae. Complete tumor resec‐
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tion can be easily achieved with a partial hepatectomy when the intrahepatic extent is limit‐
ed to one or two sections (PRETEXT I and II). When the tumor involves three sections
(PRETEXT III), preoperative neoadjuvant chemotherapy can make lesions initially consid‐
ered ‘‘unresectable” become resectable with a trisegmentectomy. [55]
Figure 7. Couinaud’s liver segmentation.
In centrally located HB, resection of Couinaud’s segments 4, 5 and 8 (‘‘central hepatecto‐
my”) can occasionally be performed by expert hands. When an accessory right hepatic vein
of appropriate size is present to drain remaining segments 5–7, subtotal hepatectomy re‐
moving segments 1–4 and 8 can be successfully performed. [55]
3.5. Liver transplantation
A growing experience with liver transplantation has shown that liver transplant is a good
treatment option in children with unresectable primary tumors and without demonstrable
metastatic disease after neoadjuvant chemotherapy and pulmonary metastasectomy if nec‐
essary. In large solitary, and especially multifocal, hepatoblastomas invading all four sec‐
tors of the liver,  transplantation has resulted in long-term disease free survival in up to
80% of children. [73] While most agree that ‘‘extreme’’ resection of tumors without liver
transplant will  avoid the need for long-term immunosuppressive therapy, hazardous at‐
tempts at partial hepatectomy in children with major venous involvement or with exten‐
sive  multifocal  tumors  should  be  discouraged.  [56,  69,  74,  75,  76]  Extensive  hepatic
surgery in  children should be  carried out  in  centers  that  have a  facility  for  liver  trans‐
plant, where surgical expertise, as well as willingness to embark on more radical surgery
with a transplant ‘‘safety net’’ is likely to be greater. [76]
Previous studies have validated the concept of total hepatectomy and primary orthotopic
liver transplantation (OLT) for unresectable HB. In SIOPEL-1, [77] 12 patients (8% of all pa‐
tients enrolled from 1990 to 1994) underwent liver transplantation as the primary surgical
option (after appropriate preoperative chemotherapy) in seven children, and as a rescue
procedure in five children because of incomplete partial resection or tumor relapse after par‐
tial hepatectomy. The long-term, disease-free patient survival was 66% for the entire series
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and 85% and 40% for primary transplants and rescue transplants, respectively. Current fol‐
low up is >10 years for all patients. All eight patients with PRETEXT IV tumors and all six
patients with multifocal HB were cured of their disease. Of the seven patients with macro‐
scopic extension into the portal vein and/or the hepatic veins/vena cava, 71% became long-
term, disease-free survivors, as well as four of five (80%) children who had lung metastases
at presentation with complete clearance of lung lesions after chemotherapy. [55]
An extensive review of the world experience collected 147 cases of liver transplantation for
HB. [77] Data were contributed by 24 centers (12 in North America, 10 in Europe, 1 in Japan
and Australia each). Twenty-eight (19% of the total) patients presented with macroscopic ve‐
nous extension and 12 (8%) with lung metastases. A total of 106 patients (72%) underwent a
primary transplant and 41 (28%) received a rescue transplant, either for incomplete resection
with partial hepatectomy or for tumor relapse after previous partial hepatectomy. Twenty-
eight (19%) received a live, donor-related liver transplant, and 119 (81%) received a de‐
ceased donor liver graft. Median follow up since diagnosis for surviving patients was 38
months (range 1– 121 months). Overall disease-free survival at 6 years post-transplant was
82% and 30% for primary transplants and for rescue transplants, respectively. Multivariate
statistical analysis showed no difference in regard to gender, age, and lung metastases at
presentation or type of transplant. For primary transplants, the only parameter significantly
related to overall survival was macroscopic venous invasion (P = 0.045). Remarkably, the 6-
year, disease-free survival (82%) for the 106 patients who received a primary transplant was
similar to the 3-year, progression-free survival (89%) for the 77 HB patients with standard-
risk hepatoblastoma confined to the liver and involving no more than 3 hepatic sections that
were enrolled in the SIOPEL-2 study. [67] In a recent review of the UNOS database in the
USA concerning liver transplantation in 135 children transplanted for unresectable or recur‐
rent HB (1987–2004), the one, five, and 10-year survival was 79%, 69%, and 66% respectively.
[78] The median age at transplantation was 2.9 ± 2.5 years. Sixteen percent received a graft
from a live donor. Fifty-five percent of the deaths were due to metastases or recurrent dis‐
ease. The latest ELTR report, including 129 patients transplanted for HB has shown a 1- and
5-year survival of 100% and 74%, respectively. [55, 79]
3.6. Timing of transplantation
Timing of liver transplantation should not be delayed in excess of a few weeks after the last
course of chemotherapy (as per protocol). An expeditious access to organ donors is required
to meet this requirement. If this is not possible with deceased donors (including split liver
grafts), a live-related donor is a valuable option. [55]
According to the results of published studies, the following guidelines have been developed
for early consultation with a transplant surgeon: [55]
1. Multifocal PRETEXT IV HB is a clear and undisputed indication for primary liver trans‐
plantation, whatever the result of chemotherapy. Apparent clearance of one liver lobe
should not distract from this guideline because of the high probability of persistent mi‐
croscopic viable neoplastic cells. Pediatric oncologists should resist the temptation to in‐
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tensify chemotherapy in a vain effort to avoid transplantation. These patients should be
treated within the same protocol as patients with localized tumors amenable to partial
hepatectomy, with as many cycles of chemotherapy before and after transplantation as
patients submitted to partial hepatectomy for a localized HB.
2. Primary liver transplantation may be the best option for large, solitary PRETEXT IV
HB,  involving  all  four  sections  of  the  liver,  unless  tumor  downstaging  is  clearly
demonstrated after  initial  chemotherapy.  If  this  is  the case,  a  clear  retraction of  the
tumor from the anatomic border of one lateral sector would allow performance of a
radical trisegmentectomy.
3. Unifocal, centrally located PRETEXT II and III tumors involving main hilar structures
or all three main hepatic veins should be considered for primary liver transplantation
because these venous structures would presumably not become free of tumor after che‐
motherapy. Heroic attempts at partial hepatectomy would be best avoided because of
the risk of incomplete resection of malignant tissue.
3.7. Contraindications
Persistence of viable extrahepatic tumor deposit after chemotherapy, not amenable to surgi‐
cal resection, is the only absolute contraindication for liver transplantation. Macroscopic ve‐
nous invasion (portal vein, hepatic veins, vena cava) is not a contraindication if complete
resection of the invaded venous structures can be accomplished. When there is evidence or
suspicion of invasion of the retrohepatic vena cava, it should be resected ‘‘en-bloc” and re‐
constructed. Review of the world experience showed that venous extent was associated with
a significantly shorter survival (P = 0.045). [77] Of the nine TNM IV A/IVB patients (eight
with major intrahepatic venous invasion) reported by Reyes and associates, seven were alive
and disease-free 21–146 months after transplantation. [80]
Patients with lung metastases at presentation should not be excluded from liver transplanta‐
tion if the metastases clear completely after chemotherapy and/or surgical resection. Long-
term, disease-free survival was obtained in 80% of such patients in the SIOPEL-l study and 58%
in the world experience. Complete eradication of metastatic lesions by chemotherapy and sur‐
gical resection of any suspicious remnant after chemotherapy is a paramount pre-requisite for
transplantation. [81] When tumor resection by partial hepatectomy is incomplete or when in‐
trahepatic relapse is observed after a previous partial hepatectomy, performing a rescue liver
transplantation may be a relative contraindication because of the disappointing results ob‐
served in the SIOPEL-l study and in the reported world experience. [55]
3.8. Outcomes
In experienced surgical units, major intraoperative complications of liver resection for HB
such as severe bleeding, air embolism, and unrecognized bile duct injury are infrequent and
operative mortality is very low, even after extended hepatectomies, since children with HB
have no underlying liver disease. As an example, summarizes the 25 years (1978–2003) of
experience gained at Cliniques Saint-Luc, Brussels [82] with 53 children treated for HB.
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and 85% and 40% for primary transplants and rescue transplants, respectively. Current fol‐
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rent HB (1987–2004), the one, five, and 10-year survival was 79%, 69%, and 66% respectively.
[78] The median age at transplantation was 2.9 ± 2.5 years. Sixteen percent received a graft
from a live donor. Fifty-five percent of the deaths were due to metastases or recurrent dis‐
ease. The latest ELTR report, including 129 patients transplanted for HB has shown a 1- and
5-year survival of 100% and 74%, respectively. [55, 79]
3.6. Timing of transplantation
Timing of liver transplantation should not be delayed in excess of a few weeks after the last
course of chemotherapy (as per protocol). An expeditious access to organ donors is required
to meet this requirement. If this is not possible with deceased donors (including split liver
grafts), a live-related donor is a valuable option. [55]
According to the results of published studies, the following guidelines have been developed
for early consultation with a transplant surgeon: [55]
1. Multifocal PRETEXT IV HB is a clear and undisputed indication for primary liver trans‐
plantation, whatever the result of chemotherapy. Apparent clearance of one liver lobe
should not distract from this guideline because of the high probability of persistent mi‐
croscopic viable neoplastic cells. Pediatric oncologists should resist the temptation to in‐
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tensify chemotherapy in a vain effort to avoid transplantation. These patients should be
treated within the same protocol as patients with localized tumors amenable to partial
hepatectomy, with as many cycles of chemotherapy before and after transplantation as
patients submitted to partial hepatectomy for a localized HB.
2. Primary liver transplantation may be the best option for large, solitary PRETEXT IV
HB,  involving  all  four  sections  of  the  liver,  unless  tumor  downstaging  is  clearly
demonstrated after  initial  chemotherapy.  If  this  is  the case,  a  clear  retraction of  the
tumor from the anatomic border of one lateral sector would allow performance of a
radical trisegmentectomy.
3. Unifocal, centrally located PRETEXT II and III tumors involving main hilar structures
or all three main hepatic veins should be considered for primary liver transplantation
because these venous structures would presumably not become free of tumor after che‐
motherapy. Heroic attempts at partial hepatectomy would be best avoided because of
the risk of incomplete resection of malignant tissue.
3.7. Contraindications
Persistence of viable extrahepatic tumor deposit after chemotherapy, not amenable to surgi‐
cal resection, is the only absolute contraindication for liver transplantation. Macroscopic ve‐
nous invasion (portal vein, hepatic veins, vena cava) is not a contraindication if complete
resection of the invaded venous structures can be accomplished. When there is evidence or
suspicion of invasion of the retrohepatic vena cava, it should be resected ‘‘en-bloc” and re‐
constructed. Review of the world experience showed that venous extent was associated with
a significantly shorter survival (P = 0.045). [77] Of the nine TNM IV A/IVB patients (eight
with major intrahepatic venous invasion) reported by Reyes and associates, seven were alive
and disease-free 21–146 months after transplantation. [80]
Patients with lung metastases at presentation should not be excluded from liver transplanta‐
tion if the metastases clear completely after chemotherapy and/or surgical resection. Long-
term, disease-free survival was obtained in 80% of such patients in the SIOPEL-l study and 58%
in the world experience. Complete eradication of metastatic lesions by chemotherapy and sur‐
gical resection of any suspicious remnant after chemotherapy is a paramount pre-requisite for
transplantation. [81] When tumor resection by partial hepatectomy is incomplete or when in‐
trahepatic relapse is observed after a previous partial hepatectomy, performing a rescue liver
transplantation may be a relative contraindication because of the disappointing results ob‐
served in the SIOPEL-l study and in the reported world experience. [55]
3.8. Outcomes
In experienced surgical units, major intraoperative complications of liver resection for HB
such as severe bleeding, air embolism, and unrecognized bile duct injury are infrequent and
operative mortality is very low, even after extended hepatectomies, since children with HB
have no underlying liver disease. As an example, summarizes the 25 years (1978–2003) of
experience gained at Cliniques Saint-Luc, Brussels [82] with 53 children treated for HB.
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There were 39 partial hepatectomies, including 23 right or left trisegmentectomies, and 13
primary liver transplants (two from deceased donors and 11 from living related donors).
Only one child died from surgical complications (extensive portal vein thrombosis present
at diagnosis). Postoperative bleeding requiring reoperation was encountered in 2 patients
(3.5%). The incidence of biliary complications was 7.6% after partial hepatectomy and 23%
following liver transplantation. Actuarial disease-free survival was 89% and 79% in trans‐
plant patients and in children treated with partial hepatectomy, respectively. [55]
Although individual centers treat relatively small numbers of patients with liver cancer, the
best overall survival rates are obtained in experienced units that include liver transplanta‐
tion in their surgical armamentarium. [55, 83, 84, 85]
The most recent report from King’s college, London [86] confirms that the modern strategy
of combining chemotherapy and radical tumor resection enables the majority of children
with HB to be cured. From October 1993 to February 2007, 25 liver transplantations were
performed for HB: 18 from deceased donors and 7 from living donors. Fifteen and ten pa‐
tients were PRETEXT IV and III, respectively. All patients received preoperative chemother‐
apy following the successive SIOPEL protocols. Patient and graft survival after cadaveric
transplantation was 91%, 77.6% and 77.6% after 1, 5 and 10 years, respectively, without re‐
transplantation. Patient and graft survival after living related liver transplantation was
100%, 83.3% and 83.3%, respectively. All surviving children but one remain disease-free,
with a median follow up of 6.8 years (range: 0.9–14.9). There were five deaths at a median of
13 months post-OLT, secondary to tumor recurrence in 4 and respiratoryfailure in one. [55]
A remote data entry system is accessible online, worldwide, and free of charge. Registration
is open for patients transplanted since January 1st, 2006 (http://www.pluto.cineca.org). PLU‐
TO stands for Pediatric Liver Unresectable Tumor Observatory and was developed by the
SIOPEL strategy group. This will allow online registration of children undergoing liver
transplantation for a malignant liver tumor. The aim is to establish an international multi‐
center database with prospective registration of children (<18 years) presenting with unre‐
sectable tumor (HB, HCC, epithelioid hemangioendothelioma and other rare malignant
tumors) undergoing primary orrescue liver transplantation.
4. Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) in childhood is rare and accounts for less than 0.5% of all
pediatric malignancies, [87, 88] is the second most common malignant hepatic neoplasm in
children. HCC presents at an older age than does hepatoblastoma, with most HCC cases di‐
agnosed in children older than 5 years. [89] Its relative frequency is 0.5 to 1.0 cases per mil‐
lion children. It is more frequently encountered in older children and teenagers than in
infants. [88,90] HCC is more often encountered in males and older children between age 10
and 14 yr and the median age of onset is 12 year. [88]
Previous reports from Southeast Asia cite an annual incidence of pediatric hepatic tumors
that is roughly four times higher than western reports in children with less than 15 years of
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age. [91] This finding is largely based on the high hepatitis carrier rate, with a Taiwanese
report stating that 80% of primary liver tumors in children were hepatocellular carcinoma.
With the introduction of hepatitis B vaccine in Southeast Asia, however, there has been a
marked reduction in the incidence of hepatocellular carcinoma, although the impact of the
hepatitis B vaccine has mainly reduced the incidence of liver tumors in males. [92] Occasion‐
ally, malignant tumors in children are seen with features of both hepatocellular carcinoma
and hepatoblastoma. These tumors are more common in children with a diagnosis at later
ages than that typical of hepatoblastoma.
There is an association with pediatric HCC and pre-existing liver cirrhosis, most often because
of biliary atresia, Fanconi’s syndrome, and hepatitis B. However, most pediatric HCC are de
novo tumors and are not necessarily related to cirrhosis. [75] In certain metabolic diseases such
as hereditary tyrosinemia and glycogen storage disease type IA, there is an increased inci‐
dence of HCC. Hereditary tyrosinemia, caused by a deficiency in fumarylacetoacetate hydro‐
lase, results in a greatly increased susceptibility to HCC. This is because of the accumulation of
toxic metabolites in the liver, and the incidence of HCC is 50% by age two. Current medical
therapies for tyrosinemia markedly reduce but do not eliminate the risk of development of
HCC. Glycogen storage disease type IA is caused by a deficiency in glucose- 6-phosphatase.
This results in the development of hepatic adenomas in 50% of patients, and about 11% of pa‐
tients with adenomas because of glycogen storage disease type IA will undergo malignant
transformation into HCC. [93] Other risk factors for HCC include previous treatment with an‐
drogenic steroids, oral contraceptives and methotrexate. [94] Unlike adult HCC, pediatric
HCC often demonstrate reduced levels of cyclin D1 expression. [95] Whether this is involved
in the pathogenesis of pediatric HCC is still unclear. [96]
HCC is a malignancy of hepatocyte origin. The tumor is noted to have a fibrous capsule and
is also predisposed to vascular invasion. [97] There are two distinct groups of HCC patients
in childhood: those developing HCC in the context of advanced chronic liver disease (CLD),
and children who develop sporadic HCC without preceding liver disease. The latter group
typically affects older children. Their clinical behavior and biologic behavior are similar to
HCC in adults. Approximately 26% of cases are histologically of a fibrolamellar type, [98]
which does not appear to make a prognostic difference. Sporadic HCC in children has a rel‐
atively poor outcome, [75] while the several small series that report on HCC developing in
CLD do so in the context of liver transplantation (LT) [82, 99, 100, 101, 102] The fibrolamellar
subtype of HCC (FLHCC) accounts for 3% of HCCs and is not associated with underlying
liver disease. FLHCC lesions are solitary, encapsulated, and well defined. Up to 75% of pa‐
tients will have elevated serum AFP levels. [89, 97].
As for the pathology, HCC macroscopically are usually multifocal and invasive, commonly
involving both lobes and frequently associated with vascular invasion, extrahepatic exten‐
sion, or both at the time of diagnosis. Areas of hemorrhage and necrosis are common, and
the lesions themselves vary in consistency from soft to firm. This significantly reduces the
resectability rate. Czauderna et al report only a 36% complete tumor resection rate in a series
of 39 children recorded by the International Society of Pediatric Oncology over a 4-year time
period. [75] The microscopic features distinguishing hepatocellular carcinoma from hepato‐
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There were 39 partial hepatectomies, including 23 right or left trisegmentectomies, and 13
primary liver transplants (two from deceased donors and 11 from living related donors).
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at diagnosis). Postoperative bleeding requiring reoperation was encountered in 2 patients
(3.5%). The incidence of biliary complications was 7.6% after partial hepatectomy and 23%
following liver transplantation. Actuarial disease-free survival was 89% and 79% in trans‐
plant patients and in children treated with partial hepatectomy, respectively. [55]
Although individual centers treat relatively small numbers of patients with liver cancer, the
best overall survival rates are obtained in experienced units that include liver transplanta‐
tion in their surgical armamentarium. [55, 83, 84, 85]
The most recent report from King’s college, London [86] confirms that the modern strategy
of combining chemotherapy and radical tumor resection enables the majority of children
with HB to be cured. From October 1993 to February 2007, 25 liver transplantations were
performed for HB: 18 from deceased donors and 7 from living donors. Fifteen and ten pa‐
tients were PRETEXT IV and III, respectively. All patients received preoperative chemother‐
apy following the successive SIOPEL protocols. Patient and graft survival after cadaveric
transplantation was 91%, 77.6% and 77.6% after 1, 5 and 10 years, respectively, without re‐
transplantation. Patient and graft survival after living related liver transplantation was
100%, 83.3% and 83.3%, respectively. All surviving children but one remain disease-free,
with a median follow up of 6.8 years (range: 0.9–14.9). There were five deaths at a median of
13 months post-OLT, secondary to tumor recurrence in 4 and respiratoryfailure in one. [55]
A remote data entry system is accessible online, worldwide, and free of charge. Registration
is open for patients transplanted since January 1st, 2006 (http://www.pluto.cineca.org). PLU‐
TO stands for Pediatric Liver Unresectable Tumor Observatory and was developed by the
SIOPEL strategy group. This will allow online registration of children undergoing liver
transplantation for a malignant liver tumor. The aim is to establish an international multi‐
center database with prospective registration of children (<18 years) presenting with unre‐
sectable tumor (HB, HCC, epithelioid hemangioendothelioma and other rare malignant
tumors) undergoing primary orrescue liver transplantation.
4. Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) in childhood is rare and accounts for less than 0.5% of all
pediatric malignancies, [87, 88] is the second most common malignant hepatic neoplasm in
children. HCC presents at an older age than does hepatoblastoma, with most HCC cases di‐
agnosed in children older than 5 years. [89] Its relative frequency is 0.5 to 1.0 cases per mil‐
lion children. It is more frequently encountered in older children and teenagers than in
infants. [88,90] HCC is more often encountered in males and older children between age 10
and 14 yr and the median age of onset is 12 year. [88]
Previous reports from Southeast Asia cite an annual incidence of pediatric hepatic tumors
that is roughly four times higher than western reports in children with less than 15 years of
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age. [91] This finding is largely based on the high hepatitis carrier rate, with a Taiwanese
report stating that 80% of primary liver tumors in children were hepatocellular carcinoma.
With the introduction of hepatitis B vaccine in Southeast Asia, however, there has been a
marked reduction in the incidence of hepatocellular carcinoma, although the impact of the
hepatitis B vaccine has mainly reduced the incidence of liver tumors in males. [92] Occasion‐
ally, malignant tumors in children are seen with features of both hepatocellular carcinoma
and hepatoblastoma. These tumors are more common in children with a diagnosis at later
ages than that typical of hepatoblastoma.
There is an association with pediatric HCC and pre-existing liver cirrhosis, most often because
of biliary atresia, Fanconi’s syndrome, and hepatitis B. However, most pediatric HCC are de
novo tumors and are not necessarily related to cirrhosis. [75] In certain metabolic diseases such
as hereditary tyrosinemia and glycogen storage disease type IA, there is an increased inci‐
dence of HCC. Hereditary tyrosinemia, caused by a deficiency in fumarylacetoacetate hydro‐
lase, results in a greatly increased susceptibility to HCC. This is because of the accumulation of
toxic metabolites in the liver, and the incidence of HCC is 50% by age two. Current medical
therapies for tyrosinemia markedly reduce but do not eliminate the risk of development of
HCC. Glycogen storage disease type IA is caused by a deficiency in glucose- 6-phosphatase.
This results in the development of hepatic adenomas in 50% of patients, and about 11% of pa‐
tients with adenomas because of glycogen storage disease type IA will undergo malignant
transformation into HCC. [93] Other risk factors for HCC include previous treatment with an‐
drogenic steroids, oral contraceptives and methotrexate. [94] Unlike adult HCC, pediatric
HCC often demonstrate reduced levels of cyclin D1 expression. [95] Whether this is involved
in the pathogenesis of pediatric HCC is still unclear. [96]
HCC is a malignancy of hepatocyte origin. The tumor is noted to have a fibrous capsule and
is also predisposed to vascular invasion. [97] There are two distinct groups of HCC patients
in childhood: those developing HCC in the context of advanced chronic liver disease (CLD),
and children who develop sporadic HCC without preceding liver disease. The latter group
typically affects older children. Their clinical behavior and biologic behavior are similar to
HCC in adults. Approximately 26% of cases are histologically of a fibrolamellar type, [98]
which does not appear to make a prognostic difference. Sporadic HCC in children has a rel‐
atively poor outcome, [75] while the several small series that report on HCC developing in
CLD do so in the context of liver transplantation (LT) [82, 99, 100, 101, 102] The fibrolamellar
subtype of HCC (FLHCC) accounts for 3% of HCCs and is not associated with underlying
liver disease. FLHCC lesions are solitary, encapsulated, and well defined. Up to 75% of pa‐
tients will have elevated serum AFP levels. [89, 97].
As for the pathology, HCC macroscopically are usually multifocal and invasive, commonly
involving both lobes and frequently associated with vascular invasion, extrahepatic exten‐
sion, or both at the time of diagnosis. Areas of hemorrhage and necrosis are common, and
the lesions themselves vary in consistency from soft to firm. This significantly reduces the
resectability rate. Czauderna et al report only a 36% complete tumor resection rate in a series
of 39 children recorded by the International Society of Pediatric Oncology over a 4-year time
period. [75] The microscopic features distinguishing hepatocellular carcinoma from hepato‐
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blastoma are the presence of tumor cells larger than normal hepatocytes, broad cellular tra‐
beculae, considerable nuclear pleomorphism, nucleolar predominance, frequent tumor giant
cells, and absence of hemopoiesis. [33,94] The fibrolamellar variant of HCC is probably a
separate clinical entity. Histologically, the tumor cells are plump, with deeply eosinophilic
cytoplasm and a marked fibrous stroma separating epithelial cells into trabeculae. [103]
HCC often present as abdominal swelling associated with dull aching pain and discomfort.
Other frequent complaints are of rapid weight loss and weakness. [75] The most common
clinical sign is hepatomegaly. HCC frequently presents at the time of diagnosis with meta‐
static spread, most commonly to the regional lymph nodes, lungs and bones. [96]
4.1. Laboratory findings
Although most children with HB have an elevated serum AFP level, this marker is elevated
in 50–70% of patients with HCC and less markedly than in HB. Approximately 60–80% of
HCC present with significantly elevated AFP levels. [96] All children with HCC should be
screened for exposure to viral hepatitis B and C. Similar to HB, some children with HCC
may be anemic and others may demonstrate thrombocytosis. Children with cirrhosis-associ‐
ated HCC may present with elevated serum liver enzyme levels (AST) and those with sple‐
nomegaly may show pancytopenia. Careful assessment of hepatic functional reserve in
children with cirrhosis is important prior to embarking on major hepatic resection. Howev‐
er, no specific data are available for children regarding tests used in adults (Iodocyanine-
green (ICG) dye clearance, galactose elimination capacity). Therefore, the evaluation of the
hepatic functional reserve in children is based on standard liver tests including total biliru‐
bin, prothrombine time and INR. [55]
4.2. Imaging
The diagnostic imaging in children with HCC is not different from HB. HCC is often multi‐
focal and may present with a variable number and distribution of tumor nodules. While
identifying larger nodules is not difficult, recognizing lesions less than 1.0 cm is still a chal‐
lenge. Positron emission tomography (PET) using 18- fluorodeoxyglucose may be useful in
identifying unsuspected extrahepatic disease. [104]
Three-dimensional CT image analysis techniques are now available to estimate tumor vol‐
ume and provide detailed intrahepatic anatomy that resembles the actual intraoperative
findings. CT volumetry may permit calculation of resected tumor volume and anticipated
size of the remnant liver in planning resection. [105] Diagnostic laparoscopy is useful to de‐
termine if extra- hepatic disease is present and may avoid unnecessary attempts at resection.
Plain radiograph and CT of the chest should be obtained to rule out lung metastases. Hepat‐
ic arteriography is currently limited to instances of HCC managed by hepatic artery infusion
or transcatheter chemoembolization which can be performed in older children. [55]
On US imaging, HCC may appear as a solitary or multicentric mass most commonly involv‐
ing the right lobe of the liver, or as a diffusely infiltrating lesion. At diagnosis, these masses
appear solid, rarely contain calcification, and have variable echogenicity. Small lesions ap‐
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pear homogeneous and are most often hypoechoic. The capsule can be seen as a hypoechoic
halo. Larger lesions become necrotic, and therefore demonstrate a more heterogeneous ap‐
pearance. Doppler US may detect the high-velocity flow that is related to neovascularity, but
Doppler US is most useful for identifying venous invasion. Portal venous invasion is identi‐
fied in up to 60% of cases, [106] with hepatic venous invasion identified less commonly.
Doppler US may differentiate neoplastic thrombus from bland (benign) thrombus by detect-
ing internal neovascularity in the former. [97]
Potentially curative therapies can treat the very early and early stages of the disease. How‐
ever, less than 30% of HCC patients are detected with the disease in those stages. [107] An‐
other 20% of patients with terminal stage HCC receive recommendations for the best
supportive treatment. Since HCC is unresectable in the majority of patients at the time of the
first diagnosis, patients are often directed to nonsurgical treatments. Physicians have long
overlooked radiotherapy (RT) for HCC as radiation might induce fatal hepatic toxicity at
doses lower than the therapeutic doses. [108] However, such limitation has been overcome
by recent developments in RT technology involving precise delivery of focused high-dose
on partial volume of the liver. [109, 110, 111, 112, 113, 114] According to the Korean Liver
Cancer Study Group (KLCSG) practice guidelines, RT is considered appropriate for unre‐
sectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B,
and tumors occupying less than two-thirds of the liver. [115]
4.3. Results of resection
Based on recent experience, the optimal treatment should have been total hepatectomy and
liver transplantation. Katzenstein et al. reported on 46 children enrolled in the POG and
CCG studies - 8 with stage I, 25 with stage III, 13 with stage IV. [49] The overall event-free
survival at 5 years was 17%. The outcome was not more favorable in 10 children with FL-
HCC. No difference in survival was observed whatever the chemotherapy regimen was giv‐
en. 369 The German Cooperative Liver Study Group [116] reported the results of two
prospective trials. The survival rate of HCC was 33% and 25% in HB-89 (12 patients – 1989–
1993) and 25% in HB-94 (25 patients – 1994–1998), respectively. The SIOPEL-1 study (1990–
1994) enrolled 39 patients with HCC who were treated with neoadjuvant chemotherapy
(PLADO). Thirty-one percent had metastases, 39% had extrahepatic extension/vascular inva‐
sion, 56% had multifocal HCC while 31% had pre-existing liver disease. A partial response
to PLADO was observed in 49%, a complete tumor resection was possible in 36% (2 with
liver transplantation). The 5-year event-free survival was 17%. Adverse prognostic factors
included multifocality, metastases and vascular invasion. In SIOPEL-2 pilot study (1994–
1998), 21 patients were treated with ‘‘super-PLADO” (carboplatin, cisplatin and doxorubi‐
cine). Eighteen percent had metastases, 35% had extrahepatic extension/vascular invasion
and 53% had multifocal HCC. Partial response to SUPER-PLADO was observed in 46%;
complete tumor resection was performed in 47% (one with liver transplantation). The 3-year
overall survival was 22%. In SIOPEL-3 (1999–2004), 65 patients were treated with SUPER-
PLADO with a partial response in 40%. Thirteen underwent primary surgery. Forty-four
percent were never resectable. The 3-year event-free survival was 10%. Currently, the new
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blastoma are the presence of tumor cells larger than normal hepatocytes, broad cellular tra‐
beculae, considerable nuclear pleomorphism, nucleolar predominance, frequent tumor giant
cells, and absence of hemopoiesis. [33,94] The fibrolamellar variant of HCC is probably a
separate clinical entity. Histologically, the tumor cells are plump, with deeply eosinophilic
cytoplasm and a marked fibrous stroma separating epithelial cells into trabeculae. [103]
HCC often present as abdominal swelling associated with dull aching pain and discomfort.
Other frequent complaints are of rapid weight loss and weakness. [75] The most common
clinical sign is hepatomegaly. HCC frequently presents at the time of diagnosis with meta‐
static spread, most commonly to the regional lymph nodes, lungs and bones. [96]
4.1. Laboratory findings
Although most children with HB have an elevated serum AFP level, this marker is elevated
in 50–70% of patients with HCC and less markedly than in HB. Approximately 60–80% of
HCC present with significantly elevated AFP levels. [96] All children with HCC should be
screened for exposure to viral hepatitis B and C. Similar to HB, some children with HCC
may be anemic and others may demonstrate thrombocytosis. Children with cirrhosis-associ‐
ated HCC may present with elevated serum liver enzyme levels (AST) and those with sple‐
nomegaly may show pancytopenia. Careful assessment of hepatic functional reserve in
children with cirrhosis is important prior to embarking on major hepatic resection. Howev‐
er, no specific data are available for children regarding tests used in adults (Iodocyanine-
green (ICG) dye clearance, galactose elimination capacity). Therefore, the evaluation of the
hepatic functional reserve in children is based on standard liver tests including total biliru‐
bin, prothrombine time and INR. [55]
4.2. Imaging
The diagnostic imaging in children with HCC is not different from HB. HCC is often multi‐
focal and may present with a variable number and distribution of tumor nodules. While
identifying larger nodules is not difficult, recognizing lesions less than 1.0 cm is still a chal‐
lenge. Positron emission tomography (PET) using 18- fluorodeoxyglucose may be useful in
identifying unsuspected extrahepatic disease. [104]
Three-dimensional CT image analysis techniques are now available to estimate tumor vol‐
ume and provide detailed intrahepatic anatomy that resembles the actual intraoperative
findings. CT volumetry may permit calculation of resected tumor volume and anticipated
size of the remnant liver in planning resection. [105] Diagnostic laparoscopy is useful to de‐
termine if extra- hepatic disease is present and may avoid unnecessary attempts at resection.
Plain radiograph and CT of the chest should be obtained to rule out lung metastases. Hepat‐
ic arteriography is currently limited to instances of HCC managed by hepatic artery infusion
or transcatheter chemoembolization which can be performed in older children. [55]
On US imaging, HCC may appear as a solitary or multicentric mass most commonly involv‐
ing the right lobe of the liver, or as a diffusely infiltrating lesion. At diagnosis, these masses
appear solid, rarely contain calcification, and have variable echogenicity. Small lesions ap‐
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pear homogeneous and are most often hypoechoic. The capsule can be seen as a hypoechoic
halo. Larger lesions become necrotic, and therefore demonstrate a more heterogeneous ap‐
pearance. Doppler US may detect the high-velocity flow that is related to neovascularity, but
Doppler US is most useful for identifying venous invasion. Portal venous invasion is identi‐
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doses lower than the therapeutic doses. [108] However, such limitation has been overcome
by recent developments in RT technology involving precise delivery of focused high-dose
on partial volume of the liver. [109, 110, 111, 112, 113, 114] According to the Korean Liver
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sectable, locally advanced HCC without extrahepatic metastasis, Child-Pugh class A or B,
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survival at 5 years was 17%. The outcome was not more favorable in 10 children with FL-
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1993) and 25% in HB-94 (25 patients – 1994–1998), respectively. The SIOPEL-1 study (1990–
1994) enrolled 39 patients with HCC who were treated with neoadjuvant chemotherapy
(PLADO). Thirty-one percent had metastases, 39% had extrahepatic extension/vascular inva‐
sion, 56% had multifocal HCC while 31% had pre-existing liver disease. A partial response
to PLADO was observed in 49%, a complete tumor resection was possible in 36% (2 with
liver transplantation). The 5-year event-free survival was 17%. Adverse prognostic factors
included multifocality, metastases and vascular invasion. In SIOPEL-2 pilot study (1994–
1998), 21 patients were treated with ‘‘super-PLADO” (carboplatin, cisplatin and doxorubi‐
cine). Eighteen percent had metastases, 35% had extrahepatic extension/vascular invasion
and 53% had multifocal HCC. Partial response to SUPER-PLADO was observed in 46%;
complete tumor resection was performed in 47% (one with liver transplantation). The 3-year
overall survival was 22%. In SIOPEL-3 (1999–2004), 65 patients were treated with SUPER-
PLADO with a partial response in 40%. Thirteen underwent primary surgery. Forty-four
percent were never resectable. The 3-year event-free survival was 10%. Currently, the new
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SIOPEL-5 study is evaluating non-cirrhotic HCC patients staged according to the PRETEXT
system and receiving neoadjuvant PLADO chemotherapy and thalidomide (an anti-angio‐
genic agent) followed by surgery and postoperative metronomic chemotherapy.
4.4. Liver transplantation for hepatocellular carcinoma
Experience with liver transplantation in children with unresectable HCC is somewhat limit‐
ed but results have significantly improved over the recent years. Beaunoyer et al. reported
on 10 children with underlying liver disease in 5 and cirrhosis in 5. Six had one nodule >5
cm and 7 had >3 nodules. The 5-year actuarial survival was 83%; two died, one of recur‐
rence, while 2 with macrovascular invasion survived. Number and size of lesions or gross
vascular invasion did not significantly impact survival. [82] Reyes et al. reported on 19 chil‐
dren with HCC who underwent total hepatectomy and liver transplantation in 1989–1998;
two thirds had underlying liver disease. [80] The 5-year disease-free survival was 63% (3/6
died of recurrent HCC). In their experience, risk factors for recurrence were tumor size, vas‐
cular invasion and lymphnode involvement. [80] Austin et al. analyzed the aggregated out‐
come for OLT in HCC in 41 children <18 years (UNOS data). Patient survival was 63% at 5
year and 58% at 10 year. Recurrence was the primary cause of death in 86%. [78]
The most conventional criteria for transplantation are the so-called Milan criteria: [117] no
more than three tumors, each not more than 3 cm in size, or a single tumor, not more than 5
cm in diameter, and no evidence of extrahepatic disease or vascular invasion. Recent studies
suggest that, in an otherwise normal liver, the present cut-off for tumor size might be ex‐
panded to 6.5 cm or 7 cm. [118, 119] The evidence supports the moderate expansion of the
Milan criteria although findings from different studies lack consistency and prospective val‐
idation by pretransplant imaging. [79] There are no hard data implying that Milan criteria
can appropriately select children with a low risk of recurrence of HCC after transplantation.
Indeed, Milan criteria are derived from experience in adults with cirrhosis, whereas the ma‐
jority of children with HCC have no underlying cirrhosis. There is no prospective trial in
children while the role of OLT in non-cirrhotic liver is unknown. Moreover, there are differ‐
ences in biology [120] between adult and pediatric HCC with different molecular findings:
mutation of c- met gene in children with HCC, not in adults, level of glycin D1 (regulatory
protein of G1 phase cycle) expression is lower in children, loss of heterozygosity on chromo‐
somal arm, 13q, higher in children. There is evidence that childhood HCC might be less che‐
moresistant than adult HCC; a partial response was observed in 49% enrolled in SIOPEL-1
study. [75] The SIOPEL group has launched in 2005 a new SIOPEL-5 trial directed to non-
cirrhotic hepatocellular carcinoma in children and adolescents. It is based on the hypothesis
that the addition of an antiangiogenic drug (Thalidomide) to PLADO will result in an im‐
provement of survival with acceptable toxicity. Most likely, Sorafenib will be substituted for
Thalidomide on the basis of data obtained in adults with advanced HCC. [121]
Patients with unresectable disease restricted to the liver will be submitted to liver transplan‐
tation. Since the majority of children with HCC in western countries have no underlying liv‐
er disease, recent data suggest that liver transplantation may be quite useful treatment in
carefully selected unresectable cases. [78, 80, 82] Unlike the adult population, the frequency
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of HCC in the pediatric population is low; therefore, the experience in the application of liv‐
er transplantation in the pediatric population for HCC is limited. [122, 123, 124, 125] In pa‐
tients whose disease is confined to the liver, the use of liver transplantation is indicated.
Because chemotherapy is not beneficial at present in this group, results in patients with
more extensive disease are poor. [126]
5. Benign tumors
In general, benign tumors of the liver may arise from hepatocytes, bile duct epithelium, the
supporting mesenchymal tissue, or a combination of two or more of these. In addition to
true neoplastic conditions of the liver, a variety of nodular diseases may occur that resem‐
ble, and must therefore be differentiated from, tumours. Although most patients with be‐
nign hepatic tumors are asymptomatic, a minority may present with symptoms that may be
local or systemic. In these patients, the relationship between the symptoms and the hepatic
lesions may be difficult to correlate, and additional evaluation is necessary to rule out other
causes for the patients complaints. In most cases patients with benign hepatic lesions have
no preexisting liver disease, and the finding of a coexisting chronic liver disease such as cir‐
rhosis, chronic hepatitis B or C, or hemochromatosis should raise a suspicion for a malig‐
nant tumor. A conclusive diagnosis of a focal hepatic lesion is essential because it may
represent a primary or secondary malignancy, which may require immediate treatment. In
addition, some benign lesions carry specific risks such as rupture, bleeding, malignant trans‐
formation, consumptive coagulopathy, and disseminated intravascular coagulation. [127]
Primary liver masses constitute the third most common group of solid abdominal tumors of
childhood, [2, 128, 129] with an incidence of 0.4 to 1.9 per million children each year. [129,
130] Benign primary liver masses described in children include hemangioma/infantile hep‐
atic hemangioendothelioma, focal nodular hyperplasia, simple hepatic cysts, mesenchymal
hamartomas, adenomas, nodular regenerative hyperplasia, hematomas, arterial venous mal‐
formations, granulomas, and lymphangiomas. [2, 12, 128, 129, 130, 131, 132, 133]
Infantile hepatic hemangioendothelioma is a tumor derived from vascular endothelial cells,
which is the most diagnosed benign hepatic tumor in children. Hence it accounts for ap‐
proximately 12% of all childhood hepatic tumors,the most common benign vascular tumor
of the liver in infancy, and the most common symptomatic liver tumor during the first 6
months of life. [134, 135, 136, 137]
While the majority of benign masses may be of little consequence, morbidity and mortality
can occur from benign masses, mass effect from a tumor can cause pain, biliary obstruction
and inferior vena cava obstruction, limit lung capacity, or cause feeding difficulty. [2, 12,
129, 138] Most of the recent radiology literature concerning the liver has focused on lesions
detection or identification of specific features (enhancement patterns) that may help distin‐
guish benign from malignant hepatic tumours. Except for hemangioma and focal nodular
hyperplasia (FNH), little is know about imaging characteristics that can help identify and
distinguish among the many less common bening liver masses. [139]
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ble, and must therefore be differentiated from, tumours. Although most patients with be‐
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Infantile hepatic hemangioendothelioma is a tumor derived from vascular endothelial cells,
which is the most diagnosed benign hepatic tumor in children. Hence it accounts for ap‐
proximately 12% of all childhood hepatic tumors,the most common benign vascular tumor
of the liver in infancy, and the most common symptomatic liver tumor during the first 6
months of life. [134, 135, 136, 137]
While the majority of benign masses may be of little consequence, morbidity and mortality
can occur from benign masses, mass effect from a tumor can cause pain, biliary obstruction
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5.1. Infantile hepatic hemangioendothelioma
More than 90% are diagnosed before the age of 6 years. The typical presentation is of hepa‐
tomegaly, hemangiomas of the skin, and heart failure resulting from massive arteriovenous
shunting. [127, 140] In addition to heart failure, this tumor may cause consumption coagul‐
opathy (Kasabach–Merritt syndrome) and obstructive jaundice. [127, 141] Although well cir‐
cumscribed, this tumor is not encapsulated and often has scattered calcifications.
Microscopically, this tumor consists of multiple small vessels lined by plump endothelial
cells and surrounded by fibrous stroma.
Ultrasonography usually shows hepatomegaly and solitary or multiple hepatic lesions,
which may vary from anechoic to hyperechoic. The unenhanced CT scan demonstrates the
lesion as a well-defined hypo-attenuating mass, occasionally with calcifications. After con‐
trast injection, the lesion may show enhancement resembling hemangioma and may become
isodense on delayed images. Angiography shows dilated, irregular vascular lakes that com‐
monly persist beyond the venous phase. 99mTc-sulfur colloid scintigraphy shows the lesion
as a cold spot because of a lack of Kupffer cells within the tumor. [127]
The prognosis of this lesion is dependent on its size and its effect on the heart function.
Spontaneous regression is frequent but death may occur within the first 6 months of life be‐
cause of cardiac failure or replacement of the normal hepatic parenchyma. [127, 142] The
prognosis is usually good if heart failure is managed successfully.
Treatment is dictated by tumor-related symptoms produced by tumor size. Management of
congestive heart failure may be sufficient in some cases. If symptoms are not relieved, treat‐
ment should be aimed at decreasing the tumor size. [127]
Other treatments include hepatic artery ligation, transcatheter endovascular embolization,
and radiation therapy. [127, 143, 144] Liver transplant is increasingly recognized as a viable
treatment modality for infantile hemangioendothelioma when other treatments fail. [127, 145]
5.2. Focal Nodular Hyperplasia (FNH)
FNH is very rare in pediatric population with an age prevalence in children 7-8 years old,
although  some  cases  are  diagnosed  in  early  childhood  or  even  in  the  prenatal  period.
[146, 147] The female sex is predominant with a M/F ratio of less than 1/10 in one of the
largest series. [147, 148]
The majority (70-90%) of FNH at presentation is asymptomatic and the most common way
that the disease is discovered is when, during an occasional physical examination, hepato‐
megaly or a palpatory abdominal mass are detected. The lesion is more often unique, but
about 8% of cases may show multiple nodules, up to 30. The diameter of lesions is extremely
variable, from less than 1 cm to more than 15 cm but usually is less than 5 cm. [147]
The diagnosis in the majority of cases could be by Ultrasound, CT Scan and MRI. Needle
biopsy or open air biopsy are necessary when the radiological investigations are doubtful,
above all in case of absence of the central scar, and not rarely the differential diagnosis from
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other nodular lesions of liver may be difficult. The differential diagnosis includes different
nodular lesions of the liver. [147]
The natural evolution of FNH is unpredictable. In about 2/3 of cases, remain stable and in
about 1/3-1/4 of cases show a gradual spontaneous improvement as far as a complete remis‐
sion. In rare instances an increase in number as well as in size may occur [9]. The recent studies
in molecular biology have confirmed that FNH is not a pre-neoplastic lesion: the tissue paren‐
chymal organization is pretty the same of usual liver tissue and, moreover, even though in
some cases a clonal origin of FNH nodules have been demonstrated, until now no somatic mu‐
tation in the β-catenin gene or in the other genes implicated in the hepatocellular adenoma
(where a malignant transformation is possible) have been discovered. [147, 149, 150]
About the management the first step is, of course, the stop of oral contraceptive. Considering
the body of evidence that FNH doesn't undergo malignant transformation and that there are
only sporadic cases followed by spontaneous rupture and consequent abdominal bleeding, we
agree with the opinion that in asymptomatic cases it is opportune a careful follow-up with an
ultrasound scan every 6-12 months, and that elective surgery has probably to be limited to the
patients suffering of abdominal pain or with a voluminous or growing mass. [147, 149]
5.3. Nodular regenerative Hyperplasia (NRH)
Nodular regenerative hyperplasia (NRH) is a disease characterized by multiple nodules
composed by hepatocytes, without a fibrous tissue or central scar. The rare pediatric cases
are mostly in association with the congenital absence of portal vein (sometimes complicated
by heart disease or multi-cystic kidney dysplasia). Indeed, only about 200 cases have been
reported. Symptoms, when present, are mainly associated with the complication of portal
hypertension. [151, 152, 153, 154]
CT presentation is really different from FNH, as there are multiple hypodense lesions with
poor or absent enhancement after contrast administration. [147, 155] The typical imaging
showing anechoic and regular profile of the mass at ultrasound, easily recognize cystic le‐
sions: however CT and MRI may be necessary in selected cases. [147]
5.4. Hamartomas
Mesenchymal hamartoma is a rare, benign, developmental tumor of the liver, with occasion‐
al risk of malignancy. Histologically, it appears as a disordered arrangement of the mesen‐
chyme, bile ducts, and hepatic parenchyma. Cords of normal appearing hepatocytes are
separated by zones of loose, poorly cellular mesenchyme. The porous nature of the mesen‐
chyme permits accumulation of fluid. [156, 157] Grossly, it has stromal and cystic compo‐
nents with no capsules, and can grow to large sizes. [157, 158] The typical presentation is
one of asymptomatic, rapid abdominal distention with a palpable mass on physical exami‐
nation. The rapid expansion of the tumor is believed to be due to degeneration of the mesen‐
chyme and fluid accumulation. Other uncommon associated symptoms are vomiting, fever,
constipation, diarrhea, and weight loss. [156, 157] Laboratory investigations usually reveal
normal liver function with elevated alpha-fetoprotein, which is believed to be secreted by
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the proliferating hepatocytes within the tumor. [157, 159] The radiological appearance is one
of a large, uni or multi-cystic, avascular mass occupying part of the liver. [157, 158] Surgical
resection has been the standard treatment for this tumor.
6. Sarcoma
The third most common hepatic malignancy, after hepatoblastoma and hepatocellular carci‐
noma, is undifferentiated embryonal sarcoma. [8, 160, 161] It is believed to be a primitive
mesenchymal neoplasm, which usually behaves in a highly malignant fashion. [162] It was
first recognized as a clinicopathologic entity by Stocker and Ishak in 1978. [156] Before their
report, this tumor had been described under different names such as embryonal sarcoma
[163] mesenchymoma, [164] primary sarcoma [165] or fibromyxosarcoma. [166]
These tumors occur in children 5–10 years of age and are mesenchymal in appearance. [8, 167]
Diagnosis of primary hepatic sarcoma is challenging due to the lack of specific presenting
symptoms, lack of serological markers, non-specific findings on radiological imaging and the
rarity of the disease. [86] However, leukocytosis and elevated aspartate aminotransferase and
alkaline phosphatase are not uncommon laboratory findings. [156, 161, 162, 168, 169] The se‐
rum α-fetoprotein level is always normal. [156, 161, 162, 169] There is no correlation with hepa‐
titis B or C virus infection. Most tumors have prominent areas of cystic degeneration. [161, 162]
Multinucleated giant tumor cells with eosinophilic cytoplasm and frequent mitosis are usually
present. (Stocker and Ishak,1978 and [162] et al.,2001) PAS-positive, diastase-resistant hyaline
globules, which are believed to be lysosomes or apoptotic bodies, are frequently seen within
tumor cells as well as in extracellular stromata. [156, 162, 168, 170, 171]
Regarding the radiological imaging, undifferentiated embryonal sarcoma often show a mis‐
leading cystic appearance on CT and magnetic resonance imaging (MRI) in contrast to a pre‐
dominantly solid appearance on ultrasound. [86, 172]
Undifferentiated embryonal sarcoma of the liver behaves in a highly malignant fashion, [162,
173] and the median survival has been less than a year. [156, 162] Complete surgical resection is
the key to a favorable outcome. However, despite apparent complete resectability in somecas‐
es, local recurrence and distant metastases have been major impediments to achieving long-
term  disease-free  survival.  [162,  173]  Multidisciplinary  treatment  (chemotherapy  and
radiotherapy) has been used to achieve superior and local control and disease-free survival in
patients with Undifferentiated embryonal sarcoma of the liver. [160, 167, 173]
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the proliferating hepatocytes within the tumor. [157, 159] The radiological appearance is one
of a large, uni or multi-cystic, avascular mass occupying part of the liver. [157, 158] Surgical
resection has been the standard treatment for this tumor.
6. Sarcoma
The third most common hepatic malignancy, after hepatoblastoma and hepatocellular carci‐
noma, is undifferentiated embryonal sarcoma. [8, 160, 161] It is believed to be a primitive
mesenchymal neoplasm, which usually behaves in a highly malignant fashion. [162] It was
first recognized as a clinicopathologic entity by Stocker and Ishak in 1978. [156] Before their
report, this tumor had been described under different names such as embryonal sarcoma
[163] mesenchymoma, [164] primary sarcoma [165] or fibromyxosarcoma. [166]
These tumors occur in children 5–10 years of age and are mesenchymal in appearance. [8, 167]
Diagnosis of primary hepatic sarcoma is challenging due to the lack of specific presenting
symptoms, lack of serological markers, non-specific findings on radiological imaging and the
rarity of the disease. [86] However, leukocytosis and elevated aspartate aminotransferase and
alkaline phosphatase are not uncommon laboratory findings. [156, 161, 162, 168, 169] The se‐
rum α-fetoprotein level is always normal. [156, 161, 162, 169] There is no correlation with hepa‐
titis B or C virus infection. Most tumors have prominent areas of cystic degeneration. [161, 162]
Multinucleated giant tumor cells with eosinophilic cytoplasm and frequent mitosis are usually
present. (Stocker and Ishak,1978 and [162] et al.,2001) PAS-positive, diastase-resistant hyaline
globules, which are believed to be lysosomes or apoptotic bodies, are frequently seen within
tumor cells as well as in extracellular stromata. [156, 162, 168, 170, 171]
Regarding the radiological imaging, undifferentiated embryonal sarcoma often show a mis‐
leading cystic appearance on CT and magnetic resonance imaging (MRI) in contrast to a pre‐
dominantly solid appearance on ultrasound. [86, 172]
Undifferentiated embryonal sarcoma of the liver behaves in a highly malignant fashion, [162,
173] and the median survival has been less than a year. [156, 162] Complete surgical resection is
the key to a favorable outcome. However, despite apparent complete resectability in somecas‐
es, local recurrence and distant metastases have been major impediments to achieving long-
term  disease-free  survival.  [162,  173]  Multidisciplinary  treatment  (chemotherapy  and
radiotherapy) has been used to achieve superior and local control and disease-free survival in
patients with Undifferentiated embryonal sarcoma of the liver. [160, 167, 173]
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1. Introduction
The liver is the third-most-common site for intra-abdominal malignancy in children, follow‐
ing adrenal neuroblastoma and wilms tumor. Although the overall incidence of childhood
cancer has been slowly increasing since 1975, cancer in children and adolescents is still rare,
the incidence of primary malignant liver tumors per year is 1-1.5 per million children in the
United States [1, 2, 3, 4]. This yields a relative low rate for hepatic tumors (1.3% of all pedia‐
tric malignancies). Tumors of the liver may be either malignant or benign. Two thirds of liv‐
er tumors in children are malignant. Of these malignant tumors, hepatoblastoma (HB) and
hepatocellular carcinoma (HCC) are the most common and account for 70 persent of all hep‐
atic neoplasms. Unlike liver tumors in adults, in which the predominant histology is hepato‐
cellular carcinoma, hepatoblastoma accounts for two thirds of liver tumors in children.
Other liver malignancies in children include sarcomas, germ cell tumors, as well as rhab‐
doid tumors. Benign tumors of the liver in children include vascular tumors, hamartomas,
adenomas, and focal nodular hyperplasia (FNH). The histology and anatomy of a pediatric
liver tumor guides the treatment and prognosis [5, 6, 7, 8].
Recently, dramatic improvements in survival have been achieved for children and adoles‐
cents with liver cancer. Children and adolescents with liver cancer should be referred to
multidisciplinary team incorporates the skills of the primary care physician, pediatric surgi‐
cal subspecialists, radiation therapists, pediatric oncologists/hematologists, rehabilitation
specialists, pediatric nurse specialists, social workers, and others to ensure that children re‐
ceive treatment, supportive care, and rehabilitation that will achieve optimal survival and
quality of life. Almost all liver masses in children are surgically treated, either primarily or
following systemic chemotherapy [9, 10]. The conditions that eventuate in this choice of
therapy, when and how to accomplish it, and the medical and surgical consequences for
children of transplantation for tumors are described in guidelines for pediatric cancer cen‐
ters and their role in the treatment of pediatric patients with cancer by the American Acade‐
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my of Pediatrics [11, 12, 13]. Clinical trials for children and adolescents with cancer are
generally designed to compare potentially better therapy with therapy that is currently ac‐
cepted as standard. Clinical trials are available in many clinical institutes for liver cancer
that occur in children and adolescents, and the opportunity to participate in these trials is
offered to most patients/families [14].
2. Epidemiology of pediatric hepatic tumors
Benign lesions in children represent 30% of hepatic tumors and are most commonly vascular
in origin (eg, hemangiomas, hemangioendotheliomas). Two-thirds of hepatic neoplasms in
children are malignant. Liver cancer is also rare malignancy in children and adolescents and
account for approximately 1% of all pediatric malignancies. The malignant liver tumor is
divided into two major histologic subgroups: hepatoblastoma, affecting around 80% of chil‐
dren, and hepatocellular carcinoma (HCC) [15, 16]. The age of onset of liver cancer in chil‐
dren is related to tumor histology. Hepatoblastoma usually occur before the age of 3 years,
and approximately 90% of malignant liver tumors in children aged 4 years and younger are
hepatoblastomas. There are 2 distinct groups of HCC patients in childhood: children who
develop sporadic HCC without preceding liver disease, and those developing HCC in the
context of advanced chronic liver disease (CLD). Sporadic HCC in children has a relatively
poor outcome, while the several small series that report on HCC developing in CLD do so in
the context of liver transplantation (LT). Some biologic differences may exist between HCCs
developing in adults and children. One study reported an high radiological response (49%)
in pediatric HCC, higher than adult HCC [17].
The incidence of hepatocellular carcinoma is negligible in children aged 14 years and young‐
er. In china, the incidence of hepatic tumors in children 14 years and younger is 2.6 per
100,000, of which 81 persent are hepatoblastoma. The incidence of hepatoblastoma in the
United States increased in the last 25 years, whereas the incidence of hepatocellular carcino‐
ma in the United States has not changed appreciably over time. The cause for the increase in
incidence of hepatoblastoma is unknown, but the increasing survival of very low birth
weight premature infants, which is known to be associated with hepatoblastoma, may con‐
tribute. In Japan, the risk of hepatoblastoma in children who weighed less than 1,000 g at
birth are 15 times the risk in normal birth weight children. Other data has confirmed the
high incidence of hepatoblastoma in very low birth weight premature infants. In several
asian countries, the incidence of hepatocellular carcinoma in children is 10 times more than
that in North America. The high incidence appears to be related to the incidence of perina‐
tally acquired hepatitis B, which can be prevented in most cases by vaccination and adminis‐
tration of hepatitis B immune globulin to the newborn [18, 19].
Additional rare malignant liver tumors in children are sarcoma, including its 3 variants
rhabdomyosarcoma, embryonal or undifferentiated sarcoma, and angiosarcoma predomi‐
nantly presenting in early childhood. Also included is the exceedingly uncommon cholan‐
giocarcinoma, which can present at any age, often in the context of chronic biliary
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disease.The overall survival rate for children with hepatoblastoma is 70%, but is only 25%
for those with hepatocellular carcinoma.
3. Clinical presentation and diagnosis
Most children with liver tumors commonly present insidiously with nonspecific abdominal
discomfort, a palpable abdominal mass, feeding difficulties, and abdominal distension.
Chronic fatigue secondary to anemia thrombocytopenia, and leukocytosis and lack of appe‐
tite are often reported. Jaundice and biochemical derangement are signs of advanced neo‐
plastic change. Children with both HB and HCC may also present with weight loss, fever,
and anorexia [20, 21, 22].
Fetal and neonatal presentations include hydramnios, fetal hydrops, congestive heart fail‐
ure, and respiratory distress. Occasionally, the child may present acutely with vomiting, fe‐
ver and clinical signs of abdominal irritation, often suggestive of tumor rupture with
intraperitoneal spread. Patients with congestive heart failure have been shown to have low‐
er survival rates. Very rarely HB can present with signs of precocious puberty/virilization
due to b-HCG secretion by the tumor. Laboratory studies are performed to assess baseline
CBC count, electrolyte levels, liver enzyme levels, liver synthetic function, and α -fetopro‐
tein (AFP) levels Serum AFP remains the key clinical marker of malignant neoplastic
change, response to the treatment, and relapse. AFP levels are elevated in 50%-70% of chil‐
dren with hepatic neoplasms, and multiple studies confirm that AFP is a valuable surveil‐
lance marker in children who have previously undergone hepatic resection for malignancy.
However, there are some variants of both HB and HCC that have low or normal AFP. These
variants may have distinct histologic features and poorer prognoses [23, 24]. The initial
workup for hepatic masses includes radiographic assessment using ultrasonography.
All children with a palpable abdominal mass usually undergo an initial ultrasound to con‐
firm the location and to characterize the consistency as cystic or solid. Cystic or vascular le‐
sions may not require any further imaging. However, definitive characterization of the mass
requires a computed tomography (CT) or magnetic resonance imaging (MRI) scan. Calcifica‐
tions can be seen in a minority of liver tumors. Hypervascularized hepatic lesions with de‐
layed contrast excretion are highly suspicious of a malignant tumor.
Abdominal ultrasonography usually demonstrates a large mass, possibly with some satellite
lesions and areas of hemorrhage within the tumor. CT scanning of the abdomen and chest
are used for indeterminate or solid lesions to further delineate the location and to assess re‐
sectability (Fig. 1) and evaluate for the presence of pulmonary metastasis. MRI angiography
is frequently helpful preoperatively to determine resectability because it delineates the vas‐
cular anatomy more precisely. Local radiological availability, expertise extent, and multi‐
plicity of the lesions and to detect metastases may facilitate surgical planning and may
determine resectability, however, definitive diagnosis can be proven only through biopsy
findings [25, 26, 27].
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Figure 1. CT scan of a hepatoblastoma amenable to surgical resection.
Any child with a suspected liver tumor should also have AFP and ß-HCG serum assays. The
alpha-fetoprotein (AFP) and beta-hCG tumor markers are very helpful in diagnosis and
management of liver tumors. Alttough elevation of AFP levels is not diagnostic of hepatic
malignancy. AFP is markedly elevated in90% of hepatoblastoma cases and in many cases of
hepatocellular carcinoma, and it returns to normal with effective therapy. The level of AFP
at diagnosis and rate of decrease in AFP during treatment should be compared to the age-
adjusted normal range. Caution should be taken in normal term infants who can have AFP
levels in excess of 100,000 ng/ml, however, with a half-life of approximately 1 week, the AFP
level normalizes to 10 ng/ml over the first few months of life. Absence of elevated AFP lev‐
els at diagnosis occurs in a few percentage of children with hepatoblastoma and appears to
be associated with poor prognosis, as well as with the small cell undifferentiated variant of
hepatoblastoma. Lack of a significant decrease of AFP levels with treatment may predict a
poor response to therapy.
Beta-hCG is a hormone commonly produced by liver tumors and, in excess, can result in
precocious puberty. It’s levels may also be elevated in children with hepatoblastoma or hep‐
atocellular carcinoma, which may result in isosexual precocity in boys. Extremely high lev‐
els of beta-hCG are associated with infantile choriocarcinoma of the liver [28, 29].
Because of the association between familial adenomatous polyposis and hepatoblastoma,
obtaining a thorough family history is an important aspect of the management of a child
with a liver tumor and his family, with particular attention to any family history of colon
cancer or colonic polyps.
A chest CT is an important aspect of the workup because the lung parenchyma is the most
common distant site for metastasis. A CBC typically displays mild normocytic and normo‐
chromic anemia with thrombocytosis.
Tissue diagnosis of the tumor is essential, although some advocate that in the presence of
very high AFP in a young child (6 months to 3 years). The practice in the United States is not
to treat without a tissue sample except under the most urgent life-threatening circumstan‐
ces, such as tumor growth into the right atrium. But this may not be necessary, as avoiding
the biopsy theoretically reduces the risks of the tumor seeding. In Europe, The Childhood
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Liver Tumor Study Group of the Inter-national Society of Pediatric Oncology (SIOPEL) has
developed a preoperative evaluation of the tumor extent (PRETEXT) grading system. The
rationale for this recommendation is provided in the section on pathology. Segmental as‐
sessment of the extent of the tumor and its relation with the main hepatic vessels is of fore‐
most importance for planning the intensity of chemotherapy and eventual surgery., which
could provide a valuable tool for the risk stratification. Formal staging of the tumor should
include chest and brain CT and bone scanning [30, 31].
Benign hepatic tumors are usually diagnosed incidentally. Some children may develop the
Kasabach-Merritt phenomenon, a triad of coagulopathy, hemolytic anemia and thrombocy‐
topenia due to intralesional pooling of the blood. IHE can have an acute presentation, typi‐
cally within the first couple of weeks or months of life. Dramatic abdominal distension can
lead to major respiratory distress, prompting the need for assisted ventilation and intensive
care support. Nowadays some IHEs may be detected on routine antenatal ultrasonography,
due to their characteristic vascular multichannel appearance. A proportion of children de‐
velop a bizarre secondary hypothyroidism that is thought to be secondary to tumor produc‐
tion of the enzyme iodothyronine deiodinase, which stimulates the conversion of thyroxine
to reverse triiodothyronine and of triiodothyronine to 3,3’-diio-dothyronine, leading to a bi‐
ochemical picture of hypothyroidism, requiring thyroxin supplementation. This phenomen‐
on resolves once the tumor is removed or significantly decreases in size, usually within the
first 2 years of life.
3.1. Risk factors
Similar to other embryonal tumors, altered imprinting at the 11–15 locus has been observed
in hepatoblastoma. Rearrangements involving the pericentric region of chromosome 1 also
appear to be important in hepatoblastoma, with roughly 18% of hepatoblastomas displaying
an imbalanced translocation involving this region. Hepatoblastoma is associated with sever‐
al genetic syndromes and familial cancer predisposition conditions, such as familial ade‐
nomatous polyposis and Beckwith-Wiedemann syndrome in addition to several other rare
syndromes. Other compelling evidence suggests that acquired aberrations in the ß-
catenin/Wnt pathways are important in the pathogenesis of hepatoblastoma. Acquired chro‐
mosomal changes in tumors include numerical chromosomal changes, most commonly
trisomies of chromosomes 2, 8, and 20. Finally, epigenetic changes in methylation patterns of
DNA may be altered in hepatoblastoma.
There is limited but compelling evidence that parental exposures are associated with a high‐
er incidence of liver tumors and, more specifically, hepatoblastoma. Children from parents
who have been exposed to metals used in soldering and welding, petroleum, or paints are at
a higher risk for hepatoblastoma. Recent reports have also implicated parental smoking as a
risk factor for hepatoblastoma [32, 33].
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The incidence of hepatoblastoma is increased 1,000 to 10,000-fold in infants and children
with Beckwith-Wiedemann syndrome (BWS). BWS can be caused by either genetic muta‐
tions and be familial, or much more commonly, by epigenetic changes and be sporadic.
Hepatoblastoma is also increased in hemihypertrophy, an overgrowth syndrome caused by
the same epigenetic changes in chromosome 11p15.5 that cause many cases of BWS, but in a
genetically mosaic fashion. Either mechanism can be associated with an increased incidence
of embryonal tumors including Wilms tumor and hepatoblastoma. The gene dosage and en‐
suing increase in expression of insulin-like growth factor 2 (IGF 2) has been implicated in
the macrosomia and embryonal tumors in BWS and hemihypertrophy. When sporadic, the
types of embryonal tumors associated with BWS have frequently also undergone somatic
changes in the BWS locus and IGF 2. All children with BWS or isolated hemihypertrophy
should be screened regularly by ultrasound to detect abdominal malignancies at an early
stage. Screening using AFP levels has helped in the early detection of hepatoblastoma in
children with BWS or hemihypertrophy. Other somatic overgrowth syndromes, such as
Simpson-Golabi-Behmel syndrome, may also be associated with hepatoblastoma.
3.3. Familial adenomatous polyposis
There is an association between hepatoblastoma and familial adenomatous polyposis (FAP);
children in families that carry the APC gene are at an 800-fold increased risk for hepatoblas‐
toma. However, hepatoblastoma occurs in less than 1% of FAP family members, so ultra‐
sound and AFP screening for hepatoblastoma in members of families with FAP is
controversial. The predisposition to hepatoblastoma may be limited to a specific subset of
APC mutations. It has been recommended that all children with hepatoblastoma be exam‐
ined for congenital hypertrophy of the retinal pigment epithelium, a marker of APC muta‐
tion carriers in 70% of polyposis families. In the absence of APC germline mutations,
childhood hepatoblastomas do not have somatic mutations in the APC gene; however, they
frequently have mutations in the beta-catenin gene, the function of which is closely related
to APC.
3.4. Hepatitis B and hepatitis C infection
Hepatocellular carcinoma is associated with hepatitis B and hepatitis C infection, especially
in children with perinatally acquired hepatitis B virus [33]. Compared with adults, the incu‐
bation period from hepatitis virus infection to the genesis of hepatocellular carcinoma is ex‐
tremely short in a small subset of children with perinatally acquired virus. Widespread
hepatitis B immunization has decreased the incidence of hepatocellular carcinoma in Asia.
Mutations in the met/hepatocyte growth factor receptor gene occur in childhood hepatocel‐
lular carcinoma, and this could be the mechanism that results in a shortened incubation pe‐
riod.Hepatocellular carcinoma may also arise in very young children with mutations in the
bile salt export pump ABCB11, which causes progressive familial hepatic cholestasis. Sever‐
al specific types of nonviral liver injury and cirrhosis are associated with hepatocellular car‐
cinoma in children including tyrosinemia and biliary cirrhosis.
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3.5. Undifferentiated Embryonal Sarcoma of the Liver
Undifferentiated embryonal sarcoma of the liver (UESL) is the third most common liver ma‐
lignancy in children and adolescents, comprising 9% to 13% of liver tumors. Widespread in‐
filtration throughout the liver and pulmonary metastasis are common, usually between the
ages of 5 and 10 years. It could also presents as an abdominal mass, often with pain or ma‐
laise. It may appear solid or cystic on imaging, frequently with central necrosis. Distinctive
features are characteristic intracellular hyaline globules and marked anaplasia on a mesen‐
chymal background. Many UESL contain diverse elements of mesenchymal cell maturation,
such as smooth muscle and fat.
Strong clinical and histological evidence suggest that some UESLs arise from mesenchymal
hamartomas of the liver (MHL), which are large benign multicystic masses that present in
the first 2 years of life. Many MHLs have a characteristic translocation with a breakpoint at
19q13.4 and several UESLs have the same translocation. In a report of 11 cases of UESL, five
arose in association with MHL, and transition zones between the histologies were noted.
Some UESLs arising from MHLs may have complex karyotypes not involving 19q13.4.
3.6. Infantile Choriocarcinoma of the Liver
Choriocarcinoma of the liver is a very rare tumor that appears to originate in the placenta
and presents with a liver mass in the first few months of life. Infants are often unstable due
to hemorrhage from the tumor. Clinical diagnosis may be made without biopsy based on ex‐
tremely high serum beta-hCG levels and normal AFP levels for age.
3.7. Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer that occurs in the liver
and other organs.
Generally, children with liver masses display normal growth and development unless they
show the phenotypes associated with Beckwith-Wiedemann syndrome or the other genetic
cancer predisposition syndromes associated with liver tumors.
4. Screening
Hepatic neoplasms develop in a myriad of chronic liver disorders of childhood, often without
or with minimal symptoms. Therefore, regular screening with abdominal ultrasound and se‐
rum AFP measurement should be in place for all children with CLD at least annually. There‐
fore, awareness of antecedent conditions that permit screening is essential. Detection of a liver
tumor prior to dissemination and/or massive growth is the single most important manage‐
ment tool for all tumor types at all ages. Children with chronic hepatitis B should be also regu‐
larly checked, but because communities in which immunization has yet to be provided are
typically impoverished and medically underserved, recommendations for screening have not
yet been implemented. Some of the conditions with known increased propensity to develop




The incidence of hepatoblastoma is increased 1,000 to 10,000-fold in infants and children
with Beckwith-Wiedemann syndrome (BWS). BWS can be caused by either genetic muta‐
tions and be familial, or much more commonly, by epigenetic changes and be sporadic.
Hepatoblastoma is also increased in hemihypertrophy, an overgrowth syndrome caused by
the same epigenetic changes in chromosome 11p15.5 that cause many cases of BWS, but in a
genetically mosaic fashion. Either mechanism can be associated with an increased incidence
of embryonal tumors including Wilms tumor and hepatoblastoma. The gene dosage and en‐
suing increase in expression of insulin-like growth factor 2 (IGF 2) has been implicated in
the macrosomia and embryonal tumors in BWS and hemihypertrophy. When sporadic, the
types of embryonal tumors associated with BWS have frequently also undergone somatic
changes in the BWS locus and IGF 2. All children with BWS or isolated hemihypertrophy
should be screened regularly by ultrasound to detect abdominal malignancies at an early
stage. Screening using AFP levels has helped in the early detection of hepatoblastoma in
children with BWS or hemihypertrophy. Other somatic overgrowth syndromes, such as
Simpson-Golabi-Behmel syndrome, may also be associated with hepatoblastoma.
3.3. Familial adenomatous polyposis
There is an association between hepatoblastoma and familial adenomatous polyposis (FAP);
children in families that carry the APC gene are at an 800-fold increased risk for hepatoblas‐
toma. However, hepatoblastoma occurs in less than 1% of FAP family members, so ultra‐
sound and AFP screening for hepatoblastoma in members of families with FAP is
controversial. The predisposition to hepatoblastoma may be limited to a specific subset of
APC mutations. It has been recommended that all children with hepatoblastoma be exam‐
ined for congenital hypertrophy of the retinal pigment epithelium, a marker of APC muta‐
tion carriers in 70% of polyposis families. In the absence of APC germline mutations,
childhood hepatoblastomas do not have somatic mutations in the APC gene; however, they
frequently have mutations in the beta-catenin gene, the function of which is closely related
to APC.
3.4. Hepatitis B and hepatitis C infection
Hepatocellular carcinoma is associated with hepatitis B and hepatitis C infection, especially
in children with perinatally acquired hepatitis B virus [33]. Compared with adults, the incu‐
bation period from hepatitis virus infection to the genesis of hepatocellular carcinoma is ex‐
tremely short in a small subset of children with perinatally acquired virus. Widespread
hepatitis B immunization has decreased the incidence of hepatocellular carcinoma in Asia.
Mutations in the met/hepatocyte growth factor receptor gene occur in childhood hepatocel‐
lular carcinoma, and this could be the mechanism that results in a shortened incubation pe‐
riod.Hepatocellular carcinoma may also arise in very young children with mutations in the
bile salt export pump ABCB11, which causes progressive familial hepatic cholestasis. Sever‐
al specific types of nonviral liver injury and cirrhosis are associated with hepatocellular car‐
cinoma in children including tyrosinemia and biliary cirrhosis.
Hepatic Surgery466
3.5. Undifferentiated Embryonal Sarcoma of the Liver
Undifferentiated embryonal sarcoma of the liver (UESL) is the third most common liver ma‐
lignancy in children and adolescents, comprising 9% to 13% of liver tumors. Widespread in‐
filtration throughout the liver and pulmonary metastasis are common, usually between the
ages of 5 and 10 years. It could also presents as an abdominal mass, often with pain or ma‐
laise. It may appear solid or cystic on imaging, frequently with central necrosis. Distinctive
features are characteristic intracellular hyaline globules and marked anaplasia on a mesen‐
chymal background. Many UESL contain diverse elements of mesenchymal cell maturation,
such as smooth muscle and fat.
Strong clinical and histological evidence suggest that some UESLs arise from mesenchymal
hamartomas of the liver (MHL), which are large benign multicystic masses that present in
the first 2 years of life. Many MHLs have a characteristic translocation with a breakpoint at
19q13.4 and several UESLs have the same translocation. In a report of 11 cases of UESL, five
arose in association with MHL, and transition zones between the histologies were noted.
Some UESLs arising from MHLs may have complex karyotypes not involving 19q13.4.
3.6. Infantile Choriocarcinoma of the Liver
Choriocarcinoma of the liver is a very rare tumor that appears to originate in the placenta
and presents with a liver mass in the first few months of life. Infants are often unstable due
to hemorrhage from the tumor. Clinical diagnosis may be made without biopsy based on ex‐
tremely high serum beta-hCG levels and normal AFP levels for age.
3.7. Epithelioid Hemangioendothelioma
Epithelioid hemangioendothelioma (EHE) is a rare vascular cancer that occurs in the liver
and other organs.
Generally, children with liver masses display normal growth and development unless they
show the phenotypes associated with Beckwith-Wiedemann syndrome or the other genetic
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4. Screening
Hepatic neoplasms develop in a myriad of chronic liver disorders of childhood, often without
or with minimal symptoms. Therefore, regular screening with abdominal ultrasound and se‐
rum AFP measurement should be in place for all children with CLD at least annually. There‐
fore, awareness of antecedent conditions that permit screening is essential. Detection of a liver
tumor prior to dissemination and/or massive growth is the single most important manage‐
ment tool for all tumor types at all ages. Children with chronic hepatitis B should be also regu‐
larly checked, but because communities in which immunization has yet to be provided are
typically impoverished and medically underserved, recommendations for screening have not
yet been implemented. Some of the conditions with known increased propensity to develop
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malignancies such as tyrosinemia type 1 (even on nitizinone treatment) or bile salt export
pump (BSEP) deficiency should be assessed every 6 months. However, there is no formal
guideline for the frequency and manner of screening at this time [34, 35].
Extraordinary advances in neonatal care in the past 25 years have led to a wholly new popu‐
lation of children, the long-term survivors of birth as early as 22 to 23 weeks of gestation
with a weight less than 1000 g. In addition to many other chronic problems, they have extra‐
ordinary susceptibility to HB. HB is dramatically more common in expremature babies but
arranging effective screening programs could prove to be difficult because of their increas‐
ing numbers and fact that their long term care is typically provided outside hepatological
clinics. Monitoring much smaller cohorts of children with Beckwith-Wiedemann Syndrome
for HB is more feasible, and one study has suggested abdominal ultrasonography and se‐
rum AFP every 3 months until 4 years of age.
There are several conditions for which screening of children for primary liver cancer is recom‐
mended by virtue of the attendant risk. Hepatitis B virus can cause HCC as early as age 4 fol‐
lowing  perinatal  transmission  from  infected  carrier  mothers.  Vaccination  and  perinatal
administration of hepatitis B immunoglobulin have already reduced the incidence dramatical‐
ly. A relative risk for such prematures versus term babies of 16- to 52-fold is recognized around
the world. HB occurs at the same age as HB in term babies or later. Screening of infants with
hemihypertrophy or  hemiaplasia,  as  part  of  the  Beckwith-Wiedemann over-growth syn‐
drome, has been carried out for many years via ultrasound to detect intraabdominal malignan‐
cies.  These include Wilms’  tumor and adreno cortical  carcinoma, in addition to the less
common HB, which has a relative risk of 2280. HB is not the only proliferative lesion of the
Beckwith-Wiedemann syndrome liver, as hemangioendothelioma and mesenchymal hamar‐
toma have also been observed, either con-currently or sequentially [37, 38].
In familial adenomatous polyposis (FAP), the first manifestation of an autosomal dominant
mutation in a family may be HB in a baby, with the colonic polyps detected only afterwards
in a parent. The relative risk for children in such cohorts is 800-fold, but many examples are
due to new germ-line mutations at 5q21,22 or only in the tumor.
A series from the Children’s Oncology Group focused primarily on known FAP families but
raised the issue of de novo cases or the potential for infants of parents too young to be aware
of the symptoms of FAP themselves.
The largest report of sporadic cases looked at 50 patients and found 5 germline antigen-pre‐
senting cell (APC) mutations. This led the authors to recommend routine screening for APC
mutations in all cases of sporadic HB, including both a screen for APC deletion or duplica‐
tion and sequencing through the gene itself. In the only prospective screening study to date,
20 children with confirmed or suspected FAP were followed for 10 years by ultrasonogra‐
phy, and no tumors were detected. In FAP, other forms of hepatocellular neoplasia are also
observed, including adenoma and HCC, as well as biliary adenomas.
The timelines of the development of these various cancers in distinct tissues are not linked,
and therefore, surveillance for these cancers needs to continue throughout the patient’s life
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[39]. Chronic cholestatic syndromes may be the substrate for liver cancers, with HB, cholan‐
giocarcinoma, and in the Alagille syndrome of a paucity of intrahepatic bile ducts due to
Jagged 1 or NOTCH mutations. Also, we have observed HB in three 2-year olds with con‐
genital hepatic fibrosis and autosomal recessive polycystic disease. HB and HCC have been
seen in the explants of infants with cirrhosis due to biliary atresia as early as 1 year. On the
basis of the growth rate of HCC and with the aim of detecting tumors when they are 3 cm in
diameter, the American Association for the Study of Liver Disease and the European Associ‐
ation for the Study of the Liver recommend screening ultrasound examinations at 6-month
intervals, and some institutions shorten this interval to 3 months when the patient is on a
transplant waiting list. These organizations have also published diagnostic criteria for liver
nodules detected during the screening process.
HCC can be diagnosed noninvasively by computed tomography (CT) or magnetic reso‐
nance imaging (MRI) if a lesion 2cm in diameter within a cirrhotic liver demonstrates rap‐
id contrast enhancement during the arterial phase and washout on the delayed venous
phase. These guidelines were developed for cirrhotic adults, and there are no validated evi‐
dence-based guidelines for screening for tumors in children and adolescents with chron‐
ic liver disease.
According to adult data, ultrasound is insensitive for the diagnosis of HCC in the cirrhotic
liver and should not be used for the detection of focal liver lesions in this setting. MRI is
more sensitive than multidetector 3-phase CT for the diagnosis of regenerative and dysplas‐
tic nodules and is comparable to CT for the detection of HCC. There is a lower false-positive
rate with MRI. Interval growth is probably the best indicator of malignancy, and there is a
definite need for the establishment of protocols for follow-up imaging in centers that care
for children with diffuse liver disease.
In the case of hereditary tyrosinemia type 1 due to fumaryl acetoacetate hydrolase deficien‐
cy, prompt medical management, by blocking an enzyme upstream in the tyrosine catabolic
pathway, can avert the injury that otherwise leads to HCC more often than any other meta‐
bolic defect. However, a low risk of developing HCC remains even with adequate medical
management, so these children require life-long surveillance. Therefore, for the conditions
listed, periodic abdominal ultrasonography and serum alpha fetoprotein measurements, at
3-month intervals in the case of Beck-with-Wiedemann syndrome and similarly for the first
3 years of life for others and then every 6 months thereafter, are advocated [40, 41]. In addi‐
tion, recognition of the rare sequential occurrences of mesenchymal hamartoma and sarco‐
ma and of hemangioendothelioma with angiosarcoma indicates the need for surveillance
ultrasonography whenever a complete resection or transplant has not taken place [42, 43].
5. Staging
The process  used to  find out  if  cancer  has  spread within  the  liver  or  to  other  parts  of
the  body  is  called  staging.  The  staging  system would  be  useful  in  determining  treat‐
ment  plans  and  offers  good  prognostic  value  for  overall  and  disease-free  survival  out‐
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come.  Historically,  north  Americans  have  staged  liver  tumors  similar  to  other  solid
tumors,  with  surgical  resectability  and the  presence  of  metastases  as  the  primary  crite‐
ria.  The European staging system considers only the pretreatment extent of disease, and
was developed by the Childhood Liver Tumor Strategy Group. After childhood liver can‐
cer  has  been  diagnosed,  tests  are  done  to  find  out  if  cancer  cells  have  spread  within
the  liver  or  to  other  parts  of  the  body.  The  PRETEXT staging  system divides  the  liv‐
er  into  four  sectors,  and the number of  segments  involved by tumor indicates  stage.  A
lettering  system further  indicates  extrahepatic  involvement.The  information  gathered
from the  staging  process  determines  the  stage  of  the  disease  [44,  45].
The following tests and procedures may be used in the staging process: -CT scan (CAT
scan): This procedure is also called computed tomography, computerized tomography, or
computerized axial tomography. The pictures are made by a computer linked to an x-ray
machine. A procedure that makes a series of detailed pictures of areas inside the body, taken
from different angles. A dye may be injected into a vein or swallowed to help the organs or
tissues show up more clearly.
-MRI (magnetic resonance imaging): Also called nuclear magnetic resonance imaging
(NMRI), a procedure that uses a magnet, radio waves, and a computer to make a series of
detailed pictures of areas inside the body.
-Ultrasound exam: A procedure in which high-energy sound waves (ultrasound) are
bounced off internal tissues or organs and make echoes. The echoes form a picture of body
tissues called a sonogram. The picture can be printed to be looked at later.
-Surgery: An operation will be done to look at or remove the tumor. Tissues removed dur‐
ing surgery will be checked by a pathologist.
There are 2 staging systems for childhood liver cancer.
-Presurgical (before surgery) staging: This staging system is called PRETEXT, based on
imaging procedures such as MRI or CT, where the tumor has shown within the four parts
(sections) of the liver.
The liver is divided into 4 vertical sections.
In PRETEXT stage 1(Fig. 2A), the cancer is found in one section of the liver. Three sections of
the liver that are next to each other do not have cancer in them.
In PRETEXT stage 2 (Fig. 2B), cancer is found in one or two sections of the liver. Two sec‐
tions of the liver that are next to each other do not have cancer in them.
In PRETEXT stage 3(Fig. 2C), the cancer is found in three sections of the liver and one sec‐
tion does not have cancer. OR, cancer is found in two sections of the liver and two sections




Postsurgical (after surgery) staging: The stage is based on the amount of tumor that remains
after the patient has had surgery to look at or remove the tumor.
Stage I
In stage I, all of the cancer was removed by surgery in the liver.
Stage II
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In stage II, a small amount of cancer remains in the liver, but it can be seen only with a mi‐




In stage III, the tumor cannot be removed by surgery; orcancer that can be seen without a
microscope remains after surgery; or the cancer has spread to nearby lymph nodes.
Stage IV
In stage IV, the cancer has spread to other parts of the body. Cancer invades the surround‐
ing normal tissue. Cancer invades the lymph system and travels through the lymph vessels
to other places in the body. Cancer invades the veins and capillaries and travels through the
blood to other places in the body.
The metastasis is described as when cancer cells break away from the primary (original) tu‐
mor and travel through the lymph or blood to other places in the body, another (secondary)
tumor may form [46]. The secondary (metastatic) tumor is the same type of cancer as the pri‐
mary tumor. For example, if breast cancer spreads to the bones, the cancer cells in the bones
are actually breast cancer cells. The disease is metastatic breast cancer, not bone cancer.
Figure 4.




The key to successful treatment of malignant liver tumors in children is surgical removal,
either by tumor resection/partial hepatectomy or Live Transplantation. Historically, com‐
plete surgical resection of the primary tumor has been required to cure malignant liver tu‐
mors in children. Complete surgical resection of the primary tumor continues to be the goal
of definitive surgical procedures, but surgical resection is often combined with other treat‐
ment modalities (e.g., chemotherapy) to achieve this goal. SIOPEL recommends initial che‐
motherapy, while the American guidelines from COG require primary resection if possible,
followed by chemotherapy, unless the tumor is pure fetal type HB stage 1, when the chemo‐
therapy is not given. Both strategies have been successful in increasing the 5-year survival
rates in HB to approximately 80% due to effective chemotherapy (cisplatinum in combina‐
tion with doxorubicin or vincristine). Moreover, the timing and nature of surgical interven‐
tions are better defined for HB, and they are well-placed within the management protocols.
For HCC, however, complete surgical excision or transplantation are essential for cure, and
chemotherapy is not effective. On the whole, treatment planning by a multidisciplinary
team of cancer specialists with experience treating tumors of childhood is required to deter‐
mine and implement optimum treatment [47, 48].
The most important step in the management of benign tumors in children is confirmation of
their genuine benign nature. Multiphase contrast CT imaging and, less frequently, direct an‐
giography are required for the radiological diagnosis. Some of the benign tumors, including
IHE, mesenchymal hamartoma, and FNH, would have characteristic radiological features,
not always requiring a tissue diagnosis.
Many of the improvements in survival in childhood cancer have been made using new
therapies that have attempted to improve on the best available, accepted therapy. Clinical
trials in pediatrics are designed to compare potentially better therapy with therapy that is
currently accepted as standard.Because of the relative rarity of cancer in children, all chil‐
dren with liver cancer should be considered for entry into a clinical trial. This comparison
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may be done in a randomized study of two treatment arms or by evaluating a single new
treatment, comparing the results with those previously obtained with standard therapy [49].
6.1. Surgical approaches
The timing of the surgical approach is critical. For this reason, surgeons with experience in
pediatric liver resection and transplantation should be involved early in the decision-mak‐
ing process for determining optimal timing and extent of resection.There are three ways in
which surgery is used to treat primary pediatric liver cancer, including initial surgical resec‐
tion (alone or followed by chemotherapy), delayed surgical resection (chemotherapy fol‐
lowed by surgery) and orthotopic liver transplantation [50].
Figure 6. The lesion to resect is marked out.
Figure 7. Electrocautery is useful for dissecting through the liver capsule and parenchyma.
Resection is typically performed through a bilateral subcostal incision, and, occasionally, a
right thoracoabdominal approach is necessary for large lesions arising high in the right lobe.
Surgical resection has seen applications of newer technology. Intraoperative ultrasonogra‐
phy has been widely applied to determine the exact location of the tumor relative to the ves‐
sels. Once deemed resectable, the resection is marked out (Fig. 3, 4), and various tools may
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then be used to perform the resection; electrocautery, bipolar devices such as LigaSure, and
argon beam coagulation for hemostasis have been used.
The most frequently performed procedure is a right hepatectomy (60%) because hepatoblas‐
tomas (HBs) occur 3 times more often in the right lobe than in the left. The hilar plate is div‐
ided, exposing the bifurcation of the hepatic artery and portal vein. These structures are
ligated (Fig. 5).
Figure 8. Suture and ligation may be useful in sealing blood vessels and hepatic ducts.
In an extended right hepatectomy, the middle hepatic vein is ligated and segment 4 is resect‐
ed. The right hepatic vein is identified and ligated before any division of the hepatic paren‐
chyma. At completion, only segments 2 and 3 and the caudate lobe remain.
Left hepatic lobectomy begins the same way right hepatectomy, with division of the left
hepatic artery and left branch of the portal vein. The left and middle hepatic veins are iden‐
tified after dissection through the sinus venosus. The liver is then transected after vascular
isolation of the resected segments. An extended left hepatectomy includes removal of all or
most of segments 5 and 8. Unresectability is usually determined by involvement of hilar
structures or all hepatic veins, multicentricity, and invasion of inferior vena cava (IVC) or
portal vein. Centrally located tumors are, by definition, more likely unresectable.
Laparoscopic and robotic resections of both benign and malignant liver tumors have been
described. Their role in standard practice is still being defined.
If preoperative chemotherapy is to be administered, it is very important to consult frequent‐
ly with the surgical team concerning the timing of resection, as prolonged chemotherapy
can lead to unnecessary delays and in rare cases, tumor progression. If the tumor can be
completely excised by an experienced surgical team, less postoperative chemotherapy may
be needed.
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In PRETEXT stage 3 or 4 disease patients with involvement of major liver vessels, early in‐
volvement with an experienced pediatric liver surgeon is especially important, patients
with. Although initially thought to be a contraindication to resection, experienced liver sur‐
geons could also perform aggressive approaches avoiding transplantation for vascular in‐
volvement patients. Accomplishing a complete resection is imperative since rescue
transplant of incompletely resected patients has an inferior outcome compared to patients
who are transplanted as the primary surgical therapy.
Surgical resection of distant disease has also contributed to the cure of children with hepato‐
blastoma and is often performed at the same time as resection of the primary tumor. Resec‐
tion of pulmonary metastases is recommended when the number of metastases is limited.
When possible, resection of areas of locally invasive disease, such as in the diaphragm, and
of isolated brain metastasis is recommended. Second resection of positive margins and/or
radiation therapy may not be necessary in patients with incompletely resected hepatoblasto‐
ma whose residual tumor is microscopic and who receive subsequent chemotherapy.
Major intraoperative complications include hemorrhage, air embolism, tumor embolus, and
bile duct injury. Only 20% of the liver is necessary to maintain hepatic function; thus, post‐
operative insufficiency is rare. Postoperative complications include hemorrhage, bile leak,
abscess formation, pulmonary complications, and wound problems. Postoperative care con‐
sists of adequate fluid replacement, intravenous albumin supplementation, vitamin K, and
clotting factors for the first 3-4 days. The liver function test results generally normalize with‐
in the first 2 weeks, and hepatic insufficiency is reasonably rare. Postoperative monitoring
consists of frequent ultrasonography, chest radiography, and serial α -fetoprotein (AFP) lev‐
el measurements, generally at 3-month to 6-month intervals.
Tumor rupture at presentation, resulting in major hemorrhage that can be controlled by
transcatheter arterial embolization or partial resection to stabilize the patient, does not pre‐
clude a favorable outcome when followed by chemotherapy and definitive surgery. The de‐
cision as to which surgical approach to use depends on many factors including: PRETEXT
stage, size of the primary tumor, presence of multifocal hepatic disease, AFP levels, Vascular
involvement, preoperative chemotherapy as well as orthotopic liver transplantation criteria.
In North American clinical trials, the Children's Oncology Group (COG) has recommended
that surgery be performed initially if a complete resection can be accomplished. COG is in‐
vestigating the use of PRETEXT stage at diagnosis and after chemotherapy to determine the
optimal surgical approach and its timing. In European clinical trials, only patients with PRE‐
TEXT stage 1 receive resection surgery and all other patients are biopsied [51, 52, 53].
It is difficult to compare the North American and European approaches. Somewhat com‐
parable results for children with PRETEXT stage 1 and 2 tumors were obtained in two in‐
ternational studies. The 5-year survival of PRETEXT stage 1 and 2 patients(chemotherapy
prior to attempted surgical resection of the primary liver tumor) is 90% to 100% on the
European studies and seems to be similar to that of children treated on North Ameri‐
can studies where surgery was performed before chemotherapy. In comparison, a sur‐
vey of children with liver tumors who were treated prior to the consistent use of combination
chemotherapy found that 45 of 78 patients (57%) with hepatoblastoma who had com‐
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plete excision of the tumor survived while no children with positive margins or gross dis‐
ease following resection survived.
6.2. Orthotopic liver transplantation
Orthotopic liver transplantation was first described in 1968 by Starzl. Liver transplantation
has recently been associated with significant success in the treatment of children with unre‐
sectable hepatic tumors. The criteria currently used to evaluate adult transplant candidates
may not be applicable for pediatric patients. The main indication for transplantation is non‐
metastatic, unresectable lesions. Extrahepatic disease and lymph node involvement did not
prove to be contraindications. Hepatoblastoma (HB) now constitutes an indication for 3% of
all pediatric liver transplantations, whereas the role of liver transplantation for HCC is more
controversial. In hepatocellular carcinoma, vascular invasion, distant metastases, lymph
node involvement, tumor size, and male gender were significant risk factors for recurrence.
Because of the poor prognosis in patients with hepatocellular carcinoma, liver transplant
should be considered for disorders such as tyrosinemia and familial intrahepatic cholestasis
early in the course, prior to the development of liver failure and malignancy. Because no
good medical therapy for pediatric HCC has been identified, liver transplantation should be
carefully evaluated as front-line therapy. Additionally, successful transplantation has been
used benign lesions such as diffuse hepatic hemangiomas. In addition, liver transplantation
may be an option in children with unresectable primary tumors, without metastatic disease,
after neoadjuvant chemotherapy and pulmonary metastasectomy, if necessary. It has been
suggested that adjuvant chemotherapy following transplant may decrease the risk of tumor
recurrence. Generally, preoperative and postoperative chemotherapy are recommended, in
addition to postoperative immunosuppression [54, 55, 56].
Transplantation  may  also  be  used  in  selected  cases  of  tumor  recurrence  but  is  much
less  successful  when used for  salvage therapy.  There  are  discrepant  results  on the  out‐
comes for patients with lung metastases at diagnosis who undergo orthotopic liver trans‐
plantation  following  complete  resolution  of  lung  disease  in  response  to  pretransplant
chemotherapy.  Some  studies  have  reported  favorable  outcomes  for  this  group  of  pa‐
tients, while others have noted high rates of hepatoblastoma recurrence. All of these stud‐
ies  are  limited  by  small  patient  numbers;  further  study  is  needed  to  better  define
outcomes  for  this  subset  of  patients  [57,  58].
A review of the world experience has documented a posttransplant survival rate of 70% to
80% for children with hepatoblastomas. Intravenous invasion, positive lymph nodes, and
contiguous spread did not have a significant adverse effect on outcome.
The primary cause of death for both HB and HCC was metastatic disease. Generally, the 5-
year survival rate for patients transplanted for HB is 70%.
A study of the United Network for Organ Sharing (UNOS) database reported 135 patients
undergoing 135 transplants for HB and 43 transplants for HCC with 1-year, 5-year, and 10-
year survival of 79%, 69%, and 66% for HB, respectively, and 86%, 63%, and 58% for HCC,
respectively [59, 60]. Liver transplantation for hepatic hemangioma has been studied in 59
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patients in Europe with 1-year, 5-year, and 10-year patient survival rates of 93%, 83%, and
72%, respectively.
The availability of donor organs has increased with the use of split-liver grafting and other
"technical variant" techniques, along with living-related liver transplant techniques. Progno‐
sis in terms of graft and patient survival appear to be the same between full-size liver and
technical variant liver transplants; however, morbidity following transplant appears to be
higher in those patients who receive technical variant grafts [61, 62, 63, 64].
Early failure of liver transplant (< 30 d) is usually due to vascular complications or primary
nonfunction. Late failure is usually more a result of infection, posttransplant lymphoproli‐
ferative disease, chronic rejection, biliary complications, or recurrence of malignant disease.
These failures may warrant retransplantation. The predictors of success after retransplanta‐
tion remain unknown. The United Network for Organ Sharing (UNOS) Standard Transplant
and Research Files registry reported all children younger than 18 years listed for a liver
transplant in the United that the 5-year survival rates of 69% for hepatoblastoma and 63%
for hepatocellular carcinoma and the 10-year survival rates were similar to the 5-year rates.
Application of the Milan criteria for UNOS selection of recipients of deceased donor livers is
controversial. However, living donor liver transplants are more common with children and
the outcome is similar [65, 66, 67, 68, 69].
6.3. Chemotherapy
In recent years, virtually all children with hepatoblastoma have been treated with chemo‐
therapy, which may reduce the incidence of surgical complications at the time of resection,
and in some centers, even children with resectable hepatoblastoma are treated with preoper‐
ative chemotherapy. For PRETEXT stage 1 hepatoblastoma, it was resected and treated with
doxorubicin and cisplatin chemotherapy. The pre-resection neoadjuvant chemotherapy
(doxorubicin and cisplatin) was given to all children with PRETEXT stage 2, 3, or 4 hepato‐
blastoma with or without metastases. The chemotherapy was well tolerated. This strategy
resulted in an OS of 75% at 5 years after diagnosis. Identical overall results were seen in a
follow-up international study. Following chemotherapy, and excluding those who received
liver transplant (less than 5% of patients), complete resection was obtained in 87% of chil‐
dren. In contrast, an American Intergroup protocol for treatment of children with hepato‐
blastoma, encouraged resection at the time of diagnosis for all tumors amenable to resection
without undue risk. The protocol did not treat children with stage I tumors of purely fetal
histology with preoperative or postoperative chemotherapy unless they developed progres‐
sive disease. Further study will be needed to determine whether presurgical chemotherapy
is preferable to resection followed by chemotherapy for children with PRETEXT stage 2, 3,
and 4 hepatoblastoma [70, 71].
Routine assessment of hearing, renal, and cardiac function is standard during treatment for
pediatric malignancies. Post-chemotherapy neutropenia rarely represents additional con‐
cerns during the surgical treatment. Platinum compounds (cisplatin and carboplatin), which
have been a backbone of the successful treatment for pediatric liver tumors, are also quite
ototoxic. Around 40% of children develop significant hearing loss, which typically affects
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high-register tones, and could be delayed. Chronic dose-related nephrotoxicity remains a
significant long-term issue for both chemotherapy for malignant liver tumors and calcineur‐
in inhibitor-based immunosuppression. Therefore, early use of calcineurin inhibitor-sparing
agents, such as mycophenolate mofetil or sirolimus, is recommended for children after LT
for liver tumors. Nevertheless, it is prudent not to give chemotherapy 2 weeks before or af‐
ter resection or LT.
In rare cases, intensive platinum- and doxorubicin-based multidrug chemotherapy can in‐
duce complete regressions in approximately 50% of patients, with subsequent 3-year event-
free survival of 56% for pulmonary metastases and eliminated multinodular tumor foci in
the liver. Chemotherapy has been much more successful in the treatment of hepatoblastoma
than in hepatocellular carcinoma.
6.4. Other Treatment Approaches
Other treatment approaches such as transarterial chemoembolization, have been used for
patients with postsurgically-staged stage III hepatoblastoma. Transarterial chemoemboliza‐
tion has been used in a few children to successfully shrink tumor size to permit resec‐
tion.Cryosurgery, intratumoral injection of alcohol, and radiofrequency ablation can
successfully treat small (<5 cm) tumors in adults with cirrhotic livers. Some local approaches
such as cryosurgery, radiofrequency ablation, and transarterial chemoembolization that
suppress hepatocellular carcinoma tumor progression are used as bridging therapy in adults
to delay tumor growth while on a waiting list for cadaveric liver transplant [72].
7. Medical issues related to current chemotherapy
It is no surprise that most of the toxicity data stem from HB treatment survivors, while infor‐
mation from the HCC setting is lacking.
7.1. Recurrent hepatic tumors
The prognosis for a patient with recurrent or progressive hepatoblastoma depends on many
factors, including the site of recurrence, prior treatment, and individual patient considera‐
tions. If possible, isolated metastases should be resected completely in patients whose pri‐
mary tumor is controlled. For example, in patients with stage I hepatoblastoma at initial
diagnosis, aggressive surgical treatment of isolated pulmonary metastases that develop in
the course of the disease may make extended disease-free survival possible. Liver transplant
should be considered for patients with isolated recurrence in the liver. Combined vincris‐
tine/irinotecan has been used with some success. Some patients treated with cisplatin/
vincristine/fluorouracil could be salvaged with doxorubicin-containing regimens, but pa‐
tients treated with doxorubicin/cisplatin could not be salvaged with vincristine/fluorouracil.
Treatment in a clinical trial should be considered if all of the recurrent disease cannot be sur‐
gically removed. Phase I and phase II clinical trials may be appropriate and should be con‐
sidered [73, 74].
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The prognosis for a patient with recurrent or progressive hepatocellular carcinoma is poor.
Chemoembolization or liver transplant should be considered for those with isolated recur‐
rence in the liver. Phase I and phase II clinical trials may be appropriate and should be con‐
sidered [75, 76].
8. Summary and future issues
Management of pediatric liver tumors has significantly improved over the last 2 decades.
The principal reasons are that efficient chemotherapy and established medico-surgical treat‐
ment algorithms for HB have now integrated LT as a very valuable complementary treat‐
ment option. The management options for HCC are less effective and not well defined,
broadly mirroring the therapeutic guidelines in adults except for a more cautionary ap‐
proach to neoadjuvant and loco-regional methods. In the pediatric context the main clinical
aims are to reduce chemotherapy toxicity (predominantly ototoxicity and nephrotoxicity) in
children treated for HB and to investigate additional modes of treatment for HCC.
Improved understanding of HB and HCC biology may improve risk stratification a presen‐
tation and direct the treatment at specific molecular targets in the future. Management of
less common benign and malignant tumors should benefit from establishing international
collaborative pediatric networks such as the Pediatric Liver Unresectable Tumor Observato‐
ry (PLUTO).
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1. Introduction
The biological effects of radiofrequency (RF) waves were first reported on liver lesions by
McGahan et al. in 1990 [1].
The early reports on the efficacy and safety of radiofrequency ablation (RFA) for liver tu‐
mors have encouraged rapid spreading of the technique for the treatment of unresectable or
even resectable tumors. Nowadays RFA constitutes a wide-range therapeutical option for a
variety of tumors. The vast majority of the reports about RFA refer to malignant liver tu‐
mors. There are only few authors who attest the efficiency of this in situ ablative method for
benign liver tumors (e.g. hepatic cavernous hemangioma, hepatic adenoma). RFA must be
integrated in a complex multimodal treatment for patient with liver tumors. Selected pa‐
tients may also benefit of simultaneous and/or consecutive association of RFA with other
treatments like surgery, chemotherapy, and other in situ ablation procedures.
All the authors concur to the fact that RFA is a technology-based treatment. However, the
importance of operator experience in this treatment must not be alluded. Not only the com‐
plete knowledge of the RF armamentarium but also patient and approach selection for RFA
are mandatory to certify this method as an effective and safe technique for treatment of the
liver tumors [2].
It must be underscore that RFA is not just a simple technique of inserting a needle to “cook”
the tumors but is a new technology in the treatment of liver tumors with a steep learning
curve which may offer these patients a 50-95% chance of destroying these lesions [3].
While RFA is most commonly performed in the radiology departments through a percuta‐
neous approach, our experience over 5 years determines us to advocate for the laparoscopic
ablation of liver tumor using RF. Even if it is still a debate on the correlation of the different
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RFA approaches with the results in terms of recurrence and survival, our recommendation
is to use laparoscopic RFA (LRFA) whenever possible.
With this paper we intend to offer a review regarding the laparoscopic ablations with RF for
patients suffering from liver tumors. We aim to describe the RF and ultrasound equipment,
define the selection criteria of the patients for this kind of approach, present the ablation
procedure, and the follow-up criteria, and discuss the LRFA outcomes in terms of procedur‐
al-related morbidity and mortality, tumor recurrence, and patient survival.
2. Methods
A review of relevant articles was undertaken based on a Medline search from January 1998
till January 2012.
2.1. Mechanism of RFA
When high-frequency (350-500 kHz) alternating current passes the tissues, polar molecules
(e.g. water molecules) are orientated in conformity with the field polarity [4]. With every change
of the polarity of the alternating current polar molecules are moving in attempt to follow its
direction. Their ionic vibration results in dielectrical losses into tissues because of molecular
friction. The dielectric losses generate heat (frictional heating) which causes thermal tissues
injuries. The extension and type of the thermal lesions depend on the temperature and dura‐
tion of current applications. These lesions begin at 420C. Above this level the time of lethal
exposion drops progressively: 8 min at 460C, 4-5 min at 50ºC. At 60ºC the cellular death is
inevitable due to irreversible lesions of mitochondrial and cytoplasmatic enzymes secon‐
dary to thermal protein denaturation [5]. Tissue desiccation occurs at 100ºC. But quick tissue
heating over 100ºC has the disadvantage of fast increasing thetissue impedance due to char‐
ring, which consecutively restricts the heat propagation and eventually coagulation necrosis
[5]. Malignant cells are more prone to damages due to hyperthermia than normal cells [6].
2.2. Indications of RFA
RFA is now gaining popularity as the preferred modality of local ablation for patients with
malignant liver tumors who are not surgical candidates (table 1).
RFA is used to treat liver lesions considered unresectable due to their bulky volume, posi‐
tion near key vessels, multiplicity or insufficiency of remnant liver parenchyma.
In terms of the extend of hepatic disease we consider safe to perform LRFA on patients with
total tumor volume less than 20% contrary with opinion of other authors who reported good
results in patients with up to 50% total liver replacement [3].
RFA has an important role in converting nonresectable in resectable tumors and also in in‐
creasing resectability of multiple liver tumors. Resections of such tumors are feasible d’em‐
blee or in two-stage procedure. RFA of the small and deeply situated tumor(s) in one
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hepatic lobe can be associated with resection of a large tumor or multiple tumors located in
the controlateral lobe or with controlateral portal vein ligation. The procedure can also be
performed before liver resection for tumors located in the section plane in order to obtain
disease-free margins.
Patients with liver tumor but with general contraindications for hepatic resection or those
who refuse the operation are also candidates for RFA.
Moreover, the application of RFA has now expanded to patients as a bridge to liver trans‐
plantation. RFA proved benefits for patients with cirrhotic and HCC who are within Milano
criteria on the waiting list for liver transplantation. It also have been shown to result in
down staging the HCC in cirrhotic patients beyound the Milano criteria and thus in listing
these patients for liver transplantation.
Patient with primary or metastatic hepatic tumor(s) which are not candidates for hepatic resection
                       Tumor characteristics
                                        multiple diffuse bilobar
                                                           in association with hepatic resection
                                                           in association with transarterial chemoembolization of hepatic artery
                                       deeply situated
                                       near the portal pedicles, hepatic veins, inferior vena cava
                                       recurrence after major hepatectomies
                                       small HCC on cirrhosis in patients (in Milan criteria) on waiting list for LTx
                              large HCC on cirrhosis in patients (out of Milan criteria) to be included on the waiting list after
                                       downstaging
                                       large unresectable tumor for downstaging followed by hepatectomy
                                       number ≤ 5 (14)
                                       maximum diameter ≤ 5 (7, 8) cm
                      Poor liver parenchyma function
                      Patient with benign hepatic tumor
                      Co-morbidities which increase the anesthesia-surgical risk
                      Patient refusal of hepatic resection
Patient expectation survival ≥ 3 months
Other tumor localizations which can be treated
Written informed consent of the patient
Table 1. Indications of RFA.
Based on some studies there are authors who plead for RFA even as a substitute to hepatic
resection for small liver tumors.
Patients with hepatic malignancies, except those with neuroendocrine tumors, should be ap‐
proached with curative intent and the goal of extending survival. Curative intent means that
similar to liver resection the ablation has to completely destroy not only the tumor but also
at least 0.5-1 cm zone of normal liver parenchyma.
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RFA approaches with the results in terms of recurrence and survival, our recommendation
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the controlateral lobe or with controlateral portal vein ligation. The procedure can also be
performed before liver resection for tumors located in the section plane in order to obtain
disease-free margins.
Patients with liver tumor but with general contraindications for hepatic resection or those
who refuse the operation are also candidates for RFA.
Moreover, the application of RFA has now expanded to patients as a bridge to liver trans‐
plantation. RFA proved benefits for patients with cirrhotic and HCC who are within Milano
criteria on the waiting list for liver transplantation. It also have been shown to result in
down staging the HCC in cirrhotic patients beyound the Milano criteria and thus in listing
these patients for liver transplantation.
Patient with primary or metastatic hepatic tumor(s) which are not candidates for hepatic resection
                       Tumor characteristics
                                        multiple diffuse bilobar
                                                           in association with hepatic resection
                                                           in association with transarterial chemoembolization of hepatic artery
                                       deeply situated
                                       near the portal pedicles, hepatic veins, inferior vena cava
                                       recurrence after major hepatectomies
                                       small HCC on cirrhosis in patients (in Milan criteria) on waiting list for LTx
                              large HCC on cirrhosis in patients (out of Milan criteria) to be included on the waiting list after
                                       downstaging
                                       large unresectable tumor for downstaging followed by hepatectomy
                                       number ≤ 5 (14)
                                       maximum diameter ≤ 5 (7, 8) cm
                      Poor liver parenchyma function
                      Patient with benign hepatic tumor
                      Co-morbidities which increase the anesthesia-surgical risk
                      Patient refusal of hepatic resection
Patient expectation survival ≥ 3 months
Other tumor localizations which can be treated
Written informed consent of the patient
Table 1. Indications of RFA.
Based on some studies there are authors who plead for RFA even as a substitute to hepatic
resection for small liver tumors.
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RFA was successfully used to treat patients with symptomatic and rapid-growth hepatic
cavernous hemangioma [7]. Application of LRFA for the treatment of benign tumor proved
to be safe and indicated also in patients with liver adenoma [8].
2.2.1. LRFA advantages
We advocate the laparoscopic approach to ablate the liver tumors with RF due to its advan‐
tages over the other two methods: percutaneous and open.
Laparoscopy represents a reliable diagnostic tool. Some authors consider that every liver re‐
section must be preceded by abdominal laparoscopic assessment of the disease [9]. By iden‐
tifying extrahepatic lesions, laparoscopy can up-stage the patients with cancer and can deem
these as unresectable or untreatable with in situ ablation procedures (except those with neu‐
roendocrine tumors).
Two third of the patients with advanced liver insufficiency being evaluated for orthotopic
liver transplantation are restaged after exploratory laparoscopy, laparoscopic ultrasound
(LUS) and Ultrasound-guided biopsy, half being downstaged and half upstaged [10]. This
finding determines some authors to indicate laparoscopic staging followed by LRFA for pa‐
tients with adenocirrhosis evaluated for liver transplantation unless there are unequivocal
clinical data supporting the stage of hepatocellular carcinoma [10].
Unsuspected intra-abdominal extrahepatic metastases can be noted in up to 26% of patients
with colorectal liver metastases [11].
Moreove laparoscopy either alone or in association with intraoperative ultrasound examina‐
tion can diagnose other liver lesions missed by the preoperative imaging examinations in up
to 38% cases [12]. LUS can detect lesions less than 2 cm in diameter.
The laparoscopic approach proved to be safe for the treatment of subcapsular tumors due to
the possibility of direct visualization and active protection of the surrounding structures
(gallbladder, stomach, duodenum, colon, diaphragm) and possibility to control the potential
bleeding from these lesions.
The pneumoperitoneum creates a working camera which not only removes the surrounding
structures from the liver but also reduces the respiratory movements of the liver and thus
facilitates the placement of the RF needle.
LRFA is also able to ablate deep-sited lesions difficult or impossible to be visualized by per‐
cutaneous US or to be punctured percutaneously. Some authors consider that for lesions lo‐
cated beneath the diaphragm laparoscopic approach can be associated [13] or even replaced
with the thoracoscopic one [14, 15].
For treating patients with large or multiple liver tumors LRFA seems to be the first choice.
Nevertheless, for tumors larger than 60 mm in diameter, tumors more than 5, and tumors
close to the hepatic vein or inferior vena cava, some author consider RFA via laparotomy to
be safer than LRFA [16].
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During LRFA the Pringle maneuver can be used if it is necessary. Pneumoperitoneum per se
has the advantage to decrease the blood flow and increase the area of ablation [17].
In patients with multiple hepatic lesions surgeons with high expertise can performed LRFA
in association with laparoscopic hepatic resection.
Comparing with the open technique, LRFA determines less intra-operative blood loss and
fewer postoperative complications [16].
Due to its minimal surgical trauma, LRFA determines a fast recovery time and short hospi‐
tal stay. It is our practice to discharge the patient 24-48 hours after the operation.
The benefits of LRFA in cirrhotic patients are certain when comparing with the open ap‐
proach. First, preservation of the abdominal wall and lack of the need to mobilize the liver
avoid interruption of large collateral veins and perihepatic ligaments, thus decreasing post‐
operative ascitic syndrome. Second, nonexposure of the viscera restricts the electrolytic and
protein losses and hence the fluids requirements which secondary improves absorption of
ascitis. Third, the laparoscopic approach is associated with lower intraoperative blood loss
due to the haemostatic effect of the positive pressure of peritoneum, meticulous intraopera‐
tive manipulations of the tissue under magnification, and smaller abdominal incisions. It
was reported that intraoperative blood loss is a major risk factor of postoperative morbidity
and death [18].
For liver tumor recurrences, LRFA can be repeated as needed.
It is still not finally settled which is the best RFA approach in terms of recurrence and sur‐
vival but we favor the laparoscopic one based on literature data and our experience.
2.2.2. Hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and fourth in annual
mortality. Its incidence continues to grow up secondary to the increasing prevalence of viral
hepatitis [19]. Hepatic resection and liver transplantation are considered the mainstay of
treatment of HCC being proven as the most effective treatments in means of disease-free in‐
terval and survival. However, less than 20% of HCC can be treated surgically because of
multifocal diseases, proximity of the tumor to key vascular or biliary structures precluding a
margin-negative resection, and inadequate functional hepatic reserve with cirrhosis. Usual‐
ly, noncirrhotic or Child A cirrhotic patients with single small HCC (≤5 cm) or up to three
lesions ≤3 cm are indicated for surgery.
2.2.2.1. Bridge to transplantation
The efficacy of RFA in wait-listed transplant candidates has been studied. Johnson et al. re‐
ported eight pretransplant patients treated solely by RFA and matched to a similar group by
age, sex, Child-Turcotte-Pugh class, and Model for End-Stage Liver Disease (MELD) score
who did not undergo treatment prior to transplant.[20] Patients pretreated with RFA were
able to remain on the transplant list for longer periods of time than their matched counter‐
parts. Dropout rates without RFA have been shown to be as high as 40%; however, the use
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Hepatocellular carcinoma (HCC) is the fifth most common malignancy and fourth in annual
mortality. Its incidence continues to grow up secondary to the increasing prevalence of viral
hepatitis [19]. Hepatic resection and liver transplantation are considered the mainstay of
treatment of HCC being proven as the most effective treatments in means of disease-free in‐
terval and survival. However, less than 20% of HCC can be treated surgically because of
multifocal diseases, proximity of the tumor to key vascular or biliary structures precluding a
margin-negative resection, and inadequate functional hepatic reserve with cirrhosis. Usual‐
ly, noncirrhotic or Child A cirrhotic patients with single small HCC (≤5 cm) or up to three
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The efficacy of RFA in wait-listed transplant candidates has been studied. Johnson et al. re‐
ported eight pretransplant patients treated solely by RFA and matched to a similar group by
age, sex, Child-Turcotte-Pugh class, and Model for End-Stage Liver Disease (MELD) score
who did not undergo treatment prior to transplant.[20] Patients pretreated with RFA were
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parts. Dropout rates without RFA have been shown to be as high as 40%; however, the use
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of RFA has decreased them to as low as 20%. The use of RFA as a bridge to transplantation
has proven to be an effective strategy. Control of tumor size and the theoretical prevention
of metastatic disease formation allow patients to remain on the waiting list for longer peri‐
ods, increasing their likelihood of obtaining a donor organ. RFA remains limited in its abili‐
ty to provide complete necrosis of large tumors and should not be expected to do so in
patients who are near the upper limits of transplant candidacy because of size criteria.
The need for an accurate intrahepatic staging is crucial for patients with HCC candidates to
an aggressive surgical or ablative treatment. Combinations of resection and ablation may be
required in certain cases, extending the indications for the laparoscopic approach to hepato‐
cellular carcinoma in liver cirrhosis. Laparoscopy with LUS seems to be useful to identify
unsuspected new nodules and to help in choosing the most suitable treatment. Laparoscopy
with LUS could represent a sound preliminary examination in patients who are candidates
to liver transplantation in order to both improve the staging and guide an interstitial thera‐
py as a bridge to the transplantation itself [21].
2.2.2.2. Resection versus RFA
Surgical resection is the gold standard of treatment for HCC in noncirrhotic and cirrhotic
patients who can tolerate hepatic resection. Noncirrhotic patients with HCC can usually un‐
dergo resection. However, patients with underlying cirrhosis are rarely candidates for resec‐
tion and often face a dismal prognosis. As a result, prospective studies comparing patients
who are surgical candidates and underwent RFA with those who underwent resection are
fairly limited.
2.2.2.3. The use of RFA in nonsurgical candidates
The reported rate of resectable HCC is low and ranges from 9% to 27%. It is limited by the
proximity of the tumor to major vascular and biliary structures that would preclude nega‐
tive resection margins, but more importantly by the degree of underlying liver disease and
Ability of the patient to tolerate hepatectomy. Small tumors are generally best suited for
RFA and provide the best results. However, larger lesions have also been ablated with
mixed success, occasionally even providing overall long-term survival of some patients with
HCC. Small lesions are generally considered those that are <3–3.5 cm in diameter.
Larger lesions are known to be more difficult to treat using RFA. Tumors >3 cm may require
repositioning of the electrode or multiple treatment sessions in order to obtain clear mar‐
gins. However, even using a more aggressive approach, the efficacy of RFA has been proven
to be limited by tumor size. Lesions measuring >5 cm have at best only a 50% chance of be‐
ing completely ablated.
Therefore, most authors do not recommend the use of RFA for tumors >5–6 cm because of
the technical limitations of the current used equipment and their inability to provide com‐
plete coagulative necrosis.
Despite the tumor size limitations of RFA, its use in unresectable HCC is significant. Those
who are not transplant candidates or are unable to undergo resection face a dismal progno‐
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sis, and RFA provides a chance for survival, especially for patients with smaller lesions.
However, the use of RFA should be discouraged in patients with large lesions or those who
have evidence of metastatic disease, because these groups have such a poor outcome that
RFA is unlikely to provide any tangible benefit.
2.2.2.4. Surgical resection in combination with LRFA
Patients with multifocal disease may be treated by a combined approach using both surgical
resection and RFA. The bulk of the tumor burden is initially resected, and RFA is then per‐
formed on any remaining unresectable lesions. However, there are few data to support this
approach, especially in the setting of HCC. Most agree that if HCC has progressed so exten‐
sively, the patient is unlikely to be cured even by aggressive combined modalities of this na‐
ture. Additionally, although well tolerated intraoperatively, RFA combined with hepatic
resection does place the patient at a higher risk for postoperative liver failure and death.
This is especially true in the cirrhotic patient with poor hepatic reserve prior to intervention.
Therefore, the role of LRFA in conjunction with resection must be used judiciously and
mandates further reviews before it can be recommended in the treatment of HCC.
2.2.3. Metastatic colorectal cancer
The liver is the most common site of distant metastases second only to lymph nodes [22].
Initially considered to be a terminal diagnosis, treatment of these lesions has provided sig‐
nificantly better outcomes for many of these patients, in comparision to those untreated.
Akin with the primary liver masses, surgical resection remains the gold standard therapy
for liver metastases from colorectal cancer.
Colorectal cancer is the leading cause of cancer death in US. At the time of exploration for
their primary tumor 16-25% of patients have liver metastases and about 25% will develop
such lesions in the disease course.
Colorectal cancer is responsible for up to 75% of liver metastases that undergo surgical treat‐
ment. For those who undergo resection of isolated liver metastases, the 5-year survival rate
has recently been shown to be as high as 58% [23]. Prospective studies that compare RFA
with Resection in operative candidates are extremely limited.
Unfortunately, up to 80% of the patients diagnosed with stage IV disease are not candidates
for resection. For unresectable liver metastases, alternative options, such as RFA alone or in
conjunction with other therapeutic modalities, are being explored to further improve surviv‐
al [24]. Criteria for unresectable metastases include bilobar disease that cannot be complete‐
ly excised, proximity to major vasculature structures precluding margin-negative resection,
and comorbid conditions that preclude surgery [25]. For these untreated patients, survival is
<5%–10% at 5 years [26].
Large trials evaluating the combination of RFA and resection are limited, and therefore it is
difficult to draw definitive conclusions regarding its efficacy and safety. As larger portions
of hepatic parenchyma are resected or ablated, the risk for liver failure increases, making it
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to be limited by tumor size. Lesions measuring >5 cm have at best only a 50% chance of be‐
ing completely ablated.
Therefore, most authors do not recommend the use of RFA for tumors >5–6 cm because of
the technical limitations of the current used equipment and their inability to provide com‐
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Despite the tumor size limitations of RFA, its use in unresectable HCC is significant. Those
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2.2.2.4. Surgical resection in combination with LRFA
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resection and RFA. The bulk of the tumor burden is initially resected, and RFA is then per‐
formed on any remaining unresectable lesions. However, there are few data to support this
approach, especially in the setting of HCC. Most agree that if HCC has progressed so exten‐
sively, the patient is unlikely to be cured even by aggressive combined modalities of this na‐
ture. Additionally, although well tolerated intraoperatively, RFA combined with hepatic
resection does place the patient at a higher risk for postoperative liver failure and death.
This is especially true in the cirrhotic patient with poor hepatic reserve prior to intervention.
Therefore, the role of LRFA in conjunction with resection must be used judiciously and
mandates further reviews before it can be recommended in the treatment of HCC.
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The liver is the most common site of distant metastases second only to lymph nodes [22].
Initially considered to be a terminal diagnosis, treatment of these lesions has provided sig‐
nificantly better outcomes for many of these patients, in comparision to those untreated.
Akin with the primary liver masses, surgical resection remains the gold standard therapy
for liver metastases from colorectal cancer.
Colorectal cancer is the leading cause of cancer death in US. At the time of exploration for
their primary tumor 16-25% of patients have liver metastases and about 25% will develop
such lesions in the disease course.
Colorectal cancer is responsible for up to 75% of liver metastases that undergo surgical treat‐
ment. For those who undergo resection of isolated liver metastases, the 5-year survival rate
has recently been shown to be as high as 58% [23]. Prospective studies that compare RFA
with Resection in operative candidates are extremely limited.
Unfortunately, up to 80% of the patients diagnosed with stage IV disease are not candidates
for resection. For unresectable liver metastases, alternative options, such as RFA alone or in
conjunction with other therapeutic modalities, are being explored to further improve surviv‐
al [24]. Criteria for unresectable metastases include bilobar disease that cannot be complete‐
ly excised, proximity to major vasculature structures precluding margin-negative resection,
and comorbid conditions that preclude surgery [25]. For these untreated patients, survival is
<5%–10% at 5 years [26].
Large trials evaluating the combination of RFA and resection are limited, and therefore it is
difficult to draw definitive conclusions regarding its efficacy and safety. As larger portions
of hepatic parenchyma are resected or ablated, the risk for liver failure increases, making it
Laparoscopic Radiofrequency Ablation of Liver Tumors
http://dx.doi.org/10.5772/52830
495
difficult to support the use of a combined approach without achieving a survival benefit. At
this time, there are few data to support combining RFA with surgical resection.
2.2.4. Liver metastasis from neuroendocrine tumors
Liver metastases occur in 5-90% of patients with neuroendocrine tumors and the specific
pattern of these is an indolent course, which may be dominated by symptoms related to hor‐
monal secretion.
The goal of surgical resection and RFA in most cases of both primary and metastatic liver
disease is curative. However, neuroendocrine tumors represent a unique group of slowly
growing, often highly symptomatic tumors that are unlikely to be cured by resection. The
untreated patients with unresectable neuroendocrine liver metastases have a 5-year survival
rate of 25-38%.[27] In patients with metastatic neuroendocrine tumors who are unlikely to
be cured by surgery or unable to tolerate an invasive form of treatment, RFA has been
shown to ameliorate the symptoms (95%), significantly or completely control the symptoms
(80%), and partially or significantly decrease the circulating hormone levels (65%) [28, 29].
LRFA seems appealing for these patients because the recurrence rate after resection is >80%
at 5 years. Moreover, in case of liver recurrence, LRFA can be repeated for maintaining tu‐
mor control in the liver without increasing morbidity.
2.2.5. Liver metastasis from nonneuroendocrine and noncolorectal tumors
Regarding the nonneuroendocrine and noncolorectal liver metastases there are few reports
on the utility of RFA to treat them. Patients with liver metastases from sarcoma, breast can‐
cer, gastric cancer, pancreatic adenocarcinoma, or malignant melanoma are predicted to
have a short survival due to the rapid diffusely disseminated disease. The overall median
survival for these patients is 33 months. The aim for these patients is to prolong life with
treatments which have low side effects and offer a good quality of life. Notwithstanding the
curative intention of the treatments, most of them are ultimately proven to be palliative due
to the progression of the disease. For these patients LRFA has not only curative but also de‐
bulking target. For the patients with nonresectable liver metastases, LRFA offers an overall
median survival of more than 51 months [30].
2.3. Contraindications of LRFA
These contraindication are:
• Patients ≤ 18 years-old or ≥ 80 years-old,
• Sever coagulopathy (PLT <50.000/mm3, PT, APTT >1,5N),
• Renal failure (serum creatinin > 2,5 mg/dl),
• Jaundice (bilirubinemia > 3 mg/dl, bile duct dilatation),
• Acute infection,
• Tumor vascular or organ invasion,
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• Patients with cardiac pacemaker, implanted metallic pieces,
• Sever mental disturbances,
• Pregnancy and breast feeding.
2.4. Patient preparation for LRFA
For all patients admitted for LRFA a baseline evaluation has to be done within one week be‐
fore the procedure. Besides history and clinical examinations, there are some mandatory lab‐
oratory tests and imaging examinations.
Laboratory tests consist of complete blood cell counts, coagulation profile, renal and liver
panel, and appropriate serum tumor markers.
Imaging examinations include percutaneous abdominal ultrasound, computer tomography,
magnetic resonance imaging (MRI), chest Rx, and, in selected cases, positron emission to‐
mography using 18FDG [12].
The patients known with cardiac problems should have a pretreatment cardiologic assess‐
ment in order to prevent the possible arrhythmia due to RFA. Without being an absolute
contraindication, patients with implanted cardiac pacemakers need special attention before,
during and after the procedure.
Due to the great risk of biliary injury during RFA of the central liver tumors, some authors
place preoperative prophylactic biliary stents in patients with such lesions [12].
A dose of intravenous antibiotics is given just before RFA. The duration of administration
depends on the various protocol used, being up to 5 days [2].
Informed consent of the patient is obtained before the procedure.
For LRFA the most used is the supine position of the patient. Only when there is a predomi‐
nance of the disease in the posterior segments of the liver the patient is put on the operating
table in left lateral position [31].
The LRFA is performed under general anesthesia.
2.5. The RF-equipment
2.5.1. The RF-equipment
Historically, the major impediment on RFA has been the size of the area to be ablated which
could be the explanation of the Achilles’ heel of this procedure: local tumor recurrence. In
order to improve the results, RF equipments have been continuously perfected.
The rapid increase of temperature (above 100°C) during RFA, leading to charring of the tis‐
sue and increase of impedance, was shown to be the main cause of the small coagulation
volumes. Many electrodes have been designed to improve energy deposition on tissue and
further increase coagulation volume. Nowadays there are various single or combined type
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difficult to support the use of a combined approach without achieving a survival benefit. At
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of electrodes. The main types are: single, cluster, multitined expandable, spiral expandable,







Power 250 W 200 W 200 W 60 W 200W 250 W
Frequency 460 kHz 480 kHz 480 kHz 375 kHz 480kHz 470 kHz
Ablation control Impedance and
temperature
Impedance Impedance Impedance Impedance Impedance
Energy delivery Monopolar
bipolar


























Expended Wet  Cooled
MRI Yes (XL) Yes (single or
cluster)
Yes (3.5cm) Yes Yes Yes (mono/
multipolar)
Table 2. Different characteristics of RF equipments and probes.
2.5.2. The ultrasound equipment
The ultrasound equipment used for ablation must have either a fixed or flexible linear lapa‐
roscopic ultrasound probe (figure 1A) or a fixed forward-viewing convex-array transducer
(figure 2B) and the possibility of Doppler imaging.
For improvement of tumor visualization and targeting for RFA, a prototype tracked ultrasound-
guided laparoscopic surgery system was design and used in clinical practice by some au‐
thors [33].  By tracking two-dimensional ultrasound images in physical space, the system
generates three-dimensional ultrasound volumes. Once the tumor is manually identified in
this volume, a targeting system is used to guide the tip of the RFA probe inside the tumor [33].
A picture-in-picture box with the quarter-size laparoscopic image superimposed over the
full-sized ultrasound image is of paramount importance for the coordination of the move‐
ment of the instruments.
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Figure 1. Ultrasound equipment. A. Ultrasound machine with flexible liniar transductor for laparoscopy. B. Ultrasound
machine with fixed convex transductor for laparoscopy
2.6. LRFA technique
2.6.1. Pneumoperitoneum induction
In many centers the Veress technique remains the most widespread method of induction of
peritoneum. Because the most common complications of laparoscopic surgery are related to
insertion of the Veress needle and the first trocar, alternatives such Hasson’s open method
or optical access trocar-insertion emerged. These alternative methods are especially useful in
patients with previous operations and intraabdominal adhesions.
The Hasson’s open method implies the transversing of the tissue planes under direct view
and carries the disadvantages of continuous air leaks and prolonged operating time. Besides
it can be cumbersome in obese patients.
The optical access trocars have been developed as an alternative means of transversing the
tissue planes under direct view. We advocate the use of optical access trocar which in our
department is the standard device for obtaining abdominal access in laparoscopic practice
since 1995 [34]. The method consists in introduction into abdomen of a 12-mm disposable
Optiview® trocar (Ethicon Endo-surgery Cincinnati, OH) or a 5-12 mm VisiportTM Plus Opti‐
cal trocar (Covidien)with an inserted 00 laparoscope.
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and carries the disadvantages of continuous air leaks and prolonged operating time. Besides
it can be cumbersome in obese patients.
The optical access trocars have been developed as an alternative means of transversing the
tissue planes under direct view. We advocate the use of optical access trocar which in our
department is the standard device for obtaining abdominal access in laparoscopic practice
since 1995 [34]. The method consists in introduction into abdomen of a 12-mm disposable
Optiview® trocar (Ethicon Endo-surgery Cincinnati, OH) or a 5-12 mm VisiportTM Plus Opti‐
cal trocar (Covidien)with an inserted 00 laparoscope.




Most of the patients submitted for LRFA can be treated with placement of two right subcos‐
tal ports. The umbilical placement of one trocar represents an impediment to reach the dome
of the liver from such a location.
Selected patients need insertion of the third or fourth trocar (figure 2). The additional trocars
may be needed for dissection of the intra-abdominal adhesions, performing cholecystectomy,
retraction of the adjacent organs, or multiple needle insertion for treating multiple tumors.
Figure 2. Patient with previous laparotomy, placed in supine position for LRFA of bilateral liver metastases. Three tro‐
cars are inserted: one for video, one for ultrasound transductor, and one aditional trocar for forceps. The RF probe is
percutaneously introduced.
2.6.3. Abdominal exploration
All adhesions that interfere with proper exploration of the abdomen are taken down. A sys‐
tematic and thorough visual exploration of the abdominal cavity is performed, and all peri‐
toneal surfaces are carefully examined for possible deposits, paying special attention to the
undersurface of the diaphragm, the hepatic round ligament, and the omentum. Lymph no‐
des in the hepatoduodenal ligament are examined for enlargement. The quality of the liver
parenchyma with regard to the degree of cirrhosis or steatosis is also assessed.
Laparoscopic ultrasound is performed systematically in a longitudinal fashion, different from
the transverse orientation in intraoperative ultrasound. For laparoscopic ultrasound liver
scanning, most authors use the linear probe. For a better visualization of the upper seg‐
ments or caudate lobe some authors favor the use of others probes. In some cases for a better
contact between the convex liver surface and the probe, instillation of normal saline solution
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into peritoneum can be very helpful to provide an acoustic window. Sometimes the abdo‐
men need to be desufflated to improve contact with the liver. The laparoscope and LUS probe
can be interchanged between the ports to provide different views of the liver and to enable
varying placements of the probe on the liver surface. Generally it is not needed to take down
the falciform ligament but the creation of a window in the falciform ligament allows the
exploration of the liver in patients with dense midline adhesions. Maintaining visual guid‐
ance of the probe’s position on the liver with the laparoscope aids in orientation. Scanning is
started with visualization of the point at which the three liver veins drain into the inferior
caval vein. The number and size of hepatic lesions and their segmental locations are careful‐
ly documented. The exact location of the liver masses relative to the central vascular struc‐
tures is aided by color Doppler, and the distance to the vessels is measured in centimeters,
considering a safe margin for ablation of 1 cm. Color Doppler is also used to assess the vascularity
of the hepatic lesions. The distance between hepatic lesion and surrounding viscera is evalu‐
ated in order to plan the ablation process.
2.6.4. Tumor biopsy
Once the lesions are mapped in the liver, a core biopsy is performed under ultrasound guid‐
ance using an 18-gauge spring-loaded biopsy gun (Microinvasive) and sent for frozen sec‐
tion to confirm malignancy. In some HHC, obtaining of proper amount of tumoral tissue is
difficult due to its inconsistency and repeated biopsy are needed. The tumor biopsy can also
be Obtained after the RFA having the advantage of harvesting a more consistent tissue frag‐
ment and avoiding the possible bleeding from liver puncture site. Tissue samples are taken
only from representative tumors and not from all.
 
2.6.5. RF needle insertion
Laparoscopic introduction of the RF electrodes into the liver tumors are ultrasound guided
and the operator has to plan very carefully the insertions. This represents the most difficult
part of the procedure, and most beginners under treat due to this.
Introduction of the electrodes especially to ablate large tumors, tumors near great vessels or
poor visualized tumor is very demanding using the fix or flexible linear-type ultrasound
probe (figure 1A). Often small and deep-seated tumors necessitate repeated trial-and-error
insertions of the RF electrode. The safety and the complete necrosis of ablation is very much
dependent on the RF electrode positioning.
For ablation of liver tumors under the guidance of a linear-type probe, the RF electrode
must be inserted from the abdominal wall cranially and parallel to the ultrasound probe. For
accurate tumoral insertion of the RF probe operator has to mentally establish in three di‐
mensions the insertion site and angle on the abdominal wall and also on the surface of the
liver. For small and deep-seated tumors, insertion of the electrode can be very difficult due
to the impossibility to observe the needle on a single image. Therefore, the ultrasound probe
has to be moved according to the position of the needle tip.
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ments or caudate lobe some authors favor the use of others probes. In some cases for a better
contact between the convex liver surface and the probe, instillation of normal saline solution
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caval vein. The number and size of hepatic lesions and their segmental locations are careful‐
ly documented. The exact location of the liver masses relative to the central vascular struc‐
tures is aided by color Doppler, and the distance to the vessels is measured in centimeters,
considering a safe margin for ablation of 1 cm. Color Doppler is also used to assess the vascularity
of the hepatic lesions. The distance between hepatic lesion and surrounding viscera is evalu‐
ated in order to plan the ablation process.
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difficult due to its inconsistency and repeated biopsy are needed. The tumor biopsy can also
be Obtained after the RFA having the advantage of harvesting a more consistent tissue frag‐
ment and avoiding the possible bleeding from liver puncture site. Tissue samples are taken
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2.6.5. RF needle insertion
Laparoscopic introduction of the RF electrodes into the liver tumors are ultrasound guided
and the operator has to plan very carefully the insertions. This represents the most difficult
part of the procedure, and most beginners under treat due to this.
Introduction of the electrodes especially to ablate large tumors, tumors near great vessels or
poor visualized tumor is very demanding using the fix or flexible linear-type ultrasound
probe (figure 1A). Often small and deep-seated tumors necessitate repeated trial-and-error
insertions of the RF electrode. The safety and the complete necrosis of ablation is very much
dependent on the RF electrode positioning.
For ablation of liver tumors under the guidance of a linear-type probe, the RF electrode
must be inserted from the abdominal wall cranially and parallel to the ultrasound probe. For
accurate tumoral insertion of the RF probe operator has to mentally establish in three di‐
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to the impossibility to observe the needle on a single image. Therefore, the ultrasound probe
has to be moved according to the position of the needle tip.
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Continuous monitorization of the position of the needle tip on the ultrasound image imme‐
diately after  puncturing the liver is  possible using the laparoscopic system with a fixed
forward-viewing convex-array transducer,  with a guide groove on the back of  the shaft
(figure 1B) [35]. Perpendicular direction of scanning of this transducer enable the easy and
accurate puncture of the deep-seated tumors. Unlike with other conventional linear-type, it
is not necessary to consider the insertion site on the abdominal wall and surface of the liver.
This transducer facilitates the needle insertion in tumors situated in segment VII, VIII, for
which scanning by linear-type probes is more difficult [35]. Some authors advocate the use
of the forward-viewing convex-array probe for lesions situated in segment I arguing that
this US-probe makes not only the imaging of the caudate lobe easily but also avoid the
insertion of the needle through segment IV which has the risk to damage major vessels and
biliary ducts [36].
Positioning the needle tip depends on the type of the electrode used. If a straight (nonex‐
pendable) electrode is used then it is advanced under US-guidance until its tip reaches and
passes the deep margin of the lesion in order to obtain a safe oncological rim of normal pa‐
renchyma. Depending on the tumor size and noninsulated distance of the electrode it might
take more than one application to complete the lesion ablation. Repositioning the electrode
is performed to obtain overlapping spherical or cylindrical ablations.
If the electrode has Christmas tree-type deployment then the tip of the electrode is posi‐
tioned also in correlation with the tumor diameter and the active size of the electrode. If on‐
ly one ablation is planned the tip of the electrode is advanced till it reaches the superficial
margin and the prongs are progressively deployed. If more than one ablation is intended
then the tip of the electrode is positioned into the tumor considering the dimension of the
prongs. After completing the first ablation, the prongs are undeployed, the electrode is re‐
tracted by 2-2.5 cm, the prongs are again deployed, and ablation reinitiated.
If one considers the use of an umbrella-type expandable electrode, the tip of the electrode
usually targets the center of the tumor. In case of a large tumor, the positioning of the elec‐
trode is similar with the previous expandable type.
Using the first-generation RITA Medical System model 30 (4 arrays) or model 70 (7 arrays), a
single ablation cycle is enough to destroy a tumor <3 cm. For tumors >3 cm overlapping
ablations are necessary using these probes. Using the second-generation of probes - RITA
Medical System Starbust XL (9 arrays, 5 cm) - the tumors <3 cm are ablated with a single 3
cm ablation, those of 3-4 cm with a single 4 cm ablation, those of 4-5 cm with one cycle of a 5
cm ablation and those of >5 cm with application of 2-4 cycles of ablation to obtain adequate
margins [29]. The new RITA System Starbust XLi enhanced permits ablation of the 5-7 cm
sized tumors with a single ablation cycle.
In patients with multiple lesions the duration of the ablation process can be shorten using
simultaneously two RF needles. However these simultaneous ablations are very demanding
due to real-time monitorization. In case of performing these, care must be taken to place the
needles apart otherwise much larger ablation area can result.
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Withdrawal of the RF needle after the ablation needs some consideration to discuss. RFA of
the needle track is needed not only to control the bleeding but also to avoid recurrences
along it. Bleeding from the needle track is seldom a problem but it might be cumbersome in
cirrhotic patients. Generally RF ablation with application of a 20-30W power suffices. If not,
laparoscopy permits us to control the bleeding by other means: electrocautery, haemostatics,
argon application.
2.6.6. Real-time monitoring of the ablation process
The ablation process is assessed in three ways:
1. monitoring the thermocouples temperatures,
2. observing the ablation effect by ultrasound,
3. checking the absence of the Doppler signal into the previously vascularized tumors.
Except of RITA generators all the others deliver energy to tissues automatically based on im‐
pedance feed-back control. Because the damages of the tissues are well established at certain
temperatures, we favor the use of RITA generators which control the ablation process using
the thermocouple temperature. The device can be manually preset to the target temperature.
We use for ablation a preset 1050C temperature at thermocouples. During the ablation proce‐
dure the temperatures of the thermocouples are monitorized and visualized on the display
of the device. The process can also be registered on a notebook connected to the system.
Aiming the enlargement of the ablation area, many authors have developed their own proto‐
col of ablation [37]. Due to animal experimental studies and our clinical experience, LRFA has
become a standardized operation. The time of ablation process depends on the tumor vol‐
ume. The mainstay is to achieve the target temperature progressively till the full deploy‐
ment appropriate to the tumor diameter. Our protocol is to deploy progressively the prongs
of the RF needle. The prongs are deployed at 2 cm and subsequently to 3 cm until target
temperature of 1050C is reached at all thermocouples. Then the catheter is advanced to 4 cm
and consecutively to 5 cm and maintain for 7 min at each deployment [37]. If the target
temperatures cannot be achieved the prongs are completely retracted and the catheter rotat‐
ed with 450 and then the prongs redeployed. While advancing the deployment of the prongs,
the temperature of the thermocouples decreases and then progressively increases. Some‐
times the reposition of the needle is needed to avoid the vicinity of the great vessels or to
maintain the prongs inside the liver parenchyma. Even when one to three prongs cannot reach
the highest temperature, the ablation procedure is continued taking them out of equation.
After the ablation is ceased, the monitoring of the thermocouples temperature is observed
and it should be noticed that it drops rapidly over the 10-20 s and slower after. The temper‐
atures higher then 60-700C at 1 min after ablation are considered relevant to a successful
ablation. In case of uncertain ablation, the needle is 450 rotated and the tines are again fully
deployed. If the temperatures are above 600C the ablation is well done. If not, the ablation
is repeated.
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The ultrasound visualization of the tumor ablation is possible due to the microbubbles for‐
mation into the tissue. These are caused by out gassing of dissolved nitrogen. The area of the
tumor becomes progressively hypoechoic and due to the gas shadow the deep edge of the
tumor is obscured (figure 3). This justify the planning of the ablation process from the deep‐
est tumor area to the superficial one. In about 10 min the gas is reabsorbed and the tumor
regains the initial aspect with the exception of some amount of gas and the needle track.
Figure 3. RFA ablation of HCC. A. Positioning the tip of the electrode in the hepatic tumor. B. RFA is started and micro‐
bubbles of gas determine appearance of hyperechoic images in the tumor. C. The extension of ablated tissue obscures
the deep edge of the tumor. From image collection of Dr. Boros Mirela.
Doppler control of the ablation process is useful in case of vascularized tumors to certify the
disappearance of the flow. Usage of the micro bubble contrast agents (e.g. SonoVue ® Bracco
International B.V., Holland) can add more help in assessment of the liver blood flow.
Fluorescence spectroscopy was tried in porcine models aiming to detect hepatocellular ther‐
mal damage in real time and hence ensure adequate tumor ablation [38].
Due to the skin burn complications reported after RFA, the monitorization of the skin tem‐
perature under the grounding pads needs to be mentioned. Especially in patients with large
or multiple tumors the position of the grounding pads is essential. The common position is
at the same distance on the anterior surface of the tights. These neutral electrodes are need‐
ed only when RF monopolar electrodes are used. The bipolar electrodes do not necessitate
these pads. It was showed that placing the ground pad over the patient’s back resulted in
delivering an increased power to the tumor itself and decreasing the time to reach the target
temperature [31]. When planning to use two needles two pair of grounding pad are mount‐
ed on the patient’s back and tight. After completing the ablation the peripheral small tumors
become volcanic crater-like and the larger ones appear as a depressed mass.
2.2.7. Useful intraoperative maneuvers
2.6.7.1. Saline-enhanced LRFA
Hypertonic saline injected through a side port on the shaft of the electrode prior to ablation
can be uniformly distributed within an encapsulated HCC and thus increase ionicity and
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conduction within the tumor. The result is an increased volume of ablation up to 6-7 cm di‐
ameter. On the contrary, this method is not safe for patients with scirrhous colorectal liver
metastases due to the unpredictability distribution of hypertonic saline.
2.6.7.2. Saline infusion systems
The electrodes designed with tiny channels can be used to infuse small volumes of saline
into tumor during ablation process in order to prevent desiccation and charring of the tumor
that would otherwise prevent conductivity and limit the ablation volume.
2.6.7.3. Vascular occlusion
The application of the Pringle maneuver for limited amounts of time has been shown by
some authors [39] to increase ablation volumes but was found inefficient by others [40]. The
vascular pedicle occlusion might be justified due to reduction of the heat-sink effect [41]. To‐
tal vascular exclusion of the liver was shown to result in the greatest increase in necrosis vol‐
ume when compared to no occlusion or Pringle maneuver [42].
The possibility of vessel damage or thrombosis secondary to RFA with vascular inflow oc‐
clusion was pointed out by some authors [43]. These vascular side effects could be increased
in such cases when one or more of electrode prongs are placed in the lumen of a vessel [44].
Moreover, increased ablation secondary to Pringle maneuver carries with it an associated
risk of biliary, portal, or parenchymal injury [45].
We consider reasonable not to perform Pringle maneuver also because laparoscopy results
in a 30-40% reduction of the blood flow as it was stated by other authors [46].
2.6.7.4. Cooling of the biliary tract
Despite the major vessels, major biliary ducts are deemed to be vulnerable to hyperthermia.
Damage of these ducts were reported to occur when the RF needle was located less than 5
mm apart from these [36]. As with the biliary ducts, gallbladder is submitted to damages
during and after the ablation process. For tumors situated in segment I, IV, V, in the proxim‐
ity of the gallbladder cholecystectomy may be recommended before starting the ablation in
order to avoid organ perforation or inflammation. The method to prevent the occurrence of
biliary system damages is cooling it by pouring cold saline solution onto the surface of the
bile duct and gallbladder [36] or by infusing a 40 C saline solution quickly through a catheter
placed in the bile duct via choledochotomy [47].
3. Results
3.1. Follow-up
Postablation syndrome is a self-limited flu-like syndrome. This systemic inflammatory reac‐
tion occurs in one third of patients after RFA and usually depends on the extension of the
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ablated lesion(s) and ablation time. Its clinical manifestations are milder compared with cry‐
otherapy and consist in transient fever, pain, malaise, myalgia, nausea, and vomiting [48].
The laboratory tests which attest the inflammation are leukocytosis, elevation of serum
transaminases, and bilirubin level. The laboratory analysis are performed in the first day af‐
ter ablation. The WBC count increases more in patients with normal livers and less in pa‐
tients with previous chemotherapy and cirrhosis [49]. The most dramatic elevations are
noticed with AST (14-fold) and ALT (10-fold) but with a fast return to baseline within a
week. Serum bilirubin, alkaline phosphatase, and GGT also increase immediately after abla‐
tion but with a slower return to baseline up to 3 months. The degree of these elevations is
more pronounced in patients with normal hepatic parenchyma than in patients with hepatic
steatosis, fibrosis, or cirrhosis [49]. Despite what it would be expected because of the cell
death, serum potassium and lactate dehydrogenase levels remain stable after RFA.
To test the tumor markers, blood sample is obtained 1 week after ablation, every 3 months
for 2 years, and every 6 months thereafter.
Grayscale ultrasonography of LRFA ablated liver tumor may show hypoechoic, hyperecho‐
ic, or mixed appearance. It can be used to early diagnose the hepatic abscess as complication
of RFA.
The triphasic (noncontrast, arterial, portal-venous) CT scan is performed to establish a base‐
line at 1 week postablation and on regular basis every 3 months for 2 years, 6 months for 2
years and yearly thereafter (figure 4).
Figure 4. LRFA of a multicentric HCC on cirrhotic liver. The upper images show a hepatic tumor in segment II pre and
postablation. The lower images show a hepatic tumor in segment IV pre and postablation. Tactic cholecystectomy was
performed during the same operation. There is no tumor recurrence after 3 months postablation.
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In the first week postablation, the destroyed tumors appear on contrast-enhanced CT
(CECT) with low attenuation when comparing to the normal liver tissue. CECT scan per‐
formed in the first 2 weeks postablation may underestimate the actual result due to the pres‐
ence of granulomatous hypervascularized healing around necrosis which can be
misinterpreted as residual viable tumor.
The small ablated lesions have a spherical, “punched out” shape contrary to the large ablat‐
ed lesions which have a more irregular shape. The success of ablation is announced by CT
demonstration of a larger lesion due to the ablation of a rim of nontumoral hepatic paren‐
chyma (figure 5). On further CT scanning the lesion will decrease in size. Any increase in
lesion size, irregularity of the edges, or contrast enhancement diagnoses either the incom‐
plete necrosis or local recurrence. Sometimes the appreciation of the contrast enhancement
of the lesion might be very difficult especially when comparing the pre- and postablation
hypodense liver masses. The assessment of CT Hounsfield unit of the preablated liver lesion
was shown to be very reliable in assessment of its evolution. The quantitative measurement
of tissue density expressed in Hounsfield unit scale is reproducible over time and is machine
independent. In successfully ablated lesions there is a measurable decrease in contrast up‐
take, which is indicated by the minimal increase in Hounsfield unit density following the
administration of contrast in postablation scans [50].
Contrast-enhanced ultrasonography (CEUS) is also useful to provide information regarding
ablated lesion but has low sensitivity in identifying the safety margin and incomplete cover‐
age of the liver in patients at high risk of developing new hepatic tumors.
Figure 5. Follow-up of HCC with LFRA. A. RMI is diagnostic for a 2 cm sized tumor situated in caudate lobe. B. Two
months after LRFA the tumor is hypodense on CECT and a little larger than prior ablation with a diameter of 2.8 cm.
The ablation was successfully completed.
If the CT imaging is doubtful, MRI or PET is indicated. Unenhanced or contrast-enhanced
MRI can be used post-LRFA. MRI has a higher sensitivity than CT for detection of recur‐
rences at 2 months (89% vs. 44%) [51] but at 4 months there is no difference between them.
Despite its higher sensitivity for local recurrence comparing with multidetector CT (MDCT),
radiolabeled deoxyglucose ([18F]FDG) PET/CT is limited to few centers.
In case of further uncertain imaging results for tumor recurrence, percutaneous biopsy or
exploratory laparoscopy with LUS examination and biopsy may be needed [52]. In case of
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rences at 2 months (89% vs. 44%) [51] but at 4 months there is no difference between them.
Despite its higher sensitivity for local recurrence comparing with multidetector CT (MDCT),
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positive malignant fresh sections, the tumor recurrence must be reablated including the
whole previous lesion due to the 23% risk of viable tumoral cells in the core of the lesion and
respecting 0.5-1 cm edge of oncological safety.[52]
Quality of life is assessed pre- and postablation using different questionnaires.
3.2. Morbidity and mortality
The type of complications after LRFA are mainly the same with those encountered after
percutaneous or open approach but with an intermediate rate. The specific complications for
the laparoscopic approach are those linked to the introduction of Veress needle and trocars.
In LRFA there have not been reported thermal damages of the neighboring organs. The rate
of complications seems to be non-related with the histological pattern of the tumor. It has also
been proven on large cohort of patients that the rates of complications are comparable if it is
the first RFA (5%), repeated RFA (1%), or RFA combined with other procedures (3%) [49].
Hepatic abscess represents the most common complication registered after RFA and is relat‐
ed mostly to large area of necrotic tissue. One explanation for development of hepatic ab‐
scess is the retrograde enteric bacterial contamination of the biliary tract from bilioenteric
anastomosis or Oddi sphincterectomy. In patients with previous Whipple procedure the in‐
cidence of the liver abscess is 40% much more higher than in patients without bilioenteric
anastomosis (0.4%) [49]. Considering these, some authors avoid performance of RFA on
such patients [2]. In case of performing LRFA for the patients with bilioenteric anastomosis,
there should be a close follow-up aiming the early diagnosis and treatment of this complica‐
tion and a longer antibioprofilaxy. The hepatic abscess can be treated with antibiotics and
percutaneous drainage.
Other possible complications are ascitis, liver failure, and respiratory complications.
Thrombocytopenia (excluding patients with preexisting thrombocytemia) and gross mioglo‐
binuria are seldom encountered, being related to the extensive procedure for large or multi‐
ple tumors. Acute renal failure due to mioglobinuria is much less encountered as a
complication of RFA than cryotherapy and it can be prevented with high hydration of the
patient during and after the procedure.
Skin burns are a rare complication with LRFA.
Overall, LRFA is safe and well tolerated, with a per procedure mortality of less than 1%.
3.3. Parietal seeding
Parietal seeding is less a problem in laparoscopic than in percutaneous RFA and can be cop‐
ed with the aid of a 14 G venous needle or a 2 mm trocar placed through the abdominal
wall. The RF electrode is introduced through these large sheaths [53]. For cluster needle
such a precaution is not feasible.
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3.4. Local recurrence
Local recurrence is defined if the lesion is within 2 cm of the ablated tumor. Remote or distal
recurrence is defined when the lesion is at least 2 cm far from the ablated tumor. [53]. Local
recurrence is the best measure to assess the technical success of RFA.
Theoretically, the recurrent lesions are due to viable malignant cells that escaped thermal in‐
jury during the ablative procedure. This could be the explanation of the recurrences which
mainly occur at the periphery of the lesions [50].
The wide range of local recurrence after RFA between 1.8% and 60% reflects difference in
tumor type, size, number, liver segmental location, approach, ablation margin, blood vessel
proximity, operator experience, and - last but not least - type of RF probe and generator
used [54, 55].
The higher rates of recurrence seen within certain tumor histology types are likely a reflec‐
tion of tumor biology (e.g. density, vascularity, heat conduction) but also of parenchymal
milieu (e.g. cirrhosis) [55]. Patients with metastases from colorectal cancer, hepatocellular
carcinoma, and melanoma have higher rates of local recurrence comparing with other ma‐
lignant liver tumors [56].
LRFA results In a tumoral recurrence of 5.8% which is similar with 4.4% obtained in open
approach but significant lesser comparing with 16.4% reported with the percutaneous ap‐
proach [55].
In case of limited hepatic recurrences after other ablative procedures or in selected cases af‐
ter liver resection, it is our believe that LRFA deserves to be the first-choice treatment. In
case of multiple hepatic recurrences, transarterial chemoembolization (TACE) is needed in
association with LRFA performed for the larger lesions [57].
3.5. Association of LRFA with other therapeutic methods
In patients with multiple liver masses, LRFA can be performed in association with laparo‐
scopic liver resections [58]. LRFA is indicated for deep-situated (<3 cm) tumors while resec‐
tion is feasible and safety for exophitic/subcapsular tumors. The association of resection
with RFA was found to be a safe procedure with long term outcomes better than the abla‐
tion but poorer than resection alone [59].
Due to the progression of the malignant disease most of the patients will develop recurrenc‐
es after LRFA [53, 60]. Because better survival rates have been obtained with the association
of regional chemotherapy, some authors recommend the placement of hepatic arterial infu‐
sion pump (HAIP) in all patients who undergo RFA [61]. Concomitant LRFA and HAIP are
safe and feasible [62].
LRFA is a therapeutic option for the patients with primary digestive cancer and synchronic
liver metastases. A rule of thumb is to perform surgery for the primary indication that
brings the patient to the operation (i.e. colorectal, pancreas resection, ileostomy reversal).
The surgery for digestive tract can be performed either by laparoscopy or laparotomy and is
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followed by LRFA. A laparotomy should be converted for LRFA because laparoscopic ap‐
proach facilitates accurate needle placement [63]. Moreover, LRFA avoids the need of large
incision for liver access. For selected cases with colorectal tumors and liver dissemination in
which liver resection might increase the operative risk, the ablation of the hepatic lesions is
recommended to be performed laparoscopically in the same operative session. The tumor
ablation combined with other operative procedures was shown to be safe and not to in‐
crease the risk of morbidity and hospital stay [63].
4. Conclusion
Laparoscopic exploration and intraoperative ultrasound permit an accurate staging of ma‐
lignant disease. In unresectable malignant liver tumors, LRFA represents a safe and effective
treatment especially when percutaneus approach to the lesions is deemed difficult. LRFA
can also be a substitute for hepatic resection in patients with small malignant tumors or be‐
nign liver tumors. LRFA proved to be safe for the treatment of subcapsular tumors due to
the possibility of direct visualization, active protection of the surrounding structures, and
control of the potential bleeding from these lesions. Deep-situated lesions difficult or impos‐
sible to be visualized by percutaneous US and/or punctured percutaneously can be success‐
fully ablated by laparoscopy. Laparoscopic approach is the first choice for ablation of large
or multiple liver tumors with possible association of surgical resection or portal vein liga‐
tion. LRFA represents a good bridge therapy for prevention of tumor progression and
downstaging of multiple lesions for patients with HCC and cirrhosis on the waiting list for
liver transplantation. LRFA is associated with less intraoperative blood loss and fewer post‐
operative complications when compared with open procedure. Due to its minimal surgical
trauma, this procedure determines a fast recovery time and short hospital stay. Tumoral re‐
currence after LRFA is similar to the open approach but significant lesser comparing with
percutaneous one. In case of incomplete thermal ablation or tumor recurrence, LRFA can be
repeated or followed by transarterial chemoembolization.
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currence after LRFA is similar to the open approach but significant lesser comparing with
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1. Introduction
Bleeding from esophagogastricvarices is a catastrophic complication of chronic liver disease.
There are various treatments for esophagogastricvarices, such as endoscopic treatment, in‐
terventional radioligy, and surgical procedure [1-3]. Recently, "General Rules for Recording
Endoscopic Findings of EsophagogastricVarices [4]" were establised and endoscopic treat‐
ment further improved survival rates [5].
Many years ago, operation was the only treatment available. A number of surgical proce‐
dures have been developed to manage esophagogastricvarices [6]. Broadly, these can be
classified as shunting and nonshunting procedures.
We showed the surgical procedures for the treatment of esophagogastricvarices.
2. Operation technique
2.1. Shunting procedures
There are various shunting procedures for the treatment of esophagogastricvarices [7-25].
There are two types of shunting procedures, nonselective shunt and selective shunt. Nonse‐
lective shunts, such as portacaval or mesocaval shunts, reduce portal venous pressure and
improve esophagogastricvarices. While nonselective shunt is associated with a high risk of
hepatic encephalopathy secondary to the hyperammonemia that is caused by impaired pro‐
tein metabolism in the liver [26-28].
Selective shunts, such as distal splenorenal shunt (DSRS) or left gastric venous caval shunt
(Inokuchi shunt), maintain portal pressure and selectively reduce esophagogastricvariceal
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pressure. Shunt surgery is the best procedure in terms of preventing recurrent bleeding
[20-22], but carries a high risk of postoperative encephalopathy, especially after nonselective
shunt [26-28]. Even in selective shunt, loss of shunt selectivity occurs occasionally, leading to
postoperative encephalopathy [8, 14].
2.1.1. Nonselective shunt
2.1.1.1. Portacaval and mesocaval shunt
The mesocaval shunt was initially used to control bleeding from esophageal varices in chil‐
dren with congenital abnormalities of the hepatobiliary system. The procedure consisted of
transposition of the divided inferior vena cava and the divided superior mesenteric vein,
hence its name, mesocaval shunt. This operation was modified, and some reports have de‐
scribed a portacaval or mesocaval interposition shunt with a graft (H-graft mesocaval shunt)
[9, 10, 29-33]. Millikan et al. [26] have reported that the incidence of hyperammonemia after
nonselective shunt procedures was as high as 75%.
2.1.2. Selective shunt
2.1.2.1. Left gastric venous caval shunt (Inokuchi shunt)
To assure postoperative portal perfusion and to prevent Eck’s syndrome, in 1967 Inokuchi
designed a selective shunt, called the left gastric venous caval shunt [7, 19, 23-25].
After dilatation, and engorgement of the left gastric vein is confirmed by splenoportogra‐
phy, the gastrohepatic ligament is opened and the left gastric vein is identified, and dis‐
sected  2  cm  towards  its  junction  with  the  portal  system  or  splenic  vein.  The  vein
dissection must be done carefully to avoid hemorrhage, since the wall of the left gastric
vein is weak due to increased portal vein pressure. The anastomosis is then performed be‐
tween the distal end of the transected left gastric vein and the inferior vena cava. The au‐
tograft, the great saphenous vein, is anastomosed to the inferior vena cava in an end-to-
side  fashion,  and  opposite  end  is  pulled  through  the  suprapancreatic  space.  After  the
anastomosis  is  completed,  a  splenectomysi  done.  If  splenectomy is  not  indicated,  short
gastric  vein ligation is  necessary in order  to  decrease the collateral  circulation from the
greater curvature of the stomach. The selection of a caval anastomosis procedure depends
upon anatomical individuality or operative difficulty or both. The left gastric venous-caval
shunt  can be modified in  three  ways,  left  gastric-spermatic  (ovarian)  shunt,  left  gastric-
adrenal shunt, or left gastric-renal shunt.
Postoperative mean portal pressure was 335 mm of water, and although it is decreased whe
compared to 363 mm water at laparotomy, this may be the result of solenectomy. On the




Original DSRS: The DSRS is a selective shunt that was developed by Warren (original DSRS)
in 1967 [12] to preserve portal blood flow through the liver while lowering variceal pressure.
The hope was that both bleeding and hyperammonemia would be prevented. DSRS effec‐
tively prevents rebleeding, but still carries a risk of hyperammonemia [14].
The procedure for DSRS consists of anastomosis of the distal end of the splenic vein to the
left renal vein, and devascularization of left gastric artery and vein. The specific objectives of
DSRS as stated in the original publication [12] were : 1) selective reduction of pressure and
volume of flow through gastroesophageal veins; 2) maintaining portal venous perfusion of
the liver; and 3) maintaining continual venous hypertension in the intestinal bed. These
three objectives formed a basis for much subsequent work.
Henderson et al. [34]compared hemodynamics between alcoholic and nonalcoholic cirrhotic
patients after DSRS. Portal perfusion and liver blood flow are maintained, both quantitative‐
ly and qualitatively, in nonalcoholic patients with cirrhosis, resulting in better hepatocyte
function and improved survival.
Stenosis of a DSRS shunt may lead to inadequate variceal decompression, accompanied by a
risk of rebleeding. Henderson et al. [35]reported that the patients with stenosis of a DSRS
were successfully managed by balloon dilation. All of the shunts were patent, but showed a
mean pressure gradient of 15 millimeters of mercury, which was reduced to a mean of 7 mil‐
limeters of mercury by dilation. Although, repeat angiography should be performed in pa‐
tients with rebleeding or reappearance of varices after DSRS to determine the cause.
DSRS + splenopancreatic disconnection (SPD): Belghiti et al. [8] reported loss of shunt selec‐
tivity during long-term follow-up in patients who underwent original DSRS, confirmed via
the pancreatic vein. Warren et al. [36] subsequently improved the DSRS procedure by add‐
ing SPD, i.e., skeletonization of the splenic vein from the pancreas to its bifurcation at the
splenic hilum. The operation technique is as follows: The pancreas is approached through
the lesser sac, with the additional takedown of the splenic flexure to improve access to the
retropancreatic plane. The whole pancreas is mobilized along its inferior border from the su‐
perior mesenteric vein to the splenic hilus. The pancreatic perforating veins are ligated as
they enter the splenic vein. It is imperative to sufficiently dissect the splenic vein from the
pancreas and to carefully manipulate the junction between the splenic and superior mesen‐
teric vein to ensure that skeletonization proceeds to the renal vein without kinking. The key
to the entire procedure lies in accurate identification and ligation of the pancreatic perforat‐
ing veins as they enter the splenic vein. The anastomosis should also be performed without
tension or kinking of the splenic vein. Typically, the anastomosis lies just in front of the li‐
gated adrenal vein on the left renal vein with continuous suture.
Moon et al. [37] examined the outcomes of DSRS+SPD in children to evaluate the usefulness
of this operation. The platelet count and white cell count increased significantly after DSRS
+SPD. Spleen size decreased significantly. No patient underwent subsequent transplantation
or endoscopic treatment for esophagogastricvarices after DSRS+SPD.
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DSRS + SPD + gastric transection (GT): Loss of shunt selectivity was still observed via collat‐
eral pathways through the stomach [20]. We therefore modified DSRS by additionally per‐
forming SPD and GT to prevent loss of shunt selectivity. GT involved transection and
anastomosis of the upper stomach with an autosuture instrument. The short gastric arteries
and veins were spared. Katoh et al. [38] performed transection and re-suture of the seromus‐
cular layer of the upper stomach to prevent loss of selectivity after DSRS + SPD. They called
this procedure “superselective DSRS.” We performed transection of all layers, whereas Ka‐
toh et al. transected only the seromuscular layer of the upper stomach.
We compared long-term results for three types of DSRS for the treatment of esophageal vari‐
ces.  Additional treatment for recurrent varices was required in the original DSRS group
(9.1%), DSRS with SPD group (18.2%), and DSRS with SPD plus GT group (4.3%). All of the
patients with recurrent varices had shunt stenosis within the first year after DSRS. The preva‐
lence of hyperammonemia in the DSRS with SPD plus GT group was significantly lower than
that in the original DSRS group and the DSRS with SPD group (P<0.01). There were no signifi‐
cant differences in survival among the three groups. DSRS with SPD plus GT may reduce the
incidence of postoperative hyperammonemia [14]. Kanaya et al. [39] have reported that the
incidence of hyperammonemia after DSRS with SPD plus gastric disconnection (transection
of only the seromuscular layer of the upper stomach) was 3.2%. We found that the prevalence
of hyperammonemia after DSRS with SPD plus GT was 0% at 1 year, 9.1% at 5 years, and 9.1%
at 10 years [14]. The loss of shunt selectivity promotes hyperammonemia and decreases por‐
tal blood flow. High serum ammonia concentrations result in encephalopathy. We previously
reported that obliteration of portosystemic shunts followed by partial splenic embolization is
beneficial in patients with portosystemic encephalopathy. Portal venous pressures were simi‐
lar before and after treatment in patients who underwent embolization of portosystemic
shunts followed by partial splenic embolization [40, 41]. In patients who had portosystemic
encephalopathy after DSRS, however, elevated portal venous pressures after embolization of
portosystemic shunts can notreduced by partial splenic embolization. Fisher et al. [42] have
reported normalization of hyperammonemia after administration of a solution enriched with
branched chain amino acids. All patients with hyperammonemia in our study should re‐
ceived branched chain amino acids [14]. However, patients with hyperammonemia require
long-term nutritional support, negatively affecting their quality of life. Liver dysfunction was
controlled with good nutritional support. We found no significant differences in cumulative
survival among the original DSRS group, DSRS with SPD group, and DSRS with SPD plus GT
group [14]. Kanaya et al. [39] have reported better 5- and 7-year survival rates after DSRS with
SPD plus gastric disconnection than after standard DSRS.
Santambrogio et al. [43] compared endoscopic injection sclerotherapy (EIS) with DSRS for
the prevention of recurrent variceal bleeding in cirrhotic patients who underwent long-term
follow-up. They concluded that DSRS with a correct portal-azygos disconnection more effec‐
tively prevents varicealrebleeding than EIS in a subgroup of patients with good liver func‐
tion. However, this positive effect did not influence long-term survival because other factors
(e.g., hepatocellular carcinoma) were more important determinants of the outcomes of the
cirrhotic patients with portal hypertension.
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Rikkers et al. (13)performed a prospective, randomized trial to evaluate the effectiveness of
DSRS for the treatment of cirrhotic patients who previously had bleeding from esophageal
varices. A total of 55 patients were randomly assined to receive a DSRS (26 patients) or a
nonselective shunt (29 patients). Three operative deaths occurred in each group. Early post‐
operative angiography revealed preservation of hepatic portal perfusion in 14 of 16 selective
patients (88%), but in only 1 of 20 nonselective patients (p<0.001). Quantitative measures of
hepatic function (maximal rate of urea synthesis and Child’s score) were similar to preoper‐
ative values in the selective shunt, but had significantly decreased in the nonselective shunt
on the first postoperative evaluation. Encephalopathy has not developed in any patient with
continued portal perfusion, as compared with 45% of patients without portal flow (p<0.05).
No significant differences the between selective and nonselective shunt have been detected
with respect to total cumulative mortality (10 selective, 38%; 8 nonselective, 28%), shunt oc‐
clusion (2 selective, 10%; 5 nonselective, 18%), or recurrent variceal hemorrhage (1 selective,
4%; 2 nonselective, 8%). Overall, postoperative encephalopathy has developed in significant‐
ly fewer selective patients (3 selective, 12%; 15 nonselective, 52%; p<0.001). Therefore, they
conclude that the DSRS, especially when its objective of maintaining hepatic portal perfu‐
sion is achieved, results in significantly less morbidity than nonselective shunt.
Warren et al. (44) reported the metabolic basis of portosystemic encephalopathy and com‐
pared the effects of selective vs. nonselective shunts. Metabolic studies were done in the Clini‐
cal  Research  Unit  during  a  14-day  stay  under  carefully  controlled  dietary  conditions.
Maximal rate of urea systhesis did not change in patients with DSRS, but decreased signifi‐
cantly in those with nonselective shunt. Likewise, ammonium chloride tolerance, defined as
the smallest dose required to produce a 40-μg/dL rise in the plasma ammonia concentration,
was unchanged in the DSRS group, but significantly worsened in the nonselective shunt
group.
Galambos et al. [45]compared nonselective shunt with selective shunt for the treatment of
bleeding esophageal varices in a randomized controlled trial. A total of 48 patients were ran‐
domly assigned to receive a nonselective shunt (24 patients) or a selective shunt (24 pa‐
tients). Mortality rates, the frequencies of shunt occlusion, and the frequencies of recurrent
gastrointestinal bleeding were similar. Encephalopathy developed more often after a nonse‐
lective shunt than after a selective shunt. Nonselective shunts consistently diverted the hep‐
atopetal mesenteric-portal flow from the liver. Deterioration of hepatic function was greater
after nonselective than selective shunt.
2.2. Nonshunting procedures
Historically, nonshunting procedures were developed in an attempt to decrease the high rates
of encephalopathy associated with portosystemic anastomoses. An alternative to total shunt
was developed by Sugiura and Futagawa in 1973 [46]. Esophageal transection (ET) disrupts
the blood supply to esophagogastricvarices. ET solves the problem of hepatic encephalop‐
athy; unfortunately, however, varices can recur because portal pressure remains high.
Various nonshunting procedures, such as the Hassab operation, ET, splenectomy, or termi‐
nal esophago-proximal gastrectomy, have been developed to treat esophagogastricvarices
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DSRS + SPD + gastric transection (GT): Loss of shunt selectivity was still observed via collat‐
eral pathways through the stomach [20]. We therefore modified DSRS by additionally per‐
forming SPD and GT to prevent loss of shunt selectivity. GT involved transection and
anastomosis of the upper stomach with an autosuture instrument. The short gastric arteries
and veins were spared. Katoh et al. [38] performed transection and re-suture of the seromus‐
cular layer of the upper stomach to prevent loss of selectivity after DSRS + SPD. They called
this procedure “superselective DSRS.” We performed transection of all layers, whereas Ka‐
toh et al. transected only the seromuscular layer of the upper stomach.
We compared long-term results for three types of DSRS for the treatment of esophageal vari‐
ces.  Additional treatment for recurrent varices was required in the original DSRS group
(9.1%), DSRS with SPD group (18.2%), and DSRS with SPD plus GT group (4.3%). All of the
patients with recurrent varices had shunt stenosis within the first year after DSRS. The preva‐
lence of hyperammonemia in the DSRS with SPD plus GT group was significantly lower than
that in the original DSRS group and the DSRS with SPD group (P<0.01). There were no signifi‐
cant differences in survival among the three groups. DSRS with SPD plus GT may reduce the
incidence of postoperative hyperammonemia [14]. Kanaya et al. [39] have reported that the
incidence of hyperammonemia after DSRS with SPD plus gastric disconnection (transection
of only the seromuscular layer of the upper stomach) was 3.2%. We found that the prevalence
of hyperammonemia after DSRS with SPD plus GT was 0% at 1 year, 9.1% at 5 years, and 9.1%
at 10 years [14]. The loss of shunt selectivity promotes hyperammonemia and decreases por‐
tal blood flow. High serum ammonia concentrations result in encephalopathy. We previously
reported that obliteration of portosystemic shunts followed by partial splenic embolization is
beneficial in patients with portosystemic encephalopathy. Portal venous pressures were simi‐
lar before and after treatment in patients who underwent embolization of portosystemic
shunts followed by partial splenic embolization [40, 41]. In patients who had portosystemic
encephalopathy after DSRS, however, elevated portal venous pressures after embolization of
portosystemic shunts can notreduced by partial splenic embolization. Fisher et al. [42] have
reported normalization of hyperammonemia after administration of a solution enriched with
branched chain amino acids. All patients with hyperammonemia in our study should re‐
ceived branched chain amino acids [14]. However, patients with hyperammonemia require
long-term nutritional support, negatively affecting their quality of life. Liver dysfunction was
controlled with good nutritional support. We found no significant differences in cumulative
survival among the original DSRS group, DSRS with SPD group, and DSRS with SPD plus GT
group [14]. Kanaya et al. [39] have reported better 5- and 7-year survival rates after DSRS with
SPD plus gastric disconnection than after standard DSRS.
Santambrogio et al. [43] compared endoscopic injection sclerotherapy (EIS) with DSRS for
the prevention of recurrent variceal bleeding in cirrhotic patients who underwent long-term
follow-up. They concluded that DSRS with a correct portal-azygos disconnection more effec‐
tively prevents varicealrebleeding than EIS in a subgroup of patients with good liver func‐
tion. However, this positive effect did not influence long-term survival because other factors
(e.g., hepatocellular carcinoma) were more important determinants of the outcomes of the
cirrhotic patients with portal hypertension.
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Rikkers et al. (13)performed a prospective, randomized trial to evaluate the effectiveness of
DSRS for the treatment of cirrhotic patients who previously had bleeding from esophageal
varices. A total of 55 patients were randomly assined to receive a DSRS (26 patients) or a
nonselective shunt (29 patients). Three operative deaths occurred in each group. Early post‐
operative angiography revealed preservation of hepatic portal perfusion in 14 of 16 selective
patients (88%), but in only 1 of 20 nonselective patients (p<0.001). Quantitative measures of
hepatic function (maximal rate of urea synthesis and Child’s score) were similar to preoper‐
ative values in the selective shunt, but had significantly decreased in the nonselective shunt
on the first postoperative evaluation. Encephalopathy has not developed in any patient with
continued portal perfusion, as compared with 45% of patients without portal flow (p<0.05).
No significant differences the between selective and nonselective shunt have been detected
with respect to total cumulative mortality (10 selective, 38%; 8 nonselective, 28%), shunt oc‐
clusion (2 selective, 10%; 5 nonselective, 18%), or recurrent variceal hemorrhage (1 selective,
4%; 2 nonselective, 8%). Overall, postoperative encephalopathy has developed in significant‐
ly fewer selective patients (3 selective, 12%; 15 nonselective, 52%; p<0.001). Therefore, they
conclude that the DSRS, especially when its objective of maintaining hepatic portal perfu‐
sion is achieved, results in significantly less morbidity than nonselective shunt.
Warren et al. (44) reported the metabolic basis of portosystemic encephalopathy and com‐
pared the effects of selective vs. nonselective shunts. Metabolic studies were done in the Clini‐
cal  Research  Unit  during  a  14-day  stay  under  carefully  controlled  dietary  conditions.
Maximal rate of urea systhesis did not change in patients with DSRS, but decreased signifi‐
cantly in those with nonselective shunt. Likewise, ammonium chloride tolerance, defined as
the smallest dose required to produce a 40-μg/dL rise in the plasma ammonia concentration,
was unchanged in the DSRS group, but significantly worsened in the nonselective shunt
group.
Galambos et al. [45]compared nonselective shunt with selective shunt for the treatment of
bleeding esophageal varices in a randomized controlled trial. A total of 48 patients were ran‐
domly assigned to receive a nonselective shunt (24 patients) or a selective shunt (24 pa‐
tients). Mortality rates, the frequencies of shunt occlusion, and the frequencies of recurrent
gastrointestinal bleeding were similar. Encephalopathy developed more often after a nonse‐
lective shunt than after a selective shunt. Nonselective shunts consistently diverted the hep‐
atopetal mesenteric-portal flow from the liver. Deterioration of hepatic function was greater
after nonselective than selective shunt.
2.2. Nonshunting procedures
Historically, nonshunting procedures were developed in an attempt to decrease the high rates
of encephalopathy associated with portosystemic anastomoses. An alternative to total shunt
was developed by Sugiura and Futagawa in 1973 [46]. Esophageal transection (ET) disrupts
the blood supply to esophagogastricvarices. ET solves the problem of hepatic encephalop‐
athy; unfortunately, however, varices can recur because portal pressure remains high.
Various nonshunting procedures, such as the Hassab operation, ET, splenectomy, or termi‐
nal esophago-proximal gastrectomy, have been developed to treat esophagogastricvarices
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[46-49]. All nonshunting procedures performesplenectomy. Portal vein thrombosis is not a
rare complication of splenectomy and can be fatal in patients with hypersplenism. Kawana‐
ka et al. reported that low antithrombin 3 activity and futher decreases in this activity are
associated with portal vein thrombosis after splenectomy in cirrhotic patients, and that treat‐
ment with antithrombin 3 concentrates is likely to prevent the development of portal vein
thrombosis in thease patients [50].
2.2.1. Splenectomy
Splenectomy was one of the earliest nonshunting procedures. It was found to be generally
ineffective for preventing recurrent variceal bleeding [51]. Despite elimination of the splenic
component of the portal circulation, portal hypertension is maintained after simple splenec‐
tomy, and the risk of continued bleeding via the splenic venous branches is high.
Recently, laparosopicsplenectomy is wadely accepted as a standard treatment for hemato‐
logic disorders such as idiopathic thrombocytopenic purpura. Laparoscopic splenectomy is
improved safty in liver cirrhosis patients with portal hypertension [52].
2.2.2. Hassab operation
In 1967, Hassab [47] reported a successful technique for gastroesophageal decongestion and
splenectomy, developed in Egypt. Most of his patients had schistosomiasis. The operation
entailed removal of the spleen as well as devascularization of the cardiac portion of the
stomach and abdominal portion of the esophagus, including the supraphrenic veins. By li‐
gating the left gastric artery and splenic artery, portal blood flow was also decreased, there‐
by decompressing the portal system. Recently, the Hassab operation has been employed in
patients with varices limited to the stomach.
2.2.3. Terminal esophago-proximal gastrectomy
Terminal esophago-proximal gastrectomy involves proximal gastric transection and autosuture
proximal gastrectomy in association with extensive devascularization and splenectomy [49].
2.2.4. ET
Among non-shunting procedures for the treatment of esophagogastricvarices, ET has been
the most popular operation. ET in Japan was first performed in 1967 [53], using a modifica‐
tion of Walker’s procedure for transthoracic ET [54]. The procedure was then refined by Su‐
giura and Futagawa in 1973 [46]. ET consists of paraesophagealdevascularization,
esophageal transection and reanastomosis, splenectomy, and pyloroplasty. First, splenecto‐
my with devascularization of the greater curvature was performed. Devascularization of the
lesser curvature was done from the angle to the esophagogastric junction, and the left gas‐
tric artery was ligated and divided. The esophagus and cardia were devascularized from the
lesser to the greater curvature. Then, the vagal nerve and paraesophageal vessels were ligat‐
ed and divided. The esophagus was completely transected above the esophagogastric junc‐
tion, and the mucosa was anastomosed with interrupted sutures, performed recently with
Hepatic Surgery522
an autosuture instrument. ET was done using three different approaches, transthoracic,
thoracoabdominal, and transabdominal. Devascularization of the esophagus and the stom‐
ach is most extensive and complete in the thoracoabdominal approach; however, this is the
most drastic procedure.
Sugiura et al. [55] reported on 636 patients with portal hypertension in whom ETs with par‐
aesophagogastricdevascularization were performed to manage esophageal varices. The op‐
erative mortality rates were as follows: emergency cases 13.7%, elective cases 3.2%,
prophylactic cases 4.3%, and overall 5.2%. There were no deaths among the 233 patients in
Child’s class A; the 232 patients in class B had a 2% mortality rate, and the 171 patients in
class C had a 17% mortality rate. The 10-year actuarial survival rates in patients with cirrho‐
sis were 55% in emergency cases, 72% in prophylactic cases, and 72% in elective cases. In
patients without cirrhosis, the corresponding survival rates were 90%, 96%, and 95%, re‐
spectively. The recurrence rate of variceal bleeding or varices was less than 5%. They con‐
cluded that the Sugiura procedure is safe and effective for controlling esophageal varices
and prolongs the long-term survival of patients with portal hypertension.
In our study, however, the recurrence rate of varices after ET was high [21]. We examined he‐
modynamic changes associated with recurrent esophageal varices after ET and evaluated the
effectiveness of EIS for their treatment. Nineteen patients with recurrent esophageal varices af‐
ter ET were treated by EIS. Endoscopic varicealography during injection sclerotherapy (EVIS),
following oral blockage of flow by a balloon, identified three patterns: type 1 (common type),
continuous filling by the feeder vessel of the varix; type 2 (retrograde disappearing type), con‐
firmed hepatofugal flow; and type 3 (immediate washout type), immediate washout of con‐
trast medium. Angiography showed that the hepatofugal feeder vessel was the right gastric
vein in all cases. Recurrent esophageal varices were classified as type 1 in 14 patients (73.7%),
type 2 in 4 (21.1%), and type 3 in 1 (5.3%). Fewer treatment sessions were required in type 1 than
in type 2 varices (p<0.005). Recurrent varices were completely eradicated in all patients except
the patient with type 3 disease. Cumulative re-recurrence rates at 5 and 10 years were higher in
type 1 than in type 2 varices without significance (28.6% and 71.4% vs. 25.0% and 25.0%, respec‐
tively). Cumulative survival rates after EIS at 5 and 10 years also were similar for type 1 and
type 2 varices (77.1% and 66.1% vs. 66.7% and 66.7%). EIS was thus effective for the manage‐
ment of recurrent esophageal varices after ET, excluding type 3 disease [56].
Cleva et al. [57] compared the systemic hemodynamic effects of DSRS with those of esopha‐
gogastricdevascularization and splenectomy in patients treated for schistosomal portal hy‐
pertension. The hyperdynamic circulatory state observed in Manson’s schistosomiasis was
corrected by esophagogastricdevascularization and splenectomy, but persisted in patients
who underwent DSRS. Similarly, the elevated mean pulmonary artery pressure resolved af‐
ter esophagogastricdevascularization and splenectomy, but persisted after DSRS. They con‐
cluded that esophagogastricdevascularization and splenectomy seems to be the most
physiologic operation for patients with schistosomal portal hypertension.
We compared the long-term results of DSRS and ET in cirrhotic patients with complete vari‐
ceal eradication who were followed up for at least 3 years. There was no recurrent varix in
the DSRS group. The cumulative recurrence rates of varices in the ET group were 31.6% and
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[46-49]. All nonshunting procedures performesplenectomy. Portal vein thrombosis is not a
rare complication of splenectomy and can be fatal in patients with hypersplenism. Kawana‐
ka et al. reported that low antithrombin 3 activity and futher decreases in this activity are
associated with portal vein thrombosis after splenectomy in cirrhotic patients, and that treat‐
ment with antithrombin 3 concentrates is likely to prevent the development of portal vein
thrombosis in thease patients [50].
2.2.1. Splenectomy
Splenectomy was one of the earliest nonshunting procedures. It was found to be generally
ineffective for preventing recurrent variceal bleeding [51]. Despite elimination of the splenic
component of the portal circulation, portal hypertension is maintained after simple splenec‐
tomy, and the risk of continued bleeding via the splenic venous branches is high.
Recently, laparosopicsplenectomy is wadely accepted as a standard treatment for hemato‐
logic disorders such as idiopathic thrombocytopenic purpura. Laparoscopic splenectomy is
improved safty in liver cirrhosis patients with portal hypertension [52].
2.2.2. Hassab operation
In 1967, Hassab [47] reported a successful technique for gastroesophageal decongestion and
splenectomy, developed in Egypt. Most of his patients had schistosomiasis. The operation
entailed removal of the spleen as well as devascularization of the cardiac portion of the
stomach and abdominal portion of the esophagus, including the supraphrenic veins. By li‐
gating the left gastric artery and splenic artery, portal blood flow was also decreased, there‐
by decompressing the portal system. Recently, the Hassab operation has been employed in
patients with varices limited to the stomach.
2.2.3. Terminal esophago-proximal gastrectomy
Terminal esophago-proximal gastrectomy involves proximal gastric transection and autosuture
proximal gastrectomy in association with extensive devascularization and splenectomy [49].
2.2.4. ET
Among non-shunting procedures for the treatment of esophagogastricvarices, ET has been
the most popular operation. ET in Japan was first performed in 1967 [53], using a modifica‐
tion of Walker’s procedure for transthoracic ET [54]. The procedure was then refined by Su‐
giura and Futagawa in 1973 [46]. ET consists of paraesophagealdevascularization,
esophageal transection and reanastomosis, splenectomy, and pyloroplasty. First, splenecto‐
my with devascularization of the greater curvature was performed. Devascularization of the
lesser curvature was done from the angle to the esophagogastric junction, and the left gas‐
tric artery was ligated and divided. The esophagus and cardia were devascularized from the
lesser to the greater curvature. Then, the vagal nerve and paraesophageal vessels were ligat‐
ed and divided. The esophagus was completely transected above the esophagogastric junc‐
tion, and the mucosa was anastomosed with interrupted sutures, performed recently with
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an autosuture instrument. ET was done using three different approaches, transthoracic,
thoracoabdominal, and transabdominal. Devascularization of the esophagus and the stom‐
ach is most extensive and complete in the thoracoabdominal approach; however, this is the
most drastic procedure.
Sugiura et al. [55] reported on 636 patients with portal hypertension in whom ETs with par‐
aesophagogastricdevascularization were performed to manage esophageal varices. The op‐
erative mortality rates were as follows: emergency cases 13.7%, elective cases 3.2%,
prophylactic cases 4.3%, and overall 5.2%. There were no deaths among the 233 patients in
Child’s class A; the 232 patients in class B had a 2% mortality rate, and the 171 patients in
class C had a 17% mortality rate. The 10-year actuarial survival rates in patients with cirrho‐
sis were 55% in emergency cases, 72% in prophylactic cases, and 72% in elective cases. In
patients without cirrhosis, the corresponding survival rates were 90%, 96%, and 95%, re‐
spectively. The recurrence rate of variceal bleeding or varices was less than 5%. They con‐
cluded that the Sugiura procedure is safe and effective for controlling esophageal varices
and prolongs the long-term survival of patients with portal hypertension.
In our study, however, the recurrence rate of varices after ET was high [21]. We examined he‐
modynamic changes associated with recurrent esophageal varices after ET and evaluated the
effectiveness of EIS for their treatment. Nineteen patients with recurrent esophageal varices af‐
ter ET were treated by EIS. Endoscopic varicealography during injection sclerotherapy (EVIS),
following oral blockage of flow by a balloon, identified three patterns: type 1 (common type),
continuous filling by the feeder vessel of the varix; type 2 (retrograde disappearing type), con‐
firmed hepatofugal flow; and type 3 (immediate washout type), immediate washout of con‐
trast medium. Angiography showed that the hepatofugal feeder vessel was the right gastric
vein in all cases. Recurrent esophageal varices were classified as type 1 in 14 patients (73.7%),
type 2 in 4 (21.1%), and type 3 in 1 (5.3%). Fewer treatment sessions were required in type 1 than
in type 2 varices (p<0.005). Recurrent varices were completely eradicated in all patients except
the patient with type 3 disease. Cumulative re-recurrence rates at 5 and 10 years were higher in
type 1 than in type 2 varices without significance (28.6% and 71.4% vs. 25.0% and 25.0%, respec‐
tively). Cumulative survival rates after EIS at 5 and 10 years also were similar for type 1 and
type 2 varices (77.1% and 66.1% vs. 66.7% and 66.7%). EIS was thus effective for the manage‐
ment of recurrent esophageal varices after ET, excluding type 3 disease [56].
Cleva et al. [57] compared the systemic hemodynamic effects of DSRS with those of esopha‐
gogastricdevascularization and splenectomy in patients treated for schistosomal portal hy‐
pertension. The hyperdynamic circulatory state observed in Manson’s schistosomiasis was
corrected by esophagogastricdevascularization and splenectomy, but persisted in patients
who underwent DSRS. Similarly, the elevated mean pulmonary artery pressure resolved af‐
ter esophagogastricdevascularization and splenectomy, but persisted after DSRS. They con‐
cluded that esophagogastricdevascularization and splenectomy seems to be the most
physiologic operation for patients with schistosomal portal hypertension.
We compared the long-term results of DSRS and ET in cirrhotic patients with complete vari‐
ceal eradication who were followed up for at least 3 years. There was no recurrent varix in
the DSRS group. The cumulative recurrence rates of varices in the ET group were 31.6% and
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52.5% at 5 and 10 years, respectively. The cumulative rates of hyperammonemia at 5 and 10
years were significantly higher in the DSRS group (30.4%, 30.4%) than in the ET group (0%,
5.6%) (p=0.009). The cumulative survival rates in the DSRS group vs. the ET group were
90.9% vs. 94.7% at 5 years and 85.2% vs. 81.7% at 10 years (NS). These results suggest that
DSRS is more effective than ET in preventing recurrence of esophageal varices, but is associ‐
ated with a higher incidence of hyperammonemia [21]. In that study, no patient who under‐
went DSRS with complete eradication had recurrent varices. When collateral pathways to
the esophagus develop after DSRS, flow is via the short gastric veins, the splenic vein, and
the left renal vein. After ET, collateral pathways to the esophagus develop across the trans‐
ection site and generate new varices. Most of the recurrent varices in the ET group were
supplied by the right gastric vein across the transection site [56]. However, collateral flow in
the DSRS group decreased hepatic blood flow and led to the development of postoperative
hyperammonemia. Rikkers et al. [58] reported that patients with no hepatic portal perfusion
had the worst survival and greatest morbidity after DSRS.
Idiopathic portal hypertension (IPH) is a disease of unknown etiology characterized by spleno‐
megaly, anemia, and portal hypertension. This disorder develops in the absence of liver cirrho‐
sis, extrahepatic portal vein occlusion, schistosomiasis, or any other identifiable cause [59, 60].
We evaluated the results of shunting and nonshunting procedures for the treatment of esopha‐
gogastricvarices in patients with IPH. Esophagogastricvarices were completely eradicated in 3
(75.0%) patients in the shunting group and 4 (80.0%) in the nonshunting group. Additional en‐
doscopic treatment (one session) was performed in 2 patients with incompletely eradicated
varices. There was no recurrence in the shunting group. In the nonshunting group, esophago‐
gastricvarices recurred in all  4 patients with completely eradicated varices.  All  recurrent
esophageal varices were completely eradicated. Postoperative platelet counts (×104/μL) were
significantly lower in the shunting group (10.0±2.6) than in the nonshunting group (42.0±14.0)
(p=0.0029). The increase in the platelet count after operation was significantly lower in the
shunting group (1.7±0.2 times) than in the nonshunting group (5.8±2.9 times) (p=0.0267). No
patient received anticoagulants postoperatively. Portal venous thrombus did not develop in
the shunting group, but appeared in 4 patients (80.0%) in the nonshunting group. No patient
had loss of shunt selectivity or portal-systemic encephalopathy. One patient in the nonshunt‐
ing group died of cerebral hemorrhage; all others are alive. Shunting procedure, DSRS, was
suggested to be useful for the management of esophagogastricvarices in patients with IPH [61].
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gastricvarices recurred in all  4 patients with completely eradicated varices.  All  recurrent
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(p=0.0029). The increase in the platelet count after operation was significantly lower in the
shunting group (1.7±0.2 times) than in the nonshunting group (5.8±2.9 times) (p=0.0267). No
patient received anticoagulants postoperatively. Portal venous thrombus did not develop in
the shunting group, but appeared in 4 patients (80.0%) in the nonshunting group. No patient
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ing group died of cerebral hemorrhage; all others are alive. Shunting procedure, DSRS, was
suggested to be useful for the management of esophagogastricvarices in patients with IPH [61].
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1. Introduction
Portal hypertension (PH), a detrimental complication of many diseases, is abnormalities in
pre-, intra- or post-hepatic portal venous system. Intrahepatic PH is the most common type,
which is mainly cause by liver cirrhosis [1], liver cancer, and sometimes intrahepatic vascu‐
lar abnormalities [2].
Hepatic venous pressure gradient (HVPG) is the difference between wedged hepatic venous
pressure and infra vena cava pressure. PH is defined as an HVPG higher than 5 mmHg [3].
According to absence or presence of complications (splenomegaly and hypersplenism,
esophageal varices and ascites), PH can be classified into compensated or decompensated
phase. Meanwhile, an HVPG higher than 10 mmHg has been considered as a direct predic‐
tor of decompensation and a 10-year-follow-up study showed the significant worse long-
term survival when HVPG ＞ 10 mmHg [4-6].
In cirrhotic PH, increased intrahepatic vascular resistance (IHVR) is the primary factor [7, 8]
and subsequently increased portal vein inflow (PVI) worsens the situation of PH patients.
This review will focus on the physiopathological changes happened in PH.
2. Correlation between vasoactive substances and IHVR/PVI
2.1. Nitric oxide
Nitric oxide (NO) is a potential vasodilator, produced by NO synthase (NOS). In a rat PH
model induced by Thioacetamide, contraction of hepatic stellate cells, which resulting the
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1. Introduction
Portal hypertension (PH), a detrimental complication of many diseases, is abnormalities in
pre-, intra- or post-hepatic portal venous system. Intrahepatic PH is the most common type,
which is mainly cause by liver cirrhosis [1], liver cancer, and sometimes intrahepatic vascu‐
lar abnormalities [2].
Hepatic venous pressure gradient (HVPG) is the difference between wedged hepatic venous
pressure and infra vena cava pressure. PH is defined as an HVPG higher than 5 mmHg [3].
According to absence or presence of complications (splenomegaly and hypersplenism,
esophageal varices and ascites), PH can be classified into compensated or decompensated
phase. Meanwhile, an HVPG higher than 10 mmHg has been considered as a direct predic‐
tor of decompensation and a 10-year-follow-up study showed the significant worse long-
term survival when HVPG ＞ 10 mmHg [4-6].
In cirrhotic PH, increased intrahepatic vascular resistance (IHVR) is the primary factor [7, 8]
and subsequently increased portal vein inflow (PVI) worsens the situation of PH patients.
This review will focus on the physiopathological changes happened in PH.
2. Correlation between vasoactive substances and IHVR/PVI
2.1. Nitric oxide
Nitric oxide (NO) is a potential vasodilator, produced by NO synthase (NOS). In a rat PH
model induced by Thioacetamide, contraction of hepatic stellate cells, which resulting the
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increase of intrahepatic vascular tone, was inhibited by incubated with nitroflurbiprofen in
vitro, a nitric oxide-releasing cyclooxygenase inhibitor in a dose-dependent manner. In wild-
type BDL mice, expression of NOS, especially eNOS was down-regulated [9]. Moreover, the
significantly elevated total intrahepatic resistance was reduced significantly in vivo by the
drug, indicating a potential role of NO on portal pressure [10]. In another rat PH model in‐
duced by bile-duct-ligation, intrahepatic vascular resistance increased significantly. Besides,
relative level of phos-NOS decreased compared with sham group, leading to an inhibition of
intrahepatic NO, although the relative mRNA level was increased [11]. Intrahepatic NO pro‐
duction is largely mediated by endothelial NO synthase (eNOS) and impaired when cirrho‐
sis and secondary endothelial dysfunction existed, leading to the increase of intrahepatic
vascular resistance. But the inhibition of NO might be the result of up-regulation of caveo‐
lin-1, a down-regulator of eNOS [12].
Contrastingly, extrahepatic NO is increased in PH patients. A clinical trial has shown that
serum nitrate level was positively correlated with clinical presentation, (e.g. pulse rate, jaun‐
dice, hepatic encephalopathy, lower limb edema) and esophageal varices [13]. It is well es‐
tablished that NO results in dilation of splanchnic and systemic circulation as a powerful
vasodilator and blood level of NO is increased as PH progresses [14-16]. Administration of
CCl4 to eNOS(-/-) mice also led to an elevated NO production, which is eNOS independent
[17]. Another study suggested that iNOS might be involved [18].
2.2. Carbon monoxide
Carbon monoxide (CO), a vasodilator producing by heme oxygenases (HOs) from heme
[19],  changes as HO-1 expression altered in PH patients [20,  21],  which shares the same
characters  with  NO [12].  Expression  of  intrahepatic  HO-1  and -2  decreased in  cirrhotic
rats  than  that  in  normal  ones.  In  situ  perfusion  with  CO-releasing  molecule-2,  which
leads to relaxation of hepatic stellate cells, and HO-1 inducer hemin could attenuated in‐
creased IHVR. ZnPP caused a higher IHVR attributing to inhibition of intrahepatic HO-1
in cirrhotic liver[22].
But things are different in splanchnic and systemic circulation. Reportedly, portal vein pres‐
sure (PVP) was significantly higher in bile-duct-ligated rats than that in sham group. Mean‐
while, mRNA and protein level of HO-1 was also elevated significantly in lung [23].A
clinical study has shown an activated HO/CO system in cirrhotic patients while the HO-1
activity and plasma level of CO were related with the severity of PH [20]. Arterial blood gas
analysis showed an increase of COHb in bile-duct-ligated rats which could be reversed by
ZnPP [23]. HO-1 could promote expression of VEGF and thereafter lead to formation of col‐
lateral vessels and higher splanchnic circulation [24].
2.3. Endothelin
Endothelin-1 (ET-1) is the most powerful vasoconstrictor in ETs family [25], which is pri‐
marily synthesized and acts in liver mainly in a paracrine fashion via ET A receptor causing
vessel constriction [26]. In liver cirrhotic rats induced by carbon tetrachloride, both plasma
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ET-1 level and PVP elevated dramatically while the mean hepatic tissue portal inflow re‐
duced. And, perfusion with an antagonist of ET A receptor led to a reduction of plasma ET-1
level and PVP but did not improve the hepatic infusion suggesting that ET-1 was involved
in development of PH [26]. It is consistent with a previous study which had demonstrated
that liver blood inflow fluctuated in ET A and B receptors antagonist infusion groups and
control group [27]. ET A and B receptors play different roles in CCl4-induced portal hyper‐
tensive rats. Antagonism of ET A or B receptor led to a reduced or increased of PVP and
sinusoidal area in the cirrhotic rats respectively [28]. However, activation of ET B receptor
leads to production of other vasoactive molecules, e.g. TXA2 [29]. Besides, antagonism of ET
A receptor alone cannot improve splanchnic circulation indicating ET B receptor plays a role
on regulation in PH [30].
2.4. RAAS
It is well established that renin -angiotensin II (Ang II) -aldosterone -system (RAAS) plays
an important role on body circulation. Ang II promotes proliferation and contraction of HSC
and formation of collagen, leading to liver fibrosis [31]. In hepatorenal syndrome, a severe
complication of cirrhotic portal hypertension with hyperdynamic circulation, systemic re‐
sistance, circulatory renin activity and plasma aldosterone were significantly increased [32].
Besides, angiotensin converting enzyme (ACE) and Ang II elevated in liver cirrhosis [33, 34].
Role of RAAS on portal pressure provides a new therapeutic alternative [35]. Animal model
studies and clinical trials have shown that blockade of Ang II type 1 receptor (AT1R) signifi‐
cantly reduced portal perfusion pressure and HVPG [36-39]. ACE inhibitor also effects to re‐
duce portal pressure in cirrhotic patients [40]. Inhibition of RAAS by losartan could also
lead to a reduction of eNOS and ROS level in BDL rats [41].
2.5. Catecholamines
Catecholamines (CA) cause general physiological changes including increases in heart rate,
blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous sys‐
tem. In BDL cirrhotic rats, noradrenaline correlated with perfusion pressure dose-depend‐
ently, and this constrictive effect might be normalized by phentolamine but not propranolol,
indicating that noradrenaline influences PVP through α-receptor on portal-systemic collater‐
als [42]. In short-term PH induced by partial portal vein ligation (PVL), antagonism of phen‐
tolamine on α-receptor was reduced; meanwhile, release of noradrenaline was down-
regulated as NO up-regulated, indicating a potential role of CA, together with NO, on
hyperhemodynamics and increased PVI [43]. Besides, expressions of tyrosine hydroxylase
and dopamine β-hydroxylase were down-regulated in superior mesenteric artery revealing
genetic regulation of adrenergic neurotransmitter system participating in the splanchnic
vasodilation in PH [44]. Nevertheless, protein level of α-receptor was higher in cirrhotic liv‐
ers than in normal livers; activation of these α-receptors located on HSC induced calcium
spikes and HSC constriction through MAPK, NK-κB and AP-1 pathways, resulting in in‐
creased intrahepatic resistance [45]. When response to β-blockers was defined as a reduction
＞ 10% in HVPG from baseline, the proportion of non-responsers decreased, the rate of first-
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bleeding among them increased and the diagnostic acuracy improved significantly contrast‐
ing with a 20% cut-off value.[46] Also, acute responsers to β-blockers have a better long-
term outcome.[47]
2.6. Cannabinoid
Correlation between Cannabinoid and portal hypertension was paid attention in the last
decades. Administration of anandamide, an endogenous cannabinoid, resulted in a drop of
systemic circulation, mainly mean arterial pressure, although venous pressure changes veri‐
fied, because of its effect on heart rate. Contrastingly, PVI and PVP increased in a dose-de‐
pendent fashion [48]. Treatment with antagonist of cannabinoid CB1 receptor in rats might
lead to an elevation of blood pressure and a reduction of PVI and PVP, indicating cannabi‐
noid is responsible for the dilation of systemic circulation [49]. It is in agreement with hu‐
man. In cirrhotic patients, plasma level of cannabinoid was increased regardless of well-
compensated or not [50]. But things are different in liver. Expression of CB1 receptor was
dramatically down-regulated in both wild-type and eNOS knock-out group mice [9]. How‐
ever, more researches are needed.
2.7. Cyclooxygenase, prostanoids and TXA2
Activation of COX-2/prostanoid pathway promotes production of TXA2 and PGE2 [51]. In
BDL rats,  TXB2,  a stable metabolic of TXA2  in isolated liver perfusate and PVP were in‐
creased in a  time-dependent manner.  Both inhibition of  Kuffer  cells  and COX attenuate
these  changes.  Further  results  indicated  that  COX-2  interact  with  Kuffer  cells-derived
TXA2 was involved and its expression increased significantly [52]. Another group report‐
ed  that  COX-1  and  PGI2  were  responsible  for  decreased  splanchnic  resistance  and  in‐
creased PVI [53, 54].  However, elevated PVP of intrahepatic or pre-hepatic hypertension
rats might be reduced by short-  or long-term administration of COX inhibitor [18].  It  is
consistent  with  Graupera  M et.  al.  [55].  In  BDL portal  hypertensive  rats,  elevated  ET-1
interacted with Kuffer cells, increasing the responsiveness of p38MAPK through ET B re‐
ceptor,  activating cPLA2 and promoting production of TXA2, contributing to progression
of portal hypertension [29].
2.8. Reactive oxygen species
Reactive oxygen species  (ROS) is  involved in many pathologic  processes.  In the case of
PH, ROS level increases when circulatory NO decreases [56]. Administration of tempol, a
type  of  superoxide  dismutase,  normalizes  these  changes  with  statistical  significance  in
endothelial  cells  and  cirrhotic  liver,  reduces  intrahepatic  vessel  resistance  and  conse‐
quently  increases  PVI  [57].  ROS also  takes  part  in  oxidative  stress  [58],  lipid  peroxida‐
tion,  apoptosis  and  dysfunction  of  endothelial  cells  [41].  Reportedly,  carvedilol,  a  β-
blocker might ameliorate oxidative stress as well as inflammation and fibrosis in a CCl4-
induced liver damage model, by reducing depletion of antioxidant enzyme, formation of
collagen,  and activation  of  NF-κB pathway,  indicating  a  relationship  between ROS and
liver damage and fibrosis [59].
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3. Cytokines and liver fibrosis
Cytokine is a group of soluble protein or polypeptide, regulating immunologic response
and hematopoiesis, participating inflammatory damage and repair. It consists of interleu‐
kins  (IL),  interferons  (IFN),  tumor  necrosis  factors  (TNF),  colony  stimulating  factors
(CSF), chemokines, and growth factors. It has been reported that serum levels IL-6, TNF-
α [60,  61],  and IL-1β [62]  were elevated in hepatoportal  sclerosis,  and plasma IL-6 level
was correlated with the deterioration of liver function [63]. Although IL-6 was increased,
expression  of  IL-6  receptor  in  cirrhotic  liver  was  decreased,  leading  to  a  reduction  of
hepatocyte  response  to  IL-6,  accompanied  by  an  increase  of  gp130,  indicating  gp130
might be the potential negative regulator of liver IL-6 signal pathway [64]. In chronic pa‐
tients  with  hepatitis  C  and/or  schistosomal,  plasma IL-4  level,  as  well  as  ROS,  was  in‐
creased and correlated with portal  vein diameter,  suggesting IL-4 might plays a role on
PVI [65].  A clinical trial has shown that administration of probiotic led to a trend to re‐
duction of  plasma endotoxin,  a mild but significant increase of  TNF-α and a significant
reduction  of  aldosterone  [66].  Besides,  increased  PVP  induced  a  up-regulation  of  α-
smooth muscle actin and collagen Ⅳ and ethanol exposure enhanced expression of TGF-β
and production of  extracellular  matrix  via  ERK1/2-JNK and p38MAPK pathway respec‐
tively,  leading  to  fibrosis  of  liver  [67].  Reportedly,  IL-18  gene  knock-out  mice  fed  with
methionine-choline-deficient  diet  (MCDD)  showed significant  exacerbated  inflammation,
revealing IL-18 was a negative regulator of non-alcoholic fatty liver disease and non-alco‐
holic steatohepatitis. Tnf mRNA, but not il-6 or il-1b levelm was higher in db/db (Asc-/-)
group than db/db (wt) group, indicating TNF-α expression drove the progression of non-
alcoholic  steatohepatitis  [68].  In  another  type  of  liver  cirrhosis  caused by  chronic  infec‐
tion  of  schistosomiasis,  inflammation  and  following  tissue  repair  led  to  obstruction  of
intrahepatic  vessels  and  increased  intrahepatic  resistance.  These  defenses  in  liver  was
mediated by IL-10.  But  surprisingly,  blockade of  IL-10R resulted in  an elevation of  PH
and a reduction of parasitic antigen specific B cells, but worsened pulmonary accumula‐
tion of  eggs without an increase of  PVP [69].  Co-infection of  bacteria  led to production
of  IL-17  [70].  Consistently,  knock-out  of  IL-10,  IL-12p40,  and IL-13Rα2 contributed to  a
progressive and lethal liver fibrosis, showing the anti-fibrosis effects of these Th2-derived
interleukins in schistosomiasis mansoni treated mice [71].  As demonstrated by Pinter M
et. Al. [72], responders to sorafenib showed a decreased HVPG and VEGF, PDGF, PIGF,
RhoA kinase,  and TNF-α expression,  revealed a  potential  effect  of  these  growth factors
and TNF-α on  HVPG.  And level  of  soluble  TNF-α receptor  in  portal  vein  and hepatic
vein was correlated with model for end-stage liver disease score, in accordance with pre‐
vious studies [73]. However, intrahepatic TNF-α, IL-1β, IL-4, and IL-10 were down-regu‐
lated  while  splanchnic  levels  were  increased  [74].  It  is  shown  that  IFN  is  involved  in
progression of hypertension, especially in viral infection- associated hepatitis [60, 75, 76].
Nowadays, IFN is usually used as antiviral treatment. Combination of 5-fluorouracil and
IFN  might  reduce  the  portal  hypertension  related  events  [77].  Also,  combination  with
IFN enhanced the viral clearance effect of ribavirin [78]. But IFN alone therapy only led
to a temporary reduction of viral DNA load [79]. As documented, TGF-β promotes liver
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tion,  apoptosis  and  dysfunction  of  endothelial  cells  [41].  Reportedly,  carvedilol,  a  β-
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fibrosis  in  rats  with  biliary  cirrhosis,  cooperates  with  IFN-γ,  IL-4,  and  TNF-α,  etc  [80].
More studies are needed to illustrate the detail effects of cytokines network on portal hy‐
pertension and liver fibrosis.
4. Molecules in further physiopathological progression
4.1. Splenomegaly and hypersplenism
Volume of spleen or splenomegaly in cirrhotic hypertension patients is primarily attribut‐
ed  to  increased  splanchnic  circulation  and  congestion,  in  which  vasoactive  substances
play  important  roles.  And  the  main  pathologic  changes  are  lower  counts  of  red  blood
cells,  white  blood  cells,  and  platelets.  Compared  to  normal  spleen,  lymphocytes  in  PH
spleen were relatively reduced with a similar distribution;  but total  number of  lympho‐
cytes was increased due to the increase of spleen weight,  with an elevated proliferation
[81, 82].  MicroRNAome analysis showed that microRNA, expecially miR-615-3p was up-
regulated in PH spleen significantly [83, 84]. It targeted on ligand-dependent nuclear re‐
ceptor  corepressor  (LCoR),  promoted  the  phagocytic  capacity  of  macrophages  through
PPARγ pathway [84].  On the other hand, phagocytic capacity of macrophages might be
inhibit  by  Phosphatidylinositol  3-kinase  regulatory  subunit  1  (PI3KR1)  knock-down,  ac‐
companied by down-regulation of  IL-1β and TNF-α [85].  Similarly,  expressions of  IL-1β
and NALP3, a potential NF-κB activator participating in inflammation and immunologic
response  were  up-regulated  significantly  in  CCl4-induced  cirrhotic  PH group compared
to  control  group,  together  with  typical  splenomegaly  histopathological  changes  [86].  In
cirrhotic spleen, different from extrahepatic portal vein obstruction, thromopoietin (TPO)
was reduced and this  reduction is  positively  correlated with exacerbation of  liver  func‐
tion, leading to a decrease of platelet counts [87].
4.2. Esophageal varices
Cirrhotic hypertension is characterized by hyperdynamic circulation and increased intrahe‐
patic resistance as discussed before in this review. Splanchnic vasodilation results in increas‐
ing in HVPG. When HVPG is higher than 12 mmHg, risk of esophageal varices dramatically
increased [88, 89]. Generally speaking, esophageal varices, as well as development of other
collateral vessels, occur after HVPG and is followed by variceal bleeding [90]. Angiogenesis
is associated with esophageal varices and portal hypertension, and expressions of VEGF are
up-regulated, alone or together with TNF-α or PEGF[91-93]. Inhibition of VEGF/VEGF re‐
ceptor pathway led to a decrease in hyperdynamic splanchnic circulation and collateral ves‐
sels [94]. Besides, metabolic disturbances occurred in cirrhotic PH lead to an elevation of
glucagon [95]. The ratio of glycated albumin (GA) to glycated hemoglobin (HbA1c) was as‐
sociated positively with the progression of liver cirrhosis, and patients with elevated GA/
HbA1c ratio have severer esophageal variceal and higher risk of bleeding in HCV-related
cirrhotic patients. This parameter might become a potential biomarker to predict the prog‐
nosis of these patients [96].
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4.3. Ascites
Portal hypertension in cirrhotic liver diseases is a main cause of ascites. As discussed before,
vasoactive substances lead to an elevation of intrahepatic vessels resistance and a relative de‐
crease of blood back-flow to liver. Besides, mechanisms below are involved: 1) hyperdynamic
circulation. Hyperdynamic circulation is associated with disturbance of vasoactive substances.
It is characterized by increased cardiac index and plasma volume and decreased systemic and
splanchnic resistance [90]. 2) hypoalbuminemia following damage of liver function. One of the
hyperalbuminemia occurred in cirrhotic PH is dysfunction of hepatocytes. In is shown that hy‐
pertension is a negative regulator to the number and structure of hepatocytes [97]. Poor blood
supply induced by liver fibrosis and disturbance of hemodynamics results in intrahepatic hy‐
poxia and damage of hepatocytes. Besides, primary liver diseases also cause inflammation and
damage in liver. 3) renal function changes. This part will be discussed below.
4.4. Hepatorenal syndrome
It is well established that main cause of hepatorenal syndrome (HRS) is constriction of vessels in
kidney induced by reduction of effective circulating blood volume (ECBV). As discussed previ‐
ously, ECBV is reduced by systemic and splanchnic vasodilation induced by changes of NO, ET,
PGs and TXA2. Besides, some localized physiopathologic should be paid attention on. Expres‐
sion of HO-1 in kidney was significantly reduced in BDL-induced cirrhotic rats [98]. Cyctatin C
was increased in decompensated liver cirrhosis and HRS, thus it could be used as a predictor of
HRS [99, 100]. Additionally, plasma level of ADAMTS13 was decreased and supplemental ther‐
apy might improve prognosis of patients with severe liver cirrhosis and HRS [101, 102].
4.5. Hepatic encephalopathy
Hepatic encephalopathy (HE) in portal hypertension is defined as C type HE. In PVL-in‐
duced PH rats, chemokine changes in splanchnic system, liver, and central nervous system
(CNS) are different [103]. As reported, in CNS, CX3CL1/CX3CR1 and SDF1-α/CXCR4 were
increased. The former one promotes inflammation in CNS while the latter one modulates
neuron activity through inhibitory neurotransmitters, e.g. gamma-amino butyric acid (GA‐
BA) [104]. ROS also participates in pre-hepatic portal hypertension [105, 106]. GABA level is
also negatively regulated by dehydroepiandrosterone sulfate (DHEAS), which reduced in
cirrhotic HE [107]. Besides, IL-6 has synergistic effect with ammonia in cirrotic HE patients
[108]. Ammonia impairs brain eNOS activity, leading to significant abnormality of NO regu‐
lation and disturbance of blood supply [109]. Due to liver dysfunction in HE patients, ele‐
vated plasma manganese also indicates a bad prognosis [110].
5. Conclusion
Portal hypertension concerns a great number of molecules and complicated physiopatholog‐
ic mechanisms. It can be classified into pre-, intra-, and post-hepatic PH according to the pri‐
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fibrosis  in  rats  with  biliary  cirrhosis,  cooperates  with  IFN-γ,  IL-4,  and  TNF-α,  etc  [80].
More studies are needed to illustrate the detail effects of cytokines network on portal hy‐
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cells,  white  blood  cells,  and  platelets.  Compared  to  normal  spleen,  lymphocytes  in  PH
spleen were relatively reduced with a similar distribution;  but total  number of  lympho‐
cytes was increased due to the increase of spleen weight,  with an elevated proliferation
[81, 82].  MicroRNAome analysis showed that microRNA, expecially miR-615-3p was up-
regulated in PH spleen significantly [83, 84]. It targeted on ligand-dependent nuclear re‐
ceptor  corepressor  (LCoR),  promoted  the  phagocytic  capacity  of  macrophages  through
PPARγ pathway [84].  On the other hand, phagocytic capacity of macrophages might be
inhibit  by  Phosphatidylinositol  3-kinase  regulatory  subunit  1  (PI3KR1)  knock-down,  ac‐
companied by down-regulation of  IL-1β and TNF-α [85].  Similarly,  expressions of  IL-1β
and NALP3, a potential NF-κB activator participating in inflammation and immunologic
response  were  up-regulated  significantly  in  CCl4-induced  cirrhotic  PH group compared
to  control  group,  together  with  typical  splenomegaly  histopathological  changes  [86].  In
cirrhotic spleen, different from extrahepatic portal vein obstruction, thromopoietin (TPO)
was reduced and this  reduction is  positively  correlated with exacerbation of  liver  func‐
tion, leading to a decrease of platelet counts [87].
4.2. Esophageal varices
Cirrhotic hypertension is characterized by hyperdynamic circulation and increased intrahe‐
patic resistance as discussed before in this review. Splanchnic vasodilation results in increas‐
ing in HVPG. When HVPG is higher than 12 mmHg, risk of esophageal varices dramatically
increased [88, 89]. Generally speaking, esophageal varices, as well as development of other
collateral vessels, occur after HVPG and is followed by variceal bleeding [90]. Angiogenesis
is associated with esophageal varices and portal hypertension, and expressions of VEGF are
up-regulated, alone or together with TNF-α or PEGF[91-93]. Inhibition of VEGF/VEGF re‐
ceptor pathway led to a decrease in hyperdynamic splanchnic circulation and collateral ves‐
sels [94]. Besides, metabolic disturbances occurred in cirrhotic PH lead to an elevation of
glucagon [95]. The ratio of glycated albumin (GA) to glycated hemoglobin (HbA1c) was as‐
sociated positively with the progression of liver cirrhosis, and patients with elevated GA/
HbA1c ratio have severer esophageal variceal and higher risk of bleeding in HCV-related
cirrhotic patients. This parameter might become a potential biomarker to predict the prog‐
nosis of these patients [96].
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vasoactive substances lead to an elevation of intrahepatic vessels resistance and a relative de‐
crease of blood back-flow to liver. Besides, mechanisms below are involved: 1) hyperdynamic
circulation. Hyperdynamic circulation is associated with disturbance of vasoactive substances.
It is characterized by increased cardiac index and plasma volume and decreased systemic and
splanchnic resistance [90]. 2) hypoalbuminemia following damage of liver function. One of the
hyperalbuminemia occurred in cirrhotic PH is dysfunction of hepatocytes. In is shown that hy‐
pertension is a negative regulator to the number and structure of hepatocytes [97]. Poor blood
supply induced by liver fibrosis and disturbance of hemodynamics results in intrahepatic hy‐
poxia and damage of hepatocytes. Besides, primary liver diseases also cause inflammation and
damage in liver. 3) renal function changes. This part will be discussed below.
4.4. Hepatorenal syndrome
It is well established that main cause of hepatorenal syndrome (HRS) is constriction of vessels in
kidney induced by reduction of effective circulating blood volume (ECBV). As discussed previ‐
ously, ECBV is reduced by systemic and splanchnic vasodilation induced by changes of NO, ET,
PGs and TXA2. Besides, some localized physiopathologic should be paid attention on. Expres‐
sion of HO-1 in kidney was significantly reduced in BDL-induced cirrhotic rats [98]. Cyctatin C
was increased in decompensated liver cirrhosis and HRS, thus it could be used as a predictor of
HRS [99, 100]. Additionally, plasma level of ADAMTS13 was decreased and supplemental ther‐
apy might improve prognosis of patients with severe liver cirrhosis and HRS [101, 102].
4.5. Hepatic encephalopathy
Hepatic encephalopathy (HE) in portal hypertension is defined as C type HE. In PVL-in‐
duced PH rats, chemokine changes in splanchnic system, liver, and central nervous system
(CNS) are different [103]. As reported, in CNS, CX3CL1/CX3CR1 and SDF1-α/CXCR4 were
increased. The former one promotes inflammation in CNS while the latter one modulates
neuron activity through inhibitory neurotransmitters, e.g. gamma-amino butyric acid (GA‐
BA) [104]. ROS also participates in pre-hepatic portal hypertension [105, 106]. GABA level is
also negatively regulated by dehydroepiandrosterone sulfate (DHEAS), which reduced in
cirrhotic HE [107]. Besides, IL-6 has synergistic effect with ammonia in cirrotic HE patients
[108]. Ammonia impairs brain eNOS activity, leading to significant abnormality of NO regu‐
lation and disturbance of blood supply [109]. Due to liver dysfunction in HE patients, ele‐
vated plasma manganese also indicates a bad prognosis [110].
5. Conclusion
Portal hypertension concerns a great number of molecules and complicated physiopatholog‐
ic mechanisms. It can be classified into pre-, intra-, and post-hepatic PH according to the pri‐
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mary disease, with similar but not same involvement of molecules and mechanisms.
However, we can still conclude that: 1) vasoactive substances play an important in systemic,
splanchnic, hepatic, and even neurologic circulations which are closely related to blood sup‐
ply, affecting the development, progression, and outcome of PH; 2) imbalance of pro-/anti-
inflammatory cytokines lead to a systemic and/or localized regulation of signal pathways
and modulate gene expression and silencing, cell proliferation and apoptosis, tissue damage
and repair, and eventually life and death; 3) accumulating research advancements provide
us new targets for treatment of PH, but it has a long way to go from bench to bedside.
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1. Introduction
Hepatic veno-occlusive disease (HVOD): was described as a non portal cirrhosis occurring
frequently in children and occasionally in adults. Now it is considered an important cause of
non cirrhotic portal hypertension particularly in children [1].
Rollins 1989 [2], stated that HVOD is a non-thrombotic obliteration of small intrahepatic
veins by loose connective tissues. The venous occlusion may be progressive and lead to mas‐
sive hepatocellular necrosis. However the precise pathogenesis is still obscure but also most
likely relates to venous endothelial injury.
Originally the syndrome was described in South Africa at 1920, but at present it is endemic
in Jamaica, encountered in Afghanistan and India. The syndrome was described under dif‐
ferent names, from Jamaica the disease was described under the term Jamaican veno-occlu‐
sive disease, in India the disease was given the term Indian childhood Cirrhosis (ICC), in
Europe HVOD has been called endophlebitis obliterans of which sporadic cases were descri‐
bed, as in Germany. Hepatic veno- occlusive disease was examined by scanning electron mi‐
croscopy (SEM). SEM correlated its histology and postmortem examination and disclosed
microscopic occlusion of the centrilobular and sublobular veins in the liver, these veins were
occluded partially or completely by intimal and medial thickening of their walls due to pro‐
liferation of collagen and reticulin fibers. In addition to venous obliteration, which had not
been demonstrated by other techniques, frequent occlusion of the sinusoidal opening into
the central veins was observed by SEM. [4], [5], [6].
© 2013 Salama; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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Causes of non cirrhotic portal hypertension
Intrahepatic Extrahepatic
Schistosomiasis Extrahepatic portal vein thrombosis
Extrahepatic portal vein thrombosis Splenic vein thrombosis










Hepatic veno-occlusive disease has been recognized as being due to the toxic effects of some
remedies, recently pyrrolizidine alkaloids mostly involved, as in senecio (bush teas) and cro‐
talaria (comfrey trees). It is also now seen as complication of high dose of anti-neoplastic
chemotherapy, especially in the setting of bone marrow transplantation. HVOD may be
familial, so the term “veno occlusive familial hepatic disease” [7], [8], [9].
2. Hepatic veno-occlusive disease (HVOD) in Egypt: Overview
In Egypt Hashem 1939 [7], gave the first reference to this syndrome, in his study of portal
cirrhosis among Egyptian children. Since 1939 several reports pointed out the occurrence of
a specific syndrome among Egyptian children who rapidly developed abdominal distention
with ascites and hepatomegaly. In 1965, Safouh et al [11]; reported that 54 Egyptian children
were studied and the term "Hepatic vein occlusion disease in Egyptian children" was ap‐
plied. At the same year, El Gholmy 1956 [10], studied a group of patients and introduced the
term “Infantile cirrhosis of Egypt”
The different reports from Egypt, thereafter, describing the syndrome, the clinical picture,
the pathology and the etiology revealed that HVOD is not uncommon among Egyptian in‐
fants and young children. They also have shown clearly for the first time that hepatic vein
occlusion should be considered in the diagnosis of Egyptian children presenting with hepa‐
tosplenomegaly [11].
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Safouh 1965 [11], reported that the Egyptian hepatic vein occlusion is the result of enhanced
thrombotic activity of the blood with the formation of fibrinous thrombi followed by organi‐
zation and thickening or closure of the vessels, a finding which seems peculiar to the Egyp‐
tian cases and thus differs from the classical HVOD.
3. Clinical Picture of HVOD
Clinical diagnosis is based on; hepatomegaly and/or right upper quadrant pain, ascites or
unexplained weight gain and also jaundice may or may not present [7].
The acute stage starts abruptly with abdominal discomfort or pain accompanied by hepato‐
megaly and ascites, nausea and vomiting are common. Histologically the liver shows an
edematous endophlebitis of the central veins associated with centrilobular congestion, hem‐
orrhage and necrosis. Mclean 1969 [12], has shown experimentally that the block occurs first
at the outlets of the sinusoids. Patients surviving the acute stage may progress to the suba‐
cute stage with persistent hepatomegaly and ascites which then diminish if an adequate col‐




Mild continuous dragging pain in right hypochondrium
Anorexia, nausea and vomiting
Rapidly filling ascites
Distended veins over the abdomin
Oliguria and pedal edema
Hepatomegaly
Splenomegaly in some cases
Tandon 1977
4. Diagnosis of HVOD
In the acute phase the diagnosis is usually readily made from the history and the character‐
istic clinical picture. In the sub-acute and chronic stages the diagnosis may be more difficult.
In all stages the diagnosis is confirmed by the characteristic histopathological findings of liv‐
er biopsy in the absence of extrahepatic venous obstruction.
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1. Safouh et al; 1965 [11] reported the following results:
# Most of the cases showed some degree of anemia.
# Total and differential leukocytic counts did not show any constant deviation from normal.
# Liver function tests showed that : * Serum bilirubin was always below 3 mg/dl, * Serum
AST varied between 20 and 60 units, * Serum ALT and alkaline phosphatase were found to
be normal.
# Erythrocyte sedimentation rate ( ESR ) was low in spite of advanced state of the disease.
# The pattern of serum total proteins showed a state of hypoproteinemia ranging from 4-5
gm/dl and the albumen fraction is usually is decreased but globulin fraction may be in‐
creased.
2. Millis and Bale 1976 [13], stated that a feature of their cases is the partial immune deficien‐
cy. However, such a state of hypogammaglobulinemia reported by them goes parallel with
findings in the acute cases only, that their cases were quite a different group of patients suf‐
fering from genetic immunodeficiency as observed from the very early appearance of the
syndrome in some of them being as early as days.
3. Serum procollagen type III is an early and sensitive marker in VOD after BM transplanta‐
tion, usually above 100 ng /ml.
4. Serum protein S,C, liedin factor
4.2. Ultrasonographic scaning of the liver:
It is of definite help in the diagnosis of this syndrome, it showed that the liver is enlarged es‐
pecially the caudate lobe, splenic enlargement is usually of mild degree and ascites is always
found in acute cases. Narrowing of inferior vena cava could be detected in 40% of cases. Ex‐
amination of the terminal parts of the hepatic veins demonstrated their occlusion or attenua‐
tion, a finding which is considered a new and significant contribution to the early diagnosis
of this syndrome [14].
4.3. Inferior vena cava angiogram:
Presented as narrow or closed intra-hepatic portion of the inferior vena cava with marked
collaterals [14].
4.4. Liver biopsy:
In the acute stage it shows centrilobular hemorrhage, necrosis and sinusoidal dilatation. In
the chronic stage it presents picture of micronodular cirrhosis with normal portal tracts [7].
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4.5. Other tools of investigations [14]
• The ascitic fluid is a main laboratory field of investigations. It usually shows protein val‐
ues ranging between 1-3.5 gms/dl with occasional lymphocytes.
• Other sophisticated modules of investigations might be carried out : liver isotopic scan‐
ning, splenoportal venogram and arterio-venography of the portal system.
5. Management of Hepatic veno-occlusive disease:
No effective therapy until now especially in this type of Egyptian children. The target of available
line is, may be, to reduce the complications, to reduce the stress of the patients and keep the
patients in nearly comfortable life, but the following measures could be used safely [14].
5.1. Preventive measures:
• More investigation for the etiology of the disease especially pyrrolizidine alkaloids.
• Encouraging the breast feeding for two years as Glorious Qura’n says. (Sorra El bakara ),
regulation and careful inspection of diet after weaning [11].
• Good nutrition of the mother
• What about copper utensils ?? it suspected to play a role in indian cirrhosis !
5.2. Conservative measures :
• Follow up, because a grossly abnormal scan of liver and spleen in a patient with HVOD
has been normalized completely without any interference.
• Colonic lavage to wash out the toxic metabolites.
5.3. Medical treatment:
• Low doses of heparin or anticoagulants, adapted dose of prostacyclin.
• Anti inflammatory or steroids.
• Use of Vit C, use of Vit. E and Glutamine (source of glutathione) as antioxidants [15].
• Use of recombinant tissue plasminogen activator (rtPA), especially in patients after BM trans‐
plantation, Urokinase especially in cases with bleeding diathesis leading to thrombotic
HVOD [15], [16], [17].
• Diuretics for ascites.
• Large doses of glucose together with insulin to aid glycogen deposition in the liver and so
help its nutrition.
• Cupper chelation treatment (Di-penecillamine)
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5.4. Surgical treatment [18].
5.4.1. Treatment of ascites :
• Frequent aspiration (partial or full)
• TIPS ( transjagular intrahepatic portosystemic shunt)
• Hepatic and portal decompression for interactable ascites.
• LeVeen, peritoneojagular shunt.
5.4.2. Treatment of portal hypertension:
• Porto-systemic shunt as porto-caval, spleno-renal or meso-atrial.
• Acute venous obstruction could be treated by hepatofugal portal flow via veno-venous
bypass to drain arterial blood flow.
5.4.3. Liver transplantation:
• It is now a part of the therapeutic armamentarium for this condition.
6. Therapeutic paracentesis [21].
The first study re-evaluating paracentesis as a treatment of cirrhotic patients with ascites
consisted of a randomized controlled trial comparing repeated large-volume paracentesis
(4-6 l/day until the disappearance of ascites) plus intravenous albumin infusion (40g after
each tap) with standard diuretic therapy (frusemide plus spironolactone) in I17 patients
with tense ascites and avid sodium retention who were admitted to several hospitals in the
Barcelona area. This study, later confirmed by two more trials performed in Milan and Bar‐
celona, showed the following results:
1. paracentesis was more effective than diuretics in eliminating ascites (96.5 versus 72.8%);
2. paracentesis plus albumin infusion did not induce significant changes in hepatic and renal
function, serum electrolytes, cardiac output, plasma volume, plasma renin activity and plas‐
ma concentration of noradrenaline and antidiuretic hormone.
3. the incidence of hyponatremia, hepatic encephalopathy and renal impairment was much
lower in patients treated with paracentesis.
4. the duration of hospital stay was lower in patients treated with paracentesis.
5. there were no significant probability of re-admission, probability of survival and causes of
death between the two groups of patients.
Tito et al., later investigated whether ascites can be safely mobilized by total paracentesis
(complete removal of ascites by a single paracentesis) plus intravenous albumin infusion
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(6-8 g/l removed) in a one day hospitalization regime. The incidence of complications and
the clinical course of the disease, as estimated by the probability of readmission to hospital,
causes of re-admission, probability of survival and causes of death, were comparable to
those reported by the same group of investigators in patients treated with repeated large-
volume paracentesis.
In conclusion, these studies demonstrate that mobilization of ascites by paracentesis associat‐
ed with intravenous albumin infusion does not impair systemic haemodynamics and renal
function in patients with cirrhosis and tense ascites. Therapeutic paracentesis should be the
treatment of choice for cirrhotic patients admitted to hospital with tense ascites, because it is
more effective in mobilizing associated with a lower incidence of complications and reduce the
duration of hospitalization. To avoid re-accumulation of ascites, patients treated with paracent‐
esis require dietary sodium restriction and administration of diuretics after the procedures.
Subsequently, a trial was performed to establish whether intravenous albumin infusion is
necessary in cirrhotic patients with tense ascites treated with repeated large-volume para‐
centesis. It was observed that paracentesis plus intravenous albumin does not induce signifi‐
cant changes in standard renal function testes, plasma renin activity and plasma aldosterone
concentration. In contrast, paracentesis without albumin was associated with a significant
increase in blood urea nitrogen, a marked elevation in plasma renin activity and plasma al‐
dosterone concentration, and a significant reduction in serum sodium concentration. The
number of patients developing hyponatremia and renal impairment was remarkably higher
in patients treated with repeated large-volume paracentesis without intravenous albumin
infusion. There are two detailed investigations assessing the effects of large-volume para‐
centesis without albumin infusion on systemic haemodynamics vasoactive hormones and
renal function. A significant increase in cardiac output was observed 1 hour after treatment
in both studies. Some hours later, however, a significant drop below baseline values was ob‐
served in cardiac output, pulmonary wedge capillary pressure and central venous pressure.
Plasma renin activity increased and plasma atrial natriuretic peptide concentration de‐
creased. The adverse effects observed after complete mobilization of ascites by paracentesis
without albumin expansion did not occur in patients in whom ascites was only partially mo‐
bilized by paracentesis without colloid replacement. In conclusion, these studies demon‐
strate that complete mobilization of ascites by paracentesis without plasma volume
expansion is followed by a reduction in effective intravascular volume, which leads to acti‐
vation of the renin-aldosterone system and may impair renal function. The infusion of intra‐
venous albumin is an important measure to prevent these abnormalities in cirrhotic patients
with tense ascites treated with large-volume or total paracentesis.
Five randomized controlled trials and one prospective study aimed at investigating whether
albumin can be substituted by less expensive plasma expanders (dextran-70,  dextran-40,
Haemaccel 5% and isotonic saline) have recently been reported. It has been observed that total
or repeated large-volume paracentesis associated with intravenous administration of dex‐
tran-70 or Haemaccel is not associated with significant changes in renal and hepatic func‐
tion. The incidence of hyponatremia, renal impairment and hepatic encephalopathy in patients
receiving dextran-70 or Haemaccel was comparable with that in patients receiving albumin.
Egyptian Hepatic Veno-Occlusive Disease: Surgical Point of View
http://dx.doi.org/10.5772/50685
555
5.4. Surgical treatment [18].
5.4.1. Treatment of ascites :
• Frequent aspiration (partial or full)
• TIPS ( transjagular intrahepatic portosystemic shunt)
• Hepatic and portal decompression for interactable ascites.
• LeVeen, peritoneojagular shunt.
5.4.2. Treatment of portal hypertension:
• Porto-systemic shunt as porto-caval, spleno-renal or meso-atrial.
• Acute venous obstruction could be treated by hepatofugal portal flow via veno-venous
bypass to drain arterial blood flow.
5.4.3. Liver transplantation:
• It is now a part of the therapeutic armamentarium for this condition.
6. Therapeutic paracentesis [21].
The first study re-evaluating paracentesis as a treatment of cirrhotic patients with ascites
consisted of a randomized controlled trial comparing repeated large-volume paracentesis
(4-6 l/day until the disappearance of ascites) plus intravenous albumin infusion (40g after
each tap) with standard diuretic therapy (frusemide plus spironolactone) in I17 patients
with tense ascites and avid sodium retention who were admitted to several hospitals in the
Barcelona area. This study, later confirmed by two more trials performed in Milan and Bar‐
celona, showed the following results:
1. paracentesis was more effective than diuretics in eliminating ascites (96.5 versus 72.8%);
2. paracentesis plus albumin infusion did not induce significant changes in hepatic and renal
function, serum electrolytes, cardiac output, plasma volume, plasma renin activity and plas‐
ma concentration of noradrenaline and antidiuretic hormone.
3. the incidence of hyponatremia, hepatic encephalopathy and renal impairment was much
lower in patients treated with paracentesis.
4. the duration of hospital stay was lower in patients treated with paracentesis.
5. there were no significant probability of re-admission, probability of survival and causes of
death between the two groups of patients.
Tito et al., later investigated whether ascites can be safely mobilized by total paracentesis
(complete removal of ascites by a single paracentesis) plus intravenous albumin infusion
Hepatic Surgery554
(6-8 g/l removed) in a one day hospitalization regime. The incidence of complications and
the clinical course of the disease, as estimated by the probability of readmission to hospital,
causes of re-admission, probability of survival and causes of death, were comparable to
those reported by the same group of investigators in patients treated with repeated large-
volume paracentesis.
In conclusion, these studies demonstrate that mobilization of ascites by paracentesis associat‐
ed with intravenous albumin infusion does not impair systemic haemodynamics and renal
function in patients with cirrhosis and tense ascites. Therapeutic paracentesis should be the
treatment of choice for cirrhotic patients admitted to hospital with tense ascites, because it is
more effective in mobilizing associated with a lower incidence of complications and reduce the
duration of hospitalization. To avoid re-accumulation of ascites, patients treated with paracent‐
esis require dietary sodium restriction and administration of diuretics after the procedures.
Subsequently, a trial was performed to establish whether intravenous albumin infusion is
necessary in cirrhotic patients with tense ascites treated with repeated large-volume para‐
centesis. It was observed that paracentesis plus intravenous albumin does not induce signifi‐
cant changes in standard renal function testes, plasma renin activity and plasma aldosterone
concentration. In contrast, paracentesis without albumin was associated with a significant
increase in blood urea nitrogen, a marked elevation in plasma renin activity and plasma al‐
dosterone concentration, and a significant reduction in serum sodium concentration. The
number of patients developing hyponatremia and renal impairment was remarkably higher
in patients treated with repeated large-volume paracentesis without intravenous albumin
infusion. There are two detailed investigations assessing the effects of large-volume para‐
centesis without albumin infusion on systemic haemodynamics vasoactive hormones and
renal function. A significant increase in cardiac output was observed 1 hour after treatment
in both studies. Some hours later, however, a significant drop below baseline values was ob‐
served in cardiac output, pulmonary wedge capillary pressure and central venous pressure.
Plasma renin activity increased and plasma atrial natriuretic peptide concentration de‐
creased. The adverse effects observed after complete mobilization of ascites by paracentesis
without albumin expansion did not occur in patients in whom ascites was only partially mo‐
bilized by paracentesis without colloid replacement. In conclusion, these studies demon‐
strate that complete mobilization of ascites by paracentesis without plasma volume
expansion is followed by a reduction in effective intravascular volume, which leads to acti‐
vation of the renin-aldosterone system and may impair renal function. The infusion of intra‐
venous albumin is an important measure to prevent these abnormalities in cirrhotic patients
with tense ascites treated with large-volume or total paracentesis.
Five randomized controlled trials and one prospective study aimed at investigating whether
albumin can be substituted by less expensive plasma expanders (dextran-70,  dextran-40,
Haemaccel 5% and isotonic saline) have recently been reported. It has been observed that total
or repeated large-volume paracentesis associated with intravenous administration of dex‐
tran-70 or Haemaccel is not associated with significant changes in renal and hepatic func‐
tion. The incidence of hyponatremia, renal impairment and hepatic encephalopathy in patients
receiving dextran-70 or Haemaccel was comparable with that in patients receiving albumin.
Egyptian Hepatic Veno-Occlusive Disease: Surgical Point of View
http://dx.doi.org/10.5772/50685
555
In one study, patients treated with dextran-70 showed a significant increase in plasma renin
activity and aldosterone concentration. In a more recent study, however, therapeutic paracent‐
esis plus intravenous dextran-70 administration was not associated with significant changes
in plasma renin activity, which was measured 24 and 96 hours after the treatment. Cabrera et
al., in one study including 14 patients, have suggested that intravenous isotonic saline infu‐
sion can also be a safe and cost effective alternative plasma expander in cirrhotics with tense
ascites treated with paracentesis. Further studies are obviously needed to confirm their find‐
ings. It seems that dextran-40 is not as effective as albumin in preventing renal and electro‐
lyte complications after therapeutic paracentesis, as renal impairment and/or hyponatremia
developed after treatment in a relatively high proportion of patients.
Recently, a multicenter randomized trial comparing therapeutic paracentesis with PVS in
cirrhotic patients with refractory or recurrent ascites has been published. More than 40 pa‐
tients were included in each group. Both treatments were equally effective in mobilizing the
ascites during the first hospital stay, although the duration of hospitalization was signifi‐
cantly longer in the shunt group. There were also no significant differences between both
groups in the number of patients who developed complications or died. The number of re-
admissions for any reason or for ascites, was significantly higher, and the time to first re-
admission for any reason and for ascites significantly shorter in the paracentesis group than
in the shunt group. The total time in hospital during follow-up, however, was similar in the
two groups. The probability of shunt obstruction was 40 % at 1 -year follow-up. The proba‐
bility of survival was similar in both groups. In conclusion, this trial shows that, although
the LeVeen shunt was better than paracentesis in the long-term control of ascites, it did not
reduce the total time in hospital nor prolong survival. On the other hand, patients treated
with PVS required frequent re-operations due to obstruction of the prosthesis. Therapeutic
paracentesis is therefore an alternative treatment to LeVeen shunt in cirrhotic patients with
refractory ascites.
7. Peritoneovenous Shunting
In 1974 LeVeen [19], and colleagues developed a pressure-activated one-way valve for use
in a peritoneovenous shunt (PVS). This device consists of a perforated intra-abdominal tube
connected through a one-way pressure sensitive valve to a silicone tube that traverses the
subcutaneous tissue up to the neck, where it enters one of the jugular veins (usually the in‐
ternal jugular vein). The tip of the intravenous tube is located in the superior vena cava, near
the right atrium or in the right atrium itself. The shunt produces a sustained circulating
blood volume expansion by continuous passage of ascitic fluid to the general circulation.
Flow in the shunt is maintained if there is a 3-5 cm H2O pressure gradient between the ab‐
dominal cavity and the superior vena cava. A loss of this gradient causes the valve to close,
preventing blood from flowing back into the tubing. Two additional shunts have been intro‐
duced Denver and Cordis-Hakim. These latter shunts include a pumping mechanism that
allows flow to be increased or a partially occluded shunt to be cleared.
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The intravenous infusion of ascitic fluid through the shunt is associated with an increase in
circulating blood volume and cardiac output. Since arterial pressure does not rise, there is a
concomitant reduction in peripheral vascular resistance. These hemodynamic changes are
associated with an increase in the plasma concentration of atrial natriuretic factor and a sup‐
pression of plasma levels of renin, aldosterone, noradrenaline and antidiuretic hormone.
Urine volume and free water clearance increase in most patients. However, there is signifi‐
cant natriuresis in less than half of the patients, demonstrating that the PVS does not com‐
pletely correct the abnormal sodium-retaining state associated with cirrhosis. Finally, in
cirrhotic patients with moderate FRF, the PVS may improve renal blood flow and glomeru‐
lar filtration rate. These hemodynamic and hormonal changes persist in most cases and a
significant proportion of patients remains with minimal or no ascites despite a moderate so‐
dium restriction and low diuretic dosage. There are also two studies that suggest that PVS
has a positive effect on the nutritional status of patients in whom the shunt functions for a
prolonged period of time. Despite these positive effects of PVS, there are a large number of
complications, which may occur early in the postoperative period or at any time during fol‐
low-up [19], [20].
The role of PVS in the management of cirrhotic patients with ascitcs is still not well estab‐
lished. Only one prospective study showed that PVS is superior to conventional medical
therapy in the management of ascites and in improving survival. By contrast, four random‐
ized studies have failed to demonstrate a longer survival time in cirrhotic patients with as‐
cites treated with PVS compared with medical therapy. Of these studies, that which was
performed by Stanley et al., 1989 [22], is worth mentioning. They compared PVS with medi‐
cal treatment (diuretics and occasional paracentesis) in 299 patients with cirrhosis and re‐
fractory or recurrent ascites. Although early mortality and probability of survival after
randomization were similar in both therapeutic groups, PVS was more effective in the man‐
agement of ascites than was conventional medical therapy, as indicated by shorter duration
of first hospitalization, longer time to recurrence of ascites, and lower diuretic requirements
during follow-up. However, these results are not surprising, because PVS was compared
with a treatment that by definition was known to be ineffective.
The effect of PVS on survival in patients with FRF has also been studied in a randomized
controlled trial. The treated patients had some improvement in renal function, but their sur‐
vival was unaffected. Several studies have shown that morbidity and survival of cirrhotic
patients treated with PVS correlate with the degree of impairment of liver and renal func‐
tion. Therefore, the best results with this procedure should be expected to occur in those few
patients with diuretic-resistant ascites and preserved hepatic function [23].
7.1. Early complications of peritoneovenous shunting
Acute bacterial infection is the most serious early complication. Staphylococcus aureus is a
frequent isolate and represents the operative contamination of the shunt in some cases. The
prosthesis is usually colonized and the infection cannot be eradicated in most cases unless
the shunt is removed a high mortality can be expected. The prophylactic administration of
anti-staphylococcal antibiotics 24 hours before and 48 hours after surgery reduces the inci‐
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dence of early postoperative infection. Biochemical disseminated intravascular coagulation
(DIC) is seen in practically every cirrhotic patient treated with PVS in the early postopera‐
tive period. Bleeding caused by DIC develops most commonly in those patients with se‐
vere liver disease, but is now very uncommon, because many surgeons remove the ascitic
fluid before inserting the shunt and replace it with normal saline. DIC is thought to devel‐
op because of infusion of factors present in ascitic fluid that activate coagulation (thrombo‐
plastin, activated clotting factors, endotoxin, collagen, plasminogen activator and fibrin split
products). Postoperative fever, probably related to the passage of endotoxin contained in
the ascitic fluid to the general circulation, is almost a constant and disappears spontaneous‐
ly within the second postoperative week. Rapid expansion of the plasma volume is associ‐
ated with a rise in portal pressure and may increase the risk of variceal haemorrhage. This
complication can also be prevented by removing most ascitic fluid before the insertion of
the shunt [24].
7.2. Long-term complications of peritoneovenous shunting
Obstruction of the shunt is the most common complication during follow-up. It occurs in
more than 30% of patients and is usually due to deposition of fibrin within the valve or the
intravenous catheter, thrombotic obstruction of the venous limb of the prosthesis, or throm‐
bosis of the superior vena cava or right atrium initiated at the venous end of the shunt or
damaged endothelium. Shunt obstruction is generally associated with ascites re-accumula‐
tion. Shunt patency can be assessed by Doppler ultrasound or by technetium 99m scintigra‐
phy using intraperitoneal radioisotope injection. If the obstruction is confirmed, a
shuntogram after the injection of contrast into the proximal limb of the shunt may identify
the site of obstruction. Venography or digital angiography is necessary in the case of ob‐
struction of the venous tip of the shunt. Superior vena cava syndrome secondary to total ob‐
struction of the vein and pulmonary embolism are much less common. It is not clear that the
insertion of a titanium tip into the venous end of the LeVeen shunt prevents thrombotic ob‐
struction and the development of superior vena cava thrombosis. Finally, another long-term
complication of PVS is small-bowel obstruction, which occurs in approximately 10% of pa‐
tients and is due to intraperitoneal fibrosis [25].
8. Transjugular intrahepatic portosystemic shunt (TIPS)
The feasibility of intrahepatic portosystemic shunting was first demonstrated by Rosch and
colleagues 1969 in pigs. Colapinto et al; 1982 [27] reported the first application of this techni‐
que to humans. This was attempted following transhepatic obliteration of varices in 20 se‐
verely ill patients with variceal hemorrhage. The authors inflated a balloon catheter in the
intrahepatic track and left it there for 12 hours. In an initial report all six shunts studied
were patent 12 hours after the procedure and one was still patent at autopsy 6 weeks late.
Many demonstrated prolonged patency of the shunt for up to 10 months and ease of recan‐
alizing the radiopaque shunt when occlusion occurred. This expandable stent was then used
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successfully in patients with portal hypertension. Similar good results were soon reported
with the self-expanding Wall stent. Percutaneous portography was used in the early cases to
facilitate transjugular portal vein puncture. With increasing experience this has been re‐
placed by ultrasound guidance in most centers [28].
There is now an increasing array of equipment available for transjugular intrahepatic porto‐
sytemic shunt (TIPS) insertion. The most widely used needles are a standard transjugular bi‐
opsy needle with a straight or reversed bevel (Cook Ltd) or the Richter needle which has a
tapered tip and a blunt obturator (Angiomed, Karlsruhe, Germany). Another set with a
blunt cannula, through which is passed a sharp style is also available (Cook). There is also a
wider choice with regard to the type and dimensions of metal stent. In addition to the origi‐
nal Palmaz and Wall stents, there is the Strecker stent and the Memotherm stent (Angiomed,
Karlsruhe, Germany). Claimed advantages for these new stents are increased radioopacity
(Strecker stent) and improved delivery systems (Memo stent) [29].
A recent randomized controlled study compared the Palmaz and Wall stent in 90 patients
and found little difference in outcome. Early shunt thrombosis was more likely with the
Wall stent (9%), whereas stenosis of the hepatic vein was more likely with the Palmaz stent
(I3%). Experience with the other stents is limited.
As yet the long-term expectations of TIPS have not been fulfilled in those clinical situations
in which long-term efficacy is needed as prevention of variceal rebleeding, ascites, cirrhotic
hydrothorax, Budd-Chiari syndrome, and long-term amelioration of clinical status before
liver transplantation. All these indications need controlled trials against current best optimal
management before TIPS is used routinely even for an individual patient. The high stent ob‐
struction rate is the most important limiting factor, but change in stent shape, coating mate‐
rial or other technical aspects may overcome this [30].
The complications of TIPS are significant if elective and long-term use is considered, thus the
need for trials before new therapies are introduced. In an emergency situation the complica‐
tions due to TIPS are an acceptable risk, but again information from controlled trials is needed.
This is particularly true when TIPS is used as a short-term bridge to liver transplantation.
TIPS will have a place in the treatment of cirrhotic patients. At present short-term rather than
long-term indications appear to be where TIPS will have more beneficial effects [28].
9. Liver transplantation: and hepatic venous obstruction
Liver transplantation for Budd–Chiari syndrome: A European study on 248 patients from 51
centers ) [31]: The results of liver transplantation for Budd–Chiari syndrome (BCS) are poor‐
ly known and the role and timing of the procedure are still controversial. The aim of this
study was to investigate the results of transplantation for BCS, focusing on overall outcome,
on prognostic factors and on the impact of the underlying disease. Methods: An enquiry on
248 patients representing 84% of the patients transplanted for BCS in the European Liver
Transplantation Registry between 1988 and 1999. Results: Of the 248 patients, 70.4% were
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dence of early postoperative infection. Biochemical disseminated intravascular coagulation
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tion. Shunt patency can be assessed by Doppler ultrasound or by technetium 99m scintigra‐
phy using intraperitoneal radioisotope injection. If the obstruction is confirmed, a
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the site of obstruction. Venography or digital angiography is necessary in the case of ob‐
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insertion of a titanium tip into the venous end of the LeVeen shunt prevents thrombotic ob‐
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female and 29.6% male. The mean age was 35.7 years. The overall actuarial survival was
76% at 1 year, 71% at 5 years and 68% at 10 years. 77% of deaths occurred in the first 3
months: 47% were due to infection and multiple organ failure, and 18% to graft failure or
hepatic artery thrombosis. Late mortality (>1 year) occurred in nine patients, due to BCS re‐
currence in four of them. The only pre-transplant predictors of mortality on multivariate
analysis (Cox) were impaired renal function and a history of a shunt.
10. Conclusions
Liver transplantation for BCS is an effective treatment, irrespective of the underlying cause,
and should be considered before renal failure occurs [31].
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hepatic artery thrombosis. Late mortality (>1 year) occurred in nine patients, due to BCS re‐
currence in four of them. The only pre-transplant predictors of mortality on multivariate
analysis (Cox) were impaired renal function and a history of a shunt.
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and should be considered before renal failure occurs [31].
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1. Introduction
Neonatal cholestasis is one of the commonest presentations in the field of pediatric hepatol‐
ogy and gastroenterology and constitutes the major indication for liver transplantation be‐
low two years of age. Unfortunately, in spite of being common, fewer categories are
amenable to curative or palliative therapy. Moreover, delayed referral to specialized centers
is still a problem adding a more difficulty to neonatal cholestasis management. Hepatobili‐
ary surgery is a major line of therapy in some etiologies of neonatal cholestasis. Biliary atre‐
sia, choledochal cyst, spontaneous perforation of the bile duct and inspissated bile
syndrome are among the commonest known causes for hepatobiliary surgeons. However,
there is less orientation about other causes, resulting in progression to cirrhosis and end
stage liver disease without being diagnosed. One of these is the progressive familial intrahe‐
patic cholestasis (PFIC) group of diseases [1].
PFIC is an autosomal recessive liver disorder characterized by an intrahepatic cholestasis
due  to  bile  canalicular  transport  defects.  It  is  subdivided into  three  types  with  slightly
different clinical,  biochemical and histological features. PFIC types 1, 2 and 3 are due to
mutations  in  ATP8B1  (adenosine  triphosphatase,  type  8B,  member  1),  ABCB11  (adeno‐
sine  triphosphate-binding cassette,  subfamily  B,  member  11)  and ABCB4  (adenosine  tri‐
phosphate-binding  cassette,  subfamily  B,  member  4)  genes,  respectively.  Each  of  these
genes encodes a hepatocanalicular transporter which is essential for the proper secretion
and formation of bile [2].
PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also oc‐
cur later in infancy, in childhood or even during young adulthood. The shared main clinical
manifestations in all types are cholestasis and pruritus. PFIC represents 10-15 % of causes of
cholestasis in children and 10-15% of indications of liver transplantations in children [3].
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1. Introduction
Neonatal cholestasis is one of the commonest presentations in the field of pediatric hepatol‐
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low two years of age. Unfortunately, in spite of being common, fewer categories are
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ary surgery is a major line of therapy in some etiologies of neonatal cholestasis. Biliary atre‐
sia, choledochal cyst, spontaneous perforation of the bile duct and inspissated bile
syndrome are among the commonest known causes for hepatobiliary surgeons. However,
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mutations  in  ATP8B1  (adenosine  triphosphatase,  type  8B,  member  1),  ABCB11  (adeno‐
sine  triphosphate-binding cassette,  subfamily  B,  member  11)  and ABCB4  (adenosine  tri‐
phosphate-binding  cassette,  subfamily  B,  member  4)  genes,  respectively.  Each  of  these
genes encodes a hepatocanalicular transporter which is essential for the proper secretion
and formation of bile [2].
PFIC1 and PFIC2 usually appear in the first months of life, whereas onset of PFIC3 may also oc‐
cur later in infancy, in childhood or even during young adulthood. The shared main clinical
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In this chapter, we want to highlight the etiology, pathophysiology, clinical presentation and
the role of surgery in the management of this disease category, especially that medical thera‐
py is of limited value in a magnitude of cases. Moreover, liver transplant is not without sig‐
nificant side effects. So, raising the orientation about this not uncommon condition will help
in timely surgical intervention and improving patients' outcome.
2. Historical background
This disorder was first described by Clayton in 1965, and was termed Byler’s disease after an
American Amish kindred in which it was discovered [4]. Clinical features included severe pru‐
ritus, steatorrhea, poor growth and progression to cirrhosis in early childhood. A prominent
finding was a low or normal serum gamma glutamyl transpeptidase (GGT), which was dis‐
cordant with the severe cholestasis. Since its discovery, similar clinical features were described
in non-Amish children. Therefore, the more descriptive term, PFIC, is preferred [5].
However, this PFIC nomenclature is not always entirely satisfactory. A preferable term is
“bile canalicular transport disorders,” especially as it has become apparent that these genetic
disorders have numerous clinical phenotypes across all age brackets. For example, benign
recurrent intrahepatic cholestasis (BRIC) and intrahepatic cholestasis of pregnancy (ICP) can
occur in association with abnormalities in any of the three affected genes [2,6]. However, the
PFIC nomenclature is still in use due to its popularity in the literature.
Benign recurrent intrahepatic cholestasis, first described in 1959, is an intermittent form of
intrahepatic cholestasis characterized by variable periods of intense pruritus often associat‐
ed with jaundice [7]. The age of onset is variable, but it typically occurs during childhood or
adolescence. The severity and duration of attacks also vary and triggering features are not
well known. The benign designation of BRIC refers to the general lack of progressive liver
disease, although the pruritus is far from benign during an intense episode [8-10].
As the clinical spectrum between BRIC and PFIC (formerly named Byler’s disease) may be a
continuum, thus the historical nomenclature of Byler’s disease and BRIC may be outdated
[11]. So, many clinicians now refer to all these diseases in a general sense as ATP8B1,
ABCB11 and ABCB4 deficiency diseases to express the wide continuum of disease severity
between the PFIC and BRIC phenotypes [2].
3. Etiology and pathophysiology
3.1. PFIC 1 (ATP8B1 "FIC-1" deficiency)
PFIC1 is an autosomal recessive disease caused by mutations in ATP8B1 (formerly named
FIC1) gene on chromosome 18, locus q21-22. This gene encodes a transporter localized on the
canalicular membrane of hepatocytes (Figure 1), named FIC1 (ATP8B1), a P-type ATPase [12].
Hepatic Surgery564
Abbreviations: FIC1: familial intrahepatic cholestasis 1; BSEP: bile salt export pump; MDR3: multidrug resistence pro‐
tein 3.
Figure 1. A schematic representation of the hepatocyte with its canalicular membrane transporters involved in bile
formation. FIC1 is an aminophospholipid flippase, encoded by the ATP8B1 (FIC1) gene. BSEP (bile salt export pump)
(formerly sister of P-glycoprotein "SPGP") is a bile acids transporter to the bile canalicular lumen against a high concen‐
tration gradient. It is encoded by the ABCB11 (BSEP) gene. The MDR3 is a phospholipid transporter. It is encoded by the
ABCB4 (MDR3) gene.
The most widely accepted hypothesis for FIC1 function is that of an aminophospholipid
flippase, translocating phospholipids such as phosphatidylserine from the outer to the inner
leaflet of the plasma membrane [13]. So, deficiency of FIC1 in the hepatocyte results in the
loss of asymmetric distribution of phospholipids in the canalicular membrane, decreasing
both membrane stability and function of transmembrane transporters including the bile salt
export pump (BSEP) and, as such, causing bile salt retention in hepatocytes with consequent
defective bile formation; resulting in cholestasis [14-16].
Different studies have shown that ATP8B1 deficiency is associated with diminished FXR
(farnesoid X receptor) activity. The FXR is a nuclear receptor that is highly expressed in the
liver and regulates bile acid homeostasis so as to reduce its hepatocyte toxicity. Diminished
FXR activity leads to upregulation of bile acid synthesis, reduced expression of the canalicu‐
lar BSEP, and increased expression of the ileal apical sodium dependent bile acid transport‐
er (ASBT). The net effect of these changes would be increased synthesis of bile acids and
diminished its canalicular excretion, coupled with enhanced reabsorption of intestinal bile
acids, yielding marked hepatocyte bile acid overload [17,18].
ATP8B1 is abundantly expressed in a wide variety of tissues such as the small intestine,
bladder and stomach and to a lesser extent also in the liver and pancreas. This results in the
multitude of the extrahepatic manifestations such as the hearing loss, pancreatitis and diar‐
rhea, found in patients with ATP8B1 deficiency [19,20]. Over 50 distinct mutations in
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ATP8B1 are described. The mutations G308V found in Amish, D554N found in Inuits and
I661T are amongst the most frequently detected [21,22].
In vitro studies showed that ATP8B1 deficiency due to common missense mutations such as
G308V, D554N and I661T, can be regarded as a protein folding disease, with different de‐
grees of retention of the mutant protein in the endoplasmic reticulum, resulting in a de‐
creased protein expression at the plasma membrane [23]. The pathophysiologic concept of
being a protein folding disease can be used in new therapeutic interventions [24]. Incubation
at a reduced temperature could improve proper folding of some of the mutated proteins.
Similarly, the pharmacological chaperone 4-phenylbutyrate acid (4-PBA) could stabilize
misfolded proteins, partially restoring cell surface expression [25].
Mutations in ATP8B1 are also responsible for:
1. Greenland Eskimo cholestasis (Nielsen syndrome) [26].
2. Benign recurrent intrahepatic cholestasis-1 (BRIC1) [12].
3. Intrahepatic cholestasis of pregnancy-1 (ICP1) [27].
4. Down regulation of CFTR (cystic fibrosis transmembrane regulator): ATP8B1 is highly
expressed in biliary epithelial cells, and when it is abnormal in PFIC1, CFTR down reg‐
ulation in cholangiocytes has been reported which could contribute to impairment of
bile secretion [28].
3.2. PFIC 2 (ABCB11 "BSEP" deficiency)
PFIC2 is an autosomal recessive disease caused by mutations in the ABCB11 (formerly
named BSEP) gene encoding the BSEP, a liver-specific adenosine triphosphate (ATP)-bind‐
ing cassette transporter formerly known as sister of P-glycoprotein (SPGP). BSEP is located
in the hepatocyte canalicular membrane (Figure 1). ABCB11 gene is located on chromosome
2, locus q24 [29-31].
The defective canalicular BSEP expression leads to markedly diminished bile salt secretion.
This leads to bile secretory failure with secondary retention of bile salts and other biliary con‐
stituents in the hepatocytes leading to progressive liver damage and progressive cholestasis.
BSEP deficiency represents also a phenotypic continuum between BRIC2 and PFIC2. Different
mutations may cause different kinds of BSEP dysfunction, including protein lack, misfolded
protein, or protein not delivered from the Golgi to the bile canalicular membrane [31].
Generally missense mutations, e.g. E297G or D482G, lead to a less severe phenotype than mu‐
tations that are predicted to result in premature protein truncation or total failure of protein
production [31,32]. In vitro, the residual transport function of mutant proteins correlates with
the phenotypic differences between BRIC2 and PFIC2, with generally a diminished function in
BRIC2 mutants, while complete abolishment is more often seen in PFIC2 mutants [33].
Heterozygous ABCB11 mutations have also been identified in cases of ICP (ICP2) [34], drug
induced cholestasis [35] and transient neonatal cholestasis [36].
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3.3. PFIC 3 (ABCB4 "MDR3" deficiency)
PFIC3 is an autosomal recessive disorder due to mutations in the ABCB4 (formerly named
MDR3) gene located on chromosome 7, locus q21, which codes for the class III multidrug
resistance P-glycoprotein (MDR3). MDR3 is located exclusively on the canalicular mem‐
brane of the hepatocyte and serves as a phospholipid translocator (Figure 1) essential for
biliary phospholipid (e.g. phosphatidylcholine "PC") secretion [37].
PC in bile normally protects cholangiocytes from bile salt toxicity by forming mixed micelles
with it. However, a mutation of the ABCB4 gene results in decreased biliary PC secretion
and high biliary bile salt -to-PC ratio, leading to bile duct injury (cholangitis and ductular
proliferation). Also, a decreased biliary PC concentration leads to high biliary cholesterol -
to-PC ratio. The high biliary cholesterol saturation promotes crystallization of cholesterol
and the lithogenicity of bile [2,38].
Whereas biliary bile salt concentrations are normal in patients with PFIC3, serum bile salt
levels are elevated. It is explained by:
1. Downregulation of the bile acid importers to the hepatocyte, NTCP (Na+/taurocholate
cotransporting polypeptide) and OATP (organic acid transporting polypeptide) [39].
2. Upregulation of the bile acid exporter from hepatocyte at the sinusoidal membrane, MRP4
(multidrug resistance–related protein 4), mediating bile salt efflux into serum [40].
Over 45 disease-causing mutations in ABCB4 have been identified [41]. Children with mis‐
sense mutations seem to have a less severe phenotype, with later onset of disease, slower
progression and better response to treatment, as compared to patients with mutations lead‐
ing to a truncated protein [42]. Possibly this is due to residual transport activity in MDR3
protein affected by missense mutations.
Heterozygous mutations in the ABCB4 gene can also cause or predispose for a variety of other
liver diseases, such as adult biliary cirrhosis, cholelithiasis, transient neonatal cholestasis, drug
induced cholestasis and ICP. Mutations can even lead to a cascade of several phenotypes in one
patient, indicating the wide phenotypical spectrum of ABCB4 deficiency [43,44].
A small proportion of PFIC phenotypes are not due to mutations in these three genes and
therefore additional genes might be involved [2,45].
4. Clinical picture
Mutations in ATP8B1 and ABCB11 can result both in progressive cholestatic disease termed
PFIC1 and PFIC2, as well as in episodic cholestasis, referred to as BRIC type 1 and 2 respec‐
tively. This suggests that PFIC and BRIC are the two ends of a clinical spectrum, with differ‐
ent degrees of severity in between. Therefore, these diseases are preferably referred to as
ATP8B1 deficiency and ABCB11 deficiency. While mutations in ABCB4 can result in pro‐
gressive cholestatic disease only designated PFIC type 3. Similarly PFIC3 is best designated
as ABCB4 deficiency. Heterozygous mutations in any of these three genes can also be associ‐
ated with ICP. It is a transient form of cholestasis, characterized by the onset of pruritus dur‐
ing pregnancy, with postnatal resolution [2].
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Pruritus is the prominent clinical feature of PFIC; however, until an episode of jaundice in‐
tervenes, the diagnosis is often overlooked. Even then, because of the rarity of the condition,
children sometimes receive a misdiagnosis of obstructive jaundice caused by the occasional‐
ly associated choledocholithiasis in PFIC types 2 and 3 [5].
4.1. PFIC1 "Byler's disease"
• Cholestasis is a major clinical sign in PFIC1 as in all PFIC forms. It usually appears in the
first months of life in patients with PFIC1, and is characterized by recurrent episodes of
jaundice, which become permanent later in the course of the disease [3]. The variable clin‐
ical features are:
1. Jaundice: It presents with conjugated hyperbilirubinemia in the first 3–6 months of life.
The degree of jaundice may vary [46].
2. Pruritus: It is the dominant feature in the majority of patients and is often out of propor‐
tion to the level of jaundice [46]. It may initially vary in intensity and may be exacerbat‐
ed during intercurrent illness. Pruritus may not be noticed until 6 months of age
because the neural pathways necessary for concerted scratching are not fully devel‐
oped. However, affected infants often are irritable and sleep poorly with onset of cho‐
lestasis. Scratching is usually evident first as digging at the ears and eyes, which are the
first areas to show evidence of excoriation. By one year of age, patients may show gen‐
eralized mutilation of skin, usually most severe on the extensor surfaces of the arms
and legs and on the flanks of the back. The pruritus is very disabling and often re‐
sponds poorly to medical therapies [12,45].
3. Hepatomegaly is present early in life and persists with progression to cirrhosis. The rate
of progression to cirrhosis is variable, but usually develops in early childhood without
treatment. With progression to cirrhosis splenomegaly develops.
4. Fat-soluble vitamin deficiencies, including rickets, may be severe.
5. Extrahepatic disorders [19]:
• Persistent diarrhea with fat malabsorption and protein loss, leading to poor growth
and short stature.
• Bouts of pancreatitis.
• Recurrent pneumonia may also compromise growth.
• Sensorineural hearing loss may occur.
• As it has been mentioned before, ATP8B1 deficiency can lead to a continuum of disease
severity ranging from the progressive form PFIC1 to the recurrent form, BRIC1. BRIC1
will be discussed briefly in the next paragraphs.
BRIC is an intermittent form of intrahepatic cholestasis characterized by variable periods
of intense pruritus often associated with jaundice, separated by symptom-free intervals.
The benign designation of BRIC refers to the general lack of progressive liver disease, al‐
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though the pruritus is far from benign during an intense episode [10]. Two types of BRIC
are present according to the gene defect. BRIC1 is due to a mutation of ATP8B1 gene and
BRIC2, due to ABCB11 gene mutations.
The age of presentation of the first attack of jaundice ranges from 1–50 years, but jaundice
usually occurs before the age of twenty years. Attacks usually are preceded by a minor
illness and consist of a preicteric phase of 2–4 weeks (characterized by malaise, anorexia,
and pruritus) and an icteric phase that may last from 1–18 months. In some patients, hor‐
monal factors such as the use of oral contraceptives and pregnancy have been associated
with precipitation of an attack [10,47]. Patients may have severe coughing during epi‐
sodes, as is seen sometimes in patients with PFIC1 [48].
During the icteric phase, the concentrations of serum bile acid, bilirubin, and alkaline
phosphatase (ALP) are increased. Serum GGT concentration, however, remains low. Liver
biopsy results are very benign, often showing no pathologic change even during an epi‐
sode. Some specimens show hepatocellular cholestasis and cholate injury, mostly centri‐
lobular. During the asymptomatic period, all parameters (clinical, laboratory and liver
histology) are normal [49].
4.2. PFIC2 "Byler's syndrome"
• PFIC2 affected children differ from those with PFIC1 in some important respects:
The initial presentation and the evolution seem to be more severe than PFIC1, with per‐
manent jaundice from the first months of life and rapid appearance of cirrhosis and liver
failure within the first years of life [3].
They do not have extrahepatic involvement such as pancreatitis or diarrhea [45].
Early hepatocellular carcinoma (before one year of age) may complicate the course of
PFIC2 [3]. Up to 15% of the patients with ABCB11 deficiency will develop hepatocellular
carcinoma (HCC) or cholangiocarcinoma. Close surveillance for hepatobiliary malignancy
is therefore warranted in these patients [31,32,45].
At diagnosis, the cholestasis in ABCB11 deficiency results in a more detectable fat-soluble
vitamin deficiency manifestations [45].
The development of cholelithiasis in approximately one third of the patients, probably
due to the low bile salt concentration in bile, secondary to impaired BSEP function, which
might cause supersaturation of cholesterol [32].
• Patients fitting the phenotype of BRIC have been described with mutations in ABCB11.
They are called BRIC2 and are characterized by:
The age of onset and total number of recurrent episodes were highly variable. Choleli‐
thiasis  occurred in  many patients  with  BRIC2.  Several  patients  had a  relatively  early
onset of the disease and developed permanent cholestasis as adults after initial periods
of recurrent attacks.
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and pruritus) and an icteric phase that may last from 1–18 months. In some patients, hor‐
monal factors such as the use of oral contraceptives and pregnancy have been associated
with precipitation of an attack [10,47]. Patients may have severe coughing during epi‐
sodes, as is seen sometimes in patients with PFIC1 [48].
During the icteric phase, the concentrations of serum bile acid, bilirubin, and alkaline
phosphatase (ALP) are increased. Serum GGT concentration, however, remains low. Liver
biopsy results are very benign, often showing no pathologic change even during an epi‐
sode. Some specimens show hepatocellular cholestasis and cholate injury, mostly centri‐
lobular. During the asymptomatic period, all parameters (clinical, laboratory and liver
histology) are normal [49].
4.2. PFIC2 "Byler's syndrome"
• PFIC2 affected children differ from those with PFIC1 in some important respects:
The initial presentation and the evolution seem to be more severe than PFIC1, with per‐
manent jaundice from the first months of life and rapid appearance of cirrhosis and liver
failure within the first years of life [3].
They do not have extrahepatic involvement such as pancreatitis or diarrhea [45].
Early hepatocellular carcinoma (before one year of age) may complicate the course of
PFIC2 [3]. Up to 15% of the patients with ABCB11 deficiency will develop hepatocellular
carcinoma (HCC) or cholangiocarcinoma. Close surveillance for hepatobiliary malignancy
is therefore warranted in these patients [31,32,45].
At diagnosis, the cholestasis in ABCB11 deficiency results in a more detectable fat-soluble
vitamin deficiency manifestations [45].
The development of cholelithiasis in approximately one third of the patients, probably
due to the low bile salt concentration in bile, secondary to impaired BSEP function, which
might cause supersaturation of cholesterol [32].
• Patients fitting the phenotype of BRIC have been described with mutations in ABCB11.
They are called BRIC2 and are characterized by:
The age of onset and total number of recurrent episodes were highly variable. Choleli‐
thiasis  occurred in  many patients  with  BRIC2.  Several  patients  had a  relatively  early
onset of the disease and developed permanent cholestasis as adults after initial periods
of recurrent attacks.
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Occasionally BRIC will progress to the more severe and permanent form of PFIC, indi‐
cative  of  a  clinical  continuum,  with  intermediate  phenotypes  between  mild  and pro‐
gressive disease [2,11].
4.3. PFIC3 "MDR3 deficiency"
Mutations in the ABCB4 gene can cause or predispose to a variety of liver diseases with dif‐
ferent age of presentation. Moreover, it can even lead to a cascade of several phenotypes in
one patient, indicating the wide phenotypical spectrum of ABCB4 deficiency [43].
1. PFIC3: it is characterized by:
• Cholestasis developing within the first year of life in about one third of patients and
rarely in the neonatal period. It may also manifest later in infancy, in childhood or
even in young adulthood [3,45].
• Pruritus occurs less frequently than in the other types of PFIC and is usually mild.
• Jaundice may be less prominent than pruritus.
• Height and weight may be below normal as the disease progresses.
• Hepatomegaly, and at later stages splenomegaly, as a manifestation of portal hyperten‐
sion is often observed. Liver disease tends to evolve slowly to biliary cirrhosis with
or without overt cholestatic jaundice [42,50].
• Cholelithiasis may develop in older children.
• No extrahepatic features or occurrence of malignancies are described in association
with PFIC3 [42,50].
2. Adult biliary cirrhosis: gastrointestinal bleeding due to portal hypertension and cirrhosis
may be the presenting symptom in adolescent or young adult patients [3].
3. ICP: some cases of ICP have been associated with heterozygous mutations in ABCB4 [43].
4. Heterozygous mutations in the ABCB4 gene can also cause or predispose for transient
neonatal cholestasis and drug induced cholestasis [44].
5. Diagnosis
Diagnosis is dependent firstly on suspicion. The most alarming point making PFIC in the
scope of diagnosis is the presence of significant pruritus out of proportion to the level of
jaundice especially in the setting of low GGT. However, accurate diagnosis is dependent on
a constellation of a clinical, biochemical, radiological, histopathological, immunohistochemi‐
cal studies and finally can be confirmed by genetic testing for mutations (Table 1).
1. Biochemical parameters:
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• Serum GGT is repeatedly normal or low in PFIC1 & PFIC2, while it is elevated in
PFIC3 often more than ten times the normal value. In PFIC1 and PFIC2, the serum
GGT concentration may increase to greater than 100 IU/L in patients receiving micro‐
somal inducers such as phenobarbital and rifampicin [51].
The mechanism for the low serum concentration of GGT in PFIC1 and 2 is not clear.
GGT is normally bound to the canalicular membrane by a glycosyl phosphatidyl inosi‐
tol (GPI) anchor. In obstructive cholestasis, when excessive amounts of bile salts accu‐
mulate in the canalicular lumen under increased pressure, GGT is released from the
membrane by detergent action and refluxes back into serum, possibly via leaky inter‐
cellular junctions. However, in PFIC and BRIC types 1 and 2, the reduced concentra‐
tions of biliary bile acids preserve canalicular GGT localization. This explanation is not
entirely satisfactory as serum GGT is elevated in most other forms of intrahepatic cho‐
lestasis in which biliary bile acid levels are low. Preliminary studies indicate that some
canalicular proteins, including GGT and carcinoembryonic antigen (CEA), are poorly
expressed at the canaliculus in PFIC1 and 2. It is possible that low serum GGT levels re‐
sult from the lack of canalicular GGT available for elution as well as from the inade‐
quate concentrations of intracanalicular bile acids to act as detergents [51,52].
• Serum transaminases: In PFIC1 serum transaminases are mildly elevated. While in pa‐
tients with PFIC2, serum transaminases levels are usually elevated to at least five
times normal values. In PFIC3, serum aminotransferases, conjugated bilirubin, and
ALP are all significantly elevated [2,45].
• Serum cholesterol: it is characteristically low or normal in all the three types [3].
• Serum bile acid concentration: it is elevated in all the three types [44,45].
• Alpha-fetoprotein: it is elevated at diagnosis in PFIC2 than that in PFIC1 [12,45].
• Absent serum lipoprotein X (LPX) in PFIC3: because measurement of biliary phospholi‐
pids is impractical in the evaluation of most patients, measurement of serum LPX
may serve as a surrogate marker for PFIC3. LPX is the predominant lipoprotein in
the plasma of cholestatic patients. LPX is absent from the serum of patients with ho‐
mozygous ABCB4 mutations. LPX is probably composed of biliary vesicles that are
formed at the subapical compartment of the hepatocyte, transcytosed to sinusoidal
membrane, and released into plasma. This process is absolutely dependent on MDR3,
but the precise mechanism has not been defined [50,53].
2. Biliary bile analysis:
Biliary bile analysis is performed on gallbladder bile or on bile collected by duodenal aspira‐
tion (pure choledochal bile). In case of gallbladder punction, bile contamination by blood
may falsify bile analysis. In case of duodenal aspiration, bile dilution or bile contamination
by alimentary phospholipids may falsify bile analysis [3].
The biliary bile salt concentration is dramatically decreased (<1 mmol/L) in PFIC2 patients [54]
and only mildly decreased in PFIC1 patients (3–8 mmol/L) [19]. The normal concentration of
biliary primary bile salts distinguishes PFIC3 patients from those with PFIC1 and PFIC2 [42].
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tion (pure choledochal bile). In case of gallbladder punction, bile contamination by blood
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In PFIC3 patients, the cardinal feature is the dramatically decreased biliary phospholipid
level  (1–15% of  total  biliary lipids;  normal  range 19–24%).  Biliary bile  salt-to-phospholi‐
pid is approximately 5-fold higher than in wild type bile, as is also biliary cholesterol-to-
phospholipid [3].
3. Radiological:
Initial ultrasonography of the liver is performed to exclude biliary tract disease. Typically,
ultrasonography is normal but may reveal a huge gallbladder in PFIC3. Sometimes, biliary
stones may be identified in both PFIC2 and PFIC3 [3].
Cholangiography performed in a limited number of  patients  with PFIC3 showed a nor‐
mal biliary tree, excluding sclerosing cholangitis, and allowed bile to be collected for bili‐
ary lipid analysis [42].
4. Histopathology: Liver biopsy shows:
• In PFIC1
Light microscopy (LM): on routine hematoxylin and eosin (H & E) staining, liver biopsy
shows bland cholestasis with almost no inflammation. It shows canalicular bile plugs of
distinctive color. Small-duct paucity may be present. Fibrosis starts early, with approxi‐
mately 75 % of patients having some fibrosis by 2 years of age. Fibrosis may appear ini‐
tially either as pericentral sclerosis or portal fibrosis, or sometimes both. Portal to
central bridging then develops in association with lacy lobular fibrosis and eventually
leads to cirrhosis. Proliferating bile ductules are observed at the edge of the portal tracts
in patients with significant fibrosis. The rate of progression of the fibrosis is highly vari‐
able but correlates loosely with the severity of the clinical disease [45].
On electron microscopy (EM), canalicular bile plugs shows characteristic granular
appearance “chunky bile”.
• In PFIC2
LM: on H & E stains, there is inflammation with giant cell hepatitis, fibrosis and duct
reaction [45].
On EM, bile appears amorphous [45].
• In PFIC3
LM: on H & E stains, bile ductular proliferation and mixed inflammatory infiltrates
are  observed  in  the  early  stages  despite  patency  of  intra-  and  extrahepatic  bile
ducts. Cholestasis with slight giant cell transformation and isolated eosinophilic ne‐
crotic hepatocytes may also be present. Periductal sclerosis affecting the interlobu‐
lar  bile  ducts  eventually  occurs.  Extensive  portal  fibrosis  evolves  into  biliary
cirrhosis in older children [42].
EM of liver has not been reported in proven cases.
5. Immunohistochemical staining:
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Commercially available MDR3 and BSEP antibodies allow liver immunostaining to be per‐
formed. Absence of canalicular or mild immunostaining is in favor of a gene defect. Howev‐
er, normal staining does not exclude a gene defect as a mutation may induce a loss of
function but normal synthesis [31,42].
6. Genetic testing:
Molecular analysis remains the definitive diagnostic technique for PFIC. Gene analysis is
usually performed by DNA sequencing of the 27 coding exons (coding exons 2-28) of the
ATP8B1, ABCB11, and ABCB4 genes and their splice junctions [3]. The use of a resequensing
chip dedicated to genetic cholestasis could facilitate identification of gene mutation [55].
3 
 
 PFIC-1 PFIC-2 PFIC-3 
Synonyms Byler disease 
ATP8B1 deficiency  
FIC1 deficiency 
Byler syndrome  
ABCB11 deficiency  
BSEP deficiency 
ABCB4 deficiency  
MDR3 deficiency  
Gene defect ATP8B1 (FIC1) ABCB11 (BSEP) ABCB4 (MDR3) 
Locus 18q21-22 2q24 7q21 
Transport defect Aminophospholipid Bile acid Phospholipids    
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HCC No Risk from the 1
st
 year No 
Clinical spectrum of 
gene defect 














GGT Normal or low Normal or low Elevated 
Transaminases Mildly elevated More elevated Elevated  
Bile acids Elevated More elevated Elevated 
Cholesterol Normal Normal Normal  
Alpha fetoprotein Not significantly 
elevated 
More elevated -- 
Histopathological Bland cholestasis (LM) 
Coarse granular bile (EM)
Giant cell hepatitis 
(LM) 
Amorphous bile (EM) 
Ductular proliferation 
(LM) 
Immunohistochemical -- Absent or reduced 
BSEP staining in the 
majority of patients 
Absent or reduced 
MDR3 staining in 
about 50 % of patients 
 
Table 1. Summary of the criteria of different PFIC types.
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chip dedicated to genetic cholestasis could facilitate identification of gene mutation [55].
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Two groups of diseases are in differential diagnosis with PFIC group of disorders. For
PFIC1 and PFIC2, it is to be differentiated from other cholestatic disorders with low GGT.
While for PFIC3, when it presents early it, is to be differentiated from cholestatic disorders
with high GGT and when it presents in an older age, childhood or adolescence, it is to be
differentiated from other causes of chronic liver diseases at respective ages.
• Cholestasis with low GGT:
1. Inborn errors of bile acid metabolism [6].
2. Familial hypercholanemia: familial hypercholanemia represents a PFIC-like disorder
due to a bile canalicular tight junction protein defect combined with a defect of pri‐
mary bile acid conjugation. Cholestasis is due to impaired transport of unconjugated
bile acids into bile and to bile leakage into plasma through abnormal canalicular tight
junctions increasing paracellular permeability [56].
3. Arthrogryposis-  renal  dysfunction  cholestasis  (ARC)  syndrome is  a  complex  dis‐
ease due to mutation of VPS33B  involved in intracellular trafficking and targeting
of apical proteins. The gene defect results in a loss of apical protein expression in
the liver and kidneys [57].
• Cholestasis with high GGT:
1. Biliary atresia [58].
2. Neonatal sclerosing cholangitis [59].
3. Congenital cytomegalovirus (CMV) infection.
4. Alpha1-antitrypsin deficiency disease [60].
5. North American Indian Childhood Cirrhosis (NAIC) [61].
6. Aagenaes syndrome (hereditary cholestasis with lymphedema): a very rare familial
cholestatic disorder with cholestasis and lower limb edema [62].
• Causes of chronic liver disease:
1. Chronic viral hepatitis.
2. Autoimmune  liver  diseases:  autoimmune  hepatitis  and  autoimmune  sclerosing
cholangitis.
3. Metabolic liver disorders, e.g., Wilson disease and alpha1-antitrypsin deficiency.
7. Treatment
Initial treatment of PFIC includes the use of cholestyramine, ursodeoxycholic acid, rifampi‐
cin, and phenobarbital [63-65]. Until the late 1980s, liver transplantation was the only effec‐
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tive therapy for those who did not respond to medical treatment [66,67]. Later on, less
invasive non-transplant surgical approaches were proposed and undertaken early in the
course of the disease with promising initial results [68]. In this section, a brief overview
about the different lines of management for PFIC patients will be given.
7.1. Medical therapy
Unfortunately, most forms of medical therapy for PFIC types 1, 2, and 3 are of limited effec‐
tiveness. Nevertheless, several treatment modalities can be used in specific patients to im‐
prove quality of life or prevent progression of the disease [2,69].
• Cholestyramine is an anion-exchange resin that binds bile salts, preventing their re-absorp‐
tion in the enterohepatic circulation. In PFIC, relief of pruritus and normalization of bio‐
chemical parameters is only described rarely with cholestyramine. However, in patients
with BRIC it can be helpful in shortening episodes [2].
• Rifampicin, although it accelerates the hepatic detoxification and excretion of compounds,
such as bilirubin and bile salts, it has been used with limited efficacy in patients with
PFIC [51]. Nevertheless, in patients with BRIC it can completely abort an episode.
• Ursodeoxycholic acid (UDCA) is a relatively hydrophilic bile salt, which is less cytotoxic
than endogenous bile salts. Upon oral administration (20 mg/kg/day), it will partially re‐
place endogenous bile salts in the bile salt pool, reducing injury of the hepatocytes during
cholestasis. In PFIC3 regular administration of UDCA normalizes liver function tests and
improves clinical parameters in up to 50% of the patients. The therapeutic effect appears
to be dependent on the type of mutation, with premature stop codons leading to a trun‐
cated protein being associated with nearly no response to therapy. UDCA should there‐
fore be the first choice in the initial therapeutic management of patients with ABCB4
deficiency, especially when a missense mutation in the corresponding gene is found [42].
In patients with PFIC1 or PFIC2, the results of UDCA treatment are conflicting, ranging
from clear improvement to no effect at all.
In this respect, the recommended treatment strategy is to start with UDCA therapy in all
types  of  PFIC,  especially  PFIC3.  If  no  appropriate  response,  especially  regarding  pruri‐
tus,  add the  other  medical  lines  of  therapy.  Those  who will  not  respond are  shifted to
surgical treatment [3,45,65,66].
7.2. Surgical treatment
Surgical treatment for PFIC is an important major line of therapy. If no complete clinical or
biochemical improvement is obtained with medical therapy, more invasive therapy such as
biliary diversion or even liver transplantation is necessary [2,70].
Interruption of the enterohepatic circulation through biliary diversion has yielded excellent
clinical, biochemical, and histologic response in a number of children with PFIC, provided the
procedure is performed before the development of significant hepatic fibrosis [46]. It reduces
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In this respect, the recommended treatment strategy is to start with UDCA therapy in all
types  of  PFIC,  especially  PFIC3.  If  no  appropriate  response,  especially  regarding  pruri‐
tus,  add the  other  medical  lines  of  therapy.  Those  who will  not  respond are  shifted to
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7.2. Surgical treatment
Surgical treatment for PFIC is an important major line of therapy. If no complete clinical or
biochemical improvement is obtained with medical therapy, more invasive therapy such as
biliary diversion or even liver transplantation is necessary [2,70].
Interruption of the enterohepatic circulation through biliary diversion has yielded excellent
clinical, biochemical, and histologic response in a number of children with PFIC, provided the
procedure is performed before the development of significant hepatic fibrosis [46]. It reduces
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the accumulation of toxic bile salts by decreasing their intestinal re-uptake. It is unclear if these
approaches are optimal for specific genetic forms of PFIC rather than others. It is possible that
these interventions may be best for severe PFIC1 and milder phenotypic variants of PFIC2. Na‐
sobiliary drainage may help to select potential responders to biliary diversion [71].
There are three major non-transplant surgical techniques to permanently interrupt the enter‐
ohepatic circulation, namely partial external biliary diversion (PEBD), ileal bypass (IB) and
partial internal biliary diversion (PIBD).
• Partial external biliary diversion (PEBD):
PEBD interrupts the enterohepatic circulation of bile salts by partially diverting bile from the
gallbladder through a loop of jejunum connecting the gallbladder to the abdominal skin [72].
In 1988, Whitington and Whitington [68] introduced cholecystojejunocutaneostomy as a
PEBD for the surgical treatment of PFIC, to increase the elimination of bile acids accumulat‐
ed within the body and thus control the intractable pruritus. In this procedure, one end of a
loop of jejunum is anastamosed to the dome of the gallbladder, whereas the other is used to
form a cutaneous ostomy (Figure 2A). Bile in the gallbladder then flows either out of the os‐
tomy or into the intestine. Typically 30–50% of bile drains out of the ostomy and is discard‐
ed. Two variants on the original PEBD have also been described; one using a laparoscopic
technique [73] and the other using an appendiceal conduit [74].
Results of PEBD are promising with respect to pruritus, jaundice and histology, both in pa‐
tients with PFIC1 and PFIC2, with at least partial improvement in more than 75% of the pa‐
tients [66,72]. Although this seems promising, at present it is unclear whether in patients
responding to PEBD liver transplantation can also be avoided at long-term follow-up [75].
Moreover, some patients do not benefit from biliary surgery at all. Obviously in these pa‐
tients liver transplantation should be considered [72].
The type of mutation seems to be associated with the outcome of PEBD, with better progno‐
sis in disease caused by milder mutations, especially for the ABCB11 mutations E297G and
D482G [32,45]. However, when severe fibrosis is already present at the moment of PEBD,
prognosis is worse [72]. One patient with PFIC3 who underwent PEBD was described in lit‐
erature; this patient showed no improvement [67].
No serious PEBD complications are reported, although problems with the stoma (stenosis,
recurrent  bleeding) (Figure 2)  sometimes make a re-operation necessary.  In addition ex‐
cessive stomal losses can cause dehydration and electrolyte imbalance,  while cholangitis
can also develop [72,75].
The permanent character of the PEBD makes it less suitable for patients with episodic cho‐
lestasis (BRIC). In these patients temporary nasobiliary drainage (NBD) to interrupt the en‐
terohepatic circulation can be endoscopically introduced. This procedure is effective in most
of these patients, resolving pruritus and normalising bile salts within short time [10,71].
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Figure 2. A seven years old child diagnosed as PFIC2 underwent PEBD at the age of 2 years old with good outcome.
He had recurrent bleeding from the osteal opening (a). Endoscopy through the osteal opening (b) showed free jejunal
loop (c) till its proximal end at the gall bladder (d). The source of bleeding was the stoma itself.
• Terminal ileal exclusion or ileal bypass (IB):
Although most of PFIC patients and their parents tolerate well PEBD with its external bili‐
ary fistula and the need for stoma care, sometimes it becomes a real problem, particularly
for children of school age and teenagers, who may feel uncomfortable to participate in all
activities with their friends. Moreover, there is still a group of patients who cannot undergo
PEBD because of a previous cholecystectomy, or who develop postoperative electrolyte in‐
balance due to the excessive daily amount of bile [5,76].
To deal with these problems, an IB technique was proposed. In IB, the terminal ileum is
skipped by an ileocolonic anastomosis. It was developed as an alternative treatment to
PEBD, that avoids a long-term stoma complications. In 1994, Whitington et al. described a
good initial outcome of IB in two patients after cholecystectomy, but a chronic diarrhea oc‐
curred one year later. In 1998, Holland et al. described this procedure in PFIC children after
cholecystectomy. All patients were supplemented with vitamin B12 and folic acid. Interest‐
ingly, no diarrhea was reported postoperatively. Early results were very promising, with a
relief of pruritus and normalization of bilirubin level. Nevertheless, relapse of cholestatsis
occurred in half of the patients. The authors underline that IB is not as effective as PEBD and
therefore it should not be considered as the primary treatment in children with PFIC [5,51].
The rational of this technique was that the vast majority of intestinal bile salts are reabsor‐
bed in the distal ileum; that is the distal 15% of the small intestine. Therefore, exclusion of
this segment of intestine may lead to bile acid wasting. The small intestine is transected at a
point that demarcates the distal 15% of the small intestine, and a blind loop is formed with
the distal ileal segment. The proximal loop of the intestine is sewn end-to-side to the cecum,
completing the internal bypass of the distal ileum. Accurate assessment of the appropriate
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amount of ileum for bypass is likely to be critical; too little is unlikely to be therapeutic and
too much is likely to yield bile acid–induced diarrhea. Mutational analysis may be used
eventually to predict which patients are most likely to benefit from surgery. After IB, symp‐
toms may recur within one year requiring conversion to PEBD [5,77].
• Partial internal biliary diversion (PIBD):
PIBD interrupts the enterohepatic circulation of bile salts by partially diverting bile from the
gallbladder through a loop of jejunum connecting the gallbladder to the colon [46,76].
This operation combines the advantages of partially diverting the biliary flow from the en‐
terohepatic cycle (such as the PEBD does), while at the same time avoiding an external bili‐
ary fistula. In addition, this operation lacks the potential for malabsorption that may result
from partially excluding the terminal ileum from the intestinal transit. There is, however, a
potential for choleretic diarrhea, which may result from large amounts of bile salts entering
the colon. Because of this, it was strongly emphasized that the conduit should be made at
least 15 cm long to create a certain resistance to the bile flow; it is believed that this stimu‐
lates a certain amount of bile to flow through the normal biliary tract to the duodenum. This
problem occurred in a transient way in a few of the patients and it can be controlled with
the use of cholestyramine for a limited span of time [46].
Through an upper midline abdominal incision, the gallbladder and the liver are evaluated.
An intestinal conduit is constructed using a 15- to 20-cm segment of midjejunum, which is
sutured initially to the gallbladder wall and then terminolaterally to the midportion of the
ascending colon. The distal end of the jejunum is slightly tapered in a way that the jejunum
could reach the colon in an isoperistaltic direction to prevent colonic contents from entering
the conduit. The clinical and laboratory results described for PIBD make it a very attractive
surgical option for the treatment of PFICs in children with a normal gallbladder. However,
long-term follow-up is necessary to evaluate late results and eventual complications associ‐
ated with this technique [46].
If  all  previously  described therapies  fails  in  controlling pruritus,  when there  is  an end-
stage PFIC liver disease, or when the disease is progressive despite treatment; orthotopic
liver transplantation (OLT) remains the only alternative [78-80].  Before the development
of liver transplantation, therapy for these patients was generally ineffective. With the ad‐
vent of liver transplantation, many PFIC patients were treated with this life-saving proce‐
dure  [70,78].  At  one  time,  PFIC  was  among  the  5  most  common  indications  for  liver
transplantation in children [81,82].
Although OLT is associated with serious surgical risks and lifetime immunosuppressive
therapy is necessary, it usually gives complete correction of phenotype in patients with
PFIC2 and PFIC3 deficiency in which the disease is hepatocyte specific. However, phenotyp‐
ic recurrence of severe PFIC2 deficiency post-transplantation can occur as a result of the for‐
mation of autoantibodies against BSEP [83,84]. Intensifying immunosuppressive therapy
may resolve this problem.
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In contrast, in PFIC1, liver transplantation is potentially fraught with a number of potential
complications related to the extrahepatic expression of the ATP8B1 gene. The most promi‐
nent posttransplantation problems include intractable diarrhea, hepatic steatosis, poor
growth, and recurrent pancreatitis. Worsening diarrhea post liver transplant might be due
to an imbalance between bile salt excretion and re-absorption, since the hepatic graft ex‐
cretes a normal amount of bile salts, whereas the intestine remains functionally impaired.
The resulting increased amount of bile salts in the ileum and colon induces or worsens diar‐
rhea, which might respond to cholestyramine treatment [19,85]. Therefore, in PFIC1, non-
transplant surgical approaches should be considered the preferred first-line of therapy.
In summary, children with PFIC do better with non-transplant surgical interventions than
they do with the natural history of disease, which is uniformly fatal. Successful outcomes
have been demonstrated, with marked improvements in clinical symptoms, laboratory val‐
ues, growth and histology. It appears that the success rate is high enough that many patients
may do better with a non-transplant procedure than transplant given the posttransplant
morbidities associated with immunotherapy. Those with more advanced disease are most
likely to have a poor outcome with non-transplant surgical procedures. This may encourage
clinicians to consider a surgical intervention early in the course of disease before significant
hepatic scarring develops [76].
Some authors proposed that the treatment strategy is to perform PEBD rapidly after diagno‐
sis in patients with PFIC1 & PFIC2 and to consider OLT when treatment fails. In patients
with PFIC3, UDCA treatment is the first-line therapy; if not successful it is followed by liver
transplantation. In patients with episodic cholestasis (BRIC) medical treatment with rifampi‐
cin with or without cholestyramine can be attempted at the start of an attack. If medication
is not successful in aborting the cholestatic episode NBD can be performed [2,69]. In BRIC
patients who progress to a more permanent form of cholestasis, or in patients with very fre‐
quent or debilitating attacks, a biliary diversion can be considered [69].
7.3. New and future therapies
New and future therapies for PFIC patients include hepatocyte transplantation, the use of
nuclear receptor ligands, enhancing the expression of the mutated transporter protein by
employing chaperones and mutation specific therapy [2,69].
Hepatocyte transplantation has been successful in partially repopulating the liver, diminish‐
ing pathology in a mouse model of ABCB4 deficiency, but unfortunately not yet in patients
[86]. In ABCB11 deficiency it is doubtful whether hepatocyte transplantation is a good thera‐
peutic option since possible premalignant cells are left in place.
Certain nuclear receptors regulate bile formation. The key nuclear receptor in bile formation
is the bile salt sensor FXR. Activated FXR transactivates a number of genes, resulting in im‐
proved bile salt excretion and detoxification. Targeting FXR with synthetic ligands is ex‐
plored as a possible therapeutic option for cholestasis syndromes [87].
A pharmacological chaperone is defined as a small molecule that specifically binds to its tar‐
get protein and induces or promotes proper folding and trafficking of the protein [88]. Some
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ary fistula. In addition, this operation lacks the potential for malabsorption that may result
from partially excluding the terminal ileum from the intestinal transit. There is, however, a
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lates a certain amount of bile to flow through the normal biliary tract to the duodenum. This
problem occurred in a transient way in a few of the patients and it can be controlled with
the use of cholestyramine for a limited span of time [46].
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sutured initially to the gallbladder wall and then terminolaterally to the midportion of the
ascending colon. The distal end of the jejunum is slightly tapered in a way that the jejunum
could reach the colon in an isoperistaltic direction to prevent colonic contents from entering
the conduit. The clinical and laboratory results described for PIBD make it a very attractive
surgical option for the treatment of PFICs in children with a normal gallbladder. However,
long-term follow-up is necessary to evaluate late results and eventual complications associ‐
ated with this technique [46].
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liver transplantation (OLT) remains the only alternative [78-80].  Before the development
of liver transplantation, therapy for these patients was generally ineffective. With the ad‐
vent of liver transplantation, many PFIC patients were treated with this life-saving proce‐
dure  [70,78].  At  one  time,  PFIC  was  among  the  5  most  common  indications  for  liver
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Although OLT is associated with serious surgical risks and lifetime immunosuppressive
therapy is necessary, it usually gives complete correction of phenotype in patients with
PFIC2 and PFIC3 deficiency in which the disease is hepatocyte specific. However, phenotyp‐
ic recurrence of severe PFIC2 deficiency post-transplantation can occur as a result of the for‐
mation of autoantibodies against BSEP [83,84]. Intensifying immunosuppressive therapy
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nuclear receptor ligands, enhancing the expression of the mutated transporter protein by
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peutic option since possible premalignant cells are left in place.
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plored as a possible therapeutic option for cholestasis syndromes [87].
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researchers have investigated the usefulness of pharmacological chaperones for treatment of
diseases caused by folding-defective membrane proteins [24,89,90]. Pharmacological chaper‐
ones such as 4-phenylbutyrate acid (4-PBA) have been shown to stabilize proteins misfolded
due to missense mutations, thereby preventing degradation in the endoplasmic reticulum.
In vitro, 4-PBA enhances cell surface protein expression for some of the missense mutations
found in ATP8B1 deficiency and ABCB11 deficiency [25,91]. Misawa et al [24], showed that
bile acids do act as pharmacological chaperones of E297G BSEP. They also described the dis‐
covery and structural development of non-steroidal compounds with potent pharmacologi‐
cal chaperone activity for E297G BSEP.
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found in ATP8B1 deficiency and ABCB11 deficiency [25,91]. Misawa et al [24], showed that
bile acids do act as pharmacological chaperones of E297G BSEP. They also described the dis‐
covery and structural development of non-steroidal compounds with potent pharmacologi‐
cal chaperone activity for E297G BSEP.
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1. Introduction:
The liver is the most commonly injured solid abdominal organ, despite its relative protected
location [1, 2]. Treatment of traumatic liver injuries is based on patient physiology, mecha‐
nism and degree of injury, associated abdominal and extra-abdominal injuries and local ex‐
pertise. Non-operative management has evolved into the treatment of choice for most
patients with blunt liver injuries who are hemodynamically stable and success rates for non-
operative management commonly are greater than 95%. With the sweeping shift towards
the non-operative management, most hepatic injuries can be treated conservatively [3, 4, 5].
More recently several authors have highlighted an excessive use of non-operative manage‐
ment (NOM), which for some high grade liver injuries is pushed far beyond the reasonable
limits, carrying increased morbidity at short and long term, such as bilomas, biliary fistula,
early or late haemorrhage, false aneurysm, arterio-venous fistulae, haemobilia, liver abscess,
and liver necrosis [5]. Incidence of complications attributed to NOM increases in concert with
the grade of injury. In a series of 337 patients with liver injury grades III-V treated non-opera‐
tively, those with grade III had a complication rate of 1%, grade IV 21%, and grade V 63% [6].
2. Mechanism of injury and anatomic consideration:
Road traffic accident, antisocial violent behaviours, industrial and farming accidents are the
commonest mode of injury to the liver. Though the liver is protected by the rib cage, as the
largest solid organ in the abdomen, the liver is particularly vulnerable to the ability of com‐
pressive abdominal blows to rupture its relatively thin capsule. The vasculature consists of
wide-bore, thin-walled vessels with a high blood flow, and injury is usually associated with
significant blood loss. Blunt trauma in a road traffic accident, or fall from a height, may re‐
sult in a deceleration injury as the liver continues to move on impact. This leads to tears at
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1. Introduction:
The liver is the most commonly injured solid abdominal organ, despite its relative protected
location [1, 2]. Treatment of traumatic liver injuries is based on patient physiology, mecha‐
nism and degree of injury, associated abdominal and extra-abdominal injuries and local ex‐
pertise. Non-operative management has evolved into the treatment of choice for most
patients with blunt liver injuries who are hemodynamically stable and success rates for non-
operative management commonly are greater than 95%. With the sweeping shift towards
the non-operative management, most hepatic injuries can be treated conservatively [3, 4, 5].
More recently several authors have highlighted an excessive use of non-operative manage‐
ment (NOM), which for some high grade liver injuries is pushed far beyond the reasonable
limits, carrying increased morbidity at short and long term, such as bilomas, biliary fistula,
early or late haemorrhage, false aneurysm, arterio-venous fistulae, haemobilia, liver abscess,
and liver necrosis [5]. Incidence of complications attributed to NOM increases in concert with
the grade of injury. In a series of 337 patients with liver injury grades III-V treated non-opera‐
tively, those with grade III had a complication rate of 1%, grade IV 21%, and grade V 63% [6].
2. Mechanism of injury and anatomic consideration:
Road traffic accident, antisocial violent behaviours, industrial and farming accidents are the
commonest mode of injury to the liver. Though the liver is protected by the rib cage, as the
largest solid organ in the abdomen, the liver is particularly vulnerable to the ability of com‐
pressive abdominal blows to rupture its relatively thin capsule. The vasculature consists of
wide-bore, thin-walled vessels with a high blood flow, and injury is usually associated with
significant blood loss. Blunt trauma in a road traffic accident, or fall from a height, may re‐
sult in a deceleration injury as the liver continues to move on impact. This leads to tears at
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sites of fixation to the diaphragm and abdominal wall. A well-recognised deceleration injury
involves a fracture between the posterior sector (segments VI and VII) and the anterior sec‐
tor (segments V and VIII) of the right lobe. This type of injury can lead to rupture of right
hepatic vein and significant bleeding. In contrast, direct blow on right upper abdomen dur‐
ing vehicular accident or direct blow by a weapon or fist can lead to stellate type of injury to
the central liver (segment IV, V and VIII). This type of injury can lead to massive bleeding
from portal vein or hepatic vein and can also lead to bile duct injury.
Penetrating injuries may be associated with a significant vascular injury. For example, a stab
injury may cause major bleeding from one of the three hepatic veins or the vena cava and
also from the portal vein or hepatic artery if it involves the hilum. Gunshots may similarly
disrupt these major vessels; this disruption may be much more marked than with stab
wounds due to the cavitation effect, particularly with bullets from high-velocity weapons.
The connection between the thin-walled hepatic veins and the inferior vena cava (IVC), at
the site where the ligamentous mechanism anchors the liver to the diaphragm and posterior
abdominal wall, represents a vulnerable area, particularly to shearing forces during blunt
injury. Disruption here leads to the ‘‘juxtahepatic’’ venous injuries, which are usually associ‐
ated with major blood loss and present a particularly challenging management problem.
3. Grade of liver injury:
The severity of liver injuries ranges from the relatively inconsequential minor capsular tear
to extensive disruption of both lobes with associated hepatic vein, portal vein, or vena caval
injury. Several classifications have been advised to grade the liver injury and management
accordingly. Following table shows the grade of liver injury. Grade I & II are successfully
managed non-operatively in most cases. Grade IV and onward injuries will eventually re‐
quire emergency exploration. Grade III injuries require observation and if such patients are
hemodynamically stable will recover with conservative treatment. Such patients should be
closely followed in ICU with serial monitoring of hemoglobin and hematocrit level along
with cardio-respiratory monitoring. Any fall in hematocrit or hemodynamic instability not
responding to fluid resuscitation warrants urgent exploration.
Liver organ injuriy scale
Grade description
I Hematoma Subcapsular, <10% surface area
Laceration Capsular tear, < 1 cm parenchymal depth
II Hematoma Subcapsular, <10%-50% surface area; intraparenchymal, <10 cm in diameter
Laceration 1-3 cm parenchymal depth, <10 in Length
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III Hematoma Subcapsular,>50% surface area or expanding; ruptured subcapsular or
parenchymal hematoma
Laceration >3cm parenchymal depth
IV Hematoma Parenchymal disruption involving 25%-75% of hepatic lobe or 1-3 Couinaud
segments within a single lobe
V Laceration Parenchymal disruption involving >75% of hepatic lobe >3 Couinaud
segments within a single lobe
Vascular Juxtahepatic venous injuries; ie, retrohepatic vena cava/central major
hepatic vein
VI Hepatic avulsion
Table 1. Liver Organ Injury Scale.
4. Early Measures:
4.1. Resuscitation and treatment of Hemodynamic instability:
It is generally accepted that initial resuscitation and management is the same as for any pa‐
tient with major trauma and should follow the Advanced Trauma Life Support (ATLS) prin‐
ciples of aggressive fluid resuscitation, guided by monitoring of central venous pressure and
urinary output [7]. Management should also be directed toward avoidance of any of the sin‐
ister triad of hypothermia, coagulopathy, and acidosis, which are associated with signifi‐
cantly increased mortality. Mechanisms to avoid hypothermia are standard now in major
centres and include the use of rewarming blankets and heat exchanger pumps for rapid in‐
fusion of resuscitation fluids and blood [8].
The next management phase depends largely on the response to resuscitation and the stability
of the patient. Liver injury should be suspected in all patients with blunt or penetrating thora‐
coabdominal trauma but particularly in shocked patients with blunt or penetrating trauma to
the right side. There are two major determinants to consider when making decisions in sus‐
pected liver trauma: hemodynamic stability and mechanism of injury. In general, hemody‐
namic instability  or  peritonism makes decision-making in  trauma more straightforward,
although ultimately, the surgical procedure required may be complex. Management decisions
are more challenging when patients are hemodynamically stable as the array of potential ther‐
apeutic modalities are substantial and the patient’s future clinical course is unknown [9].
4.2. Advanced Trauma Life Support:
The appropriate evaluation and management of liver injuries results from an organized ap‐
proach to abdominal trauma. Experience and technical developments over the past several
decades make the current approach both logical and effective. It is generally accepted that ini‐
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closely followed in ICU with serial monitoring of hemoglobin and hematocrit level along
with cardio-respiratory monitoring. Any fall in hematocrit or hemodynamic instability not
responding to fluid resuscitation warrants urgent exploration.
Liver organ injuriy scale
Grade description
I Hematoma Subcapsular, <10% surface area
Laceration Capsular tear, < 1 cm parenchymal depth
II Hematoma Subcapsular, <10%-50% surface area; intraparenchymal, <10 cm in diameter
Laceration 1-3 cm parenchymal depth, <10 in Length
Hepatic Surgery590
Liver organ injuriy scale
III Hematoma Subcapsular,>50% surface area or expanding; ruptured subcapsular or
parenchymal hematoma
Laceration >3cm parenchymal depth
IV Hematoma Parenchymal disruption involving 25%-75% of hepatic lobe or 1-3 Couinaud
segments within a single lobe
V Laceration Parenchymal disruption involving >75% of hepatic lobe >3 Couinaud
segments within a single lobe
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urinary output [7]. Management should also be directed toward avoidance of any of the sin‐
ister triad of hypothermia, coagulopathy, and acidosis, which are associated with signifi‐
cantly increased mortality. Mechanisms to avoid hypothermia are standard now in major
centres and include the use of rewarming blankets and heat exchanger pumps for rapid in‐
fusion of resuscitation fluids and blood [8].
The next management phase depends largely on the response to resuscitation and the stability
of the patient. Liver injury should be suspected in all patients with blunt or penetrating thora‐
coabdominal trauma but particularly in shocked patients with blunt or penetrating trauma to
the right side. There are two major determinants to consider when making decisions in sus‐
pected liver trauma: hemodynamic stability and mechanism of injury. In general, hemody‐
namic instability  or  peritonism makes decision-making in  trauma more straightforward,
although ultimately, the surgical procedure required may be complex. Management decisions
are more challenging when patients are hemodynamically stable as the array of potential ther‐
apeutic modalities are substantial and the patient’s future clinical course is unknown [9].
4.2. Advanced Trauma Life Support:
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proach to abdominal trauma. Experience and technical developments over the past several
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tial resuscitation and management is the same as for any patient with major trauma and should
follow the Advanced Trauma Life Support (ATLS) principles of aggressive fluid resuscitation,
guided by monitoring of central venous pressure and urinary output [7]. Management should
also be directed toward avoidance of any of the sinister triad of hypothermia, coagulopathy,
and acidosis, which are associated with significantly increased mortality.
4.3. Focused assessment by ultrasound for trauma (FAST):
Ultrasonography (USG) is the most important and readily available investigation for any pa‐
tient with blunt or sharp abdominal injury. It is particularly useful for detecting injury to
parenchymal organs and the presence of free intraperitoneal fluid or blood. USG is a quick,
non-invasive, inexpensive, and transportable tool, used with increasing frequency in the ini‐
tial workup of patients with abdominal trauma [10].
The particular relevance to major liver injury is the focused assessment by ultrasound for
trauma (FAST), often performed in the emergency department, which involves a rapid ex‐
amination of several areas, namely, the pericardial region, right upper quadrant (includ‐
ing Morrison’s pouch), left upper quadrant, and the pelvis, specifically looking for free
fluid. One of the main limitations of USG is that parenchymal injuries, sometimes rele‐
vant and requiring surgical or embolization therapy, may be present without combined per‐
itoneal fluid [11,12].
On the basis of detection of free fluid or parenchymal injury, the sensitivity of USG has been
found to be 72% to 95% for abdominal organ injuries, 51% to 92% for liver lesions, and 98%
for grade III or higher liver injuries [13]. Richards et al reported 56% and 68% sensitivity of
FAST and complete USG, respectively, in detecting childhood abdominal trauma [11].
Detection of peritoneal fluid is the first step in FAST. Fluid in the right upper quadrant or in
the right upper quadrant and pelvic recess suggests hepatic injury, as opposed to splenic,
renal, or enteric injury [14]. Fluid limited to the left upper quadrant or to both upper quad‐
rants is not seen in patients with isolated liver trauma [14]. Hemoperitoneum recognition
must prompt further imaging, but its absence does not definitely exclude parenchymal in‐
jury. Clinical assessment and observation are also relevant in combination with USG. With
special reference to liver trauma, it has been noted that patients with negative USG results
but with an aspartate aminotransferase level of greater than 360 IU/L should undergo CT
imaging because of potentially overlooked hepatic injury, whereas patients with normal lev‐
els can be effectively discharged [15].
Although FAST provides a rapid assessment of liver disruption and intraperitoneal bleed‐
ing, it is a limited scan that is highly operator dependent. It is very important to note that a
negative FAST scan does not safely rule out injury [12, 16]. Due to the operator dependence
of the modality, different end points, and inconsistent comparative gold standards in the
studies, the reported specificities, sensitivities, and overall accuracies are variable [17]. It has
been demonstrated that up to a quarter of hepatic and splenic injuries, as well as renal, blad‐
der, pancreatic, mesenteric, and gut injuries, can be missed if ultrasound is used as the pri‐
mary investigative modality in the stable patient. However, while the possibility of false
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negatives is ever present, the combination of a negative ultrasound scan and normal clinical
examination and observations almost excludes liver injury in the event of significant blunt
trauma [12, 18].
4.4. Computed Tomography:
The wide availability of high-resolution CT has changed the manner in which blunt abdomi‐
nal trauma is diagnosed and managed (figure 1). Currently, multi-detector computed tomog‐
raphy (MDCT) scanning with intravenous contrast is the gold standard diagnostic modality in
hemodynamically stable patients with intra-abdominal fluid detected with FAST.
CT has a sensitivity of 92% to 97% and a specificity of 98.7% for detection of liver injury. The
type and grade of liver injury, the volume of hemoperitoneum, and differentiation between
clotted blood and active bleeding can be identified. In addition to increasing the rate of detec‐
tion of liver lesions following trauma, CT has also helped to improve the understanding of the
course of liver injuries [19]. CT scan also allows diagnosis of associated intraperitoneal and ret‐
roperitoneal injuries, including splenic, renal, bowel, and chest trauma, and pelvic fractures.
Even though NOM has proven to be of tremendous benefit, a couple of controversies re‐
garding the current management of trauma patients should be discussed. Advances in CT
technology have improved the practitioner’s ability to determine the degree of injury and to
identify patients who are more likely to fail NOM. However, until now, MDCT scanning has
not been able to differentiate, in a precise manner, among which patients should be treated
conservatively, which would benefit from angio-embolization and which would respond
best to a surgical response.
Figure 1. CT scan images of blunt abdominal trauma patients. (A) CT scan of liver showing intraparenchymal hemato‐
ma in segment VI. (B) CT scan of liver showing intraparenchymal hematoma in segment VI and extending to segment
VII and V.
Although CT is the investigative gold standard, it is important to remember that it involves
exposure to high levels of ionising radiation and the use of intravenous contrast may com‐
promise renal function. In the majority of hospitals the use of CT requires movement of the
patient away from adequate resuscitation facilities to the X-ray department, highlighting the
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tial resuscitation and management is the same as for any patient with major trauma and should
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and acidosis, which are associated with significantly increased mortality.
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Although FAST provides a rapid assessment of liver disruption and intraperitoneal bleed‐
ing, it is a limited scan that is highly operator dependent. It is very important to note that a
negative FAST scan does not safely rule out injury [12, 16]. Due to the operator dependence
of the modality, different end points, and inconsistent comparative gold standards in the
studies, the reported specificities, sensitivities, and overall accuracies are variable [17]. It has
been demonstrated that up to a quarter of hepatic and splenic injuries, as well as renal, blad‐
der, pancreatic, mesenteric, and gut injuries, can be missed if ultrasound is used as the pri‐
mary investigative modality in the stable patient. However, while the possibility of false
Hepatic Surgery592
negatives is ever present, the combination of a negative ultrasound scan and normal clinical
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trauma [12, 18].
4.4. Computed Tomography:
The wide availability of high-resolution CT has changed the manner in which blunt abdomi‐
nal trauma is diagnosed and managed (figure 1). Currently, multi-detector computed tomog‐
raphy (MDCT) scanning with intravenous contrast is the gold standard diagnostic modality in
hemodynamically stable patients with intra-abdominal fluid detected with FAST.
CT has a sensitivity of 92% to 97% and a specificity of 98.7% for detection of liver injury. The
type and grade of liver injury, the volume of hemoperitoneum, and differentiation between
clotted blood and active bleeding can be identified. In addition to increasing the rate of detec‐
tion of liver lesions following trauma, CT has also helped to improve the understanding of the
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Even though NOM has proven to be of tremendous benefit, a couple of controversies re‐
garding the current management of trauma patients should be discussed. Advances in CT
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identify patients who are more likely to fail NOM. However, until now, MDCT scanning has
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Although CT is the investigative gold standard, it is important to remember that it involves
exposure to high levels of ionising radiation and the use of intravenous contrast may com‐
promise renal function. In the majority of hospitals the use of CT requires movement of the
patient away from adequate resuscitation facilities to the X-ray department, highlighting the
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importance of hemodynamic stability in patients with abdominal trauma being considered
for CT examination [16].
4.5. Diagnostic laparoscopy:
The use of laparoscopy for trauma patients has been slower to evolve partly due to factors
inherent in the trauma population and some limitations of the laparoscopic technique. Ini‐
tially, the evaluation of peritoneal violation in hemodynamically stable patients was seen as
the greatest benefit of laparoscopy for trauma [20]. Improvements in laparoscopic training
and technology have enabled an increase in the use of diagnostic and therapeutic proce‐
dures in trauma patients.
Figure 2. Algorithm - Advanced trauma life support, FAST- focused assessment by ultrasound for trauma. ATLS for
managing liver trauma patients.
There are a number of series describing the successful haemostasis of minor liver injuries, in
both the civilian [21] and military setting [22], although it is likely that these were self-limit‐
ing injuries anyway.
5. Management of hepatic Trauma:
There are two major determinants to consider when making decisions in suspected liver
trauma: hemodynamic stability and mechanism of injury. In general, hemodynamic instabil‐
ity or peritonism makes decision-making in trauma more straightforward, although ulti‐
mately, the surgical procedure required may be complex (figure 2). Management decisions
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are more challenging when patients are hemodynamically stable as the array of potential
therapeutic modalities are substantial and the patient’s future clinical course is unknown [9].
5.1. Non operative management:
Hogarth Pringle, in 1908, provided the first description of operative management of liver
trauma. Unfortunately, all eight patients died and Pringle recommended conservative non-
operative management of these patients. In the modern surgical literature, non-operative
management was first reported in 1972 and has been one of the most significant changes in
the treatment of liver injuries over the last two decades [23, 24].
Initiated in pediatric trauma patients [25], nonsurgical management of blunt liver trauma
has become recognized as an appropriate treatment option for hemodynamically stable
adult patients with blunt hepatic injury [26, 27].
With the wide availability and improved quality of CT scanning, and the more modern, less
invasive intervention options, such as angio-embolization, NOM has evolved into the treat‐
ment of choice for hemodynamically stable patients. Although angio-embolization has been
defined the logical augmentation of damage control techniques for controlling hemorrhage,
the overall liver-related complication rate can be as high as 60.6% with 42.2% incidence of
major hepatic necrosis [28]. Non-operative management (NOM) consists of close observa‐
tion of the patient completed with angio-embolization, if necessary. Observational manage‐
ment involves admission to a unit and the monitoring of vital signs, with strict bed rest,
frequent monitoring of hemoglobin concentration and serial abdominal examinations [29].
Following factors contribute to conservative management of liver trauma:
i. Realization that more than 50% of liver injuries stop bleeding spontaneously at the
time of exploration
ii. Availability of CT scan imaging for better assessment of grade of liver injury and
associated injuries
iii. The success of non-operative management in paediatric patients
iv. Knowledge that the liver has tremendous capacity of healing after injury,
v. Improved critical care management in specialized unit
vi. The introduction of angio-embolization which allows patients with specific CT
findings to potentially be treated in a minimally invasive manner.
Given the availability of angio-embolization, trauma surgeons are more likely to initiate
non-operative treatment, even in higher grade injuries, because, in the event of failure, inter‐
vention in the form of angio-embolization is possible and, in the event of angio-emboliza‐
tion failure, surgical intervention is possible. Criteria for non-operative management include
foremost, hemodynamic stability, absence of other abdominal injuries that require laparoto‐
my, immediate availability of resources including a fully staffed operating room, and a vigi‐
lant surgeon. While non-operative management was initially introduced for minor injuries,
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importance of hemodynamic stability in patients with abdominal trauma being considered
for CT examination [16].
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tially, the evaluation of peritoneal violation in hemodynamically stable patients was seen as
the greatest benefit of laparoscopy for trauma [20]. Improvements in laparoscopic training
and technology have enabled an increase in the use of diagnostic and therapeutic proce‐
dures in trauma patients.
Figure 2. Algorithm - Advanced trauma life support, FAST- focused assessment by ultrasound for trauma. ATLS for
managing liver trauma patients.
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are more challenging when patients are hemodynamically stable as the array of potential
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Following factors contribute to conservative management of liver trauma:
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iii. The success of non-operative management in paediatric patients
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Given the availability of angio-embolization, trauma surgeons are more likely to initiate
non-operative treatment, even in higher grade injuries, because, in the event of failure, inter‐
vention in the form of angio-embolization is possible and, in the event of angio-emboliza‐
tion failure, surgical intervention is possible. Criteria for non-operative management include
foremost, hemodynamic stability, absence of other abdominal injuries that require laparoto‐
my, immediate availability of resources including a fully staffed operating room, and a vigi‐
lant surgeon. While non-operative management was initially introduced for minor injuries,
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it was soon in vogue for more severe injuries (grades III–V) [6, 30]. Close observation and
repeated scans are usually recommended to document non-expansion of hematoma and
healing of the injuries over time. The shift towards non-operative management of liver inju‐
ries has resulted in a lower mortality rate, but still a significant percentage of complications
[31]. The current reported success rate of non-operative management of hepatic trauma
ranges from 82% to 100%. Twenty-five percent of patients with blunt hepatic injury man‐
aged non-operatively, 92% of whom have grade IV or V injury will require an intervention
for complications [5].
Despite the reduction of mortality that has been achieved using angio-embolization, some
studies describe a rise in severe but treatable complications such as hepatic necrosis, ab‐
scesses or bile leakage [6, 28]. Gallbladder ischemia, hepatic parenchymal necrosis and bilo‐
ma may also occur, and in patients with a high grade liver injury (grade 4 and 5) the
incidence of complications can be high [32].
A determinant of the success of NOM is the level of cooperation between different special‐
ists in the hospital. Good teamwork among the trauma surgeon, the anaesthesiologist and
the interventional radiologist leads to a quicker understanding of the underlying injuries
and thus shortens the time between entering the hospital and the initiation of therapeutic
interventions. This seems obvious in level 1 trauma centers, but can be a matter of concern,
especially in level II or III trauma centers.
While there has been considerable debate about the grade of liver injury and the acceptable
volume of hemoperitoneum, it is now generally accepted that the ultimate decisive factor in
favour of non-operative management is the hemodynamic stability of the patient, irrespec‐
tive of the grade of injury or the volume of hemoperitoneum. It is also essential that appro‐
priate clinical and radiological follow-up is arranged [33].
The rate of liver-related complications is low, and generally ranges from 0% to 7% [31]. Liv‐
er-related complication rates in high-grade liver injury patients are 11-13% and can be pre‐
dicted by the grade of liver injury and the volume of packed red blood cells transfused at 24
hours post-injury [6, 34]. Incidence of complications attributed to NOM increases in concert
with the grade of injury. In a series of 337 patients with liver injury grades III-V treated non-
operatively, those with grade III had a complication rate of 1%, grade IV 21%, and grade V
63% [6]. Patients with grades IV and V injuries are more likely to require operation, and to
have complications of non-operative treatment. Therefore, although it is not essential to per‐
form liver resection at the first laparotomy, if bleeding has been effectively controlled, in‐
creasing evidence suggests that liver resection should be considered as a surgical option in
patients with complex liver injury, as an initial or delayed strategy, which can be accom‐
plished with low mortality and liver related morbidity in experienced hands [3].
Some of the complications related to conservative management of liver injuries are bile
leaks, liver abscess, delayed haemorrhage, false aneurysm, arterio-venous fistulae, haemo‐
bilia, liver and gall bladder necrosis. Carrillo described complications in up to 85% of pa‐
tients with a high (≥4) Abbreviated Injury Score (AIS) in a series of 32 patients who were
treated non-operatively [27].
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High grade liver injury (>3) treated with NOM and angio-embolization may be associated
with severe complications like liver necrosis, bile leaks and severe sepsis. Mortality has been
noted in up to 11% of patients in high grade liver injury treated conservatively [35]. Al‐
though angio-embolization has been defined the logical augmentation of damage control
techniques for controlling hemorrhage, the overall liver-related complication rate can be as
high as 60.6% with 42.2% incidence of major hepatic necrosis [28]. Early liver lobectomy in
such cases required lesser number of procedures and achieved lower complication rate and
lower mortality compared to less aggressive approaches such as serial operative debride‐
ments and/or percutaneous drainage [36].
5.2. Transarterial Embolization (TAE):
TAE of blunt hepatic injury was first recognized as a safe and effective treatment for the
control of recurrent postoperative hemorrhage, hemobilia and hepatic artery-portal vein fis‐
tulas in the late 1970s [37]. Hashimoto et al. [38] also showed the efficacy of emergency TAE
in four patients with severe complex hepatic injury and suggested that this method may be
useful in nonsurgical management of unstable patients with severe hepatic injury. This mul‐
tidisciplinary approach to the management of complex hepatic injuries is becoming much
more important as the role of interventional radiology expands. Denton et al. [39] reported
successful use of a combination of arterial embolization and transhepatic venous stenting in
the management of a grade V injury involving the retrohepatic vena cava in a patient whose
injury had been temporarily controlled by perihepatic packing. Recent more extensive series
of angiography for control of hepatic haemorrhage have reported increasing success, with
identification and control of bleeding rates ranging from 68 to 87%. [40] Angiography and
embolization or stenting is a very useful adjunctive technique in the stable patient who is
being managed non-operatively or in the patient who either has been stabilised by perihe‐
patic packing or has re-bled after a period of initial stability.
The recent literature reveals that the increased use of angio-embolization and decreased mor‐
tality rates result in increased frequencies of severe complications, such as liver necrosis,
bile leakage and intra-abdominal abscesses [28, 32, 41]. Indications of angiography in hemo‐
dynamically stable patients are high grade liver injury in CT scan, evidence of arterial vas‐
cular injury, and the presence of hepatic venous injury [41]. Angio-embolization can be used
immediately after a damage control laparotomy as part of the primary haemorrhage con‐
trol strategy [42]. Alternatively, angio-embolization can be used in post-operative patients
to manage ongoing bleeding not associated with hemodynamic compromise [32]. This can
involve not only angio-embolization, but also the placement of stents to reconstruct vascu‐
lature [39].
5.3. Complications of non-operative management:
5.3.1. Biliary complications:
Bile leaks are a frequent complication in the non-operative management of liver injuries, oc‐
curring in 6% to 20% of cases. Bile leaks present either as trauma, drainage of bile through
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and thus shortens the time between entering the hospital and the initiation of therapeutic
interventions. This seems obvious in level 1 trauma centers, but can be a matter of concern,
especially in level II or III trauma centers.
While there has been considerable debate about the grade of liver injury and the acceptable
volume of hemoperitoneum, it is now generally accepted that the ultimate decisive factor in
favour of non-operative management is the hemodynamic stability of the patient, irrespec‐
tive of the grade of injury or the volume of hemoperitoneum. It is also essential that appro‐
priate clinical and radiological follow-up is arranged [33].
The rate of liver-related complications is low, and generally ranges from 0% to 7% [31]. Liv‐
er-related complication rates in high-grade liver injury patients are 11-13% and can be pre‐
dicted by the grade of liver injury and the volume of packed red blood cells transfused at 24
hours post-injury [6, 34]. Incidence of complications attributed to NOM increases in concert
with the grade of injury. In a series of 337 patients with liver injury grades III-V treated non-
operatively, those with grade III had a complication rate of 1%, grade IV 21%, and grade V
63% [6]. Patients with grades IV and V injuries are more likely to require operation, and to
have complications of non-operative treatment. Therefore, although it is not essential to per‐
form liver resection at the first laparotomy, if bleeding has been effectively controlled, in‐
creasing evidence suggests that liver resection should be considered as a surgical option in
patients with complex liver injury, as an initial or delayed strategy, which can be accom‐
plished with low mortality and liver related morbidity in experienced hands [3].
Some of the complications related to conservative management of liver injuries are bile
leaks, liver abscess, delayed haemorrhage, false aneurysm, arterio-venous fistulae, haemo‐
bilia, liver and gall bladder necrosis. Carrillo described complications in up to 85% of pa‐
tients with a high (≥4) Abbreviated Injury Score (AIS) in a series of 32 patients who were
treated non-operatively [27].
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cular injury, and the presence of hepatic venous injury [41]. Angio-embolization can be used
immediately after a damage control laparotomy as part of the primary haemorrhage con‐
trol strategy [42]. Alternatively, angio-embolization can be used in post-operative patients
to manage ongoing bleeding not associated with hemodynamic compromise [32]. This can
involve not only angio-embolization, but also the placement of stents to reconstruct vascu‐
lature [39].
5.3. Complications of non-operative management:
5.3.1. Biliary complications:
Bile leaks are a frequent complication in the non-operative management of liver injuries, oc‐
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surgically placed drain, or percutaneously placed catheter to drain biloma. The time of pre‐
sentation of biliary leaks is variable. Ultrasound and CT scan are used to diagnose a biloma,
whereas a hepatobiliary iminodiacetic acid scan is used to show an active bile leak.
Majority of bile leaks can be treated by ultrasound or CT-guided percutaneous drainage or
ERCP and stenting.
5.3.2. Delayed haemorrhage:
The prevalence of delayed haemorrhage following non-operative management of blunt liver
injury ranges from 1.7 to 5.9% [27, 43]. The mechanism of delayed hemorrhage may be relat‐
ed to an expanding injury or to a pseudoaneurysm induced by a biloma which eventually
causes an expanding hematoma and free rupture into the peritoneal cavity. Early bleeding
episodes are attributed directly to the traumatic insult, while late hemorrhage is probably
related to infectious hepatic complications. Angio-embolization may prove an useful techni‐
que to deal with such complications.
5.4. Operative management:
Patients with associated liver and spleen injuries are twice as likely to fail non-operative
therapy as those with only a single organ injured [44]. Missing associated intra-abdominal
injury and delayed treatment, significantly affects the outcome. This occurs more often in
conjunction with liver than with splenic injury, especially pancreas and bowel injury are sig‐
nificantly associated with liver injury in blunt trauma.
Patients  with  high grade  liver  injury  who are  hemodynamically  unstable  require  surgi‐
cal  management.  Failure of  NOM also requires  urgent  exploration and appropriate  sur‐
gical  management.
Anesthesia must ensure that blood products are already in the room. The massive transfu‐
sion protocol should be activated so that the blood bank is always ahead of the patient’s
needs for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate. Ade‐
quate vascular access and arterial blood pressure monitoring are essential. It is important to
preferentially have venous access above the diaphragm. Resuscitation fluids infused under
pressure through femoral access will exacerbate hepatic venous bleeding, at times dramati‐
cally so. Massive transfusion protocols should be activated early to prevent any delay in re‐
suscitation with blood products.
The most widely adopted incision for the patient with liver trauma is a long midline laparot‐
omy, which can be extended to the right chest if a posterior right lobe injury, major hepatic
venous injury, or vena caval injury is encountered. An effective alternative, which gives
good exposure and avoids a thoracotomy, is a right subcostal extension. A bilateral subcos‐
tal incision is sometimes favoured by hepatobiliary surgeons if there is an obvious penetrat‐
ing through-and-through liver injury. This allows excellent exposure of the right lobe of the
liver, the hepatic veins, and vena cava without having to open the chest or diaphragm; how‐
ever, it does compromise access to the lower abdomen.
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If a major liver injury is encountered, immediate control of bleeding is an absolute priority
because the greatest threat to the patient’s life at this juncture is exsanguination. Liver
should immediately be manually closed and compressed. Patients with massive hemoperi‐
toneum are at risk of coagulopathy, hypothermia and acidosis. Measures should be taken to
prevent and treat all these consequences of massive bleeding. If this still does not control the
bleeding, pedicle occlusion (Pringle manoeuvre) should be applied using an atraumatic vas‐
cular clamp or non-crushing bowel clamp. If bleeding stops after Pringle manoeuvre, the
bleeding is from branches of portal vein or hepatic artery. If bleeding continuous after this
manoeuvre, the bleeding is likely to be from hepatic vein or IVC. The time of Pringle ma‐
noeuvre is controversial, but it can be applied up to 1 hour without compromising the blood
supply to the liver.
5.4.1. Damage control surgery:
The concept of damage control was introduced by Stone et al [45] in the 1980s and promul‐
gated by the group at Ben Taub in 1992 [46]. This came after the report by Denver General in
patients sustaining fatal hepatic hemorrhage.
After trauma, hemostasis was not possible as patients were hypothermic, acidotic, and re‐
ceiving large volumes of packed red cells before blood component or fresh blood [47]. This
led to the concept of the “bloody vicious cycle.” The term “damage control” was popular‐
ized by the group at the University of Pennsylvania in the 1993 [48]. They described initial
control of haemorrhage and contamination followed by packing and temporary abdominal
closure, ICU restoration of normal physiology, and delayed definitive repair of intra-ab‐
dominal injuries. The decision for damage control should be made very early in the opera‐
tion before the onset of severe coagulopathy, acidosis, and hypothermia. Early institution of
packing as a damage control technique has been shown to lessen mortality [49].
The damage control concept is very appropriate for the management of major liver injuries.
The three key factors that interact to produce a deteriorating metabolic situation are hypo‐
thermia, coagulopathy, and acidosis. Patients in this condition are at the limit of their phys‐
iological reserve and persistence with prolonged and complex surgical repair attempts will
cause exceptionally high mortality [50]. Early recognition of hypo-thermia, coagulopathy,
and acidosis is the key to the damage control approach. It is recommended that definitive
surgery should cease and a damage control approach be adopted when hypothermia is dete‐
riorating or a temperature of 34oC is reached, when coagulopathy has developed (nonsurgi‐
cal oozing or prothrombin time greater than 50% above normal), or when acidosis exists
(pH<7.2 despite adequate volume resuscitation).
Once the patient is stabilized, patient is returned to the operation theatre and definitive sur‐
gery is undertaken if needed.
5.4.2. Perihepatic packing:
Tamponade which is achieved by manual compression that can then be maintained by
packs, which can also be manually compressed if bleeding continues. Packs placed in an an‐
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cal  management.  Failure of  NOM also requires  urgent  exploration and appropriate  sur‐
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Anesthesia must ensure that blood products are already in the room. The massive transfu‐
sion protocol should be activated so that the blood bank is always ahead of the patient’s
needs for packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate. Ade‐
quate vascular access and arterial blood pressure monitoring are essential. It is important to
preferentially have venous access above the diaphragm. Resuscitation fluids infused under
pressure through femoral access will exacerbate hepatic venous bleeding, at times dramati‐
cally so. Massive transfusion protocols should be activated early to prevent any delay in re‐
suscitation with blood products.
The most widely adopted incision for the patient with liver trauma is a long midline laparot‐
omy, which can be extended to the right chest if a posterior right lobe injury, major hepatic
venous injury, or vena caval injury is encountered. An effective alternative, which gives
good exposure and avoids a thoracotomy, is a right subcostal extension. A bilateral subcos‐
tal incision is sometimes favoured by hepatobiliary surgeons if there is an obvious penetrat‐
ing through-and-through liver injury. This allows excellent exposure of the right lobe of the
liver, the hepatic veins, and vena cava without having to open the chest or diaphragm; how‐
ever, it does compromise access to the lower abdomen.
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tion before the onset of severe coagulopathy, acidosis, and hypothermia. Early institution of
packing as a damage control technique has been shown to lessen mortality [49].
The damage control concept is very appropriate for the management of major liver injuries.
The three key factors that interact to produce a deteriorating metabolic situation are hypo‐
thermia, coagulopathy, and acidosis. Patients in this condition are at the limit of their phys‐
iological reserve and persistence with prolonged and complex surgical repair attempts will
cause exceptionally high mortality [50]. Early recognition of hypo-thermia, coagulopathy,
and acidosis is the key to the damage control approach. It is recommended that definitive
surgery should cease and a damage control approach be adopted when hypothermia is dete‐
riorating or a temperature of 34oC is reached, when coagulopathy has developed (nonsurgi‐
cal oozing or prothrombin time greater than 50% above normal), or when acidosis exists
(pH<7.2 despite adequate volume resuscitation).
Once the patient is stabilized, patient is returned to the operation theatre and definitive sur‐
gery is undertaken if needed.
5.4.2. Perihepatic packing:
Tamponade which is achieved by manual compression that can then be maintained by
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terio-posterior axis will often distract the injured liver further and worsen the bleeding. The
lobes of the liver must be compressed back to normal position, essentially back toward mid‐
line. Simultaneously, the liver is pushed toward the diaphragm. Maintenance of this ana‐
tomic compression by the first or second assistant is critical to reduce bleeding as the
surgeon assesses the liver injury or mobilizes the liver. Perihepatic packing can help to
maintain this tamponade. Most minor venous bleeding and small lacerations to the paren‐
chyma can be temporized by this manoeuvre. Haemostatic agents such as surgicell, throm‐
bin-soaked gel foam, or fibrin glue are useful adjuncts.
Packing is not as effective for the injuries to the left hemiliver, because with the abdomen
open, there is insufficient abdominal and thoracic wall anterior to the left hemiliver to pro‐
vide adequate compression. Fortunately, haemorrhage from the left hemiliver can be con‐
trolled by dividing the left triangular and left coronary ligaments and compressing the left
hemiliver between the hands.
Packs must be placed around the liver to reconstitute its anatomical shape. Packs should
never be inserted into the hepatic wound, as it will tear the vessels and will increase the
bleeding. It is also important to avoid excessive packing, as compression of IVC can lead to
resultant decreased venous return, and reduces left ventricular filling. Excessive packing can
also lead to compartment syndrome and multi-organ failure [51]. Conversely under-packing
is associated with increased transfusion requirements and unplanned re-look laparotomies
[52]. To reduce the risk of abdominal compartment syndrome, some advocate closing the
upper part of the wound to enhance the tamponade effect but leaving the lower two-thirds
open and temporarily covered with a silastic sheet sutured to the skin edges [53, 54].
Perihepatic packing will control profuse haemorrhage in up to 80% of patients undergoing
laparotomy and will allow intraoperative resuscitation (resuscitative packing) [50, 55]. In the
management of severe injuries of the liver, packing has emerged as the key to effective dam‐
age control [56]. However, more definitive ‘‘therapeutic’’ packing is also a very effective
technique, particularly when used judiciously to prevent the cascade of hypothermia, coa‐
gulopathy, and acidosis [57].
Once the patient is stabilized, temporary closure of the abdomen is done and patient is shift‐
ed to the ICU. Packs can be removed after 36-48 hours. Broad spectrum antibiotics should be
started to prevent sepsis. The exact timing of the removal of packs is controversial, but they
should not be removed before 24 hours as this is related to re-bleeding and leaving them in
place for 24 hours or more does improve outcome [58]. Even delayed removal (up to 1
week) has been reported without increasing the morbidity [59]. During removal, the packs
should gently be removed after soaking with saline. Liver should be checked for re- bleed‐
ing and if adequate hemostasis is achieved, closure of the abdomen can be done after put‐
ting a drain.
5.4.3. Hepatorrhaphy:
This is an older technique which involves passing deep parenchymal sutures to bring dis‐
rupted tissue together compressing bleeding vessels and reducing dead space. The major
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drawback of this procedure is ischemic necrosis and infection of the liver parenchyma.
However, some advocate hepatorrhaphy for “hard-to-reach” areas such as the dome and
posterior portion of the right lobe.
5.4.3.1. Mesh Wrapping:
Mesh-wrapping is a quick and technically feasible method to achieve definitive hemostasis
in severe liver trauma. It can be combined ideally with conventional procedures. Mesh-
wrapping technique provides a highly selective, tight compression confined to the liver and
does not produce an increased intra-abdominal pressure. Emphasis should be given in two
important technical aspects while mesh wrapping. First, the traumatized liver has to be
slung with the mesh under enough tension to create a tamponade effect. In addition the
mesh should be attached into two anchoring stable points. The diaphragmatic crus and the
falciform ligament provide the best options to stabilize the mesh. The mesh is resorbable
and therefore reoperation for removal is not necessary. Furthermore, the resulting product
of mesh hydrolysis has a bacteriostatic effect, minimizing the risk of infection [60].
5.4.4. Hepatotomy and selective vascular ligation:
Combined hepatotomy and selective vascular ligation has emerged as the preferred method
of management for major hepatic venous, portal venous, and arterial injuries in many cen‐
tres [61]. For control of major vascular injuries, Pachter et al. recommend a rapid and exten‐
sive finger fracture, often through normal parenchyma, to reach the site of injury. However,
it is important to emphasise that with a major hepatic venous injury, significant haemor‐
rhage may occur while attempting to extend a deep liver laceration and that this bleeding
will not be controlled by a Pringle clamp and increased morbidity may be incurred. Hepa‐
totomy is done under Pringle manoeuvre and finger fracture method is used to divide the
parenchyma to ligate the bleeding vessels. Pringle clamp is released intermittently to identi‐
fy bleeding vessels.
5.4.5. Non-anatomical resection of liver:
This refers to removal of devitalised parenchyma using the line of injury as the boundary of
the resection rather than standard anatomical planes [62]. Resectional debridement is indi‐
cated for peripheral portion of nonviable hepatic parenchyma. Debridement is rarely a tech‐
nique practised in isolation and is frequently used in conjunction with inflow control and
hepatotomy. This allows for haemorrhage control prior to resection of all devitalised tissue
while usually involves crossing traditional anatomical boundaries hence the term “non-ana‐
tomical resection”. All devitalized tissues should be removed without making any attempt
to resect normal parenchyma. Operative time should be as short as possible.
Except in rare circumstances, the amount of tissue removed should not be more than 25% of
the liver. In some cases simple completion of an extensive parenchymal avulsion may suf‐
fice, e.g., when there has been an avulsion of the posterior sector of the right lobe (segments
VI and VII). This type of injury is often associated with a right hepatic vein laceration and
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completion of the ‘‘resection’’ will allow control and suture of this. In such situations, vascu‐
lar stapling devices are extremely useful for rapid and secure division of major veins.
5.4.6. Anatomical resection of liver:
The final alternative for patients with extensive injury to one hemiliver is anatomic hepatic
resection. In elective circumstances, anatomic hemi-hepatectomies can be performed with
excellent results; however, in the setting of trauma, the mortality associated with this proce‐
dure exceeds 50% in most series [63, 64]. This, plus the fact that the time and magnitude of
the surgery goes against the later principles of conservative surgery and damage control,
has resulted in anatomical resection being practised rarely and it is now performed in only
approximately 2–4% major liver trauma cases [51].
Hepatic resection for an injured segment of the liver definitively controls bleeding, potential
bile leak, and removes devitalized tissue. However, the role of hepatic resection in the man‐
agement of liver injury remains controversial. The traditional poor results and lack of enthu‐
siasm for this technique have been contradicted by the results of some recent series
particularly that from Strong et al. who achieved excellent results in a series of 37 patients,
11 of whom (33%) had grade V juxtahepatic venous injuries [61]. These results probably re‐
flect the fact that this procedure was performed in a specialist liver resection and transplan‐
tation unit, and while the majority of liver injuries continue to be managed initially in
trauma centres or district hospitals, it is likely that more conservative and damage control
procedures will remain the most widely practised techniques.
5.4.7. Intrahepatic balloon tamponade:
Intrahepatic balloon tamponade is useful for transhepatic penetrating injury. A device can
either be fashioned from a Foley catheter and Penrose drain [65] or a Sengstaken-Blakemore
tube. The device is gently delivered into the length of the tract and then inflated, often with
a radio-opaque contrast fluid so integrity and position can be later confirmed radiologically
if required. Once the patient is stabilized and coagulation and acidosis is corrected, the bal‐
loon can be deflated and removed during re-laparotomy.
5.4.8. Total vascular exclusion:
Total vascular exclusion of liver is sometimes used for extensive retrohepatic venous inju‐
ries. The technique involves clamping of the portal triad and infra- and supra-hepatic IVC
and therefore requires experience with mobilisation of the liver as done in liver resection
and transplantation. Excellent results were reported for this technique by Khaneja et al. [66]
who used it to manage grade V penetrating injuries with 90% of patients surviving the oper‐
ation and an overall survival rate of 70%.
The major drawback of this technique is decreased venous return due to clamping of IVC.
This will lead to further hypotension in patient who is already in hypothermia and hypoten‐
sion. This procedure can only be feasible in experienced hand in high volume centres.
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5.4.9. Liver transplantation:
This remains a therapy of last resort limited to specialist centres with the literature limited to
occasional case reports and series [67]. While liver transplantation may be life-saving for
major liver trauma, the logistical problems will mean that it remains a limited option, availa‐
ble only in specialist centres.
6. Postoperative complications and mortality:
Overall mortality for patients with hepatic injuries is approximately 10%. The most common
cause of death is exsanguination, followed by MODS and intracranial haemorrhage. Liver
trauma is a morbid injury with complication rates from recent series ranges from between
8.1% to 30% [68].
6.1. Postoperative haemorrhage:
Primary exsanguinating haemorrhage is a major source of mortality, but most studies report
secondary haemorrhage occurring in 3- 6% of survivors with no significant difference be‐
tween blunt and penetrating mechanisms [69]. Surgical haemorrhage (ie discrete bleeding)
and disseminated intravascular coagulation account for the majority of causes in even pro‐
portions. In patients managed by peri-hepatic packing, patients who had packs removed at
<36hrs had more episodes of haemorrhage requiring re-packing than those with removal be‐
tween 36 hours and 72 hours.
In most instances of persistent postoperative haemorrhage, the patient is best served by be‐
ing returned to the operation room. Angiography with embolization may be considered in
selected patients. If the reason for haemorrhage is coagulopathy, it should be corrected first
and then patients should be reassessed.
6.2. Sepsis and abscess:
Post-operative sepsis occurs in 12-32% of patients. Minor morbidity occurs with urinary
tract, surgical wound and respiratory tract sepsis. More serious are intra-abdominal abscess‐
es which occur in up 24% of patients and are associated with concomitant bowel injury,
higher grades of liver injury (IV and V) and massive transfusion [70].
An abdominal CT with intravenous and oral contrast should be performed to diagnose the
cause of sepsis. Majority of the abscesses can be drained percutaneously under USG or CT-
guidance; however, infected hematoma and infected necrotic liver tissue cannot be expected
to respond to percutaneous drainage. Operative drainage may be a better option in such
type of patients.
6.3. Biloma:
Bilomas are loculated collection of bile, which is with or without infection. CT-guided per‐
cutaneous drainage is the best option for infected bilomas. If the biloma is sterile, it will
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eventually be resorbed. Biliary ascites is caused by disruption of major bile duct. Reopera‐
tion after the establishment of appropriate drainage is the prudent course.
Biliary fistulas occur in approximately 3% of the patients with major liver injury [71]. They
are usually of little consequences and generally close without specific treatment.
7. Injuries to the Bile ducts and gall bladder:
Extrahepatic  bile  ducts  are  rarely  injured  during  blunt  or  penetrating  abdominal  inju‐
ries [72, 73]. Diagnosis is usually made during surgery or sometimes postoperatively. Man‐
agement  of  bile  duct  injury  detected  postoperatively  has  already  been  described.  If
laparotomy is  performed for  patient  with  trauma,  collection  of  bile  in  to  the  right  up‐
per quadrant suggest  major bile  duct  injury.  Sometimes it  is  very difficult  to detect  the
site  of  bile  duct  injury,  as  associated  disruption  of  liver  parenchyma and  haemor‐
rhage  makes  detection  a  challenging  task.
Management of bile duct injury is further complicated by small calibre and thin wall of the
bile duct. Bile duct injury ranges from small laceration to tissue loss or complete disruption.
Primary repair may be attempted when there is small laceration and no tissue loss. When
there is a tissue loss or the laceration is larger than 25% to 50% of the diameter of the duct,
the treatment option is a Roux-en-Y choledocho-jejunostomy [74, 75]. Isolated injury to left
or right hepatic duct is even more challenging and should only be managed by experienced
hepatobiliary surgeon. If expertise is not available, large bore tube should be kept and pa‐
tient should be transferred to higher centre. If both the ducts are injured, both the ducts
should be intubated by separate tubes and brought out. Elective repair should be undertak‐
en once the patient is stable and after adequate assessment of injury by cholangiogram.
Injury to the gall bladder is treated either by repair or cholecystectomy.
8. Summary:
The management of injuries of the liver has evolved significantly throughout the last two
decades. Non-operative techniques for the management of grade IV–V injuries in stable pa‐
tients have been established, although there is a higher failure rate for these injuries com‐
pared with grade I–III injuries. Because of the progress that has been made in the quality
and wide availability of the MDCT scan combined with minimally invasive intervention op‐
tions like angio-embolization, NOM has evolved to be the treatment of choice for hemody‐
namically stable patients. In terms of surgical management there has been a definite move
away from major, time-consuming procedures toward conservative surgery and damage
control. The preferred surgical technique for inaccessible bleeding within a laceration is rap‐
id finger fracture hepatotomy, Kelly –crush hepatic transection and direct suture or ligation.
Prolonged attempts at surgical control and repair should be avoided, and definitive perihe‐
patic packing should be employed at an early stage in the persistently unstable patient or at
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the first signs of coagulopathy. Formal anatomical resection carries a high morbidity when
used for haemorrhage control, although in an experienced centre this may be appropriate.
Hepatorrhaphy has become discouraged due to complications of sepsis and bleeding, but
may be a useful technique in penetrating trauma where the liver is difficult to access.
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1. Introduction
The word liver was derived from the old English word “life’’ [1]. Survival without the liver
is impossible for more than a few hours except in very unusual circumstances. The liver is
the largest intra-abdominal solid organ; with its friable parenchyma, its thin capsule, and its
relatively fixed position in relation to the spine, makes it particularly prone to injury. As a
result of its larger size and proximity to the ribs, the right hemi-liver is injured more com‐
monly than the left. It’s the second most commonly injured organ in abdominal trauma, but
damage to the liver is the most common cause of death after abdominal injury [2], [3]. Man‐
agement of Liver Trauma may vary widely from non operative management (NOM) with or
without angioembolization to Damage Control Surgery (DCS) [4]. DCS is mainly centered
on stopping the bleeding by packing, Pringles, and vascular exclusion to totally replacing
the liver by a liver transplant [5].
Although blunt liver trauma accounts for 15-20% of abdominal injuries,  it  is  responsible
for more than 50% of deaths resulting from blunt abdominal trauma. The mortality rate
is  higher  with  blunt  abdominal  trauma  than  with  penetrating  injuries[6].  In  Europe,
blunt  trauma predominates  (80-90  per  cent  of  all  liver  injuries)[6]-[8],  while  penetrating
injuries account for 66 per cent of liver trauma in South Africa [9] and up to 88 per cent
in North America [10]-[13]. Unfortunately, we don't have enough data for the Arab coun‐
tries  though we are  one  of  the  highest  countries  in  motor  vehicle  accidents  with  more
than 9000 deaths per year.
As a result of this high mortality rate, emergency surgery was frequently indicated in pa‐
tients with hepatic injury in the past. However, advances in diagnostic imaging, better mon‐
itoring facilities and the introduction of damage control strategy in trauma has influenced
our approach in the management of liver trauma [14].
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1. Introduction
The word liver was derived from the old English word “life’’ [1]. Survival without the liver
is impossible for more than a few hours except in very unusual circumstances. The liver is
the largest intra-abdominal solid organ; with its friable parenchyma, its thin capsule, and its
relatively fixed position in relation to the spine, makes it particularly prone to injury. As a
result of its larger size and proximity to the ribs, the right hemi-liver is injured more com‐
monly than the left. It’s the second most commonly injured organ in abdominal trauma, but
damage to the liver is the most common cause of death after abdominal injury [2], [3]. Man‐
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without angioembolization to Damage Control Surgery (DCS) [4]. DCS is mainly centered
on stopping the bleeding by packing, Pringles, and vascular exclusion to totally replacing
the liver by a liver transplant [5].
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injuries account for 66 per cent of liver trauma in South Africa [9] and up to 88 per cent
in North America [10]-[13]. Unfortunately, we don't have enough data for the Arab coun‐
tries  though we are  one  of  the  highest  countries  in  motor  vehicle  accidents  with  more
than 9000 deaths per year.
As a result of this high mortality rate, emergency surgery was frequently indicated in pa‐
tients with hepatic injury in the past. However, advances in diagnostic imaging, better mon‐
itoring facilities and the introduction of damage control strategy in trauma has influenced
our approach in the management of liver trauma [14].
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2. Anatomy
In this part we will describe the anatomy of the liver and its attachments in relation to what
is needed in liver trauma, to achieve good mobilization with haemorrhage control to reach
the first stage of damage control.
2.1. Surface anatomy
It’s important to know the location of the liver and its surface anatomy to be able to choose
the best incision, to determine if it is involved in a penetrating trauma, and to think of it
when you have a chest trauma especially on the right lower chest. When viewed from the
front (fig. 1), the normal liver surface markings are [15]:
Upper margin: at the xiphisternal joint arching upwords on both sides. On the left it runs for
7-8cm from the mid-line. On the right, it reaches the fifth rib.
Right boarder: it curves downword from the seventh to the eleventh rib in the mid axillary
line.
Inferior boarder: along a line that joins both right lower and upper left points.
Figure 1. Surface anatomy of the liver
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2.2. Gross anatomy
The liver has three surfaces [16]
• Diaphragmatic Surface:
This is covered with peritoneum to act as a sheath around the liver. In the midline the falci‐
form ligament is attached and divides the liver into the right and left anatomical liver, or
better descried it runs between the left lateral section (segment 2 and 3) and the left medial
section (segment 4).
• Visceral Surface:
The sharp inferior border of the liver joins the diaphragmatic surface with the visceral sur‐
face of the liver. The main structures are lined in an H shaped. The cross part is made of the
porta hepatis (hilum of the liver). The right limb is made of the inferior vena cava. The left
limb is made of the contiuity of the fissures for the ligamentum teres anteriorly and the liga‐
mentum venosum posteriorly. On the left side lies the caudate lobe and on the right lies the
bare area of the liver.
• Posterior Surface (fig 2):
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The IVC runs in the centre of the posterior surface. A firous band called the ligamentum
venae cavae (hepato-caval ligament) covers part of the IVC posteriorly. The rest of the poste‐
rior surface is made of by the ligaments (the left and right triangular ligaments, and the cor‐
onary ligament) which attach the liver to the diaphragm.
2.3. Ligaments of the liver
The falciform ligament consists of two closely layers of peritoneum. The ligamentum teres
runs on its free edge with a small paraumbilical vein. On the right it forms the upper layer
of the coronary ligament, witch continues inferiorly to form the right triangular ligament,
then to the lower coronary ligament. On the left, the falciform ligament forms the anterior
layer of the left triangular ligament. (fig 3 &4)
Figure 3. Diaphragmatic surface of the liver and its ligaments
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Figure 4. Posterior surface of the liver and its ligaments
2.4. Caudate lobe
The caudate lobe is the dorsal portion of the liver lying posteriorly and embracing the retro‐
hepatic IVC in a semi circumferential fashion. It lies between the IVC posteriorly, the portal
triad inferiorly and the hepatic veins superiorly. There is a series of short hepatic veins
which drains directly from the caudate lobe to the retrohepatic IVC. Thus it is surrounded
by important structures that can be involved in liver trauma 17 (Fig 5).
2.5. The glissonian sheath
Glisson’s capsule which covers the liver extends into the liver at the hilus and covers the
portal triad were it is called the Glisson’s sheath. With relation to liver trauma it is impor‐
tant to know only the extrahepatic portion of the Glissonian pedicle which is called the hep‐
atodudenal ligament. This is very important when a Pringle manoeuvre is needed. It usually
composed of connective tissue and peritoneum up to the hepatic hilum. They surround the
portal vein posteriorly, the hepatic artery anteriorly and to the left, and the common bile
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Figure 5. The caudate lobe: front view
Figure 6. Structures within the glissonian sheath
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2.6. Retrohepatic IVC and its branches (fig 7)
In relation to liver trauma we can divide the retrohepatic IVC into four parts:
The suprahepatic group; which is composed of both right and left inferior phrenic veins
which drain the right and left diaphragm.
The hepatic veins; which are composed of the right, middle and left hepatic vein. There are
multiple variations that can exist and its knowledge is important in liver surgery.
The retrohepatic group; which is composed of short veins that drain part of the right hemi-
liver and the caudate lobe directly into the IVC. These veins are short and very fragile and
are prone to injury.
Lastly, the infrahepatic group; which consists mainly of both the right and left adrenal veins.
These veins are frequently injured in trauma and if not considered during mobilizing the
right liver [19].
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Penetrating and blunt trauma are the two principal mechanisms for liver trauma. Motor ve‐
hicle accidents account for the majority of blunt trauma, whereas knife and gunshot wounds
constitute the major cause of penetrating injuries
Two types of blunt liver trauma have been described: deceleration (shearing) injuries occur
in motor vehicle accidents and in falls from a height where there is movement of the liver in
its relatively fixed position, thereby producing a laceration of its relatively thin capsule and
parenchyma at the sites of attachment to the diaphragm[13].
The other type of liver injuries is crush injury. Crush injuries follow direct trauma to the ab‐
domen over the liver area. Decelerating injuries typically create lacerations between the
right posterior section (segments 6 and 7) and the right anterior section (segments 5 and 8),
which can extend to involve major vessels. Crush injuries can lead to damage to the central
portion of the liver (segment 4, 5 and 8) and also may cause bleeding from the caudate lobe
(segment 1)[12]-[13]. Blunt trauma can cause parenchymal hepatic injury with intact Glis‐
son's capsule, leading to an intraparenchymal or subcapsular haematoma[12]-[13].
Penetrating injuries are usually associated with gunshot or stab wounds, with the former
usually resulting in more tissue damage due to the cavitation effect as the bullet traverses
the liver substance [13]-[20]. These injuries usually require surgery more often than blunt in‐
juries when the liver is involved.
4. Diagnosis
Signs and symptoms of hepatic injuries are related to the amount of blood loss, peritoneal
irritation, right upper quadrant tenderness, and guarding. Rebound abdominal tenderness
is common but nonspecific. Occasionally, patients with blunt abdominal trauma do well ini‐
tially, but they subsequently develop a liver abscess, presumably due to unrecognized liver
damage. These patients present with signs and symptoms of deep-seated infection [21]. Pa‐
tients may present with severe peritonism due to bile peritonitis resulting from bile leaks.
Signs of blood loss, such as shock, hypotension, and a falling hematocrit level, may domi‐
nate the picture [21] As resuscitation proceeds, a detailed physical examination is carried
out. Most conventional texts emphasis the need for a careful history and physical examina‐
tion of the abdomen. While this is undoubted importance, it is extremely difficult to assess
the abdomen in the trauma situation as the history may not be available and all the existing
physical signs are misleading. Fresh blood is not a peritoneal irritant [22]. The mechanism of
injury is critically important in assessing the potential for abdominal injury. This informa‐
tion may be obtained from the patient, relatives, police or emergency care personnel [22]
Following initial assessment, a conscious patient, who is haemodynamically unstable fol‐
lowing blunt trauma and has generalized peritonism, should undergo immediate laparoto‐
my without further investigation [13]. Urgent laparotomy is also indicated in patients who
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have sustained a stab wound to the abdomen and are haemodynamically unstable. If the pa‐
tient is stable and a liver injury is suspected, imaging studies should be performed [21]-[23]
However, haemodynamically stable patients with suspected liver injury can be investigated
at this stage to define the nature of the injury.
Ultrasonography (FAST) has gained increased acceptance, particularly in the emergency de‐
partment, for the rapid evaluation of patients with blunt or penetrating abdominal trauma
[24]-[29]. It is cheap, portable and noninvasive, compare to peritoneal lavage and it does not
use radiation or iodinated contrast media [30]-[32]. Its sensitivity for the presence of intra-
abdominal fluid in patients with trauma ranges from 75 to 93.8% and the specificity from 97
to 100% [24]-[25]. However, some pitfalls remain in abdominal ultrasonography. Injuries at
the dome or lateral segments of the liver can easily by missed with ultrasound, especially in
the presence of ileus or if the patient cannot cooperate because of pain. Hepatic laceration or
hematomas are usually difficult to distinguish, especially in the acute phase, because they
are isoechoic to the normal liver [33]-[34].
Kalogeropoulu and colleagues (2006) demonstrated the usefulness of contrast enhanced ul‐
trasonography in penetrating liver trauma [35]. It increases the sensitivity and the specificity
of ultrasound in evaluation of abdominal trauma not only in detection of free peritoneal flu‐
id but also in the visualization of the parenchymal lacerations. The use of contrast in addi‐
tion to the conventional ultrasound scanning does not significantly prolong the examination
time, compared with a contrast enhanced CT scan. Furthermore repeated doses of the con‐
trast can be injected to scan the rest of the solid abdominal organs such spleen and kidneys
if a more complex trauma is suspected [35]. However, US is operator dependent, were you
may not find an expert ultrasonographer in the middle of the night. In addition, US contrast
is not wildly available in every casualty.
Computed tomography (CT) is the gold standard investigation for the evaluation of a stable
patient with suspected liver trauma [36]-[39]. CT has high sensitivity and specificity for de‐
tecting liver injuries which increase as the time between injury and scanning increases, evi‐
dently because haematomas and lacerations become better defined [40]. Contrast-enhanced
CT, is accurate in localizing the site and extent of liver and associated injuries, providing vi‐
tal information for treatment in patients. CT without intravenous contrast enhancement is of
limited value in hepatic trauma, but it can be useful in identifying or following up a hemo‐
peritoneum [41]-[43].
CT scanning allows reasonably accurate grading of liver injuries and provides crude quanti‐
tation of the degree of hemoperitoneum. CT scanning is mandatory for patients with blunt
trauma whose liver injury is to be managed nonoperatively. CT has also been useful for de‐
tecting missile tracts in penetrating trauma patients. Such information is imperative for sur‐
geons who want to attempt nonoperative management of penetrating wounds [44]-[47]
Although CT is very useful in the evaluation of stable patients with abdominal trauma, most
authors agree that unstable patients, with either blunt or penetrating trauma, are unlikely to
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Figure 8. A CT demonstrating a grade 4 liver injury that was treated surgically
False-positive errors in the diagnosis of liver injury with CT scans may occur as a result of
beam-hardening artifacts from adjacent ribs, which can mimic contusion or hematoma. An
air-contrast level within the stomach in a patient with a nasogastric tube can produce streak
artifacts throughout the left lateral section of the liver; these may mimic intrahepatic lacera‐
tions and/or hemorrhage. The nature of these artifacts can be confirmed if the patient is
scanned in a decubitus position [48].
False-negative findings may occur in the setting of a fatty liver only when contrast-enhanced
CT scan are obtained. On these images, the enhanced fatty liver may become isoattenuating
relative to the laceration or hematoma. In this situation, a nonenhanced CT scan may pro‐
vide useful information regarding hepatic injury. Focal fatty infiltration may also mimic
hepatic hematoma, laceration, or infarction. Hepatic lacerations with a branching pattern
can mimic unopacified portal or hepatic veins or dilated intrahepatic bile ducts. Careful
evaluation of all branching intrahepatic structures is important and the diagnosis is made
with serial images to differentiate the various structures [48]-[49]
MRI has a limited role in the evaluation of blunt abdominal trauma, and it has no advantage
over CT scanning. Theoretically, MRI can be used in follow-up monitoring of patients with
blunt abdominal trauma, and MRI may be useful in young and pregnant women with ab‐
dominal trauma in whom the radiation dose is a concern [6], [50].
MRCP has been used in the assessment of pancreatic duct trauma and its sequelae, and it
can be used to image biliary trauma. Another potential use of MRI is in patients with renal
failure and in patients who are allergic to radiographic contrast medium. MRI offers no sig‐
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nificant advantage over CT scanning for routine evaluation of acute abdominal trauma. Ex‐
perience is insufficient for assessing the value of the special circumstances mentioned above.
Sufficient experience has not been gained in the use of MRI to establish false-positive and
false-negative findings [6]
Angiography has no role in the evaluation of unstable patients. However, if the patient is
stable, cross-sectional imaging may provide sufficient detail to treat the patient conserva‐
tively. A dynamic angiographic study may demonstrate the site of active bleeding. This
when combined with angiographic embolization, especially in high-grade liver injury is of
significant value and may be the only treatment required [51]-[52]. Although angiography is
useful in selected patients, both false-positive and false-negative results occur in patients
with hepatic trauma [6]
Endoscopic retrograde cholangiopancreatography (ERCP) may help in the delineation of the
biliary tree in patient with liver trauma, and stents may be used to treat biliary Leaks [53]-
[54] (Fig 9).
Figure 9. ERCP demonstrating a bile leak from the main right duct
Diagnostic laparoscopy has been used successfully in patients with abdominal trauma [55]-
[58], and laparoscopic fibrin glue in managing liver injuries has also been reported [60].The
benefits of laparoscopic assessment include reducing negative and non-therapeutic laparot‐
omy rates, patient morbidity rates, hospital stay and treatment costs [56]-[57]. Raphael and
colleagues(1999) reviewed 37 studies with more than 1,900 trauma patients (including those
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tool. They came out with the conclusion that "Laparoscopy has been applied safely and ef‐
fectively as a screening tool in stable patients with acute trauma. Because of the large num‐
ber of missed injuries when used as a diagnostic tool, its value in this context is limited.
Laparoscopy has been reported infrequently as a therapeutic tool in selected patients, and
its use in this context requires further study.[61].
5. Classification of liver injury
Liver trauma ranges from a minor capsular tear, with or without parenchymal injury, to ex‐
tensive disruption involving both hemi liver with associated hepatic vein or vena caval in‐
jury. In 1989, the Organ Injury Scaling Committee of the American Association for the
Surgery of Trauma produced a Hepatic Injury Scale [62] by which hepatic injuries are de‐
scribed in most major trauma centers (Table 1). Grade I or II injuries are considered minor;
they represent 80-90 per cent of all cases and usually require minimal or no operative treat‐
ment [1], [63]. Grade III-V injuries are generally considered severe and often require surgical
intervention, while grade VI injuries are regarded as incompatible with survival.
Grade Type of Injury Description of injury
I (fig 10) Hematoma
Laceration
Subcapsular, < 10% surface area
Capsular tear, < 1cm parenchymal depth
II (Fig 11) Hematoma
Laceration
Subcapsular, 10% to 50% surface area
Capsular tear, 1-3cm parenchymal depth and < 10cm in length
III (Fig 12) Hematoma
Laceration
Subcapsular, > 50% surface area or expanding
Intraparenchymal hematoma > 2cm or expanding
Capsular tear, >3cm parenchymal depth
IV (Fig 13) Hematoma
Laceration
Ruptured intraparenchymal hematoma with active bleeding
Parenchymal disruption involving 25-50% of hepatic lobe
V Laceration
Vascular
Parenchymal disruption involving >50% of hepatic lobe
Juxtahepatic venous injuries
VI Vascular Hepatic avulsion
Table 1. Classification of liver injury
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Figure 10. Grade 1 liver injury treated non surgically
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Figure 12. Grade 3 liver injury that was treated non surgically




The countercurrent argument was that nonoperative treatment (NOM) was associated with
virtually a 100% mortality rate, so all patients with suspected or diagnosed liver injuries
must have an operation. Improved mortality rates during and after World War II assured
the primacy of operative treatment [64].
Three observations prompted the move towards nonoperative treatment. First, the practice
of nonoperative treatment was initially advocated for splenic injuries and then extended to
the liver. The success in children led to attempts of nonoperative treatment in adults [65]-
[66] Second, the high rate of nontherapeutic operations in many patients with blunt hepatic
injuries was not in patients’ best interest. Third, the advent of CT scanning greatly facilitated
both diagnosis and grading of injuries and gave some reassurance that the intestinal injuries
had not occurred.
There has been several reports started since 1985, were Trunkey etal [67], defined the criteria
for NOM:
• haemodynamic stability
• absence of peritoneal sign
• Availability of CT
• Monitor in ICU
• Facility of immediate surgery
• Absence of other organ injuries
These criteria has become more and more less strict, were multiple reports are trending
more to NOM [3]. There is no time limit for NOM, continues monitoring is the only key to
take the patient to the operating room [68]. Other reports even went to the extreme as if the
patient had risk factors by the injury severity score (ISS) [69] and all patients should be treat‐
ed first by NOM regardless of their trauma [70]. However, all of these reports mentioned
that this is possible with the addition of angiography and embolization that made the NOM
more feasible and more successful.
The success rate of nonoperative treatment has been remarkably high. The necessity for op‐
erations for ongoing hemorrhage has been reported to be from 5% to 15%. There remains a
concern over missed bowel injuries that have been reported from 1% to 3%.[71]-[75].
Nonoperative treatment of abdominal stab wounds has been practiced successfully in nu‐
merous centers and is on the rise. NOM of gunshot wounds has been more controversial,
however, many reports are calling to add these group of patients to the NOM group [76]-
[79] Demetriades and colleagues(2006) reported 152 patients with penetrating solid organ
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in the last few years NOM has emerged a huge mile stone. Appropriately selected patients
with liver gunshot injuries deemed feasible, safe, and effective, regardless of the liver injury
severity [77]. However, they all mentioned that CT scan was mandatory before adopting the
NOM. Another report stated that regardless of the grade of liver trauma, NOM is safe and
effective in appropriately selected patients with liver gun shoot injuries treated in centers
with suitable facilities [79].
6.2. Operative
6.2.1. Damage control surgery
As the first intention when taking the patient to the operating room is to do damage control
surgery (DCS). This usually implies saving the patient’s life and stopping the bleeding. This
will make the patient more stable and in a better physiologically and hemodynamically state
to be able to have the definitive treatment.
Skin preparation should allow for extension of a midline abdominal incision to a median
sternotomy or  right  thoracotomy,  if  necessary,  for  adequate  exposure  of  posterior  liver
injuries  [81]-[82].  If  the  indication  for  surgery  is  an  obvious  penetrating  through-and-
through liver injury, or the patient failed the NOM and is clear liver injury only a bilat‐
eral  subcostal  incision  is  a  useful  alternative  and  has  been  adopted  by  some  to  have
better liver exposure (fig 14).
Figure 14. Mobilization of the right hemi-liver to achieve excellent exposure of the injury
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DCS includes perihepatic packing and partial abdominal closure or Bogota bag. Usually an
average of six laparotomy pads can be packed to get the tamponade effect between the liver
and the abdominal wall. The timing of re-exploration is controversy but usually 12-24 hours
is safe time for re-exploration were the patients condition permits (fig 15).
Figure 15. Packs as it was done in the first DCS were the bleeding stopped, fingers demonstrating the liver laceration
Even 30 years after the resurrection of packing as a treatment alternative, it remains an im‐
portant part of the armamentarium of surgeons in managing difficult hepatic injuries. It is
always better to have a patient with packs to come and deal with on another day, than try‐
ing to stop the bleeding with no success, especially if the surgeon has limited experience,
which usually happens in the first operation. As many hospitals have a general surgeon on-
call with limited liver or trauma experience.
If a major liver injury is encountered, initial control of bleeding can be achieved with tempo‐
rary tamponade of the right upper quadrant using packs, portal triad occlusion (Pringle ma‐
noeuvre) (Fig 16a &b), bimanual compression of the liver or even manual compression of
the abdominal aorta above the coeliac trunk [83]-[84]. Attempts to evaluate the liver injury
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Figure 16. a. Tape inserted around the portal triad. b. Pringles manouver were the clamp is gently applied to occlude
the portal triad
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Digital compression of the portal triad (Pringle manoeuvre) can be used diagnostically and
compression can be maintained with an atraumatic vascular clamp if haemorrhage decreas‐
es [85]. The clamp should be occluded only to the degree necessary to compress the blood
vessels in order not to injure the common bile duct. If haemorrhage is unaffected by portal
triad occlusion, major vena cava injury or atypical vascular anatomy should be suspected
86-87 Although the permitted occlusion time of the portal triad is controversial, most au‐
thors now agree that clamping of the hepatic pedicle for up to 1h is well tolerated with no
adverse effects on liver function [81],[88]
After initial intraoperative resuscitation, the liver must be mobilized adequately to allow a
thorough examination of the damaged area, unless the injury is already accessible through
the incision [81,84,89] The liver is mobilized by dividing the falciform, triangular and coro‐
nary ligaments, and by placing abdominal packs posteriorly to maintain this position [90].
This manoeuvre allows the surgeon to determine the nature and severity of the injury and to
decide on the necessary surgical technique. Care should be taken to avoid impairing venous
return, by either excessive lifting and/or rotation of the mobilized liver, or excessive packing
causing caval compression [90].
There are several tricks to stop the bleeding other than the one mentioned before, however
we advise that most of these should be done by experienced surgeons in a stable patient or if
the patient is still bleeding after trying the previous methods mentioned. Several specific
modalities began to be used more often to treat arterial bleeding. Hepatorrhaphy was used
with increased frequency. When the arterial bleeding occurred deep within the hepatic pa‐
renchyma, a tractotomy was advocated to expose and suture ligate the arterial flow. But
control of deep arterial bleeding was often technically difficult to accomplish.[91]-[93]
In response to futile attempts to directly suture ligate arterial bleeding, Dr Aaron’s group
performed ligation of the hepatic artery.[94] Initially performed at the Louisville General
Hospital  to  control  arterial  hemorrhage from a  ruptured hepatic  adenoma,  Mays found
this technique useful to control arterial bleeding in trauma patients. A literal explosion in
its use occurred in Louisville, and surgeons there proposed it to prevent rebleeding.[95]-
[96]  A high  rate  of  infection  led  to  reconsideration  of  its  use,  and it  was  subsequently
used less frequently [103],  although it  remained an operation that could occasionally be
life-saving.97-98
Major venous bleeding was recognized as a major source of mortality, particularly in pa‐
tients who had been in high-speed motor vehicle crashes. The nearly uniform lethality of
retrohepatic  vena caval  injuries  with attempt at  direct  repair  led to  the development of
the atriocaval  shunt.  This  technique,  developed by Schrock and associates,  [99]  theoreti‐
cally  bypassed  the  caval  injury  and  allowed direct  suture  repair  of  the  cava  itself  and
main hepatic veins. The operation required opening the chest to expose the atria. This bi‐
cavitary  exposure  accelerated  hypothermia  and  coagulopathy  in  many  patients.  Conse‐
quently, the mortality rate remained high, but the concept of direct repair of this deadly
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Both previously mentioned bleeding problems often were treated initially with temporary
inflow occlusion by clamping the portal triad. The concept of inflow occlusion actually pre‐
dated Pringle, [85] but his work published in 1908 was rediscovered and popularized in the
1960s after rarely being mentioned in the literature for more than 50 years.
Diffuse bleeding from damaged or devitalized liver increasingly required surgical treat‐
ment. Reports on civilian liver injuries from the 1950s generally cautioned against debride‐
ment of damaged liver for fear it would worsen preexisting hemorrhage. Absorbable gauze
packing and drainage were mostly used for this problem. As the forces of injury increased,
other techniques were required.
Resectioned debridement was increasingly used. There was a brief flurry of activity with use
of major anatomic resections, but the high mortality rate of this procedure led to discontinu‐
ing its use in most centers.[100]-[101] The omental pedicle described for liver injury in 1910
and mentioned occasionally through the years was reintroduced by Stone and Lamb[102]
and gained widespread popularity.
In summary; as a general surgeon facing a major hepatic injury in the middle of the night
think of NOM and try not to rush to the operating room unless clearly indicated. However,
if you were forced to the operating room do the minimal to stop the bleeding (DCS). If major
procedure is required, the decision must be made early in the operation were technical /clin‐
ical expertise and speed are critical. Plan definitive surgeries in a stable patient were optimal
condition ably.
6.2.2. Definitive surgery
This is usually carried out in a stable patient by an experienced surgeon at a second stage to
deal with a certain problem (Fig 17). One of the commonest problem is bile leak and collec‐
tion with an incidence of 6-20 %. This is usually after the patient recovered, were they devel‐
op an intra-abdominal collection that is best treated by a radiological applied drain. Then it
can be investigated by MRCP or ERCP. The MRCP is non invasive, however with the collec‐
tion it can have very little input. ERCP is advocated by some to be much better were the leak
is identified and can be treated by sphinctrotomy and a stent [104] with very high success
rate [105]. However, some of these patients fail and require surgical ligation of the leak
which is much easier when the location is identified pre-operatively and a stent is in place to
increase the success rate.
Another reason to go to the operating room is liver necrosis and abscess formation that
occurs  when  bleeding  stoops  and  demarcation  of  the  live  is  obvious.  Liver  necrosis
might increase with attempts to stop the bleeding with angioembolization in NOM or by
arterial  ligation and packing in DCS.The best  option will  be to drain the abscess  radio‐
logically were this might be sufficient. However, if not we advise operative drainage and
an anatomical liver resection to maintain adequate live tissue and maintain a good vas‐
cular supply. This should be carried out by an experienced liver surgeon to get the best
result (Fig 18).
Hepatic Surgery630
Figure 17. Full mobilization in a second look operation to stop the bleeding and to do definitive surgery.
Figure 18. Liver necrosis following embolization with NOM for bleeding. The patient was treated by right hemi hepa‐
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Liver resection might be necessary with reported frequency of 2% to 5% in most series, with
an overall mortality of 17.8% and morbidity around 30%.[106-108] (Fig 19).
Figure 19. Liver trauma which was treated with a right posterior sectionectomy (seg 6&7)
Liver transplantation has been reported in the literature as an extreme intervention in cases
of severe and complicated hepatic trauma. The main indications for liver transplant in such
cases were uncontrollable bleeding and postoperative hepatic insufficiency. Liver transplant
for trauma is a rare condition with 20 cases described in the literature [109]. Esquivel et al.
first reported the use of liver transplantation in two patients with progressive hepatic failure
and uncontrollable bleeding. [110]. The transplant decision is difficult because usual criteria
are not validated, liver’s potential recovery is difficult to evaluate and sepsis and head inju‐
ries often associated, complicating the decision because of their own prognosis. [111].
7. Complications
7.1. Non operative
The most common complication of NOM is failure, ending with the patient in the operating
room. This is even more serious, because the patient most of the time is in a worse state than
what he was and bleeding (the leading cause) is still ongoing. This also is more profound if
it occurs in the middle of the night or with a surgeon of limited liver expertise. It should be
borne in mind that this most common complication usually arises as a result of inappropri‐
ate selection of a patient for conservative management [23]. The failure rate ranges from
6-10% [68, 112] especially when it was combined with arterial emobolization, however, the




Figure 20. a. Failed NOM showing the bleeding from the liver dome. b. Same patient with grade 4 liver injury that
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Complications can arise from injuries that have not been recognized at the time of initial
presentation or /and become apparent after initial delay. Associated injuries seem to be the
most important factors predisposing to postoperative problems [114]-[117].
In a recent multicenter study, hepatic complications developed in 5% (13 of 264) of patients
with grade 3 injuries, 22% (36 of 166) of patients with grade 4 injuries, and 52% (12 of 23) of
patients with grade 5 injuries. Univariate analysis revealed 24-hour crystalloid, total and
first 24-hour packed red blood cells, fresh frozen plasma, platelet, and cryoprecipitate re‐
quirements and liver injury grade to be significant, but only liver injury grade and 24-hour
transfusion requirement predicted complications by multivariable analysis. They came out
with the Conclusion that NOM of high-grade liver injuries is associated with significant
morbidity and correlates with grade of liver injury. Screening patients with transfusion re‐
quirements and high-grade injuries may result in earlier diagnosis and treatment of hepatic-
related complications [118]. We have discussed in the previous section the management of
each of these complications as a part of the operative management to liver trauma.
7.2. Operative
Rebleeding in the postoperative period is a challenging problem. Delayed haemorrhage is
the most common complication of the non-operative management of hepatic injuries and is
the usual indication for a delayed operation [119]. Coagulopathy, inadequate initial surgical
repair and missed retrohepatic venous injury may result in further haemorrhage. Confirmed
coagulation defects should be corrected as rapidly as possible with fresh frozen plasma and
platelet transfusions.
Some authors recommend reoperation after transfusion of 10 units of blood in 24 h [120],
however the limit of 6 units in the first 12 h seems to be more reasonable [121]-[122]. In cases
with slow rebleeding when the limit of 6 units has not been exceeded, embolization of the
bleeding vessels may be helpful [122]. Multiple bleeding vessels is usually the cause of fail‐
ure because the vascular lesions distal to the area of embolization with rich collateral circu‐
lation, or bleeding from the portal or hepatic veins [123]-[125]
Late complications like sepsis, bile leak and liver failure occur at a later stage. Intra-abdomi‐
nal sepsis in the postoperative period occurs in approximately 7-12 per cent of patients 126
Predisposing factors include the presence of shock and increased transfusion requirements,
increased severity of liver injury, associated injuries such as small bowel or colonic perfora‐
tion, the use of perihepatic packs, superficial suturing of deep lacerations with intrahepatic
haematoma formation, and the presence of devitalized parenchyma. Adequate initial surgi‐
cal management in an effort to reduce transfusion requirements, with debridement of all de‐
vitalized tissue and early removal of perihepatic packs, has been recommended to reduce
the incidence of septic complications [81],.
Arteriovenous fistula is not an uncommon complication with an incidence of less than 3%. It
can manifest after liver injury as an arterioportal fistula that can result in portal hypaerten‐
sion and is usually treated by embolization [127].
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8. Outcome
The mortality rate from liver trauma has fallen from 66 per cent in World War I, to 27 per
cent in World War II, to current levels of 10-15 per cent [8],[10],[12],[128]-[129]. Better knowl‐
edge of liver pathophysiology and anatomy, and enhanced resuscitation, anaesthesia and in‐
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Longmire, called it a “hostile” organ because it welcomes malignant cells and sepsis 
so warmly, bleeds so copiously, and is often the ?rst organ to be injured in blunt 
abdominal trauma. To balance these negative factors, the liver has two great attributes: 
its ability to regenerate after massive loss of substance, and its ability, in many cases, 
to forgive insult. This book covers a wide spectrum of topics including, history of 
liver surgery, surgical anatomy of the liver, techniques of liver resection, benign and 
malignant liver tumors, portal hypertension, and liver trauma. Some important topics 
were covered in more than one chapter like liver trauma, portal hypertension and 
pediatric liver tumors.
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